feel better live longer september interim update updates information corporate responsibility report published march inserted relevant sections report highlighted blue boxes similar style text responsibility report head office registered office glaxosmithkline plc great west road brentford middlesex tw gs uk tel corporate responsibility report september corporate responsibility report selected full report see following outlines updates made report september contents overview corporate responsibility gsk contribution global health access medicines research practices ethical conduct supply chain environmental sustainability people human rights public policy patient advocacy work communities find corporate responsibility glaxosmithkline online wwwgskcomresponsibility home responsibility resources downloads sep interim update corporate responsibility report september interim update updates information corporate responsibility report published march inserted relevant sections report outlined access medicines formation unit dedicated expanding access medicines people living least developed countries gsks ranking top access medicine index second successive time independent administration pool open innovation neglected tropical diseases bio ventures global health gsk becoming one first manufacturers sign advance market commitment agreement gavi launch us programme provide adult vaccines free charge eligible low income individuals progress viiv healthcare including award first grants positive action children fund two new partnerships designed improve management paediatric hiv worldwide progress research new hiv treatments extension policy voluntary licences pages updates include response hn flu pandemic launch new third party code conduct suppliers us healthcare reform us patient protection affordable care act ppaca implementation updated labelling labacontaining products accordance fdas directions labacontaining products decision awaited fda future use avandia pages corporate responsibility report contents downloaded full corporate responsibility report overview access medicines cont flexible pricing least developed countries corporate responsibility gsk middleincome countries message ceo developed countries corporate responsibility principles partnerships acquisitions business case corporate responsibility technology transfers joint ventures key issues portfolio expansion advocacy government relations corporate responsibility governance case studies audit assurance qas risk management stakeholder engagement research practices benchmarking reporting emerging technologies cloning technology stem cell research corporate responsibility data summary genetic research animal research contribution global health human tissue research responding pandemic flu maintaining confidentiality disease prevention research participants disease awareness medical governance treating ill health clinical research research development planning approval qas informed consent training auditing access medicines posttrial treatment clinical trials developing world approach clinical trials children improving access developing countries public disclosure clinical research approach intellectual property patient needs rd new approach hiv patient safety viiv healthcare patient safety governance framework hivaids research collecting reporting safety data pricing hivaids medicines performance voluntary licensing working healthcare professionals rd developing world case studies rd neglected tropical diseases qas products formulations developing world proprietary knowledge pool medicines developing world vaccines developing world corporate responsibility report contents ethical conduct environmental sustainability cont code conduct business ethics materials interactions healthcare professionals mass efficiency marketing ethics input materials interactions healthcare professionals reach directtoconsumer advertising pharmaceuticals environment training awareness packaging leading example environmental performace performance water monitoring compliance waste water waste case studies emissions air assurance statement response land qas supplier performance transparency supply chain summary data responsibility supply chain stakeholder engagement human rights clause assurance choosing suppliers gsk response assurance monitoring engagement case studies supply chain performance qas training capacity building supplier diversity people fair treatment suppliers maintaining quality values behaviours security supply inclusion diversity counterfeiting developing people case studies leading people qas restructuring communication consultation environmental sustainability reward recognition health safety sustainability gsk health safety management managing environmental sustainability hazard assessment communication plans targets safety programmes integration business principles health wellbeing programmes awareness recognition health business continuity audits compliance training awareness climate change energy performance propellants case studies facilities processes qas transport travel performance plans corporate responsibility report contents human rights employees suppliers communities society activities embargoed countries public policy patient advocacy approach external affairs public policy activity advocacy healthcare reform advocacy healthcare disease prevention advocacy research practices advocacy patient safety advocacy intellectual property advocacy pricing competitiveness political contributions lobbying expenditures patient advocacy transparency understanding patients advocacy qas work communities community investment employee involvement preventing disease eliminating lymphatic filariasis p ersonal hygiene sanitation education phase local programmes r esponding disasters around world building community capacity upporting healthcare least developed countries combating hivaids positive action combating malaria africa malaria partnership local programmes supporting science education corporate responsibility report september corporate responsibility report selected full report see following outlines updates made report september contents overview corporate responsibility gsk contribution global health access medicines research practices ethical conduct supply chain environmental sustainability people human rights public policy patient advocacy work communities find corporate responsibility glaxosmithkline online wwwgskcomresponsibility home responsibility overview corporate responsibility report overview read approach follow links find cr report online download pdf version overview corporate responsibility gsk responsible business means operating way reflects values treating stakeholders respect connecting business decisions societys healthcare needs business makes valuable contribution society however know research development manufacture sale medicines vaccines consumer products raise ethical issues aim open transparent tackle seek minimise negative impacts maximise benefits business approach guided corporate responsibility principles read approach cr gsk contribution global health medicines vaccines consumer healthcare products make real difference patients lives research new treatments address needs patients healthcare payers make products widely available possible heart responsibility means gsk central commercial success make contribution investing research development new medicines vaccines treating ill health diseases diabetes cancer preventing disease vaccines consumer healthcare products read contribution global health access medicines tackling healthcare crisis requires global partnership gsk committed playing full part increasing access medicines morally right thing contributes success building trust business increasing revenues invest rd medicines vaccines meet patient needs around world make available affordable preferential pricing arrangements voluntary licences forming innovative partnerships support research neglected tropical diseases support strengthening healthcare infrastructure worlds least developed countries read access medicines research practices maintaining high ethical standards rd key ensuring quality research maximising benefits minimising risks medicines vaccines patient safety priority monitor swiftly report potential safety issues regulators rd policies global apply high standards wherever operate paallg ae oaf animal research use emerging technologies rigorous procedures assurance processes ensure clinical trials conducted according internationally recognised standards welfare participants protected disclose results clinical trials advance medical science inform prescribers patients read research practices ethical conduct committed creating strong ethical culture gsk developing strong policies recruiting right people equipping tools make ethical decisions gsk employees contractors must comply code conduct sets fundamental ethical standards follow guidance policies employee guide business conduct regional marketing codes ensure demonstrate high ethical conduct marketing products doctors hospitals governments run regular training courses emphasise key ethics integrity messages read ethical conduct supply chain patients depend uninterrupted flow high quality medicines makes maintaining high standards supply chain vital meeting patients needs work suppliers score minimum health safety environment standard monitor performance supplier contracts include human rights clauses work ensure quality materials buy stop counterfeiting gsk products read supply chain environmental sustainability increasing efforts environmental sustainability need optimise efficiency increase use renewable materials energy prioritised reducing impact climate change lowering water use set challenging targets reduce energy climate change impact operations transport per cent per cent increasing efficiency use materials also priority aim achieve level five times performance read environmental sustainability people employ people countries across world goal gsk employer choice value empower people place great emphasis achieve also achieve employees must demonstrate companys values behaviours daily work committed creating inclusive diverse working environment offer employees variety training development opportunities communicate regularly workforce consult employees representatives taking action affects read people human rights work hard protect human rights within sphere influence includes employees suppliers communities society committed upholding un universal declaration human rights oecd guidelines multinational enterprises core labour standards set international labour organization signatory un global compact voluntary global standard human rights labour environment anticorruption read human rights public policy patient advocacy public policy activity support legislation policy encourage scientific innovation balance interests business stakeholders also work patient groups professional groups help give members voice healthcare debate aim increase stakeholder trust gsk transparent lobbying public policy work publish annual public policy activity website report memberships trade associations us federal eu institutions lobbying expenditures also publish information work patient groups including details funding provide gsk make political contributions read public policy patient advocacy work communities donate money time medicines equipment support communities around world programmes long term focus preventing disease building healthcare capacity communities promoting education encourage employees actively support causes care run volunteering programmes make easier get involved read work communities back tophome responsibility overview corporate responsibility report overview read approach follow links find cr report online download pdf version overview corporate responsibility gsk responsible business means operating way reflects values treating stakeholders respect connecting business decisions societys healthcare needs business makes valuable contribution society however know research development manufacture sale medicines vaccines consumer products raise ethical issues aim open transparent tackle seek minimise negative impacts maximise benefits business approach guided corporate responsibility principles read approach cr gsk contribution global health medicines vaccines consumer healthcare products make real difference patients lives research new treatments address needs patients healthcare payers make products widely available possible heart responsibility means gsk central commercial success make contribution investing research development new medicines vaccines treating ill health diseases diabetes cancer preventing disease vaccines consumer healthcare products read contribution global health access medicines tackling healthcare crisis requires global partnership gsk committed playing full part increasing access medicines morally right thing contributes success building trust business increasing revenues invest rd medicines vaccines meet patient needs around world make available affordable preferential pricing arrangements voluntary licences forming innovative partnerships support research neglected tropical diseases support strengthening healthcare infrastructure worlds least developed countries read access medicines research practices maintaining high ethical standards rd key ensuring quality research maximising benefits minimising risks medicines vaccines patient safety priority monitor swiftly report potential safety issues regulators rd policies global apply high standards wherever operate areas animal research use emerging technologies rigorous procedures assurance processes ensure clinical trials conducted according internationally recognised standards welfare participants protected disclose results clinical trials advance medical science inform prescribers patients read research practices ethical conduct committed creating strong ethical culture gsk developing strong policies recruiting right people equipping tools make ethical decisions gsk employees contractors must comply code conduct sets fundamental ethical standards follow guidance policies employee guide business conduct regional marketing codes ensure demonstrate high ethical conduct marketing products doctors hospitals governments run regular training courses emphasise key ethics integrity messages read ethical conduct supply chain patients depend uninterrupted flow high quality medicines makes maintaining high standards supply chain vital meeting patients needs work suppliers score minimum health safety environment standard monitor performance supplier contracts include human rights clauses work ensure quality materials buy stop counterfeiting gsk products read supply chain environmental sustainability increasing efforts environmental sustainability need optimise efficiency increase use renewable materials energy prioritised reducing impact climate change lowering water use set challenging targets reduce energy climate change impact operations transport per cent per cent increasing efficiency use materials also priority aim achieve level five times performance read environmental sustainability people employ people countries across world goal gsk employer choice value empower people place great emphasis achieve also achieve employees must demonstrate companys values behaviours daily work committed creating inclusive diverse working environment offer employees variety training development opportunities communicate regularly workforce consult employees representatives taking action affects read people human rights work hard protect human rights within sphere influence includes employees suppliers communities society committed upholding un universal declaration human rights oecd guidelines multinational enterprises core labour standards set international labour organization signatory un global compact voluntary global standard human rights labour environment anticorruption read human rights public policy patient advocacy public policy activity support legislation policy encourage scientific innovation balance interests business stakeholders also work patient groups professional groups help give members voice healthcare debate aim increase stakeholder trust gsk transparent lobbying public policy work publish annual public policy activity website report memberships trade associations us federal eu institutions lobbying expenditures also publish information work patient groups including details funding provide gsk make political contributions read public policy patient advocacy work communities donate money time medicines equipment support communities around world programmes long term focus preventing disease building healthcare capacity communities promoting education encourage employees actively support causes care run volunteering programmes make easier get involved read work communities back tophome responsibility overview corporate responsibility report overview read approach follow links find cr report online download pdf version overview corporate responsibility gsk responsible business means operating way reflects values treating stakeholders respect connecting business decisions societys healthcare needs business makes valuable contribution society however know research development manufacture sale medicines vaccines consumer products raise ethical issues aim open transparent tackle seek minimise negative impacts maximise benefits business approach guided corporate responsibility principles read approach cr gsk contribution global health medicines vaccines consumer healthcare products make real difference patients lives research new treatments address needs patients healthcare payers make products widely available possible heart responsibility means gsk central commercial success make contribution investing research development new medicines vaccines treating ill health diseases diabetes cancer preventing disease vaccines consumer healthcare products read contribution global health access medicines tackling healthcare crisis requires global partnership gsk committed playing full part increasing access medicines morally right thing contributes success building trust business increasing revenues invest rd medicines vaccines meet patient needs around world make available affordable preferential pricing arrangements voluntary licences forming innovative partnerships support research neglected tropical diseases support strengthening healthcare infrastructure worlds least developed countries read access medicines research practices maintaining high ethical standards rd key ensuring quality research maximising benefits minimising risks medicines vaccines patient safety priority monitor swiftly report potential safety issues regulators rd policies global apply high standards wherever operate areas animal research use emerging technologies rigorous procedures assurance processes ensure clinical trials conducted according internationally recognised standards welfare participants protected disclose results clinical trials advance medical science inform prescribers patients read research practices ethical conduct committed creating strong ethical culture gsk developing strong policies recruiting right people equipping tools make ethical decisions gsk employees contractors must comply code conduct sets fundamental ethical standards follow guidance policies employee guide business conduct regional marketing codes ensure demonstrate high ethical conduct marketing products doctors hospitals governments run regular training courses emphasise key ethics integrity messages read ethical conduct supply chain patients depend uninterrupted flow high quality medicines makes maintaining high standards supply chain vital meeting patients needs work suppliers score minimum health safety environment standard monitor performance supplier contracts include human rights clauses work ensure quality materials buy stop counterfeiting gsk products read supply chain environmental sustainability increasing efforts environmental sustainability need optimise efficiency increase use renewable materials energy prioritised reducing impact climate change lowering water use set challenging targets reduce energy climate change impact operations transport per cent per cent increasing efficiency use materials also priority aim achieve level five times performance read environmental sustainability people employ people countries across world goal gsk employer choice value empower people place great emphasis achieve also achieve employees must demonstrate companys values behaviours daily work committed creating inclusive diverse working environment offer employees variety training development opportunities communicate regularly workforce consult employees representatives taking action affects read people human rights work hard protect human rights within sphere influence includes employees suppliers communities society committed upholding un universal declaration human rights oecd guidelines multinational enterprises core labour standards set international labour organization signatory un global compact voluntary global standard human rights labour environment anticorruption read human rights public policy patient advocacy public policy activity support legislation policy encourage scientific innovation balance interests business stakeholders also work patient groups professional groups help give members voice healthcare debate aim increase stakeholder trust gsk transparent lobbying public policy work publish annual public policy activity website report memberships trade associations us federal eu institutions lobbying expenditures also publish information work patient groups including details funding provide gsk make political contributions read public policy patient advocacy work communities donate money time medicines equipment support communities around world programmes long term focus preventing disease building healthcare capacity communities promoting education encourage employees actively support causes care run volunteering programmes make easier get involved read work communities back top home responsibility overview corporate responsibility report overview read approach follow links find cr report online download pdf version overview corporate responsibility gsk responsible business means operating way reflects values treating stakeholders respect connecting business decisions societys healthcare needs business makes valuable contribution society however know research development manufacture sale medicines vaccines consumer products raise ethical issues aim open transparent tackle seek minimise negative impacts maximise benefits business approach guided corporate responsibility principles read approach cr gsk contribution global health medicines vaccines consumer healthcare products make real difference patients lives research new treatments address needs patients healthcare payers make products widely available possible heart responsibility means gsk central commercial success make contribution investing research development new medicines vaccines treating ill health diseases diabetes cancer preventing disease vaccines consumer healthcare products read contribution global health access medicines tackling healthcare crisis requires global partnership gsk committed playing full part increasing access medicines morally right thing contributes success building trust business increasing revenues invest rd medicines vaccines meet patient needs around world make available affordable preferential pricing arrangements voluntary licences forming innovative partnerships support research neglected tropical diseases support strengthening healthcare infrastructure worlds least developed countries read access medicines research practices maintaining high ethical standards rd key ensuring quality research maximising benefits minimising risks medicines vaccines patient safety priority monitor swiftly report potential safety issues regulators rd policies global apply high standards wherever operate areas animal research use emerging technologies rigorous procedures assurance processes ensure clinical trials conducted according internationally recognised standards welfare participants protected disclose results clinical trials advance medical science inform prescribers patients read research practices ethical conduct committed creating strong ethical culture gsk developing strong policies recruiting right people equipping tools make ethical decisions gsk employees contractors must comply code conduct sets fundamental ethical standards follow guidance policies employee guide business conduct regional marketing codes ensure demonstrate high ethical conduct marketing products doctors hospitals governments run regular training courses emphasise key ethics integrity messages read ethical conduct supply chain patients depend uninterrupted flow high quality medicines makes maintaining high standards supply chain vital meeting patients needs work suppliers score minimum health safety environment standard monitor performance supplier contracts include human rights clauses work ensure quality materials buy stop counterfeiting gsk products read supply chain environmental sustainability increasing efforts environmental sustainability need optimise efficiency increase use renewable materials energy prioritised reducing impact climate change lowering water use set challenging targets reduce energy climate change impact operations transport per cent per cent increasing efficiency use materials also priority aim achieve level five times performance read environmental sustainability people employ people countries across world goal gsk employer choice value empower people place great emphasis achieve also achieve employees must demonstrate companys values behaviours daily work committed creating inclusive diverse working environment offer employees variety training development opportunities communicate regularly workforce consult employees representatives taking action affects read people human rights work hard protect human rights within sphere influence includes employees suppliers communities society committed upholding un universal declaration human rights oecd guidelines multinational enterprises core labour standards set international labour organization signatory un global compact voluntary global standard human rights labour environment anticorruption read human rights public policy patient advocacy public policy activity support legislation policy encourage scientific innovation balance interests business stakeholders also work patient groups professional groups help give members voice healthcare debate aim increase stakeholder trust gsk transparent lobbying public policy work publish annual public policy activity website report memberships trade associations us federal eu institutions lobbying expenditures also publish information work patient groups including details funding provide gsk make political contributions read public policy patient advocacy work communities donate money time medicines equipment support communities around world programmes long term focus preventing disease building healthcare capacity communities promoting education encourage employees actively support causes care run volunteering programmes make easier get involved read work communities back top home responsibility corporate responsibility gsk corporate responsibility report corporate responsibility gsk believe strong values central business success place great importance achieve also achieve responsible business means operating way reflects values treating stakeholders respect connecting business decisions societys healthcare needs seek minimise negative impacts maximise benefits business approach guided corporate responsibility principles read responsible business means gsk message ceo andrew witty business case corporate responsibility gsk makes valuable contribution society medicines vaccines consumer healthcare products produce improve peoples lives however know research development manufacture sale medicines vaccines raise ethical issues aim open transparent tackle seek understand respond views stakeholders subjects established management processes help advance progress cr principles ensure identify manage responsibility reputational risks business mission values spirit gsk framework enables us achieve mission improve quality human life enabling people feel better live longer includes company values respect people patient focused transparency integrity see people information back top home responsibility corporate responsibility gsk corporate responsibility report corporate responsibility gsk believe strong values central business success place great importance achieve also achieve responsible business means operating way reflects values treating stakeholders respect connecting business decisions societys healthcare needs seek minimise negative impacts maximise benefits business approach guided corporate responsibility principles read responsible business means gsk message ceo andrew witty business case corporate responsibility gsk makes valuable contribution society medicines vaccines consumer healthcare products produce improve peoples lives however know research development manufacture sale medicines vaccines raise ethical issues aim open transparent tackle seek understand respond views stakeholders subjects established management processes help advance progress cr principles ensure identify manage responsibility reputational risks business mission values spirit gsk framework enables us achieve mission improve quality human life enabling people feel better live longer includes company values respect people patient focused transparency integrity see people information back top home responsibility corporate responsibility gsk message ceo corporate responsibility report message ceo gsk changing welcome gsks corporate responsibility report provides information activities ambition gsk create valuesbased business employees investors wider society proud rely want run business highest ethical standards adapting changing responsive needs society since became ceo gsk focusing changing business improve financial performance diversifying sales growth improving returns investment make rd know part successful sustainable business fulfilling social responsibilities making company responsive flexible open societys expectations making progress many areas improving access medicines enhancing research opportunities neglected tropical diseases raising ethical standards conducting research business activities open transparent way run business making changes needed reach ambitious energy climate change targets proving challenge stepping efforts achieve access medicines encouraging rd neglected tropical diseases believe access medicines defining issue industry took significant steps forward reduced price patented medicines worlds poorest countries per cent uk price resulting increase sales volumes suggests patients accessing medicines also reinvesting per cent profits selling medicines markets projects strengthen healthcare infrastructure least developed countries middle income countries developing flexible approach pricing better reflects ability pay pilot studies showed promising improvements access products flexible approach pricing extended also unique opportunity candidate malaria vaccine developed collaboration path malaria vaccine initiative bill melinda gates foundation african research organisations vaccine still development however already thinking access want set price sustainable also low possible january announced set price covers costs makes small return reinvest rd next generation malaria vaccines vaccines diseases developing world tackling acute need medicines treat neglected tropical diseases needs innovative approaches partnerships set open innovation agenda launch new collaborations share intellectual property knowhow create broadbased partnerships give researchers access expertise processes facilities infrastructure example publishing information compounds shown activity malaria parasite seek rights compounds researchers discover new treatment malaria another important aspect open innovation open lab creating tres cantos rd campus dedicated research combating diseases developing world open lab researchers across world especially developing countries able work gsk projects accessing expertise knowhow processes industrial scale help fund external partnerships gsk set notforprofit foundation initial investment million transparency social responsibilities go beyond enhancing rd efforts improving access medicines vaccines believe open transparent business help us build trust stakeholders continue publish results clinical studies clinical study register include names principal clinical investigators institutions work also seek publication results clinical studies full scientific papers peer reviewed journals believe company make commitment sometimes case journal want publish paper include additional information help interpretation study results clinical study register also publishing information payments healthcare professionals started publishing speaking consulting fees paid us healthcare professionals plans place extend countries also set new standards funding medical education us ensure support programmes bring greatest improvements patient health commitment gsk real opportunity make difference patients society know always committed making changes business achieve believe made good progress excited opportunities evolve gsks business look forward updating future progress andrew witty chief executive officer back tophome responsibility corporate responsibility gsk message ceo corporate responsibility report message ceo gsk changing welcome gsks corporate responsibility report provides information activities ambition gsk create valuesbased business employees investors wider society proud rely want run business highest ethical standards adapting changing responsive needs society since became ceo gsk focusing changing business improve financial performance diversifying sales growth improving returns investment make rd know part successful sustainable business fulfilling social responsibilities making company responsive flexible open societys expectations making progress many areas improving access medicines enhancing research opportunities neglected tropical diseases raising ethical standards conducting research business activities open transparent way run business making changes needed reach ambitious energy climate change targets proving challenge stepping efforts achieve access medicines encouraging rd neglected tropical diseases believe access medicines defining issue industry took significant steps forward reduced price patented medicines worlds poorest countries per cent uk price resulting increase sales volumes suggests patients accessing medicines also reinvesting per cent profits selling medicines markets projects strengthen healthcare infrastructure least developed countries middle income countries developing flexible approach pricing better reflects ability pay pilot studies showed promising improvements access products flexible approach pricing extended also unique opportunity candidate malaria vaccine developed collaboration path malaria vaccine initiative bill melinda gates foundation african research organisations vaccine still development however already thinking access want set price sustainable also low possible january announced set price covers costs makes small return reinvest rd next generation malaria vaccines vaccines diseases developing world tackling acute need medicines treat neglected tropical diseases needs innovative approaches partnerships set open innovation agenda launch new collaborations share intellectual property knowhow create broadbased partnerships give researchers access expertise processes facilities infrastructure example publishing information compounds shown activity malaria parasite seek rights compounds researchers discover new treatment malaria another important aspect open innovation open lab creating tres cantos rd campus dedicated research combating diseases developing world open lab researchers across world especially developing countries able work gsk projects accessing expertise knowhow processes industrial scale help fund external partnerships gsk set notforprofit foundation initial investment million transparency social responsibilities go beyond enhancing rd efforts improving access medicines vaccines believe open transparent business help us build trust stakeholders continue publish results clinical studies clinical study register include names principal clinical investigators institutions work also seek publication results clinical studies full scientific papers peer reviewed journals believe company make commitment sometimes case journal want publish paper include additional information help interpretation study results clinical study register also publishing information payments healthcare professionals started publishing speaking consulting fees paid us healthcare professionals plans place extend countries also set new standards funding medical education us ensure support programmes bring greatest improvements patient health commitment gsk real opportunity make difference patients society know always committed making changes business achieve believe made good progress excited opportunities evolve gsks business look forward updating future progress andrew witty chief executive officer back top home responsibility corporate responsibility gsk message ceo corporate responsibility report message ceo gsk changing welcome gsks corporate responsibility report provides information activities ambition gsk create valuesbased business employees investors wider society proud rely want run business highest ethical standards adapting changing responsive needs society since became ceo gsk focusing changing business improve financial performance diversifying sales growth improving returns investment make rd know part successful sustainable business fulfilling social responsibilities making company responsive flexible open societys expectations making progress many areas improving access medicines enhancing research opportunities neglected tropical diseases raising ethical standards conducting research business activities open transparent way run business making changes needed reach ambitious energy climate change targets proving challenge stepping efforts achieve access medicines encouraging rd neglected tropical diseases believe access medicines defining issue industry took significant steps forward reduced price patented medicines worlds poorest countries per cent uk price resulting increase sales volumes suggests patients accessing medicines also reinvesting per cent profits selling medicines markets projects strengthen healthcare infrastructure least developed countries middle income countries developing flexible approach pricing better reflects ability pay pilot studies showed promising improvements access products flexible approach pricing extended also unique opportunity candidate malaria vaccine developed collaboration path malaria vaccine initiative bill melinda gates foundation african research organisations vaccine still development however already thinking access want set price sustainable also low possible january announced set price covers costs makes small return reinvest rd next generation malaria vaccines vaccines diseases developing world tackling acute need medicines treat neglected tropical diseases needs innovative approaches partnerships set open innovation agenda launch new collaborations share intellectual property knowhow create broadbased partnerships give researchers access expertise processes facilities infrastructure example publishing information compounds shown activity malaria parasite seek rights compounds researchers discover new treatment malaria another important aspect open innovation open lab creating tres cantos rd campus dedicated research combating diseases developing world open lab researchers across world especially developing countries able work gsk projects accessing expertise knowhow processes industrial scale help fund external partnerships gsk set notforprofit foundation initial investment million transparency social responsibilities go beyond enhancing rd efforts improving access medicines vaccines believe open transparent business help us build trust stakeholders continue publish results clinical studies clinical study register include names principal clinical investigators institutions work also seek publication results clinical studies full scientific papers peer reviewed journals believe company make commitment sometimes case journal want publish paper include additional information help interpretation study results clinical study register also publishing information payments healthcare professionals started publishing speaking consulting fees paid us healthcare professionals plans place extend countries also set new standards funding medical education us ensure support programmes bring greatest improvements patient health commitment gsk real opportunity make difference patients society know always committed making changes business achieve believe made good progress excited opportunities evolve gsks business look forward updating future progress andrew witty chief executive officer back top home responsibility corporate responsibility gsk corporate responsibility principles corporate responsibility report corporate responsibility principles corporate responsibility principles identify key responsibility issues provide guidance employees standards gsk committed employment practices treat employees respect dignity encourage diversity ensure fair treatment phases employment provide safe healthy working environment support employees perform full potential take responsibility performance reputation business read employment practices human rights committed upholding un universal declaration human rights oecd guidelines multinational enterprises core labour standards set international labour organization expect standards suppliers contractors business partners working gsks behalf read approach human rights access medicines continue research develop medicines treat diseases developing world find sustainable ways improve access medicines disadvantaged people seek partnerships support activity read approach access medicines leadership advocacy establish challenging standards corporate responsibility appropriate complexities specific needs business building external guidelines experience share best practice seek influence others remaining competitive order sustain business read approach public policy patient advocacy community investmentwe make positive contribution communities operate invest health education programmes partnerships aim bring sustainable improvements underserved people developed developing world read work communities engagement stakeholders want understand concerns interest corporate responsibility issues engage range stakeholders communicate openly addressing cr issues ways aim meet needs different groups allowing us pursue legitimate business goals read stakeholder engagement standards ethical conduct expect employees meet high ethical standards aspects business conducting activities honesty integrity adhering cr principles complying applicable laws regulations read ethical conduct research innovation undertaking research innovating may explore apply new technologies constructively engage stakeholders concerns may arise ensure products subject rigorous scientific evaluation testing safety effectiveness quality comply exceed regulations legal standards applicable research development products read research practices products customers promote products line high ethical medical scientific standards comply applicable laws regulations read marketing ethics caring environment operate environmentally responsible manner systematic management environmental impacts measurement performance setting challenging performance targets improve efficiency activities minimise material energy use waste generated aim find opportunities use renewable materials recycle waste read environmental sustainability back tophome responsibility corporate responsibility gsk corporate responsibility principles corporate responsibility report corporate responsibility principles corporate responsibility principles identify key responsibility issues provide guidance employees standards gsk committed employment practices treat employees respect dignity encourage diversity ensure fair treatment phases employment provide safe healthy working environment support employees perform full potential take responsibility performance reputation business read employment practices human rights committed upholding un universal declaration human rights oecd guidelines multinational enterprises core labour standards set international labour organization expect standards suppliers contractors business partners working gsks behalf read approach human rights access medicines continue research develop medicines treat diseases developing world find sustainable ways improve access medicines disadvantaged people seek partnerships support activity read approach access medicines leadership advocacy establish challenging standards corporate responsibility appropriate complexities specific needs business building external guidelines experience share best practice seek influence others remaining competitive order sustain business read approach public policy patient advocacy community investmentwe make positive contribution communities operate invest health education programmes partnerships aim bring sustainable improvements underserved people developed developing world read work communities engagement stakeholders want understand concerns interest corporate responsibility issues engage range stakeholders communicate openly addressing cr issues ways aim meet needs different groups allowing us pursue legitimate business goals read stakeholder engagement standards ethical conduct expect employees meet high ethical standards aspects business conducting activities honesty integrity adhering cr principles complying applicable laws regulations read ethical conduct research innovation undertaking research innovating may explore apply new technologies constructively engage stakeholders concerns may arise ensure products subject rigorous scientific evaluation testing safety effectiveness quality comply exceed regulations legal standards applicable research development products read research practices products customers promote products line high ethical medical scientific standards comply applicable laws regulations read marketing ethics caring environment operate environmentally responsible manner systematic management environmental impacts measurement performance setting challenging performance targets improve efficiency activities minimise material energy use waste generated aim find opportunities use renewable materials recycle waste read environmental sustainability back top home responsibility corporate responsibility gsk corporate responsibility principles corporate responsibility report corporate responsibility principles corporate responsibility principles identify key responsibility issues provide guidance employees standards gsk committed employment practices treat employees respect dignity encourage diversity ensure fair treatment phases employment provide safe healthy working environment support employees perform full potential take responsibility performance reputation business read employment practices human rights committed upholding un universal declaration human rights oecd guidelines multinational enterprises core labour standards set international labour organization expect standards suppliers contractors business partners working gsks behalf read approach human rights access medicines continue research develop medicines treat diseases developing world find sustainable ways improve access medicines disadvantaged people seek partnerships support activity read approach access medicines leadership advocacy establish challenging standards corporate responsibility appropriate complexities specific needs business building external guidelines experience share best practice seek influence others remaining competitive order sustain business read approach public policy patient advocacy community investmentwe make positive contribution communities operate invest health education programmes partnerships aim bring sustainable improvements underserved people developed developing world read work communities engagement stakeholders want understand concerns interest corporate responsibility issues engage range stakeholders communicate openly addressing cr issues ways aim meet needs different groups allowing us pursue legitimate business goals read stakeholder engagement standards ethical conduct expect employees meet high ethical standards aspects business conducting activities honesty integrity adhering cr principles complying applicable laws regulations read ethical conduct research innovation undertaking research innovating may explore apply new technologies constructively engage stakeholders concerns may arise ensure products subject rigorous scientific evaluation testing safety effectiveness quality comply exceed regulations legal standards applicable research development products read research practices products customers promote products line high ethical medical scientific standards comply applicable laws regulations read marketing ethics caring environment operate environmentally responsible manner systematic management environmental impacts measurement performance setting challenging performance targets improve efficiency activities minimise material energy use waste generated aim find opportunities use renewable materials recycle waste read environmental sustainability back top home responsibility corporate responsibility gsk business case corporate responsibility corporate responsibility report business case corporate responsibility demonstrating practices responsible ethical benefits business improves reputation following ways engenders greater trust gsk products ability attract retain motivate talented people becoming increasingly important fewer young people major markets choose sciencebased careers constructive engagement stakeholders helps us prevent avoidable conflict identify innovative approaches benefit gsk wider society greater access markets ability influence healthcare policy improved relationships regulators healthcare payers helping governments increase access medicines resolve healthcare challenges particularly important greater ability anticipate prepare legislative changes maintain competitive advantage helping maintain support intellectual property system finding innovative ways increase access medicines reduced costs efficient use resources increased environmental efficiency strategy focused delivering three strategic priorities transform gsk company delivers growth less risk improved longterm financial performance successful sustainable business must also fulfil social responsibilities making company responsive flexible open strategic priorities grow diversified global business diversifying business create balanced product portfolio move away reliance traditional white pill western markets investing key growth areas emerging markets japan vaccines consumer healthcare business deliver products value aim sustain industryleading pipeline products ensuring demonstrate value healthcare providers rd strategy built around focusing best science diversifying externalisation research improving returns investment simplify operating model gsk large default complex organisation transforming operational model reduce complexities improve efficiency reduce costs updates progress priorities measures operate responsibility integrity please visit annual report website back top home responsibility corporate responsibility gsk business case corporate responsibility corporate responsibility report business case corporate responsibility demonstrating practices responsible ethical benefits business improves reputation following ways engenders greater trust gsk products ability attract retain motivate talented people becoming increasingly important fewer young people major markets choose sciencebased careers constructive engagement stakeholders helps us prevent avoidable conflict identify innovative approaches benefit gsk wider society greater access markets ability influence healthcare policy improved relationships regulators healthcare payers helping governments increase access medicines resolve healthcare challenges particularly important greater ability anticipate prepare legislative changes maintain competitive advantage helping maintain support intellectual property system finding innovative ways increase access medicines reduced costs efficient use resources increased environmental efficiency strategy focused delivering three strategic priorities transform gsk company delivers growth less risk improved longterm financial performance successful sustainable business must also fulfil social responsibilities making company responsive flexible open strategic priorities grow diversified global business diversifying business create balanced product portfolio move away reliance traditional white pill western markets investing key growth areas emerging markets japan vaccines consumer healthcare business deliver products value aim sustain industryleading pipeline products ensuring demonstrate value healthcare providers rd strategy built around focusing best science diversifying externalisation research improving returns investment simplify operating model gsk large default complex organisation transforming operational model reduce complexities improve efficiency reduce costs updates progress priorities measures operate responsibility integrity please visit annual report website back top home responsibility corporate responsibility gsk key issues corporate responsibility report key issues cr reporting focused material significant relevant issues business following factors influence materiality assessment business strategy risk management processes stakeholder interest including investor feedback changes business operations example types product produce locations operate existing proposed legislation public opinion press coverage identified following responsibility issues material gsk contribution core business makes health research development manufacture sale medicines vaccines increasing access medicines underserved communities ethical standards research development sales marketing environmental impact particularly climate change see corporate responsibility governance risk management decisionmaking processes back top home responsibility corporate responsibility gsk key issues corporate responsibility report key issues cr reporting focused material significant relevant issues business following factors influence materiality assessment business strategy risk management processes stakeholder interest including investor feedback changes business operations example types product produce locations operate existing proposed legislation public opinion press coverage identified following responsibility issues material gsk contribution core business makes health research development manufacture sale medicines vaccines increasing access medicines underserved communities ethical standards research development sales marketing environmental impact particularly climate change see corporate responsibility governance risk management decisionmaking processes back top home responsibility corporate responsibility gsk corporate responsibility governance corporate responsibility report corporate responsibility governance corporate responsibility committee crc nonexecutive directors provides highlevel guidance approach cr ceo members corporate executive team cet accountable responsible management business participate crc meetings committee members sir christopher gent chair dr stephanie burns mr james murdoch dr daniel podolsky sir ian prosser mr tom de swaan committee meets three times year review policies progress cr principles committee reviews performance five cr principles annually access medicines standards ethical conduct research innovation employment practices community investment principles discussed least every two years committee reports findings board management corporate responsibility crc reviewed gsks activity number areas including pandemic 'flu including access vaccine antiviral medicines developing countries access pricing medicines developing countries rd diseases developing world patent pool community partnerships investment humanitarian donations sales marketing practices including harmonisation gsk codes practice disclosure payments healthcare professionals communication clinical trial results use animals research employment practices including diversity inclusion employee wellbeing employee relations including consultation arrangements employment litigation us supply chain management climate change energy use reduction manufacturing efficiency data privacy corruption prevention committee also reviews signs annual performance information published website annual cr highlights document augment engagement stakeholder opinion march sophia tickell appointed independent external advisor corporate responsibility committee sophia director pharma futures series aims better align societal shareholder value chairs international advisory group medicines transparency alliance sophia extensive experience constructively challenging companies increase understanding societal expectations develop strategies meet gained experience work journalist latin america work international development advocacy work oxfam recently role director sustainability think tank consultancy sustainability issues sophia attends meetings corporate responsibility committee advises company capacity corporate responsibility risks risk oversight compliance council rocc coordinates management significant business risks rocc also considers reputational corporate responsibility risks read risk management management structure cr covers diverse range issues gsk believe managed within business functions relevant subject experts work crossfunctional team made representatives key business areas oversees development implementation communication policies including responsibility elements across gsk members senior managers direct access corporate executive team small central cr team coordinate policy development reporting specifically respect cr communicate socially responsible investors stakeholders sustainability council senior executives across business meets via teleconference four times year oversee gsks environmental sustainability plans progress measuring performance established metrics key performance indicators track performance responsibility issues may mr james murdoch joined committee mr tom de swaan ceased member committee sir ian prosser retired board back tophome responsibility corporate responsibility gsk corporate responsibility governance corporate responsibility report corporate responsibility governance corporate responsibility committee crc nonexecutive directors provides highlevel guidance approach cr ceo members corporate executive team cet accountable responsible management business participate crc meetings committee members sir christopher gent chair dr stephanie burns mr james murdoch dr daniel podolsky sir ian prosser mr tom de swaan committee meets three times year review policies progress cr principles committee reviews performance five cr principles annually access medicines standards ethical conduct research innovation employment practices community investment principles discussed least every two years committee reports findings board management corporate responsibility crc reviewed gsks activity number areas including pandemic 'flu including access vaccine antiviral medicines developing countries access pricing medicines developing countries rd diseases developing world patent pool community partnerships investment humanitarian donations sales marketing practices including harmonisation gsk codes practice disclosure payments healthcare professionals communication clinical trial results use animals research employment practices including diversity inclusion employee wellbeing employee relations including consultation arrangements employment litigation us supply chain management climate change energy use reduction manufacturing efficiency data privacy corruption prevention committee also reviews signs annual performance information published website annual cr highlights document augment engagement stakeholder opinion march sophia tickell appointed independent external advisor corporate responsibility committee sophia director pharma futures series aims better align societal shareholder value chairs international advisory group medicines transparency alliance sophia extensive experience constructively challenging companies increase understanding societal expectations develop strategies meet gained experience work journalist latin america work international development advocacy work oxfam recently role director sustainability think tank consultancy sustainability issues sophia attends meetings corporate responsibility committee advises company capacity corporate responsibility risks risk oversight compliance council rocc coordinates management significant business risks rocc also considers reputational corporate responsibility risks read risk management management structure cr covers diverse range issues gsk believe managed within business functions relevant subject experts work crossfunctional team made representatives key business areas oversees development implementation communication policies including responsibility elements across gsk members senior managers direct access corporate executive team small central cr team coordinate policy development reporting specifically respect cr communicate socially responsible investors stakeholders sustainability council senior executives across business meets via teleconference four times year oversee gsks environmental sustainability plans progress measuring performance established metrics key performance indicators track performance responsibility issues may mr james murdoch joined committee mr tom de swaan ceased member committee sir ian prosser retired board back top home responsibility corporate responsibility gsk corporate responsibility governance corporate responsibility report corporate responsibility governance corporate responsibility committee crc nonexecutive directors provides highlevel guidance approach cr ceo members corporate executive team cet accountable responsible management business participate crc meetings committee members sir christopher gent chair dr stephanie burns mr james murdoch dr daniel podolsky sir ian prosser mr tom de swaan committee meets three times year review policies progress cr principles committee reviews performance five cr principles annually access medicines standards ethical conduct research innovation employment practices community investment principles discussed least every two years committee reports findings board management corporate responsibility crc reviewed gsks activity number areas including pandemic 'flu including access vaccine antiviral medicines developing countries access pricing medicines developing countries rd diseases developing world patent pool community partnerships investment humanitarian donations sales marketing practices including harmonisation gsk codes practice disclosure payments healthcare professionals communication clinical trial results use animals research employment practices including diversity inclusion employee wellbeing employee relations including consultation arrangements employment litigation us supply chain management climate change energy use reduction manufacturing efficiency data privacy corruption prevention committee also reviews signs annual performance information published website annual cr highlights document augment engagement stakeholder opinion march sophia tickell appointed independent external advisor corporate responsibility committee sophia director pharma futures series aims better align societal shareholder value chairs international advisory group medicines transparency alliance sophia extensive experience constructively challenging companies increase understanding societal expectations develop strategies meet gained experience work journalist latin america work international development advocacy work oxfam recently role director sustainability think tank consultancy sustainability issues sophia attends meetings corporate responsibility committee advises company capacity corporate responsibility risks risk oversight compliance council rocc coordinates management significant business risks rocc also considers reputational corporate responsibility risks read risk management management structure cr covers diverse range issues gsk believe managed within business functions relevant subject experts work crossfunctional team made representatives key business areas oversees development implementation communication policies including responsibility elements across gsk members senior managers direct access corporate executive team small central cr team coordinate policy development reporting specifically respect cr communicate socially responsible investors stakeholders sustainability council senior executives across business meets via teleconference four times year oversee gsks environmental sustainability plans progress measuring performance established metrics key performance indicators track performance responsibility issues may mr james murdoch joined committee mr tom de swaan ceased member committee sir ian prosser retired board back top home responsibility corporate responsibility gsk audit assurance corporate responsibility report audit assurance many aspects responsibility performance monitored internal external assurance processes gsks internal audit group responsibility independently assessing compliance laws regulations company standards adequacy effectiveness management significant risk areas reporting audit risk committee gsk employs approximately fulltime internal auditors audits range duration two weeks simple activities scope limited several months audit involving complex highly technical processes audit teams may supplemented external experts specific technical skills use guest auditors within businesses issues control deficiencies identified audit team recommend improvements gsk managers develop corrective preventative action plans eliminate causes noncompliance gaps internal controls audit assurance department see track plans completion report results senior management audit risk committee explain improvements made internal audit processes outline external assurance processes report strengthening internal audit assurance reviewed strengthened internal audit processes line industry best practice audit assurance department created improve consistency oversight across business objectives develop manage gsk assurance programme align audit activity key business risks improve efficiency effectiveness internal audit activity previously many audit activities managed within business units new structure promotes greater independence audit activities provides holistic view risks managed across company direct reporting line audit risk committee helps ensure significant issues escalated timely manner four internal audit groups environment health safety sustainability internal audit ehss ia group internal audit gia manufacturing internal audit mia research development internal audit rd ia strategic risk evaluations strategic risk evaluation sre approach new way providing assurance enabling effective risk management gsk sres conducted partnership assurance teams business units aim quantify risks develop appropriate mitigation strategies launched quickly without schedule routine audit process therefore suitable newly identified risks circumstances existing risk suddenly becomes significant due changes business strategy external environment read assurance internal audit risk management corporate governance section annual report external assurance cr report information provide environment health safety activities gsk externally assured sgs independent external assurer assurance process includes verification key environment health safety data site visits telephone calls ehs professionals review systems processes collecting collating analysing interpreting data read assurance statement sgs assure one section cr report every year year bureau veritas provided assurance ethical conduct section report cr report information access medicines externally assured read responded recommendations made assurers access medicines section cr report back tophome responsibility corporate responsibility gsk audit assurance corporate responsibility report audit assurance many aspects responsibility performance monitored internal external assurance processes gsks internal audit group responsibility independently assessing compliance laws regulations company standards adequacy effectiveness management significant risk areas reporting audit risk committee gsk employs approximately fulltime internal auditors audits range duration two weeks simple activities scope limited several months audit involving complex highly technical processes audit teams may supplemented external experts specific technical skills use guest auditors within businesses issues control deficiencies identified audit team recommend improvements gsk managers develop corrective preventative action plans eliminate causes noncompliance gaps internal controls audit assurance department see track plans completion report results senior management audit risk committee explain improvements made internal audit processes outline external assurance processes report strengthening internal audit assurance reviewed strengthened internal audit processes line industry best practice audit assurance department created improve consistency oversight across business objectives develop manage gsk assurance programme align audit activity key business risks improve efficiency effectiveness internal audit activity previously many audit activities managed within business units new structure promotes greater independence audit activities provides holistic view risks managed across company direct reporting line audit risk committee helps ensure significant issues escalated timely manner four internal audit groups environment health safety sustainability internal audit ehss ia group internal audit gia manufacturing internal audit mia research development internal audit rd ia strategic risk evaluations strategic risk evaluation sre approach new way providing assurance enabling effective risk management gsk sres conducted partnership assurance teams business units aim quantify risks develop appropriate mitigation strategies launched quickly without schedule routine audit process therefore suitable newly identified risks circumstances existing risk suddenly becomes significant due changes business strategy external environment read assurance internal audit risk management corporate governance section annual report external assurance cr report information provide environment health safety activities gsk externally assured sgs independent external assurer assurance process includes verification key environment health safety data site visits telephone calls ehs professionals review systems processes collecting collating analysing interpreting data read assurance statement sgs assure one section cr report every year year bureau veritas provided assurance ethical conduct section report cr report information access medicines externally assured read responded recommendations made assurers access medicines section cr report back top home responsibility corporate responsibility gsk audit assurance corporate responsibility report audit assurance many aspects responsibility performance monitored internal external assurance processes gsks internal audit group responsibility independently assessing compliance laws regulations company standards adequacy effectiveness management significant risk areas reporting audit risk committee gsk employs approximately fulltime internal auditors audits range duration two weeks simple activities scope limited several months audit involving complex highly technical processes audit teams may supplemented external experts specific technical skills use guest auditors within businesses issues control deficiencies identified audit team recommend improvements gsk managers develop corrective preventative action plans eliminate causes noncompliance gaps internal controls audit assurance department see track plans completion report results senior management audit risk committee explain improvements made internal audit processes outline external assurance processes report strengthening internal audit assurance reviewed strengthened internal audit processes line industry best practice audit assurance department created improve consistency oversight across business objectives develop manage gsk assurance programme align audit activity key business risks improve efficiency effectiveness internal audit activity previously many audit activities managed within business units new structure promotes greater independence audit activities provides holistic view risks managed across company direct reporting line audit risk committee helps ensure significant issues escalated timely manner four internal audit groups environment health safety sustainability internal audit ehss ia group internal audit gia manufacturing internal audit mia research development internal audit rd ia strategic risk evaluations strategic risk evaluation sre approach new way providing assurance enabling effective risk management gsk sres conducted partnership assurance teams business units aim quantify risks develop appropriate mitigation strategies launched quickly without schedule routine audit process therefore suitable newly identified risks circumstances existing risk suddenly becomes significant due changes business strategy external environment read assurance internal audit risk management corporate governance section annual report external assurance cr report information provide environment health safety activities gsk externally assured sgs independent external assurer assurance process includes verification key environment health safety data site visits telephone calls ehs professionals review systems processes collecting collating analysing interpreting data read assurance statement sgs assure one section cr report every year year bureau veritas provided assurance ethical conduct section report cr report information access medicines externally assured read responded recommendations made assurers access medicines section cr report back top home responsibility corporate responsibility gsk risk management corporate responsibility report risk management nonfinancial reputational risks included core risk management processes risk oversight compliance council rocc coordinates management significant business risks rocc meets regularly review assess significant risks mitigation plans providing oversight internal controls ensure compliance applicable laws regulations internal gsk policies chaired gsks corporate compliance officer includes several corporate executive team cet members heads departments internal control risk management assurance audit compliance responsibilities continued strengthen risk management processes relaunched risk management legal compliance policy new policy provides clarity roles responsibilities people internal control framework cet members formally responsible establishing appropriate risk management structure within business unit identify mitigate significant risks business unit must review significant risks least year include identifying operational risks legal compliance risks risks achievement strategic goals objectives ensures significant risks connected changes management direction external environment identified business units corporate functions required present annually rocc audit risk committee detailing risk management compliance approach provide balanced assessment status internal controls key risks highlight significant compliance issues also changing way allocate audit resources ensure sufficient attention paid areas highest risk based recent annual cet risk workshop following significant risks facing gsk risk rd deliver commercially successful products patent infringement litigation potential changes intellectual property laws regulations weakness intellectual property protection certain countries risk substantial adverse outcome litigation government investigations product liability litigation antitrust litigation sales marketing regulation third party competition governmental payer controls regulatory controls risk interruption product supply risk concentration sales wholesalers global political economic conditions taxation treasury pandemic influenza environmental liabilities accounting standards failure third party providers protection electronic information assets alliances acquisitions attraction retention applying gsk 's strategic priorities risk factors section annual report details significant risks gsk alliances acquisitions due diligence acquired several new businesses line strategic priority grow diversified global business growth business must undermine commitment high quality ethical environmental workplace standards due diligence integral due diligence processes designed identify risks posed new business acquisitions including ethical social environmental risks due diligence usually managed relevant manager corporate development department conjunction regional business development managers oversight provided head corporate development chief strategy officer depending nature deal technical scientific experts may also involved working improve skills involved due diligence processes share good practices across business back tophome responsibility corporate responsibility gsk risk management corporate responsibility report risk management nonfinancial reputational risks included core risk management processes risk oversight compliance council rocc coordinates management significant business risks rocc meets regularly review assess significant risks mitigation plans providing oversight internal controls ensure compliance applicable laws regulations internal gsk policies chaired gsks corporate compliance officer includes several corporate executive team cet members heads departments internal control risk management assurance audit compliance responsibilities continued strengthen risk management processes relaunched risk management legal compliance policy new policy provides clarity roles responsibilities people internal control framework cet members formally responsible establishing appropriate risk management structure within business unit identify mitigate significant risks business unit must review significant risks least year include identifying operational risks legal compliance risks risks achievement strategic goals objectives ensures significant risks connected changes management direction external environment identified business units corporate functions required present annually rocc audit risk committee detailing risk management compliance approach provide balanced assessment status internal controls key risks highlight significant compliance issues also changing way allocate audit resources ensure sufficient attention paid areas highest risk based recent annual cet risk workshop following significant risks facing gsk risk rd deliver commercially successful products patent infringement litigation potential changes intellectual property laws regulations weakness intellectual property protection certain countries risk substantial adverse outcome litigation government investigations product liability litigation antitrust litigation sales marketing regulation third party competition governmental payer controls regulatory controls risk interruption product supply risk concentration sales wholesalers global political economic conditions taxation treasury pandemic influenza environmental liabilities accounting standards failure third party providers protection electronic information assets alliances acquisitions attraction retention applying gsk 's strategic priorities risk factors section annual report details significant risks gsk alliances acquisitions due diligence acquired several new businesses line strategic priority grow diversified global business growth business must undermine commitment high quality ethical environmental workplace standards due diligence integral due diligence processes designed identify risks posed new business acquisitions including ethical social environmental risks due diligence usually managed relevant manager corporate development department conjunction regional business development managers oversight provided head corporate development chief strategy officer depending nature deal technical scientific experts may also involved working improve skills involved due diligence processes share good practices across business back top home responsibility corporate responsibility gsk risk management corporate responsibility report risk management nonfinancial reputational risks included core risk management processes risk oversight compliance council rocc coordinates management significant business risks rocc meets regularly review assess significant risks mitigation plans providing oversight internal controls ensure compliance applicable laws regulations internal gsk policies chaired gsks corporate compliance officer includes several corporate executive team cet members heads departments internal control risk management assurance audit compliance responsibilities continued strengthen risk management processes relaunched risk management legal compliance policy new policy provides clarity roles responsibilities people internal control framework cet members formally responsible establishing appropriate risk management structure within business unit identify mitigate significant risks business unit must review significant risks least year include identifying operational risks legal compliance risks risks achievement strategic goals objectives ensures significant risks connected changes management direction external environment identified business units corporate functions required present annually rocc audit risk committee detailing risk management compliance approach provide balanced assessment status internal controls key risks highlight significant compliance issues also changing way allocate audit resources ensure sufficient attention paid areas highest risk based recent annual cet risk workshop following significant risks facing gsk risk rd deliver commercially successful products patent infringement litigation potential changes intellectual property laws regulations weakness intellectual property protection certain countries risk substantial adverse outcome litigation government investigations product liability litigation antitrust litigation sales marketing regulation third party competition governmental payer controls regulatory controls risk interruption product supply risk concentration sales wholesalers global political economic conditions taxation treasury pandemic influenza environmental liabilities accounting standards failure third party providers protection electronic information assets alliances acquisitions attraction retention applying gsk 's strategic priorities risk factors section annual report details significant risks gsk alliances acquisitions due diligence acquired several new businesses line strategic priority grow diversified global business growth business must undermine commitment high quality ethical environmental workplace standards due diligence integral due diligence processes designed identify risks posed new business acquisitions including ethical social environmental risks due diligence usually managed relevant manager corporate development department conjunction regional business development managers oversight provided head corporate development chief strategy officer depending nature deal technical scientific experts may also involved working improve skills involved due diligence processes share good practices across business back top home responsibility corporate responsibility gsk stakeholder engagement corporate responsibility report stakeholder engagement stakeholder engagement dialogue enables us keep touch views opinions societies operate helps us identify important issues shape responses interest shareholders wider society regular engagement means better informed emerging current issues changing societal expectations provides opportunity us voice approach responsibility issues obtain important feedback build trust discussion takes place normal course business example scientists regularly meet academics researchers pharmaceutical companies advisory boards medical conferences describe engage stakeholders give examples engagement stakeholder group provide information responding feedback receive find examples engagement stakeholders throughout website provided training year help managers markets communicate local stakeholders approach responsible business transparency contact welcome feedback information contained report please contact us corporate responsibility glaxosmithkline plc great west road brentford middlesex tw gs united kingdom csrcontactgskcom back top home responsibility corporate responsibility gsk stakeholder engagement corporate responsibility report stakeholder engagement stakeholder engagement dialogue enables us keep touch views opinions societies operate helps us identify important issues shape responses interest shareholders wider society regular engagement means better informed emerging current issues changing societal expectations provides opportunity us voice approach responsibility issues obtain important feedback build trust discussion takes place normal course business example scientists regularly meet academics researchers pharmaceutical companies advisory boards medical conferences describe engage stakeholders give examples engagement stakeholder group provide information responding feedback receive find examples engagement stakeholders throughout website provided training year help managers markets communicate local stakeholders approach responsible business transparency contact welcome feedback information contained report please contact us corporate responsibility glaxosmithkline plc great west road brentford middlesex tw gs united kingdom csrcontactgskcom back top home responsibility corporate responsibility gsk stakeholder engagement engage corporate responsibility report engage healthcare professionals engage healthcare professionals many ways including sales representatives running clinical trials read research ethics policies governing relationships healthcare professionals patients gsk researchers scientists meet patients part focus patient initiative engagement influences understanding diseases research priorities read focus patient also support work patient advocacy groups conduct market research via third parties understand patient needs governments regulators engage debate legislation seek influence policy decisions affect gsk also engage governments responsibilityrelated issues healthcare providers engage healthcare providers government affairs marketing access medicines activities investors meet regularly investors socially responsible investors read investor engagement activities employees seek feedback employees regular surveys also consult employees changes affect discuss business developments regional national consultation forums local communities interactions local communities managed individual gsk sites read financial practical support communities multilateral agencies engage multilateral agencies access public health initiatives nongovernmental organisations ngos engage international local ngos access education public health programmes part public policy work also engage regularly animal welfare organisations read animal research gsk scientific community academic partnerships important gsk part scientific debates involved number academic collaborations suppliers hold global regional supplier review meetings senior gsk managers address interact suppliers key issues read engagement suppliers peer companies engage peer companies membership pharmaceutical industry organisations example efpia phrma ifpma collaboration specific projects back tophome responsibility corporate responsibility gsk stakeholder engagement engage corporate responsibility report engage healthcare professionals engage healthcare professionals many ways including sales representatives running clinical trials read research ethics policies governing relationships healthcare professionals patients gsk researchers scientists meet patients part focus patient initiative engagement influences understanding diseases research priorities read focus patient also support work patient advocacy groups conduct market research via third parties understand patient needs governments regulators engage debate legislation seek influence policy decisions affect gsk also engage governments responsibilityrelated issues healthcare providers engage healthcare providers government affairs marketing access medicines activities investors meet regularly investors socially responsible investors read investor engagement activities employees seek feedback employees regular surveys also consult employees changes affect discuss business developments regional national consultation forums local communities interactions local communities managed individual gsk sites read financial practical support communities multilateral agencies engage multilateral agencies access public health initiatives nongovernmental organisations ngos engage international local ngos access education public health programmes part public policy work also engage regularly animal welfare organisations read animal research gsk scientific community academic partnerships important gsk part scientific debates involved number academic collaborations suppliers hold global regional supplier review meetings senior gsk managers address interact suppliers key issues read engagement suppliers peer companies engage peer companies membership pharmaceutical industry organisations example efpia phrma ifpma collaboration specific projects back top home responsibility corporate responsibility gsk stakeholder engagement engage corporate responsibility report engage healthcare professionals engage healthcare professionals many ways including sales representatives running clinical trials read research ethics policies governing relationships healthcare professionals patients gsk researchers scientists meet patients part focus patient initiative engagement influences understanding diseases research priorities read focus patient also support work patient advocacy groups conduct market research via third parties understand patient needs governments regulators engage debate legislation seek influence policy decisions affect gsk also engage governments responsibilityrelated issues healthcare providers engage healthcare providers government affairs marketing access medicines activities investors meet regularly investors socially responsible investors read investor engagement activities employees seek feedback employees regular surveys also consult employees changes affect discuss business developments regional national consultation forums local communities interactions local communities managed individual gsk sites read financial practical support communities multilateral agencies engage multilateral agencies access public health initiatives nongovernmental organisations ngos engage international local ngos access education public health programmes part public policy work also engage regularly animal welfare organisations read animal research gsk scientific community academic partnerships important gsk part scientific debates involved number academic collaborations suppliers hold global regional supplier review meetings senior gsk managers address interact suppliers key issues read engagement suppliers peer companies engage peer companies membership pharmaceutical industry organisations example efpia phrma ifpma collaboration specific projects back top home responsibility corporate responsibility gsk stakeholder engagement engagement employees corporate responsibility report engagement employees important employees know commitment corporate responsibility understand responsibilities keep uptodate progress read approach embedding ethical culture gsk keep employees informed corporate responsibility mygsk intranet site spirit internal quarterly magazine feature articles responsibility issues read engage employees environmental issues articles responsibility issues published spirit included articles launch viiv healthcare new commitments tackle hiv gsks approach pandemic flu community investment programmes range environmental initiatives year published four editions spirit distributing copies edition internally online version magazine available intranet offering access employees distributed corporate responsibility highlights spirit magazine directly corporate executive team gsk board senior managers site directors communications staff news articles icons intranet site used guide users directly cr report shorter cr highlights document directs people website raising awareness online cr report publicising website company intranet also ran employee cr survey sent randomly selected people across gsk employees across business took part answered questions range responsibility issues including awareness corporate responsibility issues consider important per cent heard term corporate responsibility per cent recognised employees accountable one areas corporate responsibility ethical business conduct access medicines health safety three areas identified employees important also areas employees believe company address complements regular employee surveys track employee views wider range issues back top home responsibility corporate responsibility gsk stakeholder engagement engagement employees corporate responsibility report engagement employees important employees know commitment corporate responsibility understand responsibilities keep uptodate progress read approach embedding ethical culture gsk keep employees informed corporate responsibility mygsk intranet site spirit internal quarterly magazine feature articles responsibility issues read engage employees environmental issues articles responsibility issues published spirit included articles launch viiv healthcare new commitments tackle hiv gsks approach pandemic flu community investment programmes range environmental initiatives year published four editions spirit distributing copies edition internally online version magazine available intranet offering access employees distributed corporate responsibility highlights spirit magazine directly corporate executive team gsk board senior managers site directors communications staff news articles icons intranet site used guide users directly cr report shorter cr highlights document directs people website raising awareness online cr report publicising website company intranet also ran employee cr survey sent randomly selected people across gsk employees across business took part answered questions range responsibility issues including awareness corporate responsibility issues consider important per cent heard term corporate responsibility per cent recognised employees accountable one areas corporate responsibility ethical business conduct access medicines health safety three areas identified employees important also areas employees believe company address complements regular employee surveys track employee views wider range issues back top home responsibility corporate responsibility gsk stakeholder engagement engagement investors corporate responsibility report engagement investors interactions investors socially responsible investment sri analysts throughout year wide variety responsibility issues sri analysts also attended briefings consumer healthcare business approach emerging markets part broader investor relations programme investor questions discussions responsibility issues raised investors concerned access medicines animal research clinical trial results disclosure clinical trials developing world employment practices including diversity health safety employee consultation talent attraction environmental issues including climate change nanotechnology packaging renewable raw materials water management ethical conduct including codes conduct antibribery corruption audit internal controls operations embargoed countries patient safety political contributions sales marketing practices stem cell research supply chain standards human rights also disclose information greenhouse gas emissions carbon disclosure project cdp back top home responsibility corporate responsibility gsk stakeholder engagement engagement investors corporate responsibility report engagement investors interactions investors socially responsible investment sri analysts throughout year wide variety responsibility issues sri analysts also attended briefings consumer healthcare business approach emerging markets part broader investor relations programme investor questions discussions responsibility issues raised investors concerned access medicines animal research clinical trial results disclosure clinical trials developing world employment practices including diversity health safety employee consultation talent attraction environmental issues including climate change nanotechnology packaging renewable raw materials water management ethical conduct including codes conduct antibribery corruption audit internal controls operations embargoed countries patient safety political contributions sales marketing practices stem cell research supply chain standards human rights also disclose information greenhouse gas emissions carbon disclosure project cdp back top home responsibility corporate responsibility gsk stakeholder engagement engagement stakeholders corporate responsibility report engagement stakeholders engagement access medicines engagement issues relating access medicines described access medicines section report includes workshop experts access medicines get feedback new initiatives least developed countries gsk previously conducted three formal stakeholder discussions get feedback approach different issues relating access medicines information discussions found access medicines section cr report engagement ehss many sites engage stakeholders locally activities open days newsletters community projects read environment health safety stakeholder panel uk provided independent feedback companywide performance since ipsos mori survey gsk participated ipsos mori survey rates companies according cr experts ngos perception cr performance two thirds people surveyed thought gsk took responsibilities seriously gsk fifthhighest rated company question companies back top home responsibility corporate responsibility gsk stakeholder engagement engagement stakeholders corporate responsibility report engagement stakeholders engagement access medicines engagement issues relating access medicines described access medicines section report includes workshop experts access medicines get feedback new initiatives least developed countries gsk previously conducted three formal stakeholder discussions get feedback approach different issues relating access medicines information discussions found access medicines section cr report engagement ehss many sites engage stakeholders locally activities open days newsletters community projects read environment health safety stakeholder panel uk provided independent feedback companywide performance since ipsos mori survey gsk participated ipsos mori survey rates companies according cr experts ngos perception cr performance two thirds people surveyed thought gsk took responsibilities seriously gsk fifthhighest rated company question companies back top home responsibility corporate responsibility gsk benchmarking corporate responsibility report benchmarking gsk received following ratings benchmarking organisations number awards relating corporate responsibility indexes organisation access medicines index access medicines foundation innovest strategic value advisers gsk ranked top access medicines index rated companies performance according eight criteria management influence research development patenting capacity pricing drug donations philanthropy publication next access medicines index expected mid organisation dow jones sustainability index rating gsk continued member dow jones sustainability index covers top ten per cent sustainable companies sector gsk awarded bronze class distinction survey published organisation ftsegood rating gsk included ftsegood index benchmarks companies corporate responsibility parameters including environmental sustainability stakeholder relationships human rights supply chain labour standards business ethics organisation business community communitymark rating gsk one companies manufacturing company awarded new communitymark following independent assessment outstanding community investment mark endorsed uk government voluntary sector leaders given work local national level uk well larger international programmes companies awarded mark three year period monitored ensure continued commitment excellence gsk retained communitymark awards relating corporate responsibility scrip corporate social responsibility award received gsks efforts increase access medicines developing world first award responsible capitalism presented andrew witty award honours bupsaingee ss f leaders consistently demonstrated social responsibility integral part commercial success healthright international health human rights award presented gsk extraordinary leadership cause health human rights management today uk admired company awards gsk rated fifth overall rated top ability attract develop retain talent financial soundness assessment made industry peers reporting organisation sustainability global reporters benchmark rating report scored per cent improvement seven per cent report average per cent pharmaceutical companies benchmarked sustainability strengths identified included clear articulation material issues gsk impacts alignment responsibility activities business strategy consideration corporate responsibility core management processes areas suggested improvement included development metrics targets back tophome responsibility corporate responsibility gsk benchmarking corporate responsibility report benchmarking gsk received following ratings benchmarking organisations number awards relating corporate responsibility indexes organisation access medicines index access medicines foundation innovest strategic value advisers gsk ranked top access medicines index rated companies performance according eight criteria management influence research development patenting capacity pricing drug donations philanthropy publication next access medicines index expected mid organisation dow jones sustainability index rating gsk continued member dow jones sustainability index covers top ten per cent sustainable companies sector gsk awarded bronze class distinction survey published organisation ftsegood rating gsk included ftsegood index benchmarks companies corporate responsibility parameters including environmental sustainability stakeholder relationships human rights supply chain labour standards business ethics organisation business community communitymark rating gsk one companies manufacturing company awarded new communitymark following independent assessment outstanding community investment mark endorsed uk government voluntary sector leaders given work local national level uk well larger international programmes companies awarded mark three year period monitored ensure continued commitment excellence gsk retained communitymark awards relating corporate responsibility scrip corporate social responsibility award received gsks efforts increase access medicines developing world first award responsible capitalism presented andrew witty award honours business leaders consistently demonstrated social responsibility integral part commercial success healthright international health human rights award presented gsk extraordinary leadership cause health human rights management today uk admired company awards gsk rated fifth overall rated top ability attract develop retain talent financial soundness assessment made industry peers reporting organisation sustainability global reporters benchmark rating report scored per cent improvement seven per cent report average per cent pharmaceutical companies benchmarked sustainability strengths identified included clear articulation material issues gsk impacts alignment responsibility activities business strategy consideration corporate responsibility core management processes areas suggested improvement included development metrics targets back top home responsibility corporate responsibility gsk benchmarking corporate responsibility report benchmarking gsk received following ratings benchmarking organisations number awards relating corporate responsibility indexes organisation access medicines index access medicines foundation innovest strategic value advisers gsk ranked top access medicines index rated companies performance according eight criteria management influence research development patenting capacity pricing drug donations philanthropy publication next access medicines index expected mid organisation dow jones sustainability index rating gsk continued member dow jones sustainability index covers top ten per cent sustainable companies sector gsk awarded bronze class distinction survey published organisation ftsegood rating gsk included ftsegood index benchmarks companies corporate responsibility parameters including environmental sustainability stakeholder relationships human rights supply chain labour standards business ethics organisation business community communitymark rating gsk one companies manufacturing company awarded new communitymark following independent assessment outstanding community investment mark endorsed uk government voluntary sector leaders given work local national level uk well larger international programmes companies awarded mark three year period monitored ensure continued commitment excellence gsk retained communitymark awards relating corporate responsibility scrip corporate social responsibility award received gsks efforts increase access medicines developing world first award responsible capitalism presented andrew witty award honours business leaders consistently demonstrated social responsibility integral part commercial success healthright international health human rights award presented gsk extraordinary leadership cause health human rights management today uk admired company awards gsk rated fifth overall rated top ability attract develop retain talent financial soundness assessment made industry peers reporting organisation sustainability global reporters benchmark rating report scored per cent improvement seven per cent report average per cent pharmaceutical companies benchmarked sustainability strengths identified included clear articulation material issues gsk impacts alignment responsibility activities business strategy consideration corporate responsibility core management processes areas suggested improvement included development metrics targets back top home responsibility corporate responsibility gsk reporting corporate responsibility report reporting corporate responsibility report reflects commitment open transparent business activities report cr activities performance annually via website read use website selected performance information also downloaded building custom report year made overview available site help users understand breadth activities find relevant information report site map search function also added help users locate specific areas interest corporate responsibility highlights document available print provides details performance encourages readers find website data data relate worldwide operations calendar year except stated data environment health safety sections independently assured sgs ethical conduct section bureau veritas information approach external assurance provided audit assurance section brandnames appearing italics throughout report trademarks either owned andor licensed gsk associated companies reporting standards use external guidelines inform reporting relevant base report global reporting initiative gri guidelines produced gri index show elements guidelines covered report aid comparison company reports also joined un global compact provided index show reporting line global compact expectations back top home responsibility corporate responsibility gsk reporting corporate responsibility report reporting corporate responsibility report reflects commitment open transparent business activities report cr activities performance annually via website read use website selected performance information also downloaded building custom report year made overview available site help users understand breadth activities find relevant information report site map search function also added help users locate specific areas interest corporate responsibility highlights document available print provides details performance encourages readers find website data data relate worldwide operations calendar year except stated data environment health safety sections independently assured sgs ethical conduct section bureau veritas information approach external assurance provided audit assurance section brandnames appearing italics throughout report trademarks either owned andor licensed gsk associated companies reporting standards use external guidelines inform reporting relevant base report global reporting initiative gri guidelines produced gri index show elements guidelines covered report aid comparison company reports also joined un global compact provided index show reporting line global compact expectations back top home responsibility corporate responsibility gsk corporate responsibility data summary corporate responsibility report corporate responsibility data summary metric access medicines number combivir epivir tablets shipped millions number generic arvs supplied licence gsk millions gsk combivir notforprofit price per day voluntary licences granted generic manufacturers gsk arvs cumulative total value products donated gsk patient assistance program us millions cost wholesale price wac research development expenditure rd billions number trials published gsk clinical study register cumulative total ethical conduct number employees completing certification gsk code conduct number contacts ethics compliance channels employment women management grades ethnic diversity people colour us ethnic diversity ethnic minorities uk reportable injury illness rate per hours worked environment total climate change impact thousand tonnes co equivalent climate change impact energy operations transport climate change impact patient use inhalers energy operations transport million gigajoules water consumption million cubic metres wastewater chemical oxygen demand cod thousand tonnes nonhazardous waste disposed thousand tonnes hazardous waste disposed thousand tonnes volatile organic compound emissions thousand tonnes community investment total community investment expenditure millions cost wholesale price wac value humanitarian product donations including albendazole millions cost wholesale price wac number albendazole tablets donated prevention lymphatic filariasis millions includes freight delivery costs mdecins sans frontires pricing report lists average cost generic equivalents eight currently force reduction due one company granted voluntary licence ceasing trade restated figures reflect value cost average cost goods rather wholesale acquisition price wac second year valued donations way believe accurate reflection true cost gsk therefore transparent figures remain wac includes contacts line managers compliance officers confidential integrity helplines offsite post office box us climate change impact calculated co equivalent using greenhouse gas protocol developed world resources institute world business council sustainable development year review co factors update data years appropriate energy transport climate change impact patient use inhalers calculated prior back tophome responsibility corporate responsibility gsk corporate responsibility data summary corporate responsibility report corporate responsibility data summary metric access medicines number combivir epivir tablets shipped millions number generic arvs supplied licence gsk millions gsk combivir notforprofit price per day voluntary licences granted generic manufacturers gsk arvs cumulative total value products donated gsk patient assistance program us millions cost wholesale price wac research development expenditure rd billions number trials published gsk clinical study register cumulative total ethical conduct number employees completing certification gsk code conduct number contacts ethics compliance channels employment women management grades ethnic diversity people colour us ethnic diversity ethnic minorities uk reportable injury illness rate per hours worked environment total climate change impact thousand tonnes co equivalent climate change impact energy operations transport climate change impact patient use inhalers energy operations transport million gigajoules water consumption million cubic metres wastewater chemical oxygen demand cod thousand tonnes nonhazardous waste disposed thousand tonnes hazardous waste disposed thousand tonnes volatile organic compound emissions thousand tonnes community investment total community investment expenditure millions cost wholesale price wac value humanitarian product donations including albendazole millions cost wholesale price wac number albendazole tablets donated prevention lymphatic filariasis millions includes freight delivery costs mdecins sans frontires pricing report lists average cost generic equivalents eight currently force reduction due one company granted voluntary licence ceasing trade restated figures reflect value cost average cost goods rather wholesale acquisition price wac second year valued donations way believe accurate reflection true cost gsk therefore transparent figures remain wac includes contacts line managers compliance officers confidential integrity helplines offsite post office box us climate change impact calculated co equivalent using greenhouse gas protocol developed world resources institute world business council sustainable development year review co factors update data years appropriate energy transport climate change impact patient use inhalers calculated prior back top home responsibility corporate responsibility gsk corporate responsibility data summary corporate responsibility report corporate responsibility data summary metric access medicines number combivir epivir tablets shipped millions number generic arvs supplied licence gsk millions gsk combivir notforprofit price per day voluntary licences granted generic manufacturers gsk arvs cumulative total value products donated gsk patient assistance program us millions cost wholesale price wac research development expenditure rd billions number trials published gsk clinical study register cumulative total ethical conduct number employees completing certification gsk code conduct number contacts ethics compliance channels employment women management grades ethnic diversity people colour us ethnic diversity ethnic minorities uk reportable injury illness rate per hours worked environment total climate change impact thousand tonnes co equivalent climate change impact energy operations transport climate change impact patient use inhalers energy operations transport million gigajoules water consumption million cubic metres wastewater chemical oxygen demand cod thousand tonnes nonhazardous waste disposed thousand tonnes hazardous waste disposed thousand tonnes volatile organic compound emissions thousand tonnes community investment total community investment expenditure millions cost wholesale price wac value humanitarian product donations including albendazole millions cost wholesale price wac number albendazole tablets donated prevention lymphatic filariasis millions includes freight delivery costs mdecins sans frontires pricing report lists average cost generic equivalents eight currently force reduction due one company granted voluntary licence ceasing trade restated figures reflect value cost average cost goods rather wholesale acquisition price wac second year valued donations way believe accurate reflection true cost gsk therefore transparent figures remain wac includes contacts line managers compliance officers confidential integrity helplines offsite post office box us climate change impact calculated co equivalent using greenhouse gas protocol developed world resources institute world business council sustainable development year review co factors update data years appropriate energy transport climate change impact patient use inhalers calculated prior back top home responsibility contribution global health corporate responsibility report contribution global health medicines vaccines consumer healthcare products make real difference patients lives committed maximising contribution health researching new treatments address needs patients healthcare payers making products widely available possible heart responsibility means gsk central commercial success make contribution four key areas preventing disease gsk leading producer vaccines used developed developing countries also prevent disease community investment overthecounter products disease awareness work patient groups run campaigns raise awareness disease treating ill health many products treat diseases place high burden society investing rd pipeline includes new medicines vaccines needed developing developed countries partnering others accelerate development new treatments responding pandemic flu products partnerships help treat prevent contribution limited products accessible affordable committed increasing access medicines vaccines countries read access medicines also support healthcare community investment cost disease ill health expensive individual society often result poverty also important cause poverty patients mean loss quality life loss earnings shortened life expectancy place great burden families instance need care sick relatives reduce attendance school work governments employers taxpayers mean increased healthcare costs loss workforce productivity africa parts asia aids serious effect social economic development undermining progress towards millennium development goals poverty reduction efforts world bank estimates deaths working age adults hivaids may subtract one per cent year gdp economic growth subsaharan african countries south africa hivaids may depress gdp much per cent next decade malaria estimated cost african nations least billion year lost economic output economic cost tbrelated deaths including hiv coinfection subsaharan africa estimated billion read research diseases developing world efforts help people countries access essential medicines vaccines according us governments centers disease control prevention cdc costs chronic disease us alone include billion year direct indirect costs due diabetes billion annual medical care costs arthritis total costs including medical care lost productivity almost billion billion projected cost heart disease stroke read working partnership us combat chronic disease role vaccines preventing disease wwwwhointtradeglossarystoryenindexhtml rollback malaria httprbmwhointglobaladvocacyprhtml httpwwwwhointmediacentrenewsreleasesprenindexhtml wwwcdcgovnccdphpoverviewhtm back tophome responsibility contribution global health corporate responsibility report contribution global health medicines vaccines consumer healthcare products make real difference patients lives committed maximising contribution health researching new treatments address needs patients healthcare payers making products widely available possible heart responsibility means gsk central commercial success make contribution four key areas preventing disease gsk leading producer vaccines used developed developing countries also prevent disease community investment overthecounter products disease awareness work patient groups run campaigns raise awareness disease treating ill health many products treat diseases place high burden society investing rd pipeline includes new medicines vaccines needed developing developed countries partnering others accelerate development new treatments responding pandemic flu products partnerships help treat prevent contribution limited products accessible affordable committed increasing access medicines vaccines countries read access medicines also support healthcare community investment cost disease ill health expensive individual society often result poverty also important cause poverty patients mean loss quality life loss earnings shortened life expectancy place great burden families instance need care sick relatives reduce attendance school work governments employers taxpayers mean increased healthcare costs loss workforce productivity africa parts asia aids serious effect social economic development undermining progress towards millennium development goals poverty reduction efforts world bank estimates deaths working age adults hivaids may subtract one per cent year gdp economic growth subsaharan african countries south africa hivaids may depress gdp much per cent next decade malaria estimated cost african nations least billion year lost economic output economic cost tbrelated deaths including hiv coinfection subsaharan africa estimated billion read research diseases developing world efforts help people countries access essential medicines vaccines according us governments centers disease control prevention cdc costs chronic disease us alone include billion year direct indirect costs due diabetes billion annual medical care costs arthritis total costs including medical care lost productivity almost billion billion projected cost heart disease stroke read working partnership us combat chronic disease role vaccines preventing disease wwwwhointtradeglossarystoryenindexhtml rollback malaria httprbmwhointglobaladvocacyprhtml httpwwwwhointmediacentrenewsreleasesprenindexhtml wwwcdcgovnccdphpoverviewhtm back top home responsibility contribution global health corporate responsibility report contribution global health medicines vaccines consumer healthcare products make real difference patients lives committed maximising contribution health researching new treatments address needs patients healthcare payers making products widely available possible heart responsibility means gsk central commercial success make contribution four key areas preventing disease gsk leading producer vaccines used developed developing countries also prevent disease community investment overthecounter products disease awareness work patient groups run campaigns raise awareness disease treating ill health many products treat diseases place high burden society investing rd pipeline includes new medicines vaccines needed developing developed countries partnering others accelerate development new treatments responding pandemic flu products partnerships help treat prevent contribution limited products accessible affordable committed increasing access medicines vaccines countries read access medicines also support healthcare community investment cost disease ill health expensive individual society often result poverty also important cause poverty patients mean loss quality life loss earnings shortened life expectancy place great burden families instance need care sick relatives reduce attendance school work governments employers taxpayers mean increased healthcare costs loss workforce productivity africa parts asia aids serious effect social economic development undermining progress towards millennium development goals poverty reduction efforts world bank estimates deaths working age adults hivaids may subtract one per cent year gdp economic growth subsaharan african countries south africa hivaids may depress gdp much per cent next decade malaria estimated cost african nations least billion year lost economic output economic cost tbrelated deaths including hiv coinfection subsaharan africa estimated billion read research diseases developing world efforts help people countries access essential medicines vaccines according us governments centers disease control prevention cdc costs chronic disease us alone include billion year direct indirect costs due diabetes billion annual medical care costs arthritis total costs including medical care lost productivity almost billion billion projected cost heart disease stroke read working partnership us combat chronic disease role vaccines preventing disease wwwwhointtradeglossarystoryenindexhtml rollback malaria httprbmwhointglobaladvocacyprhtml httpwwwwhointmediacentrenewsreleasesprenindexhtml wwwcdcgovnccdphpoverviewhtm back top home responsibility contribution global health responding pandemic flu corporate responsibility report responding pandemic flu updated september world health organization declared outbreak pandemic flu june gsk responded rapidly meet needs governments health authorities response made possible investment decade research development manufacturing capacity flu vaccines antiviral medicines pandemics highly unpredictable fortunately terms populationlevel impacts hn pandemic flu serious initially feared although greater impact groups including pregnant women young people certain chronic health conditions result relatively moderate nature pandemic government health authority demands pandemic flu vaccines antiviral medicines fallen gsk recognises governments needs plans evolved understanding hn pandemic increased committed working find fair solutions gsk hn vaccine supply additionally reviewing pandemic response identify provide flexible offering future pandemics minimising risk business hn pandemic update august emergency committee reassessed epidemiological virological situation hn pandemic assessment emergency committee concluded levels patterns hn transmission seen differ significantly observed pandemic based recent observations evidence strong recent flu pandemic patterns transitioning towards seasonal patterns flu products launched pandemic response measures soon declared hn outbreak pandemic accordance classification system gsk products available governments support public health needs protecting population pandemic flu include hn pandemic vaccines pandemrix arepanrix relenza flu antiviral medicine meet potential increased demand products invested approximately us billion previous years increase manufacturing existing sites establish new manufacturing lines also accelerated production antibiotics used treat secondary bacterial infections associated flu vaccines immediately receiving hn pandemic virus strain early june began complex process developing manufacturing vaccines manufacturing sites germany canada respectively help protect population vaccines consist hn flu antigen adjuvant person vaccinated antigen triggers immune response hn virus use adjuvant allowed less antigen used per dose vaccine enabling significantly doses vaccine produced limited period time fullscale vaccine production started july hn vaccines pandemrix antigen manufactured germany arepanrix similar vaccine antigen manufactured canada received first approvals use september october respectively since supplied million hn pandemic vaccine doses governments gsk committed highest standards patient safety hn vaccine safety data receive clinical trials vaccination programme usage continuously reviewed evaluated signals vaccine safety quality issues addition several years extensive safety efficacy testing candidate pandemic vaccines including adjuvant combined hn avian flu antigen hn pandemic flu vaccines evaluated clinical trials involving subjects including healthy adults elderly people children additionally several programs established evaluate safety vaccinated instance uk completed analysing post licensure study monitor safety vaccine used mass vaccination programme working collaboration medicines healthcare products regulatory agency mhra department health general practitioner research network gprn data clinical trials well independent safety evaluations several regulatory authorities including european medicines agency aug confirmed benefitrisk profile pandemic hn vaccines positive lerouxroels et al antigen sparing crossreactive immunity adjuvanted rhn prototype pandemic influenza vaccine randomised controlled trial lancet relenza relenza zanamivir antiviral medicine licensed treatment prevention influenza unprecedented demand relenza following hn outbreak distributed existing supplies equitably increased production three existing manufacturing sites established two production lines result annual production capacity relenza rose million treatment courses three times previous maximum output achieve level production introduced relenza rotacaps additional relenza presentation manufactured large quantities worked hard quickly obtain approval relenza rotacaps could reach full production capacity gsk worked regulatory authorities eu find appropriate mechanism allow governments purchase product appropriate pending local approval total supplied million doses relenza governments response specific requests physicians treating severely ill hospitalised patients flu supplied unlicensed formulation antiviral medicine clinical development requests typically treating patients licensed antiviral medicines either ineffective intravenous route administration required several clinicians subsequently wrote case reports experience using unlicensed treatment however efficacy safety remain unproven yet evaluated clinical trials actiprotect actiprotect singleuse disposable respirator face mask antiviral coating inactivates flu viruses gsk continues offer actiprotect governments identified need personal protective equipment part preparations future pandemic responding needs pilgrims hajj attending hajj onceinalifetime pilgrimage many muslims every year millions people journey mecca saudi arabia worship together world 's largest annual religious gathering hajj took place late november coinciding northern hemisphere flu season predicted surge pandemic flu cases raised risk hn pandemic virus might spread rapidly among pilgrims worship eat sleep close proximity potentially endangering health families communities returned home concerned possible spread virus saudi arabian government announced summer attendees must vaccinated hn pandemic virus arrival mecca gsk worked contractholding governments mainly europe find solution ensured highrisk group protected hn due time gsk immediately established plan ensure access vaccine many countries origin hajj pilgrims worked closely relevant governments obtain regulatory approval vaccine producing shipping required doses short period time also shipped consignment vaccine saudi arabia instead turning nonvaccinated people away border could offer option immunised upon arrival donations developing world many developing country governments limited resources available protect populations pandemics strongly endorse principles set bill melinda gates foundation help guide global allocation pandemic vaccines support message global community take steps necessary protect populations including without resources protect gsk committed facilitating access relenza pandemic flu vaccines countries operate tieredpricing policy products make relenza available notforprofit price least developed countries read approach improving access medicines november signed agreement donate million doses hn pandemic vaccine developing nations also made available two million treatment courses relenza donate use developing countries required ensure product availability developing countries allocated per cent hn vaccine production capacity canadian manufacturing site per cent relenza production capacity developing countries total hn vaccine donation shipments beginning january currently stands around million doses different countries remain committed working support developing countries event future pandemic reflecting lessons learned many governments national health organisations intergovernmental bodies conducting reviews response hn pandemic beginning plan future pandemics gsk reflecting lessons learned listening feedback governments partners using comments adapt improve pandemic response offering back tophome responsibility contribution global health responding pandemic flu corporate responsibility report responding pandemic flu updated september world health organization declared outbreak pandemic flu june gsk responded rapidly meet needs governments health authorities response made possible investment decade research development manufacturing capacity flu vaccines antiviral medicines pandemics highly unpredictable fortunately terms populationlevel impacts hn pandemic flu serious initially feared although greater impact groups including pregnant women young people certain chronic health conditions result relatively moderate nature pandemic government health authority demands pandemic flu vaccines antiviral medicines fallen gsk recognises governments needs plans evolved understanding hn pandemic increased committed working find fair solutions gsk hn vaccine supply additionally reviewing pandemic response identify provide flexible offering future pandemics minimising risk business hn pandemic update august emergency committee reassessed epidemiological virological situation hn pandemic assessment emergency committee concluded levels patterns hn transmission seen differ significantly observed pandemic based recent observations evidence strong recent flu pandemic patterns transitioning towards seasonal patterns flu products launched pandemic response measures soon declared hn outbreak pandemic accordance classification system gsk products available governments support public health needs protecting population pandemic flu include hn pandemic vaccines pandemrix arepanrix relenza flu antiviral medicine meet potential increased demand products invested approximately us billion previous years increase manufacturing existing sites establish new manufacturing lines also accelerated production antibiotics used treat secondary bacterial infections associated flu vaccines immediately receiving hn pandemic virus strain early june began complex process developing manufacturing vaccines manufacturing sites germany canada respectively help protect population vaccines consist hn flu antigen adjuvant person vaccinated antigen triggers immune response hn virus use adjuvant allowed less antigen used per dose vaccine enabling significantly doses vaccine produced limited period time fullscale vaccine production started july hn vaccines pandemrix antigen manufactured germany arepanrix similar vaccine antigen manufactured canada received first approvals use september october respectively since supplied million hn pandemic vaccine doses governments gsk committed highest standards patient safety hn vaccine safety data receive clinical trials vaccination programme usage continuously reviewed evaluated signals vaccine safety quality issues addition several years extensive safety efficacy testing candidate pandemic vaccines including adjuvant combined hn avian flu antigen hn pandemic flu vaccines evaluated clinical trials involving subjects including healthy adults elderly people children additionally several programs established evaluate safety vaccinated instance uk completed analysing post licensure study monitor safety vaccine used mass vaccination programme working collaboration medicines healthcare products regulatory agency mhra department health general practitioner research network gprn data clinical trials well independent safety evaluations several regulatory authorities including european medicines agency aug confirmed benefitrisk profile pandemic hn vaccines positive lerouxroels et al antigen sparing crossreactive immunity adjuvanted rhn prototype pandemic influenza vaccine randomised controlled trial lancet relenza relenza zanamivir antiviral medicine licensed treatment prevention influenza unprecedented demand relenza following hn outbreak distributed existing supplies equitably increased production three existing manufacturing sites established two production lines result annual production capacity relenza rose million treatment courses three times previous maximum output achieve level production introduced relenza rotacaps additional relenza presentation manufactured large quantities worked hard quickly obtain approval relenza rotacaps could reach full production capacity gsk worked regulatory authorities eu find appropriate mechanism allow governments purchase product appropriate pending local approval total supplied million doses relenza governments response specific requests physicians treating severely ill hospitalised patients flu supplied unlicensed formulation antiviral medicine clinical development requests typically treating patients licensed antiviral medicines either ineffective intravenous route administration required several clinicians subsequently wrote case reports experience using unlicensed treatment however efficacy safety remain unproven yet evaluated clinical trials actiprotect actiprotect singleuse disposable respirator face mask antiviral coating inactivates flu viruses gsk continues offer actiprotect governments identified need personal protective equipment part preparations future pandemic responding needs pilgrims hajj attending hajj onceinalifetime pilgrimage many muslims every year millions people journey mecca saudi arabia worship together world 's largest annual religious gathering hajj took place late november coinciding northern hemisphere flu season predicted surge pandemic flu cases raised risk hn pandemic virus might spread rapidly among pilgrims worship eat sleep close proximity potentially endangering health families communities returned home concerned possible spread virus saudi arabian government announced summer attendees must vaccinated hn pandemic virus arrival mecca gsk worked contractholding governments mainly europe find solution ensured highrisk group protected hn due time gsk immediately established plan ensure access vaccine many countries origin hajj pilgrims worked closely relevant governments obtain regulatory approval vaccine producing shipping required doses short period time also shipped consignment vaccine saudi arabia instead turning nonvaccinated people away border could offer option immunised upon arrival donations developing world many developing country governments limited resources available protect populations pandemics strongly endorse principles set bill melinda gates foundation help guide global allocation pandemic vaccines support message global community take steps necessary protect populations including without resources protect gsk committed facilitating access relenza pandemic flu vaccines countries operate tieredpricing policy products make relenza available notforprofit price least developed countries read approach improving access medicines november signed agreement donate million doses hn pandemic vaccine developing nations also made available two million treatment courses relenza donate use developing countries required ensure product availability developing countries allocated per cent hn vaccine production capacity canadian manufacturing site per cent relenza production capacity developing countries total hn vaccine donation shipments beginning january currently stands around million doses different countries remain committed working support developing countries event future pandemic reflecting lessons learned many governments national health organisations intergovernmental bodies conducting reviews response hn pandemic beginning plan future pandemics gsk reflecting lessons learned listening feedback governments partners using comments adapt improve pandemic response offering back tophome responsibility contribution global health responding pandemic flu corporate responsibility report responding pandemic flu updated september world health organization declared outbreak pandemic flu june gsk responded rapidly meet needs governments health authorities response made possible investment decade research development manufacturing capacity flu vaccines antiviral medicines pandemics highly unpredictable fortunately terms populationlevel impacts hn pandemic flu serious initially feared although greater impact groups including pregnant women young people certain chronic health conditions result relatively moderate nature pandemic government health authority demands pandemic flu vaccines antiviral medicines fallen gsk recognises governments needs plans evolved understanding hn pandemic increased committed working find fair solutions gsk hn vaccine supply additionally reviewing pandemic response identify provide flexible offering future pandemics minimising risk business hn pandemic update august emergency committee reassessed epidemiological virological situation hn pandemic assessment emergency committee concluded levels patterns hn transmission seen differ significantly observed pandemic based recent observations evidence strong recent flu pandemic patterns transitioning towards seasonal patterns flu products launched pandemic response measures soon declared hn outbreak pandemic accordance classification system gsk products available governments support public health needs protecting population pandemic flu include hn pandemic vaccines pandemrix arepanrix relenza flu antiviral medicine meet potential increased demand products invested approximately us billion previous years increase manufacturing existing sites establish new manufacturing lines also accelerated production antibiotics used treat secondary bacterial infections associated flu vaccines immediately receiving hn pandemic virus strain early june began complex process developing manufacturing vaccines manufacturing sites germany canada respectively help protect population vaccines consist hn flu antigen adjuvant person vaccinated antigen triggers immune response hn virus use adjuvant allowed less antigen used per dose vaccine enabling significantly doses vaccine produced limited period time fullscale vaccine production started july hn vaccines pandemrix antigen manufactured germany arepanrix similar vaccine antigen manufactured canada received first approvals use september october respectively since supplied million hn pandemic vaccine doses governments gsk committed highest standards patient safety hn vaccine safety data receive clinical trials vaccination programme usage continuously reviewed evaluated signals vaccine safety quality issues addition several years extensive safety efficacy testing candidate pandemic vaccines including adjuvant combined hn avian flu antigen hn pandemic flu vaccines evaluated clinical trials involving subjects including healthy adults elderly people children additionally several programs established evaluate safety vaccinated instance uk completed analysing post licensure study monitor safety vaccine used mass vaccination programme working collaboration medicines healthcare products regulatory agency mhra department health general practitioner research network gprn data clinical trials well independent safety evaluations several regulatory authorities including european medicines agency aug confirmed benefitrisk profile pandemic hn vaccines positive lerouxroels et al antigen sparing crossreactive immunity adjuvanted rhn prototype pandemic influenza vaccine randomised controlled trial lancet relenza relenza zanamivir antiviral medicine licensed treatment prevention influenza unprecedented demand relenza following hn outbreak distributed existing supplies equitably increased production three existing manufacturing sites established two production lines result annual production capacity relenza rose million treatment courses three times previous maximum output achieve level production introduced relenza rotacaps additional relenza presentation manufactured large quantities worked hard quickly obtain approval relenza rotacaps could reach full production capacity gsk worked regulatory authorities eu find appropriate mechanism allow governments purchase product appropriate pending local approval total supplied million doses relenza governments response specific requests physicians treating severely ill hospitalised patients flu supplied unlicensed formulation antiviral medicine clinical development requests typically treating patients licensed antiviral medicines either ineffective intravenous route administration required several clinicians subsequently wrote case reports experience using unlicensed treatment however efficacy safety remain unproven yet evaluated clinical trials actiprotect actiprotect singleuse disposable respirator face mask antiviral coating inactivates flu viruses gsk continues offer actiprotect governments identified need personal protective equipment part preparations future pandemic responding needs pilgrims hajj attending hajj onceinalifetime pilgrimage many muslims every year millions people journey mecca saudi arabia worship together world 's largest annual religious gathering hajj took place late november coinciding northern hemisphere flu season predicted surge pandemic flu cases raised risk hn pandemic virus might spread rapidly among pilgrims worship eat sleep close proximity potentially endangering health families communities returned home concerned possible spread virus saudi arabian government announced summer attendees must vaccinated hn pandemic virus arrival mecca gsk worked contractholding governments mainly europe find solution ensured highrisk group protected hn due time gsk immediately established plan ensure access vaccine many countries origin hajj pilgrims worked closely relevant governments obtain regulatory approval vaccine producing shipping required doses short period time also shipped consignment vaccine saudi arabia instead turning nonvaccinated people away border could offer option immunised upon arrival donations developing world many developing country governments limited resources available protect populations pandemics strongly endorse principles set bill melinda gates foundation help guide global allocation pandemic vaccines support message global community take steps necessary protect populations including without resources protect gsk committed facilitating access relenza pandemic flu vaccines countries operate tieredpricing policy products make relenza available notforprofit price least developed countries read approach improving access medicines november signed agreement donate million doses hn pandemic vaccine developing nations also made available two million treatment courses relenza donate use developing countries required ensure product availability developing countries allocated per cent hn vaccine production capacity canadian manufacturing site per cent relenza production capacity developing countries total hn vaccine donation shipments beginning january currently stands around million doses different countries remain committed working support developing countries event future pandemic reflecting lessons learned many governments national health organisations intergovernmental bodies conducting reviews response hn pandemic beginning plan future pandemics gsk reflecting lessons learned listening feedback governments partners using comments adapt improve pandemic response offering back top home responsibility contribution global health responding pandemic flu corporate responsibility report responding pandemic flu updated september world health organization declared outbreak pandemic flu june gsk responded rapidly meet needs governments health authorities response made possible investment decade research development manufacturing capacity flu vaccines antiviral medicines pandemics highly unpredictable fortunately terms populationlevel impacts hn pandemic flu serious initially feared although greater impact groups including pregnant women young people certain chronic health conditions result relatively moderate nature pandemic government health authority demands pandemic flu vaccines antiviral medicines fallen gsk recognises governments needs plans evolved understanding hn pandemic increased committed working find fair solutions gsk hn vaccine supply additionally reviewing pandemic response identify provide flexible offering future pandemics minimising risk business hn pandemic update august emergency committee reassessed epidemiological virological situation hn pandemic assessment emergency committee concluded levels patterns hn transmission seen differ significantly observed pandemic based recent observations evidence strong recent flu pandemic patterns transitioning towards seasonal patterns flu products launched pandemic response measures soon declared hn outbreak pandemic accordance classification system gsk products available governments support public health needs protecting population pandemic flu include hn pandemic vaccines pandemrix arepanrix relenza flu antiviral medicine meet potential increased demand products invested approximately us billion previous years increase manufacturing existing sites establish new manufacturing lines also accelerated production antibiotics used treat secondary bacterial infections associated flu vaccines immediately receiving hn pandemic virus strain early june began complex process developing manufacturing vaccines manufacturing sites germany canada respectively help protect population vaccines consist hn flu antigen adjuvant person vaccinated antigen triggers immune response hn virus use adjuvant allowed less antigen used per dose vaccine enabling significantly doses vaccine produced limited period time fullscale vaccine production started july hn vaccines pandemrix antigen manufactured germany arepanrix similar vaccine antigen manufactured canada received first approvals use september october respectively since supplied million hn pandemic vaccine doses governments gsk committed highest standards patient safety hn vaccine safety data receive clinical trials vaccination programme usage continuously reviewed evaluated signals vaccine safety quality issues addition several years extensive safety efficacy testing candidate pandemic vaccines including adjuvant combined hn avian flu antigen hn pandemic flu vaccines evaluated clinical trials involving subjects including healthy adults elderly people children additionally several programs established evaluate safety vaccinated instance uk completed analysing post licensure study monitor safety vaccine used mass vaccination programme working collaboration medicines healthcare products regulatory agency mhra department health general practitioner research network gprn data clinical trials well independent safety evaluations several regulatory authorities including european medicines agency aug confirmed benefitrisk profile pandemic hn vaccines positive lerouxroels et al antigen sparing crossreactive immunity adjuvanted rhn prototype pandemic influenza vaccine randomised controlled trial lancet relenza relenza zanamivir antiviral medicine licensed treatment prevention influenza unprecedented demand relenza following hn outbreak distributed existing supplies equitably increased production three existing manufacturing sites established two production lines result annual production capacity relenza rose million treatment courses three times previous maximum output achieve level production introduced relenza rotacaps additional relenza presentation manufactured large quantities worked hard quickly obtain approval relenza rotacaps could reach full production capacity gsk worked regulatory authorities eu find appropriate mechanism allow governments purchase product appropriate pending local approval total supplied million doses relenza governments response specific requests physicians treating severely ill hospitalised patients flu supplied unlicensed formulation antiviral medicine clinical development requests typically treating patients licensed antiviral medicines either ineffective intravenous route administration required several clinicians subsequently wrote case reports experience using unlicensed treatment however efficacy safety remain unproven yet evaluated clinical trials actiprotect actiprotect singleuse disposable respirator face mask antiviral coating inactivates flu viruses gsk continues offer actiprotect governments identified need personal protective equipment part preparations future pandemic responding needs pilgrims hajj attending hajj onceinalifetime pilgrimage many muslims every year millions people journey mecca saudi arabia worship together world 's largest annual religious gathering hajj took place late november coinciding northern hemisphere flu season predicted surge pandemic flu cases raised risk hn pandemic virus might spread rapidly among pilgrims worship eat sleep close proximity potentially endangering health families communities returned home concerned possible spread virus saudi arabian government announced summer attendees must vaccinated hn pandemic virus arrival mecca gsk worked contractholding governments mainly europe find solution ensured highrisk group protected hn due time gsk immediately established plan ensure access vaccine many countries origin hajj pilgrims worked closely relevant governments obtain regulatory approval vaccine producing shipping required doses short period time also shipped consignment vaccine saudi arabia instead turning nonvaccinated people away border could offer option immunised upon arrival donations developing world many developing country governments limited resources available protect populations pandemics strongly endorse principles set bill melinda gates foundation help guide global allocation pandemic vaccines support message global community take steps necessary protect populations including without resources protect gsk committed facilitating access relenza pandemic flu vaccines countries operate tieredpricing policy products make relenza available notforprofit price least developed countries read approach improving access medicines november signed agreement donate million doses hn pandemic vaccine developing nations also made available two million treatment courses relenza donate use developing countries required ensure product availability developing countries allocated per cent hn vaccine production capacity canadian manufacturing site per cent relenza production capacity developing countries total hn vaccine donation shipments beginning january currently stands around million doses different countries remain committed working support developing countries event future pandemic reflecting lessons learned many governments national health organisations intergovernmental bodies conducting reviews response hn pandemic beginning plan future pandemics gsk reflecting lessons learned listening feedback governments partners using comments adapt improve pandemic response offering back top home responsibility contribution global health disease prevention corporate responsibility report disease prevention preventing disease improves health avoids human suffering reduce cost managing preventable chronic diseases vaccines play vital role preventing serious disease one world 's largest vaccines producers growing vaccines portfolio key element business strategy area make significant contribution global health also develop overthecounter products help people reduce risk ill health stopping smoking losing weight maintaining good oral health many community investment projects focus disease prevention including support global alliance eliminate lymphatic filariasis phase handwashing programme home responsibility contribution global health disease prevention corporate responsibility report disease prevention preventing disease improves health avoids human suffering reduce cost managing preventable chronic diseases vaccines play vital role preventing serious disease one world 's largest vaccines producers growing vaccines portfolio key element business strategy area make significant contribution global health also develop overthecounter products help people reduce risk ill health stopping smoking losing weight maintaining good oral health many community investment projects focus disease prevention including support global alliance eliminate lymphatic filariasis phase handwashing programme home responsibility contribution global health disease prevention role vaccines corporate responsibility report role vaccines vaccines play major role preventing eliminating disease immunisation acknowledged world health organization 'among costeffective health investments ' estimated least three million deaths prevented children saved disability due vaccines every year section describes vaccine pipeline portfolio increase access vaccines use vaccines pandemic flu cervical cancer rotavirus polio vaccine portfolio pipeline vaccines approved marketing address medical needs developing developed countries cover leading causes childhood mortality defined current vaccine portfolio provides protection following diseases cervical cancer chickenpox diphtheria hepatitis b influenza seasonal hn measles meningitis mumps otitis media pneumococcal disease polio rotavirus rubella tetanus typhoid whooping cough pertussis scientists work vaccine research gsk vaccine pipeline recognised largest industry potential new vaccines since successfully launched four new vaccines cervical cancer pneumococcal disease rotavirus hn pandemic flu obtained approval europe prepandemic pandemic hn avian flu vaccine onethird vaccines pipeline target diseases particularly prevalent developing world including three infectious disease priorities hiv malaria tuberculosis read progress areas access medicines section increasing access vaccines vaccines still underused many countries estimated lives two million children could saved year existing vaccines made accessible need require sustained financing development innovative vaccination programmes aim increase affordability gsk vaccines developing countries longstanding commitment tiered pricing read tiered pricing vaccines included immunisation campaigns countries worldwide delivered billion vaccine doses nearly billion shipped use developing countries contribute achieving millennium development goal 'reduce child mortality ' ensuring vaccines included expanded immunisation programmes worlds vulnerable children gsk involved project improve infrastructure childhood immunisation programmes india millions mothers children receive basic immunisations strategy increase access vaccines middleincome countries piloting two projects egypt mexico develop network new clinics people easily obtain immunisations local communities also increasing involvement technology transfer helps emerging markets develop research manufacturing capabilities increasing access markets gsk launched technology transfer collaboration brazil joint venture china read examples pandemic flu pandemrix read preparations response hn pandemic including vaccine pandemrix cervical cancer cervarix cervical cancers preventable vaccination human papillomavirus hpv combined cervical screening gsks vaccine hpv cervarix available countries around world committed accelerating global access vaccine since launch cervarix approximately ten million doses distributed worldwide vaccine selected immunisation programmes several countries including national programmes netherlands uk regional programmes across italy poland spain example uk cervarix chosen vaccine national immunisation programme nip largest human papillomavirus immunisation programme world date million doses vaccine delivered across uk since nip launch september doses cervarix administered since netherlands national immunisation programme launched june granted prequalification cervarix means vaccine purchased un agencies gavi alliance partnership developing countries gsk participating several hpv vaccination demonstration projects developing countries help implementation hpv vaccination programmes locally includes initiatives led nonprofit organisation path india uganda donated doses cervarix programmes preliminary results first year uganda project demonstrated high vaccination coverage indicates feasibility hpv vaccination resourceconstrained areas also exploring use innovative publicprivate partnerships increase availability cervarix traditionally underserved groups one option explored partner major international nongovernmental organisation partnership able use organisations distribution networks create sustainable expansion access vaccine developing countries deaths cervical cancer occur results pilot programme launched south america encouraging underserved groups achieving greater access vaccine read flexible pricing cervarix philippines rotavirus rotarix rotavirus severe diarrhoeal illness second biggest killer children five years age children die two million go hospital year per cent deaths occur lowincome countries africa asia june world health organization awarded global prequalification rotarix vaccine rotavirus following initial regional prequalification europe americas move accelerate access vaccine asia africa whos expert advisory group also recommended rotavirus vaccination included national immunisation programmes commitment make rotarix available infants around world work partnership example nonprofit organisations path committed finding ways help prevent pricing becoming barrier access developing world haemophilus influenzae type b hiberix haemophilus influenza type b hib often severe potentially deadly bacterial infection cause meningitis response shortage hib vaccine us gsk received accelerated approval us food drug administration fda vaccine hiberix booster dose young children time hiberix already available nearly countries supplied fda information safety efficacy approval enabled us respond public health need meant could quickly make vaccine available children could complete full schedule hib vaccinations ehreth j global value vaccination vaccine gsk received two awards recognising vaccine pipeline scrip awards nd annual vaccine industry excellence awards world health organisation wkly epidemiol rec back tophome responsibility contribution global health disease prevention role vaccines corporate responsibility report role vaccines vaccines play major role preventing eliminating disease immunisation acknowledged world health organization 'among costeffective health investments ' estimated least three million deaths prevented children saved disability due vaccines every year section describes vaccine pipeline portfolio increase access vaccines use vaccines pandemic flu cervical cancer rotavirus polio vaccine portfolio pipeline vaccines approved marketing address medical needs developing developed countries cover leading causes childhood mortality defined current vaccine portfolio provides protection following diseases cervical cancer chickenpox diphtheria hepatitis b influenza seasonal hn measles meningitis mumps otitis media pneumococcal disease polio rotavirus rubella tetanus typhoid whooping cough pertussis scientists work vaccine research gsk vaccine pipeline recognised largest industry potential new vaccines since successfully launched four new vaccines cervical cancer pneumococcal disease rotavirus hn pandemic flu obtained approval europe prepandemic pandemic hn avian flu vaccine onethird vaccines pipeline target diseases particularly prevalent developing world including three infectious disease priorities hiv malaria tuberculosis read progress areas access medicines section increasing access vaccines vaccines still underused many countries estimated lives two million children could saved year existing vaccines made accessible need require sustained financing development innovative vaccination programmes aim increase affordability gsk vaccines developing countries longstanding commitment tiered pricing read tiered pricing vaccines included immunisation campaigns countries worldwide delivered billion vaccine doses nearly billion shipped use developing countries contribute achieving millennium development goal 'reduce child mortality ' ensuring vaccines included expanded immunisation programmes worlds vulnerable children gsk involved project improve infrastructure childhood immunisation programmes india millions mothers children receive basic immunisations strategy increase access vaccines middleincome countries piloting two projects egypt mexico develop network new clinics people easily obtain immunisations local communities also increasing involvement technology transfer helps emerging markets develop research manufacturing capabilities increasing access markets gsk launched technology transfer collaboration brazil joint venture china read examples pandemic flu pandemrix read preparations response hn pandemic including vaccine pandemrix cervical cancer cervarix cervical cancers preventable vaccination human papillomavirus hpv combined cervical screening gsks vaccine hpv cervarix available countries around world committed accelerating global access vaccine since launch cervarix approximately ten million doses distributed worldwide vaccine selected immunisation programmes several countries including national programmes netherlands uk regional programmes across italy poland spain example uk cervarix chosen vaccine national immunisation programme nip largest human papillomavirus immunisation programme world date million doses vaccine delivered across uk since nip launch september doses cervarix administered since netherlands national immunisation programme launched june granted prequalification cervarix means vaccine purchased un agencies gavi alliance partnership developing countries gsk participating several hpv vaccination demonstration projects developing countries help implementation hpv vaccination programmes locally includes initiatives led nonprofit organisation path india uganda donated doses cervarix programmes preliminary results first year uganda project demonstrated high vaccination coverage indicates feasibility hpv vaccination resourceconstrained areas also exploring use innovative publicprivate partnerships increase availability cervarix traditionally underserved groups one option explored partner major international nongovernmental organisation partnership able use organisations distribution networks create sustainable expansion access vaccine developing countries deaths cervical cancer occur results pilot programme launched south america encouraging underserved groups achieving greater access vaccine read flexible pricing cervarix philippines rotavirus rotarix rotavirus severe diarrhoeal illness second biggest killer children five years age children die two million go hospital year per cent deaths occur lowincome countries africa asia june world health organization awarded global prequalification rotarix vaccine rotavirus following initial regional prequalification europe americas move accelerate access vaccine asia africa whos expert advisory group also recommended rotavirus vaccination included national immunisation programmes commitment make rotarix available infants around world work partnership example nonprofit organisations path committed finding ways help prevent pricing becoming barrier access developing world haemophilus influenzae type b hiberix haemophilus influenza type b hib often severe potentially deadly bacterial infection cause meningitis response shortage hib vaccine us gsk received accelerated approval us food drug administration fda vaccine hiberix booster dose young children time hiberix already available nearly countries supplied fda information safety efficacy approval enabled us respond public health need meant could quickly make vaccine available children could complete full schedule hib vaccinations ehreth j global value vaccination vaccine gsk received two awards recognising vaccine pipeline scrip awards nd annual vaccine industry excellence awards world health organisation wkly epidemiol rec back tophome responsibility contribution global health disease prevention role vaccines corporate responsibility report role vaccines vaccines play major role preventing eliminating disease immunisation acknowledged world health organization 'among costeffective health investments ' estimated least three million deaths prevented children saved disability due vaccines every year section describes vaccine pipeline portfolio increase access vaccines use vaccines pandemic flu cervical cancer rotavirus polio vaccine portfolio pipeline vaccines approved marketing address medical needs developing developed countries cover leading causes childhood mortality defined current vaccine portfolio provides protection following diseases cervical cancer chickenpox diphtheria hepatitis b influenza seasonal hn measles meningitis mumps otitis media pneumococcal disease polio rotavirus rubella tetanus typhoid whooping cough pertussis scientists work vaccine research gsk vaccine pipeline recognised largest industry potential new vaccines since successfully launched four new vaccines cervical cancer pneumococcal disease rotavirus hn pandemic flu obtained approval europe prepandemic pandemic hn avian flu vaccine onethird vaccines pipeline target diseases particularly prevalent developing world including three infectious disease priorities hiv malaria tuberculosis read progress areas access medicines section increasing access vaccines vaccines still underused many countries estimated lives two million children could saved year existing vaccines made accessible need require sustained financing development innovative vaccination programmes aim increase affordability gsk vaccines developing countries longstanding commitment tiered pricing read tiered pricing vaccines included immunisation campaigns countries worldwide delivered billion vaccine doses nearly billion shipped use developing countries contribute achieving millennium development goal 'reduce child mortality ' ensuring vaccines included expanded immunisation programmes worlds vulnerable children gsk involved project improve infrastructure childhood immunisation programmes india millions mothers children receive basic immunisations strategy increase access vaccines middleincome countries piloting two projects egypt mexico develop network new clinics people easily obtain immunisations local communities also increasing involvement technology transfer helps emerging markets develop research manufacturing capabilities increasing access markets gsk launched technology transfer collaboration brazil joint venture china read examples pandemic flu pandemrix read preparations response hn pandemic including vaccine pandemrix cervical cancer cervarix cervical cancers preventable vaccination human papillomavirus hpv combined cervical screening gsks vaccine hpv cervarix available countries around world committed accelerating global access vaccine since launch cervarix approximately ten million doses distributed worldwide vaccine selected immunisation programmes several countries including national programmes netherlands uk regional programmes across italy poland spain example uk cervarix chosen vaccine national immunisation programme nip largest human papillomavirus immunisation programme world date million doses vaccine delivered across uk since nip launch september doses cervarix administered since netherlands national immunisation programme launched june granted prequalification cervarix means vaccine purchased un agencies gavi alliance partnership developing countries gsk participating several hpv vaccination demonstration projects developing countries help implementation hpv vaccination programmes locally includes initiatives led nonprofit organisation path india uganda donated doses cervarix programmes preliminary results first year uganda project demonstrated high vaccination coverage indicates feasibility hpv vaccination resourceconstrained areas also exploring use innovative publicprivate partnerships increase availability cervarix traditionally underserved groups one option explored partner major international nongovernmental organisation partnership able use organisations distribution networks create sustainable expansion access vaccine developing countries deaths cervical cancer occur results pilot programme launched south america encouraging underserved groups achieving greater access vaccine read flexible pricing cervarix philippines rotavirus rotarix rotavirus severe diarrhoeal illness second biggest killer children five years age children die two million go hospital year per cent deaths occur lowincome countries africa asia june world health organization awarded global prequalification rotarix vaccine rotavirus following initial regional prequalification europe americas move accelerate access vaccine asia africa whos expert advisory group also recommended rotavirus vaccination included national immunisation programmes commitment make rotarix available infants around world work partnership example nonprofit organisations path committed finding ways help prevent pricing becoming barrier access developing world haemophilus influenzae type b hiberix haemophilus influenza type b hib often severe potentially deadly bacterial infection cause meningitis response shortage hib vaccine us gsk received accelerated approval us food drug administration fda vaccine hiberix booster dose young children time hiberix already available nearly countries supplied fda information safety efficacy approval enabled us respond public health need meant could quickly make vaccine available children could complete full schedule hib vaccinations ehreth j global value vaccination vaccine gsk received two awards recognising vaccine pipeline scrip awards nd annual vaccine industry excellence awards world health organisation wkly epidemiol rec back top home responsibility contribution global health disease prevention role vaccines corporate responsibility report role vaccines vaccines play major role preventing eliminating disease immunisation acknowledged world health organization 'among costeffective health investments ' estimated least three million deaths prevented children saved disability due vaccines every year section describes vaccine pipeline portfolio increase access vaccines use vaccines pandemic flu cervical cancer rotavirus polio vaccine portfolio pipeline vaccines approved marketing address medical needs developing developed countries cover leading causes childhood mortality defined current vaccine portfolio provides protection following diseases cervical cancer chickenpox diphtheria hepatitis b influenza seasonal hn measles meningitis mumps otitis media pneumococcal disease polio rotavirus rubella tetanus typhoid whooping cough pertussis scientists work vaccine research gsk vaccine pipeline recognised largest industry potential new vaccines since successfully launched four new vaccines cervical cancer pneumococcal disease rotavirus hn pandemic flu obtained approval europe prepandemic pandemic hn avian flu vaccine onethird vaccines pipeline target diseases particularly prevalent developing world including three infectious disease priorities hiv malaria tuberculosis read progress areas access medicines section increasing access vaccines vaccines still underused many countries estimated lives two million children could saved year existing vaccines made accessible need require sustained financing development innovative vaccination programmes aim increase affordability gsk vaccines developing countries longstanding commitment tiered pricing read tiered pricing vaccines included immunisation campaigns countries worldwide delivered billion vaccine doses nearly billion shipped use developing countries contribute achieving millennium development goal 'reduce child mortality ' ensuring vaccines included expanded immunisation programmes worlds vulnerable children gsk involved project improve infrastructure childhood immunisation programmes india millions mothers children receive basic immunisations strategy increase access vaccines middleincome countries piloting two projects egypt mexico develop network new clinics people easily obtain immunisations local communities also increasing involvement technology transfer helps emerging markets develop research manufacturing capabilities increasing access markets gsk launched technology transfer collaboration brazil joint venture china read examples pandemic flu pandemrix read preparations response hn pandemic including vaccine pandemrix cervical cancer cervarix cervical cancers preventable vaccination human papillomavirus hpv combined cervical screening gsks vaccine hpv cervarix available countries around world committed accelerating global access vaccine since launch cervarix approximately ten million doses distributed worldwide vaccine selected immunisation programmes several countries including national programmes netherlands uk regional programmes across italy poland spain example uk cervarix chosen vaccine national immunisation programme nip largest human papillomavirus immunisation programme world date million doses vaccine delivered across uk since nip launch september doses cervarix administered since netherlands national immunisation programme launched june granted prequalification cervarix means vaccine purchased un agencies gavi alliance partnership developing countries gsk participating several hpv vaccination demonstration projects developing countries help implementation hpv vaccination programmes locally includes initiatives led nonprofit organisation path india uganda donated doses cervarix programmes preliminary results first year uganda project demonstrated high vaccination coverage indicates feasibility hpv vaccination resourceconstrained areas also exploring use innovative publicprivate partnerships increase availability cervarix traditionally underserved groups one option explored partner major international nongovernmental organisation partnership able use organisations distribution networks create sustainable expansion access vaccine developing countries deaths cervical cancer occur results pilot programme launched south america encouraging underserved groups achieving greater access vaccine read flexible pricing cervarix philippines rotavirus rotarix rotavirus severe diarrhoeal illness second biggest killer children five years age children die two million go hospital year per cent deaths occur lowincome countries africa asia june world health organization awarded global prequalification rotarix vaccine rotavirus following initial regional prequalification europe americas move accelerate access vaccine asia africa whos expert advisory group also recommended rotavirus vaccination included national immunisation programmes commitment make rotarix available infants around world work partnership example nonprofit organisations path committed finding ways help prevent pricing becoming barrier access developing world haemophilus influenzae type b hiberix haemophilus influenza type b hib often severe potentially deadly bacterial infection cause meningitis response shortage hib vaccine us gsk received accelerated approval us food drug administration fda vaccine hiberix booster dose young children time hiberix already available nearly countries supplied fda information safety efficacy approval enabled us respond public health need meant could quickly make vaccine available children could complete full schedule hib vaccinations ehreth j global value vaccination vaccine gsk received two awards recognising vaccine pipeline scrip awards nd annual vaccine industry excellence awards world health organisation wkly epidemiol rec back top home responsibility contribution global health disease prevention products corporate responsibility report products gsk produces overthecounter medicines products help people protect disease includes consumer healthcare products smoking cessation weight loss oral healthcare smoking cessation smoking major public health problem contributing around five million premature deaths worldwide every year nicotine replacement therapies nrt significantly increase smokers chance stopping gsk created first overthecounter nrt market range nicotine replacement brands including niquitin cqnicoderm commit lozenge nicorette helped million people stop smoking since world health organization added nrt gum core list essential medicines considered reference minimum medicine needs basic healthcare system lists effective safe costeffective medicines priority conditions inclusion nrt gum recognises significant public health benefits class medicines contribution preventing serious diseases helping people stop smoking estimate around per cent smokers currently access gsk nrt continue launch nrt products new markets including argentina recognise poverty major barrier nrt purchase especially emerging markets offer smaller pack sizes one way address example recently launched pack brazil contains four lozenges bought equivalent approximately us us supported petition new york commissioner health asking food drug administration fda allow overthecounter nrt products sold widely wherever cigarettes sold permit sale smaller packs fewer doses would much lower prices welcome citizen petition filed jointly association treatment tobacco use dependence society research nicotine tobacco early urges fda adopt flexible regulatory approach expand access use nrt products support government antismoking initiatives several countries example provide smoking cessation education counselling support help lowincome smokers brazil uk support national health services stop smoking clinics providing educational materials online telephone support smokers also help train nurses pharmacists stop smoking advisers committed finding new ways help smokers quit reached agreement nabi biopharmaceuticals nicvax nicvax recently entered phase iii trials development treatment nicotine addiction prevention smoking relapse smoker quit preventing obesity obesity major cause ill health disease diabetes alli overthecounter weightloss treatment helps people lose weight combined lowfat reduced calorie diet alli marketed us since europe since march since launch us million starter packs sold helping millions people lose weight europe approximately million people tried alli first year adding number people helped weight loss efforts read case study ensure alli marketed responsibly oral healthcare good oral health help prevent gum disease tooth decay health benefits oral healthcare products include toothpastes mouth washes denture cleaners facility weybridge uk makes global brands aquafresh sensodyne largest oral healthcare research centre europe employees facility regularly visit oral healthcare conferences publish articles journals promote importance using oral healthcare products cosponsor innovation oral care awards international association dental research run award scheme recognises innovative research preventing mouth infections improving oral healthcare diagnostics began expand phase handwashing campaign include focus oral healthcare also launched global campaign importance twominute tooth brushing worked independent experts demonstrate first time brushing two minutes improve fluoride 's ability protect tooth enamel early signs decay educational programme includes expert outreach dental professionals also directtoconsumer communications using new information encourage patient compliance good oral hygiene routine back tophome responsibility contribution global health disease prevention products corporate responsibility report products gsk produces overthecounter medicines products help people protect disease includes consumer healthcare products smoking cessation weight loss oral healthcare smoking cessation smoking major public health problem contributing around five million premature deaths worldwide every year nicotine replacement therapies nrt significantly increase smokers chance stopping gsk created first overthecounter nrt market range nicotine replacement brands including niquitin cqnicoderm commit lozenge nicorette helped million people stop smoking since world health organization added nrt gum core list essential medicines considered reference minimum medicine needs basic healthcare system lists effective safe costeffective medicines priority conditions inclusion nrt gum recognises significant public health benefits class medicines contribution preventing serious diseases helping people stop smoking estimate around per cent smokers currently access gsk nrt continue launch nrt products new markets including argentina recognise poverty major barrier nrt purchase especially emerging markets offer smaller pack sizes one way address example recently launched pack brazil contains four lozenges bought equivalent approximately us us supported petition new york commissioner health asking food drug administration fda allow overthecounter nrt products sold widely wherever cigarettes sold permit sale smaller packs fewer doses would much lower prices welcome citizen petition filed jointly association treatment tobacco use dependence society research nicotine tobacco early urges fda adopt flexible regulatory approach expand access use nrt products support government antismoking initiatives several countries example provide smoking cessation education counselling support help lowincome smokers brazil uk support national health services stop smoking clinics providing educational materials online telephone support smokers also help train nurses pharmacists stop smoking advisers committed finding new ways help smokers quit reached agreement nabi biopharmaceuticals nicvax nicvax recently entered phase iii trials development treatment nicotine addiction prevention smoking relapse smoker quit preventing obesity obesity major cause ill health disease diabetes alli overthecounter weightloss treatment helps people lose weight combined lowfat reduced calorie diet alli marketed us since europe since march since launch us million starter packs sold helping millions people lose weight europe approximately million people tried alli first year adding number people helped weight loss efforts read case study ensure alli marketed responsibly oral healthcare good oral health help prevent gum disease tooth decay health benefits oral healthcare products include toothpastes mouth washes denture cleaners facility weybridge uk makes global brands aquafresh sensodyne largest oral healthcare research centre europe employees facility regularly visit oral healthcare conferences publish articles journals promote importance using oral healthcare products cosponsor innovation oral care awards international association dental research run award scheme recognises innovative research preventing mouth infections improving oral healthcare diagnostics began expand phase handwashing campaign include focus oral healthcare also launched global campaign importance twominute tooth brushing worked independent experts demonstrate first time brushing two minutes improve fluoride 's ability protect tooth enamel early signs decay educational programme includes expert outreach dental professionals also directtoconsumer communications using new information encourage patient compliance good oral hygiene routine back top home responsibility contribution global health disease prevention products corporate responsibility report products gsk produces overthecounter medicines products help people protect disease includes consumer healthcare products smoking cessation weight loss oral healthcare smoking cessation smoking major public health problem contributing around five million premature deaths worldwide every year nicotine replacement therapies nrt significantly increase smokers chance stopping gsk created first overthecounter nrt market range nicotine replacement brands including niquitin cqnicoderm commit lozenge nicorette helped million people stop smoking since world health organization added nrt gum core list essential medicines considered reference minimum medicine needs basic healthcare system lists effective safe costeffective medicines priority conditions inclusion nrt gum recognises significant public health benefits class medicines contribution preventing serious diseases helping people stop smoking estimate around per cent smokers currently access gsk nrt continue launch nrt products new markets including argentina recognise poverty major barrier nrt purchase especially emerging markets offer smaller pack sizes one way address example recently launched pack brazil contains four lozenges bought equivalent approximately us us supported petition new york commissioner health asking food drug administration fda allow overthecounter nrt products sold widely wherever cigarettes sold permit sale smaller packs fewer doses would much lower prices welcome citizen petition filed jointly association treatment tobacco use dependence society research nicotine tobacco early urges fda adopt flexible regulatory approach expand access use nrt products support government antismoking initiatives several countries example provide smoking cessation education counselling support help lowincome smokers brazil uk support national health services stop smoking clinics providing educational materials online telephone support smokers also help train nurses pharmacists stop smoking advisers committed finding new ways help smokers quit reached agreement nabi biopharmaceuticals nicvax nicvax recently entered phase iii trials development treatment nicotine addiction prevention smoking relapse smoker quit preventing obesity obesity major cause ill health disease diabetes alli overthecounter weightloss treatment helps people lose weight combined lowfat reduced calorie diet alli marketed us since europe since march since launch us million starter packs sold helping millions people lose weight europe approximately million people tried alli first year adding number people helped weight loss efforts read case study ensure alli marketed responsibly oral healthcare good oral health help prevent gum disease tooth decay health benefits oral healthcare products include toothpastes mouth washes denture cleaners facility weybridge uk makes global brands aquafresh sensodyne largest oral healthcare research centre europe employees facility regularly visit oral healthcare conferences publish articles journals promote importance using oral healthcare products cosponsor innovation oral care awards international association dental research run award scheme recognises innovative research preventing mouth infections improving oral healthcare diagnostics began expand phase handwashing campaign include focus oral healthcare also launched global campaign importance twominute tooth brushing worked independent experts demonstrate first time brushing two minutes improve fluoride 's ability protect tooth enamel early signs decay educational programme includes expert outreach dental professionals also directtoconsumer communications using new information encourage patient compliance good oral hygiene routine back top home responsibility contribution global health disease awareness corporate responsibility report disease awareness help raise awareness healthrelated issues among healthcare professionals public work patient groups disease awareness campaigns take place coincide launch new product market raising awareness disease positive impact public health create commercial benefits gsk disease awareness campaigns included promoting coordination asian ngos promote vaccination nongovernmental organisations ngos play vital role improving access vaccines developing world raising awareness importance immunisation however many priorities reconcile often lack resources ensure work gets wide reach necessary benefit ngos organisations february gsk collaborated asian development bank save children host workshop role immunisation improving maternal newborn child health asia nearly ngos came together event manila philippines joined global alliance vaccines immunisation gavi united nations childrens fund unicef participants discussed challenges face getting vaccines people need shared best practices developed innovative ways collaborate feedback attendees showed event success number ngos subsequently established regional network committed greater advocacy healthcare childhood immunisations raising awareness dengue fever treatment people know correct treatment dengue fever debilitating disease transmitted mosquitoes tropical subtropical regions especially children people often use feverreducers aspirin exacerbate bleeding symptom dengue fever paracetamol recommended effective symptomatic treatment dengue fever also seek medical treatment late increases risk serious complications death gsk position take lead raising global awareness among healthcare professionals public dengue fever threat panadol gsks overthecounter paracetamol brand strong presence regions dengue fever prevalent notably asia africa middle east central south america initiated sponsored dengue fever public awareness campaign highrisk areas including caribbean southeast asia worked collaboration organisations unicef pan america health organization also engage locally respected campaign ambassadors campaigns increase awareness television radio pr activities well roadside banners posters hospitals public health centres pharmacies drugstores local media picked activities helping raise awareness health professionals targeted campaigns provided information help diagnosis treatment free panadol samples distributed hospitals campaign run costa rica contributed per cent reduction dengue fever cases reported board health campaign run number cases increased per cent gsk activated campaign collaboration board health end ' save lives ' campaign contributed per cent reduction dengue cases similarly panadol campaign contributed decreases southeast asian dengue cases especially indonesia dengue fever fatality rate dropped per cent previous year cpaamgep ai gonf ran indonesia continue activities raise awareness public provide training healthcare professionals raising awareness immunisation us vaccines crucial disease prevention effective people access choose immunised adult immunisation cost effective good public health policy many adults us immunised even though vaccines prevent potentially serious diseases available part us healthcare initiative 'triple solution ' gsk raising awareness among adults us importance immunisation get vaccinated vaccinated also reaching parents via 'more medicine ' blog designed increase objectivity online debate childhood immunisations invited mothers blog visit vaccine filling packaging plant marietta pa engage general dialogue immunisation discussions specific vaccines line fda regulation improving community awareness partnership washington redskins launched new partnership national football league team washington redskins help fans improve health initiative targets childhood obesity cardiovascular disease women breast prostate cancer number awarenessraising events held redskins games throughout season including specially themed thinkpink match recognise breast cancer awareness month series health screening events us army veterans families veterans day also sponsored new redskins youth fitness zone help boys girls aged combat obesity read veterans screening event back tophome responsibility contribution global health disease awareness corporate responsibility report disease awareness help raise awareness healthrelated issues among healthcare professionals public work patient groups disease awareness campaigns take place coincide launch new product market raising awareness disease positive impact public health create commercial benefits gsk disease awareness campaigns included promoting coordination asian ngos promote vaccination nongovernmental organisations ngos play vital role improving access vaccines developing world raising awareness importance immunisation however many priorities reconcile often lack resources ensure work gets wide reach necessary benefit ngos organisations february gsk collaborated asian development bank save children host workshop role immunisation improving maternal newborn child health asia nearly ngos came together event manila philippines joined global alliance vaccines immunisation gavi united nations childrens fund unicef participants discussed challenges face getting vaccines people need shared best practices developed innovative ways collaborate feedback attendees showed event success number ngos subsequently established regional network committed greater advocacy healthcare childhood immunisations raising awareness dengue fever treatment people know correct treatment dengue fever debilitating disease transmitted mosquitoes tropical subtropical regions especially children people often use feverreducers aspirin exacerbate bleeding symptom dengue fever paracetamol recommended effective symptomatic treatment dengue fever also seek medical treatment late increases risk serious complications death gsk position take lead raising global awareness among healthcare professionals public dengue fever threat panadol gsks overthecounter paracetamol brand strong presence regions dengue fever prevalent notably asia africa middle east central south america initiated sponsored dengue fever public awareness campaign highrisk areas including caribbean southeast asia worked collaboration organisations unicef pan america health organization also engage locally respected campaign ambassadors campaigns increase awareness television radio pr activities well roadside banners posters hospitals public health centres pharmacies drugstores local media picked activities helping raise awareness health professionals targeted campaigns provided information help diagnosis treatment free panadol samples distributed hospitals campaign run costa rica contributed per cent reduction dengue fever cases reported board health campaign run number cases increased per cent gsk activated campaign collaboration board health end ' save lives ' campaign contributed per cent reduction dengue cases similarly panadol campaign contributed decreases southeast asian dengue cases especially indonesia dengue fever fatality rate dropped per cent previous year campaign ran indonesia continue activities raise awareness public provide training healthcare professionals raising awareness immunisation us vaccines crucial disease prevention effective people access choose immunised adult immunisation cost effective good public health policy many adults us immunised even though vaccines prevent potentially serious diseases available part us healthcare initiative 'triple solution ' gsk raising awareness among adults us importance immunisation get vaccinated vaccinated also reaching parents via 'more medicine ' blog designed increase objectivity online debate childhood immunisations invited mothers blog visit vaccine filling packaging plant marietta pa engage general dialogue immunisation discussions specific vaccines line fda regulation improving community awareness partnership washington redskins launched new partnership national football league team washington redskins help fans improve health initiative targets childhood obesity cardiovascular disease women breast prostate cancer number awarenessraising events held redskins games throughout season including specially themed thinkpink match recognise breast cancer awareness month series health screening events us army veterans families veterans day also sponsored new redskins youth fitness zone help boys girls aged combat obesity read veterans screening event back top home responsibility contribution global health disease awareness corporate responsibility report disease awareness help raise awareness healthrelated issues among healthcare professionals public work patient groups disease awareness campaigns take place coincide launch new product market raising awareness disease positive impact public health create commercial benefits gsk disease awareness campaigns included promoting coordination asian ngos promote vaccination nongovernmental organisations ngos play vital role improving access vaccines developing world raising awareness importance immunisation however many priorities reconcile often lack resources ensure work gets wide reach necessary benefit ngos organisations february gsk collaborated asian development bank save children host workshop role immunisation improving maternal newborn child health asia nearly ngos came together event manila philippines joined global alliance vaccines immunisation gavi united nations childrens fund unicef participants discussed challenges face getting vaccines people need shared best practices developed innovative ways collaborate feedback attendees showed event success number ngos subsequently established regional network committed greater advocacy healthcare childhood immunisations raising awareness dengue fever treatment people know correct treatment dengue fever debilitating disease transmitted mosquitoes tropical subtropical regions especially children people often use feverreducers aspirin exacerbate bleeding symptom dengue fever paracetamol recommended effective symptomatic treatment dengue fever also seek medical treatment late increases risk serious complications death gsk position take lead raising global awareness among healthcare professionals public dengue fever threat panadol gsks overthecounter paracetamol brand strong presence regions dengue fever prevalent notably asia africa middle east central south america initiated sponsored dengue fever public awareness campaign highrisk areas including caribbean southeast asia worked collaboration organisations unicef pan america health organization also engage locally respected campaign ambassadors campaigns increase awareness television radio pr activities well roadside banners posters hospitals public health centres pharmacies drugstores local media picked activities helping raise awareness health professionals targeted campaigns provided information help diagnosis treatment free panadol samples distributed hospitals campaign run costa rica contributed per cent reduction dengue fever cases reported board health campaign run number cases increased per cent gsk activated campaign collaboration board health end ' save lives ' campaign contributed per cent reduction dengue cases similarly panadol campaign contributed decreases southeast asian dengue cases especially indonesia dengue fever fatality rate dropped per cent previous year campaign ran indonesia continue activities raise awareness public provide training healthcare professionals raising awareness immunisation us vaccines crucial disease prevention effective people access choose immunised adult immunisation cost effective good public health policy many adults us immunised even though vaccines prevent potentially serious diseases available part us healthcare initiative 'triple solution ' gsk raising awareness among adults us importance immunisation get vaccinated vaccinated also reaching parents via 'more medicine ' blog designed increase objectivity online debate childhood immunisations invited mothers blog visit vaccine filling packaging plant marietta pa engage general dialogue immunisation discussions specific vaccines line fda regulation improving community awareness partnership washington redskins launched new partnership national football league team washington redskins help fans improve health initiative targets childhood obesity cardiovascular disease women breast prostate cancer number awarenessraising events held redskins games throughout season including specially themed thinkpink match recognise breast cancer awareness month series health screening events us army veterans families veterans day also sponsored new redskins youth fitness zone help boys girls aged combat obesity read veterans screening event back top home responsibility contribution global health treating ill health corporate responsibility report treating ill health medicines vaccines consumer healthcare products help treat prevent serious disease gsk medicines target diseases developed developing worlds following areas antibacterials antibiotics antimalarials infections malaria antivirals hivaids herpes hepatitis b influenza cardiovascular heart failure hypertension deep vein thrombosis central nervous system migraine epilepsy anxiety depression parkinson 's disease smoking cessation anaesthesia analgesia antiemetics dermatology eczema dermatitis psoriasis metabolic diabetes osteoporosis obesity oncology breast cervical lung ovarian cancer nonhodgkins lymphoma leukaemia idiopathic thrombocytopaenic purpura respiratory immunoinflammation asthma chronic obstructive pulmonary disease rhinitis post operative ileus urogenital prostatic hypertrophy overactive bladder read vaccines prevent serious diseases paracetamol paracetamol widely used lowcost medicine treating adult child pain fever listed one world health organization 's essential medicines gsk produces ten billion tablets year overthecounter paracetamol product panadol available countries includes low middleincome countries provide affordable lowcost singledose packs medical guidelines across globe recommend paracetamol medicine panadol firstline oral painkiller chronic diseases osteoarthritis due efficacy safety profile cost effectiveness also firstchoice treatment conditions headache backache children 's fever guidance supportive care infected hn 'swine flu ' virus strain highlighted paracetamol antipyretic fever reducer choice flu symptom management read response pandemic flu paracetamol recommended treatment symptoms dengue fever debilitating life threatening disease transmitted mosquitoes tropical subtropical regions billion people risk infection twofifths worlds population countries read efforts increase awareness dengue fever correct treatment products help improve health number ways antiretrovirals arvs combivir help patients control effects hiv infection many years sell arvs least developed countries countries subsaharan africa notfor profit prices read responsible pricing developing world many diseases diabetes progressive patients receive right treatment suffer severe complications example every day us diabetes cause estimated lower limb amputations cases blindness people experiencing kidney failure avandia diabetes treatment helps patients control blood sugar many medicines asthma diabetes help patients chronic diseases live full productive lives gsk preventative treatments asthma seretideadvair control symptoms asthma prevent asthma attacks produce antibiotics treat respiratory tract infections donate antibiotics help relief efforts disaster areas read improving access medicines prevention intervention innovation triple solution healthcare costs us concern patients healthcare payers pharmaceutical industry alike increase prevalence many chronic diseases asthma diabetes heart disease major contributing factor expenditures us healthcare exceeded trillion additionally absence work due ill health significant cost often goes unrecognised worked government employers others us find new ways address problem chronic diseases reducing healthcare costs prevention addressing causes chronic diseases obesity smoking poor diet lack exercise intervention properly managing chronic diseases prevent complications avoid hospitalisation costs reduce time away work innovation developing new treatments costly unmet medical needs alzheimers disease stroke example helped employers public private sectors across us create health management programmes remove barriers healthcare access reduce healthcare costs improve health programmes encourage employers provide preventative services health screenings workers develop disease management programmes help employees control symptoms stick treatment regimens establish comprehensive wellness initiatives obesity smoking leading products work triple solution closely connected public policy advocacy healthcare reform launched website information approach encourages americans get involved healthcare debate back tophome responsibility contribution global health treating ill health corporate responsibility report treating ill health medicines vaccines consumer healthcare products help treat prevent serious disease gsk medicines target diseases developed developing worlds following areas antibacterials antibiotics antimalarials infections malaria antivirals hivaids herpes hepatitis b influenza cardiovascular heart failure hypertension deep vein thrombosis central nervous system migraine epilepsy anxiety depression parkinson 's disease smoking cessation anaesthesia analgesia antiemetics dermatology eczema dermatitis psoriasis metabolic diabetes osteoporosis obesity oncology breast cervical lung ovarian cancer nonhodgkins lymphoma leukaemia idiopathic thrombocytopaenic purpura respiratory immunoinflammation asthma chronic obstructive pulmonary disease rhinitis post operative ileus urogenital prostatic hypertrophy overactive bladder read vaccines prevent serious diseases paracetamol paracetamol widely used lowcost medicine treating adult child pain fever listed one world health organization 's essential medicines gsk produces ten billion tablets year overthecounter paracetamol product panadol available countries includes low middleincome countries provide affordable lowcost singledose packs medical guidelines across globe recommend paracetamol medicine panadol firstline oral painkiller chronic diseases osteoarthritis due efficacy safety profile cost effectiveness also firstchoice treatment conditions headache backache children 's fever guidance supportive care infected hn 'swine flu ' virus strain highlighted paracetamol antipyretic fever reducer choice flu symptom management read response pandemic flu paracetamol recommended treatment symptoms dengue fever debilitating life threatening disease transmitted mosquitoes tropical subtropical regions billion people risk infection twofifths worlds population countries read efforts increase awareness dengue fever correct treatment products help improve health number ways antiretrovirals arvs combivir help patients control effects hiv infection many years sell arvs least developed countries countries subsaharan africa notfor profit prices read responsible pricing developing world many diseases diabetes progressive patients receive right treatment suffer severe complications example every day us diabetes cause estimated lower limb amputations cases blindness people experiencing kidney failure avandia diabetes treatment helps patients control blood sugar many medicines asthma diabetes help patients chronic diseases live full productive lives gsk preventative treatments asthma seretideadvair control symptoms asthma prevent asthma attacks produce antibiotics treat respiratory tract infections donate antibiotics help relief efforts disaster areas read improving access medicines prevention intervention innovation triple solution healthcare costs us concern patients healthcare payers pharmaceutical industry alike increase prevalence many chronic diseases asthma diabetes heart disease major contributing factor expenditures us healthcare exceeded trillion additionally absence work due ill health significant cost often goes unrecognised worked government employers others us find new ways address problem chronic diseases reducing healthcare costs prevention addressing causes chronic diseases obesity smoking poor diet lack exercise intervention properly managing chronic diseases prevent complications avoid hospitalisation costs reduce time away work innovation developing new treatments costly unmet medical needs alzheimers disease stroke example helped employers public private sectors across us create health management programmes remove barriers healthcare access reduce healthcare costs improve health programmes encourage employers provide preventative services health screenings workers develop disease management programmes help employees control symptoms stick treatment regimens establish comprehensive wellness initiatives obesity smoking leading products work triple solution closely connected public policy advocacy healthcare reform launched website information approach encourages americans get involved healthcare debate back top home responsibility contribution global health treating ill health corporate responsibility report treating ill health medicines vaccines consumer healthcare products help treat prevent serious disease gsk medicines target diseases developed developing worlds following areas antibacterials antibiotics antimalarials infections malaria antivirals hivaids herpes hepatitis b influenza cardiovascular heart failure hypertension deep vein thrombosis central nervous system migraine epilepsy anxiety depression parkinson 's disease smoking cessation anaesthesia analgesia antiemetics dermatology eczema dermatitis psoriasis metabolic diabetes osteoporosis obesity oncology breast cervical lung ovarian cancer nonhodgkins lymphoma leukaemia idiopathic thrombocytopaenic purpura respiratory immunoinflammation asthma chronic obstructive pulmonary disease rhinitis post operative ileus urogenital prostatic hypertrophy overactive bladder read vaccines prevent serious diseases paracetamol paracetamol widely used lowcost medicine treating adult child pain fever listed one world health organization 's essential medicines gsk produces ten billion tablets year overthecounter paracetamol product panadol available countries includes low middleincome countries provide affordable lowcost singledose packs medical guidelines across globe recommend paracetamol medicine panadol firstline oral painkiller chronic diseases osteoarthritis due efficacy safety profile cost effectiveness also firstchoice treatment conditions headache backache children 's fever guidance supportive care infected hn 'swine flu ' virus strain highlighted paracetamol antipyretic fever reducer choice flu symptom management read response pandemic flu paracetamol recommended treatment symptoms dengue fever debilitating life threatening disease transmitted mosquitoes tropical subtropical regions billion people risk infection twofifths worlds population countries read efforts increase awareness dengue fever correct treatment products help improve health number ways antiretrovirals arvs combivir help patients control effects hiv infection many years sell arvs least developed countries countries subsaharan africa notfor profit prices read responsible pricing developing world many diseases diabetes progressive patients receive right treatment suffer severe complications example every day us diabetes cause estimated lower limb amputations cases blindness people experiencing kidney failure avandia diabetes treatment helps patients control blood sugar many medicines asthma diabetes help patients chronic diseases live full productive lives gsk preventative treatments asthma seretideadvair control symptoms asthma prevent asthma attacks produce antibiotics treat respiratory tract infections donate antibiotics help relief efforts disaster areas read improving access medicines prevention intervention innovation triple solution healthcare costs us concern patients healthcare payers pharmaceutical industry alike increase prevalence many chronic diseases asthma diabetes heart disease major contributing factor expenditures us healthcare exceeded trillion additionally absence work due ill health significant cost often goes unrecognised worked government employers others us find new ways address problem chronic diseases reducing healthcare costs prevention addressing causes chronic diseases obesity smoking poor diet lack exercise intervention properly managing chronic diseases prevent complications avoid hospitalisation costs reduce time away work innovation developing new treatments costly unmet medical needs alzheimers disease stroke example helped employers public private sectors across us create health management programmes remove barriers healthcare access reduce healthcare costs improve health programmes encourage employers provide preventative services health screenings workers develop disease management programmes help employees control symptoms stick treatment regimens establish comprehensive wellness initiatives obesity smoking leading products work triple solution closely connected public policy advocacy healthcare reform launched website information approach encourages americans get involved healthcare debate back top home responsibility contribution global health research development corporate responsibility report research development despite advances healthcare still many diseases cure treatments could improved continued research innovation essential address unmet medical needs spent billion rd per cent expenditure pharmaceutical rd remainder vaccine research investment rd new medicines vaccines core business seeking develop new treatments help many different patient groups treatments need provide value currently available treatments patients payer focus efforts areas greatest need advances science offer best opportunities discover new medicines use emerging technologies research research teams apply insight expertise also welcome new science ideas outside gsk access diverse knowledge form alliances academia ngos biotechnology firms pharmaceutical companies committed transparency rd process publicly disclose outcomes clinical studies read research practices section section outlines gsks research activities collaborations partnerships funding help advance scientific understanding back top home responsibility contribution global health research development corporate responsibility report research development despite advances healthcare still many diseases cure treatments could improved continued research innovation essential address unmet medical needs spent billion rd per cent expenditure pharmaceutical rd remainder vaccine research investment rd new medicines vaccines core business seeking develop new treatments help many different patient groups treatments need provide value currently available treatments patients payer focus efforts areas greatest need advances science offer best opportunities discover new medicines use emerging technologies research research teams apply insight expertise also welcome new science ideas outside gsk access diverse knowledge form alliances academia ngos biotechnology firms pharmaceutical companies committed transparency rd process publicly disclose outcomes clinical studies read research practices section section outlines gsks research activities collaborations partnerships funding help advance scientific understanding back top home responsibility contribution global health research development research activites corporate responsibility report research activities focus research therapy areas recent advances science mean likely greater opportunities finding new treatments nearly prescription medicines vaccines clinical development phase iii development registration earlystage pharmaceutical research activities currently focused biopharmaceuticals immunoinflammatory diseases infectious diseases metabolic pathways neurosciences oncology ophthalmology respiratory diseases latestage pipeline includes products targeting range diseases including many forms cancer infections respiratory diseases autoimmune disorders metabolic cardiovascular disease neurological diseases research efforts continue guided advances science needs patients established three new research units including tempero pharmaceuticals tasked discovering greater understanding signalling systems inflammation autoimmune diseases opportunities offer new medicines epigenetics discovery performance unit looks potential new treatments based modification genetic signalling regenerative medicines discovery performance unit maximise potential stem cell science gsk committed meeting needs patients wherever live launched new research unit help shape product portfolio better suit needs patients gsk 's emerging markets asia pacific regions also celebrated second year rd facility china see feature box entirely new compounds vaccines constitute per cent pipeline past three years gsk entirely new compounds new chemical entities approved us food drug administration company gsk products approved including arzerra ofatumumab chronic lymphocytic leukemia pandemrix hn pandemic flu vaccine synflorix streptococcus pneumoniae disease prophylaxis infants children votrient pazopanib treatment advanced renal cell carcinoma prix galien awarded serious blood disorder treatment promacta us prix galien 'best biotechnology product ' award promacta eltrombopag recently launched treatment serious blood disorder award recognises promacta 's ability treat thrombocytopenia patients chronic immune idiopathic thrombocytopenic purpura itp prix galien award one industrys highest accolades pharmaceutical rd award recognises technical scientific clinical research skills necessary develop innovative medicines make significant impact improving patient care addressing unmet need treatment also highlighted one top medical innovations cleveland clinics medical innovations summit made submissions new products product line extensions next months potential launch six brand new medicines vaccines including benlysta first potential treatment lupus years also created new leading specialist dermatology business acquisition stiefel laboratories new business projects latestage development across wide variety dermatological conditions acne dermatoses fungal infection read pipeline progress product approvals annual report rd china chinese rd centre opened employees housed stateoftheart facilities shanghai centre investigating neurodegenerative disorders alzheimers disease parkinsons disease multiple sclerosis centre already progressing early pipeline target validation candidate selection intend develop centre lead facility global discovery development activities neurodegenerative disorders also building comprehensive collection compounds isolated traditional chinese medicinal sources effort carried chinese academic institutions costs conducting research china lower markets however lower costs primary reason opening facility china offers huge pool scientific talent recruitment roadshow reached phd graduates ten top universities rd china conducted gsks global quality ethical standards rd policies monitoring procedures global apply operations china read ensure high ethical standards rd activity back tophome responsibility contribution global health research development research activites corporate responsibility report research activities focus research therapy areas recent advances science mean likely greater opportunities finding new treatments nearly prescription medicines vaccines clinical development phase iii development registration earlystage pharmaceutical research activities currently focused biopharmaceuticals immunoinflammatory diseases infectious diseases metabolic pathways neurosciences oncology ophthalmology respiratory diseases latestage pipeline includes products targeting range diseases including many forms cancer infections respiratory diseases autoimmune disorders metabolic cardiovascular disease neurological diseases research efforts continue guided advances science needs patients established three new research units including tempero pharmaceuticals tasked discovering greater understanding signalling systems inflammation autoimmune diseases opportunities offer new medicines epigenetics discovery performance unit looks potential new treatments based modification genetic signalling regenerative medicines discovery performance unit maximise potential stem cell science gsk committed meeting needs patients wherever live launched new research unit help shape product portfolio better suit needs patients gsk 's emerging markets asia pacific regions also celebrated second year rd facility china see feature box entirely new compounds vaccines constitute per cent pipeline past three years gsk entirely new compounds new chemical entities approved us food drug administration company gsk products approved including arzerra ofatumumab chronic lymphocytic leukemia pandemrix hn pandemic flu vaccine synflorix streptococcus pneumoniae disease prophylaxis infants children votrient pazopanib treatment advanced renal cell carcinoma prix galien awarded serious blood disorder treatment promacta us prix galien 'best biotechnology product ' award promacta eltrombopag recently launched treatment serious blood disorder award recognises promacta 's ability treat thrombocytopenia patients chronic immune idiopathic thrombocytopenic purpura itp prix galien award one industrys highest accolades pharmaceutical rd award recognises technical scientific clinical research skills necessary develop innovative medicines make significant impact improving patient care addressing unmet need treatment also highlighted one top medical innovations cleveland clinics medical innovations summit made submissions new products product line extensions next months potential launch six brand new medicines vaccines including benlysta first potential treatment lupus years also created new leading specialist dermatology business acquisition stiefel laboratories new business projects latestage development across wide variety dermatological conditions acne dermatoses fungal infection read pipeline progress product approvals annual report rd china chinese rd centre opened employees housed stateoftheart facilities shanghai centre investigating neurodegenerative disorders alzheimers disease parkinsons disease multiple sclerosis centre already progressing early pipeline target validation candidate selection intend develop centre lead facility global discovery development activities neurodegenerative disorders also building comprehensive collection compounds isolated traditional chinese medicinal sources effort carried chinese academic institutions costs conducting research china lower markets however lower costs primary reason opening facility china offers huge pool scientific talent recruitment roadshow reached phd graduates ten top universities rd china conducted gsks global quality ethical standards rd policies monitoring procedures global apply operations china read ensure high ethical standards rd activity back top home responsibility contribution global health research development research activites corporate responsibility report research activities focus research therapy areas recent advances science mean likely greater opportunities finding new treatments nearly prescription medicines vaccines clinical development phase iii development registration earlystage pharmaceutical research activities currently focused biopharmaceuticals immunoinflammatory diseases infectious diseases metabolic pathways neurosciences oncology ophthalmology respiratory diseases latestage pipeline includes products targeting range diseases including many forms cancer infections respiratory diseases autoimmune disorders metabolic cardiovascular disease neurological diseases research efforts continue guided advances science needs patients established three new research units including tempero pharmaceuticals tasked discovering greater understanding signalling systems inflammation autoimmune diseases opportunities offer new medicines epigenetics discovery performance unit looks potential new treatments based modification genetic signalling regenerative medicines discovery performance unit maximise potential stem cell science gsk committed meeting needs patients wherever live launched new research unit help shape product portfolio better suit needs patients gsk 's emerging markets asia pacific regions also celebrated second year rd facility china see feature box entirely new compounds vaccines constitute per cent pipeline past three years gsk entirely new compounds new chemical entities approved us food drug administration company gsk products approved including arzerra ofatumumab chronic lymphocytic leukemia pandemrix hn pandemic flu vaccine synflorix streptococcus pneumoniae disease prophylaxis infants children votrient pazopanib treatment advanced renal cell carcinoma prix galien awarded serious blood disorder treatment promacta us prix galien 'best biotechnology product ' award promacta eltrombopag recently launched treatment serious blood disorder award recognises promacta 's ability treat thrombocytopenia patients chronic immune idiopathic thrombocytopenic purpura itp prix galien award one industrys highest accolades pharmaceutical rd award recognises technical scientific clinical research skills necessary develop innovative medicines make significant impact improving patient care addressing unmet need treatment also highlighted one top medical innovations cleveland clinics medical innovations summit made submissions new products product line extensions next months potential launch six brand new medicines vaccines including benlysta first potential treatment lupus years also created new leading specialist dermatology business acquisition stiefel laboratories new business projects latestage development across wide variety dermatological conditions acne dermatoses fungal infection read pipeline progress product approvals annual report rd china chinese rd centre opened employees housed stateoftheart facilities shanghai centre investigating neurodegenerative disorders alzheimers disease parkinsons disease multiple sclerosis centre already progressing early pipeline target validation candidate selection intend develop centre lead facility global discovery development activities neurodegenerative disorders also building comprehensive collection compounds isolated traditional chinese medicinal sources effort carried chinese academic institutions costs conducting research china lower markets however lower costs primary reason opening facility china offers huge pool scientific talent recruitment roadshow reached phd graduates ten top universities rd china conducted gsks global quality ethical standards rd policies monitoring procedures global apply operations china read ensure high ethical standards rd activity back top home responsibility contribution global health research development contributing scientific understanding corporate responsibility report contributing scientific understanding gsk large pool scientists recognise monopoly research best science committed accelerating discovery new medicines vaccines collaborating external partners open sharing scientific understanding external partner collaborations underway complement internal discovery performance units also fund basic medical research conducted outside gsk increase understanding human body impact disease frequently foundation future advances diagnosis treatment prevention disease rd policies global apply high standards wherever operate collaborate organisations whose principles aligned gsk research conducted part collaboration raise awareness policies beginning collaboration include clauses collaboration agreement requiring compliance principles read ensure high ethical standards rd activity opening new dialogues working spirit greater collaboration part looking making new alliances supporting research neglected tropical diseases opening tres cantos rd site external scientists establishing knowledge pool allowing others access intellectual property develop new treatments developing world read knowledge pool announced alliance uk government wellcome trust east england development agency creation biotechnology science park located gsk 's rd site stevenage uk project aims create hub innovation life sciences research companies located park shared access specialist skills equipment expertise simulate new innovation drug development gsk partnering wellcome trust joint million investment generate 'chemical probes ' proteins involved epigenetic signalling make available researchers without restriction publicprivate partnership led structural genomics consortium involves national institutes healths chemical genomics centre washington us university oxford initiative could offer new model future interactions academia industry collaborating accelerate drug development november gsk pfizer jointly launched viiv healthcare major new collaboration accelerate development vaccines treatments hivaids read viiv healthcare gsk involved innovative medicines initiative imi billion collaborative research programme founded european commission european pharmaceutical industry imi brings together large small biopharmaceutical healthcare companies academia regulators patient groups aim removing barriers discovery development new medicines results collaborations widely shared broader research community benefit knowledge gained gsk involved projects funded imi focus diverse topics gsk coordinator imi project aimed developing tools accelerate drug discovery alzheimers disease gsk also participating research projects range areas including oncology infectious diseases electronic health records pharmacokinetic modelling funded second wave imi projects gsk working path malaria vaccine initiative mvi since develop paediatric vaccine malaria rtss partnership announced study results showed rtss provides infants young children significant protection malaria phase lll studies started may run seven countries across africa read vaccines developing world new specialist unit research develop medicines rare diseases february announced formation new standalone unit research develop medicines rare diseases defined europe diseases affect fewer one people rare diseases identified yet treatments available ten per cent conditions despite rarity condition number diseases means six eight per cent population may affected rare disease many genetic origin start childhood cause lifelong debility premature death new unit seek build existing capabilities partnerships establish inlicensing opportunities gsk announced two collaborations companies prosensa jcr pharmaceutica involved researching developing medicines rare diseases alliance prosensa focuses developing nucleic acid based therapeutics intended treat specific different subpopulations patients suffering duchenne muscular dystrophy dmd part agreement jcr pharmaceuticals japanese developer manufacturer bioactive products gsk obtained global rights number enzyme replacement therapies could upon approval used treat orphan diseases hunter syndrome fabry disease gaucher disease entry new therapeutic area forms part gsk 's strategy deliver products value improve returns rd focus areas higher probability success risk associated product discovery development rare diseases generally lower disease areas disease definitions clear clinical trials tend small robust endpoints wwworphanet portal rare diseases orphan drugs wwwfdagov analysis approved therapies us since vs known rare diseases 'rare diseases understanding public health priority ' european organisation rare diseases november patient safety collaborating others improve safe use medicines patients work includes cochairing serious adverse event consortiums saec scientific management committee read work saec aims improve patient safety genetic research industry lead innovative medicines initiatives patient safety project aims develop methodologies enhance assessment benefitrisk profile new medicines founding member uks public private collaborations stem cells safer medicines organisation investigating potential human stem cells screen potential new medicines safety toxicology read patient safety gsk academic collaborations invest research capabilities universities fund leadingedge academic research projects support science students provided support million alliances academic institutions support benefits academic institutions increased funding technology transfer access research facilities expertise contributes better scientific understanding capability countries operate benefits gsk enabling us tap rd expertise activity outside company expands potential recruitment pool better trained scientists academic collaborations included newly launched million two year project wellcome trust develop antibiotic treat methicillinresistant staphylococcus aureus mrsa financed wellcome trust seed funding initiative gskwellcome trust research programme use gsks knowledge structureactivity relationships novel class antibacterial molecules partnership academics universities london exeter kings college securing million grants engineering physical sciences research council epsrc develop systems deliver drugs across blood brain barrier would allow better treatment diseases affecting brain epilepsy schizophrenia two awards totalling million given medical research council gsk scientists hammersmith hospital clinical imaging centre provide threeyear training programmes radiochemistry brain imaging research develop new ways modelling pharmacological interactions brain partnership geneticists duke university medical center leading discovery two new genes associated chronic obstructive pulmonary disease copd increasing understanding genetic risk factors respiratory disease new partnership university washington apply new statistical methods rapidly analyse large sets genetic data predict responses new therapies identifying genes influence drug response collaboration university college london academic discovery performance unit dpu develop new treatment amyloidosis rare potentially fatal condition academic dpu new initiative combine best academic thinking gsks industry expertise back tophome responsibility contribution global health research development contributing scientific understanding corporate responsibility report contributing scientific understanding gsk large pool scientists recognise monopoly research best science committed accelerating discovery new medicines vaccines collaborating external partners open sharing scientific understanding external partner collaborations underway complement internal discovery performance units also fund basic medical research conducted outside gsk increase understanding human body impact disease frequently foundation future advances diagnosis treatment prevention disease rd policies global apply high standards wherever operate collaborate organisations whose principles aligned gsk research conducted part collaboration raise awareness policies beginning collaboration include clauses collaboration agreement requiring compliance principles read ensure high ethical standards rd activity opening new dialogues working spirit greater collaboration part looking making new alliances supporting research neglected tropical diseases opening tres cantos rd site external scientists establishing knowledge pool allowing others access intellectual property develop new treatments developing world read knowledge pool announced alliance uk government wellcome trust east england development agency creation biotechnology science park located gsk 's rd site stevenage uk project aims create hub innovation life sciences research companies located park shared access specialist skills equipment expertise simulate new innovation drug development gsk partnering wellcome trust joint million investment generate 'chemical probes ' proteins involved epigenetic signalling make available researchers without restriction publicprivate partnership led structural genomics consortium involves national institutes healths chemical genomics centre washington us university oxford initiative could offer new model future interactions academia industry collaborating accelerate drug development november gsk pfizer jointly launched viiv healthcare major new collaboration accelerate development vaccines treatments hivaids read viiv healthcare gsk involved innovative medicines initiative imi billion collaborative research programme founded european commission european pharmaceutical industry imi brings together large small biopharmaceutical healthcare companies academia regulators patient groups aim removing barriers discovery development new medicines results collaborations widely shared broader research community benefit knowledge gained gsk involved projects funded imi focus diverse topics gsk coordinator imi project aimed developing tools accelerate drug discovery alzheimers disease gsk also participating research projects range areas including oncology infectious diseases electronic health records pharmacokinetic modelling funded second wave imi projects gsk working path malaria vaccine initiative mvi since develop paediatric vaccine malaria rtss partnership announced study results showed rtss provides infants young children significant protection malaria phase lll studies started may run seven countries across africa read vaccines developing world new specialist unit research develop medicines rare diseases february announced formation new standalone unit research develop medicines rare diseases defined europe diseases affect fewer one people rare diseases identified yet treatments available ten per cent conditions despite rarity condition number diseases means six eight per cent population may affected rare disease many genetic origin start childhood cause lifelong debility premature death new unit seek build existing capabilities partnerships establish inlicensing opportunities gsk announced two collaborations companies prosensa jcr pharmaceutica involved researching developing medicines rare diseases alliance prosensa focuses developing nucleic acid based therapeutics intended treat specific different subpopulations patients suffering duchenne muscular dystrophy dmd part agreement jcr pharmaceuticals japanese developer manufacturer bioactive products gsk obtained global rights number enzyme replacement therapies could upon approval used treat orphan diseases hunter syndrome fabry disease gaucher disease entry new therapeutic area forms part gsk 's strategy deliver products value improve returns rd focus areas higher probability success risk associated product discovery development rare diseases generally lower disease areas disease definitions clear clinical trials tend small robust endpoints wwworphanet portal rare diseases orphan drugs wwwfdagov analysis approved therapies us since vs known rare diseases 'rare diseases understanding public health priority ' european organisation rare diseases november patient safety collaborating others improve safe use medicines patients work includes cochairing serious adverse event consortiums saec scientific management committee read work saec aims improve patient safety genetic research industry lead innovative medicines initiatives patient safety project aims develop methodologies enhance assessment benefitrisk profile new medicines founding member uks public private collaborations stem cells safer medicines organisation investigating potential human stem cells screen potential new medicines safety toxicology read patient safety gsk academic collaborations invest research capabilities universities fund leadingedge academic research projects support science students provided support million alliances academic institutions support benefits academic institutions increased funding technology transfer access research facilities expertise contributes better scientific understanding capability countries operate benefits gsk enabling us tap rd expertise activity outside company expands potential recruitment pool better trained scientists academic collaborations included newly launched million two year project wellcome trust develop antibiotic treat methicillinresistant staphylococcus aureus mrsa financed wellcome trust seed funding initiative gskwellcome trust research programme use gsks knowledge structureactivity relationships novel class antibacterial molecules partnership academics universities london exeter kings college securing million grants engineering physical sciences research council epsrc develop systems deliver drugs across blood brain barrier would allow better treatment diseases affecting brain epilepsy schizophrenia two awards totalling million given medical research council gsk scientists hammersmith hospital clinical imaging centre provide threeyear training programmes radiochemistry brain imaging research develop new ways modelling pharmacological interactions brain partnership geneticists duke university medical center leading discovery two new genes associated chronic obstructive pulmonary disease copd increasing understanding genetic risk factors respiratory disease new partnership university washington apply new statistical methods rapidly analyse large sets genetic data predict responses new therapies identifying genes influence drug response collaboration university college london academic discovery performance unit dpu develop new treatment amyloidosis rare potentially fatal condition academic dpu new initiative combine best academic thinking gsks industry expertise back tophome responsibility contribution global health research development contributing scientific understanding corporate responsibility report contributing scientific understanding gsk large pool scientists recognise monopoly research best science committed accelerating discovery new medicines vaccines collaborating external partners open sharing scientific understanding external partner collaborations underway complement internal discovery performance units also fund basic medical research conducted outside gsk increase understanding human body impact disease frequently foundation future advances diagnosis treatment prevention disease rd policies global apply high standards wherever operate collaborate organisations whose principles aligned gsk research conducted part collaboration raise awareness policies beginning collaboration include clauses collaboration agreement requiring compliance principles read ensure high ethical standards rd activity opening new dialogues working spirit greater collaboration part looking making new alliances supporting research neglected tropical diseases opening tres cantos rd site external scientists establishing knowledge pool allowing others access intellectual property develop new treatments developing world read knowledge pool announced alliance uk government wellcome trust east england development agency creation biotechnology science park located gsk 's rd site stevenage uk project aims create hub innovation life sciences research companies located park shared access specialist skills equipment expertise simulate new innovation drug development gsk partnering wellcome trust joint million investment generate 'chemical probes ' proteins involved epigenetic signalling make available researchers without restriction publicprivate partnership led structural genomics consortium involves national institutes healths chemical genomics centre washington us university oxford initiative could offer new model future interactions academia industry collaborating accelerate drug development november gsk pfizer jointly launched viiv healthcare major new collaboration accelerate development vaccines treatments hivaids read viiv healthcare gsk involved innovative medicines initiative imi billion collaborative research programme founded european commission european pharmaceutical industry imi brings together large small biopharmaceutical healthcare companies academia regulators patient groups aim removing barriers discovery development new medicines results collaborations widely shared broader research community benefit knowledge gained gsk involved projects funded imi focus diverse topics gsk coordinator imi project aimed developing tools accelerate drug discovery alzheimers disease gsk also participating research projects range areas including oncology infectious diseases electronic health records pharmacokinetic modelling funded second wave imi projects gsk working path malaria vaccine initiative mvi since develop paediatric vaccine malaria rtss partnership announced study results showed rtss provides infants young children significant protection malaria phase lll studies started may run seven countries across africa read vaccines developing world new specialist unit research develop medicines rare diseases february announced formation new standalone unit research develop medicines rare diseases defined europe diseases affect fewer one people rare diseases identified yet treatments available ten per cent conditions despite rarity condition number diseases means six eight per cent population may affected rare disease many genetic origin start childhood cause lifelong debility premature death new unit seek build existing capabilities partnerships establish inlicensing opportunities gsk announced two collaborations companies prosensa jcr pharmaceutica involved researching developing medicines rare diseases alliance prosensa focuses developing nucleic acid based therapeutics intended treat specific different subpopulations patients suffering duchenne muscular dystrophy dmd part agreement jcr pharmaceuticals japanese developer manufacturer bioactive products gsk obtained global rights number enzyme replacement therapies could upon approval used treat orphan diseases hunter syndrome fabry disease gaucher disease entry new therapeutic area forms part gsk 's strategy deliver products value improve returns rd focus areas higher probability success risk associated product discovery development rare diseases generally lower disease areas disease definitions clear clinical trials tend small robust endpoints wwworphanet portal rare diseases orphan drugs wwwfdagov analysis approved therapies us since vs known rare diseases 'rare diseases understanding public health priority ' european organisation rare diseases november patient safety collaborating others improve safe use medicines patients work includes cochairing serious adverse event consortiums saec scientific management committee read work saec aims improve patient safety genetic research industry lead innovative medicines initiatives patient safety project aims develop methodologies enhance assessment benefitrisk profile new medicines founding member uks public private collaborations stem cells safer medicines organisation investigating potential human stem cells screen potential new medicines safety toxicology read patient safety gsk academic collaborations invest research capabilities universities fund leadingedge academic research projects support science students provided support million alliances academic institutions support benefits academic institutions increased funding technology transfer access research facilities expertise contributes better scientific understanding capability countries operate benefits gsk enabling us tap rd expertise activity outside company expands potential recruitment pool better trained scientists academic collaborations included newly launched million two year project wellcome trust develop antibiotic treat methicillinresistant staphylococcus aureus mrsa financed wellcome trust seed funding initiative gskwellcome trust research programme use gsks knowledge structureactivity relationships novel class antibacterial molecules partnership academics universities london exeter kings college securing million grants engineering physical sciences research council epsrc develop systems deliver drugs across blood brain barrier would allow better treatment diseases affecting brain epilepsy schizophrenia two awards totalling million given medical research council gsk scientists hammersmith hospital clinical imaging centre provide threeyear training programmes radiochemistry brain imaging research develop new ways modelling pharmacological interactions brain partnership geneticists duke university medical center leading discovery two new genes associated chronic obstructive pulmonary disease copd increasing understanding genetic risk factors respiratory disease new partnership university washington apply new statistical methods rapidly analyse large sets genetic data predict responses new therapies identifying genes influence drug response collaboration university college london academic discovery performance unit dpu develop new treatment amyloidosis rare potentially fatal condition academic dpu new initiative combine best academic thinking gsks industry expertise back top home responsibility contribution global health research development contributing scientific understanding corporate responsibility report contributing scientific understanding gsk large pool scientists recognise monopoly research best science committed accelerating discovery new medicines vaccines collaborating external partners open sharing scientific understanding external partner collaborations underway complement internal discovery performance units also fund basic medical research conducted outside gsk increase understanding human body impact disease frequently foundation future advances diagnosis treatment prevention disease rd policies global apply high standards wherever operate collaborate organisations whose principles aligned gsk research conducted part collaboration raise awareness policies beginning collaboration include clauses collaboration agreement requiring compliance principles read ensure high ethical standards rd activity opening new dialogues working spirit greater collaboration part looking making new alliances supporting research neglected tropical diseases opening tres cantos rd site external scientists establishing knowledge pool allowing others access intellectual property develop new treatments developing world read knowledge pool announced alliance uk government wellcome trust east england development agency creation biotechnology science park located gsk 's rd site stevenage uk project aims create hub innovation life sciences research companies located park shared access specialist skills equipment expertise simulate new innovation drug development gsk partnering wellcome trust joint million investment generate 'chemical probes ' proteins involved epigenetic signalling make available researchers without restriction publicprivate partnership led structural genomics consortium involves national institutes healths chemical genomics centre washington us university oxford initiative could offer new model future interactions academia industry collaborating accelerate drug development november gsk pfizer jointly launched viiv healthcare major new collaboration accelerate development vaccines treatments hivaids read viiv healthcare gsk involved innovative medicines initiative imi billion collaborative research programme founded european commission european pharmaceutical industry imi brings together large small biopharmaceutical healthcare companies academia regulators patient groups aim removing barriers discovery development new medicines results collaborations widely shared broader research community benefit knowledge gained gsk involved projects funded imi focus diverse topics gsk coordinator imi project aimed developing tools accelerate drug discovery alzheimers disease gsk also participating research projects range areas including oncology infectious diseases electronic health records pharmacokinetic modelling funded second wave imi projects gsk working path malaria vaccine initiative mvi since develop paediatric vaccine malaria rtss partnership announced study results showed rtss provides infants young children significant protection malaria phase lll studies started may run seven countries across africa read vaccines developing world new specialist unit research develop medicines rare diseases february announced formation new standalone unit research develop medicines rare diseases defined europe diseases affect fewer one people rare diseases identified yet treatments available ten per cent conditions despite rarity condition number diseases means six eight per cent population may affected rare disease many genetic origin start childhood cause lifelong debility premature death new unit seek build existing capabilities partnerships establish inlicensing opportunities gsk announced two collaborations companies prosensa jcr pharmaceutica involved researching developing medicines rare diseases alliance prosensa focuses developing nucleic acid based therapeutics intended treat specific different subpopulations patients suffering duchenne muscular dystrophy dmd part agreement jcr pharmaceuticals japanese developer manufacturer bioactive products gsk obtained global rights number enzyme replacement therapies could upon approval used treat orphan diseases hunter syndrome fabry disease gaucher disease entry new therapeutic area forms part gsk 's strategy deliver products value improve returns rd focus areas higher probability success risk associated product discovery development rare diseases generally lower disease areas disease definitions clear clinical trials tend small robust endpoints wwworphanet portal rare diseases orphan drugs wwwfdagov analysis approved therapies us since vs known rare diseases 'rare diseases understanding public health priority ' european organisation rare diseases november patient safety collaborating others improve safe use medicines patients work includes cochairing serious adverse event consortiums saec scientific management committee read work saec aims improve patient safety genetic research industry lead innovative medicines initiatives patient safety project aims develop methodologies enhance assessment benefitrisk profile new medicines founding member uks public private collaborations stem cells safer medicines organisation investigating potential human stem cells screen potential new medicines safety toxicology read patient safety gsk academic collaborations invest research capabilities universities fund leadingedge academic research projects support science students provided support million alliances academic institutions support benefits academic institutions increased funding technology transfer access research facilities expertise contributes better scientific understanding capability countries operate benefits gsk enabling us tap rd expertise activity outside company expands potential recruitment pool better trained scientists academic collaborations included newly launched million two year project wellcome trust develop antibiotic treat methicillinresistant staphylococcus aureus mrsa financed wellcome trust seed funding initiative gskwellcome trust research programme use gsks knowledge structureactivity relationships novel class antibacterial molecules partnership academics universities london exeter kings college securing million grants engineering physical sciences research council epsrc develop systems deliver drugs across blood brain barrier would allow better treatment diseases affecting brain epilepsy schizophrenia two awards totalling million given medical research council gsk scientists hammersmith hospital clinical imaging centre provide threeyear training programmes radiochemistry brain imaging research develop new ways modelling pharmacological interactions brain partnership geneticists duke university medical center leading discovery two new genes associated chronic obstructive pulmonary disease copd increasing understanding genetic risk factors respiratory disease new partnership university washington apply new statistical methods rapidly analyse large sets genetic data predict responses new therapies identifying genes influence drug response collaboration university college london academic discovery performance unit dpu develop new treatment amyloidosis rare potentially fatal condition academic dpu new initiative combine best academic thinking gsks industry expertise back top home responsibility contribution global health qas corporate responsibility report qas respond questions raised stakeholders goal cure disease find treatments ongoing chronic use ideally want cure disease antibiotics help treat diseases caused bacterial infection antiparasitic medicines help prevent treat prevalent diseases lymphatic filariasis malaria unfortunately known cure diseases medicines help reduce symptoms may need taken long periods medicines still valuable may enable patient normal lifestyle example remaining work looking family many cases continuing research find cure ideally want prevent disease occurring first place vaccines important role factors consider prioritising rd efforts three main interrelated factors science patient need value potential new medicine therapy add compared existing treatment options assess scientific opportunities determine advances scientific disease understanding may lead innovative new ways treat prevent disease used outcome recent systematic therapy area review looking scientific understanding therapy areas refocus research effort continually evaluate scientific information obtain compounds help us predict whether developed effective welltolerated medicines assessing patient need fundamental rd gsk ranges looking medicines treat diseases current effective treatments development medicines improve existing treatments terms safety efficacy ease use assessment potential new treatments also recognises factors product provide advantages others available many patients could benefit new therapy range conditions may suitable treating better able meet patient needs likely product seen provide value provision healthcare however always possible achieve return investment example developing treatments diseases prevalent developing world cases return investment limited patient need high may seek ways share costs risks associated drug development researching drugs treat serious diseases pipeline product range includes products major causes mortality morbidity disease product launches included arzerra ofatumumab treatment chronic lymphocytic leukemia pandemrix hn pandemic flu vaccine synflorix streptococcus pneumoniae disease prophylaxis infants children votrient pazopanib advanced renal cell carcinoma topselling products treat asthma chronic obstructive pulmonary disease diabetes herpes influenza vaccines portfolio includes vaccines prevent influenza hepatitis rotavirus human papillomavirus infection cause cervical cancer also make vaccines prevent many childhood illnesses measles rubella measure rd productivity ultimate measure productivity delivery new medicines meet patients needs gsk received product approvals completed new filings last three years gsk obtained fda approvals nmes vaccines company delivery set continued goal maintaining around assets latestage pipeline however given research development take longer ten years measure productivity number ways rd process including number compounds pipeline emerging risks benefits compounds success progressing compounds pipeline clinical trial phases l lll market registration speed progress pipeline indication efficiency rd processes true research productivity falling large pharmaceutical companies gsk managing investment pharmaceutical rd risen number new medicines gaining regulatory approval remained relatively constant decreased believe many reasons including increasing focus rd chronic degenerative diseases alzheimers scientifically challenging require longer clinical trials increased failure rates significant investment industry new technologies help deliver innovative medicines longer term example systems biology tools genomewide association scans new preclinical models sophisticated imaging equipment extensive requirements regulators healthcare payers including need conduct larger clinical studies evaluate longterm outcome treatment medicine well higher hurdles approval effectiveness existing treatments conditions demonstrating improved safety efficacy new treatment increasingly difficult approach focus meeting patients needs increasing effectiveness efficiency rd example discovery performance units dpus within established centres excellence drug discovery dpus small groups scientists focused specific disease molecular pathway structured efficient possible organisations combine entrepreneurial approach small company resources reach larger organisation committed accelerating discovery new medicines vaccines collaborating external partners open sharing scientific understanding external partner collaborations underway complement internal dpus back tophome responsibility contribution global health qas corporate responsibility report qas respond questions raised stakeholders goal cure disease find treatments ongoing chronic use ideally want cure disease antibiotics help treat diseases caused bacterial infection antiparasitic medicines help prevent treat prevalent diseases lymphatic filariasis malaria unfortunately known cure diseases medicines help reduce symptoms may need taken long periods medicines still valuable may enable patient normal lifestyle example remaining work looking family many cases continuing research find cure ideally want prevent disease occurring first place vaccines important role factors consider prioritising rd efforts three main interrelated factors science patient need value potential new medicine therapy add compared existing treatment options assess scientific opportunities determine advances scientific disease understanding may lead innovative new ways treat prevent disease used outcome recent systematic therapy area review looking scientific understanding therapy areas refocus research effort continually evaluate scientific information obtain compounds help us predict whether developed effective welltolerated medicines assessing patient need fundamental rd gsk ranges looking medicines treat diseases current effective treatments development medicines improve existing treatments terms safety efficacy ease use assessment potential new treatments also recognises factors product provide advantages others available many patients could benefit new therapy range conditions may suitable treating better able meet patient needs likely product seen provide value provision healthcare however always possible achieve return investment example developing treatments diseases prevalent developing world cases return investment limited patient need high may seek ways share costs risks associated drug development researching drugs treat serious diseases pipeline product range includes products major causes mortality morbidity disease product launches included arzerra ofatumumab treatment chronic lymphocytic leukemia pandemrix hn pandemic flu vaccine synflorix streptococcus pneumoniae disease prophylaxis infants children votrient pazopanib advanced renal cell carcinoma topselling products treat asthma chronic obstructive pulmonary disease diabetes herpes influenza vaccines portfolio includes vaccines prevent influenza hepatitis rotavirus human papillomavirus infection cause cervical cancer also make vaccines prevent many childhood illnesses measles rubella measure rd productivity ultimate measure productivity delivery new medicines meet patients needs gsk received product approvals completed new filings last three years gsk obtained fda approvals nmes vaccines company delivery set continued goal maintaining around assets latestage pipeline however given research development take longer ten years measure productivity number ways rd process including number compounds pipeline emerging risks benefits compounds success progressing compounds pipeline clinical trial phases l lll market registration speed progress pipeline indication efficiency rd processes true research productivity falling large pharmaceutical companies gsk managing investment pharmaceutical rd risen number new medicines gaining regulatory approval remained relatively constant decreased believe many reasons including increasing focus rd chronic degenerative diseases alzheimers scientifically challenging require longer clinical trials increased failure rates significant investment industry new technologies help deliver innovative medicines longer term example systems biology tools genomewide association scans new preclinical models sophisticated imaging equipment extensive requirements regulators healthcare payers including need conduct larger clinical studies evaluate longterm outcome treatment medicine well higher hurdles approval effectiveness existing treatments conditions demonstrating improved safety efficacy new treatment increasingly difficult approach focus meeting patients needs increasing effectiveness efficiency rd example discovery performance units dpus within established centres excellence drug discovery dpus small groups scientists focused specific disease molecular pathway structured efficient possible organisations combine entrepreneurial approach small company resources reach larger organisation committed accelerating discovery new medicines vaccines collaborating external partners open sharing scientific understanding external partner collaborations underway complement internal dpus back top home responsibility contribution global health qas corporate responsibility report qas respond questions raised stakeholders goal cure disease find treatments ongoing chronic use ideally want cure disease antibiotics help treat diseases caused bacterial infection antiparasitic medicines help prevent treat prevalent diseases lymphatic filariasis malaria unfortunately known cure diseases medicines help reduce symptoms may need taken long periods medicines still valuable may enable patient normal lifestyle example remaining work looking family many cases continuing research find cure ideally want prevent disease occurring first place vaccines important role factors consider prioritising rd efforts three main interrelated factors science patient need value potential new medicine therapy add compared existing treatment options assess scientific opportunities determine advances scientific disease understanding may lead innovative new ways treat prevent disease used outcome recent systematic therapy area review looking scientific understanding therapy areas refocus research effort continually evaluate scientific information obtain compounds help us predict whether developed effective welltolerated medicines assessing patient need fundamental rd gsk ranges looking medicines treat diseases current effective treatments development medicines improve existing treatments terms safety efficacy ease use assessment potential new treatments also recognises factors product provide advantages others available many patients could benefit new therapy range conditions may suitable treating better able meet patient needs likely product seen provide value provision healthcare however always possible achieve return investment example developing treatments diseases prevalent developing world cases return investment limited patient need high may seek ways share costs risks associated drug development researching drugs treat serious diseases pipeline product range includes products major causes mortality morbidity disease product launches included arzerra ofatumumab treatment chronic lymphocytic leukemia pandemrix hn pandemic flu vaccine synflorix streptococcus pneumoniae disease prophylaxis infants children votrient pazopanib advanced renal cell carcinoma topselling products treat asthma chronic obstructive pulmonary disease diabetes herpes influenza vaccines portfolio includes vaccines prevent influenza hepatitis rotavirus human papillomavirus infection cause cervical cancer also make vaccines prevent many childhood illnesses measles rubella measure rd productivity ultimate measure productivity delivery new medicines meet patients needs gsk received product approvals completed new filings last three years gsk obtained fda approvals nmes vaccines company delivery set continued goal maintaining around assets latestage pipeline however given research development take longer ten years measure productivity number ways rd process including number compounds pipeline emerging risks benefits compounds success progressing compounds pipeline clinical trial phases l lll market registration speed progress pipeline indication efficiency rd processes true research productivity falling large pharmaceutical companies gsk managing investment pharmaceutical rd risen number new medicines gaining regulatory approval remained relatively constant decreased believe many reasons including increasing focus rd chronic degenerative diseases alzheimers scientifically challenging require longer clinical trials increased failure rates significant investment industry new technologies help deliver innovative medicines longer term example systems biology tools genomewide association scans new preclinical models sophisticated imaging equipment extensive requirements regulators healthcare payers including need conduct larger clinical studies evaluate longterm outcome treatment medicine well higher hurdles approval effectiveness existing treatments conditions demonstrating improved safety efficacy new treatment increasingly difficult approach focus meeting patients needs increasing effectiveness efficiency rd example discovery performance units dpus within established centres excellence drug discovery dpus small groups scientists focused specific disease molecular pathway structured efficient possible organisations combine entrepreneurial approach small company resources reach larger organisation committed accelerating discovery new medicines vaccines collaborating external partners open sharing scientific understanding external partner collaborations underway complement internal dpus back top home responsibility access medicines corporate responsibility report access medicines providing access healthcare one worlds pressing social challenges every year millions worlds poorest people die curable preventable infectious diseases suffer unnecessary ill health access basic healthcare services including essential medicines cost healthcare also barrier access patients developed world particularly us many people healthcare insurance want increase access medicines vaccines countries believe right thing contribute business success striving meet societys healthcare needs build trust business helps safeguard licence operate long term barriers access many complex factors hamper access medicines developing countries many people living poverty access enough food clean water functioning healthcare system adequate medicines prevalent diseases may lacking range issues including limited prospect return rd investment neglected diseases added unified registration system medicines makes registration process costly complex time consuming individual regulatory authorities sufficient capacity deal effectively numerous complex product registrations many developing countries distribution network medicines weak lack basic infrastructure hospitals clinics healthcare professionals barriers often compounded insufficient political action resulting inadequate funding across aspects healthcare system middleincome countries health system may developed large differences income levels prevent many people accessing healthcare however problems must excuse inaction rather indicate action needed breaking barriers despite significant progress last decade example fight aids know increase access complexity access challenge means address issue acting alone prioritise areas make difference core business activities skills resources particular means initiatives improve affordability conduct encourage investment rd diseases developing world speech harvard medical school february gsks ceo andrew witty outlined access strategy announced number new initiatives reported cr report january andrew gave speech council foreign relations cfr new york outlined progress achieved commitments contained harvard speech expanded gsks approach breaking barriers innovation access medicines developing world cfr speech addressed four areas establishing independent open lab research neglected tropical diseases making publicly available information compounds compound library identified screening activity malaria parasite launch new collaborations share intellectual property knowhow accelerate delivery new medicines neglected tropical diseases creating sustainable pricing model malaria candidate vaccine information areas found section back tophome responsibility access medicines corporate responsibility report access medicines providing access healthcare one worlds pressing social challenges every year millions worlds poorest people die curable preventable infectious diseases suffer unnecessary ill health access basic healthcare services including essential medicines cost healthcare also barrier access patients developed world particularly us many people healthcare insurance want increase access medicines vaccines countries believe right thing contribute business success striving meet societys healthcare needs build trust business helps safeguard licence operate long term barriers access many complex factors hamper access medicines developing countries many people living poverty access enough food clean water functioning healthcare system adequate medicines prevalent diseases may lacking range issues including limited prospect return rd investment neglected diseases added unified registration system medicines makes registration process costly complex time consuming individual regulatory authorities sufficient capacity deal effectively numerous complex product registrations many developing countries distribution network medicines weak lack basic infrastructure hospitals clinics healthcare professionals barriers often compounded insufficient political action resulting inadequate funding across aspects healthcare system middleincome countries health system may developed large differences income levels prevent many people accessing healthcare however problems must excuse inaction rather indicate action needed breaking barriers despite significant progress last decade example fight aids know increase access complexity access challenge means address issue acting alone prioritise areas make difference core business activities skills resources particular means initiatives improve affordability conduct encourage investment rd diseases developing world speech harvard medical school february gsks ceo andrew witty outlined access strategy announced number new initiatives reported cr report january andrew gave speech council foreign relations cfr new york outlined progress achieved commitments contained harvard speech expanded gsks approach breaking barriers innovation access medicines developing world cfr speech addressed four areas establishing independent open lab research neglected tropical diseases making publicly available information compounds compound library identified screening activity malaria parasite launch new collaborations share intellectual property knowhow accelerate delivery new medicines neglected tropical diseases creating sustainable pricing model malaria candidate vaccine information areas found section back top home responsibility access medicines corporate responsibility report access medicines providing access healthcare one worlds pressing social challenges every year millions worlds poorest people die curable preventable infectious diseases suffer unnecessary ill health access basic healthcare services including essential medicines cost healthcare also barrier access patients developed world particularly us many people healthcare insurance want increase access medicines vaccines countries believe right thing contribute business success striving meet societys healthcare needs build trust business helps safeguard licence operate long term barriers access many complex factors hamper access medicines developing countries many people living poverty access enough food clean water functioning healthcare system adequate medicines prevalent diseases may lacking range issues including limited prospect return rd investment neglected diseases added unified registration system medicines makes registration process costly complex time consuming individual regulatory authorities sufficient capacity deal effectively numerous complex product registrations many developing countries distribution network medicines weak lack basic infrastructure hospitals clinics healthcare professionals barriers often compounded insufficient political action resulting inadequate funding across aspects healthcare system middleincome countries health system may developed large differences income levels prevent many people accessing healthcare however problems must excuse inaction rather indicate action needed breaking barriers despite significant progress last decade example fight aids know increase access complexity access challenge means address issue acting alone prioritise areas make difference core business activities skills resources particular means initiatives improve affordability conduct encourage investment rd diseases developing world speech harvard medical school february gsks ceo andrew witty outlined access strategy announced number new initiatives reported cr report january andrew gave speech council foreign relations cfr new york outlined progress achieved commitments contained harvard speech expanded gsks approach breaking barriers innovation access medicines developing world cfr speech addressed four areas establishing independent open lab research neglected tropical diseases making publicly available information compounds compound library identified screening activity malaria parasite launch new collaborations share intellectual property knowhow accelerate delivery new medicines neglected tropical diseases creating sustainable pricing model malaria candidate vaccine information areas found section back top home responsibility access medicines approach corporate responsibility report approach committed playing full part improving access medicines abbas hussain president gsks emerging markets region leads access efforts developing countries discussed reviewed corporate executive team gsks senior executive management team corporate responsibility committee board access medicines global problem requires global commitment barriers access vary significantly individual countries depending poverty income levels coverage quality healthcare infrastructure political commitment resources allocated healthcare tailor approach focus researchbased pharmaceutical company make difference explain approach increasing access least developed countries middleincome countries developed world extending access developing countries countries suffer inequalities income distribution access healthcare inequalities often particularly pronounced developing countries infectious diseases noncommunicable diseases present sectors society scale impact overall disease burden different segments vary illustrated past researchbased pharmaceutical industry tended focus higher income sectors society developing countries able afford healthcare provision achieve growth business extend access medicines less well sectors society need improve affordability medicines develop product range suited sectors society achieve pursuing number pricing strategies refocusing rd activities seeking innovative partnerships try reach people would otherwise access products examples strategies covered report section partnerships combine resources expertise companies governments international agencies academic institutions ngos communities play key role areas approach know partnership achieve patients alone mean developing countries deciding classify countries looking access medicines policies imperfect art rather science term developing country used broadly include worlds poorest countries well worlds largest economies brazil china india russia formulating pricing access policies tend use three groupings overlaps uns list least developed countries ldcs countries subsaharan africa ssa middleincome countries ldcs countries subsaharan africa well defined fairly stable international organisations also refer ldcs including wto particular doha declaration trips agreement public health generally ldcs countries ssa also either ability pay least impact hivaids pandemic acutely felt middleincome countries normally use world bank categories lowermiddle income uppermiddle income overlap world bank middleincome countries ldc ssa groupings example angola botswana cameroon gabon kiribati namibia nigeria south africa classed middleincome world bank gsk uses term developing countries include ldcs ssa middleincome countries definitions developing countries used organisations include countries outside world bank high income classification nonoecd countries strictly adhere world bank classifications would exclude equatorial guinea many caribbean islands access policies complication world bank classifications revised annually basing policies ranking could lead country eligibility changing year year used non oecd countries definition would rule mexico may soon exclude countries chile russia brazil china india indonesia south africa likely become oecd members talk middleincome countries normally referring world bank classifications excluding countries ldcs ssa highincome countries equatorial guinea many caribbean islands least developed countries ldcs challenge increasing access medicines particularly acute worlds poorest countries defined un regions approach includes research invest rd new medicines vaccines prevent treat neglected tropical diseases encouraging innovation outside gsk knowledge pool opening tres cantos research centre pricing cap prices patented medicines ldcs offer notforprofit prices hivaids medicines adopt tiered pricing vaccines partnerships important work others range partnerships extend reach activities example grant voluntary licences generic versions anti retrovirals signed agreement aspen expand portfolio subsaharan africa healthcare infrastructure investing per cent profits medicines ldcs back projects strengthen healthcare infrastructure countries community investment donate money expertise support disease prevention community healthcare reinvestment profits community investment programmes covered detail community investment section report update september july announced formation new operating unit dedicated expanding access medicines people living least developed countries ldcs new developing countries market access group integrate existing business ldcs one business unit provide focus strategic approaches expand access medicines people living countries unit another important step ensuring access medicines integral way business access medicines index gsk ranked top access medicines index rated companies performance according eight criteria management influence research development patenting capacity pricing drug donations philanthropy publication next access medicines index expected june update september gsk ranked top access medicine index second successive time june index produced access medicines foundation financial analysts riskmetrics aims supply pharmaceutical companies investors governments nongovernmental organisations stakeholders independent impartial reliable information pharmaceutical companies efforts improve global access medicine index assessed rdbased pharmaceutical companies seven generics companies performance seven criteria management influence rd pricing patenting capability philanthropy gsk ranked highest six seven categories gsk welcomes acknowledgment atm index report gives gsk industry efforts pleased progress achieved recent years recognised clearly still done consider recommendations atm index carefully continue look areas make biggest difference middleincome countries middleincome countries mics defined world bank brazil china thailand indonesia large affluent middle class offering significant business opportunities gsk many mics also large numbers people living extreme poverty healthcare demands often outstrip available resources mics represent increasingly important customers industry also present significant access challenges expand regions believe efforts successful deliver greater access medicines lowincome groups better segments society includes making medicines vaccines affordable developing products address countrys health needs using right channels reach people need approach includes research invest rd new medicines vaccines prevent treat neglected tropical diseases encouraging innovation outside gsk knowledge pool opening tres cantos research centre pricing developing flexible pricing strategy aims make medicines affordable segments society inlicensing joint ventures acquisitions expanding portfolio middleincome countries well transferring manufacturing research expertise community investment also support community programmes number middleincome countries developed countries access medicines issue developing world even developed countries patients afford medicines need adopting range flexible pricing models reflect commitment work governments stakeholders support efforts deliver medicines vaccines many people possible ldcs world bank classification oecd countries back tophome responsibility access medicines approach corporate responsibility report approach committed playing full part improving access medicines abbas hussain president gsks emerging markets region leads access efforts developing countries discussed reviewed corporate executive team gsks senior executive management team corporate responsibility committee board access medicines global problem requires global commitment barriers access vary significantly individual countries depending poverty income levels coverage quality healthcare infrastructure political commitment resources allocated healthcare tailor approach focus researchbased pharmaceutical company make difference explain approach increasing access least developed countries middleincome countries developed world extending access developing countries countries suffer inequalities income distribution access healthcare inequalities often particularly pronounced developing countries infectious diseases noncommunicable diseases present sectors society scale impact overall disease burden different segments vary illustrated past researchbased pharmaceutical industry tended focus higher income sectors society developing countries able afford healthcare provision achieve growth business extend access medicines less well sectors society need improve affordability medicines develop product range suited sectors society achieve pursuing number pricing strategies refocusing rd activities seeking innovative partnerships try reach people would otherwise access products examples strategies covered report section partnerships combine resources expertise companies governments international agencies academic institutions ngos communities play key role areas approach know partnership achieve patients alone mean developing countries deciding classify countries looking access medicines policies imperfect art rather science term developing country used broadly include worlds poorest countries well worlds largest economies brazil china india russia formulating pricing access policies tend use three groupings overlaps uns list least developed countries ldcs countries subsaharan africa ssa middleincome countries ldcs countries subsaharan africa well defined fairly stable international organisations also refer ldcs including wto particular doha declaration trips agreement public health generally ldcs countries ssa also either ability pay least impact hivaids pandemic acutely felt middleincome countries normally use world bank categories lowermiddle income uppermiddle income overlap world bank middleincome countries ldc ssa groupings example angola botswana cameroon gabon kiribati namibia nigeria south africa classed middleincome world bank gsk uses term developing countries include ldcs ssa middleincome countries definitions developing countries used organisations include countries outside world bank high income classification nonoecd countries strictly adhere world bank classifications would exclude equatorial guinea many caribbean islands access policies complication world bank classifications revised annually basing policies ranking could lead country eligibility changing year year used non oecd countries definition would rule mexico may soon exclude countries chile russia brazil china india indonesia south africa likely become oecd members talk middleincome countries normally referring world bank classifications excluding countries ldcs ssa highincome countries equatorial guinea many caribbean islands least developed countries ldcs challenge increasing access medicines particularly acute worlds poorest countries defined un regions approach includes research invest rd new medicines vaccines prevent treat neglected tropical diseases encouraging innovation outside gsk knowledge pool opening tres cantos research centre pricing cap prices patented medicines ldcs offer notforprofit prices hivaids medicines adopt tiered pricing vaccines partnerships important work others range partnerships extend reach activities example grant voluntary licences generic versions anti retrovirals signed agreement aspen expand portfolio subsaharan africa healthcare infrastructure investing per cent profits medicines ldcs back projects strengthen healthcare infrastructure countries community investment donate money expertise support disease prevention community healthcare reinvestment profits community investment programmes covered detail community investment section report update september july announced formation new operating unit dedicated expanding access medicines people living least developed countries ldcs new developing countries market access group integrate existing business ldcs one business unit provide focus strategic approaches expand access medicines people living countries unit another important step ensuring access medicines integral way business access medicines index gsk ranked top access medicines index rated companies performance according eight criteria management influence research development patenting capacity pricing drug donations philanthropy publication next access medicines index expected june update september gsk ranked top access medicine index second successive time june index produced access medicines foundation financial analysts riskmetrics aims supply pharmaceutical companies investors governments nongovernmental organisations stakeholders independent impartial reliable information pharmaceutical companies efforts improve global access medicine index assessed rdbased pharmaceutical companies seven generics companies performance seven criteria management influence rd pricing patenting capability philanthropy gsk ranked highest six seven categories gsk welcomes acknowledgment atm index report gives gsk industry efforts pleased progress achieved recent years recognised clearly still done consider recommendations atm index carefully continue look areas make biggest difference middleincome countries middleincome countries mics defined world bank brazil china thailand indonesia large affluent middle class offering significant business opportunities gsk many mics also large numbers people living extreme poverty healthcare demands often outstrip available resources mics represent increasingly important customers industry also present significant access challenges expand regions believe efforts successful deliver greater access medicines lowincome groups better segments society includes making medicines vaccines affordable developing products address countrys health needs using right channels reach people need approach includes research invest rd new medicines vaccines prevent treat neglected tropical diseases encouraging innovation outside gsk knowledge pool opening tres cantos research centre pricing developing flexible pricing strategy aims make medicines affordable segments society inlicensing joint ventures acquisitions expanding portfolio middleincome countries well transferring manufacturing research expertise community investment also support community programmes number middleincome countries developed countries access medicines issue developing world even developed countries patients afford medicines need adopting range flexible pricing models reflect commitment work governments stakeholders support efforts deliver medicines vaccines many people possible ldcs world bank classification oecd countries back tophome responsibility access medicines approach corporate responsibility report approach committed playing full part improving access medicines abbas hussain president gsks emerging markets region leads access efforts developing countries discussed reviewed corporate executive team gsks senior executive management team corporate responsibility committee board access medicines global problem requires global commitment barriers access vary significantly individual countries depending poverty income levels coverage quality healthcare infrastructure political commitment resources allocated healthcare tailor approach focus researchbased pharmaceutical company make difference explain approach increasing access least developed countries middleincome countries developed world extending access developing countries countries suffer inequalities income distribution access healthcare inequalities often particularly pronounced developing countries infectious diseases noncommunicable diseases present sectors society scale impact overall disease burden different segments vary illustrated past researchbased pharmaceutical industry tended focus higher income sectors society developing countries able afford healthcare provision achieve growth business extend access medicines less well sectors society need improve affordability medicines develop product range suited sectors society achieve pursuing number pricing strategies refocusing rd activities seeking innovative partnerships try reach people would otherwise access products examples strategies covered report section partnerships combine resources expertise companies governments international agencies academic institutions ngos communities play key role areas approach know partnership achieve patients alone mean developing countries deciding classify countries looking access medicines policies imperfect art rather science term developing country used broadly include worlds poorest countries well worlds largest economies brazil china india russia formulating pricing access policies tend use three groupings overlaps uns list least developed countries ldcs countries subsaharan africa ssa middleincome countries ldcs countries subsaharan africa well defined fairly stable international organisations also refer ldcs including wto particular doha declaration trips agreement public health generally ldcs countries ssa also either ability pay least impact hivaids pandemic acutely felt middleincome countries normally use world bank categories lowermiddle income uppermiddle income overlap world bank middleincome countries ldc ssa groupings example angola botswana cameroon gabon kiribati namibia nigeria south africa classed middleincome world bank gsk uses term developing countries include ldcs ssa middleincome countries definitions developing countries used organisations include countries outside world bank high income classification nonoecd countries strictly adhere world bank classifications would exclude equatorial guinea many caribbean islands access policies complication world bank classifications revised annually basing policies ranking could lead country eligibility changing year year used non oecd countries definition would rule mexico may soon exclude countries chile russia brazil china india indonesia south africa likely become oecd members talk middleincome countries normally referring world bank classifications excluding countries ldcs ssa highincome countries equatorial guinea many caribbean islands least developed countries ldcs challenge increasing access medicines particularly acute worlds poorest countries defined un regions approach includes research invest rd new medicines vaccines prevent treat neglected tropical diseases encouraging innovation outside gsk knowledge pool opening tres cantos research centre pricing cap prices patented medicines ldcs offer notforprofit prices hivaids medicines adopt tiered pricing vaccines partnerships important work others range partnerships extend reach activities example grant voluntary licences generic versions anti retrovirals signed agreement aspen expand portfolio subsaharan africa healthcare infrastructure investing per cent profits medicines ldcs back projects strengthen healthcare infrastructure countries community investment donate money expertise support disease prevention community healthcare reinvestment profits community investment programmes covered detail community investment section report update september july announced formation new operating unit dedicated expanding access medicines people living least developed countries ldcs new developing countries market access group integrate existing business ldcs one business unit provide focus strategic approaches expand access medicines people living countries unit another important step ensuring access medicines integral way business access medicines index gsk ranked top access medicines index rated companies performance according eight criteria management influence research development patenting capacity pricing drug donations philanthropy publication next access medicines index expected june update september gsk ranked top access medicine index second successive time june index produced access medicines foundation financial analysts riskmetrics aims supply pharmaceutical companies investors governments nongovernmental organisations stakeholders independent impartial reliable information pharmaceutical companies efforts improve global access medicine index assessed rdbased pharmaceutical companies seven generics companies performance seven criteria management influence rd pricing patenting capability philanthropy gsk ranked highest six seven categories gsk welcomes acknowledgment atm index report gives gsk industry efforts pleased progress achieved recent years recognised clearly still done consider recommendations atm index carefully continue look areas make biggest difference middleincome countries middleincome countries mics defined world bank brazil china thailand indonesia large affluent middle class offering significant business opportunities gsk many mics also large numbers people living extreme poverty healthcare demands often outstrip available resources mics represent increasingly important customers industry also present significant access challenges expand regions believe efforts successful deliver greater access medicines lowincome groups better segments society includes making medicines vaccines affordable developing products address countrys health needs using right channels reach people need approach includes research invest rd new medicines vaccines prevent treat neglected tropical diseases encouraging innovation outside gsk knowledge pool opening tres cantos research centre pricing developing flexible pricing strategy aims make medicines affordable segments society inlicensing joint ventures acquisitions expanding portfolio middleincome countries well transferring manufacturing research expertise community investment also support community programmes number middleincome countries developed countries access medicines issue developing world even developed countries patients afford medicines need adopting range flexible pricing models reflect commitment work governments stakeholders support efforts deliver medicines vaccines many people possible ldcs world bank classification oecd countries back tophome responsibility access medicines approach corporate responsibility report approach committed playing full part improving access medicines abbas hussain president gsks emerging markets region leads access efforts developing countries discussed reviewed corporate executive team gsks senior executive management team corporate responsibility committee board access medicines global problem requires global commitment barriers access vary significantly individual countries depending poverty income levels coverage quality healthcare infrastructure political commitment resources allocated healthcare tailor approach focus researchbased pharmaceutical company make difference explain approach increasing access least developed countries middleincome countries developed world extending access developing countries countries suffer inequalities income distribution access healthcare inequalities often particularly pronounced developing countries infectious diseases noncommunicable diseases present sectors society scale impact overall disease burden different segments vary illustrated past researchbased pharmaceutical industry tended focus higher income sectors society developing countries able afford healthcare provision achieve growth business extend access medicines less well sectors society need improve affordability medicines develop product range suited sectors society achieve pursuing number pricing strategies refocusing rd activities seeking innovative partnerships try reach people would otherwise access products examples strategies covered report section partnerships combine resources expertise companies governments international agencies academic institutions ngos communities play key role areas approach know partnership achieve patients alone mean developing countries deciding classify countries looking access medicines policies imperfect art rather science term developing country used broadly include worlds poorest countries well worlds largest economies brazil china india russia formulating pricing access policies tend use three groupings overlaps uns list least developed countries ldcs countries subsaharan africa ssa middleincome countries ldcs countries subsaharan africa well defined fairly stable international organisations also refer ldcs including wto particular doha declaration trips agreement public health generally ldcs countries ssa also either ability pay least impact hivaids pandemic acutely felt middleincome countries normally use world bank categories lowermiddle income uppermiddle income overlap world bank middleincome countries ldc ssa groupings example angola botswana cameroon gabon kiribati namibia nigeria south africa classed middleincome world bank gsk uses term developing countries include ldcs ssa middleincome countries definitions developing countries used organisations include countries outside world bank high income classification nonoecd countries strictly adhere world bank classifications would exclude equatorial guinea many caribbean islands access policies complication world bank classifications revised annually basing policies ranking could lead country eligibility changing year year used non oecd countries definition would rule mexico may soon exclude countries chile russia brazil china india indonesia south africa likely become oecd members talk middleincome countries normally referring world bank classifications excluding countries ldcs ssa highincome countries equatorial guinea many caribbean islands least developed countries ldcs challenge increasing access medicines particularly acute worlds poorest countries defined un regions approach includes research invest rd new medicines vaccines prevent treat neglected tropical diseases encouraging innovation outside gsk knowledge pool opening tres cantos research centre pricing cap prices patented medicines ldcs offer notforprofit prices hivaids medicines adopt tiered pricing vaccines partnerships important work others range partnerships extend reach activities example grant voluntary licences generic versions anti retrovirals signed agreement aspen expand portfolio subsaharan africa healthcare infrastructure investing per cent profits medicines ldcs back projects strengthen healthcare infrastructure countries community investment donate money expertise support disease prevention community healthcare reinvestment profits community investment programmes covered detail community investment section report update september july announced formation new operating unit dedicated expanding access medicines people living least developed countries ldcs new developing countries market access group integrate existing business ldcs one business unit provide focus strategic approaches expand access medicines people living countries unit another important step ensuring access medicines integral way business access medicines index gsk ranked top access medicines index rated companies performance according eight criteria management influence research development patenting capacity pricing drug donations philanthropy publication next access medicines index expected june update september gsk ranked top access medicine index second successive time june index produced access medicines foundation financial analysts riskmetrics aims supply pharmaceutical companies investors governments nongovernmental organisations stakeholders independent impartial reliable information pharmaceutical companies efforts improve global access medicine index assessed rdbased pharmaceutical companies seven generics companies performance seven criteria management influence rd pricing patenting capability philanthropy gsk ranked highest six seven categories gsk welcomes acknowledgment atm index report gives gsk industry efforts pleased progress achieved recent years recognised clearly still done consider recommendations atm index carefully continue look areas make biggest difference middleincome countries middleincome countries mics defined world bank brazil china thailand indonesia large affluent middle class offering significant business opportunities gsk many mics also large numbers people living extreme poverty healthcare demands often outstrip available resources mics represent increasingly important customers industry also present significant access challenges expand regions believe efforts successful deliver greater access medicines lowincome groups better segments society includes making medicines vaccines affordable developing products address countrys health needs using right channels reach people need approach includes research invest rd new medicines vaccines prevent treat neglected tropical diseases encouraging innovation outside gsk knowledge pool opening tres cantos research centre pricing developing flexible pricing strategy aims make medicines affordable segments society inlicensing joint ventures acquisitions expanding portfolio middleincome countries well transferring manufacturing research expertise community investment also support community programmes number middleincome countries developed countries access medicines issue developing world even developed countries patients afford medicines need adopting range flexible pricing models reflect commitment work governments stakeholders support efforts deliver medicines vaccines many people possible ldcs world bank classification oecd countries back top home responsibility access medicines approach corporate responsibility report approach committed playing full part improving access medicines abbas hussain president gsks emerging markets region leads access efforts developing countries discussed reviewed corporate executive team gsks senior executive management team corporate responsibility committee board access medicines global problem requires global commitment barriers access vary significantly individual countries depending poverty income levels coverage quality healthcare infrastructure political commitment resources allocated healthcare tailor approach focus researchbased pharmaceutical company make difference explain approach increasing access least developed countries middleincome countries developed world extending access developing countries countries suffer inequalities income distribution access healthcare inequalities often particularly pronounced developing countries infectious diseases noncommunicable diseases present sectors society scale impact overall disease burden different segments vary illustrated past researchbased pharmaceutical industry tended focus higher income sectors society developing countries able afford healthcare provision achieve growth business extend access medicines less well sectors society need improve affordability medicines develop product range suited sectors society achieve pursuing number pricing strategies refocusing rd activities seeking innovative partnerships try reach people would otherwise access products examples strategies covered report section partnerships combine resources expertise companies governments international agencies academic institutions ngos communities play key role areas approach know partnership achieve patients alone mean developing countries deciding classify countries looking access medicines policies imperfect art rather science term developing country used broadly include worlds poorest countries well worlds largest economies brazil china india russia formulating pricing access policies tend use three groupings overlaps uns list least developed countries ldcs countries subsaharan africa ssa middleincome countries ldcs countries subsaharan africa well defined fairly stable international organisations also refer ldcs including wto particular doha declaration trips agreement public health generally ldcs countries ssa also either ability pay least impact hivaids pandemic acutely felt middleincome countries normally use world bank categories lowermiddle income uppermiddle income overlap world bank middleincome countries ldc ssa groupings example angola botswana cameroon gabon kiribati namibia nigeria south africa classed middleincome world bank gsk uses term developing countries include ldcs ssa middleincome countries definitions developing countries used organisations include countries outside world bank high income classification nonoecd countries strictly adhere world bank classifications would exclude equatorial guinea many caribbean islands access policies complication world bank classifications revised annually basing policies ranking could lead country eligibility changing year year used non oecd countries definition would rule mexico may soon exclude countries chile russia brazil china india indonesia south africa likely become oecd members talk middleincome countries normally referring world bank classifications excluding countries ldcs ssa highincome countries equatorial guinea many caribbean islands least developed countries ldcs challenge increasing access medicines particularly acute worlds poorest countries defined un regions approach includes research invest rd new medicines vaccines prevent treat neglected tropical diseases encouraging innovation outside gsk knowledge pool opening tres cantos research centre pricing cap prices patented medicines ldcs offer notforprofit prices hivaids medicines adopt tiered pricing vaccines partnerships important work others range partnerships extend reach activities example grant voluntary licences generic versions anti retrovirals signed agreement aspen expand portfolio subsaharan africa healthcare infrastructure investing per cent profits medicines ldcs back projects strengthen healthcare infrastructure countries community investment donate money expertise support disease prevention community healthcare reinvestment profits community investment programmes covered detail community investment section report update september july announced formation new operating unit dedicated expanding access medicines people living least developed countries ldcs new developing countries market access group integrate existing business ldcs one business unit provide focus strategic approaches expand access medicines people living countries unit another important step ensuring access medicines integral way business access medicines index gsk ranked top access medicines index rated companies performance according eight criteria management influence research development patenting capacity pricing drug donations philanthropy publication next access medicines index expected june update september gsk ranked top access medicine index second successive time june index produced access medicines foundation financial analysts riskmetrics aims supply pharmaceutical companies investors governments nongovernmental organisations stakeholders independent impartial reliable information pharmaceutical companies efforts improve global access medicine index assessed rdbased pharmaceutical companies seven generics companies performance seven criteria management influence rd pricing patenting capability philanthropy gsk ranked highest six seven categories gsk welcomes acknowledgment atm index report gives gsk industry efforts pleased progress achieved recent years recognised clearly still done consider recommendations atm index carefully continue look areas make biggest difference middleincome countries middleincome countries mics defined world bank brazil china thailand indonesia large affluent middle class offering significant business opportunities gsk many mics also large numbers people living extreme poverty healthcare demands often outstrip available resources mics represent increasingly important customers industry also present significant access challenges expand regions believe efforts successful deliver greater access medicines lowincome groups better segments society includes making medicines vaccines affordable developing products address countrys health needs using right channels reach people need approach includes research invest rd new medicines vaccines prevent treat neglected tropical diseases encouraging innovation outside gsk knowledge pool opening tres cantos research centre pricing developing flexible pricing strategy aims make medicines affordable segments society inlicensing joint ventures acquisitions expanding portfolio middleincome countries well transferring manufacturing research expertise community investment also support community programmes number middleincome countries developed countries access medicines issue developing world even developed countries patients afford medicines need adopting range flexible pricing models reflect commitment work governments stakeholders support efforts deliver medicines vaccines many people possible ldcs world bank classification oecd countries back top home responsibility access medicines approach improving access developing countries corporate responsibility report improving access developing countries improving access healthcare developing countries least developed middleincome countries requires holistic approach embracing prevention treatment efforts fundamentally strengthen health systems stakeholders need contribute pharmaceutical companies including gsk must make medicines affordable possible people worlds poorest communities sustainable manner must invest research diseases developing world new prevention tools treatments urgently needed must also work stakeholders seek innovative solutions delivering medicines vaccines people need wealthy nations continue generous development assistance give welcome new funding coming global fund fight aids tb malaria bill melinda gates foundation pepfar us presidents emergency plan aids relief unitaid others however funds still inadequate need predictable sustainable fund research strengthen health systems purchase medicines vaccines support disease prevention point stress advocacy efforts g developed countries developing countries show genuine political commitment prioritising healthcare national budgets addressing stigma improving affordability removing import tariffs medicines middleincome countries support tiered pricing approach based partly ability pay seeking lowest prices offered worlds poorest countries making return better countries able offer lowest prices poorest countries another key message advocacy efforts new commitments february ceo andrew witty delivered speech titled big pharma catalyst change reaffirmed gsks ongoing commitment improving access medicines particular committed expanding efforts improve health least developed countries summary announced seeking partnerships opening doors diseases developing world research centre tres cantos spain exploring flexible approach intellectual property rights stimulate research medicines least developed countries ldcs creating proprietary knowledge pool neglected tropical diseases placed approximately patent families granted patents pending applications pool help others develop new medicines neglected diseases reducing prices patented medicines ldcs higher per cent developed world price long covers cost goods made price reductions april products across ldcs average reduction per cent looking move supplier drugs partner delivering healthcare working partners ngos reinvest per cent profit make selling medicines ldcs help strengthen healthcare infrastructure countries sales ldcs relatively low profit limited initially funding amounts around million year july announced number new initiatives tackle hivaids developing world included new positive action children fund million ten years help prevent mothertochild transmission hiv support orphans vulnerable children million seed funding support publicprivate partnership research development new hivaids medicines children new commitment collaborate companies develop fixeddosed combinations currently available hiv treatments royaltyfree voluntary licences manufacture abacavir november launched viiv healthcare new specialist company dedicated discovery delivery treatments hiv collaboration gsk pfizer believe combining resources expertise accomplish treatment hiv globally either company achieve viiv healthcare deliver hiv commitments announced july read new approach hiv back tophome responsibility access medicines approach improving access developing countries corporate responsibility report improving access developing countries improving access healthcare developing countries least developed middleincome countries requires holistic approach embracing prevention treatment efforts fundamentally strengthen health systems stakeholders need contribute pharmaceutical companies including gsk must make medicines affordable possible people worlds poorest communities sustainable manner must invest research diseases developing world new prevention tools treatments urgently needed must also work stakeholders seek innovative solutions delivering medicines vaccines people need wealthy nations continue generous development assistance give welcome new funding coming global fund fight aids tb malaria bill melinda gates foundation pepfar us presidents emergency plan aids relief unitaid others however funds still inadequate need predictable sustainable fund research strengthen health systems purchase medicines vaccines support disease prevention point stress advocacy efforts g developed countries developing countries show genuine political commitment prioritising healthcare national budgets addressing stigma improving affordability removing import tariffs medicines middleincome countries support tiered pricing approach based partly ability pay seeking lowest prices offered worlds poorest countries making return better countries able offer lowest prices poorest countries another key message advocacy efforts new commitments february ceo andrew witty delivered speech titled big pharma catalyst change reaffirmed gsks ongoing commitment improving access medicines particular committed expanding efforts improve health least developed countries summary announced seeking partnerships opening doors diseases developing world research centre tres cantos spain exploring flexible approach intellectual property rights stimulate research medicines least developed countries ldcs creating proprietary knowledge pool neglected tropical diseases placed approximately patent families granted patents pending applications pool help others develop new medicines neglected diseases reducing prices patented medicines ldcs higher per cent developed world price long covers cost goods made price reductions april products across ldcs average reduction per cent looking move supplier drugs partner delivering healthcare working partners ngos reinvest per cent profit make selling medicines ldcs help strengthen healthcare infrastructure countries sales ldcs relatively low profit limited initially funding amounts around million year july announced number new initiatives tackle hivaids developing world included new positive action children fund million ten years help prevent mothertochild transmission hiv support orphans vulnerable children million seed funding support publicprivate partnership research development new hivaids medicines children new commitment collaborate companies develop fixeddosed combinations currently available hiv treatments royaltyfree voluntary licences manufacture abacavir november launched viiv healthcare new specialist company dedicated discovery delivery treatments hiv collaboration gsk pfizer believe combining resources expertise accomplish treatment hiv globally either company achieve viiv healthcare deliver hiv commitments announced july read new approach hiv back top home responsibility access medicines approach improving access developing countries corporate responsibility report improving access developing countries improving access healthcare developing countries least developed middleincome countries requires holistic approach embracing prevention treatment efforts fundamentally strengthen health systems stakeholders need contribute pharmaceutical companies including gsk must make medicines affordable possible people worlds poorest communities sustainable manner must invest research diseases developing world new prevention tools treatments urgently needed must also work stakeholders seek innovative solutions delivering medicines vaccines people need wealthy nations continue generous development assistance give welcome new funding coming global fund fight aids tb malaria bill melinda gates foundation pepfar us presidents emergency plan aids relief unitaid others however funds still inadequate need predictable sustainable fund research strengthen health systems purchase medicines vaccines support disease prevention point stress advocacy efforts g developed countries developing countries show genuine political commitment prioritising healthcare national budgets addressing stigma improving affordability removing import tariffs medicines middleincome countries support tiered pricing approach based partly ability pay seeking lowest prices offered worlds poorest countries making return better countries able offer lowest prices poorest countries another key message advocacy efforts new commitments february ceo andrew witty delivered speech titled big pharma catalyst change reaffirmed gsks ongoing commitment improving access medicines particular committed expanding efforts improve health least developed countries summary announced seeking partnerships opening doors diseases developing world research centre tres cantos spain exploring flexible approach intellectual property rights stimulate research medicines least developed countries ldcs creating proprietary knowledge pool neglected tropical diseases placed approximately patent families granted patents pending applications pool help others develop new medicines neglected diseases reducing prices patented medicines ldcs higher per cent developed world price long covers cost goods made price reductions april products across ldcs average reduction per cent looking move supplier drugs partner delivering healthcare working partners ngos reinvest per cent profit make selling medicines ldcs help strengthen healthcare infrastructure countries sales ldcs relatively low profit limited initially funding amounts around million year july announced number new initiatives tackle hivaids developing world included new positive action children fund million ten years help prevent mothertochild transmission hiv support orphans vulnerable children million seed funding support publicprivate partnership research development new hivaids medicines children new commitment collaborate companies develop fixeddosed combinations currently available hiv treatments royaltyfree voluntary licences manufacture abacavir november launched viiv healthcare new specialist company dedicated discovery delivery treatments hiv collaboration gsk pfizer believe combining resources expertise accomplish treatment hiv globally either company achieve viiv healthcare deliver hiv commitments announced july read new approach hiv back top home responsibility access medicines approach approach intellectual property corporate responsibility report approach intellectual property role intellectual property ip rights patents play access medicines continues subject discussion contention products viable market opportunity exists patents ip rights play vital role encouraging innovation needed develop new treatments many serious lifethreatening diseases without limited period exclusivity patents provide multibillion rd investment would commercially viable diseases developing world commercial opportunity exists particularly neglected tropical diseases new approaches required product development publicprivate partnerships medicines malaria venture tb alliance believe concerns ip barrier access developing world sometimes overstated risk diverting understanding efforts away key access problems developing world lack healthcare infrastructure resources however continue explore approaches flexible ip believe help tackle healthcare crisis developing countries example grant voluntary licences allow local companies manufacture hivaids medicines needed also created knowledge pool neglected tropical diseases least developed countries hope stimulate research new treatments diseases vital countries provide environment encourages innovation support intellectual property ip rights avoid measures widespread compulsory licensing remove incentives innovation investment rd supportive environment ip generally encourage companies flexible ip stimulate research treatments neglected diseases position intellectual property ip rights back top home responsibility access medicines approach approach intellectual property corporate responsibility report approach intellectual property role intellectual property ip rights patents play access medicines continues subject discussion contention products viable market opportunity exists patents ip rights play vital role encouraging innovation needed develop new treatments many serious lifethreatening diseases without limited period exclusivity patents provide multibillion rd investment would commercially viable diseases developing world commercial opportunity exists particularly neglected tropical diseases new approaches required product development publicprivate partnerships medicines malaria venture tb alliance believe concerns ip barrier access developing world sometimes overstated risk diverting understanding efforts away key access problems developing world lack healthcare infrastructure resources however continue explore approaches flexible ip believe help tackle healthcare crisis developing countries example grant voluntary licences allow local companies manufacture hivaids medicines needed also created knowledge pool neglected tropical diseases least developed countries hope stimulate research new treatments diseases vital countries provide environment encourages innovation support intellectual property ip rights avoid measures widespread compulsory licensing remove incentives innovation investment rd supportive environment ip generally encourage companies flexible ip stimulate research treatments neglected diseases position intellectual property ip rights back top home responsibility access medicines new approach hiv corporate responsibility report new approach hiv million people worldwide living hiv twothirds per cent new infections among children subsaharan africa global efforts tackle aids must maintained reinforced new hiv treatments urgently needed counter problems drug resistance april partnership pfizer announced plans create new specialist company solely focused research development commercialisation hiv medicines viiv healthcare launched november expect viiv healthcare bring commercial benefits gsk pfizer reach patients accomplish treatment hiv either companys businesses could achieved alone improving access hiv medicines everyone priority new business creation new company example developing new partnerships business models benefit global health viiv healthcare shares gsks commitment increase access medicines continue offer hiv medicines notforprofit prices facilitate new voluntary licences worlds poorest countries longstanding positive action programme established gsk focuses prevention hiv tackling hivrelated stigma discrimination positive action core viiv healthcares partnership programmes supporting local communities impacted hivaids globally viiv healthcare core objective address lack treatments formulations children living hiv significant unmet medical need manage new commitments announced improve research development access medicines children subsaharan africa support healthcare people living hiv aids new positive action children fund million ten years help prevent mothertochild transmission hiv support orphans vulnerable children million seed funding support publicprivate partnership research development new hivaids medicines children new commitment collaborate companies develop fixeddosed combinations currently available hiv treatments royaltyfree voluntary licences manufacture abacavir update september positive action children fund first grants awarded june viiv healthcare awarded first grants positive action children fund grants worth million used support projects focused preventing hiv transmission mothertochild supporting young people hiv africa india new paediatric hiv partnerships announced viiv healthcare announced two new partnerships designed improve management paediatric hiv worldwide company committed us million two years support elizabeth glaser pediatric aids foundation works increase early detection hiv improve access lifesaving care treatment infants children hivaids africa asia viiv healthcare contribute us million twoyear partnership treat asia bangkokbased programme run amfar foundation aids research support help strengthen clinical research programmes increase access treatment infants children hivaids accelerating access initiative accelerating access initiative aai publicprivate partnership accelerate access care treatment hivaids gsk founder member aai formed may viiv healthcare assumed gsks membership aai aai partnership unaids world bank unicef unfpa eight researchbased pharmaceutical companies abbott laboratories boehringer ingelheim bristolmyers squibb gilead sciences johnson johnson merck co inc roche viiv healthcare objectives aai accelerate sustained access increase use appropriate good quality interventions preventiontreatment hivaids ensure care treatment reach significantly greater numbers people need new alliances involving committed governments private industry un development assistance agencies nongovernmental organisations people living hivaids although impossible quantify directly efforts aai companies partners made significant contribution increase number people receiving antiretrovirals low middleincome countries according latest data unaids four million people access hiv treatment end tenfold increase five years unaids global aids epidemic factsheet back tophome responsibility access medicines new approach hiv corporate responsibility report new approach hiv million people worldwide living hiv twothirds per cent new infections among children subsaharan africa global efforts tackle aids must maintained reinforced new hiv treatments urgently needed counter problems drug resistance april partnership pfizer announced plans create new specialist company solely focused research development commercialisation hiv medicines viiv healthcare launched november expect viiv healthcare bring commercial benefits gsk pfizer reach patients accomplish treatment hiv either companys businesses could achieved alone improving access hiv medicines everyone priority new business creation new company example developing new partnerships business models benefit global health viiv healthcare shares gsks commitment increase access medicines continue offer hiv medicines notforprofit prices facilitate new voluntary licences worlds poorest countries longstanding positive action programme established gsk focuses prevention hiv tackling hivrelated stigma discrimination positive action core viiv healthcares partnership programmes supporting local communities impacted hivaids globally viiv healthcare core objective address lack treatments formulations children living hiv significant unmet medical need manage new commitments announced improve research development access medicines children subsaharan africa support healthcare people living hiv aids new positive action children fund million ten years help prevent mothertochild transmission hiv support orphans vulnerable children million seed funding support publicprivate partnership research development new hivaids medicines children new commitment collaborate companies develop fixeddosed combinations currently available hiv treatments royaltyfree voluntary licences manufacture abacavir update september positive action children fund first grants awarded june viiv healthcare awarded first grants positive action children fund grants worth million used support projects focused preventing hiv transmission mothertochild supporting young people hiv africa india new paediatric hiv partnerships announced viiv healthcare announced two new partnerships designed improve management paediatric hiv worldwide company committed us million two years support elizabeth glaser pediatric aids foundation works increase early detection hiv improve access lifesaving care treatment infants children hivaids africa asia viiv healthcare contribute us million twoyear partnership treat asia bangkokbased programme run amfar foundation aids research support help strengthen clinical research programmes increase access treatment infants children hivaids accelerating access initiative accelerating access initiative aai publicprivate partnership accelerate access care treatment hivaids gsk founder member aai formed may viiv healthcare assumed gsks membership aai aai partnership unaids world bank unicef unfpa eight researchbased pharmaceutical companies abbott laboratories boehringer ingelheim bristolmyers squibb gilead sciences johnson johnson merck co inc roche viiv healthcare objectives aai accelerate sustained access increase use appropriate good quality interventions preventiontreatment hivaids ensure care treatment reach significantly greater numbers people need new alliances involving committed governments private industry un development assistance agencies nongovernmental organisations people living hivaids although impossible quantify directly efforts aai companies partners made significant contribution increase number people receiving antiretrovirals low middleincome countries according latest data unaids four million people access hiv treatment end tenfold increase five years unaids global aids epidemic factsheet back top home responsibility access medicines new approach hiv corporate responsibility report new approach hiv million people worldwide living hiv twothirds per cent new infections among children subsaharan africa global efforts tackle aids must maintained reinforced new hiv treatments urgently needed counter problems drug resistance april partnership pfizer announced plans create new specialist company solely focused research development commercialisation hiv medicines viiv healthcare launched november expect viiv healthcare bring commercial benefits gsk pfizer reach patients accomplish treatment hiv either companys businesses could achieved alone improving access hiv medicines everyone priority new business creation new company example developing new partnerships business models benefit global health viiv healthcare shares gsks commitment increase access medicines continue offer hiv medicines notforprofit prices facilitate new voluntary licences worlds poorest countries longstanding positive action programme established gsk focuses prevention hiv tackling hivrelated stigma discrimination positive action core viiv healthcares partnership programmes supporting local communities impacted hivaids globally viiv healthcare core objective address lack treatments formulations children living hiv significant unmet medical need manage new commitments announced improve research development access medicines children subsaharan africa support healthcare people living hiv aids new positive action children fund million ten years help prevent mothertochild transmission hiv support orphans vulnerable children million seed funding support publicprivate partnership research development new hivaids medicines children new commitment collaborate companies develop fixeddosed combinations currently available hiv treatments royaltyfree voluntary licences manufacture abacavir update september positive action children fund first grants awarded june viiv healthcare awarded first grants positive action children fund grants worth million used support projects focused preventing hiv transmission mothertochild supporting young people hiv africa india new paediatric hiv partnerships announced viiv healthcare announced two new partnerships designed improve management paediatric hiv worldwide company committed us million two years support elizabeth glaser pediatric aids foundation works increase early detection hiv improve access lifesaving care treatment infants children hivaids africa asia viiv healthcare contribute us million twoyear partnership treat asia bangkokbased programme run amfar foundation aids research support help strengthen clinical research programmes increase access treatment infants children hivaids accelerating access initiative accelerating access initiative aai publicprivate partnership accelerate access care treatment hivaids gsk founder member aai formed may viiv healthcare assumed gsks membership aai aai partnership unaids world bank unicef unfpa eight researchbased pharmaceutical companies abbott laboratories boehringer ingelheim bristolmyers squibb gilead sciences johnson johnson merck co inc roche viiv healthcare objectives aai accelerate sustained access increase use appropriate good quality interventions preventiontreatment hivaids ensure care treatment reach significantly greater numbers people need new alliances involving committed governments private industry un development assistance agencies nongovernmental organisations people living hivaids although impossible quantify directly efforts aai companies partners made significant contribution increase number people receiving antiretrovirals low middleincome countries according latest data unaids four million people access hiv treatment end tenfold increase five years unaids global aids epidemic factsheet back top home responsibility access medicines new approach hiv viiv healthcare corporate responsibility report viiv healthcare viiv healthcare invest research development innovative hiv treatments formulations improve adherence treatment help tackle drug resistance company invest rd hiv medicines conducted gsk pfizer exclusive rights first negotiation relation new hivrelated medicine developed either company gsk continue rd relating hiv vaccines facts new company broad portfolio ten marketed products industryleading pipeline seven innovative potential medicines per cent share worldwide hiv market equity split per cent gsk per cent pfizer viiv healthcares pipeline includes seven innovative targeted medicines including five compounds phase ii development including early stage research projects altogether viiv healthcare molecules develop possible new hiv treatments viiv healthcare continue invest earlystage research discovery hiv medicines well rd viiv healthcare form strategic partnerships licensing arrangements organisations companys portfolio ten marketed products including combivir kivexa selzentrycelsentri generated sales around billion provide financial stability support investment rd unitaid patent pool hivaids medicines unitaid continued work develop patent pool hivaids medicines share unitaids commitment meeting unmet medical needs relating hiv gsk viiv held number meetings unitaid viiv healthcare remains discussion unitaid details proposal gsk participated unitaids event world health assembly may met unitaid july september also september gsk met consultancy unitaid appointed develop implementation plan business models pool november viiv healthcare met unitaid consultancy december unitaid published implementation plan pool developing legal framework pool viiv healthcare working actively unitaid process meantime viiv healthcare continue seek ways expand access products widespread licensing approach notforprofit preferential pricing intensified focus rd paediatric antiretrovirals arvs viiv healthcare lead discussions unitaid proposals develop key developments communicated viiv healthcare unitaid medicines patent pool initiative unitaid panel presentationsstatements nd wha back top home responsibility access medicines new approach hiv viiv healthcare corporate responsibility report viiv healthcare viiv healthcare invest research development innovative hiv treatments formulations improve adherence treatment help tackle drug resistance company invest rd hiv medicines conducted gsk pfizer exclusive rights first negotiation relation new hivrelated medicine developed either company gsk continue rd relating hiv vaccines facts new company broad portfolio ten marketed products industryleading pipeline seven innovative potential medicines per cent share worldwide hiv market equity split per cent gsk per cent pfizer viiv healthcares pipeline includes seven innovative targeted medicines including five compounds phase ii development including early stage research projects altogether viiv healthcare molecules develop possible new hiv treatments viiv healthcare continue invest earlystage research discovery hiv medicines well rd viiv healthcare form strategic partnerships licensing arrangements organisations companys portfolio ten marketed products including combivir kivexa selzentrycelsentri generated sales around billion provide financial stability support investment rd unitaid patent pool hivaids medicines unitaid continued work develop patent pool hivaids medicines share unitaids commitment meeting unmet medical needs relating hiv gsk viiv held number meetings unitaid viiv healthcare remains discussion unitaid details proposal gsk participated unitaids event world health assembly may met unitaid july september also september gsk met consultancy unitaid appointed develop implementation plan business models pool november viiv healthcare met unitaid consultancy december unitaid published implementation plan pool developing legal framework pool viiv healthcare working actively unitaid process meantime viiv healthcare continue seek ways expand access products widespread licensing approach notforprofit preferential pricing intensified focus rd paediatric antiretrovirals arvs viiv healthcare lead discussions unitaid proposals develop key developments communicated viiv healthcare unitaid medicines patent pool initiative unitaid panel presentationsstatements nd wha back top home responsibility access medicines new approach hiv viiv healthcare corporate responsibility report viiv healthcare viiv healthcare invest research development innovative hiv treatments formulations improve adherence treatment help tackle drug resistance company invest rd hiv medicines conducted gsk pfizer exclusive rights first negotiation relation new hivrelated medicine developed either company gsk continue rd relating hiv vaccines facts new company broad portfolio ten marketed products industryleading pipeline seven innovative potential medicines per cent share worldwide hiv market equity split per cent gsk per cent pfizer viiv healthcares pipeline includes seven innovative targeted medicines including five compounds phase ii development including early stage research projects altogether viiv healthcare molecules develop possible new hiv treatments viiv healthcare continue invest earlystage research discovery hiv medicines well rd viiv healthcare form strategic partnerships licensing arrangements organisations companys portfolio ten marketed products including combivir kivexa selzentrycelsentri generated sales around billion provide financial stability support investment rd unitaid patent pool hivaids medicines unitaid continued work develop patent pool hivaids medicines share unitaids commitment meeting unmet medical needs relating hiv gsk viiv held number meetings unitaid viiv healthcare remains discussion unitaid details proposal gsk participated unitaids event world health assembly may met unitaid july september also september gsk met consultancy unitaid appointed develop implementation plan business models pool november viiv healthcare met unitaid consultancy december unitaid published implementation plan pool developing legal framework pool viiv healthcare working actively unitaid process meantime viiv healthcare continue seek ways expand access products widespread licensing approach notforprofit preferential pricing intensified focus rd paediatric antiretrovirals arvs viiv healthcare lead discussions unitaid proposals develop key developments communicated viiv healthcare unitaid medicines patent pool initiative unitaid panel presentationsstatements nd wha back top home responsibility access medicines new approach hiv hivaids research corporate responsibility report hivaids research behalf viiv healthcare gsk committed development new molecules target unmet medical needs hiv treatment children hivaids remains significant unmet medical need pressing need new medicines tackle problems drug resistance complex treatment regimens side effects associated current treatments viiv healthcare launched november hiv performance rd pricing licensing written though gsk managed hiv business full year treatment children hivaids developed scored tablets corresponding paediatric dosing schedules enable anti retrovirals arvs broken two smaller doses administered children weighing kg makes easier children treated tablets rather liquid formulations tablets often easier store distribute also less complicated administer liquid formulations currently available particularly two three medicines combined one pill children get older need take larger volumes liquid formulations unicef stated access tablet form arvs could improve treatment options children able swallow tablets scored tablets epivir combivir ziagen approved europe us scored tablets also approved pending approval many developing countries child weighing kg take half tablet combivir morning second half evening combination another arv instead requiring ml epivir solution twice day plus ml retrovir solution three times daily gsk provided support many key clinical studies informed current prevention mothertochild transmission pmtct paediatric treatment guidelines continues number key collaborative trials committed support five currently active paediatric treatment studies resourcepoor countries determine best ways implement expand access hivaids treatment addition also currently supporting ten clinical trials evaluating strategies pmtct resource poor countries breastfeeding often unavoidable addressing impact pmtct regimens future health treatment options mother infant research new hiv treatments integrase inhibitors represent important new class compounds treatment hiv increasingly clear secondgeneration integrase inhibitors needed address issues drug resistance dosing complexity together partners shionogi two secondgeneration integrase inhibitors phase ii clinical development lead candidate sgsk demonstrated high potency low doses increased ability treat strains hiv resistant currently available integrase inhibitors update september collaboration shionogi generated promising results phase iib clinical trials indicating novel oncedaily unboosted investigational hiv integrase inhibitor sgsk one development worldwide potent antiviral activity could provide important therapy patients living hiv shionogiviiv presented trial results findings xviii international aids conference vienna austria july treatment enter phase iii clinical trials february announced licence agreement idenix pharmaceuticals inc granting gsk exclusive worldwide rights idx novel nonnucleoside reverse transcriptase inhibitor nnrti phase clinical development developed idenix treatment hivaids new nnrtis needed address increasing prevalence viral resistance side effects associated drug class date idx demonstrated high potency low doses high barrier drug resistance favourable riskbenefit profile convenience onceaday administration gsk progressed idx gsk phase clinical trials agent shown limited drug interaction potential well tolerated days treatment phase b studies anticipated begin mid evaluate gsk treatmentnaive treatmentexperienced patient populations hiv collaborative research trials international hiv collaborative research trials crt programme resourcepoor settings supporting clinical trials sponsored external organisations uks medical research council us national institutes health nih crts focus predominantly public healthrelated issues developing world prevention mothertochild hiv transmission paediatric adult treatment strategies start treatment hivtb coinfection gsk donates study antiretrovirals andor financial support also provides scientific input throughout life study end trials underway two planned involving approximately patients nineteen trials conducted sites africa five paediatric studies one provide first significant clinical data resourcepoor setting efficacy safety pharmacokinetics gsk nrti scored tablets committed hiv crt studies asia latin america african countries countries south africa india uganda thailand zimbabwe cambodia kenya vietnam botswana brazil zambia haiti tanzania peru malawi argentina back tophome responsibility access medicines new approach hiv hivaids research corporate responsibility report hivaids research behalf viiv healthcare gsk committed development new molecules target unmet medical needs hiv treatment children hivaids remains significant unmet medical need pressing need new medicines tackle problems drug resistance complex treatment regimens side effects associated current treatments viiv healthcare launched november hiv performance rd pricing licensing written though gsk managed hiv business full year treatment children hivaids developed scored tablets corresponding paediatric dosing schedules enable anti retrovirals arvs broken two smaller doses administered children weighing kg makes easier children treated tablets rather liquid formulations tablets often easier store distribute also less complicated administer liquid formulations currently available particularly two three medicines combined one pill children get older need take larger volumes liquid formulations unicef stated access tablet form arvs could improve treatment options children able swallow tablets scored tablets epivir combivir ziagen approved europe us scored tablets also approved pending approval many developing countries child weighing kg take half tablet combivir morning second half evening combination another arv instead requiring ml epivir solution twice day plus ml retrovir solution three times daily gsk provided support many key clinical studies informed current prevention mothertochild transmission pmtct paediatric treatment guidelines continues number key collaborative trials committed support five currently active paediatric treatment studies resourcepoor countries determine best ways implement expand access hivaids treatment addition also currently supporting ten clinical trials evaluating strategies pmtct resource poor countries breastfeeding often unavoidable addressing impact pmtct regimens future health treatment options mother infant research new hiv treatments integrase inhibitors represent important new class compounds treatment hiv increasingly clear secondgeneration integrase inhibitors needed address issues drug resistance dosing complexity together partners shionogi two secondgeneration integrase inhibitors phase ii clinical development lead candidate sgsk demonstrated high potency low doses increased ability treat strains hiv resistant currently available integrase inhibitors update september collaboration shionogi generated promising results phase iib clinical trials indicating novel oncedaily unboosted investigational hiv integrase inhibitor sgsk one development worldwide potent antiviral activity could provide important therapy patients living hiv shionogiviiv presented trial results findings xviii international aids conference vienna austria july treatment enter phase iii clinical trials february announced licence agreement idenix pharmaceuticals inc granting gsk exclusive worldwide rights idx novel nonnucleoside reverse transcriptase inhibitor nnrti phase clinical development developed idenix treatment hivaids new nnrtis needed address increasing prevalence viral resistance side effects associated drug class date idx demonstrated high potency low doses high barrier drug resistance favourable riskbenefit profile convenience onceaday administration gsk progressed idx gsk phase clinical trials agent shown limited drug interaction potential well tolerated days treatment phase b studies anticipated begin mid evaluate gsk treatmentnaive treatmentexperienced patient populations hiv collaborative research trials international hiv collaborative research trials crt programme resourcepoor settings supporting clinical trials sponsored external organisations uks medical research council us national institutes health nih crts focus predominantly public healthrelated issues developing world prevention mothertochild hiv transmission paediatric adult treatment strategies start treatment hivtb coinfection gsk donates study antiretrovirals andor financial support also provides scientific input throughout life study end trials underway two planned involving approximately patients nineteen trials conducted sites africa five paediatric studies one provide first significant clinical data resourcepoor setting efficacy safety pharmacokinetics gsk nrti scored tablets committed hiv crt studies asia latin america african countries countries south africa india uganda thailand zimbabwe cambodia kenya vietnam botswana brazil zambia haiti tanzania peru malawi argentina back top home responsibility access medicines new approach hiv hivaids research corporate responsibility report hivaids research behalf viiv healthcare gsk committed development new molecules target unmet medical needs hiv treatment children hivaids remains significant unmet medical need pressing need new medicines tackle problems drug resistance complex treatment regimens side effects associated current treatments viiv healthcare launched november hiv performance rd pricing licensing written though gsk managed hiv business full year treatment children hivaids developed scored tablets corresponding paediatric dosing schedules enable anti retrovirals arvs broken two smaller doses administered children weighing kg makes easier children treated tablets rather liquid formulations tablets often easier store distribute also less complicated administer liquid formulations currently available particularly two three medicines combined one pill children get older need take larger volumes liquid formulations unicef stated access tablet form arvs could improve treatment options children able swallow tablets scored tablets epivir combivir ziagen approved europe us scored tablets also approved pending approval many developing countries child weighing kg take half tablet combivir morning second half evening combination another arv instead requiring ml epivir solution twice day plus ml retrovir solution three times daily gsk provided support many key clinical studies informed current prevention mothertochild transmission pmtct paediatric treatment guidelines continues number key collaborative trials committed support five currently active paediatric treatment studies resourcepoor countries determine best ways implement expand access hivaids treatment addition also currently supporting ten clinical trials evaluating strategies pmtct resource poor countries breastfeeding often unavoidable addressing impact pmtct regimens future health treatment options mother infant research new hiv treatments integrase inhibitors represent important new class compounds treatment hiv increasingly clear secondgeneration integrase inhibitors needed address issues drug resistance dosing complexity together partners shionogi two secondgeneration integrase inhibitors phase ii clinical development lead candidate sgsk demonstrated high potency low doses increased ability treat strains hiv resistant currently available integrase inhibitors update september collaboration shionogi generated promising results phase iib clinical trials indicating novel oncedaily unboosted investigational hiv integrase inhibitor sgsk one development worldwide potent antiviral activity could provide important therapy patients living hiv shionogiviiv presented trial results findings xviii international aids conference vienna austria july treatment enter phase iii clinical trials february announced licence agreement idenix pharmaceuticals inc granting gsk exclusive worldwide rights idx novel nonnucleoside reverse transcriptase inhibitor nnrti phase clinical development developed idenix treatment hivaids new nnrtis needed address increasing prevalence viral resistance side effects associated drug class date idx demonstrated high potency low doses high barrier drug resistance favourable riskbenefit profile convenience onceaday administration gsk progressed idx gsk phase clinical trials agent shown limited drug interaction potential well tolerated days treatment phase b studies anticipated begin mid evaluate gsk treatmentnaive treatmentexperienced patient populations hiv collaborative research trials international hiv collaborative research trials crt programme resourcepoor settings supporting clinical trials sponsored external organisations uks medical research council us national institutes health nih crts focus predominantly public healthrelated issues developing world prevention mothertochild hiv transmission paediatric adult treatment strategies start treatment hivtb coinfection gsk donates study antiretrovirals andor financial support also provides scientific input throughout life study end trials underway two planned involving approximately patients nineteen trials conducted sites africa five paediatric studies one provide first significant clinical data resourcepoor setting efficacy safety pharmacokinetics gsk nrti scored tablets committed hiv crt studies asia latin america african countries countries south africa india uganda thailand zimbabwe cambodia kenya vietnam botswana brazil zambia haiti tanzania peru malawi argentina back top home responsibility access medicines new approach hiv pricing hivaids medicines corporate responsibility report pricing hivaids medicines least developed countries subsaharan africa gsk offered hivaids medicines forprofit nfp prices since viiv healthcare maintain commitment include additional products portfolio middleincome countries viiv healthcare explore range pricing solutions balance commercial objectives need increase access medicines afford pay markets viiv healthcare launched november hiv performance rd pricing licensing reported though gsk managed hiv business full year notforprofit nfp prices arvs key facts notforprofit prices apply antiretrovirals gsk offered preferential pricing antiretrovirals since formal nfp pricing since nfp prices sustainable make profit cover costs means sustain supply highquality products long needed nfp prices available least developed countries subsaharan africa total countries addition pepfar projects eligible global fund projects bring number countries eligible customers include public sector customers nfp organisations well private employers subsaharan africa providing treatment uninsured staff combivir leading combination arv available day nfp prices include insurance freight costs unlike prices quoted generic companies applicable orders size dependent large order quantities least developed countries notforprofit prices february reduced profit nfp prices arvs fifth time since combivir leading arv sells per patient per year least developed countries compared clearly improvement affordability important recognise people living less day communities inadequate healthcare systems price affordable without significant additional resources directed towards healthcare shipped million tablets nfp combivir million tablets nfp epivir developing world compared million million respectively decline supply arvs outweighed growth volumes licensees licensees supplied million tablets versions epivir combivir african countries figures include syrup capsule formulations therefore conservative giving estimate arv treatments shipped preferential prices gsk gsk licensees supply combivir epivir tablets gsk gsk licensees includes preferentially priced tablets supplied gsk tablets supplied licensees gsk supplied arvs nfp prices countries compared reflects countries moving away supply gsk supply licensees viiv healthcare continue look new customers nfp arvs countries regularly review nfp prices however may well licensees able produce firstline arvs lower costs continue increase share business patients receiving treatment difficult estimate number patients treated result preferential pricing agreements since control healthcare provision however unaids estimates four million people developing world access arvs end tenfold increase five years report accelerating access initiative aai suggests december around patients developing countries receiving least one arv treatment supplied nine rdbased pharmaceutical companies aai two years since december total number patients developing countries receiving treatment aai companies increased per cent addition increase africa number patients treated least one arv supplied aai companies asia doubled middleincome countries preferential pricing hivaids medicines negotiate preferential pricing arrangements hivaids medicines middleincome countries casebycase basis prices lower paid developed countries low nfp prices paid least developed countries done bilaterally dialogue governments believe approach appropriate burden disease resources available address burden vary significantly country country within countries arrangements combine viable sustainable commercial return gsk improved affordability healthcare systems concerned key focus viiv healthcare back tophome responsibility access medicines new approach hiv pricing hivaids medicines corporate responsibility report pricing hivaids medicines least developed countries subsaharan africa gsk offered hivaids medicines forprofit nfp prices since viiv healthcare maintain commitment include additional products portfolio middleincome countries viiv healthcare explore range pricing solutions balance commercial objectives need increase access medicines afford pay markets viiv healthcare launched november hiv performance rd pricing licensing reported though gsk managed hiv business full year notforprofit nfp prices arvs key facts notforprofit prices apply antiretrovirals gsk offered preferential pricing antiretrovirals since formal nfp pricing since nfp prices sustainable make profit cover costs means sustain supply highquality products long needed nfp prices available least developed countries subsaharan africa total countries addition pepfar projects eligible global fund projects bring number countries eligible customers include public sector customers nfp organisations well private employers subsaharan africa providing treatment uninsured staff combivir leading combination arv available day nfp prices include insurance freight costs unlike prices quoted generic companies applicable orders size dependent large order quantities least developed countries notforprofit prices february reduced profit nfp prices arvs fifth time since combivir leading arv sells per patient per year least developed countries compared clearly improvement affordability important recognise people living less day communities inadequate healthcare systems price affordable without significant additional resources directed towards healthcare shipped million tablets nfp combivir million tablets nfp epivir developing world compared million million respectively decline supply arvs outweighed growth volumes licensees licensees supplied million tablets versions epivir combivir african countries figures include syrup capsule formulations therefore conservative giving estimate arv treatments shipped preferential prices gsk gsk licensees supply combivir epivir tablets gsk gsk licensees includes preferentially priced tablets supplied gsk tablets supplied licensees gsk supplied arvs nfp prices countries compared reflects countries moving away supply gsk supply licensees viiv healthcare continue look new customers nfp arvs countries regularly review nfp prices however may well licensees able produce firstline arvs lower costs continue increase share business patients receiving treatment difficult estimate number patients treated result preferential pricing agreements since control healthcare provision however unaids estimates four million people developing world access arvs end tenfold increase five years report accelerating access initiative aai suggests december around patients developing countries receiving least one arv treatment supplied nine rdbased pharmaceutical companies aai two years since december total number patients developing countries receiving treatment aai companies increased per cent addition increase africa number patients treated least one arv supplied aai companies asia doubled middleincome countries preferential pricing hivaids medicines negotiate preferential pricing arrangements hivaids medicines middleincome countries casebycase basis prices lower paid developed countries low nfp prices paid least developed countries done bilaterally dialogue governments believe approach appropriate burden disease resources available address burden vary significantly country country within countries arrangements combine viable sustainable commercial return gsk improved affordability healthcare systems concerned key focus viiv healthcare back top home responsibility access medicines new approach hiv pricing hivaids medicines corporate responsibility report pricing hivaids medicines least developed countries subsaharan africa gsk offered hivaids medicines forprofit nfp prices since viiv healthcare maintain commitment include additional products portfolio middleincome countries viiv healthcare explore range pricing solutions balance commercial objectives need increase access medicines afford pay markets viiv healthcare launched november hiv performance rd pricing licensing reported though gsk managed hiv business full year notforprofit nfp prices arvs key facts notforprofit prices apply antiretrovirals gsk offered preferential pricing antiretrovirals since formal nfp pricing since nfp prices sustainable make profit cover costs means sustain supply highquality products long needed nfp prices available least developed countries subsaharan africa total countries addition pepfar projects eligible global fund projects bring number countries eligible customers include public sector customers nfp organisations well private employers subsaharan africa providing treatment uninsured staff combivir leading combination arv available day nfp prices include insurance freight costs unlike prices quoted generic companies applicable orders size dependent large order quantities least developed countries notforprofit prices february reduced profit nfp prices arvs fifth time since combivir leading arv sells per patient per year least developed countries compared clearly improvement affordability important recognise people living less day communities inadequate healthcare systems price affordable without significant additional resources directed towards healthcare shipped million tablets nfp combivir million tablets nfp epivir developing world compared million million respectively decline supply arvs outweighed growth volumes licensees licensees supplied million tablets versions epivir combivir african countries figures include syrup capsule formulations therefore conservative giving estimate arv treatments shipped preferential prices gsk gsk licensees supply combivir epivir tablets gsk gsk licensees includes preferentially priced tablets supplied gsk tablets supplied licensees gsk supplied arvs nfp prices countries compared reflects countries moving away supply gsk supply licensees viiv healthcare continue look new customers nfp arvs countries regularly review nfp prices however may well licensees able produce firstline arvs lower costs continue increase share business patients receiving treatment difficult estimate number patients treated result preferential pricing agreements since control healthcare provision however unaids estimates four million people developing world access arvs end tenfold increase five years report accelerating access initiative aai suggests december around patients developing countries receiving least one arv treatment supplied nine rdbased pharmaceutical companies aai two years since december total number patients developing countries receiving treatment aai companies increased per cent addition increase africa number patients treated least one arv supplied aai companies asia doubled middleincome countries preferential pricing hivaids medicines negotiate preferential pricing arrangements hivaids medicines middleincome countries casebycase basis prices lower paid developed countries low nfp prices paid least developed countries done bilaterally dialogue governments believe approach appropriate burden disease resources available address burden vary significantly country country within countries arrangements combine viable sustainable commercial return gsk improved affordability healthcare systems concerned key focus viiv healthcare back top home responsibility access medicines new approach hiv voluntary licensing corporate responsibility report voluntary licensing viiv healthcare launched november hiv performance rd pricing licensing reported though gsk managed hiv business full year voluntary licences patent holders allow third party company manufacture sell versions products help increase availability hiv medicines contribute better security supply people assume generics always cheaper branded products seen many solution access crisis developing world pharmaceutical companies increasing pressure grant licences lifespan patent however generics always cheaper success voluntary licence depend right licensees chosen particularly true treatment chronic disease hivaids sustainable supply good quality antiretrovirals arvs essential gsk prepared grant royalty free voluntary licences covering subsaharan africa arvs appropriate third parties licences allow licensees combine arvs companies rights granted first voluntary licence vl arvs negotiated eight licensing agreements arvs subsaharan africa july agreed royalty free voluntary licence enable aspen produce arv abacavir written existing licensees offering add abacavir licences february six licences amended include abacavir also july extended existing licences cover subsaharan africa previously regional made licences royalty free since august allowed apotex canadian company manufacture generic fixeddose combination arv containing two molecules gsk patent rights treatment hivaids rwanda consent granted canadas access medicines regime reflects wto f agreement enables governments authorise production certain patented medicines export gsk agreed waive royalties basis apotexs triple combination generic arv supplied notforprofit basis licensees supplied million tablets versions epivir combivir africa represents nearly per cent growth welcome trend gives customers sub saharan africa greater choice improves affordability contributes better security supply update september viiv healthcare extended policy voluntary licences consider requests genuine partners case case basis grant royalty free voluntary licences entire current future antiretroviral portfolio generics companies countries people hiv live includes least developed countries low income countries subsaharan africa viiv healthcare collaborators shire pharmaceuticals shionogi agreed waive rights royalty payments countries order improve access products compulsory licences compulsory licences issued governments involve intellectual property rights taken away rights holder compulsory licences one flexibilities world trade organizations trips agreement intellectual property used address public health concerns however widespread use compulsory licences undermine intellectual property framework counter productive long term rd new treatments especially commercial markets exist hivaids depends protection intellectual property compulsory licensing see public policy position back tophome responsibility access medicines new approach hiv voluntary licensing corporate responsibility report voluntary licensing viiv healthcare launched november hiv performance rd pricing licensing reported though gsk managed hiv business full year voluntary licences patent holders allow third party company manufacture sell versions products help increase availability hiv medicines contribute better security supply people assume generics always cheaper branded products seen many solution access crisis developing world pharmaceutical companies increasing pressure grant licences lifespan patent however generics always cheaper success voluntary licence depend right licensees chosen particularly true treatment chronic disease hivaids sustainable supply good quality antiretrovirals arvs essential gsk prepared grant royalty free voluntary licences covering subsaharan africa arvs appropriate third parties licences allow licensees combine arvs companies rights granted first voluntary licence vl arvs negotiated eight licensing agreements arvs subsaharan africa july agreed royalty free voluntary licence enable aspen produce arv abacavir written existing licensees offering add abacavir licences february six licences amended include abacavir also july extended existing licences cover subsaharan africa previously regional made licences royalty free since august allowed apotex canadian company manufacture generic fixeddose combination arv containing two molecules gsk patent rights treatment hivaids rwanda consent granted canadas access medicines regime reflects wto f agreement enables governments authorise production certain patented medicines export gsk agreed waive royalties basis apotexs triple combination generic arv supplied notforprofit basis licensees supplied million tablets versions epivir combivir africa represents nearly per cent growth welcome trend gives customers sub saharan africa greater choice improves affordability contributes better security supply update september viiv healthcare extended policy voluntary licences consider requests genuine partners case case basis grant royalty free voluntary licences entire current future antiretroviral portfolio generics companies countries people hiv live includes least developed countries low income countries subsaharan africa viiv healthcare collaborators shire pharmaceuticals shionogi agreed waive rights royalty payments countries order improve access products compulsory licences compulsory licences issued governments involve intellectual property rights taken away rights holder compulsory licences one flexibilities world trade organizations trips agreement intellectual property used address public health concerns however widespread use compulsory licences undermine intellectual property framework counter productive long term rd new treatments especially commercial markets exist hivaids depends protection intellectual property compulsory licensing see public policy position back top home responsibility access medicines new approach hiv voluntary licensing corporate responsibility report voluntary licensing viiv healthcare launched november hiv performance rd pricing licensing reported though gsk managed hiv business full year voluntary licences patent holders allow third party company manufacture sell versions products help increase availability hiv medicines contribute better security supply people assume generics always cheaper branded products seen many solution access crisis developing world pharmaceutical companies increasing pressure grant licences lifespan patent however generics always cheaper success voluntary licence depend right licensees chosen particularly true treatment chronic disease hivaids sustainable supply good quality antiretrovirals arvs essential gsk prepared grant royalty free voluntary licences covering subsaharan africa arvs appropriate third parties licences allow licensees combine arvs companies rights granted first voluntary licence vl arvs negotiated eight licensing agreements arvs subsaharan africa july agreed royalty free voluntary licence enable aspen produce arv abacavir written existing licensees offering add abacavir licences february six licences amended include abacavir also july extended existing licences cover subsaharan africa previously regional made licences royalty free since august allowed apotex canadian company manufacture generic fixeddose combination arv containing two molecules gsk patent rights treatment hivaids rwanda consent granted canadas access medicines regime reflects wto f agreement enables governments authorise production certain patented medicines export gsk agreed waive royalties basis apotexs triple combination generic arv supplied notforprofit basis licensees supplied million tablets versions epivir combivir africa represents nearly per cent growth welcome trend gives customers sub saharan africa greater choice improves affordability contributes better security supply update september viiv healthcare extended policy voluntary licences consider requests genuine partners case case basis grant royalty free voluntary licences entire current future antiretroviral portfolio generics companies countries people hiv live includes least developed countries low income countries subsaharan africa viiv healthcare collaborators shire pharmaceuticals shionogi agreed waive rights royalty payments countries order improve access products compulsory licences compulsory licences issued governments involve intellectual property rights taken away rights holder compulsory licences one flexibilities world trade organizations trips agreement intellectual property used address public health concerns however widespread use compulsory licences undermine intellectual property framework counter productive long term rd new treatments especially commercial markets exist hivaids depends protection intellectual property compulsory licensing see public policy position back top home responsibility access medicines rd developing world corporate responsibility report rd developing world aim make major contribution health developing countries researching developing affordable new vaccines treatments urgently needed diseases disproportionately affecting developing countries effective prevention methods treatments largely normal market incentives innovation exist cases treatments become less effective due drug resistance concern developing countries greater burden infectious diseases sometimes treatments suitable settings difficult administer areas poor healthcare infrastructure expensive produce example medicine requires refrigeration would suitable use areas without fridges storage longstanding commitment develop new treatments vaccines diseases specifically affecting developing countries addition increasingly aim make gsk medicines vaccines suitable use developing world rd portfolio diseases developing world includes projects diseases particular relevance developing countries bacterial meningitis chlamydia chagas disease dengue fever hepatitis e hivaids human african trypanosomiasis leishmaniasis malaria pandemic flu pneumococcal disease tb gsk one companies researching new vaccines treatments three world health organizations priority infectious diseases hivaids malaria tb challenge improving healthcare developing world enormous far complex addressed one group organisation alone given scale task means finding new ways industry academia ngos governments work together pursuing call open innovation approach three elements establishing independent open lab research neglected tropical diseases making publicly available compounds library shown efficacy malaria parasite launch new collaborations share intellectual property knowhow accelerate delivery new medicines neglected tropical diseases explained detail following sections research units dedicated rd group focused diseases developing world fully integrated pharmaceutical rd organisation group includes scientists based uk us developing world drug discovery centre tres cantos spain group prioritises projects based socioeconomic public health benefits rather commercial returns similar group active vaccines organisation belgium complement group tres cantos working neglected tropical diseases ntd launched new rd unit focused developing products formulations diseases affect people developing world unit champions needs patients developing world across gsks rd operations unit focus products latestage clinical development facilitate final development registration developing countries additionally working strategic external partners deliver objective developing product portfolio suited disease burden suffered patients developing countries gsk scientists working treatment projects ddw make access medicines priority right start rd process researching new ddw treatment emphasise factors heat humidity resistance product must able survive hot climate refrigeration facilities may available ease use must easy use settings limited healthcare facilities example onceaday tablets taken home preferable injectable medicine must administered hospital clinic affordability price one important factors look molecules formulations straightforward manufacture therefore inexpensive produce tufts center study drug development pharmaceutical industry profile washington dc phrma march back tophome responsibility access medicines rd developing world corporate responsibility report rd developing world aim make major contribution health developing countries researching developing affordable new vaccines treatments urgently needed diseases disproportionately affecting developing countries effective prevention methods treatments largely normal market incentives innovation exist cases treatments become less effective due drug resistance concern developing countries greater burden infectious diseases sometimes treatments suitable settings difficult administer areas poor healthcare infrastructure expensive produce example medicine requires refrigeration would suitable use areas without fridges storage longstanding commitment develop new treatments vaccines diseases specifically affecting developing countries addition increasingly aim make gsk medicines vaccines suitable use developing world rd portfolio diseases developing world includes projects diseases particular relevance developing countries bacterial meningitis chlamydia chagas disease dengue fever hepatitis e hivaids human african trypanosomiasis leishmaniasis malaria pandemic flu pneumococcal disease tb gsk one companies researching new vaccines treatments three world health organizations priority infectious diseases hivaids malaria tb challenge improving healthcare developing world enormous far complex addressed one group organisation alone given scale task means finding new ways industry academia ngos governments work together pursuing call open innovation approach three elements establishing independent open lab research neglected tropical diseases making publicly available compounds library shown efficacy malaria parasite launch new collaborations share intellectual property knowhow accelerate delivery new medicines neglected tropical diseases explained detail following sections research units dedicated rd group focused diseases developing world fully integrated pharmaceutical rd organisation group includes scientists based uk us developing world drug discovery centre tres cantos spain group prioritises projects based socioeconomic public health benefits rather commercial returns similar group active vaccines organisation belgium complement group tres cantos working neglected tropical diseases ntd launched new rd unit focused developing products formulations diseases affect people developing world unit champions needs patients developing world across gsks rd operations unit focus products latestage clinical development facilitate final development registration developing countries additionally working strategic external partners deliver objective developing product portfolio suited disease burden suffered patients developing countries gsk scientists working treatment projects ddw make access medicines priority right start rd process researching new ddw treatment emphasise factors heat humidity resistance product must able survive hot climate refrigeration facilities may available ease use must easy use settings limited healthcare facilities example onceaday tablets taken home preferable injectable medicine must administered hospital clinic affordability price one important factors look molecules formulations straightforward manufacture therefore inexpensive produce tufts center study drug development pharmaceutical industry profile washington dc phrma march back top home responsibility access medicines rd developing world corporate responsibility report rd developing world aim make major contribution health developing countries researching developing affordable new vaccines treatments urgently needed diseases disproportionately affecting developing countries effective prevention methods treatments largely normal market incentives innovation exist cases treatments become less effective due drug resistance concern developing countries greater burden infectious diseases sometimes treatments suitable settings difficult administer areas poor healthcare infrastructure expensive produce example medicine requires refrigeration would suitable use areas without fridges storage longstanding commitment develop new treatments vaccines diseases specifically affecting developing countries addition increasingly aim make gsk medicines vaccines suitable use developing world rd portfolio diseases developing world includes projects diseases particular relevance developing countries bacterial meningitis chlamydia chagas disease dengue fever hepatitis e hivaids human african trypanosomiasis leishmaniasis malaria pandemic flu pneumococcal disease tb gsk one companies researching new vaccines treatments three world health organizations priority infectious diseases hivaids malaria tb challenge improving healthcare developing world enormous far complex addressed one group organisation alone given scale task means finding new ways industry academia ngos governments work together pursuing call open innovation approach three elements establishing independent open lab research neglected tropical diseases making publicly available compounds library shown efficacy malaria parasite launch new collaborations share intellectual property knowhow accelerate delivery new medicines neglected tropical diseases explained detail following sections research units dedicated rd group focused diseases developing world fully integrated pharmaceutical rd organisation group includes scientists based uk us developing world drug discovery centre tres cantos spain group prioritises projects based socioeconomic public health benefits rather commercial returns similar group active vaccines organisation belgium complement group tres cantos working neglected tropical diseases ntd launched new rd unit focused developing products formulations diseases affect people developing world unit champions needs patients developing world across gsks rd operations unit focus products latestage clinical development facilitate final development registration developing countries additionally working strategic external partners deliver objective developing product portfolio suited disease burden suffered patients developing countries gsk scientists working treatment projects ddw make access medicines priority right start rd process researching new ddw treatment emphasise factors heat humidity resistance product must able survive hot climate refrigeration facilities may available ease use must easy use settings limited healthcare facilities example onceaday tablets taken home preferable injectable medicine must administered hospital clinic affordability price one important factors look molecules formulations straightforward manufacture therefore inexpensive produce tufts center study drug development pharmaceutical industry profile washington dc phrma march back top home responsibility access medicines rd developing world rd neglected tropical diseases corporate responsibility report rd neglected tropical diseases research centre tres cantos spain worked develop new treatments combat diseases developing world since established start initiative worked closely publicprivate partnerships groups including medicines malaria venture mmv global alliance tb drug development tb alliance scientists working centre many posts partly funded partners despite level collaboration believe research diseases disproportionately affect developing world still fragmented stimulate research area opening facility tres cantos new ways working known open lab vision tres cantos facility become global centre excellence stimulates research collaboration want form new collaborations bring new partners facility seek shared investment participation governments ngos businesses groups open lab inviting scientists gsk launched open lab tres cantos one way share expertise seek stimulate open innovation drug discovery diseases developing world open lab create spaces tres cantos scientists around globe gsk initiate projects encourage universities notforprofit partnerships research institutes come us proposals set think gsk help projects collaborations scientists home laboratory gsk tres cantos visiting researchers access facilities scientists knowhow projects clear objectives shared aim discovering new medicines diseases developing world meet needs external researchers expanding facilities tres cantos establishing notforprofit foundation initial investment million funding used support visiting scientists research projects sharing research information part commitment open innovation drug discovery diseases developing world january committed making widely freely available research information could help identify potential new treatments malaria gsk screened two million chemicals compound library looking potential efficacy deadliest form malaria parasite p falciparum took five people working special bio hazard unit months screen two million compounds done hand given dangers working malaria parasite normally screening automated takes weeks committed making public hits screening compounds including chemical structures related data type data first step road developing new medicines believe first company make comprehensive data available making information publicly available gsk hopes many scientists review information analyse data faster could hopefully lead additional research could help drive discovery new medicines would also encourage groups including academics pharmaceutical companies make compounds related information publicly available essentially example open source applied drug discovery know data increases value connected data eyes looking problem potential solutions may arise speaking time announcement timothy wells chief scientific officer medicines malaria venture said gsks new initiatives potential dramatically alter way world approaches research development neglected diseases providing access level information sees gsk set would hope new trend could revolutionise urgent search new medicines tackle malaria sharing data start build public database knowledge powerful human genome databases publicprivate partnerships biomedical rd costly risky timeconsuming activity diseases disproportionately affect developing world market exists developed countries hivaids accept rd costs risks involved expectation market wealthy countries make return rd investment diseases developing world return investment expected pursue new ways working one solution publicprivate partnership ppp model businesses public sector work together ppps make work commercially viable sharing risks costs involved ppp companies gsk provide rd technology manufacturing distribution expertise academic institutions may also provide research disease area knowledge public sector partners governments organisations bill melinda gates foundation help fund development delivery costs ensure medicines vaccines get people need funds usually channelled organisations medicines malaria venture mmv also help coordinate global rd activity ppps becoming increasingly important transformed landscape development medicines vaccines diseases developing world promising pipelines malaria tb world ever seen ppps work many different ways example partnerships centred dedicated diseases developing world discovery centre tres cantos global vaccines business headquartered belgium gsk provides facilities medicinal drug discovery meets running costs around half scientific posts tres cantos subsidised partner organisations mmv global alliance tb drug development drugs neglected diseases initiative compounds move clinical development gsk provides clinical regulatory manufacturing expertise resources global rd supply network partners help fund cost running clinical trials address issues access distribution reduces costs development gets new products patients faster research programmes overseen joint steering committees representatives gsk partners terms agreements new treatments resulting ppps made available disease endemic countries affordable prices back tophome responsibility access medicines rd developing world rd neglected tropical diseases corporate responsibility report rd neglected tropical diseases research centre tres cantos spain worked develop new treatments combat diseases developing world since established start initiative worked closely publicprivate partnerships groups including medicines malaria venture mmv global alliance tb drug development tb alliance scientists working centre many posts partly funded partners despite level collaboration believe research diseases disproportionately affect developing world still fragmented stimulate research area opening facility tres cantos new ways working known open lab vision tres cantos facility become global centre excellence stimulates research collaboration want form new collaborations bring new partners facility seek shared investment participation governments ngos businesses groups open lab inviting scientists gsk launched open lab tres cantos one way share expertise seek stimulate open innovation drug discovery diseases developing world open lab create spaces tres cantos scientists around globe gsk initiate projects encourage universities notforprofit partnerships research institutes come us proposals set think gsk help projects collaborations scientists home laboratory gsk tres cantos visiting researchers access facilities scientists knowhow projects clear objectives shared aim discovering new medicines diseases developing world meet needs external researchers expanding facilities tres cantos establishing notforprofit foundation initial investment million funding used support visiting scientists research projects sharing research information part commitment open innovation drug discovery diseases developing world january committed making widely freely available research information could help identify potential new treatments malaria gsk screened two million chemicals compound library looking potential efficacy deadliest form malaria parasite p falciparum took five people working special bio hazard unit months screen two million compounds done hand given dangers working malaria parasite normally screening automated takes weeks committed making public hits screening compounds including chemical structures related data type data first step road developing new medicines believe first company make comprehensive data available making information publicly available gsk hopes many scientists review information analyse data faster could hopefully lead additional research could help drive discovery new medicines would also encourage groups including academics pharmaceutical companies make compounds related information publicly available essentially example open source applied drug discovery know data increases value connected data eyes looking problem potential solutions may arise speaking time announcement timothy wells chief scientific officer medicines malaria venture said gsks new initiatives potential dramatically alter way world approaches research development neglected diseases providing access level information sees gsk set would hope new trend could revolutionise urgent search new medicines tackle malaria sharing data start build public database knowledge powerful human genome databases publicprivate partnerships biomedical rd costly risky timeconsuming activity diseases disproportionately affect developing world market exists developed countries hivaids accept rd costs risks involved expectation market wealthy countries make return rd investment diseases developing world return investment expected pursue new ways working one solution publicprivate partnership ppp model businesses public sector work together ppps make work commercially viable sharing risks costs involved ppp companies gsk provide rd technology manufacturing distribution expertise academic institutions may also provide research disease area knowledge public sector partners governments organisations bill melinda gates foundation help fund development delivery costs ensure medicines vaccines get people need funds usually channelled organisations medicines malaria venture mmv also help coordinate global rd activity ppps becoming increasingly important transformed landscape development medicines vaccines diseases developing world promising pipelines malaria tb world ever seen ppps work many different ways example partnerships centred dedicated diseases developing world discovery centre tres cantos global vaccines business headquartered belgium gsk provides facilities medicinal drug discovery meets running costs around half scientific posts tres cantos subsidised partner organisations mmv global alliance tb drug development drugs neglected diseases initiative compounds move clinical development gsk provides clinical regulatory manufacturing expertise resources global rd supply network partners help fund cost running clinical trials address issues access distribution reduces costs development gets new products patients faster research programmes overseen joint steering committees representatives gsk partners terms agreements new treatments resulting ppps made available disease endemic countries affordable prices back top home responsibility access medicines rd developing world rd neglected tropical diseases corporate responsibility report rd neglected tropical diseases research centre tres cantos spain worked develop new treatments combat diseases developing world since established start initiative worked closely publicprivate partnerships groups including medicines malaria venture mmv global alliance tb drug development tb alliance scientists working centre many posts partly funded partners despite level collaboration believe research diseases disproportionately affect developing world still fragmented stimulate research area opening facility tres cantos new ways working known open lab vision tres cantos facility become global centre excellence stimulates research collaboration want form new collaborations bring new partners facility seek shared investment participation governments ngos businesses groups open lab inviting scientists gsk launched open lab tres cantos one way share expertise seek stimulate open innovation drug discovery diseases developing world open lab create spaces tres cantos scientists around globe gsk initiate projects encourage universities notforprofit partnerships research institutes come us proposals set think gsk help projects collaborations scientists home laboratory gsk tres cantos visiting researchers access facilities scientists knowhow projects clear objectives shared aim discovering new medicines diseases developing world meet needs external researchers expanding facilities tres cantos establishing notforprofit foundation initial investment million funding used support visiting scientists research projects sharing research information part commitment open innovation drug discovery diseases developing world january committed making widely freely available research information could help identify potential new treatments malaria gsk screened two million chemicals compound library looking potential efficacy deadliest form malaria parasite p falciparum took five people working special bio hazard unit months screen two million compounds done hand given dangers working malaria parasite normally screening automated takes weeks committed making public hits screening compounds including chemical structures related data type data first step road developing new medicines believe first company make comprehensive data available making information publicly available gsk hopes many scientists review information analyse data faster could hopefully lead additional research could help drive discovery new medicines would also encourage groups including academics pharmaceutical companies make compounds related information publicly available essentially example open source applied drug discovery know data increases value connected data eyes looking problem potential solutions may arise speaking time announcement timothy wells chief scientific officer medicines malaria venture said gsks new initiatives potential dramatically alter way world approaches research development neglected diseases providing access level information sees gsk set would hope new trend could revolutionise urgent search new medicines tackle malaria sharing data start build public database knowledge powerful human genome databases publicprivate partnerships biomedical rd costly risky timeconsuming activity diseases disproportionately affect developing world market exists developed countries hivaids accept rd costs risks involved expectation market wealthy countries make return rd investment diseases developing world return investment expected pursue new ways working one solution publicprivate partnership ppp model businesses public sector work together ppps make work commercially viable sharing risks costs involved ppp companies gsk provide rd technology manufacturing distribution expertise academic institutions may also provide research disease area knowledge public sector partners governments organisations bill melinda gates foundation help fund development delivery costs ensure medicines vaccines get people need funds usually channelled organisations medicines malaria venture mmv also help coordinate global rd activity ppps becoming increasingly important transformed landscape development medicines vaccines diseases developing world promising pipelines malaria tb world ever seen ppps work many different ways example partnerships centred dedicated diseases developing world discovery centre tres cantos global vaccines business headquartered belgium gsk provides facilities medicinal drug discovery meets running costs around half scientific posts tres cantos subsidised partner organisations mmv global alliance tb drug development drugs neglected diseases initiative compounds move clinical development gsk provides clinical regulatory manufacturing expertise resources global rd supply network partners help fund cost running clinical trials address issues access distribution reduces costs development gets new products patients faster research programmes overseen joint steering committees representatives gsk partners terms agreements new treatments resulting ppps made available disease endemic countries affordable prices back top home responsibility access medicines rd developing world products formulations developing world corporate responsibility report products formulations developing world established new research unit help ensure product portfolio better suited needs patients developing countries gsks emerging markets asia pacific regions new unit champion needs developing countries among rd teams gsk seek develop product portfolio suited countries complementing work teams focusing medicines suitable europe north america seek products latestage clinical development facilitate development registration developing countries forge partnerships companies want develop products developing countries may necessary experience resources develop register medicines providing gsks local marketing regulatory clinical expertise infrastructure make wider range products available developing countries pay commercial partners royalties revenue generated sales apply development capabilities gsks branded generic pipeline working partner companies create combinations branded generics enhanced formulations meet needs developing countries support pipeline projects potential benefit patients developing countries ensure research teams take account different regional needs examples could include simpler lower cost analogues medicines registration lower doses required countries taking projects meet specific regional medical needs commercial opportunities new research unit part broader strategy focus developing countries includes partnerships expand branded generics portfolio first year operation new rd team made number achievements helping make product portfolio better suited needs patients developing countries gsk signed deal amgen make denosumab osteoporosis medicine available developing countries work amgen complete necessary clinical studies allow registration outside europe us also partnered gilead make tenofivir medicine hepatitis b available china partnership indian company dr reddys two new branded generics developing countries moved development treatment cardiovascular disease unit started four latestage projects focus developing country medical problems respiratory disease urology dermatology hepatitis b four projects worked closely regions countries make sure understood local needs trials focused specifically meet needs rather traditional way adapt trials conducted meet us eu regulatory requirements coming year spend time major market better understand medical needs healthcare priorities government relations countries back top home responsibility access medicines rd developing world products formulations developing world corporate responsibility report products formulations developing world established new research unit help ensure product portfolio better suited needs patients developing countries gsks emerging markets asia pacific regions new unit champion needs developing countries among rd teams gsk seek develop product portfolio suited countries complementing work teams focusing medicines suitable europe north america seek products latestage clinical development facilitate development registration developing countries forge partnerships companies want develop products developing countries may necessary experience resources develop register medicines providing gsks local marketing regulatory clinical expertise infrastructure make wider range products available developing countries pay commercial partners royalties revenue generated sales apply development capabilities gsks branded generic pipeline working partner companies create combinations branded generics enhanced formulations meet needs developing countries support pipeline projects potential benefit patients developing countries ensure research teams take account different regional needs examples could include simpler lower cost analogues medicines registration lower doses required countries taking projects meet specific regional medical needs commercial opportunities new research unit part broader strategy focus developing countries includes partnerships expand branded generics portfolio first year operation new rd team made number achievements helping make product portfolio better suited needs patients developing countries gsk signed deal amgen make denosumab osteoporosis medicine available developing countries work amgen complete necessary clinical studies allow registration outside europe us also partnered gilead make tenofivir medicine hepatitis b available china partnership indian company dr reddys two new branded generics developing countries moved development treatment cardiovascular disease unit started four latestage projects focus developing country medical problems respiratory disease urology dermatology hepatitis b four projects worked closely regions countries make sure understood local needs trials focused specifically meet needs rather traditional way adapt trials conducted meet us eu regulatory requirements coming year spend time major market better understand medical needs healthcare priorities government relations countries back top home responsibility access medicines rd developing world proprietary knowledge pool corporate responsibility report proprietary knowledge pool flexible intellectual property encouraging pharmaceutical companies could stimulate research help speed development medicines neglected tropical diseases ntds march created neglected tropical disease pool stimulate research medicines ntds also known diseases developing world pool focused ntds defined us food drug administration fda provided credible thirdparty list includes diseases believe priority act congress included list allowed diseases added deemed appropriate review list fda adds new diseases initiate pool published details gsk patents patent applications small molecule pharmaceuticals identified potentially useful treatment ntds since discussions three groups stakeholders discussions scientific research community could potentially benefit pool learnt appreciated us making patent information public however would really help access knowhow experience want ask us tried already results worked overcame particular challenges therefore committed making knowledge experience relates ntds available pool pool goes far beyond patents refer proprietary knowledge pool allow products developed pooled patents intellectual property sold least developed countries royalty free basis discuss terms sale countries involved january signed agreements two organisations give access information pool emory university institute drug discovery ithemba pharmaceuticals company based south africa working tb financial help south african government second group stakeholders companies could contribute assets pool july us biotechnology group alnylam became first company gsk contribute patents pool constructive discussions number companies keen see greater independence pool goal always create independent ntd pool rather gsk pool end potential administrators pool third group stakeholders talked january announced bio ventures global health bvgh take administration pool hopeful lead companies joining pool due course impact pool increase pharmaceutical biotechnology companies universities stakeholders contribute update september pool known pool open innovation neglected tropical diseases point administered bio ventures global health bvgh date patents pool may massachusetts institute technology mit became first academic institution contribute intellectual property pool followed first government agency south africas technology innovation agency tia tia intends use intellectual property pool enhance south african biotechnology sector improve quality life people affected neglected tropical diseases initially agency focus developing new medicines tuberculosis malaria august medicines malaria venture mmv became first product development partnership join pool mmvs contribution patents pool resulting research new antimalarials important milestone organization plays major role leading development new treatments disease information pool visit bvgh website neglected tropical diseases targeted pool fda list blinding trachoma buruli ulcer cholera denguedengue haemorrhagic fever fascioliasis human african trypanosomiasis sleeping sickness leishmaniasis leprosy lymphatic filariasis elephantiasis malaria onchocerciasis river blindness dracunculiasis guinea worm disease schistosomiasis bilharzia soil transmitted helminthiasis intestinal worm infection tuberculosis yaws back tophome responsibility access medicines rd developing world proprietary knowledge pool corporate responsibility report proprietary knowledge pool flexible intellectual property encouraging pharmaceutical companies could stimulate research help speed development medicines neglected tropical diseases ntds march created neglected tropical disease pool stimulate research medicines ntds also known diseases developing world pool focused ntds defined us food drug administration fda provided credible thirdparty list includes diseases believe priority act congress included list allowed diseases added deemed appropriate review list fda adds new diseases initiate pool published details gsk patents patent applications small molecule pharmaceuticals identified potentially useful treatment ntds since discussions three groups stakeholders discussions scientific research community could potentially benefit pool learnt appreciated us making patent information public however would really help access knowhow experience want ask us tried already results worked overcame particular challenges therefore committed making knowledge experience relates ntds available pool pool goes far beyond patents refer proprietary knowledge pool allow products developed pooled patents intellectual property sold least developed countries royalty free basis discuss terms sale countries involved january signed agreements two organisations give access information pool emory university institute drug discovery ithemba pharmaceuticals company based south africa working tb financial help south african government second group stakeholders companies could contribute assets pool july us biotechnology group alnylam became first company gsk contribute patents pool constructive discussions number companies keen see greater independence pool goal always create independent ntd pool rather gsk pool end potential administrators pool third group stakeholders talked january announced bio ventures global health bvgh take administration pool hopeful lead companies joining pool due course impact pool increase pharmaceutical biotechnology companies universities stakeholders contribute update september pool known pool open innovation neglected tropical diseases point administered bio ventures global health bvgh date patents pool may massachusetts institute technology mit became first academic institution contribute intellectual property pool followed first government agency south africas technology innovation agency tia tia intends use intellectual property pool enhance south african biotechnology sector improve quality life people affected neglected tropical diseases initially agency focus developing new medicines tuberculosis malaria august medicines malaria venture mmv became first product development partnership join pool mmvs contribution patents pool resulting research new antimalarials important milestone organization plays major role leading development new treatments disease information pool visit bvgh website neglected tropical diseases targeted pool fda list blinding trachoma buruli ulcer cholera denguedengue haemorrhagic fever fascioliasis human african trypanosomiasis sleeping sickness leishmaniasis leprosy lymphatic filariasis elephantiasis malaria onchocerciasis river blindness dracunculiasis guinea worm disease schistosomiasis bilharzia soil transmitted helminthiasis intestinal worm infection tuberculosis yaws back top home responsibility access medicines rd developing world proprietary knowledge pool corporate responsibility report proprietary knowledge pool flexible intellectual property encouraging pharmaceutical companies could stimulate research help speed development medicines neglected tropical diseases ntds march created neglected tropical disease pool stimulate research medicines ntds also known diseases developing world pool focused ntds defined us food drug administration fda provided credible thirdparty list includes diseases believe priority act congress included list allowed diseases added deemed appropriate review list fda adds new diseases initiate pool published details gsk patents patent applications small molecule pharmaceuticals identified potentially useful treatment ntds since discussions three groups stakeholders discussions scientific research community could potentially benefit pool learnt appreciated us making patent information public however would really help access knowhow experience want ask us tried already results worked overcame particular challenges therefore committed making knowledge experience relates ntds available pool pool goes far beyond patents refer proprietary knowledge pool allow products developed pooled patents intellectual property sold least developed countries royalty free basis discuss terms sale countries involved january signed agreements two organisations give access information pool emory university institute drug discovery ithemba pharmaceuticals company based south africa working tb financial help south african government second group stakeholders companies could contribute assets pool july us biotechnology group alnylam became first company gsk contribute patents pool constructive discussions number companies keen see greater independence pool goal always create independent ntd pool rather gsk pool end potential administrators pool third group stakeholders talked january announced bio ventures global health bvgh take administration pool hopeful lead companies joining pool due course impact pool increase pharmaceutical biotechnology companies universities stakeholders contribute update september pool known pool open innovation neglected tropical diseases point administered bio ventures global health bvgh date patents pool may massachusetts institute technology mit became first academic institution contribute intellectual property pool followed first government agency south africas technology innovation agency tia tia intends use intellectual property pool enhance south african biotechnology sector improve quality life people affected neglected tropical diseases initially agency focus developing new medicines tuberculosis malaria august medicines malaria venture mmv became first product development partnership join pool mmvs contribution patents pool resulting research new antimalarials important milestone organization plays major role leading development new treatments disease information pool visit bvgh website neglected tropical diseases targeted pool fda list blinding trachoma buruli ulcer cholera denguedengue haemorrhagic fever fascioliasis human african trypanosomiasis sleeping sickness leishmaniasis leprosy lymphatic filariasis elephantiasis malaria onchocerciasis river blindness dracunculiasis guinea worm disease schistosomiasis bilharzia soil transmitted helminthiasis intestinal worm infection tuberculosis yaws back top home responsibility access medicines rd developing world medicines developing world corporate responsibility report medicines developing world malaria work malaria treatments includes tafenoquine pyridone gsk tafenoquine developing tafenoquine potential new treatment radical cure p vivax malaria partnership medicines malaria venture mmv well causing acute infection red blood cells p vivax causes dormant infection liver cells malaria reoccur radical cure completely eliminates malaria parasites body including dormant liver stages tafenoquine offers potential one totwo day treatment course significantly shorter primaquine current standard care tafenoquine like primaquine belongs class drugs known cause acute haemolytic anaemia subjects inherited glucosephosphate dehydrogenase gpd deficiency gpd deficiency common areas malaria prevalent initial clinical study focusing understanding safety tafenoquine subjects gpd deficiency study began interim results expected dr timothy wells chief scientific officer medicines malaria venture commented tafenoquine novel inclusion mmvs portfolio given activity liver stages malaria essential part fight p vivax infections malaria elimination agenda moves forwards need increasing array tools parasite pyridone gsk pyridones new class compounds potential highly effective drugsensitive drugresistant strains p falciparum p vivax malaria developing pyridone gsk partnership mmv entered first time human clinical trials early addition backup effort ongoing identify pyridone compound issues lead gsk prevent development tuberculosis tuberculosis medicines research conducted partnership global alliance tb drug development tb alliance strong alliance forged increased number tb drug discovery projects portfolio lead tb project mycobacterium gyrase inhibitors hope progress candidate preclinical phase also researching biomarkers could help predict early stage tb patients responding treatment could significantly speed tb research currently effectiveness new tb drug determined months completion treatment visceral leishmaniasis vl sitamaquine oral onceaday candidate treatment visceral leishmaniasis vl kala azar potentially fatal parasitic disease spread sand flies data two phase proofofconcept studies kenya india encouraging overall day course per cent patients remained cured six months sitamaquine generally well tolerated patients studies however concerns regarding renal adverse events seen subjects appear treatment related interpretation data complicated particular vl associated renal impairment proceeding phase lll trials set phase llb study india compare safety tolerability day course sitamaquine intravenous amphotericin b current standard care india results showed comparable efficacy previous studies despite shorter course sitamaquine much better tolerated amphotericin small number patients mild reversible renal side effects currently discussions potential partners view progressing development also targeting vl partnership drugs neglected diseases initiative see neglected diseases strengthening partnership collaborative research effort neglected diseases march announced collaborative research effort notforprofit organisation drugs neglected diseases initiative dndi targeting neglected tropical diseases research focused compounds may activity neglected diseases including visceral leishmaniasis human african trypanosomiasis sleeping sickness chagas disease last years collaboration worked identifying developing compounds existing gsk programmes well leveraging expertise gsk researchers tres cantos facility along leading academic centres london school hygiene tropical medicine collaboration originally formed specifically address unmet patient needs current treatments diseases significant drawbacks difficulty administration severe side effects length treatment cost emerging parasitic resistance wasunna rashid jr mbui j et al phase ii doseincreasing study sitamaquine treatment visceral leishmaniasis kenya j trop med hyg jha tk sundar thakur cp et al phase ii doseranging study sitamaquine treatment visceral leishmaniasis india j trop med hyg prasad ls sen ganguly renal involvement kalaazar indian j med res jan dutra martinelli r de carvalho em et al renal involvement visceral leishmaniasis j kidney dis back tophome responsibility access medicines rd developing world medicines developing world corporate responsibility report medicines developing world malaria work malaria treatments includes tafenoquine pyridone gsk tafenoquine developing tafenoquine potential new treatment radical cure p vivax malaria partnership medicines malaria venture mmv well causing acute infection red blood cells p vivax causes dormant infection liver cells malaria reoccur radical cure completely eliminates malaria parasites body including dormant liver stages tafenoquine offers potential one totwo day treatment course significantly shorter primaquine current standard care tafenoquine like primaquine belongs class drugs known cause acute haemolytic anaemia subjects inherited glucosephosphate dehydrogenase gpd deficiency gpd deficiency common areas malaria prevalent initial clinical study focusing understanding safety tafenoquine subjects gpd deficiency study began interim results expected dr timothy wells chief scientific officer medicines malaria venture commented tafenoquine novel inclusion mmvs portfolio given activity liver stages malaria essential part fight p vivax infections malaria elimination agenda moves forwards need increasing array tools parasite pyridone gsk pyridones new class compounds potential highly effective drugsensitive drugresistant strains p falciparum p vivax malaria developing pyridone gsk partnership mmv entered first time human clinical trials early addition backup effort ongoing identify pyridone compound issues lead gsk prevent development tuberculosis tuberculosis medicines research conducted partnership global alliance tb drug development tb alliance strong alliance forged increased number tb drug discovery projects portfolio lead tb project mycobacterium gyrase inhibitors hope progress candidate preclinical phase also researching biomarkers could help predict early stage tb patients responding treatment could significantly speed tb research currently effectiveness new tb drug determined months completion treatment visceral leishmaniasis vl sitamaquine oral onceaday candidate treatment visceral leishmaniasis vl kala azar potentially fatal parasitic disease spread sand flies data two phase proofofconcept studies kenya india encouraging overall day course per cent patients remained cured six months sitamaquine generally well tolerated patients studies however concerns regarding renal adverse events seen subjects appear treatment related interpretation data complicated particular vl associated renal impairment proceeding phase lll trials set phase llb study india compare safety tolerability day course sitamaquine intravenous amphotericin b current standard care india results showed comparable efficacy previous studies despite shorter course sitamaquine much better tolerated amphotericin small number patients mild reversible renal side effects currently discussions potential partners view progressing development also targeting vl partnership drugs neglected diseases initiative see neglected diseases strengthening partnership collaborative research effort neglected diseases march announced collaborative research effort notforprofit organisation drugs neglected diseases initiative dndi targeting neglected tropical diseases research focused compounds may activity neglected diseases including visceral leishmaniasis human african trypanosomiasis sleeping sickness chagas disease last years collaboration worked identifying developing compounds existing gsk programmes well leveraging expertise gsk researchers tres cantos facility along leading academic centres london school hygiene tropical medicine collaboration originally formed specifically address unmet patient needs current treatments diseases significant drawbacks difficulty administration severe side effects length treatment cost emerging parasitic resistance wasunna rashid jr mbui j et al phase ii doseincreasing study sitamaquine treatment visceral leishmaniasis kenya j trop med hyg jha tk sundar thakur cp et al phase ii doseranging study sitamaquine treatment visceral leishmaniasis india j trop med hyg prasad ls sen ganguly renal involvement kalaazar indian j med res jan dutra martinelli r de carvalho em et al renal involvement visceral leishmaniasis j kidney dis back top home responsibility access medicines rd developing world medicines developing world corporate responsibility report medicines developing world malaria work malaria treatments includes tafenoquine pyridone gsk tafenoquine developing tafenoquine potential new treatment radical cure p vivax malaria partnership medicines malaria venture mmv well causing acute infection red blood cells p vivax causes dormant infection liver cells malaria reoccur radical cure completely eliminates malaria parasites body including dormant liver stages tafenoquine offers potential one totwo day treatment course significantly shorter primaquine current standard care tafenoquine like primaquine belongs class drugs known cause acute haemolytic anaemia subjects inherited glucosephosphate dehydrogenase gpd deficiency gpd deficiency common areas malaria prevalent initial clinical study focusing understanding safety tafenoquine subjects gpd deficiency study began interim results expected dr timothy wells chief scientific officer medicines malaria venture commented tafenoquine novel inclusion mmvs portfolio given activity liver stages malaria essential part fight p vivax infections malaria elimination agenda moves forwards need increasing array tools parasite pyridone gsk pyridones new class compounds potential highly effective drugsensitive drugresistant strains p falciparum p vivax malaria developing pyridone gsk partnership mmv entered first time human clinical trials early addition backup effort ongoing identify pyridone compound issues lead gsk prevent development tuberculosis tuberculosis medicines research conducted partnership global alliance tb drug development tb alliance strong alliance forged increased number tb drug discovery projects portfolio lead tb project mycobacterium gyrase inhibitors hope progress candidate preclinical phase also researching biomarkers could help predict early stage tb patients responding treatment could significantly speed tb research currently effectiveness new tb drug determined months completion treatment visceral leishmaniasis vl sitamaquine oral onceaday candidate treatment visceral leishmaniasis vl kala azar potentially fatal parasitic disease spread sand flies data two phase proofofconcept studies kenya india encouraging overall day course per cent patients remained cured six months sitamaquine generally well tolerated patients studies however concerns regarding renal adverse events seen subjects appear treatment related interpretation data complicated particular vl associated renal impairment proceeding phase lll trials set phase llb study india compare safety tolerability day course sitamaquine intravenous amphotericin b current standard care india results showed comparable efficacy previous studies despite shorter course sitamaquine much better tolerated amphotericin small number patients mild reversible renal side effects currently discussions potential partners view progressing development also targeting vl partnership drugs neglected diseases initiative see neglected diseases strengthening partnership collaborative research effort neglected diseases march announced collaborative research effort notforprofit organisation drugs neglected diseases initiative dndi targeting neglected tropical diseases research focused compounds may activity neglected diseases including visceral leishmaniasis human african trypanosomiasis sleeping sickness chagas disease last years collaboration worked identifying developing compounds existing gsk programmes well leveraging expertise gsk researchers tres cantos facility along leading academic centres london school hygiene tropical medicine collaboration originally formed specifically address unmet patient needs current treatments diseases significant drawbacks difficulty administration severe side effects length treatment cost emerging parasitic resistance wasunna rashid jr mbui j et al phase ii doseincreasing study sitamaquine treatment visceral leishmaniasis kenya j trop med hyg jha tk sundar thakur cp et al phase ii doseranging study sitamaquine treatment visceral leishmaniasis india j trop med hyg prasad ls sen ganguly renal involvement kalaazar indian j med res jan dutra martinelli r de carvalho em et al renal involvement visceral leishmaniasis j kidney dis back top home responsibility access medicines rd developing world vaccines developing world corporate responsibility report vaccines developing world malaria working malaria vaccine two decades invested million resources date currently developing candidate malaria vaccine rtss partnership path malaria vaccine initiative mvi contributed million candidate vaccine called rtss first malaria vaccine candidate demonstrate significant efficacy early development warrant phase iii testing recent phase ii studies showed rtss reduced clinical episodes malaria per cent eightmonth period addition rtss shown promising safety tolerability profile used alongside world health organizations standard infant vaccines rtss first vaccine designed primarily africa effective first successful vaccine human parasite notably rtss also first vaccine whose development spearheaded extended team researchers organisations spanning globe including gsk mvi bill melinda gates foundation scientists across europe north america africa gsk partners launched largescale phase iii efficacy trial rtss seven countries africa trial expected involve children schedule almost children enrolled end january christian loucq mvi director commented significance trial results saying closer ever developing malaria vaccine children africa gsks joe cohen coinventor rtss vice president rd vaccines emerging diseases hiv commented phase iii trial huge undertaking depends effective coordination among researchers regulators families communities everyone involved invested significant energy resources pave way could become worlds first malaria vaccine current plans rtss vaccine candidate would submitted regulatory authorities based efficacy children five months age additional safety immunogenicity data infant population submitted soon afterwards followed efficacy data infants available depending final clinical profile vaccine timetable regulatory process first vaccine introduction could take place next three five years read malaria vaccine case study tuberculosis tb candidate vaccine developed aeras global tb vaccine foundation early results positive suggesting vaccine safe produces strong immune reaction adults tb endemic regions hiv positive adults highly active antiretroviral therapy several anti retrovirals taken combination phase ii trials planned adolescents infants tb endemic regions hivaids involved aids vaccine research two decades pursuing three separate vaccine strategies successful aids vaccine might combine several approaches recombinant measles vector measles vaccine one powerful providing lifelong protection disease working pasteur institute paris partners develop aids vaccine fusing genes hiv virus onto measles vaccine fco candidate vaccine advanced phase lll trials hivinfected subjects ongoing extramural collaborative discovery rd programme aims identify hiv envelopebased protein vaccine capable producing broadly neutralising antibodies hiv infection addition continue collaborate international aids vaccine initiative iavi pneumococcal disease pneumococcal disease major global health issue year streptococcus pneumoniae infections estimated kill one million children five years age worldwide distinct strains serotypes pneumococcus cause vast majority invasive disease young children january european medicines agencys committee medicinal products human use issued positive opinion recommended approval gsks paediatric pneumococcal candidate vaccine synflorix paediatric vaccine proposed indicated active immunisation invasive pneumococcal disease middle ear infections acute otitis media caused spneumoniae infants children six weeks two years obtained european marketing authorisation synflorix march november received prequalification potentially lifesaving vaccine world health organization prequalification service provided facilitate access medicines less affluent countries allows un agencies purchase vaccines behalf developing countries accelerate global access synflorix also signed agreement global alliance vaccines immunization accelerate availability funding pneumococcal vaccination pilot advance market commitment amc mechanism amcs new approach public health funding designed stimulate development manufacture vaccines developing countries donors commit money guarantee price vaccines developed thus creating potential viable future market update september march gsk became one first manufacturers sign advance market commitment agreement see gavi since committed supply million doses synflorix ten years potential prevent deaths millions children worlds poorest countries agreement financed gavi five donor countries canada italy norway russia united kingdom bill melinda gates foundation guaranteed longterm order enable us invest development manufacturing capacity vaccine significantly reduce cost dose around purchase price developed countries children africa begin receiving synflorix vaccinations later back tophome responsibility access medicines rd developing world vaccines developing world corporate responsibility report vaccines developing world malaria working malaria vaccine two decades invested million resources date currently developing candidate malaria vaccine rtss partnership path malaria vaccine initiative mvi contributed million candidate vaccine called rtss first malaria vaccine candidate demonstrate significant efficacy early development warrant phase iii testing recent phase ii studies showed rtss reduced clinical episodes malaria per cent eightmonth period addition rtss shown promising safety tolerability profile used alongside world health organizations standard infant vaccines rtss first vaccine designed primarily africa effective first successful vaccine human parasite notably rtss also first vaccine whose development spearheaded extended team researchers organisations spanning globe including gsk mvi bill melinda gates foundation scientists across europe north america africa gsk partners launched largescale phase iii efficacy trial rtss seven countries africa trial expected involve children schedule almost children enrolled end january christian loucq mvi director commented significance trial results saying closer ever developing malaria vaccine children africa gsks joe cohen coinventor rtss vice president rd vaccines emerging diseases hiv commented phase iii trial huge undertaking depends effective coordination among researchers regulators families communities everyone involved invested significant energy resources pave way could become worlds first malaria vaccine current plans rtss vaccine candidate would submitted regulatory authorities based efficacy children five months age additional safety immunogenicity data infant population submitted soon afterwards followed efficacy data infants available depending final clinical profile vaccine timetable regulatory process first vaccine introduction could take place next three five years read malaria vaccine case study tuberculosis tb candidate vaccine developed aeras global tb vaccine foundation early results positive suggesting vaccine safe produces strong immune reaction adults tb endemic regions hiv positive adults highly active antiretroviral therapy several anti retrovirals taken combination phase ii trials planned adolescents infants tb endemic regions hivaids involved aids vaccine research two decades pursuing three separate vaccine strategies successful aids vaccine might combine several approaches recombinant measles vector measles vaccine one powerful providing lifelong protection disease working pasteur institute paris partners develop aids vaccine fusing genes hiv virus onto measles vaccine fco candidate vaccine advanced phase lll trials hivinfected subjects ongoing extramural collaborative discovery rd programme aims identify hiv envelopebased protein vaccine capable producing broadly neutralising antibodies hiv infection addition continue collaborate international aids vaccine initiative iavi pneumococcal disease pneumococcal disease major global health issue year streptococcus pneumoniae infections estimated kill one million children five years age worldwide distinct strains serotypes pneumococcus cause vast majority invasive disease young children january european medicines agencys committee medicinal products human use issued positive opinion recommended approval gsks paediatric pneumococcal candidate vaccine synflorix paediatric vaccine proposed indicated active immunisation invasive pneumococcal disease middle ear infections acute otitis media caused spneumoniae infants children six weeks two years obtained european marketing authorisation synflorix march november received prequalification potentially lifesaving vaccine world health organization prequalification service provided facilitate access medicines less affluent countries allows un agencies purchase vaccines behalf developing countries accelerate global access synflorix also signed agreement global alliance vaccines immunization accelerate availability funding pneumococcal vaccination pilot advance market commitment amc mechanism amcs new approach public health funding designed stimulate development manufacture vaccines developing countries donors commit money guarantee price vaccines developed thus creating potential viable future market update september march gsk became one first manufacturers sign advance market commitment agreement see gavi since committed supply million doses synflorix ten years potential prevent deaths millions children worlds poorest countries agreement financed gavi five donor countries canada italy norway russia united kingdom bill melinda gates foundation guaranteed longterm order enable us invest development manufacturing capacity vaccine significantly reduce cost dose around purchase price developed countries children africa begin receiving synflorix vaccinations later back top home responsibility access medicines rd developing world vaccines developing world corporate responsibility report vaccines developing world malaria working malaria vaccine two decades invested million resources date currently developing candidate malaria vaccine rtss partnership path malaria vaccine initiative mvi contributed million candidate vaccine called rtss first malaria vaccine candidate demonstrate significant efficacy early development warrant phase iii testing recent phase ii studies showed rtss reduced clinical episodes malaria per cent eightmonth period addition rtss shown promising safety tolerability profile used alongside world health organizations standard infant vaccines rtss first vaccine designed primarily africa effective first successful vaccine human parasite notably rtss also first vaccine whose development spearheaded extended team researchers organisations spanning globe including gsk mvi bill melinda gates foundation scientists across europe north america africa gsk partners launched largescale phase iii efficacy trial rtss seven countries africa trial expected involve children schedule almost children enrolled end january christian loucq mvi director commented significance trial results saying closer ever developing malaria vaccine children africa gsks joe cohen coinventor rtss vice president rd vaccines emerging diseases hiv commented phase iii trial huge undertaking depends effective coordination among researchers regulators families communities everyone involved invested significant energy resources pave way could become worlds first malaria vaccine current plans rtss vaccine candidate would submitted regulatory authorities based efficacy children five months age additional safety immunogenicity data infant population submitted soon afterwards followed efficacy data infants available depending final clinical profile vaccine timetable regulatory process first vaccine introduction could take place next three five years read malaria vaccine case study tuberculosis tb candidate vaccine developed aeras global tb vaccine foundation early results positive suggesting vaccine safe produces strong immune reaction adults tb endemic regions hiv positive adults highly active antiretroviral therapy several anti retrovirals taken combination phase ii trials planned adolescents infants tb endemic regions hivaids involved aids vaccine research two decades pursuing three separate vaccine strategies successful aids vaccine might combine several approaches recombinant measles vector measles vaccine one powerful providing lifelong protection disease working pasteur institute paris partners develop aids vaccine fusing genes hiv virus onto measles vaccine fco candidate vaccine advanced phase lll trials hivinfected subjects ongoing extramural collaborative discovery rd programme aims identify hiv envelopebased protein vaccine capable producing broadly neutralising antibodies hiv infection addition continue collaborate international aids vaccine initiative iavi pneumococcal disease pneumococcal disease major global health issue year streptococcus pneumoniae infections estimated kill one million children five years age worldwide distinct strains serotypes pneumococcus cause vast majority invasive disease young children january european medicines agencys committee medicinal products human use issued positive opinion recommended approval gsks paediatric pneumococcal candidate vaccine synflorix paediatric vaccine proposed indicated active immunisation invasive pneumococcal disease middle ear infections acute otitis media caused spneumoniae infants children six weeks two years obtained european marketing authorisation synflorix march november received prequalification potentially lifesaving vaccine world health organization prequalification service provided facilitate access medicines less affluent countries allows un agencies purchase vaccines behalf developing countries accelerate global access synflorix also signed agreement global alliance vaccines immunization accelerate availability funding pneumococcal vaccination pilot advance market commitment amc mechanism amcs new approach public health funding designed stimulate development manufacture vaccines developing countries donors commit money guarantee price vaccines developed thus creating potential viable future market update september march gsk became one first manufacturers sign advance market commitment agreement see gavi since committed supply million doses synflorix ten years potential prevent deaths millions children worlds poorest countries agreement financed gavi five donor countries canada italy norway russia united kingdom bill melinda gates foundation guaranteed longterm order enable us invest development manufacturing capacity vaccine significantly reduce cost dose around purchase price developed countries children africa begin receiving synflorix vaccinations later back top home responsibility access medicines flexible pricing corporate responsibility report flexible pricing pricing one factor impacts access medicines vaccines adopting range flexible pricing models reflect commitment work governments stakeholders deliver medicines vaccines many needy people possible least developed countries ldcs offer substantially reduced pricing patented medicines countries beyond subsaharan africa offer notforprofit prices hivaids medicines offer tiered pricing gsk vaccines worldwide many poorer communities within middleincome countries also need assistance however ability offer notforprofit highly preferential prices worlds poorest countries sustainable continue make adequate return medicines vaccines better markets many middle income countries also growing commercial markets gsk represent important source future business industry exploring range pricing approaches balance commercial objectives need increase access medicines afford pay markets include flexible tiered preferential pricing models tailored products local sourcing manufacturing arrangements even developed countries patients lack access medicines particular problem uninsured patients us seek price medicines fairly countries level reflects value patients payers us patient assistance programs discount savings cards provide access gsk medicines uninsured patients minimal cost also offer discount cards lithuania ukraine vaccines tiered pricing model vaccines make significant contribution public health helping prevent many potentially fatal infectious diseases immunisation acknowledged world health organization among costeffective health investments years made vaccine portfolio available preferential prices developing countries including ldcs using tiered pricing system prices linked gross national incomes defined world bank well size order length particular supply contract selling vaccines large volumes longerterm contracts able significantly reduce price individual dose developing world prices little tenth developed countries model works vaccines demand relatively predictable centralised bulk procurement groups unicef gavi paho possible work multinational organisations provide appropriate affordable vaccines developing countries tiered pricing applies across vaccine range basic polio vaccines specially developed combination vaccines target several diseases addition tiered pricing looking innovative ways increase access vaccines poorer countries one option pursued cervarix vaccine human papillomavirus partner major international nongovernmental organisation leverage distribution network create sustainable expansion access vaccine developing world cervical cancer deaths occur results pilot programme launched south america encouraging malaria vaccine hope malaria vaccine ready file regulatory authorities young african children aged five months far gsk invested million rd vaccine partner path malaria vaccine initiative mvi invested million dilemma face unlike virtually every vaccine wealthy market vaccine tiered pricing appropriate speech council foreign relations january gsks ceo andrew witty laid principles pursue setting responsible price vaccine first must set price sustainable covers costs allows investment high quality manufacture continued investment follow rd secondly want price way discourage others continuing invest rd area believe therefore would helpful launch first vaccine notforprofit price could create expectation following products would similarly priced could major disincentive investment organisations therefore set price covers costs makes small return reinvest return rd second generation malaria vaccines vaccines diseases developing world vaccine production sensitive economies scale better idea cost structure likely demand vaccine able provide guidance actual price addition price commitment gsk pledged donate least million doses vaccine path malaria vaccine initiative back tophome responsibility access medicines flexible pricing corporate responsibility report flexible pricing pricing one factor impacts access medicines vaccines adopting range flexible pricing models reflect commitment work governments stakeholders deliver medicines vaccines many needy people possible least developed countries ldcs offer substantially reduced pricing patented medicines countries beyond subsaharan africa offer notforprofit prices hivaids medicines offer tiered pricing gsk vaccines worldwide many poorer communities within middleincome countries also need assistance however ability offer notforprofit highly preferential prices worlds poorest countries sustainable continue make adequate return medicines vaccines better markets many middle income countries also growing commercial markets gsk represent important source future business industry exploring range pricing approaches balance commercial objectives need increase access medicines afford pay markets include flexible tiered preferential pricing models tailored products local sourcing manufacturing arrangements even developed countries patients lack access medicines particular problem uninsured patients us seek price medicines fairly countries level reflects value patients payers us patient assistance programs discount savings cards provide access gsk medicines uninsured patients minimal cost also offer discount cards lithuania ukraine vaccines tiered pricing model vaccines make significant contribution public health helping prevent many potentially fatal infectious diseases immunisation acknowledged world health organization among costeffective health investments years made vaccine portfolio available preferential prices developing countries including ldcs using tiered pricing system prices linked gross national incomes defined world bank well size order length particular supply contract selling vaccines large volumes longerterm contracts able significantly reduce price individual dose developing world prices little tenth developed countries model works vaccines demand relatively predictable centralised bulk procurement groups unicef gavi paho possible work multinational organisations provide appropriate affordable vaccines developing countries tiered pricing applies across vaccine range basic polio vaccines specially developed combination vaccines target several diseases addition tiered pricing looking innovative ways increase access vaccines poorer countries one option pursued cervarix vaccine human papillomavirus partner major international nongovernmental organisation leverage distribution network create sustainable expansion access vaccine developing world cervical cancer deaths occur results pilot programme launched south america encouraging malaria vaccine hope malaria vaccine ready file regulatory authorities young african children aged five months far gsk invested million rd vaccine partner path malaria vaccine initiative mvi invested million dilemma face unlike virtually every vaccine wealthy market vaccine tiered pricing appropriate speech council foreign relations january gsks ceo andrew witty laid principles pursue setting responsible price vaccine first must set price sustainable covers costs allows investment high quality manufacture continued investment follow rd secondly want price way discourage others continuing invest rd area believe therefore would helpful launch first vaccine notforprofit price could create expectation following products would similarly priced could major disincentive investment organisations therefore set price covers costs makes small return reinvest return rd second generation malaria vaccines vaccines diseases developing world vaccine production sensitive economies scale better idea cost structure likely demand vaccine able provide guidance actual price addition price commitment gsk pledged donate least million doses vaccine path malaria vaccine initiative back top home responsibility access medicines flexible pricing corporate responsibility report flexible pricing pricing one factor impacts access medicines vaccines adopting range flexible pricing models reflect commitment work governments stakeholders deliver medicines vaccines many needy people possible least developed countries ldcs offer substantially reduced pricing patented medicines countries beyond subsaharan africa offer notforprofit prices hivaids medicines offer tiered pricing gsk vaccines worldwide many poorer communities within middleincome countries also need assistance however ability offer notforprofit highly preferential prices worlds poorest countries sustainable continue make adequate return medicines vaccines better markets many middle income countries also growing commercial markets gsk represent important source future business industry exploring range pricing approaches balance commercial objectives need increase access medicines afford pay markets include flexible tiered preferential pricing models tailored products local sourcing manufacturing arrangements even developed countries patients lack access medicines particular problem uninsured patients us seek price medicines fairly countries level reflects value patients payers us patient assistance programs discount savings cards provide access gsk medicines uninsured patients minimal cost also offer discount cards lithuania ukraine vaccines tiered pricing model vaccines make significant contribution public health helping prevent many potentially fatal infectious diseases immunisation acknowledged world health organization among costeffective health investments years made vaccine portfolio available preferential prices developing countries including ldcs using tiered pricing system prices linked gross national incomes defined world bank well size order length particular supply contract selling vaccines large volumes longerterm contracts able significantly reduce price individual dose developing world prices little tenth developed countries model works vaccines demand relatively predictable centralised bulk procurement groups unicef gavi paho possible work multinational organisations provide appropriate affordable vaccines developing countries tiered pricing applies across vaccine range basic polio vaccines specially developed combination vaccines target several diseases addition tiered pricing looking innovative ways increase access vaccines poorer countries one option pursued cervarix vaccine human papillomavirus partner major international nongovernmental organisation leverage distribution network create sustainable expansion access vaccine developing world cervical cancer deaths occur results pilot programme launched south america encouraging malaria vaccine hope malaria vaccine ready file regulatory authorities young african children aged five months far gsk invested million rd vaccine partner path malaria vaccine initiative mvi invested million dilemma face unlike virtually every vaccine wealthy market vaccine tiered pricing appropriate speech council foreign relations january gsks ceo andrew witty laid principles pursue setting responsible price vaccine first must set price sustainable covers costs allows investment high quality manufacture continued investment follow rd secondly want price way discourage others continuing invest rd area believe therefore would helpful launch first vaccine notforprofit price could create expectation following products would similarly priced could major disincentive investment organisations therefore set price covers costs makes small return reinvest return rd second generation malaria vaccines vaccines diseases developing world vaccine production sensitive economies scale better idea cost structure likely demand vaccine able provide guidance actual price addition price commitment gsk pledged donate least million doses vaccine path malaria vaccine initiative back top home responsibility access medicines flexible pricing least developed countries corporate responsibility report least developed countries approach performance early announced new commitment reduce prices patented medicines least developed countries ldcs gskpatented products countries cost less per cent price uk ensuring cover manufacturing costs offer sustainable maximum price possible reduce prices commitment applies products gsk sole supplier market initially apply offpatent products generic alternatives available since generic companies typically provide even lower prices however feedback local physicians indicated need lowerpriced antibiotics given high incidence infectious diseases therefore reduced prices two antibiotics january east africa look extending ldcs many ldcs healthcare crisis dominated social economic impacts hivaids tb malaria provide antiretrovirals arvs treat hivaids notforprofit nfp prices public sector customers notforprofit organisations countries least developed countries sub saharan africa see feature box voluntary licences also help increase access arvs countries read extending product portfolio developing world preventing product diversion product diversion notforprofit medicines illegally shipped back sale better countries denies treatment patients poorer countries antidiversion measures include specially designed access packs arvs red rather white tablets epivir combivir enter voluntary licences know manufacturer ensure product diversion occur defined un back top home responsibility access medicines flexible pricing least developed countries corporate responsibility report least developed countries approach performance early announced new commitment reduce prices patented medicines least developed countries ldcs gskpatented products countries cost less per cent price uk ensuring cover manufacturing costs offer sustainable maximum price possible reduce prices commitment applies products gsk sole supplier market initially apply offpatent products generic alternatives available since generic companies typically provide even lower prices however feedback local physicians indicated need lowerpriced antibiotics given high incidence infectious diseases therefore reduced prices two antibiotics january east africa look extending ldcs many ldcs healthcare crisis dominated social economic impacts hivaids tb malaria provide antiretrovirals arvs treat hivaids notforprofit nfp prices public sector customers notforprofit organisations countries least developed countries sub saharan africa see feature box voluntary licences also help increase access arvs countries read extending product portfolio developing world preventing product diversion product diversion notforprofit medicines illegally shipped back sale better countries denies treatment patients poorer countries antidiversion measures include specially designed access packs arvs red rather white tablets epivir combivir enter voluntary licences know manufacturer ensure product diversion occur defined un back top home responsibility access medicines flexible pricing least developed countries performance corporate responsibility report least developed countries approach performance vaccines billion vaccine doses shipped one billion went developing countries including least developed middleincome countries price reductions patented medicines april reduced prices least developed countries ldcs gsk patented brands individual product lines formulations countries registered prices reduced average per cent apply following brands seretide asthma chronic obstructive pulmonary disease copd avamys rhinitis flixotide asthma malarone malaria avodart benign prostatic hypertrophy avandia type diabetes avandamet type diabetes fraxiparine anaesthetic ultiva anticoagulant arixtra venousthromboembolism vte zeffix hepatitis b risk products would diverted ldc markets better countries east africa areas west africa shared supply chains lack stringent border controls therefore introduced price reductions nonldc markets reduce risk products would diverted markets thereby reducing availability ldcs know products may meet priority health needs general population ldcs started reducing price products lack competition supplier introducing policies improve affordability products developing world work collaboration levels distribution network ensure price reductions passed patients lost intermediate markup margins work specialist rd units acquisitions strategic alliances continue develop product portfolio suited patients developing countries able implement price reductions markets april however reductions taken longer implement countries needed obtain government authorisation reductions place october ldcs existing product licences sales volumes price decreases seen significant increases sales volumes majority products following price decreases example sales often doubled instances eight times higher comparing sales higher prices first three months sales last three months significant volume increases achieved reasons seem clear example fraxiparine anaesthetic ultiva anticoagulant speciality products used hospitals rather community patient population smaller products used community francophone countries name antimalarial malarone changed malanil regulatory reasons time reduced price introduced instance saw sales volumes decline advised pharmacists customers thought apparently new product counterfeit given introduced quickly low price different trade name raised concerns quality product working inform customers name change support use malanil discounted price ensuring patients benefit instances believe price decreases passed patients however countries less control governments markups early indications suggested middlemen taking advantage price reduction passing patient working governments media ensure patients aware benefit reductions beginning see sales volumes increasing countries also received feedback physicians indicating patients using medicines patient compliance prescribed dose improved cases reductions offpatent products following positive uptake patented products reduced prices feedback local physicians indicated need lower priced antibiotics given high incidence infectious diseases thus started reduce prices augmentin zinnat per cent january east africa look extending ldcs read profit pricing arvs back tophome responsibility access medicines flexible pricing least developed countries performance corporate responsibility report least developed countries approach performance vaccines billion vaccine doses shipped one billion went developing countries including least developed middleincome countries price reductions patented medicines april reduced prices least developed countries ldcs gsk patented brands individual product lines formulations countries registered prices reduced average per cent apply following brands seretide asthma chronic obstructive pulmonary disease copd avamys rhinitis flixotide asthma malarone malaria avodart benign prostatic hypertrophy avandia type diabetes avandamet type diabetes fraxiparine anaesthetic ultiva anticoagulant arixtra venousthromboembolism vte zeffix hepatitis b risk products would diverted ldc markets better countries east africa areas west africa shared supply chains lack stringent border controls therefore introduced price reductions nonldc markets reduce risk products would diverted markets thereby reducing availability ldcs know products may meet priority health needs general population ldcs started reducing price products lack competition supplier introducing policies improve affordability products developing world work collaboration levels distribution network ensure price reductions passed patients lost intermediate markup margins work specialist rd units acquisitions strategic alliances continue develop product portfolio suited patients developing countries able implement price reductions markets april however reductions taken longer implement countries needed obtain government authorisation reductions place october ldcs existing product licences sales volumes price decreases seen significant increases sales volumes majority products following price decreases example sales often doubled instances eight times higher comparing sales higher prices first three months sales last three months significant volume increases achieved reasons seem clear example fraxiparine anaesthetic ultiva anticoagulant speciality products used hospitals rather community patient population smaller products used community francophone countries name antimalarial malarone changed malanil regulatory reasons time reduced price introduced instance saw sales volumes decline advised pharmacists customers thought apparently new product counterfeit given introduced quickly low price different trade name raised concerns quality product working inform customers name change support use malanil discounted price ensuring patients benefit instances believe price decreases passed patients however countries less control governments markups early indications suggested middlemen taking advantage price reduction passing patient working governments media ensure patients aware benefit reductions beginning see sales volumes increasing countries also received feedback physicians indicating patients using medicines patient compliance prescribed dose improved cases reductions offpatent products following positive uptake patented products reduced prices feedback local physicians indicated need lower priced antibiotics given high incidence infectious diseases thus started reduce prices augmentin zinnat per cent january east africa look extending ldcs read profit pricing arvs back top home responsibility access medicines flexible pricing least developed countries performance corporate responsibility report least developed countries approach performance vaccines billion vaccine doses shipped one billion went developing countries including least developed middleincome countries price reductions patented medicines april reduced prices least developed countries ldcs gsk patented brands individual product lines formulations countries registered prices reduced average per cent apply following brands seretide asthma chronic obstructive pulmonary disease copd avamys rhinitis flixotide asthma malarone malaria avodart benign prostatic hypertrophy avandia type diabetes avandamet type diabetes fraxiparine anaesthetic ultiva anticoagulant arixtra venousthromboembolism vte zeffix hepatitis b risk products would diverted ldc markets better countries east africa areas west africa shared supply chains lack stringent border controls therefore introduced price reductions nonldc markets reduce risk products would diverted markets thereby reducing availability ldcs know products may meet priority health needs general population ldcs started reducing price products lack competition supplier introducing policies improve affordability products developing world work collaboration levels distribution network ensure price reductions passed patients lost intermediate markup margins work specialist rd units acquisitions strategic alliances continue develop product portfolio suited patients developing countries able implement price reductions markets april however reductions taken longer implement countries needed obtain government authorisation reductions place october ldcs existing product licences sales volumes price decreases seen significant increases sales volumes majority products following price decreases example sales often doubled instances eight times higher comparing sales higher prices first three months sales last three months significant volume increases achieved reasons seem clear example fraxiparine anaesthetic ultiva anticoagulant speciality products used hospitals rather community patient population smaller products used community francophone countries name antimalarial malarone changed malanil regulatory reasons time reduced price introduced instance saw sales volumes decline advised pharmacists customers thought apparently new product counterfeit given introduced quickly low price different trade name raised concerns quality product working inform customers name change support use malanil discounted price ensuring patients benefit instances believe price decreases passed patients however countries less control governments markups early indications suggested middlemen taking advantage price reduction passing patient working governments media ensure patients aware benefit reductions beginning see sales volumes increasing countries also received feedback physicians indicating patients using medicines patient compliance prescribed dose improved cases reductions offpatent products following positive uptake patented products reduced prices feedback local physicians indicated need lower priced antibiotics given high incidence infectious diseases thus started reduce prices augmentin zinnat per cent january east africa look extending ldcs read profit pricing arvs back top home responsibility access medicines flexible pricing middleincome countries corporate responsibility report middleincome countries approach performance middleincome countries mics brazil china thailand india indonesia economically developed worlds poorest countries often large affluent middle class however many middleincome countries also large numbers people living extreme poverty healthcare demands often outstrip available resources challenges made worse increasing incidence chronic diseases asthma diabetes want improve affordability increase number people access gsk medicines vaccines also recognise markets offer important commercial opportunities example report accounting firm pricewaterhousecoopers suggested brazil china india indonesia mexico russia turkey could account per cent global pharmaceutical market growing business mics key element overall strategy past majority revenue mics come private sector healthcare providers achieve growth need go beyond high income sector increase access patients lower income levels however mics diverse terms economic status demography healthcare infrastructure vary significantly taking single pricing approach would difficult inappropriate inequitable therefore extending flexible pricing strategy mics improve affordability medicines increase access patients lower income levels remaining profitable gsk challenging work early stage approach also includes longestablished practices voluntary licences tiered pricing vaccines preferential pricing hivaids medicines also forming commercial partnerships give patients access medicines bringing products countries first time improving access medicines middleincome countries challenges low government healthcare spend relative gross domestic product gdp low one per cent gdp compared average nine per cent eu per cent us poor healthcare infrastructure including hospitals clinics doctors nurses high level income inequality within countries complicate pricing considerations affordability medicines vaccines taxes markups medicines vaccines stigma discrimination associated certain diseases use traditional medicines remote rural populations world bank classification pharma vision back top home responsibility access medicines flexible pricing middleincome countries corporate responsibility report middleincome countries approach performance middleincome countries mics brazil china thailand india indonesia economically developed worlds poorest countries often large affluent middle class however many middleincome countries also large numbers people living extreme poverty healthcare demands often outstrip available resources challenges made worse increasing incidence chronic diseases asthma diabetes want improve affordability increase number people access gsk medicines vaccines also recognise markets offer important commercial opportunities example report accounting firm pricewaterhousecoopers suggested brazil china india indonesia mexico russia turkey could account per cent global pharmaceutical market growing business mics key element overall strategy past majority revenue mics come private sector healthcare providers achieve growth need go beyond high income sector increase access patients lower income levels however mics diverse terms economic status demography healthcare infrastructure vary significantly taking single pricing approach would difficult inappropriate inequitable therefore extending flexible pricing strategy mics improve affordability medicines increase access patients lower income levels remaining profitable gsk challenging work early stage approach also includes longestablished practices voluntary licences tiered pricing vaccines preferential pricing hivaids medicines also forming commercial partnerships give patients access medicines bringing products countries first time improving access medicines middleincome countries challenges low government healthcare spend relative gross domestic product gdp low one per cent gdp compared average nine per cent eu per cent us poor healthcare infrastructure including hospitals clinics doctors nurses high level income inequality within countries complicate pricing considerations affordability medicines vaccines taxes markups medicines vaccines stigma discrimination associated certain diseases use traditional medicines remote rural populations world bank classification pharma vision back top home responsibility access medicines flexible pricing middleincome countries performance corporate responsibility report middleincome countries approach performance established practices tiered pricing vaccines vaccines available gavieligible middleincome countries mics including indonesia sri lanka cuba highly discounted prices billion vaccine doses shipped one billion went developing countries including least developed middleincome countries many vaccines included government vaccination programmes middleincome countries example rotarix rotavirus vaccine included government vaccination programmes new born babies brazil el salvador mexico panama venezuela supplied million doses vaccine vast majority went developing countries preferential pricing hivaids medicines negotiate preferential pricing arrangements hivaids medicines middleincome countries casebycase basis prices lower paid developed countries low notfor profit nfp prices paid least developed countries ldcs believe approach appropriate burden disease resources available address burden vary significantly country country within countries arrangements combine viable sustainable commercial return gsk improved affordability healthcare systems concerned read approach hivaids extending flexible pricing strategy strategy grow business middleincome countries mics increasing volume products sell increasing number patients receive achieve need flexible prices charge medicines supportive systems place price reductions big impact volume products sell significantly increase access patients experience philippines demonstrates see feature box pricing strategy encourage local operating companies take proactive approach pricing includes optimising prices reflect markets ability pay poorer countries paying less medicines better countries introducing differential pricing structures within markets reach new sectors population include business public sector organisations markets previously dealt private sector working closely mic health authorities payers agree innovative pricing programmes support help improve patient access medicines closely monitoring prices compared local competition ensuring reductions selling prices passed patients appropriate healthcare systems pricing regulations vary widely countries strategy tailored market reflect local healthcare needs commercial objectives improvements manufacturing including local sourcing manufacturing arrangements bring significant cost reductions commercial teams collaborate manufacturing teams early stage experiences one market help inform strategy another develop forums regional country teams share information best practices also need work closely groups distribution chain ensure price reductions benefit patients rather increasing profit middlemen seek opportunities work relevant partners medicines transparency alliance meta pricing complex multidimensional issue factors new product introductions reaction competitors price changes also impact gsks ability improve access medicines example however much seek evolve business model always companies lower cost base able supply lower prices gsk also price reductions may lead competitors reducing prices improve affordability benefit patients may mean sales volumes stagnate even fall also commercial risks example products sold lower prices may diverted better groups within country even countries also possible better countries may seek price reductions even though ability pay greater price reductions could start price war local generics companies resulting spiralling prices point make profit business market becomes unsustainable taking many factors account continue review prices medicines private public purchasers country ensure competitive profitable medicines available widest number people reasonably afford cervarix price reductions gsk committed ensuring pricing barrier access developing world reduced prices cervarix philippines vietnam indonesia south africa supportive systems place price reductions big impact volume products sell significantly increase access patients example reducing price cervarix per cent philippines monthly sales vaccine increased significantly settling around six times volume vaccines sold price reduction introduced change cervarix volume sales price reduction gsk long track record tiered pricing vaccines available governmentled programmes charge reduced prices countries lower levels income reduction price cervarix number countries demonstration commitment increasing access vaccines recently march reduced price cervarix nigeria per cent back tophome responsibility access medicines flexible pricing middleincome countries performance corporate responsibility report middleincome countries approach performance established practices tiered pricing vaccines vaccines available gavieligible middleincome countries mics including indonesia sri lanka cuba highly discounted prices billion vaccine doses shipped one billion went developing countries including least developed middleincome countries many vaccines included government vaccination programmes middleincome countries example rotarix rotavirus vaccine included government vaccination programmes new born babies brazil el salvador mexico panama venezuela supplied million doses vaccine vast majority went developing countries preferential pricing hivaids medicines negotiate preferential pricing arrangements hivaids medicines middleincome countries casebycase basis prices lower paid developed countries low notfor profit nfp prices paid least developed countries ldcs believe approach appropriate burden disease resources available address burden vary significantly country country within countries arrangements combine viable sustainable commercial return gsk improved affordability healthcare systems concerned read approach hivaids extending flexible pricing strategy strategy grow business middleincome countries mics increasing volume products sell increasing number patients receive achieve need flexible prices charge medicines supportive systems place price reductions big impact volume products sell significantly increase access patients experience philippines demonstrates see feature box pricing strategy encourage local operating companies take proactive approach pricing includes optimising prices reflect markets ability pay poorer countries paying less medicines better countries introducing differential pricing structures within markets reach new sectors population include business public sector organisations markets previously dealt private sector working closely mic health authorities payers agree innovative pricing programmes support help improve patient access medicines closely monitoring prices compared local competition ensuring reductions selling prices passed patients appropriate healthcare systems pricing regulations vary widely countries strategy tailored market reflect local healthcare needs commercial objectives improvements manufacturing including local sourcing manufacturing arrangements bring significant cost reductions commercial teams collaborate manufacturing teams early stage experiences one market help inform strategy another develop forums regional country teams share information best practices also need work closely groups distribution chain ensure price reductions benefit patients rather increasing profit middlemen seek opportunities work relevant partners medicines transparency alliance meta pricing complex multidimensional issue factors new product introductions reaction competitors price changes also impact gsks ability improve access medicines example however much seek evolve business model always companies lower cost base able supply lower prices gsk also price reductions may lead competitors reducing prices improve affordability benefit patients may mean sales volumes stagnate even fall also commercial risks example products sold lower prices may diverted better groups within country even countries also possible better countries may seek price reductions even though ability pay greater price reductions could start price war local generics companies resulting spiralling prices point make profit business market becomes unsustainable taking many factors account continue review prices medicines private public purchasers country ensure competitive profitable medicines available widest number people reasonably afford cervarix price reductions gsk committed ensuring pricing barrier access developing world reduced prices cervarix philippines vietnam indonesia south africa supportive systems place price reductions big impact volume products sell significantly increase access patients example reducing price cervarix per cent philippines monthly sales vaccine increased significantly settling around six times volume vaccines sold price reduction introduced change cervarix volume sales price reduction gsk long track record tiered pricing vaccines available governmentled programmes charge reduced prices countries lower levels income reduction price cervarix number countries demonstration commitment increasing access vaccines recently march reduced price cervarix nigeria per cent back top home responsibility access medicines flexible pricing middleincome countries performance corporate responsibility report middleincome countries approach performance established practices tiered pricing vaccines vaccines available gavieligible middleincome countries mics including indonesia sri lanka cuba highly discounted prices billion vaccine doses shipped one billion went developing countries including least developed middleincome countries many vaccines included government vaccination programmes middleincome countries example rotarix rotavirus vaccine included government vaccination programmes new born babies brazil el salvador mexico panama venezuela supplied million doses vaccine vast majority went developing countries preferential pricing hivaids medicines negotiate preferential pricing arrangements hivaids medicines middleincome countries casebycase basis prices lower paid developed countries low notfor profit nfp prices paid least developed countries ldcs believe approach appropriate burden disease resources available address burden vary significantly country country within countries arrangements combine viable sustainable commercial return gsk improved affordability healthcare systems concerned read approach hivaids extending flexible pricing strategy strategy grow business middleincome countries mics increasing volume products sell increasing number patients receive achieve need flexible prices charge medicines supportive systems place price reductions big impact volume products sell significantly increase access patients experience philippines demonstrates see feature box pricing strategy encourage local operating companies take proactive approach pricing includes optimising prices reflect markets ability pay poorer countries paying less medicines better countries introducing differential pricing structures within markets reach new sectors population include business public sector organisations markets previously dealt private sector working closely mic health authorities payers agree innovative pricing programmes support help improve patient access medicines closely monitoring prices compared local competition ensuring reductions selling prices passed patients appropriate healthcare systems pricing regulations vary widely countries strategy tailored market reflect local healthcare needs commercial objectives improvements manufacturing including local sourcing manufacturing arrangements bring significant cost reductions commercial teams collaborate manufacturing teams early stage experiences one market help inform strategy another develop forums regional country teams share information best practices also need work closely groups distribution chain ensure price reductions benefit patients rather increasing profit middlemen seek opportunities work relevant partners medicines transparency alliance meta pricing complex multidimensional issue factors new product introductions reaction competitors price changes also impact gsks ability improve access medicines example however much seek evolve business model always companies lower cost base able supply lower prices gsk also price reductions may lead competitors reducing prices improve affordability benefit patients may mean sales volumes stagnate even fall also commercial risks example products sold lower prices may diverted better groups within country even countries also possible better countries may seek price reductions even though ability pay greater price reductions could start price war local generics companies resulting spiralling prices point make profit business market becomes unsustainable taking many factors account continue review prices medicines private public purchasers country ensure competitive profitable medicines available widest number people reasonably afford cervarix price reductions gsk committed ensuring pricing barrier access developing world reduced prices cervarix philippines vietnam indonesia south africa supportive systems place price reductions big impact volume products sell significantly increase access patients example reducing price cervarix per cent philippines monthly sales vaccine increased significantly settling around six times volume vaccines sold price reduction introduced change cervarix volume sales price reduction gsk long track record tiered pricing vaccines available governmentled programmes charge reduced prices countries lower levels income reduction price cervarix number countries demonstration commitment increasing access vaccines recently march reduced price cervarix nigeria per cent back top home responsibility access medicines flexible pricing developed countries corporate responsibility report developed countries approach performance access medicines issue developing world even developed countries patients afford medicines need particular problem us many people health insurance limited public health provision aim price medicines fairly markets also developed patient assistance programs paps discount savings cards us introduced discount cards middle income countries pricing new products prices newly approved medicines determined countrybycountry basis countries prices negotiated directly governments payers example sickness funds private health insurers others manufacturers free set prices subject kinds government controls seek ensure price new products reflects clinical value patients terms improved therapy better safety fewer side effects providing value payers high risks associated rd need fair return investment national price regulation often balancing act managing public healthcare budgets enabling patient access rewarding innovation ensure continued investment rd sell medicines wholesalers pharmacies directly patients intermediaries often add price mark ups pharmaceutical products addition duties tariffs may imposed imported products affects price paid end customer example national health services hospitals patients approach europe countries europe require demonstration value new medicine example clinical effectiveness costeffectiveness reaching decision reimbursement government given context europe statefunded healthcare systems wider budgetary constraints cases innovative approaches price setting may needed support patient access medicines wherever possible want demonstrate full value medicines evidencebased data time introducing new medicine products allow fair price set reflects medicines proven value one affordable customers sustainable gsk however balancing requirements challenging complex example cases level uncertainty exists relation new medicine uncertainty may aspects evidence provided launch expected financial impact new medicine gsk exploring regulators policy makers innovative ways balancing fair reward medicines maintaining efficient fast patient access working governments spirit partnership order help manage risk uncertainty gsk already engaging innovative pricing programmes several countries discount cards countries gsk introduced discount cards lithuania ukraine enable lowincome patients cphagreo nic f diseases asthma obtain prescription medicines discount price programmes us patient assistance programs paps discount savings cards provide prescription medicines uninsured patients us free minimal cost gsk operates several programmes including commitment access covers cancer treatments bridges access covers medicines outpatients introduced selfenrolment system bridges access programme patients apply using simple one application well telephone help advocate gsk access provides extra help lowincome senior disabled patients enrolled medicare part programme provides free medicines eligible patients spent prescription medicines current year meet income requirements based federal poverty level federal poverty level single person couple family four member together rx access industry programme gives uninsured us citizens per cent discounts medicines gsk seven pharmaceutical companies programme open people earn four times federal poverty level nearly two million americans enrolled together rx access also working governments employers us find new ways address problem chronic diseases reducing healthcare costs update september us launched programme provide adult vaccines free charge eligible low income individuals insurance coverage vaccines us governments vaccines children programme provides vaccines young people age regardless ability pay however similar reimbursement system exist adults immunization rates among adult americans low gsk vaccines access program enable eligible adults receive fdaapproved vaccines hepatitis hepatitis b tetanus diphtheria pertussis eligible women aged also able receive cervical cancer vaccine back tophome responsibility access medicines flexible pricing developed countries corporate responsibility report developed countries approach performance access medicines issue developing world even developed countries patients afford medicines need particular problem us many people health insurance limited public health provision aim price medicines fairly markets also developed patient assistance programs paps discount savings cards us introduced discount cards middle income countries pricing new products prices newly approved medicines determined countrybycountry basis countries prices negotiated directly governments payers example sickness funds private health insurers others manufacturers free set prices subject kinds government controls seek ensure price new products reflects clinical value patients terms improved therapy better safety fewer side effects providing value payers high risks associated rd need fair return investment national price regulation often balancing act managing public healthcare budgets enabling patient access rewarding innovation ensure continued investment rd sell medicines wholesalers pharmacies directly patients intermediaries often add price mark ups pharmaceutical products addition duties tariffs may imposed imported products affects price paid end customer example national health services hospitals patients approach europe countries europe require demonstration value new medicine example clinical effectiveness costeffectiveness reaching decision reimbursement government given context europe statefunded healthcare systems wider budgetary constraints cases innovative approaches price setting may needed support patient access medicines wherever possible want demonstrate full value medicines evidencebased data time introducing new medicine products allow fair price set reflects medicines proven value one affordable customers sustainable gsk however balancing requirements challenging complex example cases level uncertainty exists relation new medicine uncertainty may aspects evidence provided launch expected financial impact new medicine gsk exploring regulators policy makers innovative ways balancing fair reward medicines maintaining efficient fast patient access working governments spirit partnership order help manage risk uncertainty gsk already engaging innovative pricing programmes several countries discount cards countries gsk introduced discount cards lithuania ukraine enable lowincome patients chronic diseases asthma obtain prescription medicines discount price programmes us patient assistance programs paps discount savings cards provide prescription medicines uninsured patients us free minimal cost gsk operates several programmes including commitment access covers cancer treatments bridges access covers medicines outpatients introduced selfenrolment system bridges access programme patients apply using simple one application well telephone help advocate gsk access provides extra help lowincome senior disabled patients enrolled medicare part programme provides free medicines eligible patients spent prescription medicines current year meet income requirements based federal poverty level federal poverty level single person couple family four member together rx access industry programme gives uninsured us citizens per cent discounts medicines gsk seven pharmaceutical companies programme open people earn four times federal poverty level nearly two million americans enrolled together rx access also working governments employers us find new ways address problem chronic diseases reducing healthcare costs update september us launched programme provide adult vaccines free charge eligible low income individuals insurance coverage vaccines us governments vaccines children programme provides vaccines young people age regardless ability pay however similar reimbursement system exist adults immunization rates among adult americans low gsk vaccines access program enable eligible adults receive fdaapproved vaccines hepatitis hepatitis b tetanus diphtheria pertussis eligible women aged also able receive cervical cancer vaccine back top home responsibility access medicines flexible pricing developed countries corporate responsibility report developed countries approach performance access medicines issue developing world even developed countries patients afford medicines need particular problem us many people health insurance limited public health provision aim price medicines fairly markets also developed patient assistance programs paps discount savings cards us introduced discount cards middle income countries pricing new products prices newly approved medicines determined countrybycountry basis countries prices negotiated directly governments payers example sickness funds private health insurers others manufacturers free set prices subject kinds government controls seek ensure price new products reflects clinical value patients terms improved therapy better safety fewer side effects providing value payers high risks associated rd need fair return investment national price regulation often balancing act managing public healthcare budgets enabling patient access rewarding innovation ensure continued investment rd sell medicines wholesalers pharmacies directly patients intermediaries often add price mark ups pharmaceutical products addition duties tariffs may imposed imported products affects price paid end customer example national health services hospitals patients approach europe countries europe require demonstration value new medicine example clinical effectiveness costeffectiveness reaching decision reimbursement government given context europe statefunded healthcare systems wider budgetary constraints cases innovative approaches price setting may needed support patient access medicines wherever possible want demonstrate full value medicines evidencebased data time introducing new medicine products allow fair price set reflects medicines proven value one affordable customers sustainable gsk however balancing requirements challenging complex example cases level uncertainty exists relation new medicine uncertainty may aspects evidence provided launch expected financial impact new medicine gsk exploring regulators policy makers innovative ways balancing fair reward medicines maintaining efficient fast patient access working governments spirit partnership order help manage risk uncertainty gsk already engaging innovative pricing programmes several countries discount cards countries gsk introduced discount cards lithuania ukraine enable lowincome patients chronic diseases asthma obtain prescription medicines discount price programmes us patient assistance programs paps discount savings cards provide prescription medicines uninsured patients us free minimal cost gsk operates several programmes including commitment access covers cancer treatments bridges access covers medicines outpatients introduced selfenrolment system bridges access programme patients apply using simple one application well telephone help advocate gsk access provides extra help lowincome senior disabled patients enrolled medicare part programme provides free medicines eligible patients spent prescription medicines current year meet income requirements based federal poverty level federal poverty level single person couple family four member together rx access industry programme gives uninsured us citizens per cent discounts medicines gsk seven pharmaceutical companies programme open people earn four times federal poverty level nearly two million americans enrolled together rx access also working governments employers us find new ways address problem chronic diseases reducing healthcare costs update september us launched programme provide adult vaccines free charge eligible low income individuals insurance coverage vaccines us governments vaccines children programme provides vaccines young people age regardless ability pay however similar reimbursement system exist adults immunization rates among adult americans low gsk vaccines access program enable eligible adults receive fdaapproved vaccines hepatitis hepatitis b tetanus diphtheria pertussis eligible women aged also able receive cervical cancer vaccine back top home responsibility access medicines flexible pricing developed countries performance corporate responsibility report developed countries approach performance pricing europe exploring flexible approaches pricing example france launching requip xr extended release results trials available show extended release form product achieved better results existing normal release form requip gsk france agreed french health authorities launch requip xr lower price existing version price would barrier access patients submitted additional study data demonstrating requip xr superior based new clinical data french authorities agreed increase price flexible approach positive example model france countries italy italian pharmaceuticals agency agreed risksharing arrangement gsk breast cancer medicine tyverb agreement italian state covers cost initial week treatment cycle patient responds positively treatment continues state 's expense patient respond cost initial treatment cycle covered gsk united kingdom initial review national institute health clinical excellence nice ruled tyverb meet required costeffectiveness threshold address gsk offers patient access programme patients able receive tyverb combination capecitabine programme gsk covers cost tyverb first weeks treatment national health service pays treatment beyond weeks patients continue benefit nice introduced supplementary guidelines assessing medicines used end patients life considered tyverb light flexible criteria despite changes date nice consider tyverb meets required costeffectiveness threshold appraisal tyverb ongoing continue discussions nice meantime number local health authorities signed gsk patient access programme order provide product suitable patients reasonable cost pharmaceutical price regulation scheme agreement regulates industry profits uk government partnership industry introduced new measures promote flexible pricing arrangements agreement recognises use medicine initially launched may fully reflect longerterm value patients nhs therefore allows company propose initial price medicine reflects value launch retaining freedom increase decrease original list price either evidence new uses medicine emerge change effective value medicine offers nhs patients discount cards countries lithuania orange card programme gives senior citizens disabled discount per cent patient copayment gsk prescription medicines far patients applied orange card pharmacies per cent pharmacies lithuania registered participate total discount given ukraine orange card programme gives significant discounts asthma chronic obstructive pulmonary disease patients need financial support purchasing seretide inhaled treatment asthma chronic obstructive pulmonary disease patients orange cards pharmacies registered participate programme total discount given seretide million programmes us patients received gsk medicines worth million us programmes value medicines calculated using average cost goods rather wholesale acquisition cost wac approach valuing medicines accurately reflects true cost gsk therefore transparent believe first pharmaceutical company adopt practice year almost patients received day prescriptions gsk medicines together rx access programme giving patients discounts since inception together rx access given two million patients savings totalling million across wide range products back tophome responsibility access medicines flexible pricing developed countries performance corporate responsibility report developed countries approach performance pricing europe exploring flexible approaches pricing example france launching requip xr extended release results trials available show extended release form product achieved better results existing normal release form requip gsk france agreed french health authorities launch requip xr lower price existing version price would barrier access patients submitted additional study data demonstrating requip xr superior based new clinical data french authorities agreed increase price flexible approach positive example model france countries italy italian pharmaceuticals agency agreed risksharing arrangement gsk breast cancer medicine tyverb agreement italian state covers cost initial week treatment cycle patient responds positively treatment continues state 's expense patient respond cost initial treatment cycle covered gsk united kingdom initial review national institute health clinical excellence nice ruled tyverb meet required costeffectiveness threshold address gsk offers patient access programme patients able receive tyverb combination capecitabine programme gsk covers cost tyverb first weeks treatment national health service pays treatment beyond weeks patients continue benefit nice introduced supplementary guidelines assessing medicines used end patients life considered tyverb light flexible criteria despite changes date nice consider tyverb meets required costeffectiveness threshold appraisal tyverb ongoing continue discussions nice meantime number local health authorities signed gsk patient access programme order provide product suitable patients reasonable cost pharmaceutical price regulation scheme agreement regulates industry profits uk government partnership industry introduced new measures promote flexible pricing arrangements agreement recognises use medicine initially launched may fully reflect longerterm value patients nhs therefore allows company propose initial price medicine reflects value launch retaining freedom increase decrease original list price either evidence new uses medicine emerge change effective value medicine offers nhs patients discount cards countries lithuania orange card programme gives senior citizens disabled discount per cent patient copayment gsk prescription medicines far patients applied orange card pharmacies per cent pharmacies lithuania registered participate total discount given ukraine orange card programme gives significant discounts asthma chronic obstructive pulmonary disease patients need financial support purchasing seretide inhaled treatment asthma chronic obstructive pulmonary disease patients orange cards pharmacies registered participate programme total discount given seretide million programmes us patients received gsk medicines worth million us programmes value medicines calculated using average cost goods rather wholesale acquisition cost wac approach valuing medicines accurately reflects true cost gsk therefore transparent believe first pharmaceutical company adopt practice year almost patients received day prescriptions gsk medicines together rx access programme giving patients discounts since inception together rx access given two million patients savings totalling million across wide range products back top home responsibility access medicines flexible pricing developed countries performance corporate responsibility report developed countries approach performance pricing europe exploring flexible approaches pricing example france launching requip xr extended release results trials available show extended release form product achieved better results existing normal release form requip gsk france agreed french health authorities launch requip xr lower price existing version price would barrier access patients submitted additional study data demonstrating requip xr superior based new clinical data french authorities agreed increase price flexible approach positive example model france countries italy italian pharmaceuticals agency agreed risksharing arrangement gsk breast cancer medicine tyverb agreement italian state covers cost initial week treatment cycle patient responds positively treatment continues state 's expense patient respond cost initial treatment cycle covered gsk united kingdom initial review national institute health clinical excellence nice ruled tyverb meet required costeffectiveness threshold address gsk offers patient access programme patients able receive tyverb combination capecitabine programme gsk covers cost tyverb first weeks treatment national health service pays treatment beyond weeks patients continue benefit nice introduced supplementary guidelines assessing medicines used end patients life considered tyverb light flexible criteria despite changes date nice consider tyverb meets required costeffectiveness threshold appraisal tyverb ongoing continue discussions nice meantime number local health authorities signed gsk patient access programme order provide product suitable patients reasonable cost pharmaceutical price regulation scheme agreement regulates industry profits uk government partnership industry introduced new measures promote flexible pricing arrangements agreement recognises use medicine initially launched may fully reflect longerterm value patients nhs therefore allows company propose initial price medicine reflects value launch retaining freedom increase decrease original list price either evidence new uses medicine emerge change effective value medicine offers nhs patients discount cards countries lithuania orange card programme gives senior citizens disabled discount per cent patient copayment gsk prescription medicines far patients applied orange card pharmacies per cent pharmacies lithuania registered participate total discount given ukraine orange card programme gives significant discounts asthma chronic obstructive pulmonary disease patients need financial support purchasing seretide inhaled treatment asthma chronic obstructive pulmonary disease patients orange cards pharmacies registered participate programme total discount given seretide million programmes us patients received gsk medicines worth million us programmes value medicines calculated using average cost goods rather wholesale acquisition cost wac approach valuing medicines accurately reflects true cost gsk therefore transparent believe first pharmaceutical company adopt practice year almost patients received day prescriptions gsk medicines together rx access programme giving patients discounts since inception together rx access given two million patients savings totalling million across wide range products back top home responsibility access medicines partnerships acquisitions corporate responsibility report partnerships acquisitions developing innovative partnerships tackle barriers access medicines developing countries tailored local healthcare needs approach includes joint ventures technology transfer arrangements help developing countries develop research manufacturing capabilities increasing access markets gsk voluntary licences enable generics companies manufacture low cost antiretrovirals treatment hiv africa expanding product portfolio pipeline developing countries new alliances acquisitions partnerships key barrier access developing countries lack healthcare infrastructure physical human although health service provider want work others improve healthcare infrastructure committed reinvest per cent profits medicines sold least developed countries back projects widen access essential medicines strengthen healthcare infrastructure countries read progress far back top home responsibility access medicines partnerships acquisitions corporate responsibility report partnerships acquisitions developing innovative partnerships tackle barriers access medicines developing countries tailored local healthcare needs approach includes joint ventures technology transfer arrangements help developing countries develop research manufacturing capabilities increasing access markets gsk voluntary licences enable generics companies manufacture low cost antiretrovirals treatment hiv africa expanding product portfolio pipeline developing countries new alliances acquisitions partnerships key barrier access developing countries lack healthcare infrastructure physical human although health service provider want work others improve healthcare infrastructure committed reinvest per cent profits medicines sold least developed countries back projects widen access essential medicines strengthen healthcare infrastructure countries read progress far back top home responsibility access medicines partnerships acquisitions technology transfers joint ventures corporate responsibility report technology transfers joint ventures pursuing joint ventures technology transfer agreements developing countries agreements benefit gsk giving us access new markets benefit developing countries expanding supply essential medicines vaccines supporting development local research manufacturing capabilities shared resources knowledge expertise developing countries though joint ventures technology transfer agreements many years feature two significant examples vaccines suitable candidate technological transfer importance public health used across whole population needed constant supply also important local production capacity able respond quickly epidemic developed network vaccine production sites countries worldwide mixture operations joint ventures collaborations partnerships developed local basis meet healthcare needs country involved developing countries suitable investment technology transfer agreements factors include economic political stability market size potential availability skilled workers supportive regulatory environment including enforcement appropriate quality safety efficacy criteria intellectual property framework availability natural resources adequate system deliver vaccine production importantly strong political needed prioritise immunisation health budgets promote partnerships enable vaccine rd support programmes vaccinate population local manufacturing help make medicines affordable always case lowest manufacturing costs achieved concentrating production large factories efficient scale existing facilities rather create new sites brazil partnering brazils oswaldo cruz foundation fiocruz since manufacture vaccines public health priorities brazil including polio haemophilus influenzae type b hib measles mumps rubella rotavirus recently pneumococcal disease local manufacturing technology transfer deal generated sales gsk vaccines helping brazil develop research manufacturing capabilities also helped us develop positive relationship brazilian government increasingly important customer gsk extended partnership fiocruz year launching joint rd initiative develop vaccine dengue fever scientists gsk fiocruz work across facilities brazil belgium new partnership enhance brazilian rd capacity gsk also provide fiocruz access technology behind synflorix vaccine protects lifethreatening infections pneumonia meningitis bacteraemia supply synflorix fiocruz technology transfer completed brazilian government incorporate vaccine national immunisation programme technology transfer agreement rotarix vaccine protects agains rotavirus cause gastroenteritis continued year since gsk via fiocruz sole supplier million doses rotavirus vaccine brazil vaccine included national programme immunizations march december technology transfer gsk biologicals fiocruzmoh agreed fiocruz produce rotarix brazilian domestic market manufacture rotarix gsk contract export deal benefited gsk fiocruz helping ensure around million babies brazil protected gsk 's rotarix five years several vaccine impact studies conducted following results brazil compared prevaccination period hospitalisation due gastroenteritis decreased per cent children years greater reduction per cent observed among children aged less year recife northern territory brazil casecontrol study showed rotarix provided high statistically significant protection per cent severe diarrhoea hospitalisations due rotavirus gastroenteritis first year life paulo largest city brazil study showed per cent reduction hospitalisations due causes gastroenteritis among children years compared prevaccine introduction period gastroenteritis due rotavirus decreased per cent compared prevaccine introduction period paulo according data state health secretariat reduction proportion cases gastroenteritis caused rotavirus per cent one per cent according mathematical model rotavirus vaccination programme brazil estimated prevent approximately million per cent rotavirus gastroenteritis cases per cent rotavirusassociated deaths period five years china announced new joint venture shenzhen neptunus interlong biotechnique co ltd shenzhen neptunus focused developing manufacturing influenza vaccines chinese market include vaccines seasonal prepandemic pandemic influenza joint venture benefit companies expertise vaccine development gsk provide access adjuvant system helps improve efficiency optimise production increasing number vaccine doses produced using smaller amount antigen shenzhen neptunus provide local manufacturing capacity rd expertise china agreed form longterm joint venture biotech company walvax develop manufacture paediatric vaccines including priorix measles mumps rubella vaccine use country gsk transfer necessary technology joint venture manufacture vaccines locally time gsk investing nearly million collaboration also granted voluntary licence simcere chinese manufacturer granting right manufacture sell zanamivir relenza containing products china sell number countries including least developed countries zanamivir antiviral help treat influenza voluntary licence driven specific concern help ensure sufficient supplies event global flu pandemic background position voluntary licensing technology transfer generally please visit public policy area website lanzieri et al data file poster presented wspid november buenos aires argentina correia jb et al j infect dis february safadi et al data file poster presented espid june brussels belgium sao paulo state health secretariat coelho de suarez p et al rev panam salud publicapan j public health gsk public policies back tophome responsibility access medicines partnerships acquisitions technology transfers joint ventures corporate responsibility report technology transfers joint ventures pursuing joint ventures technology transfer agreements developing countries agreements benefit gsk giving us access new markets benefit developing countries expanding supply essential medicines vaccines supporting development local research manufacturing capabilities shared resources knowledge expertise developing countries though joint ventures technology transfer agreements many years feature two significant examples vaccines suitable candidate technological transfer importance public health used across whole population needed constant supply also important local production capacity able respond quickly epidemic developed network vaccine production sites countries worldwide mixture operations joint ventures collaborations partnerships developed local basis meet healthcare needs country involved developing countries suitable investment technology transfer agreements factors include economic political stability market size potential availability skilled workers supportive regulatory environment including enforcement appropriate quality safety efficacy criteria intellectual property framework availability natural resources adequate system deliver vaccine production importantly strong political needed prioritise immunisation health budgets promote partnerships enable vaccine rd support programmes vaccinate population local manufacturing help make medicines affordable always case lowest manufacturing costs achieved concentrating production large factories efficient scale existing facilities rather create new sites brazil partnering brazils oswaldo cruz foundation fiocruz since manufacture vaccines public health priorities brazil including polio haemophilus influenzae type b hib measles mumps rubella rotavirus recently pneumococcal disease local manufacturing technology transfer deal generated sales gsk vaccines helping brazil develop research manufacturing capabilities also helped us develop positive relationship brazilian government increasingly important customer gsk extended partnership fiocruz year launching joint rd initiative develop vaccine dengue fever scientists gsk fiocruz work across facilities brazil belgium new partnership enhance brazilian rd capacity gsk also provide fiocruz access technology behind synflorix vaccine protects lifethreatening infections pneumonia meningitis bacteraemia supply synflorix fiocruz technology transfer completed brazilian government incorporate vaccine national immunisation programme technology transfer agreement rotarix vaccine protects agains rotavirus cause gastroenteritis continued year since gsk via fiocruz sole supplier million doses rotavirus vaccine brazil vaccine included national programme immunizations march december technology transfer gsk biologicals fiocruzmoh agreed fiocruz produce rotarix brazilian domestic market manufacture rotarix gsk contract export deal benefited gsk fiocruz helping ensure around million babies brazil protected gsk 's rotarix five years several vaccine impact studies conducted following results brazil compared prevaccination period hospitalisation due gastroenteritis decreased per cent children years greater reduction per cent observed among children aged less year recife northern territory brazil casecontrol study showed rotarix provided high statistically significant protection per cent severe diarrhoea hospitalisations due rotavirus gastroenteritis first year life paulo largest city brazil study showed per cent reduction hospitalisations due causes gastroenteritis among children years compared prevaccine introduction period gastroenteritis due rotavirus decreased per cent compared prevaccine introduction period paulo according data state health secretariat reduction proportion cases gastroenteritis caused rotavirus per cent one per cent according mathematical model rotavirus vaccination programme brazil estimated prevent approximately million per cent rotavirus gastroenteritis cases per cent rotavirusassociated deaths period five years china announced new joint venture shenzhen neptunus interlong biotechnique co ltd shenzhen neptunus focused developing manufacturing influenza vaccines chinese market include vaccines seasonal prepandemic pandemic influenza joint venture benefit companies expertise vaccine development gsk provide access adjuvant system helps improve efficiency optimise production increasing number vaccine doses produced using smaller amount antigen shenzhen neptunus provide local manufacturing capacity rd expertise china agreed form longterm joint venture biotech company walvax develop manufacture paediatric vaccines including priorix measles mumps rubella vaccine use country gsk transfer necessary technology joint venture manufacture vaccines locally time gsk investing nearly million collaboration also granted voluntary licence simcere chinese manufacturer granting right manufacture sell zanamivir relenza containing products china sell number countries including least developed countries zanamivir antiviral help treat influenza voluntary licence driven specific concern help ensure sufficient supplies event global flu pandemic background position voluntary licensing technology transfer generally please visit public policy area website lanzieri et al data file poster presented wspid november buenos aires argentina correia jb et al j infect dis february safadi et al data file poster presented espid june brussels belgium sao paulo state health secretariat coelho de suarez p et al rev panam salud publicapan j public health gsk public policies back tophome responsibility access medicines partnerships acquisitions technology transfers joint ventures corporate responsibility report technology transfers joint ventures pursuing joint ventures technology transfer agreements developing countries agreements benefit gsk giving us access new markets benefit developing countries expanding supply essential medicines vaccines supporting development local research manufacturing capabilities shared resources knowledge expertise developing countries though joint ventures technology transfer agreements many years feature two significant examples vaccines suitable candidate technological transfer importance public health used across whole population needed constant supply also important local production capacity able respond quickly epidemic developed network vaccine production sites countries worldwide mixture operations joint ventures collaborations partnerships developed local basis meet healthcare needs country involved developing countries suitable investment technology transfer agreements factors include economic political stability market size potential availability skilled workers supportive regulatory environment including enforcement appropriate quality safety efficacy criteria intellectual property framework availability natural resources adequate system deliver vaccine production importantly strong political needed prioritise immunisation health budgets promote partnerships enable vaccine rd support programmes vaccinate population local manufacturing help make medicines affordable always case lowest manufacturing costs achieved concentrating production large factories efficient scale existing facilities rather create new sites brazil partnering brazils oswaldo cruz foundation fiocruz since manufacture vaccines public health priorities brazil including polio haemophilus influenzae type b hib measles mumps rubella rotavirus recently pneumococcal disease local manufacturing technology transfer deal generated sales gsk vaccines helping brazil develop research manufacturing capabilities also helped us develop positive relationship brazilian government increasingly important customer gsk extended partnership fiocruz year launching joint rd initiative develop vaccine dengue fever scientists gsk fiocruz work across facilities brazil belgium new partnership enhance brazilian rd capacity gsk also provide fiocruz access technology behind synflorix vaccine protects lifethreatening infections pneumonia meningitis bacteraemia supply synflorix fiocruz technology transfer completed brazilian government incorporate vaccine national immunisation programme technology transfer agreement rotarix vaccine protects agains rotavirus cause gastroenteritis continued year since gsk via fiocruz sole supplier million doses rotavirus vaccine brazil vaccine included national programme immunizations march december technology transfer gsk biologicals fiocruzmoh agreed fiocruz produce rotarix brazilian domestic market manufacture rotarix gsk contract export deal benefited gsk fiocruz helping ensure around million babies brazil protected gsk 's rotarix five years several vaccine impact studies conducted following results brazil compared prevaccination period hospitalisation due gastroenteritis decreased per cent children years greater reduction per cent observed among children aged less year recife northern territory brazil casecontrol study showed rotarix provided high statistically significant protection per cent severe diarrhoea hospitalisations due rotavirus gastroenteritis first year life paulo largest city brazil study showed per cent reduction hospitalisations due causes gastroenteritis among children years compared prevaccine introduction period gastroenteritis due rotavirus decreased per cent compared prevaccine introduction period paulo according data state health secretariat reduction proportion cases gastroenteritis caused rotavirus per cent one per cent according mathematical model rotavirus vaccination programme brazil estimated prevent approximately million per cent rotavirus gastroenteritis cases per cent rotavirusassociated deaths period five years china announced new joint venture shenzhen neptunus interlong biotechnique co ltd shenzhen neptunus focused developing manufacturing influenza vaccines chinese market include vaccines seasonal prepandemic pandemic influenza joint venture benefit companies expertise vaccine development gsk provide access adjuvant system helps improve efficiency optimise production increasing number vaccine doses produced using smaller amount antigen shenzhen neptunus provide local manufacturing capacity rd expertise china agreed form longterm joint venture biotech company walvax develop manufacture paediatric vaccines including priorix measles mumps rubella vaccine use country gsk transfer necessary technology joint venture manufacture vaccines locally time gsk investing nearly million collaboration also granted voluntary licence simcere chinese manufacturer granting right manufacture sell zanamivir relenza containing products china sell number countries including least developed countries zanamivir antiviral help treat influenza voluntary licence driven specific concern help ensure sufficient supplies event global flu pandemic background position voluntary licensing technology transfer generally please visit public policy area website lanzieri et al data file poster presented wspid november buenos aires argentina correia jb et al j infect dis february safadi et al data file poster presented espid june brussels belgium sao paulo state health secretariat coelho de suarez p et al rev panam salud publicapan j public health gsk public policies back top home responsibility access medicines partnerships acquisitions technology transfers joint ventures corporate responsibility report technology transfers joint ventures pursuing joint ventures technology transfer agreements developing countries agreements benefit gsk giving us access new markets benefit developing countries expanding supply essential medicines vaccines supporting development local research manufacturing capabilities shared resources knowledge expertise developing countries though joint ventures technology transfer agreements many years feature two significant examples vaccines suitable candidate technological transfer importance public health used across whole population needed constant supply also important local production capacity able respond quickly epidemic developed network vaccine production sites countries worldwide mixture operations joint ventures collaborations partnerships developed local basis meet healthcare needs country involved developing countries suitable investment technology transfer agreements factors include economic political stability market size potential availability skilled workers supportive regulatory environment including enforcement appropriate quality safety efficacy criteria intellectual property framework availability natural resources adequate system deliver vaccine production importantly strong political needed prioritise immunisation health budgets promote partnerships enable vaccine rd support programmes vaccinate population local manufacturing help make medicines affordable always case lowest manufacturing costs achieved concentrating production large factories efficient scale existing facilities rather create new sites brazil partnering brazils oswaldo cruz foundation fiocruz since manufacture vaccines public health priorities brazil including polio haemophilus influenzae type b hib measles mumps rubella rotavirus recently pneumococcal disease local manufacturing technology transfer deal generated sales gsk vaccines helping brazil develop research manufacturing capabilities also helped us develop positive relationship brazilian government increasingly important customer gsk extended partnership fiocruz year launching joint rd initiative develop vaccine dengue fever scientists gsk fiocruz work across facilities brazil belgium new partnership enhance brazilian rd capacity gsk also provide fiocruz access technology behind synflorix vaccine protects lifethreatening infections pneumonia meningitis bacteraemia supply synflorix fiocruz technology transfer completed brazilian government incorporate vaccine national immunisation programme technology transfer agreement rotarix vaccine protects agains rotavirus cause gastroenteritis continued year since gsk via fiocruz sole supplier million doses rotavirus vaccine brazil vaccine included national programme immunizations march december technology transfer gsk biologicals fiocruzmoh agreed fiocruz produce rotarix brazilian domestic market manufacture rotarix gsk contract export deal benefited gsk fiocruz helping ensure around million babies brazil protected gsk 's rotarix five years several vaccine impact studies conducted following results brazil compared prevaccination period hospitalisation due gastroenteritis decreased per cent children years greater reduction per cent observed among children aged less year recife northern territory brazil casecontrol study showed rotarix provided high statistically significant protection per cent severe diarrhoea hospitalisations due rotavirus gastroenteritis first year life paulo largest city brazil study showed per cent reduction hospitalisations due causes gastroenteritis among children years compared prevaccine introduction period gastroenteritis due rotavirus decreased per cent compared prevaccine introduction period paulo according data state health secretariat reduction proportion cases gastroenteritis caused rotavirus per cent one per cent according mathematical model rotavirus vaccination programme brazil estimated prevent approximately million per cent rotavirus gastroenteritis cases per cent rotavirusassociated deaths period five years china announced new joint venture shenzhen neptunus interlong biotechnique co ltd shenzhen neptunus focused developing manufacturing influenza vaccines chinese market include vaccines seasonal prepandemic pandemic influenza joint venture benefit companies expertise vaccine development gsk provide access adjuvant system helps improve efficiency optimise production increasing number vaccine doses produced using smaller amount antigen shenzhen neptunus provide local manufacturing capacity rd expertise china agreed form longterm joint venture biotech company walvax develop manufacture paediatric vaccines including priorix measles mumps rubella vaccine use country gsk transfer necessary technology joint venture manufacture vaccines locally time gsk investing nearly million collaboration also granted voluntary licence simcere chinese manufacturer granting right manufacture sell zanamivir relenza containing products china sell number countries including least developed countries zanamivir antiviral help treat influenza voluntary licence driven specific concern help ensure sufficient supplies event global flu pandemic background position voluntary licensing technology transfer generally please visit public policy area website lanzieri et al data file poster presented wspid november buenos aires argentina correia jb et al j infect dis february safadi et al data file poster presented espid june brussels belgium sao paulo state health secretariat coelho de suarez p et al rev panam salud publicapan j public health gsk public policies back top home responsibility access medicines partnerships acquisitions portfolio expansion corporate responsibility report portfolio expansion approach performance growth developing countries achieved making current product range affordable however believe significant growth come expanding product portfolio make suited needs patients developing countries well developing new products rd operations achieving strategic alliances acquisition pharmaceutical companies together deals providing gsk access renewable highquality competitively priced pipeline branded pharmaceuticals products complements existing portfolio products help increase access low middleincome markets example licensing collaboration established south africabased pharmaceuticals company aspen giving us access product portfolio products licence sale developing countries focus quality secure supply chain mean collaborations provide reliable high quality choice patients many countries back top home responsibility access medicines partnerships acquisitions portfolio expansion corporate responsibility report portfolio expansion approach performance growth developing countries achieved making current product range affordable however believe significant growth come expanding product portfolio make suited needs patients developing countries well developing new products rd operations achieving strategic alliances acquisition pharmaceutical companies together deals providing gsk access renewable highquality competitively priced pipeline branded pharmaceuticals products complements existing portfolio products help increase access low middleincome markets example licensing collaboration established south africabased pharmaceuticals company aspen giving us access product portfolio products licence sale developing countries focus quality secure supply chain mean collaborations provide reliable high quality choice patients many countries back top home responsibility access medicines partnerships acquisitions portfolio expansion performance corporate responsibility report portfolio expansion approach performance alliances growth developing countries achieved strategic alliances acquisition pharmaceutical companies allows us broaden product portfolio provide medicines value patients countries licensing collaborations aspen based south africa dr reddys india giving us access portfolio low cost quality branded products across therapeutic areas cardiovascular central nervous system diabetes gastroenterology oncology license products sale gsks emerging markets asiapacific regions regulatory applications filed molecules products across regions first set products sale entered new collaboration year aspen combine commercial activities sub saharan africa agreement builds previous alliance aspen one africas leading healthcare companies terms agreement gsk aspen collaborate commercialisation current future product portfolios subsaharan africa excluding south africa vast majority combined current sales region approximately million attributable gsk collaboration build broader diverse portfolio countries aspens extensive pipeline new products expected benefit greater leverage gsks existing commercial infrastructure help us provide medicines value patients region overcome access challenges agreement cover south africa aspen extensive commercial capability transfer marketing distribution rights aspen gsks pharmaceutical products country part overall deal gsk acquired per cent shareholding aspen since increased per cent demonstrating gsks commitment investing subcontinent december entered agreement gilead develop launch hepatitis b treatment viread china agreement builds gsks strong heritage hepatitis b provides important addition current portfolio one key markets together gilead committed increasing access medicine patients asia bringing new ways address burden chronic hepatitis b needed also december gsk reached agreement take per cent stake algerian pharmaceutical manufacturing distribution group laboratoire pharmaceutique algerien lpa accelerate sales growth extend pharmaceutical portfolio algeria gsk collaborated lpa one leading pharmaceutical distribution companies algeria years taking full ownership lpa group gsk acquires branded generic pharmaceutical products analgesic cough cold dermatology areas well manufacturing facility distribution warehouse boudouaou algeria agreement lpa enable us increase access high quality healthcare products people algeria local manufacture expanded portfolio branded generics greater distribution capability lpa continue operate separate entity focus branded generics distribution gsk algeria continue focus gsks patented brands vaccines acquisitions acquisitions included bristolmyers squibb pakistan private ltd bmsp portfolio wellestablished pharmaceutical brands many occupy leading market positions key therapeutic disease areas pakistan bmsp portfolio includes antibiotics vitamins dermatology also provide new opportunities gsk cardiovascular oncology bristolmyers squibbs branded generics business lebanon jordan syria libya yemen comprises portfolio branded pharmaceuticals ucb south africas marketed product portfolio territories africa middle east asia pacific latin america result agreement gsk acquire several leading pharmaceutical brands number disease areas include keppra treatment epilepsy xyzal zyrtec treatment allergic rhinitis back tophome responsibility access medicines partnerships acquisitions portfolio expansion performance corporate responsibility report portfolio expansion approach performance alliances growth developing countries achieved strategic alliances acquisition pharmaceutical companies allows us broaden product portfolio provide medicines value patients countries licensing collaborations aspen based south africa dr reddys india giving us access portfolio low cost quality branded products across therapeutic areas cardiovascular central nervous system diabetes gastroenterology oncology license products sale gsks emerging markets asiapacific regions regulatory applications filed molecules products across regions first set products sale entered new collaboration year aspen combine commercial activities sub saharan africa agreement builds previous alliance aspen one africas leading healthcare companies terms agreement gsk aspen collaborate commercialisation current future product portfolios subsaharan africa excluding south africa vast majority combined current sales region approximately million attributable gsk collaboration build broader diverse portfolio countries aspens extensive pipeline new products expected benefit greater leverage gsks existing commercial infrastructure help us provide medicines value patients region overcome access challenges agreement cover south africa aspen extensive commercial capability transfer marketing distribution rights aspen gsks pharmaceutical products country part overall deal gsk acquired per cent shareholding aspen since increased per cent demonstrating gsks commitment investing subcontinent december entered agreement gilead develop launch hepatitis b treatment viread china agreement builds gsks strong heritage hepatitis b provides important addition current portfolio one key markets together gilead committed increasing access medicine patients asia bringing new ways address burden chronic hepatitis b needed also december gsk reached agreement take per cent stake algerian pharmaceutical manufacturing distribution group laboratoire pharmaceutique algerien lpa accelerate sales growth extend pharmaceutical portfolio algeria gsk collaborated lpa one leading pharmaceutical distribution companies algeria years taking full ownership lpa group gsk acquires branded generic pharmaceutical products analgesic cough cold dermatology areas well manufacturing facility distribution warehouse boudouaou algeria agreement lpa enable us increase access high quality healthcare products people algeria local manufacture expanded portfolio branded generics greater distribution capability lpa continue operate separate entity focus branded generics distribution gsk algeria continue focus gsks patented brands vaccines acquisitions acquisitions included bristolmyers squibb pakistan private ltd bmsp portfolio wellestablished pharmaceutical brands many occupy leading market positions key therapeutic disease areas pakistan bmsp portfolio includes antibiotics vitamins dermatology also provide new opportunities gsk cardiovascular oncology bristolmyers squibbs branded generics business lebanon jordan syria libya yemen comprises portfolio branded pharmaceuticals ucb south africas marketed product portfolio territories africa middle east asia pacific latin america result agreement gsk acquire several leading pharmaceutical brands number disease areas include keppra treatment epilepsy xyzal zyrtec treatment allergic rhinitis back top home responsibility access medicines partnerships acquisitions portfolio expansion performance corporate responsibility report portfolio expansion approach performance alliances growth developing countries achieved strategic alliances acquisition pharmaceutical companies allows us broaden product portfolio provide medicines value patients countries licensing collaborations aspen based south africa dr reddys india giving us access portfolio low cost quality branded products across therapeutic areas cardiovascular central nervous system diabetes gastroenterology oncology license products sale gsks emerging markets asiapacific regions regulatory applications filed molecules products across regions first set products sale entered new collaboration year aspen combine commercial activities sub saharan africa agreement builds previous alliance aspen one africas leading healthcare companies terms agreement gsk aspen collaborate commercialisation current future product portfolios subsaharan africa excluding south africa vast majority combined current sales region approximately million attributable gsk collaboration build broader diverse portfolio countries aspens extensive pipeline new products expected benefit greater leverage gsks existing commercial infrastructure help us provide medicines value patients region overcome access challenges agreement cover south africa aspen extensive commercial capability transfer marketing distribution rights aspen gsks pharmaceutical products country part overall deal gsk acquired per cent shareholding aspen since increased per cent demonstrating gsks commitment investing subcontinent december entered agreement gilead develop launch hepatitis b treatment viread china agreement builds gsks strong heritage hepatitis b provides important addition current portfolio one key markets together gilead committed increasing access medicine patients asia bringing new ways address burden chronic hepatitis b needed also december gsk reached agreement take per cent stake algerian pharmaceutical manufacturing distribution group laboratoire pharmaceutique algerien lpa accelerate sales growth extend pharmaceutical portfolio algeria gsk collaborated lpa one leading pharmaceutical distribution companies algeria years taking full ownership lpa group gsk acquires branded generic pharmaceutical products analgesic cough cold dermatology areas well manufacturing facility distribution warehouse boudouaou algeria agreement lpa enable us increase access high quality healthcare products people algeria local manufacture expanded portfolio branded generics greater distribution capability lpa continue operate separate entity focus branded generics distribution gsk algeria continue focus gsks patented brands vaccines acquisitions acquisitions included bristolmyers squibb pakistan private ltd bmsp portfolio wellestablished pharmaceutical brands many occupy leading market positions key therapeutic disease areas pakistan bmsp portfolio includes antibiotics vitamins dermatology also provide new opportunities gsk cardiovascular oncology bristolmyers squibbs branded generics business lebanon jordan syria libya yemen comprises portfolio branded pharmaceuticals ucb south africas marketed product portfolio territories africa middle east asia pacific latin america result agreement gsk acquire several leading pharmaceutical brands number disease areas include keppra treatment epilepsy xyzal zyrtec treatment allergic rhinitis back top home responsibility access medicines advocacy government relations corporate responsibility report advocacy government relations lobby governments policy makers advocate sustainable approach improving access healthcare approach must support innovation critical improving access longer term also responded report un special rapporteur human rights right health see advocacy advocacy work area included urging g continue making healthcare developing world major agenda item supporting development pilot advance market commitment pneumococcal vaccine engaging work whos intergovernmental working group igwg public health innovation intellectual property expert working group looking financing working uk government global health issues development department international developments dfids medicines transparency alliance meta review good practice framework pharmaceutical companies discussing ip innovation funding ngos foundations stakeholders attending executive board meetings world health assembly contributing design affordable medicines facility malaria playing leading role major global health initiatives example gsk sits boards gavi alliance participates roll back malaria board meetings participating board meetings global fund fight aids tb malaria supporting development quality assurance standards engaging negotiations wto doha round seek sustainable proinnovation outcomes addressing hivaids eu neighbouring countries european commissions bremen process engaging intergovernmental meeting pandemic influenza preparedness contributed report prepared paul hunt former un special rapporteur right health report gsks approach access medicines number senior executives including former ceo dr jp garnier chairman sir christopher gent interviewed read malaria advocacy stakeholder feedback november held stakeholder workshop experts access medicines get feedback new initiatives least developed countries read report workshop findings government relations gsk aims support work constructively governments efforts strengthen develop sustainable healthcare systems across globe read examples activities area engaging human right health may former un special rapporteur right health paul hunt published review gsks policies practices access medicines following series indepth interviews senior management well identifying good practices obstacles improving access report makes series recommendations gsk pharmaceutical industry broadly support peoples right health welcome special rapporteurs constructive engagement gsk recognition report gsks industryleading position improving access medicines agree many reports recommendations pharmaceutical industry however agree reports suggestion access medicines programmes mandated international legal norms whether relating human rights areas given lack legal obligation companies relating right health clear us recommendation report establish human rights ombudsman could operate practice committed playing part tackling global healthcare challenge global community must also provide political significant mobilisation additional resources spirit partnership see achievement right everyone enjoyment highest attainable standard health across developing world continue efforts improving initiatives applying lessons learned looking opportunities welcome special rapporteurs constructive engagement gsk provided response presented un human rights council geneva june back tophome responsibility access medicines advocacy government relations corporate responsibility report advocacy government relations lobby governments policy makers advocate sustainable approach improving access healthcare approach must support innovation critical improving access longer term also responded report un special rapporteur human rights right health see advocacy advocacy work area included urging g continue making healthcare developing world major agenda item supporting development pilot advance market commitment pneumococcal vaccine engaging work whos intergovernmental working group igwg public health innovation intellectual property expert working group looking financing working uk government global health issues development department international developments dfids medicines transparency alliance meta review good practice framework pharmaceutical companies discussing ip innovation funding ngos foundations stakeholders attending executive board meetings world health assembly contributing design affordable medicines facility malaria playing leading role major global health initiatives example gsk sits boards gavi alliance participates roll back malaria board meetings participating board meetings global fund fight aids tb malaria supporting development quality assurance standards engaging negotiations wto doha round seek sustainable proinnovation outcomes addressing hivaids eu neighbouring countries european commissions bremen process engaging intergovernmental meeting pandemic influenza preparedness contributed report prepared paul hunt former un special rapporteur right health report gsks approach access medicines number senior executives including former ceo dr jp garnier chairman sir christopher gent interviewed read malaria advocacy stakeholder feedback november held stakeholder workshop experts access medicines get feedback new initiatives least developed countries read report workshop findings government relations gsk aims support work constructively governments efforts strengthen develop sustainable healthcare systems across globe read examples activities area engaging human right health may former un special rapporteur right health paul hunt published review gsks policies practices access medicines following series indepth interviews senior management well identifying good practices obstacles improving access report makes series recommendations gsk pharmaceutical industry broadly support peoples right health welcome special rapporteurs constructive engagement gsk recognition report gsks industryleading position improving access medicines agree many reports recommendations pharmaceutical industry however agree reports suggestion access medicines programmes mandated international legal norms whether relating human rights areas given lack legal obligation companies relating right health clear us recommendation report establish human rights ombudsman could operate practice committed playing part tackling global healthcare challenge global community must also provide political significant mobilisation additional resources spirit partnership see achievement right everyone enjoyment highest attainable standard health across developing world continue efforts improving initiatives applying lessons learned looking opportunities welcome special rapporteurs constructive engagement gsk provided response presented un human rights council geneva june back top home responsibility access medicines advocacy government relations corporate responsibility report advocacy government relations lobby governments policy makers advocate sustainable approach improving access healthcare approach must support innovation critical improving access longer term also responded report un special rapporteur human rights right health see advocacy advocacy work area included urging g continue making healthcare developing world major agenda item supporting development pilot advance market commitment pneumococcal vaccine engaging work whos intergovernmental working group igwg public health innovation intellectual property expert working group looking financing working uk government global health issues development department international developments dfids medicines transparency alliance meta review good practice framework pharmaceutical companies discussing ip innovation funding ngos foundations stakeholders attending executive board meetings world health assembly contributing design affordable medicines facility malaria playing leading role major global health initiatives example gsk sits boards gavi alliance participates roll back malaria board meetings participating board meetings global fund fight aids tb malaria supporting development quality assurance standards engaging negotiations wto doha round seek sustainable proinnovation outcomes addressing hivaids eu neighbouring countries european commissions bremen process engaging intergovernmental meeting pandemic influenza preparedness contributed report prepared paul hunt former un special rapporteur right health report gsks approach access medicines number senior executives including former ceo dr jp garnier chairman sir christopher gent interviewed read malaria advocacy stakeholder feedback november held stakeholder workshop experts access medicines get feedback new initiatives least developed countries read report workshop findings government relations gsk aims support work constructively governments efforts strengthen develop sustainable healthcare systems across globe read examples activities area engaging human right health may former un special rapporteur right health paul hunt published review gsks policies practices access medicines following series indepth interviews senior management well identifying good practices obstacles improving access report makes series recommendations gsk pharmaceutical industry broadly support peoples right health welcome special rapporteurs constructive engagement gsk recognition report gsks industryleading position improving access medicines agree many reports recommendations pharmaceutical industry however agree reports suggestion access medicines programmes mandated international legal norms whether relating human rights areas given lack legal obligation companies relating right health clear us recommendation report establish human rights ombudsman could operate practice committed playing part tackling global healthcare challenge global community must also provide political significant mobilisation additional resources spirit partnership see achievement right everyone enjoyment highest attainable standard health across developing world continue efforts improving initiatives applying lessons learned looking opportunities welcome special rapporteurs constructive engagement gsk provided response presented un human rights council geneva june back top home responsibility access medicines case studies corporate responsibility report case studies trials malaria vaccine development rtss moves phase iii effective vaccine critical tackling malaria alongside prevention efforts use bed nets effective antimalarial medicines however developing vaccine complex scientific challenge vaccine yet registered rtss worlds clinically advanced malaria vaccine candidate first vaccine designed primarily use africa malaria kills people every year majority children age five rtss result groundbreaking partnership begun leading african european us research institutions path malaria vaccine initiative mvi gsk biologicals support bill melinda gates foundation phase iii efficacy trial rtss underway seven african countries burkina faso gabon kenya malawi mozambique tanzania largest malaria vaccine trial undertaken expected involve children infants age five groups vulnerable malaria children vaccinated beginning majority five months old currently enrolling second age group infants six weeks age receive vaccine part regular schedule immunisations conducting trial seven different countries across subsaharan africa researchers able evaluate vaccines efficacy variety settings diverse patterns malaria transmission example trial sites located areas yearround threat malaria others experience seasonal transmission current trials successful rtss could submitted regulatory review children five months age early gsk invested million date expects invest least another million completion mvi contributed million project far technology transfer vaccines local solution gsk partnering brazils oswaldo cruz foundation fiocruz since manufacture vaccines public health priorities including polio haemophilus influenzae type b hib measles mumps rubella rotavirus recently pneumococcal disease local manufacturing technology transfer deal generated sales gsk vaccines helping brazil advance research manufacturing capabilities helped us develop positive relationship brazilian government increasingly important customer gsk technology transfer successful brazil due favourable economic legal regulatory scientific market conditions existence right partner fiocruz capacity receive technology transfer shares vision partnership work practice gsk committed partnering governments others help meet worlds vaccination needs sustainable manner technology transfer one many options consider increasing availability vaccines developing world however believe universal solution technology transfer agreements succeed countries right business scientific environment suitable local partners conducive conditions include skilled workers carry rd high tech manufacturing supportive regulatory environment strong political commitment intellectual property protection predictable commercial environment significant investment availability partner receiving technology unfortunately many developing countries conditions yet exist evolution proprietary knowledge pool flexible intellectual property encouraging pharmaceutical companies could stimulate research help speed development medicines neglected tropical diseases ntds february announced would create ntd patent pool march published details gsk patents patent applications small molecule pharmaceuticals identified potentially useful treatment neglected tropical diseases products developed using information pool sold least developed countries royalty free basis held discussions three groups stakeholders helped us shape thinking pool scientific research community potential contributors pool potential administrators pool discussions scientific research community learnt appreciated us making patent information public however really need access knowhow experience want ask us tried already results worked overcame particular challenges therefore committed making knowledge experience relates ntds available pool reflect refer pool proprietary knowledge pool january signed agreements giving two organisations access information pool emory university institute drug discovery ithemba pharmaceuticals company based south africa working tb financial help south african government date one company us biotechnology group alnylam contributed patents pool held constructive discussions number companies could contribute assets pool told us would like see greater independence pool goal always create independent ntd pool january announced bio ventures global health bvgh take administration pool hopeful lead companies joining due course continue work bvgh alnylam stakeholders develop operating model pool achieve ultimate objective stimulating facilitating rd neglected tropical diseases back tophome responsibility access medicines case studies corporate responsibility report case studies trials malaria vaccine development rtss moves phase iii effective vaccine critical tackling malaria alongside prevention efforts use bed nets effective antimalarial medicines however developing vaccine complex scientific challenge vaccine yet registered rtss worlds clinically advanced malaria vaccine candidate first vaccine designed primarily use africa malaria kills people every year majority children age five rtss result groundbreaking partnership begun leading african european us research institutions path malaria vaccine initiative mvi gsk biologicals support bill melinda gates foundation phase iii efficacy trial rtss underway seven african countries burkina faso gabon kenya malawi mozambique tanzania largest malaria vaccine trial undertaken expected involve children infants age five groups vulnerable malaria children vaccinated beginning majority five months old currently enrolling second age group infants six weeks age receive vaccine part regular schedule immunisations conducting trial seven different countries across subsaharan africa researchers able evaluate vaccines efficacy variety settings diverse patterns malaria transmission example trial sites located areas yearround threat malaria others experience seasonal transmission current trials successful rtss could submitted regulatory review children five months age early gsk invested million date expects invest least another million completion mvi contributed million project far technology transfer vaccines local solution gsk partnering brazils oswaldo cruz foundation fiocruz since manufacture vaccines public health priorities including polio haemophilus influenzae type b hib measles mumps rubella rotavirus recently pneumococcal disease local manufacturing technology transfer deal generated sales gsk vaccines helping brazil advance research manufacturing capabilities helped us develop positive relationship brazilian government increasingly important customer gsk technology transfer successful brazil due favourable economic legal regulatory scientific market conditions existence right partner fiocruz capacity receive technology transfer shares vision partnership work practice gsk committed partnering governments others help meet worlds vaccination needs sustainable manner technology transfer one many options consider increasing availability vaccines developing world however believe universal solution technology transfer agreements succeed countries right business scientific environment suitable local partners conducive conditions include skilled workers carry rd high tech manufacturing supportive regulatory environment strong political commitment intellectual property protection predictable commercial environment significant investment availability partner receiving technology unfortunately many developing countries conditions yet exist evolution proprietary knowledge pool flexible intellectual property encouraging pharmaceutical companies could stimulate research help speed development medicines neglected tropical diseases ntds february announced would create ntd patent pool march published details gsk patents patent applications small molecule pharmaceuticals identified potentially useful treatment neglected tropical diseases products developed using information pool sold least developed countries royalty free basis held discussions three groups stakeholders helped us shape thinking pool scientific research community potential contributors pool potential administrators pool discussions scientific research community learnt appreciated us making patent information public however really need access knowhow experience want ask us tried already results worked overcame particular challenges therefore committed making knowledge experience relates ntds available pool reflect refer pool proprietary knowledge pool january signed agreements giving two organisations access information pool emory university institute drug discovery ithemba pharmaceuticals company based south africa working tb financial help south african government date one company us biotechnology group alnylam contributed patents pool held constructive discussions number companies could contribute assets pool told us would like see greater independence pool goal always create independent ntd pool january announced bio ventures global health bvgh take administration pool hopeful lead companies joining due course continue work bvgh alnylam stakeholders develop operating model pool achieve ultimate objective stimulating facilitating rd neglected tropical diseases back top home responsibility access medicines case studies corporate responsibility report case studies trials malaria vaccine development rtss moves phase iii effective vaccine critical tackling malaria alongside prevention efforts use bed nets effective antimalarial medicines however developing vaccine complex scientific challenge vaccine yet registered rtss worlds clinically advanced malaria vaccine candidate first vaccine designed primarily use africa malaria kills people every year majority children age five rtss result groundbreaking partnership begun leading african european us research institutions path malaria vaccine initiative mvi gsk biologicals support bill melinda gates foundation phase iii efficacy trial rtss underway seven african countries burkina faso gabon kenya malawi mozambique tanzania largest malaria vaccine trial undertaken expected involve children infants age five groups vulnerable malaria children vaccinated beginning majority five months old currently enrolling second age group infants six weeks age receive vaccine part regular schedule immunisations conducting trial seven different countries across subsaharan africa researchers able evaluate vaccines efficacy variety settings diverse patterns malaria transmission example trial sites located areas yearround threat malaria others experience seasonal transmission current trials successful rtss could submitted regulatory review children five months age early gsk invested million date expects invest least another million completion mvi contributed million project far technology transfer vaccines local solution gsk partnering brazils oswaldo cruz foundation fiocruz since manufacture vaccines public health priorities including polio haemophilus influenzae type b hib measles mumps rubella rotavirus recently pneumococcal disease local manufacturing technology transfer deal generated sales gsk vaccines helping brazil advance research manufacturing capabilities helped us develop positive relationship brazilian government increasingly important customer gsk technology transfer successful brazil due favourable economic legal regulatory scientific market conditions existence right partner fiocruz capacity receive technology transfer shares vision partnership work practice gsk committed partnering governments others help meet worlds vaccination needs sustainable manner technology transfer one many options consider increasing availability vaccines developing world however believe universal solution technology transfer agreements succeed countries right business scientific environment suitable local partners conducive conditions include skilled workers carry rd high tech manufacturing supportive regulatory environment strong political commitment intellectual property protection predictable commercial environment significant investment availability partner receiving technology unfortunately many developing countries conditions yet exist evolution proprietary knowledge pool flexible intellectual property encouraging pharmaceutical companies could stimulate research help speed development medicines neglected tropical diseases ntds february announced would create ntd patent pool march published details gsk patents patent applications small molecule pharmaceuticals identified potentially useful treatment neglected tropical diseases products developed using information pool sold least developed countries royalty free basis held discussions three groups stakeholders helped us shape thinking pool scientific research community potential contributors pool potential administrators pool discussions scientific research community learnt appreciated us making patent information public however really need access knowhow experience want ask us tried already results worked overcame particular challenges therefore committed making knowledge experience relates ntds available pool reflect refer pool proprietary knowledge pool january signed agreements giving two organisations access information pool emory university institute drug discovery ithemba pharmaceuticals company based south africa working tb financial help south african government date one company us biotechnology group alnylam contributed patents pool held constructive discussions number companies could contribute assets pool told us would like see greater independence pool goal always create independent ntd pool january announced bio ventures global health bvgh take administration pool hopeful lead companies joining due course continue work bvgh alnylam stakeholders develop operating model pool achieve ultimate objective stimulating facilitating rd neglected tropical diseases back top home responsibility access medicines qas corporate responsibility report qas respond questions raised stakeholders arent access programmes drop ocean given scale healthcare crisis developing world global healthcare crisis extensive complex programmes single organisation insufficient political effective investment extra resources required support healthcare development build infrastructure gsk wider pharmaceutical industry mandate expertise resources address problem alone without global partnership address issues efforts individual stakeholder inadequate primary responsibility dealing crisis lies governments call international agencies ngos support gsk committed playing full part partnerships organisations seeking act catalyst encourage stakeholders find new ways make contribution focus access programmes specific areas think make real difference example research develop medicines vaccines particularly needed developing countries make available lower prices preferential pricing arrangements voluntary licences also working identify ways contribute towards improved healthcare seeking new partnerships expanding pricing policies flexible intellectual property investing healthcare infrastructure medicines expensive wouldnt responsible thing could cut price medicines improving affordability medicines important taking steps area poverty income levels public healthcare resources vary hugely counties aim tailor pricing meet needs individual countries recognise importance pricing medicines fairly developed countries meet patient needs help relieve burden public healthcare budgets price products richer counties level enables us make enough profit gsk remains attractive prospect investors continue invest rd discover medicines vaccines bring benefits society future would able offer notforprofit highly preferential prices worlds least developed countries defined un generate reasonable return developed countries middle income countries often large wealthy middle class well poor communities exploring pricing models enable us responsibly seek commercial opportunities wealthier segments society seeking increase access medicines afford pay countries however affordability significant barrier access developing countries kevin de cock said head hivaids work countries obvious quickly elephant room current price drugs real obstacle fragility health systems particularly africa therefore unless action taken address underlying problems poverty healthcare infrastructure reducing prices alone solve problem doesnt gsk extend notforprofit prices middleincome countries offer greatest discounts countries need greatest resources limited widely accepted terms support improving healthcare services least developed countries ldcs defined un subsaharan africa includes middle income countries middleincome countries eligible notforprofit prices offered ldcs subsaharan africa many middleincome countries represent growth opportunities gsk important source future business industry exploring range pricing solutions balance commercial objectives need increase access medicines afford pay markets include optimising prices reflect markets ability pay poorer countries paying less medicines better countries introducing differential pricing structures within markets reach new sectors population include business public sector civil society organisations markets previously dealt private sector working closely mic health authorities payers agree innovative pricing schemes support help improve patient access medicines closely monitoring prices compared local competition ensuring reductions selling prices passed customers appropriate people hivaids receiving treatment developing world important progress area four million people developing world receiving treatment lifesaving antiretrovirals led decline deaths caused aids despite increase number people living hiv however much core issue many people developing countries access effective healthcare services therefore unable access medicines due poverty many clinics patients unable pay even cheapest basic generic medicines viiv healthcare bring renewed focus addressing challenges access issue complex multifaceted pricing medicines important believe many significant barriers factors play part inadequate healthcare resources lack clinics hospitals poor distribution networks low numbers trained healthcare providers high levels patient illiteracy significant stigma discrimination lack political inadequate prioritisation health government budgets announced per cent profits make selling medicines least developed countries reinvested projects strengthen infrastructure widen access dont donate aids products worlds poorest common many stakeholders including oxfam believe donations arvs offer solution aids pandemic healthcare problems developing world generally widespread crisis one requires longterm commitment treatment commitment assured donations director general margaret chan said health systems tap root better health donated drugs world wont good without infrastructure delivery limited circumstances donations may appropriate example disease elimination efforts global alliance eliminate lymphatic filariasis past donated arvs support unicef prevention mothertochild transmission programmes continue support collaborative clinical trials assess appropriate use arvs resourcepoor settings dont allow middleincome countries buy arvs generic manufacturers granted eight voluntary licences arvs african generics companies arrangements supply number middleincome countries africa middleincome countries generally economically developed least developed countries often large affluent middle class countries also large numbers people living extreme poverty healthcare demands often outstrip available resources recognise many middleincome countries need assistance however believe different approach needed one take worlds poorest countries continued refine approach offer supply products notforprofit prices worlds poorest countries sustainable continue make adequate return wealthier markets many middleincome countries also growing commercial markets gsk represent important source future business industry response markets must therefore one balances commercial objectives global commitment work governments stakeholders ensure medicines vaccines reach many possible need believe governments middleincome countries improve access increasing investment disease prevention healthcare eliminating taxation tariffs medicines creating environment allows strong private healthcare sector coexist public healthcare provision working governments find creative ways meet goals dont pharmaceutical companies work together increase access medicines recognise companies together alone seeking new partnerships example together pfizer launched viiv healthcare specialist company solely focused research development commercialisation hiv medicines viiv healthcare core objective address lack treatments formulations children living hiv significant unmet medical need encouraging companies join knowledge pool neglected tropical diseases placed approximately patent families granted patents pending applications help others develop new medicines neglected diseases also aim attract new partners including businesses tres cantos diseases developing world research centre spain aim facility becomes centre excellence stimulating research collaboration open wide range stakeholders rather one company back tophome responsibility access medicines qas corporate responsibility report qas respond questions raised stakeholders arent access programmes drop ocean given scale healthcare crisis developing world global healthcare crisis extensive complex programmes single organisation insufficient political effective investment extra resources required support healthcare development build infrastructure gsk wider pharmaceutical industry mandate expertise resources address problem alone without global partnership address issues efforts individual stakeholder inadequate primary responsibility dealing crisis lies governments call international agencies ngos support gsk committed playing full part partnerships organisations seeking act catalyst encourage stakeholders find new ways make contribution focus access programmes specific areas think make real difference example research develop medicines vaccines particularly needed developing countries make available lower prices preferential pricing arrangements voluntary licences also working identify ways contribute towards improved healthcare seeking new partnerships expanding pricing policies flexible intellectual property investing healthcare infrastructure medicines expensive wouldnt responsible thing could cut price medicines improving affordability medicines important taking steps area poverty income levels public healthcare resources vary hugely counties aim tailor pricing meet needs individual countries recognise importance pricing medicines fairly developed countries meet patient needs help relieve burden public healthcare budgets price products richer counties level enables us make enough profit gsk remains attractive prospect investors continue invest rd discover medicines vaccines bring benefits society future would able offer notforprofit highly preferential prices worlds least developed countries defined un generate reasonable return developed countries middle income countries often large wealthy middle class well poor communities exploring pricing models enable us responsibly seek commercial opportunities wealthier segments society seeking increase access medicines afford pay countries however affordability significant barrier access developing countries kevin de cock said head hivaids work countries obvious quickly elephant room current price drugs real obstacle fragility health systems particularly africa therefore unless action taken address underlying problems poverty healthcare infrastructure reducing prices alone solve problem doesnt gsk extend notforprofit prices middleincome countries offer greatest discounts countries need greatest resources limited widely accepted terms support improving healthcare services least developed countries ldcs defined un subsaharan africa includes middle income countries middleincome countries eligible notforprofit prices offered ldcs subsaharan africa many middleincome countries represent growth opportunities gsk important source future business industry exploring range pricing solutions balance commercial objectives need increase access medicines afford pay markets include optimising prices reflect markets ability pay poorer countries paying less medicines better countries introducing differential pricing structures within markets reach new sectors population include business public sector civil society organisations markets previously dealt private sector working closely mic health authorities payers agree innovative pricing schemes support help improve patient access medicines closely monitoring prices compared local competition ensuring reductions selling prices passed customers appropriate people hivaids receiving treatment developing world important progress area four million people developing world receiving treatment lifesaving antiretrovirals led decline deaths caused aids despite increase number people living hiv however much core issue many people developing countries access effective healthcare services therefore unable access medicines due poverty many clinics patients unable pay even cheapest basic generic medicines viiv healthcare bring renewed focus addressing challenges access issue complex multifaceted pricing medicines important believe many significant barriers factors play part inadequate healthcare resources lack clinics hospitals poor distribution networks low numbers trained healthcare providers high levels patient illiteracy significant stigma discrimination lack political inadequate prioritisation health government budgets announced per cent profits make selling medicines least developed countries reinvested projects strengthen infrastructure widen access dont donate aids products worlds poorest common many stakeholders including oxfam believe donations arvs offer solution aids pandemic healthcare problems developing world generally widespread crisis one requires longterm commitment treatment commitment assured donations director general margaret chan said health systems tap root better health donated drugs world wont good without infrastructure delivery limited circumstances donations may appropriate example disease elimination efforts global alliance eliminate lymphatic filariasis past donated arvs support unicef prevention mothertochild transmission programmes continue support collaborative clinical trials assess appropriate use arvs resourcepoor settings dont allow middleincome countries buy arvs generic manufacturers granted eight voluntary licences arvs african generics companies arrangements supply number middleincome countries africa middleincome countries generally economically developed least developed countries often large affluent middle class countries also large numbers people living extreme poverty healthcare demands often outstrip available resources recognise many middleincome countries need assistance however believe different approach needed one take worlds poorest countries continued refine approach offer supply products notforprofit prices worlds poorest countries sustainable continue make adequate return wealthier markets many middleincome countries also growing commercial markets gsk represent important source future business industry response markets must therefore one balances commercial objectives global commitment work governments stakeholders ensure medicines vaccines reach many possible need believe governments middleincome countries improve access increasing investment disease prevention healthcare eliminating taxation tariffs medicines creating environment allows strong private healthcare sector coexist public healthcare provision working governments find creative ways meet goals dont pharmaceutical companies work together increase access medicines recognise companies together alone seeking new partnerships example together pfizer launched viiv healthcare specialist company solely focused research development commercialisation hiv medicines viiv healthcare core objective address lack treatments formulations children living hiv significant unmet medical need encouraging companies join knowledge pool neglected tropical diseases placed approximately patent families granted patents pending applications help others develop new medicines neglected diseases also aim attract new partners including businesses tres cantos diseases developing world research centre spain aim facility becomes centre excellence stimulating research collaboration open wide range stakeholders rather one company back tophome responsibility access medicines qas corporate responsibility report qas respond questions raised stakeholders arent access programmes drop ocean given scale healthcare crisis developing world global healthcare crisis extensive complex programmes single organisation insufficient political effective investment extra resources required support healthcare development build infrastructure gsk wider pharmaceutical industry mandate expertise resources address problem alone without global partnership address issues efforts individual stakeholder inadequate primary responsibility dealing crisis lies governments call international agencies ngos support gsk committed playing full part partnerships organisations seeking act catalyst encourage stakeholders find new ways make contribution focus access programmes specific areas think make real difference example research develop medicines vaccines particularly needed developing countries make available lower prices preferential pricing arrangements voluntary licences also working identify ways contribute towards improved healthcare seeking new partnerships expanding pricing policies flexible intellectual property investing healthcare infrastructure medicines expensive wouldnt responsible thing could cut price medicines improving affordability medicines important taking steps area poverty income levels public healthcare resources vary hugely counties aim tailor pricing meet needs individual countries recognise importance pricing medicines fairly developed countries meet patient needs help relieve burden public healthcare budgets price products richer counties level enables us make enough profit gsk remains attractive prospect investors continue invest rd discover medicines vaccines bring benefits society future would able offer notforprofit highly preferential prices worlds least developed countries defined un generate reasonable return developed countries middle income countries often large wealthy middle class well poor communities exploring pricing models enable us responsibly seek commercial opportunities wealthier segments society seeking increase access medicines afford pay countries however affordability significant barrier access developing countries kevin de cock said head hivaids work countries obvious quickly elephant room current price drugs real obstacle fragility health systems particularly africa therefore unless action taken address underlying problems poverty healthcare infrastructure reducing prices alone solve problem doesnt gsk extend notforprofit prices middleincome countries offer greatest discounts countries need greatest resources limited widely accepted terms support improving healthcare services least developed countries ldcs defined un subsaharan africa includes middle income countries middleincome countries eligible notforprofit prices offered ldcs subsaharan africa many middleincome countries represent growth opportunities gsk important source future business industry exploring range pricing solutions balance commercial objectives need increase access medicines afford pay markets include optimising prices reflect markets ability pay poorer countries paying less medicines better countries introducing differential pricing structures within markets reach new sectors population include business public sector civil society organisations markets previously dealt private sector working closely mic health authorities payers agree innovative pricing schemes support help improve patient access medicines closely monitoring prices compared local competition ensuring reductions selling prices passed customers appropriate people hivaids receiving treatment developing world important progress area four million people developing world receiving treatment lifesaving antiretrovirals led decline deaths caused aids despite increase number people living hiv however much core issue many people developing countries access effective healthcare services therefore unable access medicines due poverty many clinics patients unable pay even cheapest basic generic medicines viiv healthcare bring renewed focus addressing challenges access issue complex multifaceted pricing medicines important believe many significant barriers factors play part inadequate healthcare resources lack clinics hospitals poor distribution networks low numbers trained healthcare providers high levels patient illiteracy significant stigma discrimination lack political inadequate prioritisation health government budgets announced per cent profits make selling medicines least developed countries reinvested projects strengthen infrastructure widen access dont donate aids products worlds poorest common many stakeholders including oxfam believe donations arvs offer solution aids pandemic healthcare problems developing world generally widespread crisis one requires longterm commitment treatment commitment assured donations director general margaret chan said health systems tap root better health donated drugs world wont good without infrastructure delivery limited circumstances donations may appropriate example disease elimination efforts global alliance eliminate lymphatic filariasis past donated arvs support unicef prevention mothertochild transmission programmes continue support collaborative clinical trials assess appropriate use arvs resourcepoor settings dont allow middleincome countries buy arvs generic manufacturers granted eight voluntary licences arvs african generics companies arrangements supply number middleincome countries africa middleincome countries generally economically developed least developed countries often large affluent middle class countries also large numbers people living extreme poverty healthcare demands often outstrip available resources recognise many middleincome countries need assistance however believe different approach needed one take worlds poorest countries continued refine approach offer supply products notforprofit prices worlds poorest countries sustainable continue make adequate return wealthier markets many middleincome countries also growing commercial markets gsk represent important source future business industry response markets must therefore one balances commercial objectives global commitment work governments stakeholders ensure medicines vaccines reach many possible need believe governments middleincome countries improve access increasing investment disease prevention healthcare eliminating taxation tariffs medicines creating environment allows strong private healthcare sector coexist public healthcare provision working governments find creative ways meet goals dont pharmaceutical companies work together increase access medicines recognise companies together alone seeking new partnerships example together pfizer launched viiv healthcare specialist company solely focused research development commercialisation hiv medicines viiv healthcare core objective address lack treatments formulations children living hiv significant unmet medical need encouraging companies join knowledge pool neglected tropical diseases placed approximately patent families granted patents pending applications help others develop new medicines neglected diseases also aim attract new partners including businesses tres cantos diseases developing world research centre spain aim facility becomes centre excellence stimulating research collaboration open wide range stakeholders rather one company back top home responsibility access medicines qas corporate responsibility report qas respond questions raised stakeholders arent access programmes drop ocean given scale healthcare crisis developing world global healthcare crisis extensive complex programmes single organisation insufficient political effective investment extra resources required support healthcare development build infrastructure gsk wider pharmaceutical industry mandate expertise resources address problem alone without global partnership address issues efforts individual stakeholder inadequate primary responsibility dealing crisis lies governments call international agencies ngos support gsk committed playing full part partnerships organisations seeking act catalyst encourage stakeholders find new ways make contribution focus access programmes specific areas think make real difference example research develop medicines vaccines particularly needed developing countries make available lower prices preferential pricing arrangements voluntary licences also working identify ways contribute towards improved healthcare seeking new partnerships expanding pricing policies flexible intellectual property investing healthcare infrastructure medicines expensive wouldnt responsible thing could cut price medicines improving affordability medicines important taking steps area poverty income levels public healthcare resources vary hugely counties aim tailor pricing meet needs individual countries recognise importance pricing medicines fairly developed countries meet patient needs help relieve burden public healthcare budgets price products richer counties level enables us make enough profit gsk remains attractive prospect investors continue invest rd discover medicines vaccines bring benefits society future would able offer notforprofit highly preferential prices worlds least developed countries defined un generate reasonable return developed countries middle income countries often large wealthy middle class well poor communities exploring pricing models enable us responsibly seek commercial opportunities wealthier segments society seeking increase access medicines afford pay countries however affordability significant barrier access developing countries kevin de cock said head hivaids work countries obvious quickly elephant room current price drugs real obstacle fragility health systems particularly africa therefore unless action taken address underlying problems poverty healthcare infrastructure reducing prices alone solve problem doesnt gsk extend notforprofit prices middleincome countries offer greatest discounts countries need greatest resources limited widely accepted terms support improving healthcare services least developed countries ldcs defined un subsaharan africa includes middle income countries middleincome countries eligible notforprofit prices offered ldcs subsaharan africa many middleincome countries represent growth opportunities gsk important source future business industry exploring range pricing solutions balance commercial objectives need increase access medicines afford pay markets include optimising prices reflect markets ability pay poorer countries paying less medicines better countries introducing differential pricing structures within markets reach new sectors population include business public sector civil society organisations markets previously dealt private sector working closely mic health authorities payers agree innovative pricing schemes support help improve patient access medicines closely monitoring prices compared local competition ensuring reductions selling prices passed customers appropriate people hivaids receiving treatment developing world important progress area four million people developing world receiving treatment lifesaving antiretrovirals led decline deaths caused aids despite increase number people living hiv however much core issue many people developing countries access effective healthcare services therefore unable access medicines due poverty many clinics patients unable pay even cheapest basic generic medicines viiv healthcare bring renewed focus addressing challenges access issue complex multifaceted pricing medicines important believe many significant barriers factors play part inadequate healthcare resources lack clinics hospitals poor distribution networks low numbers trained healthcare providers high levels patient illiteracy significant stigma discrimination lack political inadequate prioritisation health government budgets announced per cent profits make selling medicines least developed countries reinvested projects strengthen infrastructure widen access dont donate aids products worlds poorest common many stakeholders including oxfam believe donations arvs offer solution aids pandemic healthcare problems developing world generally widespread crisis one requires longterm commitment treatment commitment assured donations director general margaret chan said health systems tap root better health donated drugs world wont good without infrastructure delivery limited circumstances donations may appropriate example disease elimination efforts global alliance eliminate lymphatic filariasis past donated arvs support unicef prevention mothertochild transmission programmes continue support collaborative clinical trials assess appropriate use arvs resourcepoor settings dont allow middleincome countries buy arvs generic manufacturers granted eight voluntary licences arvs african generics companies arrangements supply number middleincome countries africa middleincome countries generally economically developed least developed countries often large affluent middle class countries also large numbers people living extreme poverty healthcare demands often outstrip available resources recognise many middleincome countries need assistance however believe different approach needed one take worlds poorest countries continued refine approach offer supply products notforprofit prices worlds poorest countries sustainable continue make adequate return wealthier markets many middleincome countries also growing commercial markets gsk represent important source future business industry response markets must therefore one balances commercial objectives global commitment work governments stakeholders ensure medicines vaccines reach many possible need believe governments middleincome countries improve access increasing investment disease prevention healthcare eliminating taxation tariffs medicines creating environment allows strong private healthcare sector coexist public healthcare provision working governments find creative ways meet goals dont pharmaceutical companies work together increase access medicines recognise companies together alone seeking new partnerships example together pfizer launched viiv healthcare specialist company solely focused research development commercialisation hiv medicines viiv healthcare core objective address lack treatments formulations children living hiv significant unmet medical need encouraging companies join knowledge pool neglected tropical diseases placed approximately patent families granted patents pending applications help others develop new medicines neglected diseases also aim attract new partners including businesses tres cantos diseases developing world research centre spain aim facility becomes centre excellence stimulating research collaboration open wide range stakeholders rather one company back top home responsibility research practices corporate responsibility report research practices committed focusing patient everything rd pipeline central ability meet patients ' needs high ethical standards rd key protecting participants clinical research ensuring quality research maximising benefits minimising risks medicines vaccines high ethical standards also essential us obtain regulatory approval new medicines patients doctors put trust research programmes products part strategy grow diversified global business deliver products value expanding presence emerging markets buying new businesses collaborating organisations rd policies global apply high standards wherever operate including contract organisations conduct research behalf collaborate organisations whose principles aligned gsk research conducted part collaboration raise awareness policies beginning collaboration include clauses collaboration agreement requiring compliance principles research collaborations typically overseen joint steering committee jsc made senior staff gsk collaborator continuously evaluate risks benefits medicines every stage initial research clinical trials new product approved sale committed open results clinical research use number reporting channels evaluate efficacy safety medicines use medicines make informed decisions use increase transparency committed publishing research payments make healthcare professionals starting us followed gsks europe asia pacific japan emerging markets apjem regions part commitment understand patient needs develop better medicines programme activities invite patients discuss conditions research teams recognise biomedical research raise ethical concerns including relating use emerging technologies cloning use stem cells animal research clinical research storage use human tissue protection personal information research participants participate discussions research practices regularly engage academic scientists regulators policy makers stakeholders related issues back top home responsibility research practices corporate responsibility report research practices committed focusing patient everything rd pipeline central ability meet patients ' needs high ethical standards rd key protecting participants clinical research ensuring quality research maximising benefits minimising risks medicines vaccines high ethical standards also essential us obtain regulatory approval new medicines patients doctors put trust research programmes products part strategy grow diversified global business deliver products value expanding presence emerging markets buying new businesses collaborating organisations rd policies global apply high standards wherever operate including contract organisations conduct research behalf collaborate organisations whose principles aligned gsk research conducted part collaboration raise awareness policies beginning collaboration include clauses collaboration agreement requiring compliance principles research collaborations typically overseen joint steering committee jsc made senior staff gsk collaborator continuously evaluate risks benefits medicines every stage initial research clinical trials new product approved sale committed open results clinical research use number reporting channels evaluate efficacy safety medicines use medicines make informed decisions use increase transparency committed publishing research payments make healthcare professionals starting us followed gsks europe asia pacific japan emerging markets apjem regions part commitment understand patient needs develop better medicines programme activities invite patients discuss conditions research teams recognise biomedical research raise ethical concerns including relating use emerging technologies cloning use stem cells animal research clinical research storage use human tissue protection personal information research participants participate discussions research practices regularly engage academic scientists regulators policy makers stakeholders related issues back top home responsibility research practices emerging technologies corporate responsibility report emerging technologies research capabilities expanding development technologies related areas research stem cell genetic research emerging technologies helping expand boundaries scientific understanding hold hope new ways treat serious diseases well better ways evaluate risks benefits medicines develop example advances genetic research beginning enable identification patients likely experience certain side effects medicine use emerging technologies research involved collaborative research technologies recognise research using emerging technologies give rise ethical concerns outline involvement approach use cloning technologies use stem cells genetic research use transgenic animals back top home responsibility research practices emerging technologies corporate responsibility report emerging technologies research capabilities expanding development technologies related areas research stem cell genetic research emerging technologies helping expand boundaries scientific understanding hold hope new ways treat serious diseases well better ways evaluate risks benefits medicines develop example advances genetic research beginning enable identification patients likely experience certain side effects medicine use emerging technologies research involved collaborative research technologies recognise research using emerging technologies give rise ethical concerns outline involvement approach use cloning technologies use stem cells genetic research use transgenic animals back top home responsibility research practices emerging technologies cloning technology stem cell research corporate responsibility report cloning technology stem cell research cloning technologies gsk uses cloning technologies replicate molecules cells research technologies provided better ways evaluate compounds enabling greater insight risks benefits potential medicines helping create better medicines patients technology fundamental component medicine discovery development gsk clone animals use cloning technologies intention reproducing entire human beings see medical research case read position statement cloning technologies stem cell research stem cell research recognise importance clear approach stem cell research standards apply area research position statement cloning technologies stem cell research sets standards apply using stem cells including embryonic foetal stem cells began fiveyear collaboration harvard stem cell institute hsci includes million investment support research harvard university number affiliated hospitals areas neuroscience heart disease cancer diabetes musculoskeletal diseases obesity collaboration overseen joint steering committee made hsci gsk scientists managers also founding member stem cells safer medicine scsm initiative uk scsm aims develop bank human cell lines used early medicine discovery provide early identification elimination potential toxicity issues clinical testing number public sector organisations contributing initiative including department health department innovation universities skills scottish government medical research council biotechnology biological sciences research council scsm awarded grant enable research teams investigate generation cardiac cells pluripotent stem cells funding aims advance scientific understanding medicines affect heart find ways avoid chronic cardiac side effects long term damage funding follows previous award made scsm support research generation liver cells pluripotent stem cells applied early medicine research screening read collaborating research emerging technologies back top home responsibility research practices emerging technologies cloning technology stem cell research corporate responsibility report cloning technology stem cell research cloning technologies gsk uses cloning technologies replicate molecules cells research technologies provided better ways evaluate compounds enabling greater insight risks benefits potential medicines helping create better medicines patients technology fundamental component medicine discovery development gsk clone animals use cloning technologies intention reproducing entire human beings see medical research case read position statement cloning technologies stem cell research stem cell research recognise importance clear approach stem cell research standards apply area research position statement cloning technologies stem cell research sets standards apply using stem cells including embryonic foetal stem cells began fiveyear collaboration harvard stem cell institute hsci includes million investment support research harvard university number affiliated hospitals areas neuroscience heart disease cancer diabetes musculoskeletal diseases obesity collaboration overseen joint steering committee made hsci gsk scientists managers also founding member stem cells safer medicine scsm initiative uk scsm aims develop bank human cell lines used early medicine discovery provide early identification elimination potential toxicity issues clinical testing number public sector organisations contributing initiative including department health department innovation universities skills scottish government medical research council biotechnology biological sciences research council scsm awarded grant enable research teams investigate generation cardiac cells pluripotent stem cells funding aims advance scientific understanding medicines affect heart find ways avoid chronic cardiac side effects long term damage funding follows previous award made scsm support research generation liver cells pluripotent stem cells applied early medicine research screening read collaborating research emerging technologies back top home responsibility research practices emerging technologies genetic research corporate responsibility report genetic research genetic variation underpins many aspects human health people get certain diseases others age diseases develop fast progress last four years genes identified common human diseases cumulative history genetics research diseases genetic risk factors identified include asthma alzheimer 's diabetes heart disease including coronary heart disease hypertension obesity several types cancer including prostate breast lung number autoimmune disorders gsk researchers led contributed substantially several findings discoveries others come offer promise development innovative new medicines individual differences genes also affect people respond medicines differences genes explain patients experience adverse responses certain medicines others effects individuals require greater doses medicines others achieve level efficacy groups individuals respond well treatment others recently reported genetic variations affect patients respond variety medicines including lipidlowering agents antimicrobials antiinflammatories treatments hepatitis c hivaids gsk scientists using emerging genetic information study medicines differentiated suit groups patients different genetic characteristics successful genetic research requires close collaboration organisations different areas expertise engaged number research projects involving academic partners regulatory agencies pharmaceutical companies collaborations enable use new technologies facilitate sharing research data larger scientific community example cosponsors serious adverse events consortium saec collaboration aims improve patient safety genetic research share research data dbgap us national institute health database contains results studies exploring association specific genes various medical conditions genetic component high blood pressure obesity recognise people concerns applications standards genetic research aim address concerns transparent conduct genetic research genetic analysis undertaken part gsk clinical trials done seeking obtaining informed consent participant procedure includes providing information purpose scope research access genetic research data believe pharmaceutical industry shares responsibility governments helping identify develop policy genetic research refer guidance national international groups inform genetic research activities european medicines evaluation agency us food drug administration council international organisations medical sciences read policy standards collection use storage human tissue research support conduct back top home responsibility research practices emerging technologies genetic research corporate responsibility report genetic research genetic variation underpins many aspects human health people get certain diseases others age diseases develop fast progress last four years genes identified common human diseases cumulative history genetics research diseases genetic risk factors identified include asthma alzheimer 's diabetes heart disease including coronary heart disease hypertension obesity several types cancer including prostate breast lung number autoimmune disorders gsk researchers led contributed substantially several findings discoveries others come offer promise development innovative new medicines individual differences genes also affect people respond medicines differences genes explain patients experience adverse responses certain medicines others effects individuals require greater doses medicines others achieve level efficacy groups individuals respond well treatment others recently reported genetic variations affect patients respond variety medicines including lipidlowering agents antimicrobials antiinflammatories treatments hepatitis c hivaids gsk scientists using emerging genetic information study medicines differentiated suit groups patients different genetic characteristics successful genetic research requires close collaboration organisations different areas expertise engaged number research projects involving academic partners regulatory agencies pharmaceutical companies collaborations enable use new technologies facilitate sharing research data larger scientific community example cosponsors serious adverse events consortium saec collaboration aims improve patient safety genetic research share research data dbgap us national institute health database contains results studies exploring association specific genes various medical conditions genetic component high blood pressure obesity recognise people concerns applications standards genetic research aim address concerns transparent conduct genetic research genetic analysis undertaken part gsk clinical trials done seeking obtaining informed consent participant procedure includes providing information purpose scope research access genetic research data believe pharmaceutical industry shares responsibility governments helping identify develop policy genetic research refer guidance national international groups inform genetic research activities european medicines evaluation agency us food drug administration council international organisations medical sciences read policy standards collection use storage human tissue research support conduct back top home responsibility research practices animal research corporate responsibility report animal research approach performance plans animal studies remain small vital part research many cases method demonstrate effects potential new medicine living body used humans addition research animals provide vital information causes diseases diseases may develop safety regulations require us test new medicines animals tested clinical trials vaccines tested animals time new batch produced recent vaccines cervarix rotarix synflorix developed alternative approaches accepted eu regulators animals necessary research committed acting ethically providing animals ' health wellbeing practising good animal welfare undertook comprehensive review policy care ethical use animals confirmed principles contained policy appropriate review also identified number areas would enhanced clarification strengthening based review making following changes prohibiting animal studies using great apes support principle using lowest phylogenetic order animal extending prohibition animal testing cosmetic products include medicinal products intended cosmetic use believe appropriate use animals test products enable use cosmetics even products classified medicines medical devices regulatory purposes allowing testing nonmedicinal products ingredients expressly required national regulatory authority order make health benefit claim rare instances regulator require safety efficacy testing nonmedicinal products specifying core principles policy part contracts types animal research undertaken third parties behalf including contract sponsored supported research approach ultimately gsk would like see important benefits research achieved applied humans without need animals research believe achieved foreseeable future goal use animals scientifically necessary use scientifically feasible minimise pain distress gsk animal research laboratories europe asia us animal research conducted external contractors behalf representing around nine per cent total animal use almost animals used gsk rodents mainly rats mice also use rabbits dogs non human primates fish ferrets chickens pigs cats sheep goats together account two per cent number animals used listed order magnitude use gsk remains committed rs ensuring high standards animal welfare animal studies carried us behalf senior management reviews strategy working animals annual basis rs rs set key principles improving animal welfare biomedical research replacing research using animals nonanimal alternatives species lowest possible order phylogenetically reducing number animals used experiments still obtaining information larger study refining techniques minimise pain distress maximise welfare animals launched cross functional animal quality council provides governance oversight maintaining high quality standards effective application rs gsk animal testing also appointed worldwide head animal research responsibility develop embed coordinated rs strategy across gsk 's business units ensure quantifiable progress goals strategy scientists always try devise experiments require animals possible researchers work design experiment obtain necessary information smallest number animals possible least effect animal proposed animal research must undergo ethical review go ahead assesses study design incorporation rs ethical reviews conducted independent committee based site country research take place ethical review committees include least one veterinarian least one scientist least one person without scientific background may also include specialists laboratory animal science also continue discuss latest rs developments regulators help ensure regulatory required animal testing follows approaches encourage rs culture gsk regular training staff involved care use animals raising awareness encouraging best practice communicating advances rs across gsk 's medicine discovery development teams recognising employees made outstanding advances implementing rs animal welfare awards read recent gsk advances replacing reducing refining animal use nonhuman primates studies involving animals must use lowest possible phylogenetic order animal appropriate research study therefore use nonhuman primates species lower neurophysiological sensitivity appropriate occasionally nonhuman primates may animals anatomy andor physiology disease similar humans sometimes human nonhuman primates affected respond potential medicine vaccine instance new medicine may based molecule produced primates including humans could destroyed immune systems species two common non human primates species used research macaques marmosets less half per cent animals use nonhuman primates voluntarily committed longer carry research great apes means longer use common chimpanzee used biomedical research three decades great apes used biomedical research read position statements use nonhuman primates great apes research transgenic genetically modified animals genetically modified animals also known transgenic animals genetically adapted scientists create new characteristics transgenic animals per cent used biomedical research mice transgenic strains animals developed answer specific compound diseaserelated questions part medicine discovery process example transgenic mice model alzheimer 's disease fundamental biological research new compound development target validation use transgenic models mice sometimes replace need studies higher order animals gsk worldwide standards recognising differences countryspecific regulations gsk achieves worldwide standards using core principles ethical care welfare treatment laboratory animals principles establish basis animal work conducted onbehalf gsk gsk facilities external laboratories conducting research behalf must follow legal regulatory requirements uk regulations responsibility home office europe animal research comes directive eec us covered animal welfare act animal welfare regulations aaalaci accreditation goal animal facilities accredited association assessment accreditation laboratory animal care international aaalaci private nonprofit organisation promotes humane treatment animals science voluntary accreditation assessment programmes achieve aaalaci accreditation organisation must go rigorous assessment association reviews facilities workers animal care maintain accreditation updates onsite reviews required every three years site visits conducted members aaalaci council trained professional staff accredited facilities cover per cent animals housed gsk laboratories accredited facilities belgium canada croatia italy spain uk us working extend accreditation animal facilities france hungary two small facilities us either completed refurbishment recent acquisitions also conduct animal research small facilities china may temporary due time resources needed achieve aaalac accreditation seeking sure either staying facility moving alternative meantime confident standards within units similar facilities communicating approach people hold strong views animal research testing believe important explain need animal research testing transparent engage regularly animal welfare experts investors well contributing public debate many laboratories host visits schools colleges animal welfare organisations others example hosted investor visit stevenage laboratory animal science facility scientists also go schools talk pupils role animals pharmaceutical research protest accept right lawful protest animal research part free society condemn use violence intimidation opposed animal use back tophome responsibility research practices animal research corporate responsibility report animal research approach performance plans animal studies remain small vital part research many cases method demonstrate effects potential new medicine living body used humans addition research animals provide vital information causes diseases diseases may develop safety regulations require us test new medicines animals tested clinical trials vaccines tested animals time new batch produced recent vaccines cervarix rotarix synflorix developed alternative approaches accepted eu regulators animals necessary research committed acting ethically providing animals ' health wellbeing practising good animal welfare undertook comprehensive review policy care ethical use animals confirmed principles contained policy appropriate review also identified number areas would enhanced clarification strengthening based review making following changes prohibiting animal studies using great apes support principle using lowest phylogenetic order animal extending prohibition animal testing cosmetic products include medicinal products intended cosmetic use believe appropriate use animals test products enable use cosmetics even products classified medicines medical devices regulatory purposes allowing testing nonmedicinal products ingredients expressly required national regulatory authority order make health benefit claim rare instances regulator require safety efficacy testing nonmedicinal products specifying core principles policy part contracts types animal research undertaken third parties behalf including contract sponsored supported research approach ultimately gsk would like see important benefits research achieved applied humans without need animals research believe achieved foreseeable future goal use animals scientifically necessary use scientifically feasible minimise pain distress gsk animal research laboratories europe asia us animal research conducted external contractors behalf representing around nine per cent total animal use almost animals used gsk rodents mainly rats mice also use rabbits dogs non human primates fish ferrets chickens pigs cats sheep goats together account two per cent number animals used listed order magnitude use gsk remains committed rs ensuring high standards animal welfare animal studies carried us behalf senior management reviews strategy working animals annual basis rs rs set key principles improving animal welfare biomedical research replacing research using animals nonanimal alternatives species lowest possible order phylogenetically reducing number animals used experiments still obtaining information larger study refining techniques minimise pain distress maximise welfare animals launched cross functional animal quality council provides governance oversight maintaining high quality standards effective application rs gsk animal testing also appointed worldwide head animal research responsibility develop embed coordinated rs strategy across gsk 's business units ensure quantifiable progress goals strategy scientists always try devise experiments require animals possible researchers work design experiment obtain necessary information smallest number animals possible least effect animal proposed animal research must undergo ethical review go ahead assesses study design incorporation rs ethical reviews conducted independent committee based site country research take place ethical review committees include least one veterinarian least one scientist least one person without scientific background may also include specialists laboratory animal science also continue discuss latest rs developments regulators help ensure regulatory required animal testing follows approaches encourage rs culture gsk regular training staff involved care use animals raising awareness encouraging best practice communicating advances rs across gsk 's medicine discovery development teams recognising employees made outstanding advances implementing rs animal welfare awards read recent gsk advances replacing reducing refining animal use nonhuman primates studies involving animals must use lowest possible phylogenetic order animal appropriate research study therefore use nonhuman primates species lower neurophysiological sensitivity appropriate occasionally nonhuman primates may animals anatomy andor physiology disease similar humans sometimes human nonhuman primates affected respond potential medicine vaccine instance new medicine may based molecule produced primates including humans could destroyed immune systems species two common non human primates species used research macaques marmosets less half per cent animals use nonhuman primates voluntarily committed longer carry research great apes means longer use common chimpanzee used biomedical research three decades great apes used biomedical research read position statements use nonhuman primates great apes research transgenic genetically modified animals genetically modified animals also known transgenic animals genetically adapted scientists create new characteristics transgenic animals per cent used biomedical research mice transgenic strains animals developed answer specific compound diseaserelated questions part medicine discovery process example transgenic mice model alzheimer 's disease fundamental biological research new compound development target validation use transgenic models mice sometimes replace need studies higher order animals gsk worldwide standards recognising differences countryspecific regulations gsk achieves worldwide standards using core principles ethical care welfare treatment laboratory animals principles establish basis animal work conducted onbehalf gsk gsk facilities external laboratories conducting research behalf must follow legal regulatory requirements uk regulations responsibility home office europe animal research comes directive eec us covered animal welfare act animal welfare regulations aaalaci accreditation goal animal facilities accredited association assessment accreditation laboratory animal care international aaalaci private nonprofit organisation promotes humane treatment animals science voluntary accreditation assessment programmes achieve aaalaci accreditation organisation must go rigorous assessment association reviews facilities workers animal care maintain accreditation updates onsite reviews required every three years site visits conducted members aaalaci council trained professional staff accredited facilities cover per cent animals housed gsk laboratories accredited facilities belgium canada croatia italy spain uk us working extend accreditation animal facilities france hungary two small facilities us either completed refurbishment recent acquisitions also conduct animal research small facilities china may temporary due time resources needed achieve aaalac accreditation seeking sure either staying facility moving alternative meantime confident standards within units similar facilities communicating approach people hold strong views animal research testing believe important explain need animal research testing transparent engage regularly animal welfare experts investors well contributing public debate many laboratories host visits schools colleges animal welfare organisations others example hosted investor visit stevenage laboratory animal science facility scientists also go schools talk pupils role animals pharmaceutical research protest accept right lawful protest animal research part free society condemn use violence intimidation opposed animal use back tophome responsibility research practices animal research corporate responsibility report animal research approach performance plans animal studies remain small vital part research many cases method demonstrate effects potential new medicine living body used humans addition research animals provide vital information causes diseases diseases may develop safety regulations require us test new medicines animals tested clinical trials vaccines tested animals time new batch produced recent vaccines cervarix rotarix synflorix developed alternative approaches accepted eu regulators animals necessary research committed acting ethically providing animals ' health wellbeing practising good animal welfare undertook comprehensive review policy care ethical use animals confirmed principles contained policy appropriate review also identified number areas would enhanced clarification strengthening based review making following changes prohibiting animal studies using great apes support principle using lowest phylogenetic order animal extending prohibition animal testing cosmetic products include medicinal products intended cosmetic use believe appropriate use animals test products enable use cosmetics even products classified medicines medical devices regulatory purposes allowing testing nonmedicinal products ingredients expressly required national regulatory authority order make health benefit claim rare instances regulator require safety efficacy testing nonmedicinal products specifying core principles policy part contracts types animal research undertaken third parties behalf including contract sponsored supported research approach ultimately gsk would like see important benefits research achieved applied humans without need animals research believe achieved foreseeable future goal use animals scientifically necessary use scientifically feasible minimise pain distress gsk animal research laboratories europe asia us animal research conducted external contractors behalf representing around nine per cent total animal use almost animals used gsk rodents mainly rats mice also use rabbits dogs non human primates fish ferrets chickens pigs cats sheep goats together account two per cent number animals used listed order magnitude use gsk remains committed rs ensuring high standards animal welfare animal studies carried us behalf senior management reviews strategy working animals annual basis rs rs set key principles improving animal welfare biomedical research replacing research using animals nonanimal alternatives species lowest possible order phylogenetically reducing number animals used experiments still obtaining information larger study refining techniques minimise pain distress maximise welfare animals launched cross functional animal quality council provides governance oversight maintaining high quality standards effective application rs gsk animal testing also appointed worldwide head animal research responsibility develop embed coordinated rs strategy across gsk 's business units ensure quantifiable progress goals strategy scientists always try devise experiments require animals possible researchers work design experiment obtain necessary information smallest number animals possible least effect animal proposed animal research must undergo ethical review go ahead assesses study design incorporation rs ethical reviews conducted independent committee based site country research take place ethical review committees include least one veterinarian least one scientist least one person without scientific background may also include specialists laboratory animal science also continue discuss latest rs developments regulators help ensure regulatory required animal testing follows approaches encourage rs culture gsk regular training staff involved care use animals raising awareness encouraging best practice communicating advances rs across gsk 's medicine discovery development teams recognising employees made outstanding advances implementing rs animal welfare awards read recent gsk advances replacing reducing refining animal use nonhuman primates studies involving animals must use lowest possible phylogenetic order animal appropriate research study therefore use nonhuman primates species lower neurophysiological sensitivity appropriate occasionally nonhuman primates may animals anatomy andor physiology disease similar humans sometimes human nonhuman primates affected respond potential medicine vaccine instance new medicine may based molecule produced primates including humans could destroyed immune systems species two common non human primates species used research macaques marmosets less half per cent animals use nonhuman primates voluntarily committed longer carry research great apes means longer use common chimpanzee used biomedical research three decades great apes used biomedical research read position statements use nonhuman primates great apes research transgenic genetically modified animals genetically modified animals also known transgenic animals genetically adapted scientists create new characteristics transgenic animals per cent used biomedical research mice transgenic strains animals developed answer specific compound diseaserelated questions part medicine discovery process example transgenic mice model alzheimer 's disease fundamental biological research new compound development target validation use transgenic models mice sometimes replace need studies higher order animals gsk worldwide standards recognising differences countryspecific regulations gsk achieves worldwide standards using core principles ethical care welfare treatment laboratory animals principles establish basis animal work conducted onbehalf gsk gsk facilities external laboratories conducting research behalf must follow legal regulatory requirements uk regulations responsibility home office europe animal research comes directive eec us covered animal welfare act animal welfare regulations aaalaci accreditation goal animal facilities accredited association assessment accreditation laboratory animal care international aaalaci private nonprofit organisation promotes humane treatment animals science voluntary accreditation assessment programmes achieve aaalaci accreditation organisation must go rigorous assessment association reviews facilities workers animal care maintain accreditation updates onsite reviews required every three years site visits conducted members aaalaci council trained professional staff accredited facilities cover per cent animals housed gsk laboratories accredited facilities belgium canada croatia italy spain uk us working extend accreditation animal facilities france hungary two small facilities us either completed refurbishment recent acquisitions also conduct animal research small facilities china may temporary due time resources needed achieve aaalac accreditation seeking sure either staying facility moving alternative meantime confident standards within units similar facilities communicating approach people hold strong views animal research testing believe important explain need animal research testing transparent engage regularly animal welfare experts investors well contributing public debate many laboratories host visits schools colleges animal welfare organisations others example hosted investor visit stevenage laboratory animal science facility scientists also go schools talk pupils role animals pharmaceutical research protest accept right lawful protest animal research part free society condemn use violence intimidation opposed animal use back top home responsibility research practices animal research corporate responsibility report animal research approach performance plans animal studies remain small vital part research many cases method demonstrate effects potential new medicine living body used humans addition research animals provide vital information causes diseases diseases may develop safety regulations require us test new medicines animals tested clinical trials vaccines tested animals time new batch produced recent vaccines cervarix rotarix synflorix developed alternative approaches accepted eu regulators animals necessary research committed acting ethically providing animals ' health wellbeing practising good animal welfare undertook comprehensive review policy care ethical use animals confirmed principles contained policy appropriate review also identified number areas would enhanced clarification strengthening based review making following changes prohibiting animal studies using great apes support principle using lowest phylogenetic order animal extending prohibition animal testing cosmetic products include medicinal products intended cosmetic use believe appropriate use animals test products enable use cosmetics even products classified medicines medical devices regulatory purposes allowing testing nonmedicinal products ingredients expressly required national regulatory authority order make health benefit claim rare instances regulator require safety efficacy testing nonmedicinal products specifying core principles policy part contracts types animal research undertaken third parties behalf including contract sponsored supported research approach ultimately gsk would like see important benefits research achieved applied humans without need animals research believe achieved foreseeable future goal use animals scientifically necessary use scientifically feasible minimise pain distress gsk animal research laboratories europe asia us animal research conducted external contractors behalf representing around nine per cent total animal use almost animals used gsk rodents mainly rats mice also use rabbits dogs non human primates fish ferrets chickens pigs cats sheep goats together account two per cent number animals used listed order magnitude use gsk remains committed rs ensuring high standards animal welfare animal studies carried us behalf senior management reviews strategy working animals annual basis rs rs set key principles improving animal welfare biomedical research replacing research using animals nonanimal alternatives species lowest possible order phylogenetically reducing number animals used experiments still obtaining information larger study refining techniques minimise pain distress maximise welfare animals launched cross functional animal quality council provides governance oversight maintaining high quality standards effective application rs gsk animal testing also appointed worldwide head animal research responsibility develop embed coordinated rs strategy across gsk 's business units ensure quantifiable progress goals strategy scientists always try devise experiments require animals possible researchers work design experiment obtain necessary information smallest number animals possible least effect animal proposed animal research must undergo ethical review go ahead assesses study design incorporation rs ethical reviews conducted independent committee based site country research take place ethical review committees include least one veterinarian least one scientist least one person without scientific background may also include specialists laboratory animal science also continue discuss latest rs developments regulators help ensure regulatory required animal testing follows approaches encourage rs culture gsk regular training staff involved care use animals raising awareness encouraging best practice communicating advances rs across gsk 's medicine discovery development teams recognising employees made outstanding advances implementing rs animal welfare awards read recent gsk advances replacing reducing refining animal use nonhuman primates studies involving animals must use lowest possible phylogenetic order animal appropriate research study therefore use nonhuman primates species lower neurophysiological sensitivity appropriate occasionally nonhuman primates may animals anatomy andor physiology disease similar humans sometimes human nonhuman primates affected respond potential medicine vaccine instance new medicine may based molecule produced primates including humans could destroyed immune systems species two common non human primates species used research macaques marmosets less half per cent animals use nonhuman primates voluntarily committed longer carry research great apes means longer use common chimpanzee used biomedical research three decades great apes used biomedical research read position statements use nonhuman primates great apes research transgenic genetically modified animals genetically modified animals also known transgenic animals genetically adapted scientists create new characteristics transgenic animals per cent used biomedical research mice transgenic strains animals developed answer specific compound diseaserelated questions part medicine discovery process example transgenic mice model alzheimer 's disease fundamental biological research new compound development target validation use transgenic models mice sometimes replace need studies higher order animals gsk worldwide standards recognising differences countryspecific regulations gsk achieves worldwide standards using core principles ethical care welfare treatment laboratory animals principles establish basis animal work conducted onbehalf gsk gsk facilities external laboratories conducting research behalf must follow legal regulatory requirements uk regulations responsibility home office europe animal research comes directive eec us covered animal welfare act animal welfare regulations aaalaci accreditation goal animal facilities accredited association assessment accreditation laboratory animal care international aaalaci private nonprofit organisation promotes humane treatment animals science voluntary accreditation assessment programmes achieve aaalaci accreditation organisation must go rigorous assessment association reviews facilities workers animal care maintain accreditation updates onsite reviews required every three years site visits conducted members aaalaci council trained professional staff accredited facilities cover per cent animals housed gsk laboratories accredited facilities belgium canada croatia italy spain uk us working extend accreditation animal facilities france hungary two small facilities us either completed refurbishment recent acquisitions also conduct animal research small facilities china may temporary due time resources needed achieve aaalac accreditation seeking sure either staying facility moving alternative meantime confident standards within units similar facilities communicating approach people hold strong views animal research testing believe important explain need animal research testing transparent engage regularly animal welfare experts investors well contributing public debate many laboratories host visits schools colleges animal welfare organisations others example hosted investor visit stevenage laboratory animal science facility scientists also go schools talk pupils role animals pharmaceutical research protest accept right lawful protest animal research part free society condemn use violence intimidation opposed animal use back top home responsibility research practices animal research corporate responsibility report animal research approach performance plans rs reviewed animal research gsk assess types studies performed numbers animals involved review assessed contribution animal testing process development new medicines results review provide baseline future use animals measured reviewing size animal enclosures locations around world ensure sites aligned best practice principles animal housing welfare completed review housing dogs using external experts implementation review result consistent practices husbandry dogs conduct review housing nonhuman primates external experts nonhuman primate behaviour collaboration approaches rs collaborate others promote use rs example share information methods used collect blood animals uk national centre rs ncrs methods form basis ncrs blood sampling website uk site used many laboratory staff choose appropriate technique humane efficient sampling blood working protocol us interagency coordinating committee validation alternative methods iccvam european centre validation alternative methods ecvam develop vitro assay identify severe eye irritants method evaluated company hazard identification pharmaceutical process chemicals occupational toxicology progress rs recent examples gsk advances replacing reducing refining animal use outlined working decrease number animals needed vaccine batch testing example use animals batch test process regulatory submission cervarix vaccine human papillomavirus means many markets new batches cervarix need tested animals similarly europe use laboratory based tests involve animals batch testing rotavirus vaccine rotarix synflorix vaccine pneumococcal disease developed transgenic mouse model mimics accelerated form alzheimer 's disease allowed us replace primates primary model disease fundamental biological research target validation compound optimisation carried using mouse model facilitating greater understanding disease potential future therapies implemented noninvasive method monitor heart function continuously monitoring ecg dogs nonhuman primates technique uses external apparatus attached animal without surgery record information continuously nonrestrained animals new approach eliminates need restraint requires fewer animals allowing measurements incorporated existing studies thereby eliminating need additional separate studies team gsk spain awarded harlan prize recent national congress spanish society laboratory animal science secal best scientific communication team 's poster entitled 'humane endpoints efficacy studies mouse models malaria ' work major contribution rs specifically refines endpoint protocol without reducing value scientific information animal welfare award internal animal welfare award recognises work demonstrably beyond high standards care experimental design implementation expected gsk employees involved animal experimentation receive award contribution tangible benefits terms one rs make difference animal experimentation conducted gsk animals routinely cared recent recipient internal animal welfare award team uk implemented bloodspot technology preclinical toxicokinetic tk studies using technology meant researchers needed significantly smaller volumes blood therefore meant fewer animals needed tk studies team refinement award national centre rs competition house lords award included prize money donated local charity number animals number animals used laboratories almost per cent lower rd activity increased significantly period estimate proportion animals used gsk research conducted external contractors per cent compared per cent total number animals used within laboratories contractors behalf continues decline due various factors including changing research priorities fewer batches vaccine requiring testing animals release continued focus rs initiatives animals used gsk per cent mice rats guinea pigs rodents rabbits others include animals used external contractors behalf animals used external contractors behalf per cent rodents rabbits change rd activity compared change number animals used gsk data include animal research conducted external contractors behalf rd activity combines rd budget vaccine sales two main drivers animal use back tophome responsibility research practices animal research corporate responsibility report animal research approach performance plans rs reviewed animal research gsk assess types studies performed numbers animals involved review assessed contribution animal testing process development new medicines results review provide baseline future use animals measured reviewing size animal enclosures locations around world ensure sites aligned best practice principles animal housing welfare completed review housing dogs using external experts implementation review result consistent practices husbandry dogs conduct review housing nonhuman primates external experts nonhuman primate behaviour collaboration approaches rs collaborate others promote use rs example share information methods used collect blood animals uk national centre rs ncrs methods form basis ncrs blood sampling website uk site used many laboratory staff choose appropriate technique humane efficient sampling blood working protocol us interagency coordinating committee validation alternative methods iccvam european centre validation alternative methods ecvam develop vitro assay identify severe eye irritants method evaluated company hazard identification pharmaceutical process chemicals occupational toxicology progress rs recent examples gsk advances replacing reducing refining animal use outlined working decrease number animals needed vaccine batch testing example use animals batch test process regulatory submission cervarix vaccine human papillomavirus means many markets new batches cervarix need tested animals similarly europe use laboratory based tests involve animals batch testing rotavirus vaccine rotarix synflorix vaccine pneumococcal disease developed transgenic mouse model mimics accelerated form alzheimer 's disease allowed us replace primates primary model disease fundamental biological research target validation compound optimisation carried using mouse model facilitating greater understanding disease potential future therapies implemented noninvasive method monitor heart function continuously monitoring ecg dogs nonhuman primates technique uses external apparatus attached animal without surgery record information continuously nonrestrained animals new approach eliminates need restraint requires fewer animals allowing measurements incorporated existing studies thereby eliminating need additional separate studies team gsk spain awarded harlan prize recent national congress spanish society laboratory animal science secal best scientific communication team 's poster entitled 'humane endpoints efficacy studies mouse models malaria ' work major contribution rs specifically refines endpoint protocol without reducing value scientific information animal welfare award internal animal welfare award recognises work demonstrably beyond high standards care experimental design implementation expected gsk employees involved animal experimentation receive award contribution tangible benefits terms one rs make difference animal experimentation conducted gsk animals routinely cared recent recipient internal animal welfare award team uk implemented bloodspot technology preclinical toxicokinetic tk studies using technology meant researchers needed significantly smaller volumes blood therefore meant fewer animals needed tk studies team refinement award national centre rs competition house lords award included prize money donated local charity number animals number animals used laboratories almost per cent lower rd activity increased significantly period estimate proportion animals used gsk research conducted external contractors per cent compared per cent total number animals used within laboratories contractors behalf continues decline due various factors including changing research priorities fewer batches vaccine requiring testing animals release continued focus rs initiatives animals used gsk per cent mice rats guinea pigs rodents rabbits others include animals used external contractors behalf animals used external contractors behalf per cent rodents rabbits change rd activity compared change number animals used gsk data include animal research conducted external contractors behalf rd activity combines rd budget vaccine sales two main drivers animal use back tophome responsibility research practices animal research corporate responsibility report animal research approach performance plans rs reviewed animal research gsk assess types studies performed numbers animals involved review assessed contribution animal testing process development new medicines results review provide baseline future use animals measured reviewing size animal enclosures locations around world ensure sites aligned best practice principles animal housing welfare completed review housing dogs using external experts implementation review result consistent practices husbandry dogs conduct review housing nonhuman primates external experts nonhuman primate behaviour collaboration approaches rs collaborate others promote use rs example share information methods used collect blood animals uk national centre rs ncrs methods form basis ncrs blood sampling website uk site used many laboratory staff choose appropriate technique humane efficient sampling blood working protocol us interagency coordinating committee validation alternative methods iccvam european centre validation alternative methods ecvam develop vitro assay identify severe eye irritants method evaluated company hazard identification pharmaceutical process chemicals occupational toxicology progress rs recent examples gsk advances replacing reducing refining animal use outlined working decrease number animals needed vaccine batch testing example use animals batch test process regulatory submission cervarix vaccine human papillomavirus means many markets new batches cervarix need tested animals similarly europe use laboratory based tests involve animals batch testing rotavirus vaccine rotarix synflorix vaccine pneumococcal disease developed transgenic mouse model mimics accelerated form alzheimer 's disease allowed us replace primates primary model disease fundamental biological research target validation compound optimisation carried using mouse model facilitating greater understanding disease potential future therapies implemented noninvasive method monitor heart function continuously monitoring ecg dogs nonhuman primates technique uses external apparatus attached animal without surgery record information continuously nonrestrained animals new approach eliminates need restraint requires fewer animals allowing measurements incorporated existing studies thereby eliminating need additional separate studies team gsk spain awarded harlan prize recent national congress spanish society laboratory animal science secal best scientific communication team 's poster entitled 'humane endpoints efficacy studies mouse models malaria ' work major contribution rs specifically refines endpoint protocol without reducing value scientific information animal welfare award internal animal welfare award recognises work demonstrably beyond high standards care experimental design implementation expected gsk employees involved animal experimentation receive award contribution tangible benefits terms one rs make difference animal experimentation conducted gsk animals routinely cared recent recipient internal animal welfare award team uk implemented bloodspot technology preclinical toxicokinetic tk studies using technology meant researchers needed significantly smaller volumes blood therefore meant fewer animals needed tk studies team refinement award national centre rs competition house lords award included prize money donated local charity number animals number animals used laboratories almost per cent lower rd activity increased significantly period estimate proportion animals used gsk research conducted external contractors per cent compared per cent total number animals used within laboratories contractors behalf continues decline due various factors including changing research priorities fewer batches vaccine requiring testing animals release continued focus rs initiatives animals used gsk per cent mice rats guinea pigs rodents rabbits others include animals used external contractors behalf animals used external contractors behalf per cent rodents rabbits change rd activity compared change number animals used gsk data include animal research conducted external contractors behalf rd activity combines rd budget vaccine sales two main drivers animal use back top home responsibility research practices animal research corporate responsibility report animal research approach performance plans rs reviewed animal research gsk assess types studies performed numbers animals involved review assessed contribution animal testing process development new medicines results review provide baseline future use animals measured reviewing size animal enclosures locations around world ensure sites aligned best practice principles animal housing welfare completed review housing dogs using external experts implementation review result consistent practices husbandry dogs conduct review housing nonhuman primates external experts nonhuman primate behaviour collaboration approaches rs collaborate others promote use rs example share information methods used collect blood animals uk national centre rs ncrs methods form basis ncrs blood sampling website uk site used many laboratory staff choose appropriate technique humane efficient sampling blood working protocol us interagency coordinating committee validation alternative methods iccvam european centre validation alternative methods ecvam develop vitro assay identify severe eye irritants method evaluated company hazard identification pharmaceutical process chemicals occupational toxicology progress rs recent examples gsk advances replacing reducing refining animal use outlined working decrease number animals needed vaccine batch testing example use animals batch test process regulatory submission cervarix vaccine human papillomavirus means many markets new batches cervarix need tested animals similarly europe use laboratory based tests involve animals batch testing rotavirus vaccine rotarix synflorix vaccine pneumococcal disease developed transgenic mouse model mimics accelerated form alzheimer 's disease allowed us replace primates primary model disease fundamental biological research target validation compound optimisation carried using mouse model facilitating greater understanding disease potential future therapies implemented noninvasive method monitor heart function continuously monitoring ecg dogs nonhuman primates technique uses external apparatus attached animal without surgery record information continuously nonrestrained animals new approach eliminates need restraint requires fewer animals allowing measurements incorporated existing studies thereby eliminating need additional separate studies team gsk spain awarded harlan prize recent national congress spanish society laboratory animal science secal best scientific communication team 's poster entitled 'humane endpoints efficacy studies mouse models malaria ' work major contribution rs specifically refines endpoint protocol without reducing value scientific information animal welfare award internal animal welfare award recognises work demonstrably beyond high standards care experimental design implementation expected gsk employees involved animal experimentation receive award contribution tangible benefits terms one rs make difference animal experimentation conducted gsk animals routinely cared recent recipient internal animal welfare award team uk implemented bloodspot technology preclinical toxicokinetic tk studies using technology meant researchers needed significantly smaller volumes blood therefore meant fewer animals needed tk studies team refinement award national centre rs competition house lords award included prize money donated local charity number animals number animals used laboratories almost per cent lower rd activity increased significantly period estimate proportion animals used gsk research conducted external contractors per cent compared per cent total number animals used within laboratories contractors behalf continues decline due various factors including changing research priorities fewer batches vaccine requiring testing animals release continued focus rs initiatives animals used gsk per cent mice rats guinea pigs rodents rabbits others include animals used external contractors behalf animals used external contractors behalf per cent rodents rabbits change rd activity compared change number animals used gsk data include animal research conducted external contractors behalf rd activity combines rd budget vaccine sales two main drivers animal use back top home responsibility research practices human tissue research corporate responsibility report human tissue research research using human tissue human biological samples fundamental discovery development safety monitoring gsk medicines vaccines vital research conducted manner respects rights research participants meets legal ethical obligations uk human tissue act made legal requirement gain appropriate consent ethical approval collection use storage human tissue uk introduced following events alder hey hospital bristol royal infirmary human tissue taken used stored without consent global policy apply principle needing appropriate consent ethical approval research conducted sponsored supported funded gsk ensures ethical requirements applied research using human biological samples wherever takes place uk human tissue authority inspected harlow stevenage research sites assess whether gsk meets standards necessary hold tissue storage licence routine inspection included assessment premises gsk policy processes internal governance framework capabilities lead researcher inspection concluded gsk achieved good standards complies well act suitable licensed storage tissue research back top home responsibility research practices human tissue research corporate responsibility report human tissue research research using human tissue human biological samples fundamental discovery development safety monitoring gsk medicines vaccines vital research conducted manner respects rights research participants meets legal ethical obligations uk human tissue act made legal requirement gain appropriate consent ethical approval collection use storage human tissue uk introduced following events alder hey hospital bristol royal infirmary human tissue taken used stored without consent global policy apply principle needing appropriate consent ethical approval research conducted sponsored supported funded gsk ensures ethical requirements applied research using human biological samples wherever takes place uk human tissue authority inspected harlow stevenage research sites assess whether gsk meets standards necessary hold tissue storage licence routine inspection included assessment premises gsk policy processes internal governance framework capabilities lead researcher inspection concluded gsk achieved good standards complies well act suitable licensed storage tissue research back top home responsibility research practices maintaining confidentiality research participants corporate responsibility report maintaining confidentiality research participants vital medical information collected research protected maintain confidentiality participants rigorous procedures control use research data use variety procedures protect confidentiality research participants ' data including data coding data encryption restricted access research databases third parties handling research data behalf required comply relevant data protection legislation standards collect information individuals relevant research study includes medical information health status medical conditions including occasions genetic data treatment conditions ethnic origin means vast majority instances collect store information directly identify individuals initials names addresses personal id numbers information identify individuals used specific instances required law regulations safety monitoring pharmacovigilance retain medical research data using minimum amount identifying information duration reasonably necessary meet regulatory legal research needs back top home responsibility research practices maintaining confidentiality research participants corporate responsibility report maintaining confidentiality research participants vital medical information collected research protected maintain confidentiality participants rigorous procedures control use research data use variety procedures protect confidentiality research participants ' data including data coding data encryption restricted access research databases third parties handling research data behalf required comply relevant data protection legislation standards collect information individuals relevant research study includes medical information health status medical conditions including occasions genetic data treatment conditions ethnic origin means vast majority instances collect store information directly identify individuals initials names addresses personal id numbers information identify individuals used specific instances required law regulations safety monitoring pharmacovigilance retain medical research data using minimum amount identifying information duration reasonably necessary meet regulatory legal research needs back top home responsibility research practices medical governance corporate responsibility report medical governance gsk committed highest standards ethical medical practice medical governance gsk system principles policies accountabilities ensures apply generally recognised principles good medical science medical integrity ethics standards development marketing products medical governance includes system management human safety information provides framework embed following principles patient safety fundamental operating principle gsk ahead commercial interests clinical research conducted objective scientific ethical manner protects informs participants promotional practices information provide products ethical accurate evidencebased balanced medicines used appropriately benefit minimise risks patients medical governance also ensures safety ethical compliance issues identified clinical research marketed products medical information promotional practices dealt quickly effectively possible steps taken correct root cause issue medical governance across gsk encompasses principles policies accountabilities three areas framework medical governance across businesses chief medical officer senior physician gsk responsibility authority establishing effective medical governance system corporate executive team members responsible performance compliance system within areas responsibility medical governance executive committee sets direction establishes policy medical governance subject approval corporate executive team also ensures medical governance systems operating effectively regional medical directors together regional presidents countryterritory medical directors ensure policies systems medical governance understood complied countries responsibility read patient safety governance framework plans maintaining high standards ethical medical practice requires continual commitment improving processes ensuring gsk staff collaborators aware principles strengthen medical governance framework harmonising practices across gsk raising awareness principles medical governance among employees ensure everyone involved medical governance including medical scientific commercial roles understand framework principles individual responsibilities safety reporting medical integrity high ethical standards initiative particularly target employees involved managing human safety information conducting disclosing results human subject research ensuring medical information products accurate balanced back tophome responsibility research practices medical governance corporate responsibility report medical governance gsk committed highest standards ethical medical practice medical governance gsk system principles policies accountabilities ensures apply generally recognised principles good medical science medical integrity ethics standards development marketing products medical governance includes system management human safety information provides framework embed following principles patient safety fundamental operating principle gsk ahead commercial interests clinical research conducted objective scientific ethical manner protects informs participants promotional practices information provide products ethical accurate evidencebased balanced medicines used appropriately benefit minimise risks patients medical governance also ensures safety ethical compliance issues identified clinical research marketed products medical information promotional practices dealt quickly effectively possible steps taken correct root cause issue medical governance across gsk encompasses principles policies accountabilities three areas framework medical governance across businesses chief medical officer senior physician gsk responsibility authority establishing effective medical governance system corporate executive team members responsible performance compliance system within areas responsibility medical governance executive committee sets direction establishes policy medical governance subject approval corporate executive team also ensures medical governance systems operating effectively regional medical directors together regional presidents countryterritory medical directors ensure policies systems medical governance understood complied countries responsibility read patient safety governance framework plans maintaining high standards ethical medical practice requires continual commitment improving processes ensuring gsk staff collaborators aware principles strengthen medical governance framework harmonising practices across gsk raising awareness principles medical governance among employees ensure everyone involved medical governance including medical scientific commercial roles understand framework principles individual responsibilities safety reporting medical integrity high ethical standards initiative particularly target employees involved managing human safety information conducting disclosing results human subject research ensuring medical information products accurate balanced back top home responsibility research practices medical governance corporate responsibility report medical governance gsk committed highest standards ethical medical practice medical governance gsk system principles policies accountabilities ensures apply generally recognised principles good medical science medical integrity ethics standards development marketing products medical governance includes system management human safety information provides framework embed following principles patient safety fundamental operating principle gsk ahead commercial interests clinical research conducted objective scientific ethical manner protects informs participants promotional practices information provide products ethical accurate evidencebased balanced medicines used appropriately benefit minimise risks patients medical governance also ensures safety ethical compliance issues identified clinical research marketed products medical information promotional practices dealt quickly effectively possible steps taken correct root cause issue medical governance across gsk encompasses principles policies accountabilities three areas framework medical governance across businesses chief medical officer senior physician gsk responsibility authority establishing effective medical governance system corporate executive team members responsible performance compliance system within areas responsibility medical governance executive committee sets direction establishes policy medical governance subject approval corporate executive team also ensures medical governance systems operating effectively regional medical directors together regional presidents countryterritory medical directors ensure policies systems medical governance understood complied countries responsibility read patient safety governance framework plans maintaining high standards ethical medical practice requires continual commitment improving processes ensuring gsk staff collaborators aware principles strengthen medical governance framework harmonising practices across gsk raising awareness principles medical governance among employees ensure everyone involved medical governance including medical scientific commercial roles understand framework principles individual responsibilities safety reporting medical integrity high ethical standards initiative particularly target employees involved managing human safety information conducting disclosing results human subject research ensuring medical information products accurate balanced back top home responsibility research practices clinical research corporate responsibility report clinical research conduct clinical trials assess potential compound become new medicine medicine approved marketing evaluate effect medicine approved use assess potential uses obtain additional safety data rigorous procedures assurance processes ensure clinical trials medicines conducted according good clinical practice gcp guidelines developed international conference harmonisation ich principles contained world medical association declaration helsinki 'ethical principles medical research involving human subjects ' gsksponsored clinical trials conducted ethical standards irrespective whether take place developed developing countries contract research organisations conducting studies behalf required apply gsk 's standards effect potential medicine often compared currently available medicines cases inactive substance placebo ethics conducting placebocontrolled trials sometimes questioned one patient group receives placebo provide active treatment placebo controlled trials carried compelling scientifically sound methodological reasons risks minimised reasonable relation knowledge gains patients receive placebo subject additional risk serious irreversible harm successful clinical trial programmes usually three four phases safety evaluated throughout clinical trials process safety participate clinical trials paramount importance gsk works ethics committees investigators achieve informed consent process informs volunteers study risks benefits gsk employees involved conducting trials receive training regulatory requirements gsk policies trials may audited internal audit department external regulators based risks associated trial risk factors include complexity study patient population location study previous audit history unusual findings conduct study back top home responsibility research practices clinical research corporate responsibility report clinical research conduct clinical trials assess potential compound become new medicine medicine approved marketing evaluate effect medicine approved use assess potential uses obtain additional safety data rigorous procedures assurance processes ensure clinical trials medicines conducted according good clinical practice gcp guidelines developed international conference harmonisation ich principles contained world medical association declaration helsinki 'ethical principles medical research involving human subjects ' gsksponsored clinical trials conducted ethical standards irrespective whether take place developed developing countries contract research organisations conducting studies behalf required apply gsk 's standards effect potential medicine often compared currently available medicines cases inactive substance placebo ethics conducting placebocontrolled trials sometimes questioned one patient group receives placebo provide active treatment placebo controlled trials carried compelling scientifically sound methodological reasons risks minimised reasonable relation knowledge gains patients receive placebo subject additional risk serious irreversible harm successful clinical trial programmes usually three four phases safety evaluated throughout clinical trials process safety participate clinical trials paramount importance gsk works ethics committees investigators achieve informed consent process informs volunteers study risks benefits gsk employees involved conducting trials receive training regulatory requirements gsk policies trials may audited internal audit department external regulators based risks associated trial risk factors include complexity study patient population location study previous audit history unusual findings conduct study back top home responsibility research practices clinical research planning approval corporate responsibility report planning approval protocol developed clinical trial sets purpose research explains trial conducted results analysed including details dosage duration treatment number participants required protocol defines measurements used evaluate safety efficacy medicine appropriate procedures participants wish withdraw study protocols reviewed independent ethical review committee lay people medical professionals scientists committees also review approve information provided informed consent process ethics committees power reject stop clinical trial trial protocols may also reviewed government regulatory agencies back top home responsibility research practices clinical research planning approval corporate responsibility report planning approval protocol developed clinical trial sets purpose research explains trial conducted results analysed including details dosage duration treatment number participants required protocol defines measurements used evaluate safety efficacy medicine appropriate procedures participants wish withdraw study protocols reviewed independent ethical review committee lay people medical professionals scientists committees also review approve information provided informed consent process ethics committees power reject stop clinical trial trial protocols may also reviewed government regulatory agencies back top home responsibility research practices clinical research informed consent corporate responsibility report informed consent informed consent means potential clinical trial participant voluntarily confirms willingness participate informed study risks benefits informed consent clinical trial involves reading signing consent form part wider process communicating essential information trial including risks benefits answering questions informed consent information written communicated nontechnical style lay person understand includes summary clinical trial including purpose treatment procedures schedule potential risks benefits alternatives participation provisions data protection explains participants ' rights including voluntary participation right end participation continually seek improve informed consent response feedback received actively seek input patient groups written document alone may ensure someone understands participation means therefore research team discusses person trial 's purpose procedures risks potential benefits participants rights person decides participate team continue update new information may affect whether want continue trial potential new side effects even trial person given opportunities ask questions raise concerns thus informed consent ongoing interactive process may special cases obtaining someone 's informed consent possible instance age legal consent circumstances consent sought someone allowed provide local laws regulations someone read able speak understand local language impartial witness present informed consent process confirm writing information form accurately explained potential participant able ask questions gave consent voluntarily back top home responsibility research practices clinical research informed consent corporate responsibility report informed consent informed consent means potential clinical trial participant voluntarily confirms willingness participate informed study risks benefits informed consent clinical trial involves reading signing consent form part wider process communicating essential information trial including risks benefits answering questions informed consent information written communicated nontechnical style lay person understand includes summary clinical trial including purpose treatment procedures schedule potential risks benefits alternatives participation provisions data protection explains participants ' rights including voluntary participation right end participation continually seek improve informed consent response feedback received actively seek input patient groups written document alone may ensure someone understands participation means therefore research team discusses person trial 's purpose procedures risks potential benefits participants rights person decides participate team continue update new information may affect whether want continue trial potential new side effects even trial person given opportunities ask questions raise concerns thus informed consent ongoing interactive process may special cases obtaining someone 's informed consent possible instance age legal consent circumstances consent sought someone allowed provide local laws regulations someone read able speak understand local language impartial witness present informed consent process confirm writing information form accurately explained potential participant able ask questions gave consent voluntarily back top home responsibility research practices clinical research training auditing corporate responsibility report training auditing approach performance training clinical trials employees involved designing conducting recording reporting gsksponsored clinical research studies trained good clinical practice gcp guidelines developed international conference harmonisation ich employees must completed required training undertaking roles keep detailed training records routinely requested regulatory authorities undertaking inspection gsk clinical research trials work regulators organisations continually improve quality compliance clinical trials includes training clinical researchers conduct clinical trials behalf gsk sponsors example supporting training clinical researchers india auditing clinical trials risk management compliance framework includes independent audit assessment conduct clinical trials scope audits assessments include gsk systems processes well external clinical research organisations investigators conducting clinical research behalf trials selected audit assessment based risk risk factors include complexity study patient population location study previous audit history unusual findings conduct study audit results reported quarterly rd compliance board annually risk oversight compliance council audit committee gsks board directors read corporate governance section annual report concerns issues identified fully investigated appropriate corrective action taken gsk staff corrective actions may include development new training programmes retraining individuals concerned severe cases clear breaches policy occurred appropriate disciplinary action taken including dismissal external investigators gsk may retrain investigator stop working investigator significant noncompliance identified investigative site trial data reported regulators including excluding site rationale provided exclusion regulatory authorities also carry inspections gsk investigators use conduct clinical trials back top home responsibility research practices clinical research training auditing corporate responsibility report training auditing approach performance training clinical trials employees involved designing conducting recording reporting gsksponsored clinical research studies trained good clinical practice gcp guidelines developed international conference harmonisation ich employees must completed required training undertaking roles keep detailed training records routinely requested regulatory authorities undertaking inspection gsk clinical research trials work regulators organisations continually improve quality compliance clinical trials includes training clinical researchers conduct clinical trials behalf gsk sponsors example supporting training clinical researchers india auditing clinical trials risk management compliance framework includes independent audit assessment conduct clinical trials scope audits assessments include gsk systems processes well external clinical research organisations investigators conducting clinical research behalf trials selected audit assessment based risk risk factors include complexity study patient population location study previous audit history unusual findings conduct study audit results reported quarterly rd compliance board annually risk oversight compliance council audit committee gsks board directors read corporate governance section annual report concerns issues identified fully investigated appropriate corrective action taken gsk staff corrective actions may include development new training programmes retraining individuals concerned severe cases clear breaches policy occurred appropriate disciplinary action taken including dismissal external investigators gsk may retrain investigator stop working investigator significant noncompliance identified investigative site trial data reported regulators including excluding site rationale provided exclusion regulatory authorities also carry inspections gsk investigators use conduct clinical trials back top home responsibility research practices clinical research training auditing performance corporate responsibility report training auditing performance approach performance training clinical trials training activities related good clinical practice gcp 'training activity ' represents successful completion elearning module instructorled course related gcp one employees contractors auditing clinical trials conducted audits assessments included investigator sites conducting gsksponsored trials represents approximately five per cent investigator sites participating pivotal clinical trials two gsk systems processes clinical research organisations carrying clinical trials gsks behalf six gsk local operating companies involved clinical research activities addition investigations conducted response suspected irregularities investigator sites concerns issues identified fully investigated appropriate corrective action taken inspections investigators clinical research organisations independent ethics committeesinstitutional review boards sponsors clinical trials also carried regulatory authorities ensure safety trial participants quality data trials conducted according good clinical practice inspections gsk investigators used gsk conduct clinical trials back top home responsibility research practices clinical research training auditing performance corporate responsibility report training auditing performance approach performance training clinical trials training activities related good clinical practice gcp 'training activity ' represents successful completion elearning module instructorled course related gcp one employees contractors auditing clinical trials conducted audits assessments included investigator sites conducting gsksponsored trials represents approximately five per cent investigator sites participating pivotal clinical trials two gsk systems processes clinical research organisations carrying clinical trials gsks behalf six gsk local operating companies involved clinical research activities addition investigations conducted response suspected irregularities investigator sites concerns issues identified fully investigated appropriate corrective action taken inspections investigators clinical research organisations independent ethics committeesinstitutional review boards sponsors clinical trials also carried regulatory authorities ensure safety trial participants quality data trials conducted according good clinical practice inspections gsk investigators used gsk conduct clinical trials back top home responsibility research practices clinical research posttrial treatment corporate responsibility report posttrial treatment recognise continued treatment clinical trial participants nationally licensed medicines end trial often required continued care patients general responsible funding nationally licensed medicines trial responsibility governments providers part national healthcare systems however beginning trials diseases conditions continue completion trial must assured healthcare system able provide take responsibility continued care patients exceptional circumstances nationally licensed medicines may funded gsk trial made available trial participants derived measurable medical benefit continue fund medicine funded normal healthcare infrastructure patient longer derives medical benefit may circumstances compelling medical rationale patients continue receive gsk investigational medicine clinical trial case posttrial treatment may provided clinical trial part expanded access programmes enable appropriate oversight reporting adverse events circumstances gsk fund investigational medicine long patient benefits compound approved licensed country read public policy clinical trials developing world back top home responsibility research practices clinical research posttrial treatment corporate responsibility report posttrial treatment recognise continued treatment clinical trial participants nationally licensed medicines end trial often required continued care patients general responsible funding nationally licensed medicines trial responsibility governments providers part national healthcare systems however beginning trials diseases conditions continue completion trial must assured healthcare system able provide take responsibility continued care patients exceptional circumstances nationally licensed medicines may funded gsk trial made available trial participants derived measurable medical benefit continue fund medicine funded normal healthcare infrastructure patient longer derives medical benefit may circumstances compelling medical rationale patients continue receive gsk investigational medicine clinical trial case posttrial treatment may provided clinical trial part expanded access programmes enable appropriate oversight reporting adverse events circumstances gsk fund investigational medicine long patient benefits compound approved licensed country read public policy clinical trials developing world back top home responsibility research practices clinical research clinical trials developing world corporate responsibility report clinical trials developing world gsk clinical trials wherever carried conducted high standard gsk conduct clinical trials countries know outset intent pursue registration make product available use country additional steps may needed ensure trials least developed countries conducted according good clinical practice gcp guidelines example matching objectives informed consent local culture may necessary instance involving local leaders andor family members gsk provides training ensure healthcare professionals necessary skills knowledge conduct clinical trials behalf well benefiting gsk enhancing skills healthcare professionals way brings lasting benefits communities read posttrial treatment read position statement clinical trials developing world back top home responsibility research practices clinical research clinical trials developing world corporate responsibility report clinical trials developing world gsk clinical trials wherever carried conducted high standard gsk conduct clinical trials countries know outset intent pursue registration make product available use country additional steps may needed ensure trials least developed countries conducted according good clinical practice gcp guidelines example matching objectives informed consent local culture may necessary instance involving local leaders andor family members gsk provides training ensure healthcare professionals necessary skills knowledge conduct clinical trials behalf well benefiting gsk enhancing skills healthcare professionals way brings lasting benefits communities read posttrial treatment read position statement clinical trials developing world back top home responsibility research practices clinical research clinical trials children corporate responsibility report clinical trials children children number important physiological differences adults means respond differently medicines experience different side effects clinical trials children vital develop safe effective medicines children address recognised lack medicines approved children conducting clinical trials children carries practical ethical challenges example recruitment clinical trials children particularly difficult fewer speciality centres paediatric research compared adults extra steps often need taken seeking informed consent parents well assent children agree participate children care occasionally may necessary recruit children care clinical trials example many children hivaids lost parents disease may care trials involving children care present ethical concerns without parental protection children may vulnerable take additional steps ensure high ethical standards followed approval must obtained chief medical officer delegated gsk physician children care recruited gsk clinical trial institutional review board ethics committee overseeing trial must also give explicit approval inclusion children revised standard operating procedure guidelines implement requirements phases clinical trials requirements supplement local regional ethical legal requirements back top home responsibility research practices clinical research clinical trials children corporate responsibility report clinical trials children children number important physiological differences adults means respond differently medicines experience different side effects clinical trials children vital develop safe effective medicines children address recognised lack medicines approved children conducting clinical trials children carries practical ethical challenges example recruitment clinical trials children particularly difficult fewer speciality centres paediatric research compared adults extra steps often need taken seeking informed consent parents well assent children agree participate children care occasionally may necessary recruit children care clinical trials example many children hivaids lost parents disease may care trials involving children care present ethical concerns without parental protection children may vulnerable take additional steps ensure high ethical standards followed approval must obtained chief medical officer delegated gsk physician children care recruited gsk clinical trial institutional review board ethics committee overseeing trial must also give explicit approval inclusion children revised standard operating procedure guidelines implement requirements phases clinical trials requirements supplement local regional ethical legal requirements back top home responsibility research practices public disclosure clinical research corporate responsibility report public disclosure clinical research approach performance plans pharmaceutical companies legally required disclose relevant data clinical trials appropriate regulatory authorities seeking approval new medicine approval sponsors continuing obligation provide regulatory authorities updated safety information clinical trials read patient safety safety efficacy information provided doctors prescribing information approved regulators public disclosure research fundamental advancing medical science informing prescribers patients scientific findings relating medicines committed ensuring studies made publicly available irrespective whether results perceived positive negative medicines clinical study register clinical study register website launched serves resource researchers medical professionals public use alongside locally approved prescribing information publications scientific literature initially site included summaries results clinical studies compounds subsequently became marketed medicines launched new clinical study register place old site register also includes protocol summaries ongoing studies well result summaries completed studies also enhanced searching capabilities latest figures show site receiving visitors month since included summaries results clinical studies compounds subsequently became marketed medicines january expanded register include summaries results observational research studies medicines used normal medical practice metaanalyses combine analyse results two previously conducted studies evaluate medicines summaries results studies terminated medicines compounds longer developed help inform scientific community nonproductive areas research reduce unnecessary exposure study participants similar compounds clinical trials names principal investigators participate clinical research information contained clinical study register online databases designed supplement publications scientific journals undergo independent peer review provide context interpretation research data studies published journals example perceived sufficient interest journals readers committed providing context interpretation results register help users interpret data read case study register helping improve access clinical trials information read position statement disclosure clinical trial information read principles working healthcare professionals back top home responsibility research practices public disclosure clinical research corporate responsibility report public disclosure clinical research approach performance plans pharmaceutical companies legally required disclose relevant data clinical trials appropriate regulatory authorities seeking approval new medicine approval sponsors continuing obligation provide regulatory authorities updated safety information clinical trials read patient safety safety efficacy information provided doctors prescribing information approved regulators public disclosure research fundamental advancing medical science informing prescribers patients scientific findings relating medicines committed ensuring studies made publicly available irrespective whether results perceived positive negative medicines clinical study register clinical study register website launched serves resource researchers medical professionals public use alongside locally approved prescribing information publications scientific literature initially site included summaries results clinical studies compounds subsequently became marketed medicines launched new clinical study register place old site register also includes protocol summaries ongoing studies well result summaries completed studies also enhanced searching capabilities latest figures show site receiving visitors month since included summaries results clinical studies compounds subsequently became marketed medicines january expanded register include summaries results observational research studies medicines used normal medical practice metaanalyses combine analyse results two previously conducted studies evaluate medicines summaries results studies terminated medicines compounds longer developed help inform scientific community nonproductive areas research reduce unnecessary exposure study participants similar compounds clinical trials names principal investigators participate clinical research information contained clinical study register online databases designed supplement publications scientific journals undergo independent peer review provide context interpretation research data studies published journals example perceived sufficient interest journals readers committed providing context interpretation results register help users interpret data read case study register helping improve access clinical trials information read position statement disclosure clinical trial information read principles working healthcare professionals back top home responsibility research practices public disclosure clinical research corporate responsibility report public disclosure clinical research approach performance plans pharmaceutical companies legally required disclose relevant data clinical trials appropriate regulatory authorities seeking approval new medicine approval sponsors continuing obligation provide regulatory authorities updated safety information clinical trials read patient safety safety efficacy information provided doctors prescribing information approved regulators public disclosure research fundamental advancing medical science informing prescribers patients scientific findings relating medicines committed ensuring studies made publicly available irrespective whether results perceived positive negative medicines clinical study register clinical study register website launched serves resource researchers medical professionals public use alongside locally approved prescribing information publications scientific literature initially site included summaries results clinical studies compounds subsequently became marketed medicines launched new clinical study register place old site register also includes protocol summaries ongoing studies well result summaries completed studies also enhanced searching capabilities latest figures show site receiving visitors month since included summaries results clinical studies compounds subsequently became marketed medicines january expanded register include summaries results observational research studies medicines used normal medical practice metaanalyses combine analyse results two previously conducted studies evaluate medicines summaries results studies terminated medicines compounds longer developed help inform scientific community nonproductive areas research reduce unnecessary exposure study participants similar compounds clinical trials names principal investigators participate clinical research information contained clinical study register online databases designed supplement publications scientific journals undergo independent peer review provide context interpretation research data studies published journals example perceived sufficient interest journals readers committed providing context interpretation results register help users interpret data read case study register helping improve access clinical trials information read position statement disclosure clinical trial information read principles working healthcare professionals back top home responsibility research practices public disclosure clinical research corporate responsibility report public disclosure clinical research approach performance plans end protocol summaries actively recruiting gsk clinical trials medicines gsk clinical study register total clinical trial results summaries clinical study register includes results summaries observational studies metaanalyses objective disclose trial results summaries new medicinal products register time first approval within months terminating development medicine target disclose results trials completed product approved marketing within one year trial completion studies due posting placed register less two per cent studies posted target timelines additionally identified small number studies posted previous years studies also placed register also committed seeking publication results clinical studies full scientific papers peer reviewed journals believe company make commitment paper published include additional information support interpretation study results clinical study register number results summaries gsk clinical trials gsk clinical study register cumulative total making transparency fundamental research took steps ensure employees involved rd gsk consider public disclosure integral part research important example informed consent launched extensive training awareness programmes developed tools support processes ensure meet commitments expand disclosure research results example part commitment ensuring clinical research published manuscripts peer reviewed journals possible developed training help researchers identify appropriate scientific journals develop manuscripts back top home responsibility research practices public disclosure clinical research corporate responsibility report public disclosure clinical research approach performance plans end protocol summaries actively recruiting gsk clinical trials medicines gsk clinical study register total clinical trial results summaries clinical study register includes results summaries observational studies metaanalyses objective disclose trial results summaries new medicinal products register time first approval within months terminating development medicine target disclose results trials completed product approved marketing within one year trial completion studies due posting placed register less two per cent studies posted target timelines additionally identified small number studies posted previous years studies also placed register also committed seeking publication results clinical studies full scientific papers peer reviewed journals believe company make commitment paper published include additional information support interpretation study results clinical study register number results summaries gsk clinical trials gsk clinical study register cumulative total making transparency fundamental research took steps ensure employees involved rd gsk consider public disclosure integral part research important example informed consent launched extensive training awareness programmes developed tools support processes ensure meet commitments expand disclosure research results example part commitment ensuring clinical research published manuscripts peer reviewed journals possible developed training help researchers identify appropriate scientific journals develop manuscripts back top home responsibility research practices public disclosure clinical research corporate responsibility report public disclosure clinical research approach performance plans end protocol summaries actively recruiting gsk clinical trials medicines gsk clinical study register total clinical trial results summaries clinical study register includes results summaries observational studies metaanalyses objective disclose trial results summaries new medicinal products register time first approval within months terminating development medicine target disclose results trials completed product approved marketing within one year trial completion studies due posting placed register less two per cent studies posted target timelines additionally identified small number studies posted previous years studies also placed register also committed seeking publication results clinical studies full scientific papers peer reviewed journals believe company make commitment paper published include additional information support interpretation study results clinical study register number results summaries gsk clinical trials gsk clinical study register cumulative total making transparency fundamental research took steps ensure employees involved rd gsk consider public disclosure integral part research important example informed consent launched extensive training awareness programmes developed tools support processes ensure meet commitments expand disclosure research results example part commitment ensuring clinical research published manuscripts peer reviewed journals possible developed training help researchers identify appropriate scientific journals develop manuscripts back top home responsibility research practices patient needs rd corporate responsibility report patient needs rd focus patient programme helps rd employees understand patient needs inspires help improve lives patients invite patients meet gsk scientists researchers marketers help us understand patient needs develop better medicines also shows gsk employees difference work make people 's lives held seminars patients visited gsk sites help rd employees understand realities living illness seminars included discussions kidney cancer type diabetes human papillomaviruscervical cancer chronic obstructive pulmonary disease asthma allergic rhinitis insomnia motor neurone disease osteoarthritis atherosclerosis hiv schizophrenia epilepsy total seminars attended gsk employees patient representatives working improve patients ' experience clinical trials informed consent process reviewed simplified informed consent forms make language clearer easier understand continue make improvements based feedback advisory boards include patient representatives inform employees patients helping work rd regular monthly bulletins highlight key medicines pipeline meet needs patients helps motivate employees reminding importance work conducted four feedback surveys measure effectiveness focus patient programme almost responses indicated seminars provided attendees good understanding impact disease patients ' lives raised awareness gsk 's efforts develop treatments diseases back top home responsibility research practices patient needs rd corporate responsibility report patient needs rd focus patient programme helps rd employees understand patient needs inspires help improve lives patients invite patients meet gsk scientists researchers marketers help us understand patient needs develop better medicines also shows gsk employees difference work make people 's lives held seminars patients visited gsk sites help rd employees understand realities living illness seminars included discussions kidney cancer type diabetes human papillomaviruscervical cancer chronic obstructive pulmonary disease asthma allergic rhinitis insomnia motor neurone disease osteoarthritis atherosclerosis hiv schizophrenia epilepsy total seminars attended gsk employees patient representatives working improve patients ' experience clinical trials informed consent process reviewed simplified informed consent forms make language clearer easier understand continue make improvements based feedback advisory boards include patient representatives inform employees patients helping work rd regular monthly bulletins highlight key medicines pipeline meet needs patients helps motivate employees reminding importance work conducted four feedback surveys measure effectiveness focus patient programme almost responses indicated seminars provided attendees good understanding impact disease patients ' lives raised awareness gsk 's efforts develop treatments diseases back top home responsibility research practices patient safety corporate responsibility report patient safety ensuring safety medicines medical devices critically important health wellbeing patients success business medicines potential risks well benefits although everyone takes medicine experience side effects important identify evaluate minimise safety concerns ensure overall benefits medicine outweigh risks strive serve patient interest promptly detecting potential safety issues products communicating regulators appropriate decisions made actions taken product safety assessed clinical trials product approved marketing adverse events potential safety issues side effects may detected approval product used large numbers patients policies governance framework place help us detect act adverse events dedicated team scientists healthcare professionals across world monitors communicates safety issues regulatory authorities also investing genetic research help predict individual patients respond medicine future help healthcare providers prescribe safer effective medicines read patient safety governance framework collect report safety data back top home responsibility research practices patient safety corporate responsibility report patient safety ensuring safety medicines medical devices critically important health wellbeing patients success business medicines potential risks well benefits although everyone takes medicine experience side effects important identify evaluate minimise safety concerns ensure overall benefits medicine outweigh risks strive serve patient interest promptly detecting potential safety issues products communicating regulators appropriate decisions made actions taken product safety assessed clinical trials product approved marketing adverse events potential safety issues side effects may detected approval product used large numbers patients policies governance framework place help us detect act adverse events dedicated team scientists healthcare professionals across world monitors communicates safety issues regulatory authorities also investing genetic research help predict individual patients respond medicine future help healthcare providers prescribe safer effective medicines read patient safety governance framework collect report safety data back top home responsibility research practices patient safety patient safety governance framework corporate responsibility report patient safety governance framework global safety board gsb makes decisions product safety issues board chaired chief medical officer composed senior physicians scientists role oversee safety investigational marketed medicines vaccines approve first administration investigational medicines humans define conditions use medicines vaccines minimise risks includes special safety monitoring doses durations treatments considered safe approve progression investigational medicines pivotal trials trials provide primary data regulatory approval based assess issues related patient safety arise product development marketing three central departments responsible recording investigating evaluating adverse events reporting relevant regulatory authorities example us food drug administration fda european medicines evaluation agency emea global clinical safety pharmacovigilance team gcsp part gsk research development responsible safety evaluation pharmaceuticals devices gsk biologicals clinical safety pharmacovigilance department part vaccines business responsible safety evaluation gsk vaccines consumer healthcare product safety group part consumer healthcare business responsible safety evaluation consumer healthcare products require gsk staff immediately report issues relating safety quality medicines read expectations code conduct read medical governance benefitrisk management assess balance benefits risks particular medicine throughout life cycle early development clinical trials product market evaluate document available safety information build detailed benefitrisk profile product use information develop benefitrisk management plan identifies ways improve products benefits minimise risks review update plans regularly clinical development period product approved marketing back top home responsibility research practices patient safety patient safety governance framework corporate responsibility report patient safety governance framework global safety board gsb makes decisions product safety issues board chaired chief medical officer composed senior physicians scientists role oversee safety investigational marketed medicines vaccines approve first administration investigational medicines humans define conditions use medicines vaccines minimise risks includes special safety monitoring doses durations treatments considered safe approve progression investigational medicines pivotal trials trials provide primary data regulatory approval based assess issues related patient safety arise product development marketing three central departments responsible recording investigating evaluating adverse events reporting relevant regulatory authorities example us food drug administration fda european medicines evaluation agency emea global clinical safety pharmacovigilance team gcsp part gsk research development responsible safety evaluation pharmaceuticals devices gsk biologicals clinical safety pharmacovigilance department part vaccines business responsible safety evaluation gsk vaccines consumer healthcare product safety group part consumer healthcare business responsible safety evaluation consumer healthcare products require gsk staff immediately report issues relating safety quality medicines read expectations code conduct read medical governance benefitrisk management assess balance benefits risks particular medicine throughout life cycle early development clinical trials product market evaluate document available safety information build detailed benefitrisk profile product use information develop benefitrisk management plan identifies ways improve products benefits minimise risks review update plans regularly clinical development period product approved marketing back top home responsibility research practices patient safety collecting reporting safety data corporate responsibility report collecting reporting safety data receive information adverse events possible side effects several sources including unsolicited reports health professionals patients postmarketing trials observational studies investigators submit clinical study reports regulatory authorities medical scientific literature newspapers media gsk employee required report adverse event become aware adverse events reported gsk recorded global safety database clinical trial database investigated clinical pharmacovigilance teams report potential safety issues regulatory authorities regular basis country manager responsible ensuring collection safety information reporting relevant central safety department local regulatory authority part management certification process managers confirmed compliance policy adverse event reporting specifies gsk employee responsible reporting adverse event become aware conduct work added adverse event reporting button front mygsk intranet site make reporting adverse events easier employees regulators countries also publishing information adverse events internet example data products marketed uk available via medicines healthcare products regulatory agency safety data also available canada us food drug administration fda made information database accessible public publishing quarterly report potential safety issues investigating initiated new cardiovascular outcome study involving diabetes product avandia required fda read questions raised safety avandia december combined fda advisory committee review respiratory products containing longacting beta agonists february fda proposed label changes read questions safety products containing longacting beta agonists read medical governance read position statement pharmacovigilance responding adverse events adverse events affect benefitrisk profile product corrective actions may needed minimise risk include carrying clinical trials modifying prescribing information communications physicians healthcare providers establishing specific methods minimise risk example highlighting warning prescribing information products subject limited distribution programmes prescription specialist doctors certain cases may appropriate stop clinical trial withdraw product market global labelling committees review approve prescribing information medicinal products ensure updated appropriate back tophome responsibility research practices patient safety collecting reporting safety data corporate responsibility report collecting reporting safety data receive information adverse events possible side effects several sources including unsolicited reports health professionals patients postmarketing trials observational studies investigators submit clinical study reports regulatory authorities medical scientific literature newspapers media gsk employee required report adverse event become aware adverse events reported gsk recorded global safety database clinical trial database investigated clinical pharmacovigilance teams report potential safety issues regulatory authorities regular basis country manager responsible ensuring collection safety information reporting relevant central safety department local regulatory authority part management certification process managers confirmed compliance policy adverse event reporting specifies gsk employee responsible reporting adverse event become aware conduct work added adverse event reporting button front mygsk intranet site make reporting adverse events easier employees regulators countries also publishing information adverse events internet example data products marketed uk available via medicines healthcare products regulatory agency safety data also available canada us food drug administration fda made information database accessible public publishing quarterly report potential safety issues investigating initiated new cardiovascular outcome study involving diabetes product avandia required fda read questions raised safety avandia december combined fda advisory committee review respiratory products containing longacting beta agonists february fda proposed label changes read questions safety products containing longacting beta agonists read medical governance read position statement pharmacovigilance responding adverse events adverse events affect benefitrisk profile product corrective actions may needed minimise risk include carrying clinical trials modifying prescribing information communications physicians healthcare providers establishing specific methods minimise risk example highlighting warning prescribing information products subject limited distribution programmes prescription specialist doctors certain cases may appropriate stop clinical trial withdraw product market global labelling committees review approve prescribing information medicinal products ensure updated appropriate back top home responsibility research practices patient safety collecting reporting safety data corporate responsibility report collecting reporting safety data receive information adverse events possible side effects several sources including unsolicited reports health professionals patients postmarketing trials observational studies investigators submit clinical study reports regulatory authorities medical scientific literature newspapers media gsk employee required report adverse event become aware adverse events reported gsk recorded global safety database clinical trial database investigated clinical pharmacovigilance teams report potential safety issues regulatory authorities regular basis country manager responsible ensuring collection safety information reporting relevant central safety department local regulatory authority part management certification process managers confirmed compliance policy adverse event reporting specifies gsk employee responsible reporting adverse event become aware conduct work added adverse event reporting button front mygsk intranet site make reporting adverse events easier employees regulators countries also publishing information adverse events internet example data products marketed uk available via medicines healthcare products regulatory agency safety data also available canada us food drug administration fda made information database accessible public publishing quarterly report potential safety issues investigating initiated new cardiovascular outcome study involving diabetes product avandia required fda read questions raised safety avandia december combined fda advisory committee review respiratory products containing longacting beta agonists february fda proposed label changes read questions safety products containing longacting beta agonists read medical governance read position statement pharmacovigilance responding adverse events adverse events affect benefitrisk profile product corrective actions may needed minimise risk include carrying clinical trials modifying prescribing information communications physicians healthcare providers establishing specific methods minimise risk example highlighting warning prescribing information products subject limited distribution programmes prescription specialist doctors certain cases may appropriate stop clinical trial withdraw product market global labelling committees review approve prescribing information medicinal products ensure updated appropriate back top home responsibility research practices patient safety collecting reporting safety data responding questions avandia corporate responsibility report responding questions avandia avandia treatment type diabetes metaanalysis published new england journal medicine gsk 's metaanalysis submitted fda regulators centre debate whether avandia may associated increased risk myocardial infarction death cardiovascular causes following fda advisory committee meeting fda approved updated prescribing information avandia including new text existing boxed highlighted warning november updated prescribing information summarised data fda metaanalysis myocardial ischemic events suggested risk associated avandia three longterm clinical trials comparing avandia placebo oral antidiabetes medicines confirm exclude risk revised prescribing information included 'in entirety available data risk myocardial ischemia inconclusive ' research involving avandia continued including cardiovascular outcome study called record large prospective randomised controlled study initiated clinical trial designed compare cardiovascular outcomes patients avandia added metformin sulfonylurea metformin sulfonylurea results record published june study showed combined endpoint cardiovascular hospitalisation cardiovascular death includes heart attack congestive heart failure stroke statistically different two groups average years therapy initiated new cardiovascular outcome study involving avandia called tide medicines avandia included carry risks well benefits type diabetes chronic progressive lifethreatening disease physicians often need prescribe two three medicines help patients maintain blood sugar levels array treatment options important gsk believes important avandia available support effective treatment type diabetes appropriate patients gsk responded us senate committee finance report avandia published february nissen k wolski effect rosiglitazone risk myocardial infarction death cardiovascular causes n engl j med cobitz et al retrospective evaluation congestive heart failure myocardial ischemia events patients type diabetes mellitus enrolled shortterm doubleblind randomized clinical studies rosiglitazone pharmacoepidemiology drug safety p home et al rosiglitazone evaluated cardiovascular outcomes interim analysis n engl j med ii kahn et al glycemic durability rosiglitazone metformin glyburide monotherapy n engl j med iii dream diabetes reduction assessment ramipril rosiglitazone medication trial investigators effect rosiglitazone frequency diabetes patients impaired glucose tolerance impaired fasting glucose randomised controlled trial lancet p home et al rosiglitazone evaluated cardiovascular outcomes oral agent combination therapy type diabetes record multicentre randomised openlabel trial lancet update september july joint advisory committee us food drug administration fda voted allow avandia remain market committee members voted recommendations ranging making changes current label revising label additional warnings restrictions withdrawal us market joint committees recommendations considered fda making final decision future use avandia request fda gsk susppageen de dof enrollment new patients thiazolidinedione intervention vitamin evaluation tide clinical trial pending fda review recommendations committee avandia one extensively researched diabetes medicines studied patients believe used accordance labeling avandia safe effective treatment option type diabetes please see avandia resource centre latest information avandia back tophome responsibility research practices patient safety collecting reporting safety data responding questions avandia corporate responsibility report responding questions avandia avandia treatment type diabetes metaanalysis published new england journal medicine gsk 's metaanalysis submitted fda regulators centre debate whether avandia may associated increased risk myocardial infarction death cardiovascular causes following fda advisory committee meeting fda approved updated prescribing information avandia including new text existing boxed highlighted warning november updated prescribing information summarised data fda metaanalysis myocardial ischemic events suggested risk associated avandia three longterm clinical trials comparing avandia placebo oral antidiabetes medicines confirm exclude risk revised prescribing information included 'in entirety available data risk myocardial ischemia inconclusive ' research involving avandia continued including cardiovascular outcome study called record large prospective randomised controlled study initiated clinical trial designed compare cardiovascular outcomes patients avandia added metformin sulfonylurea metformin sulfonylurea results record published june study showed combined endpoint cardiovascular hospitalisation cardiovascular death includes heart attack congestive heart failure stroke statistically different two groups average years therapy initiated new cardiovascular outcome study involving avandia called tide medicines avandia included carry risks well benefits type diabetes chronic progressive lifethreatening disease physicians often need prescribe two three medicines help patients maintain blood sugar levels array treatment options important gsk believes important avandia available support effective treatment type diabetes appropriate patients gsk responded us senate committee finance report avandia published february nissen k wolski effect rosiglitazone risk myocardial infarction death cardiovascular causes n engl j med cobitz et al retrospective evaluation congestive heart failure myocardial ischemia events patients type diabetes mellitus enrolled shortterm doubleblind randomized clinical studies rosiglitazone pharmacoepidemiology drug safety p home et al rosiglitazone evaluated cardiovascular outcomes interim analysis n engl j med ii kahn et al glycemic durability rosiglitazone metformin glyburide monotherapy n engl j med iii dream diabetes reduction assessment ramipril rosiglitazone medication trial investigators effect rosiglitazone frequency diabetes patients impaired glucose tolerance impaired fasting glucose randomised controlled trial lancet p home et al rosiglitazone evaluated cardiovascular outcomes oral agent combination therapy type diabetes record multicentre randomised openlabel trial lancet update september july joint advisory committee us food drug administration fda voted allow avandia remain market committee members voted recommendations ranging making changes current label revising label additional warnings restrictions withdrawal us market joint committees recommendations considered fda making final decision future use avandia request fda gsk suspended enrollment new patients thiazolidinedione intervention vitamin evaluation tide clinical trial pending fda review recommendations committee avandia one extensively researched diabetes medicines studied patients believe used accordance labeling avandia safe effective treatment option type diabetes please see avandia resource centre latest information avandia back top home responsibility research practices patient safety collecting reporting safety data responding questions avandia corporate responsibility report responding questions avandia avandia treatment type diabetes metaanalysis published new england journal medicine gsk 's metaanalysis submitted fda regulators centre debate whether avandia may associated increased risk myocardial infarction death cardiovascular causes following fda advisory committee meeting fda approved updated prescribing information avandia including new text existing boxed highlighted warning november updated prescribing information summarised data fda metaanalysis myocardial ischemic events suggested risk associated avandia three longterm clinical trials comparing avandia placebo oral antidiabetes medicines confirm exclude risk revised prescribing information included 'in entirety available data risk myocardial ischemia inconclusive ' research involving avandia continued including cardiovascular outcome study called record large prospective randomised controlled study initiated clinical trial designed compare cardiovascular outcomes patients avandia added metformin sulfonylurea metformin sulfonylurea results record published june study showed combined endpoint cardiovascular hospitalisation cardiovascular death includes heart attack congestive heart failure stroke statistically different two groups average years therapy initiated new cardiovascular outcome study involving avandia called tide medicines avandia included carry risks well benefits type diabetes chronic progressive lifethreatening disease physicians often need prescribe two three medicines help patients maintain blood sugar levels array treatment options important gsk believes important avandia available support effective treatment type diabetes appropriate patients gsk responded us senate committee finance report avandia published february nissen k wolski effect rosiglitazone risk myocardial infarction death cardiovascular causes n engl j med cobitz et al retrospective evaluation congestive heart failure myocardial ischemia events patients type diabetes mellitus enrolled shortterm doubleblind randomized clinical studies rosiglitazone pharmacoepidemiology drug safety p home et al rosiglitazone evaluated cardiovascular outcomes interim analysis n engl j med ii kahn et al glycemic durability rosiglitazone metformin glyburide monotherapy n engl j med iii dream diabetes reduction assessment ramipril rosiglitazone medication trial investigators effect rosiglitazone frequency diabetes patients impaired glucose tolerance impaired fasting glucose randomised controlled trial lancet p home et al rosiglitazone evaluated cardiovascular outcomes oral agent combination therapy type diabetes record multicentre randomised openlabel trial lancet update september july joint advisory committee us food drug administration fda voted allow avandia remain market committee members voted recommendations ranging making changes current label revising label additional warnings restrictions withdrawal us market joint committees recommendations considered fda making final decision future use avandia request fda gsk suspended enrollment new patients thiazolidinedione intervention vitamin evaluation tide clinical trial pending fda review recommendations committee avandia one extensively researched diabetes medicines studied patients believe used accordance labeling avandia safe effective treatment option type diabetes please see avandia resource centre latest information avandia back top home responsibility research practices patient safety collecting reporting safety data questions safety products containing long acting beta agonists corporate responsibility report responding questions safety products containing long acting beta agonists longacting beta agonists known labas daily controller medicines relieve help prevent airway constriction airway constriction one two main components asthma labas treat main component asthma inflammation treated another type daily controller medicine called inhaled corticosteroid ics labas including gsk 's product serevent used alone treatment persistent asthma leading treatment guidelines recommend labas used appropriate patients asthma combination ics gsk makes two products containing laba salmeterol seretideadvair combination salmeterol ics fluticasone serevent contains salmeterol alone december combined advisory committee us food drug administration reviewed benefitrisk profile medicines containing labas children adults asthma review included labacontaining products indicated use treating asthma gsk 's products addressed lingering concerns labas may increase risk asthmarelated death current product labels prominently warn advisory committee makes recommendations fda makes final decision actions required seretideadvair committee unanimously voted benefits seretideadvair outweigh risks patients years older committee also voted favour positive benefitrisk profile younger patients although individual votes mixed serevent committee found benefits outweigh risks treatment asthma concerns expressed potential serevent used alone treatment asthma contrary current prescribing information way would make benefitrisk profile unfavourable contrast seretideadvair combination therapy laba ics combination use assured although gsk acknowledges concerns use serevent without ics best interests asthma patients favour option allowing dual therapy using separate inhalers use separate inhalers important treatment option asthma patients need alternative ics fluticasone ics contained seretideadvair flexibility ics doses beyond available combination product also important asthma patients receive favourable reimbursement separate inhalers gsk believes appropriate labelling proactive communication risks using laba alone potential misuse serevent monotherapy acceptably reduced dual therapy using separate inhalers remains available asthma patients need september advisory committee meeting gsk submitted proposed label change fda serevent clarify use asthma patients must combination ics line prescribing information countries serevent marketed february fda proposed label changes labas requested plans communicating use healthcare providers updated information laba safety gsk working fda appropriate labelling communications protect interests patients suffer asthma update september june constructive discussions fda following agencys initial proposals february gsk implemented updated labeling labacontaining products accordance fdas directions labacontaining products updated labeling includes strengthened risk information recommendations intended promote safe use consistent gsks position fda allowed serevent single active ingredient inhaler containing salmeterol retain indication use treating asthma provided use without inhaled corticosteroid contraindicated fda also requiring clinical research potential approaches explored march advisory committee meeting consultations fda appropriate trial design ongoing fda also requiring risk evaluation management strategy includes updated medication guide use patients forthcoming communications plan educating prescribers strengthened risk information recommendations intended promote safe use back tophome responsibility research practices patient safety collecting reporting safety data questions safety products containing long acting beta agonists corporate responsibility report responding questions safety products containing long acting beta agonists longacting beta agonists known labas daily controller medicines relieve help prevent airway constriction airway constriction one two main components asthma labas treat main component asthma inflammation treated another type daily controller medicine called inhaled corticosteroid ics labas including gsk 's product serevent used alone treatment persistent asthma leading treatment guidelines recommend labas used appropriate patients asthma combination ics gsk makes two products containing laba salmeterol seretideadvair combination salmeterol ics fluticasone serevent contains salmeterol alone december combined advisory committee us food drug administration reviewed benefitrisk profile medicines containing labas children adults asthma review included labacontaining products indicated use treating asthma gsk 's products addressed lingering concerns labas may increase risk asthmarelated death current product labels prominently warn advisory committee makes recommendations fda makes final decision actions required seretideadvair committee unanimously voted benefits seretideadvair outweigh risks patients years older committee also voted favour positive benefitrisk profile younger patients although individual votes mixed serevent committee found benefits outweigh risks treatment asthma concerns expressed potential serevent used alone treatment asthma contrary current prescribing information way would make benefitrisk profile unfavourable contrast seretideadvair combination therapy laba ics combination use assured although gsk acknowledges concerns use serevent without ics best interests asthma patients favour option allowing dual therapy using separate inhalers use separate inhalers important treatment option asthma patients need alternative ics fluticasone ics contained seretideadvair flexibility ics doses beyond available combination product also important asthma patients receive favourable reimbursement separate inhalers gsk believes appropriate labelling proactive communication risks using laba alone potential misuse serevent monotherapy acceptably reduced dual therapy using separate inhalers remains available asthma patients need september advisory committee meeting gsk submitted proposed label change fda serevent clarify use asthma patients must combination ics line prescribing information countries serevent marketed february fda proposed label changes labas requested plans communicating use healthcare providers updated information laba safety gsk working fda appropriate labelling communications protect interests patients suffer asthma update september june constructive discussions fda following agencys initial proposals february gsk implemented updated labeling labacontaining products accordance fdas directions labacontaining products updated labeling includes strengthened risk information recommendations intended promote safe use consistent gsks position fda allowed serevent single active ingredient inhaler containing salmeterol retain indication use treating asthma provided use without inhaled corticosteroid contraindicated fda also requiring clinical research potential approaches explored march advisory committee meeting consultations fda appropriate trial design ongoing fda also requiring risk evaluation management strategy includes updated medication guide use patients forthcoming communications plan educating prescribers strengthened risk information recommendations intended promote safe use back top home responsibility research practices patient safety collecting reporting safety data questions safety products containing long acting beta agonists corporate responsibility report responding questions safety products containing long acting beta agonists longacting beta agonists known labas daily controller medicines relieve help prevent airway constriction airway constriction one two main components asthma labas treat main component asthma inflammation treated another type daily controller medicine called inhaled corticosteroid ics labas including gsk 's product serevent used alone treatment persistent asthma leading treatment guidelines recommend labas used appropriate patients asthma combination ics gsk makes two products containing laba salmeterol seretideadvair combination salmeterol ics fluticasone serevent contains salmeterol alone december combined advisory committee us food drug administration reviewed benefitrisk profile medicines containing labas children adults asthma review included labacontaining products indicated use treating asthma gsk 's products addressed lingering concerns labas may increase risk asthmarelated death current product labels prominently warn advisory committee makes recommendations fda makes final decision actions required seretideadvair committee unanimously voted benefits seretideadvair outweigh risks patients years older committee also voted favour positive benefitrisk profile younger patients although individual votes mixed serevent committee found benefits outweigh risks treatment asthma concerns expressed potential serevent used alone treatment asthma contrary current prescribing information way would make benefitrisk profile unfavourable contrast seretideadvair combination therapy laba ics combination use assured although gsk acknowledges concerns use serevent without ics best interests asthma patients favour option allowing dual therapy using separate inhalers use separate inhalers important treatment option asthma patients need alternative ics fluticasone ics contained seretideadvair flexibility ics doses beyond available combination product also important asthma patients receive favourable reimbursement separate inhalers gsk believes appropriate labelling proactive communication risks using laba alone potential misuse serevent monotherapy acceptably reduced dual therapy using separate inhalers remains available asthma patients need september advisory committee meeting gsk submitted proposed label change fda serevent clarify use asthma patients must combination ics line prescribing information countries serevent marketed february fda proposed label changes labas requested plans communicating use healthcare providers updated information laba safety gsk working fda appropriate labelling communications protect interests patients suffer asthma update september june constructive discussions fda following agencys initial proposals february gsk implemented updated labeling labacontaining products accordance fdas directions labacontaining products updated labeling includes strengthened risk information recommendations intended promote safe use consistent gsks position fda allowed serevent single active ingredient inhaler containing salmeterol retain indication use treating asthma provided use without inhaled corticosteroid contraindicated fda also requiring clinical research potential approaches explored march advisory committee meeting consultations fda appropriate trial design ongoing fda also requiring risk evaluation management strategy includes updated medication guide use patients forthcoming communications plan educating prescribers strengthened risk information recommendations intended promote safe use back top home responsibility research practices patient safety performance corporate responsibility report performance continued improve patient safety systems safety databases monitoring processes examples include implementing first components safetyworks semiautomated software tool developed gsk enable rapid review safety information different sources safetyworks programme received bio award awarded first prize international society pharmaco epidemiology annual meeting expanding capabilities number users molecular clinical safety programme tool optimises safety medicines testing humans integrating chemistry preclinical human safety data developing hn pandemic planning including specific actions global clinical safety pharmacovigilance team take ensure evaluation reporting safety products pandemic escalates submitted plan key regulatory agencies developing automated causality assessment druginduced liver injury clinical trials speed improve liver safety assessments working others work government officials industry partners policymakers efforts build enhanced safety system example gsk industry lead patient safety project protect european commission 's publicprivate partnership innovative medicines initiative aims develop methodologies enhance assessment benefitrisk profile new medicines participate us food drug administration 's fda critical path initiative aims improve process evaluating safety efficacy new medicines member initiatives predictive safety testing consortium brings together pharmaceutical companies share validate safety testing methods guidance fda european medicines evaluation agency emea member executive scientific oversight committees cardiac safety research consortium uses principles critical path initiative focuses improving evaluation cardiac safety development new medicines gsk key partner among us food drug administration pharmaceutical companies academia us explore development new system detection adverse events benefits medicines using large healthcare system databases read collaborative research emerging technologies serious adverse events consortium cofounded serious adverse events consortium saec collaboration involving partners working improve patient safety identifying genetic variants predict adverse events gsk scientists cochair saec scientific management committee seat board directors saec 's initial research focused two reactions considered serious enough discontinue medication druginduced liver injury druginduced serious skin rashes stevensjohnson syndrome toxic epidermal necrolysis saec released data studies months launch consortium gsk contributed patient samples scientific expertise studies back tophome responsibility research practices patient safety performance corporate responsibility report performance continued improve patient safety systems safety databases monitoring processes examples include implementing first components safetyworks semiautomated software tool developed gsk enable rapid review safety information different sources safetyworks programme received bio award awarded first prize international society pharmaco epidemiology annual meeting expanding capabilities number users molecular clinical safety programme tool optimises safety medicines testing humans integrating chemistry preclinical human safety data developing hn pandemic planning including specific actions global clinical safety pharmacovigilance team take ensure evaluation reporting safety products pandemic escalates submitted plan key regulatory agencies developing automated causality assessment druginduced liver injury clinical trials speed improve liver safety assessments working others work government officials industry partners policymakers efforts build enhanced safety system example gsk industry lead patient safety project protect european commission 's publicprivate partnership innovative medicines initiative aims develop methodologies enhance assessment benefitrisk profile new medicines participate us food drug administration 's fda critical path initiative aims improve process evaluating safety efficacy new medicines member initiatives predictive safety testing consortium brings together pharmaceutical companies share validate safety testing methods guidance fda european medicines evaluation agency emea member executive scientific oversight committees cardiac safety research consortium uses principles critical path initiative focuses improving evaluation cardiac safety development new medicines gsk key partner among us food drug administration pharmaceutical companies academia us explore development new system detection adverse events benefits medicines using large healthcare system databases read collaborative research emerging technologies serious adverse events consortium cofounded serious adverse events consortium saec collaboration involving partners working improve patient safety identifying genetic variants predict adverse events gsk scientists cochair saec scientific management committee seat board directors saec 's initial research focused two reactions considered serious enough discontinue medication druginduced liver injury druginduced serious skin rashes stevensjohnson syndrome toxic epidermal necrolysis saec released data studies months launch consortium gsk contributed patient samples scientific expertise studies back top home responsibility research practices patient safety performance corporate responsibility report performance continued improve patient safety systems safety databases monitoring processes examples include implementing first components safetyworks semiautomated software tool developed gsk enable rapid review safety information different sources safetyworks programme received bio award awarded first prize international society pharmaco epidemiology annual meeting expanding capabilities number users molecular clinical safety programme tool optimises safety medicines testing humans integrating chemistry preclinical human safety data developing hn pandemic planning including specific actions global clinical safety pharmacovigilance team take ensure evaluation reporting safety products pandemic escalates submitted plan key regulatory agencies developing automated causality assessment druginduced liver injury clinical trials speed improve liver safety assessments working others work government officials industry partners policymakers efforts build enhanced safety system example gsk industry lead patient safety project protect european commission 's publicprivate partnership innovative medicines initiative aims develop methodologies enhance assessment benefitrisk profile new medicines participate us food drug administration 's fda critical path initiative aims improve process evaluating safety efficacy new medicines member initiatives predictive safety testing consortium brings together pharmaceutical companies share validate safety testing methods guidance fda european medicines evaluation agency emea member executive scientific oversight committees cardiac safety research consortium uses principles critical path initiative focuses improving evaluation cardiac safety development new medicines gsk key partner among us food drug administration pharmaceutical companies academia us explore development new system detection adverse events benefits medicines using large healthcare system databases read collaborative research emerging technologies serious adverse events consortium cofounded serious adverse events consortium saec collaboration involving partners working improve patient safety identifying genetic variants predict adverse events gsk scientists cochair saec scientific management committee seat board directors saec 's initial research focused two reactions considered serious enough discontinue medication druginduced liver injury druginduced serious skin rashes stevensjohnson syndrome toxic epidermal necrolysis saec released data studies months launch consortium gsk contributed patient samples scientific expertise studies back top home responsibility research practices working healthcare professionals corporate responsibility report working healthcare professionals policies governing interactions gsk rd staff healthcare practitioners require clinical trial investigators must selected solely qualifications conduct good quality clinical research history using using gsk products must taken account deciding whether include exclude particular trial payments practitioners governed contracts compensation reflects fair market value work performed services provided payments offered made influence judgement whether enrol maintain participant clinical study gifts healthcare professionals involved research projects gsk permitted also committed disclose research payments made healthcare professionals institutions start payments made us healthcare professionals institutions research studies begin january first disclosure made first quarter capture payments phases medicine discovery development including clinical trials extend disclosure payments healthcare professionals institutions outside us also publishing speaking consulting fees paid us healthcare professionals read policies monitoring systems govern relationships healthcare professionals back top home responsibility research practices working healthcare professionals corporate responsibility report working healthcare professionals policies governing interactions gsk rd staff healthcare practitioners require clinical trial investigators must selected solely qualifications conduct good quality clinical research history using using gsk products must taken account deciding whether include exclude particular trial payments practitioners governed contracts compensation reflects fair market value work performed services provided payments offered made influence judgement whether enrol maintain participant clinical study gifts healthcare professionals involved research projects gsk permitted also committed disclose research payments made healthcare professionals institutions start payments made us healthcare professionals institutions research studies begin january first disclosure made first quarter capture payments phases medicine discovery development including clinical trials extend disclosure payments healthcare professionals institutions outside us also publishing speaking consulting fees paid us healthcare professionals read policies monitoring systems govern relationships healthcare professionals back top home responsibility research practices case studies corporate responsibility report case studies raising standard clinical research india year around per cent cancer cases occur developing world onefifth million cases year india indox created partnership university oxford eight indian cancer centres gsk develop new better treatments cancer partnership focuses addressing cancer treatment needs specific india enables gsk access expertise conducting phase ii iii oncology trials indox provides infrastructure support research fellowships scientists clinicians india training courses promote leading research practices also enables scientists clinicians india visit oxford learn specific cancer types research techniques indox conducting phase ii iii trials common cancers particularly prevalent india partnership aims raise standard trial management indian centres match best world extended funding indox total gsk committed million support indox httpwwwindoxorguk gsk investigators meet thailand launched gsk investigator club brought together senior doctors involved gsk research projects asiathailand network share best research practices event designed communicate disclosure policy reinforce commitment innovative research inform regulatory developments attendees learned new tools detect medicine safety issues discussed ways improve quality research data sharing personal experiences dr yuppadee javroongrit head thai food drug administration described plans inspect trial sites thailand october gsk asia pacific medical director spoke medicine development new ways bring molecules market well importance transparency disclosure research protocols results back top home responsibility research practices case studies corporate responsibility report case studies raising standard clinical research india year around per cent cancer cases occur developing world onefifth million cases year india indox created partnership university oxford eight indian cancer centres gsk develop new better treatments cancer partnership focuses addressing cancer treatment needs specific india enables gsk access expertise conducting phase ii iii oncology trials indox provides infrastructure support research fellowships scientists clinicians india training courses promote leading research practices also enables scientists clinicians india visit oxford learn specific cancer types research techniques indox conducting phase ii iii trials common cancers particularly prevalent india partnership aims raise standard trial management indian centres match best world extended funding indox total gsk committed million support indox httpwwwindoxorguk gsk investigators meet thailand launched gsk investigator club brought together senior doctors involved gsk research projects asiathailand network share best research practices event designed communicate disclosure policy reinforce commitment innovative research inform regulatory developments attendees learned new tools detect medicine safety issues discussed ways improve quality research data sharing personal experiences dr yuppadee javroongrit head thai food drug administration described plans inspect trial sites thailand october gsk asia pacific medical director spoke medicine development new ways bring molecules market well importance transparency disclosure research protocols results back top home responsibility research practices qas corporate responsibility report qas respond questions raised stakeholders sure risks healthy volunteers take experimental medicines first time minimised clinical trial take place new compound must undergo series stringent laboratory tests tests involve use animals human tissue predict effects investigational medicine human body including potential side effects basis predictions establish dosing levels sufficient margin safety andor appropriate monitoring procedures 'preclinical ' data laboratory tests proposal design 'first time human ' clinical trial reviewed gsk committee known global safety board experienced senior physicians experts independent project team regulatory authorities independent ethics committees must approve trial go ahead clinical trials designed minimise risk example initially give volunteers low dose investigational medicine increase dosing gradually carefully sequenced among subgroups cautious approach trials investigational medicine tested humans first time conducted clinical units rapid access hospital emergency care clinical trial volunteers provided information study including potential risks opportunity discuss risks researchers deciding whether participate known informed consent entering research collaborations ensure organisations partner meet research animal welfare standards recognise working collaboration organisations brings certain risks developing routine safeguards ensure partners work according core principles gsk including govern use animals research checks applied evaluating whether enter collaboration subsequently ongoing basis within framework established govern collaboration typically joint steering committee gsks willingness enter continue collaboration depends adequate assurance shared commitment core principles gsk opened rd facility china affect research standards cost reduction exercise opened new rd facility china focusing rd neurodegenerative disorders better therapies desperately needed alzheimer 's disease parkinson 's disease multiple sclerosis costs conducting research china currently relativity lower markets however lower costs reason behind decision set new facility new centre enables us benefit accessing vast talent pool knowledge life sciences china increase focus depth important disease areas rd china conducted accordance gsk 's global quality ethical standards rd policies monitoring procedures apply operations china committed significant regional local resource ensuring operations china comply chinese government requirements gsk 's global standards home responsibility research practices qas corporate responsibility report qas respond questions raised stakeholders sure risks healthy volunteers take experimental medicines first time minimised clinical trial take place new compound must undergo series stringent laboratory tests tests involve use animals human tissue predict effects investigational medicine human body including potential side effects basis predictions establish dosing levels sufficient margin safety andor appropriate monitoring procedures 'preclinical ' data laboratory tests proposal design 'first time human ' clinical trial reviewed gsk committee known global safety board experienced senior physicians experts independent project team regulatory authorities independent ethics committees must approve trial go ahead clinical trials designed minimise risk example initially give volunteers low dose investigational medicine increase dosing gradually carefully sequenced among subgroups cautious approach trials investigational medicine tested humans first time conducted clinical units rapid access hospital emergency care clinical trial volunteers provided information study including potential risks opportunity discuss risks researchers deciding whether participate known informed consent entering research collaborations ensure organisations partner meet research animal welfare standards recognise working collaboration organisations brings certain risks developing routine safeguards ensure partners work according core principles gsk including govern use animals research checks applied evaluating whether enter collaboration subsequently ongoing basis within framework established govern collaboration typically joint steering committee gsks willingness enter continue collaboration depends adequate assurance shared commitment core principles gsk opened rd facility china affect research standards cost reduction exercise opened new rd facility china focusing rd neurodegenerative disorders better therapies desperately needed alzheimer 's disease parkinson 's disease multiple sclerosis costs conducting research china currently relativity lower markets however lower costs reason behind decision set new facility new centre enables us benefit accessing vast talent pool knowledge life sciences china increase focus depth important disease areas rd china conducted accordance gsk 's global quality ethical standards rd policies monitoring procedures apply operations china committed significant regional local resource ensuring operations china comply chinese government requirements gsk 's global standards home responsibility ethical conduct corporate responsibility report ethical conduct committed creating strong ethical culture gsk developing strong policies recruiting right people equipping information need make ethical decisions putting patients first core principle ethical pharmaceutical company profit without principle short lived failure uphold high standards ethical conduct carries significant business risk erosion trust gsk products including among regulators doctors patients fines litigation resulting serious financial legal consequences damage gsks reputation code conduct sets fundamental standards employees supported employee guide business conduct helps employees make ethical decisions emphasises gsks key values show respect people patient focused commit transparency always demonstrate highest integrity conduct stress commitment performance integrity means employees must understand values stand well policies procedures underpin approach internal compliance systems designed identify address breaches codes fully investigate suspected breaches take appropriate disciplinary action including dismissal appropriate gsk expanding presence emerging markets acquired number new businesses ethical risks also reviewed part due diligence process acquisitions take steps inform employees newly acquired businesses values ethical practices ethical compass employee guide business conduct includes ethical compass helps employees deal ethical issues difficult resolve faced situation encourage people ask questions legal ethical consistent gsk policy code conduct consistent gsks mission spirit explain family friends would comfortable appeared newspaper encourage employees seek additional guidance keep asking questions certain making right choice contents externally assured bureau veritas march home responsibility ethical conduct corporate responsibility report ethical conduct committed creating strong ethical culture gsk developing strong policies recruiting right people equipping information need make ethical decisions putting patients first core principle ethical pharmaceutical company profit without principle short lived failure uphold high standards ethical conduct carries significant business risk erosion trust gsk products including among regulators doctors patients fines litigation resulting serious financial legal consequences damage gsks reputation code conduct sets fundamental standards employees supported employee guide business conduct helps employees make ethical decisions emphasises gsks key values show respect people patient focused commit transparency always demonstrate highest integrity conduct stress commitment performance integrity means employees must understand values stand well policies procedures underpin approach internal compliance systems designed identify address breaches codes fully investigate suspected breaches take appropriate disciplinary action including dismissal appropriate gsk expanding presence emerging markets acquired number new businesses ethical risks also reviewed part due diligence process acquisitions take steps inform employees newly acquired businesses values ethical practices ethical compass employee guide business conduct includes ethical compass helps employees deal ethical issues difficult resolve faced situation encourage people ask questions legal ethical consistent gsk policy code conduct consistent gsks mission spirit explain family friends would comfortable appeared newspaper encourage employees seek additional guidance keep asking questions certain making right choice contents externally assured bureau veritas march home responsibility ethical conduct corporate responsibility report ethical conduct committed creating strong ethical culture gsk developing strong policies recruiting right people equipping information need make ethical decisions putting patients first core principle ethical pharmaceutical company profit without principle short lived failure uphold high standards ethical conduct carries significant business risk erosion trust gsk products including among regulators doctors patients fines litigation resulting serious financial legal consequences damage gsks reputation code conduct sets fundamental standards employees supported employee guide business conduct helps employees make ethical decisions emphasises gsks key values show respect people patient focused commit transparency always demonstrate highest integrity conduct stress commitment performance integrity means employees must understand values stand well policies procedures underpin approach internal compliance systems designed identify address breaches codes fully investigate suspected breaches take appropriate disciplinary action including dismissal appropriate gsk expanding presence emerging markets acquired number new businesses ethical risks also reviewed part due diligence process acquisitions take steps inform employees newly acquired businesses values ethical practices ethical compass employee guide business conduct includes ethical compass helps employees deal ethical issues difficult resolve faced situation encourage people ask questions legal ethical consistent gsk policy code conduct consistent gsks mission spirit explain family friends would comfortable appeared newspaper encourage employees seek additional guidance keep asking questions certain making right choice contents externally assured bureau veritas march home responsibility ethical conduct code conduct business ethics corporate responsibility report code conduct business ethics code conduct gsk code conduct applies employees contractors key requirements include conduct business honesty integrity professional manner protects gsks good public image reputation build relationships customers vendors suppliers fellow employees based trust treat individuals respect dignity conducting business become familiar comply legal requirements gsk policy procedures avoid activities could involve lead involvement unlawful practice harm gsks reputation image avoid actual potential conflicts interest gsk appearance thereof transactions read full code conduct employee guide business conduct employee guide business conduct builds code explains employees must meet requirements contains policies guidance ensure operate within letter spirit law maintain high standards ethical business behaviour guide emphasises importance good ethical conduct ensuring continued business growth success improving quality human life includes real life scenarios published new edition employee guide helps employees understand policies aligned values sample questions employee guide business conduct question recommended use particular agent foreign country reputation person gets things done agent operates hotel room staff tells guarantee us substantial reductions tax rates customs duties pay fee advance cash seems good true problem answer anything like strong signal need investigate conduct due diligence status agent guarantee results without explaining request advance cash payment red flags us foreign corrupt practices act similar laws could held responsible agent using cash pay bribes even know exactly laws prohibit bribes improper purpose including reduction taxes customs fees question vendor offers sell gsk product manager mailing list names individuals treated depression concerns purchase list answer yes many countries including us eu established strict laws protecting healthcare information identifies individual written authorisation individual usually required gsk receive information anticompetitive behaviour policy committed free open competition succeed company high quality competitiveness products talent commitment employees corrupt anti competitive behaviour undermines fair competition inhibits economic development bad economies business people policy anticompetitive behaviour covers issues mergers abuse monopoly powers resale price maintenance predatory pricing restrictive agreements practices sets standards behaviour expect employees agents consumer healthcare legal department developed training materials designed help relevant employees better understand principles competition law gsks commitment free open competition marketplace retail sales representatives required take training annually anyone dealing pricing required take competition law training preventing bribery corruption policy october updated policy preventing bribery corruption policy also applies gsk interactions government officials third parties working behalf revised policy strengthens rules regarding payments thirdparty services explains permissible activities prohibits political contributions clarifies position prohibition facilitation payments training new policy rolled across business trainthetrainer workshops provided guidance rollout countries date applying policies practice want business companies meet high ethical standards countries operate pursue business opportunities could undermine integrity reputation looking engage local contract manufacturing company one markets country supplying products partnership local company could enable us secure longterm supply agreements government sector local company identified confident awarded longterm supply agreements however enquired cost goods initially hesitant share information us following enquiries company revealed reason higher cost goods would normally expected local company needed make payments certain government officials secure contracts breaches anticorruption policy immediately terminated discussions company example corruption prevention training piloted new anticorruption training egypt mexico panama russia united arab emirates venezuela training uses scenarios help employees understand constitutes corrupt behaviour respond encounter work example scenario gsk negotiating government officials possible tender gsk vaccine course conversations one official innocently mentions ministers wife particular interest wellknown medical charity asks gsks representative whether company would interested making donation questions issues incident raise would respond question correct response serious risk contribution named charity would seen providing benefit official order procure favourable treatment tender prohibited law gsks policy bribery take form direct payment could also personal favour promise pay future indirect payment described scenario gsks representative advise official company operates global community partnerships programme corporate level decides gsks charitable work donations company makes contents externally assured bureau veritas march back tophome responsibility ethical conduct code conduct business ethics corporate responsibility report code conduct business ethics code conduct gsk code conduct applies employees contractors key requirements include conduct business honesty integrity professional manner protects gsks good public image reputation build relationships customers vendors suppliers fellow employees based trust treat individuals respect dignity conducting business become familiar comply legal requirements gsk policy procedures avoid activities could involve lead involvement unlawful practice harm gsks reputation image avoid actual potential conflicts interest gsk appearance thereof transactions read full code conduct employee guide business conduct employee guide business conduct builds code explains employees must meet requirements contains policies guidance ensure operate within letter spirit law maintain high standards ethical business behaviour guide emphasises importance good ethical conduct ensuring continued business growth success improving quality human life includes real life scenarios published new edition employee guide helps employees understand policies aligned values sample questions employee guide business conduct question recommended use particular agent foreign country reputation person gets things done agent operates hotel room staff tells guarantee us substantial reductions tax rates customs duties pay fee advance cash seems good true problem answer anything like strong signal need investigate conduct due diligence status agent guarantee results without explaining request advance cash payment red flags us foreign corrupt practices act similar laws could held responsible agent using cash pay bribes even know exactly laws prohibit bribes improper purpose including reduction taxes customs fees question vendor offers sell gsk product manager mailing list names individuals treated depression concerns purchase list answer yes many countries including us eu established strict laws protecting healthcare information identifies individual written authorisation individual usually required gsk receive information anticompetitive behaviour policy committed free open competition succeed company high quality competitiveness products talent commitment employees corrupt anti competitive behaviour undermines fair competition inhibits economic development bad economies business people policy anticompetitive behaviour covers issues mergers abuse monopoly powers resale price maintenance predatory pricing restrictive agreements practices sets standards behaviour expect employees agents consumer healthcare legal department developed training materials designed help relevant employees better understand principles competition law gsks commitment free open competition marketplace retail sales representatives required take training annually anyone dealing pricing required take competition law training preventing bribery corruption policy october updated policy preventing bribery corruption policy also applies gsk interactions government officials third parties working behalf revised policy strengthens rules regarding payments thirdparty services explains permissible activities prohibits political contributions clarifies position prohibition facilitation payments training new policy rolled across business trainthetrainer workshops provided guidance rollout countries date applying policies practice want business companies meet high ethical standards countries operate pursue business opportunities could undermine integrity reputation looking engage local contract manufacturing company one markets country supplying products partnership local company could enable us secure longterm supply agreements government sector local company identified confident awarded longterm supply agreements however enquired cost goods initially hesitant share information us following enquiries company revealed reason higher cost goods would normally expected local company needed make payments certain government officials secure contracts breaches anticorruption policy immediately terminated discussions company example corruption prevention training piloted new anticorruption training egypt mexico panama russia united arab emirates venezuela training uses scenarios help employees understand constitutes corrupt behaviour respond encounter work example scenario gsk negotiating government officials possible tender gsk vaccine course conversations one official innocently mentions ministers wife particular interest wellknown medical charity asks gsks representative whether company would interested making donation questions issues incident raise would respond question correct response serious risk contribution named charity would seen providing benefit official order procure favourable treatment tender prohibited law gsks policy bribery take form direct payment could also personal favour promise pay future indirect payment described scenario gsks representative advise official company operates global community partnerships programme corporate level decides gsks charitable work donations company makes contents externally assured bureau veritas march back tophome responsibility ethical conduct code conduct business ethics corporate responsibility report code conduct business ethics code conduct gsk code conduct applies employees contractors key requirements include conduct business honesty integrity professional manner protects gsks good public image reputation build relationships customers vendors suppliers fellow employees based trust treat individuals respect dignity conducting business become familiar comply legal requirements gsk policy procedures avoid activities could involve lead involvement unlawful practice harm gsks reputation image avoid actual potential conflicts interest gsk appearance thereof transactions read full code conduct employee guide business conduct employee guide business conduct builds code explains employees must meet requirements contains policies guidance ensure operate within letter spirit law maintain high standards ethical business behaviour guide emphasises importance good ethical conduct ensuring continued business growth success improving quality human life includes real life scenarios published new edition employee guide helps employees understand policies aligned values sample questions employee guide business conduct question recommended use particular agent foreign country reputation person gets things done agent operates hotel room staff tells guarantee us substantial reductions tax rates customs duties pay fee advance cash seems good true problem answer anything like strong signal need investigate conduct due diligence status agent guarantee results without explaining request advance cash payment red flags us foreign corrupt practices act similar laws could held responsible agent using cash pay bribes even know exactly laws prohibit bribes improper purpose including reduction taxes customs fees question vendor offers sell gsk product manager mailing list names individuals treated depression concerns purchase list answer yes many countries including us eu established strict laws protecting healthcare information identifies individual written authorisation individual usually required gsk receive information anticompetitive behaviour policy committed free open competition succeed company high quality competitiveness products talent commitment employees corrupt anti competitive behaviour undermines fair competition inhibits economic development bad economies business people policy anticompetitive behaviour covers issues mergers abuse monopoly powers resale price maintenance predatory pricing restrictive agreements practices sets standards behaviour expect employees agents consumer healthcare legal department developed training materials designed help relevant employees better understand principles competition law gsks commitment free open competition marketplace retail sales representatives required take training annually anyone dealing pricing required take competition law training preventing bribery corruption policy october updated policy preventing bribery corruption policy also applies gsk interactions government officials third parties working behalf revised policy strengthens rules regarding payments thirdparty services explains permissible activities prohibits political contributions clarifies position prohibition facilitation payments training new policy rolled across business trainthetrainer workshops provided guidance rollout countries date applying policies practice want business companies meet high ethical standards countries operate pursue business opportunities could undermine integrity reputation looking engage local contract manufacturing company one markets country supplying products partnership local company could enable us secure longterm supply agreements government sector local company identified confident awarded longterm supply agreements however enquired cost goods initially hesitant share information us following enquiries company revealed reason higher cost goods would normally expected local company needed make payments certain government officials secure contracts breaches anticorruption policy immediately terminated discussions company example corruption prevention training piloted new anticorruption training egypt mexico panama russia united arab emirates venezuela training uses scenarios help employees understand constitutes corrupt behaviour respond encounter work example scenario gsk negotiating government officials possible tender gsk vaccine course conversations one official innocently mentions ministers wife particular interest wellknown medical charity asks gsks representative whether company would interested making donation questions issues incident raise would respond question correct response serious risk contribution named charity would seen providing benefit official order procure favourable treatment tender prohibited law gsks policy bribery take form direct payment could also personal favour promise pay future indirect payment described scenario gsks representative advise official company operates global community partnerships programme corporate level decides gsks charitable work donations company makes contents externally assured bureau veritas march back top home responsibility ethical conduct code conduct business ethics corporate responsibility report code conduct business ethics code conduct gsk code conduct applies employees contractors key requirements include conduct business honesty integrity professional manner protects gsks good public image reputation build relationships customers vendors suppliers fellow employees based trust treat individuals respect dignity conducting business become familiar comply legal requirements gsk policy procedures avoid activities could involve lead involvement unlawful practice harm gsks reputation image avoid actual potential conflicts interest gsk appearance thereof transactions read full code conduct employee guide business conduct employee guide business conduct builds code explains employees must meet requirements contains policies guidance ensure operate within letter spirit law maintain high standards ethical business behaviour guide emphasises importance good ethical conduct ensuring continued business growth success improving quality human life includes real life scenarios published new edition employee guide helps employees understand policies aligned values sample questions employee guide business conduct question recommended use particular agent foreign country reputation person gets things done agent operates hotel room staff tells guarantee us substantial reductions tax rates customs duties pay fee advance cash seems good true problem answer anything like strong signal need investigate conduct due diligence status agent guarantee results without explaining request advance cash payment red flags us foreign corrupt practices act similar laws could held responsible agent using cash pay bribes even know exactly laws prohibit bribes improper purpose including reduction taxes customs fees question vendor offers sell gsk product manager mailing list names individuals treated depression concerns purchase list answer yes many countries including us eu established strict laws protecting healthcare information identifies individual written authorisation individual usually required gsk receive information anticompetitive behaviour policy committed free open competition succeed company high quality competitiveness products talent commitment employees corrupt anti competitive behaviour undermines fair competition inhibits economic development bad economies business people policy anticompetitive behaviour covers issues mergers abuse monopoly powers resale price maintenance predatory pricing restrictive agreements practices sets standards behaviour expect employees agents consumer healthcare legal department developed training materials designed help relevant employees better understand principles competition law gsks commitment free open competition marketplace retail sales representatives required take training annually anyone dealing pricing required take competition law training preventing bribery corruption policy october updated policy preventing bribery corruption policy also applies gsk interactions government officials third parties working behalf revised policy strengthens rules regarding payments thirdparty services explains permissible activities prohibits political contributions clarifies position prohibition facilitation payments training new policy rolled across business trainthetrainer workshops provided guidance rollout countries date applying policies practice want business companies meet high ethical standards countries operate pursue business opportunities could undermine integrity reputation looking engage local contract manufacturing company one markets country supplying products partnership local company could enable us secure longterm supply agreements government sector local company identified confident awarded longterm supply agreements however enquired cost goods initially hesitant share information us following enquiries company revealed reason higher cost goods would normally expected local company needed make payments certain government officials secure contracts breaches anticorruption policy immediately terminated discussions company example corruption prevention training piloted new anticorruption training egypt mexico panama russia united arab emirates venezuela training uses scenarios help employees understand constitutes corrupt behaviour respond encounter work example scenario gsk negotiating government officials possible tender gsk vaccine course conversations one official innocently mentions ministers wife particular interest wellknown medical charity asks gsks representative whether company would interested making donation questions issues incident raise would respond question correct response serious risk contribution named charity would seen providing benefit official order procure favourable treatment tender prohibited law gsks policy bribery take form direct payment could also personal favour promise pay future indirect payment described scenario gsks representative advise official company operates global community partnerships programme corporate level decides gsks charitable work donations company makes contents externally assured bureau veritas march back top home responsibility ethical conduct interactions healthcare professionals marketing ethics corporate responsibility report interactions healthcare professionals marketing ethics market prescription medicines vaccines healthcare professionals hospitals governments countries us also advertise medicines directly consumers specialist sales representatives meet regularly doctors pharmacists inform medicines approved uses believe sales representatives play important role providing uptodate information doctors products benefits risks patients however recognise marketing pharmaceutical products raises challenging issues particular people concerned marketing pharmaceutical companies exerts undue influence doctors sales representatives always give doctors full information potential sideeffects promotion unapproved uses medicines may occurring global marketing code forbids practices unethical conduct provide regular training sales teams monitor compliance marketing codes practice sale promotion pharmaceutical products highly regulated governments medical agencies addition revised global code promotional activities interactions healthcare professionals regional marketing codes set consistent standards employees agents commit us promotional practices ethical responsible principled patientcentred prohibit kickbacks bribery inducements doctors promotion unapproved uses medicines regional codes reflect differences market structures national healthcare systems regulations least stringent global code may restrictive gsk supports efforts strengthen marketing standards across pharmaceutical industry benefits us creating level playing field countries operate helps improve reputation pharmaceutical industry whole marketing codes practice summary information information provided approved uses medicine must based valid scientific evidence must accurate balanced fair objective unambiguous date items healthcare professionals must either educational assist patients administration treatment management condition reflect local customs accordance local laws regulations industry codes items given inducement prescribe medicines medical professionals retained consultants gsk hospitality meetings gsk must host meetings venues could reasonably perceived lavish extravagant business meeting must programme venue hospitality offer attracts delegates attend gsk invite delegates guests accompany pay guests costs grants decisions grants medical education reviewed qualified medical scientific personnel gsk never use grants donations charitable contributions inducement reward prescription products contents externally assured bureau veritas march back tophome responsibility ethical conduct interactions healthcare professionals marketing ethics corporate responsibility report interactions healthcare professionals marketing ethics market prescription medicines vaccines healthcare professionals hospitals governments countries us also advertise medicines directly consumers specialist sales representatives meet regularly doctors pharmacists inform medicines approved uses believe sales representatives play important role providing uptodate information doctors products benefits risks patients however recognise marketing pharmaceutical products raises challenging issues particular people concerned marketing pharmaceutical companies exerts undue influence doctors sales representatives always give doctors full information potential sideeffects promotion unapproved uses medicines may occurring global marketing code forbids practices unethical conduct provide regular training sales teams monitor compliance marketing codes practice sale promotion pharmaceutical products highly regulated governments medical agencies addition revised global code promotional activities interactions healthcare professionals regional marketing codes set consistent standards employees agents commit us promotional practices ethical responsible principled patientcentred prohibit kickbacks bribery inducements doctors promotion unapproved uses medicines regional codes reflect differences market structures national healthcare systems regulations least stringent global code may restrictive gsk supports efforts strengthen marketing standards across pharmaceutical industry benefits us creating level playing field countries operate helps improve reputation pharmaceutical industry whole marketing codes practice summary information information provided approved uses medicine must based valid scientific evidence must accurate balanced fair objective unambiguous date items healthcare professionals must either educational assist patients administration treatment management condition reflect local customs accordance local laws regulations industry codes items given inducement prescribe medicines medical professionals retained consultants gsk hospitality meetings gsk must host meetings venues could reasonably perceived lavish extravagant business meeting must programme venue hospitality offer attracts delegates attend gsk invite delegates guests accompany pay guests costs grants decisions grants medical education reviewed qualified medical scientific personnel gsk never use grants donations charitable contributions inducement reward prescription products contents externally assured bureau veritas march back top home responsibility ethical conduct interactions healthcare professionals marketing ethics corporate responsibility report interactions healthcare professionals marketing ethics market prescription medicines vaccines healthcare professionals hospitals governments countries us also advertise medicines directly consumers specialist sales representatives meet regularly doctors pharmacists inform medicines approved uses believe sales representatives play important role providing uptodate information doctors products benefits risks patients however recognise marketing pharmaceutical products raises challenging issues particular people concerned marketing pharmaceutical companies exerts undue influence doctors sales representatives always give doctors full information potential sideeffects promotion unapproved uses medicines may occurring global marketing code forbids practices unethical conduct provide regular training sales teams monitor compliance marketing codes practice sale promotion pharmaceutical products highly regulated governments medical agencies addition revised global code promotional activities interactions healthcare professionals regional marketing codes set consistent standards employees agents commit us promotional practices ethical responsible principled patientcentred prohibit kickbacks bribery inducements doctors promotion unapproved uses medicines regional codes reflect differences market structures national healthcare systems regulations least stringent global code may restrictive gsk supports efforts strengthen marketing standards across pharmaceutical industry benefits us creating level playing field countries operate helps improve reputation pharmaceutical industry whole marketing codes practice summary information information provided approved uses medicine must based valid scientific evidence must accurate balanced fair objective unambiguous date items healthcare professionals must either educational assist patients administration treatment management condition reflect local customs accordance local laws regulations industry codes items given inducement prescribe medicines medical professionals retained consultants gsk hospitality meetings gsk must host meetings venues could reasonably perceived lavish extravagant business meeting must programme venue hospitality offer attracts delegates attend gsk invite delegates guests accompany pay guests costs grants decisions grants medical education reviewed qualified medical scientific personnel gsk never use grants donations charitable contributions inducement reward prescription products contents externally assured bureau veritas march back top home responsibility ethical conduct marketing ethics interactions healthcare professionals corporate responsibility report interactions healthcare professionals approach performance plans doctors healthcare professionals hcps valuable partners gsk providing us scientific medical expertise insights patient care gsk makes payments healthcare professionals following circumstances medical education programmes provide funding physicians pharmacists nurses healthcare professionals attend education courses conferences therapeutic areas relevant gsk consider part marketing policies state content education programme must influenced gsk provider must independently approved sponsoring speakers provide funding healthcare professionals attend conferences present research results speak healthcare issues speakers must transparent gsks support attendance speaker advisory services pay healthcare professionals speak meetings disease therapy areas relevant gsk also engage healthcare professionals learn unmet medical needs developments science treatments helps us understand current future markets products engagement may take form convening advisory panels conducting broader market research services valuable gsk believe appropriate pay hcps time expertise help develop knowledge supporting attendance educational events conferences however interest external consultants work receive excessive funding gsk work company detract significantly time spend patients conducting research could reduce professional credibility value gsk independently sources current medical expertise payments hcps must reasonable fair market value payments must take account individuals speciality area level expertise amount time spends working gsk read engage healthcare professionals conduct medical research behalf regional practices policies processes governing relationships hcps vary region comply local laws industry practices meet exceed relevant industry organisation codes including international federation pharmaceutical manufacturers associations ifpma pharmaceutical research manufacturers america phrma european federation pharmaceutical industries associations efpia united states addition requirements global code us policies practices also include limit payments hcps speaker advisory fees restricted maximum year individual physician cap us healthcare professional consultants receive total fees less per year state reporting system payments hcps line legislative requirements several us states requirement gsk grants healthcarerelated groups including patient advocacy groups physician associations exceed per cent groups annual income speaker evaluation process hcps sponsored gsk regional medical scientists evaluate high frequency speakers provide feedback effectiveness compliance gsk speaker programmes policy speaker evaluations type conducted questions doctors offlabel uses products must referred medical information department number type referrals made individual sales representatives monitored help ensure representatives promoting offlabel uses us sales marketing practices fully aligned requirements us phrma code interactions healthcare professionals cases us policies exceed phrma code requirements europe europe updated code practice interactions hcps line new code promotion published european federation pharmaceutical industries associations code specifies use consultants gsk employees responsible selecting consultants must expertise authority evaluate whether consultant suitable meet identified business need real value gsk consultant required declare consultancy arrangements speaking publicly related issue samples product samples given limited numbers limited time reference local standards hcps familiarise new product replaces previous limits less restrictive specify quantity timeframe grants donations procedure grants financial donations health organisations states must involved grant donation used must receive service return addition grants donations may given health organisation response unsolicited request purposes healthcare research must offered given understanding recipient prescribe recommend products must documented published externally meet requirement amount grant recipient published gsks website grants donations individual hcps personal benefit permitted phase lv clinical studies studies conducted medicine use approved marketing clarified principles behind studies clearly setting terms gsk collaborative studies studies must commissioned inducement prescribe supply recommend medicines must clear scientific andor educational purpose must contract institution undertaking research trial protocol must reviewed approved ethics committee gsk rd medical personnel must approve supervise studies study results distributed investigators line publications policy asia pacific japan emerging markets regions code update newly acquired companies promotion marketing code reviewed revised effective substantive changes principle however addition global policy revised code includes following hcp fees country must set annual maximum limit cap fees paid individual hcp within country grants donations may provided response requests hcps institutions long provided offered exchange prescribing medicines commitment continue prescribing medicines grants donations given institutions associations hospitals rather individual hcps gsk must assured valid purpose grant donation get involved details implemented must receive service return future gsk aim obtain written permission relevant institutions associations hcps part agreements gsk annual disclosure details grants donations including value purpose summary level data published samples revised code continues require oversight distribution product samples samples must provided inducement prescribe additional clarity included specify samples provided hcps must limited number example x samples per year limited period time example x years product launch country maximum number samples per hcp maximum time set national codes else must defined local standard operating procedure example gsk australia updated approach strengthen controls product sample distribution sales representatives longer distribute samples directly healthcare professionals instead orders taken representatives samples delivered direct surgeries central warehouse gives us better oversight number samples given hcp improves security supports aim achieve highest levels professional standards market research market research collection analysis information collection methods must unbiased nonpromotional however subsequent use statistics information may promotional two phases must therefore kept distinct local guidance must available development market research materials must contravene code doubt materials must reviewed medical department ensure research process constitute promotion clinical study market research studies must clearly identified potential participants beyond code gsk works diligently reinforce values policies newly acquired businesses part integration process example completion acquisition ucb taiwan march integration phase focused training ucbs employees gsks policies procedures majority new employees sales marketing staff gsk acquired bmss business egypt pakistan saudi arabia staff including management sales marketing teams received training compliance awareness sessions promotion marketing codes gsk code conduct adverse event reporting acquisition stiefel laboratories gsk completed acquisition stiefel july creating unique dermatology business within gsk making gsk leading global dermatology company acquisition involved integration stiefel operations across gsk business units integration gsks local operating companies delivered training covering gsks code conduct key corporate policies including pharmacovigilance promotion marketing codes contents externally assured bureau veritas march back tophome responsibility ethical conduct marketing ethics interactions healthcare professionals corporate responsibility report interactions healthcare professionals approach performance plans doctors healthcare professionals hcps valuable partners gsk providing us scientific medical expertise insights patient care gsk makes payments healthcare professionals following circumstances medical education programmes provide funding physicians pharmacists nurses healthcare professionals attend education courses conferences therapeutic areas relevant gsk consider part marketing policies state content education programme must influenced gsk provider must independently approved sponsoring speakers provide funding healthcare professionals attend conferences present research results speak healthcare issues speakers must transparent gsks support attendance speaker advisory services pay healthcare professionals speak meetings disease therapy areas relevant gsk also engage healthcare professionals learn unmet medical needs developments science treatments helps us understand current future markets products engagement may take form convening advisory panels conducting broader market research services valuable gsk believe appropriate pay hcps time expertise help develop knowledge supporting attendance educational events conferences however interest external consultants work receive excessive funding gsk work company detract significantly time spend patients conducting research could reduce professional credibility value gsk independently sources current medical expertise payments hcps must reasonable fair market value payments must take account individuals speciality area level expertise amount time spends working gsk read engage healthcare professionals conduct medical research behalf regional practices policies processes governing relationships hcps vary region comply local laws industry practices meet exceed relevant industry organisation codes including international federation pharmaceutical manufacturers associations ifpma pharmaceutical research manufacturers america phrma european federation pharmaceutical industries associations efpia united states addition requirements global code us policies practices also include limit payments hcps speaker advisory fees restricted maximum year individual physician cap us healthcare professional consultants receive total fees less per year state reporting system payments hcps line legislative requirements several us states requirement gsk grants healthcarerelated groups including patient advocacy groups physician associations exceed per cent groups annual income speaker evaluation process hcps sponsored gsk regional medical scientists evaluate high frequency speakers provide feedback effectiveness compliance gsk speaker programmes policy speaker evaluations type conducted questions doctors offlabel uses products must referred medical information department number type referrals made individual sales representatives monitored help ensure representatives promoting offlabel uses us sales marketing practices fully aligned requirements us phrma code interactions healthcare professionals cases us policies exceed phrma code requirements europe europe updated code practice interactions hcps line new code promotion published european federation pharmaceutical industries associations code specifies use consultants gsk employees responsible selecting consultants must expertise authority evaluate whether consultant suitable meet identified business need real value gsk consultant required declare consultancy arrangements speaking publicly related issue samples product samples given limited numbers limited time reference local standards hcps familiarise new product replaces previous limits less restrictive specify quantity timeframe grants donations procedure grants financial donations health organisations states must involved grant donation used must receive service return addition grants donations may given health organisation response unsolicited request purposes healthcare research must offered given understanding recipient prescribe recommend products must documented published externally meet requirement amount grant recipient published gsks website grants donations individual hcps personal benefit permitted phase lv clinical studies studies conducted medicine use approved marketing clarified principles behind studies clearly setting terms gsk collaborative studies studies must commissioned inducement prescribe supply recommend medicines must clear scientific andor educational purpose must contract institution undertaking research trial protocol must reviewed approved ethics committee gsk rd medical personnel must approve supervise studies study results distributed investigators line publications policy asia pacific japan emerging markets regions code update newly acquired companies promotion marketing code reviewed revised effective substantive changes principle however addition global policy revised code includes following hcp fees country must set annual maximum limit cap fees paid individual hcp within country grants donations may provided response requests hcps institutions long provided offered exchange prescribing medicines commitment continue prescribing medicines grants donations given institutions associations hospitals rather individual hcps gsk must assured valid purpose grant donation get involved details implemented must receive service return future gsk aim obtain written permission relevant institutions associations hcps part agreements gsk annual disclosure details grants donations including value purpose summary level data published samples revised code continues require oversight distribution product samples samples must provided inducement prescribe additional clarity included specify samples provided hcps must limited number example x samples per year limited period time example x years product launch country maximum number samples per hcp maximum time set national codes else must defined local standard operating procedure example gsk australia updated approach strengthen controls product sample distribution sales representatives longer distribute samples directly healthcare professionals instead orders taken representatives samples delivered direct surgeries central warehouse gives us better oversight number samples given hcp improves security supports aim achieve highest levels professional standards market research market research collection analysis information collection methods must unbiased nonpromotional however subsequent use statistics information may promotional two phases must therefore kept distinct local guidance must available development market research materials must contravene code doubt materials must reviewed medical department ensure research process constitute promotion clinical study market research studies must clearly identified potential participants beyond code gsk works diligently reinforce values policies newly acquired businesses part integration process example completion acquisition ucb taiwan march integration phase focused training ucbs employees gsks policies procedures majority new employees sales marketing staff gsk acquired bmss business egypt pakistan saudi arabia staff including management sales marketing teams received training compliance awareness sessions promotion marketing codes gsk code conduct adverse event reporting acquisition stiefel laboratories gsk completed acquisition stiefel july creating unique dermatology business within gsk making gsk leading global dermatology company acquisition involved integration stiefel operations across gsk business units integration gsks local operating companies delivered training covering gsks code conduct key corporate policies including pharmacovigilance promotion marketing codes contents externally assured bureau veritas march back tophome responsibility ethical conduct marketing ethics interactions healthcare professionals corporate responsibility report interactions healthcare professionals approach performance plans doctors healthcare professionals hcps valuable partners gsk providing us scientific medical expertise insights patient care gsk makes payments healthcare professionals following circumstances medical education programmes provide funding physicians pharmacists nurses healthcare professionals attend education courses conferences therapeutic areas relevant gsk consider part marketing policies state content education programme must influenced gsk provider must independently approved sponsoring speakers provide funding healthcare professionals attend conferences present research results speak healthcare issues speakers must transparent gsks support attendance speaker advisory services pay healthcare professionals speak meetings disease therapy areas relevant gsk also engage healthcare professionals learn unmet medical needs developments science treatments helps us understand current future markets products engagement may take form convening advisory panels conducting broader market research services valuable gsk believe appropriate pay hcps time expertise help develop knowledge supporting attendance educational events conferences however interest external consultants work receive excessive funding gsk work company detract significantly time spend patients conducting research could reduce professional credibility value gsk independently sources current medical expertise payments hcps must reasonable fair market value payments must take account individuals speciality area level expertise amount time spends working gsk read engage healthcare professionals conduct medical research behalf regional practices policies processes governing relationships hcps vary region comply local laws industry practices meet exceed relevant industry organisation codes including international federation pharmaceutical manufacturers associations ifpma pharmaceutical research manufacturers america phrma european federation pharmaceutical industries associations efpia united states addition requirements global code us policies practices also include limit payments hcps speaker advisory fees restricted maximum year individual physician cap us healthcare professional consultants receive total fees less per year state reporting system payments hcps line legislative requirements several us states requirement gsk grants healthcarerelated groups including patient advocacy groups physician associations exceed per cent groups annual income speaker evaluation process hcps sponsored gsk regional medical scientists evaluate high frequency speakers provide feedback effectiveness compliance gsk speaker programmes policy speaker evaluations type conducted questions doctors offlabel uses products must referred medical information department number type referrals made individual sales representatives monitored help ensure representatives promoting offlabel uses us sales marketing practices fully aligned requirements us phrma code interactions healthcare professionals cases us policies exceed phrma code requirements europe europe updated code practice interactions hcps line new code promotion published european federation pharmaceutical industries associations code specifies use consultants gsk employees responsible selecting consultants must expertise authority evaluate whether consultant suitable meet identified business need real value gsk consultant required declare consultancy arrangements speaking publicly related issue samples product samples given limited numbers limited time reference local standards hcps familiarise new product replaces previous limits less restrictive specify quantity timeframe grants donations procedure grants financial donations health organisations states must involved grant donation used must receive service return addition grants donations may given health organisation response unsolicited request purposes healthcare research must offered given understanding recipient prescribe recommend products must documented published externally meet requirement amount grant recipient published gsks website grants donations individual hcps personal benefit permitted phase lv clinical studies studies conducted medicine use approved marketing clarified principles behind studies clearly setting terms gsk collaborative studies studies must commissioned inducement prescribe supply recommend medicines must clear scientific andor educational purpose must contract institution undertaking research trial protocol must reviewed approved ethics committee gsk rd medical personnel must approve supervise studies study results distributed investigators line publications policy asia pacific japan emerging markets regions code update newly acquired companies promotion marketing code reviewed revised effective substantive changes principle however addition global policy revised code includes following hcp fees country must set annual maximum limit cap fees paid individual hcp within country grants donations may provided response requests hcps institutions long provided offered exchange prescribing medicines commitment continue prescribing medicines grants donations given institutions associations hospitals rather individual hcps gsk must assured valid purpose grant donation get involved details implemented must receive service return future gsk aim obtain written permission relevant institutions associations hcps part agreements gsk annual disclosure details grants donations including value purpose summary level data published samples revised code continues require oversight distribution product samples samples must provided inducement prescribe additional clarity included specify samples provided hcps must limited number example x samples per year limited period time example x years product launch country maximum number samples per hcp maximum time set national codes else must defined local standard operating procedure example gsk australia updated approach strengthen controls product sample distribution sales representatives longer distribute samples directly healthcare professionals instead orders taken representatives samples delivered direct surgeries central warehouse gives us better oversight number samples given hcp improves security supports aim achieve highest levels professional standards market research market research collection analysis information collection methods must unbiased nonpromotional however subsequent use statistics information may promotional two phases must therefore kept distinct local guidance must available development market research materials must contravene code doubt materials must reviewed medical department ensure research process constitute promotion clinical study market research studies must clearly identified potential participants beyond code gsk works diligently reinforce values policies newly acquired businesses part integration process example completion acquisition ucb taiwan march integration phase focused training ucbs employees gsks policies procedures majority new employees sales marketing staff gsk acquired bmss business egypt pakistan saudi arabia staff including management sales marketing teams received training compliance awareness sessions promotion marketing codes gsk code conduct adverse event reporting acquisition stiefel laboratories gsk completed acquisition stiefel july creating unique dermatology business within gsk making gsk leading global dermatology company acquisition involved integration stiefel operations across gsk business units integration gsks local operating companies delivered training covering gsks code conduct key corporate policies including pharmacovigilance promotion marketing codes contents externally assured bureau veritas march back top home responsibility ethical conduct marketing ethics interactions healthcare professionals corporate responsibility report interactions healthcare professionals approach performance plans doctors healthcare professionals hcps valuable partners gsk providing us scientific medical expertise insights patient care gsk makes payments healthcare professionals following circumstances medical education programmes provide funding physicians pharmacists nurses healthcare professionals attend education courses conferences therapeutic areas relevant gsk consider part marketing policies state content education programme must influenced gsk provider must independently approved sponsoring speakers provide funding healthcare professionals attend conferences present research results speak healthcare issues speakers must transparent gsks support attendance speaker advisory services pay healthcare professionals speak meetings disease therapy areas relevant gsk also engage healthcare professionals learn unmet medical needs developments science treatments helps us understand current future markets products engagement may take form convening advisory panels conducting broader market research services valuable gsk believe appropriate pay hcps time expertise help develop knowledge supporting attendance educational events conferences however interest external consultants work receive excessive funding gsk work company detract significantly time spend patients conducting research could reduce professional credibility value gsk independently sources current medical expertise payments hcps must reasonable fair market value payments must take account individuals speciality area level expertise amount time spends working gsk read engage healthcare professionals conduct medical research behalf regional practices policies processes governing relationships hcps vary region comply local laws industry practices meet exceed relevant industry organisation codes including international federation pharmaceutical manufacturers associations ifpma pharmaceutical research manufacturers america phrma european federation pharmaceutical industries associations efpia united states addition requirements global code us policies practices also include limit payments hcps speaker advisory fees restricted maximum year individual physician cap us healthcare professional consultants receive total fees less per year state reporting system payments hcps line legislative requirements several us states requirement gsk grants healthcarerelated groups including patient advocacy groups physician associations exceed per cent groups annual income speaker evaluation process hcps sponsored gsk regional medical scientists evaluate high frequency speakers provide feedback effectiveness compliance gsk speaker programmes policy speaker evaluations type conducted questions doctors offlabel uses products must referred medical information department number type referrals made individual sales representatives monitored help ensure representatives promoting offlabel uses us sales marketing practices fully aligned requirements us phrma code interactions healthcare professionals cases us policies exceed phrma code requirements europe europe updated code practice interactions hcps line new code promotion published european federation pharmaceutical industries associations code specifies use consultants gsk employees responsible selecting consultants must expertise authority evaluate whether consultant suitable meet identified business need real value gsk consultant required declare consultancy arrangements speaking publicly related issue samples product samples given limited numbers limited time reference local standards hcps familiarise new product replaces previous limits less restrictive specify quantity timeframe grants donations procedure grants financial donations health organisations states must involved grant donation used must receive service return addition grants donations may given health organisation response unsolicited request purposes healthcare research must offered given understanding recipient prescribe recommend products must documented published externally meet requirement amount grant recipient published gsks website grants donations individual hcps personal benefit permitted phase lv clinical studies studies conducted medicine use approved marketing clarified principles behind studies clearly setting terms gsk collaborative studies studies must commissioned inducement prescribe supply recommend medicines must clear scientific andor educational purpose must contract institution undertaking research trial protocol must reviewed approved ethics committee gsk rd medical personnel must approve supervise studies study results distributed investigators line publications policy asia pacific japan emerging markets regions code update newly acquired companies promotion marketing code reviewed revised effective substantive changes principle however addition global policy revised code includes following hcp fees country must set annual maximum limit cap fees paid individual hcp within country grants donations may provided response requests hcps institutions long provided offered exchange prescribing medicines commitment continue prescribing medicines grants donations given institutions associations hospitals rather individual hcps gsk must assured valid purpose grant donation get involved details implemented must receive service return future gsk aim obtain written permission relevant institutions associations hcps part agreements gsk annual disclosure details grants donations including value purpose summary level data published samples revised code continues require oversight distribution product samples samples must provided inducement prescribe additional clarity included specify samples provided hcps must limited number example x samples per year limited period time example x years product launch country maximum number samples per hcp maximum time set national codes else must defined local standard operating procedure example gsk australia updated approach strengthen controls product sample distribution sales representatives longer distribute samples directly healthcare professionals instead orders taken representatives samples delivered direct surgeries central warehouse gives us better oversight number samples given hcp improves security supports aim achieve highest levels professional standards market research market research collection analysis information collection methods must unbiased nonpromotional however subsequent use statistics information may promotional two phases must therefore kept distinct local guidance must available development market research materials must contravene code doubt materials must reviewed medical department ensure research process constitute promotion clinical study market research studies must clearly identified potential participants beyond code gsk works diligently reinforce values policies newly acquired businesses part integration process example completion acquisition ucb taiwan march integration phase focused training ucbs employees gsks policies procedures majority new employees sales marketing staff gsk acquired bmss business egypt pakistan saudi arabia staff including management sales marketing teams received training compliance awareness sessions promotion marketing codes gsk code conduct adverse event reporting acquisition stiefel laboratories gsk completed acquisition stiefel july creating unique dermatology business within gsk making gsk leading global dermatology company acquisition involved integration stiefel operations across gsk business units integration gsks local operating companies delivered training covering gsks code conduct key corporate policies including pharmacovigilance promotion marketing codes contents externally assured bureau veritas march back top home responsibility ethical conduct marketing ethics interactions healthcare professionals corporate responsibility report interactions healthcare professionals approach performance plans global global code promotional activities revised extended include interactions healthcare professionals november brings together existing policies sets standards promotional activities interactions healthcare professionals gsk employees must follow revised code specifies gsk hire hcp consultants support attendance medical congresses conduct meetings contains guidelines specifying types gifts gsk offer hcps applies thirdparty companies advertise promote prescription supply sale administration distribution gsk products revised code represents common baseline gsks sales marketing practices defines gsk interacts healthcare professionals globally replace regional countrylevel codes may detailed restrictive payments hcps speaking advisory services payments hcps globally must reasonable fair market value us fair market value regulatory requirement mandated new phrma code however process calculating fair market value specified us regulators gsk commissioned consultant help us calculate fair market value payments hcps ensure meet best practice standards us done calculating hourly rates different specialisms using information several national wage surveys result research standard schedule fees hcps reduced need us negotiate hcps fees made payments consistent across business simplified process approving auditing payments fees vary according hcps speciality whether hcp local regional national speaker continued develop system disclosing fees pay hcps challenge payments managed locally reported centrally within gsk disclosure hcp must uniquely identified expenditures must captured reporting began disclose payments us see report aggregate hcp fees gsks europe emerging markets asia pacificjapan regions united states continuing medical education grants gsk funds continuing medical education provides hcps latest information disease prevention diagnosis management contributes higher quality decisionmaking better patient health outcomes announced new standards funding continuing medical education hcps ensure programmes result improved patient health gsk fund independent medical education programmes clearly designed close gaps patient care decided restrict funding academic medical centres affiliated teaching patient care institutions well nationallevel professional medical associations means longer fund medical education programmes offered commercial providers change means award fewer grants total amount spend grants affected payments healthcare practitioners february began publish quarterly reports educational grants donations make hcps us post news approved grants wwwusgskcom december began publish payments made hcps speaking advisory services initial publication covered payments made april june future reports published quarterly show cumulative yeartodate total payments calendar year gsks europe emerging markets asia pacificjapan regions publish summary level data second half relating hcp payments activities simplified updated us commercial practice policies cpps support marketing code fully aligned values language used simplified make easier employees understand policies mean practice worked us pharmaceutical industry association phrma develop changes code interactions healthcare professionals gsk certified compliance code first quarter guide sale marketing gsk pharmaceutical products us aligned codes phrma code europe europe updated code practice interactions hcps line new code promotion published european federation pharmaceutical industries associations european country codes updated reflect changes european code gsks emerging markets asia pacific regions undertook routine review update promotion marketing code gsks emerging markets asia pacific regions formerly called international revised code implemented substantive changes required gsk continues focus internally educating levels management importance ethical decision making example management meeting russian business covered approaches ensuring compliance tools making ethical decisions monitoring appropriate reporting unethical cases contents externally assured bureau veritas march back tophome responsibility ethical conduct marketing ethics interactions healthcare professionals corporate responsibility report interactions healthcare professionals approach performance plans global global code promotional activities revised extended include interactions healthcare professionals november brings together existing policies sets standards promotional activities interactions healthcare professionals gsk employees must follow revised code specifies gsk hire hcp consultants support attendance medical congresses conduct meetings contains guidelines specifying types gifts gsk offer hcps applies thirdparty companies advertise promote prescription supply sale administration distribution gsk products revised code represents common baseline gsks sales marketing practices defines gsk interacts healthcare professionals globally replace regional countrylevel codes may detailed restrictive payments hcps speaking advisory services payments hcps globally must reasonable fair market value us fair market value regulatory requirement mandated new phrma code however process calculating fair market value specified us regulators gsk commissioned consultant help us calculate fair market value payments hcps ensure meet best practice standards us done calculating hourly rates different specialisms using information several national wage surveys result research standard schedule fees hcps reduced need us negotiate hcps fees made payments consistent across business simplified process approving auditing payments fees vary according hcps speciality whether hcp local regional national speaker continued develop system disclosing fees pay hcps challenge payments managed locally reported centrally within gsk disclosure hcp must uniquely identified expenditures must captured reporting began disclose payments us see report aggregate hcp fees gsks europe emerging markets asia pacificjapan regions united states continuing medical education grants gsk funds continuing medical education provides hcps latest information disease prevention diagnosis management contributes higher quality decisionmaking better patient health outcomes announced new standards funding continuing medical education hcps ensure programmes result improved patient health gsk fund independent medical education programmes clearly designed close gaps patient care decided restrict funding academic medical centres affiliated teaching patient care institutions well nationallevel professional medical associations means longer fund medical education programmes offered commercial providers change means award fewer grants total amount spend grants affected payments healthcare practitioners february began publish quarterly reports educational grants donations make hcps us post news approved grants wwwusgskcom december began publish payments made hcps speaking advisory services initial publication covered payments made april june future reports published quarterly show cumulative yeartodate total payments calendar year gsks europe emerging markets asia pacificjapan regions publish summary level data second half relating hcp payments activities simplified updated us commercial practice policies cpps support marketing code fully aligned values language used simplified make easier employees understand policies mean practice worked us pharmaceutical industry association phrma develop changes code interactions healthcare professionals gsk certified compliance code first quarter guide sale marketing gsk pharmaceutical products us aligned codes phrma code europe europe updated code practice interactions hcps line new code promotion published european federation pharmaceutical industries associations european country codes updated reflect changes european code gsks emerging markets asia pacific regions undertook routine review update promotion marketing code gsks emerging markets asia pacific regions formerly called international revised code implemented substantive changes required gsk continues focus internally educating levels management importance ethical decision making example management meeting russian business covered approaches ensuring compliance tools making ethical decisions monitoring appropriate reporting unethical cases contents externally assured bureau veritas march back top home responsibility ethical conduct marketing ethics interactions healthcare professionals corporate responsibility report interactions healthcare professionals approach performance plans global global code promotional activities revised extended include interactions healthcare professionals november brings together existing policies sets standards promotional activities interactions healthcare professionals gsk employees must follow revised code specifies gsk hire hcp consultants support attendance medical congresses conduct meetings contains guidelines specifying types gifts gsk offer hcps applies thirdparty companies advertise promote prescription supply sale administration distribution gsk products revised code represents common baseline gsks sales marketing practices defines gsk interacts healthcare professionals globally replace regional countrylevel codes may detailed restrictive payments hcps speaking advisory services payments hcps globally must reasonable fair market value us fair market value regulatory requirement mandated new phrma code however process calculating fair market value specified us regulators gsk commissioned consultant help us calculate fair market value payments hcps ensure meet best practice standards us done calculating hourly rates different specialisms using information several national wage surveys result research standard schedule fees hcps reduced need us negotiate hcps fees made payments consistent across business simplified process approving auditing payments fees vary according hcps speciality whether hcp local regional national speaker continued develop system disclosing fees pay hcps challenge payments managed locally reported centrally within gsk disclosure hcp must uniquely identified expenditures must captured reporting began disclose payments us see report aggregate hcp fees gsks europe emerging markets asia pacificjapan regions united states continuing medical education grants gsk funds continuing medical education provides hcps latest information disease prevention diagnosis management contributes higher quality decisionmaking better patient health outcomes announced new standards funding continuing medical education hcps ensure programmes result improved patient health gsk fund independent medical education programmes clearly designed close gaps patient care decided restrict funding academic medical centres affiliated teaching patient care institutions well nationallevel professional medical associations means longer fund medical education programmes offered commercial providers change means award fewer grants total amount spend grants affected payments healthcare practitioners february began publish quarterly reports educational grants donations make hcps us post news approved grants wwwusgskcom december began publish payments made hcps speaking advisory services initial publication covered payments made april june future reports published quarterly show cumulative yeartodate total payments calendar year gsks europe emerging markets asia pacificjapan regions publish summary level data second half relating hcp payments activities simplified updated us commercial practice policies cpps support marketing code fully aligned values language used simplified make easier employees understand policies mean practice worked us pharmaceutical industry association phrma develop changes code interactions healthcare professionals gsk certified compliance code first quarter guide sale marketing gsk pharmaceutical products us aligned codes phrma code europe europe updated code practice interactions hcps line new code promotion published european federation pharmaceutical industries associations european country codes updated reflect changes european code gsks emerging markets asia pacific regions undertook routine review update promotion marketing code gsks emerging markets asia pacific regions formerly called international revised code implemented substantive changes required gsk continues focus internally educating levels management importance ethical decision making example management meeting russian business covered approaches ensuring compliance tools making ethical decisions monitoring appropriate reporting unethical cases contents externally assured bureau veritas march back top home responsibility ethical conduct marketing ethics directtoconsumer advertising corporate responsibility report directtoconsumer advertising approach performance us legal advertise prescription medicines consumers television print advertisements known directtoconsumer dtc advertising new zealand bangladesh south korea also allow limited dtc advertising markets allow limited advertising select vaccines dtc advertising prescription medicines permitted markets promoting use prescription medicines directly consumers raise concerns critics believe encourages people request unnecessary treatment adding burden healthcare systems believe responsible pharmaceutical advertising useful source health information patients helps increase knowledge conditions educates patients treatment options countries us dtc advertising common industry practice would competitive disadvantage promote products way patients must still consult physicians condition appropriateness prescription medicine obtain consent receiving medicines prescription medicines us dtc communications policy based phrma guiding principles direct consumer advertisements prescription medicines detailed approval process dtc advertising includes review legal regulatory medical specialists appropriate trained us marketing employees dtc policy new dtc television advertisements submitted us food drug administration fda review comment prior broadcast members public healthcare professionals send comments complaints dtc advertising phrmas office accountability reports comments responses companies fda fund diseaseawareness campaigns designed increase understanding specific disease linked promotion gsk products also governed dtc policy diseaseawareness campaigns include television print advertisements direct mail mention specific gsk products make people aware treatments available condition encourage see doctor campaign materials branded indicate produced gsk principles dtc advertising us policy requires dtc advertising dedicate appropriate amount time educating healthcare professionals prior initiating dtc promotion new medicine new therapeutic indication approved medicine designed educate public medicine condition prescribed accurate supported evidence include information risks benefits treatments provide information treatment options diet lifestyle changes referenced prescribing information product targeted audience least per cent adults overthecounter medicines consumer healthcare products advertising overthecounter medicines oral healthcare nutritional products governed national regulations codes practice advertising overthecounter medicines also promoted pharmacists doctors dentists sales teams belong consumer healthcare products association us comply code advertising practices nonprescription medicines gsk consumer healthcare advertising reviewed copy review committees larger markets medical legal personnel smaller markets publication ensure meets standards advertising children guidelines advertising children prohibit advertising designed appeal targeted children legally mandated minimum age example comply guidelines uk buy advertising space childrens media supply vending machines primary schools sports star sponsorship important brands lucozade sport guidelines state people set appropriate example used sponsorship appeal solely children age contents externally assured bureau veritas march back tophome responsibility ethical conduct marketing ethics directtoconsumer advertising corporate responsibility report directtoconsumer advertising approach performance us legal advertise prescription medicines consumers television print advertisements known directtoconsumer dtc advertising new zealand bangladesh south korea also allow limited dtc advertising markets allow limited advertising select vaccines dtc advertising prescription medicines permitted markets promoting use prescription medicines directly consumers raise concerns critics believe encourages people request unnecessary treatment adding burden healthcare systems believe responsible pharmaceutical advertising useful source health information patients helps increase knowledge conditions educates patients treatment options countries us dtc advertising common industry practice would competitive disadvantage promote products way patients must still consult physicians condition appropriateness prescription medicine obtain consent receiving medicines prescription medicines us dtc communications policy based phrma guiding principles direct consumer advertisements prescription medicines detailed approval process dtc advertising includes review legal regulatory medical specialists appropriate trained us marketing employees dtc policy new dtc television advertisements submitted us food drug administration fda review comment prior broadcast members public healthcare professionals send comments complaints dtc advertising phrmas office accountability reports comments responses companies fda fund diseaseawareness campaigns designed increase understanding specific disease linked promotion gsk products also governed dtc policy diseaseawareness campaigns include television print advertisements direct mail mention specific gsk products make people aware treatments available condition encourage see doctor campaign materials branded indicate produced gsk principles dtc advertising us policy requires dtc advertising dedicate appropriate amount time educating healthcare professionals prior initiating dtc promotion new medicine new therapeutic indication approved medicine designed educate public medicine condition prescribed accurate supported evidence include information risks benefits treatments provide information treatment options diet lifestyle changes referenced prescribing information product targeted audience least per cent adults overthecounter medicines consumer healthcare products advertising overthecounter medicines oral healthcare nutritional products governed national regulations codes practice advertising overthecounter medicines also promoted pharmacists doctors dentists sales teams belong consumer healthcare products association us comply code advertising practices nonprescription medicines gsk consumer healthcare advertising reviewed copy review committees larger markets medical legal personnel smaller markets publication ensure meets standards advertising children guidelines advertising children prohibit advertising designed appeal targeted children legally mandated minimum age example comply guidelines uk buy advertising space childrens media supply vending machines primary schools sports star sponsorship important brands lucozade sport guidelines state people set appropriate example used sponsorship appeal solely children age contents externally assured bureau veritas march back top home responsibility ethical conduct marketing ethics directtoconsumer advertising corporate responsibility report directtoconsumer advertising approach performance us legal advertise prescription medicines consumers television print advertisements known directtoconsumer dtc advertising new zealand bangladesh south korea also allow limited dtc advertising markets allow limited advertising select vaccines dtc advertising prescription medicines permitted markets promoting use prescription medicines directly consumers raise concerns critics believe encourages people request unnecessary treatment adding burden healthcare systems believe responsible pharmaceutical advertising useful source health information patients helps increase knowledge conditions educates patients treatment options countries us dtc advertising common industry practice would competitive disadvantage promote products way patients must still consult physicians condition appropriateness prescription medicine obtain consent receiving medicines prescription medicines us dtc communications policy based phrma guiding principles direct consumer advertisements prescription medicines detailed approval process dtc advertising includes review legal regulatory medical specialists appropriate trained us marketing employees dtc policy new dtc television advertisements submitted us food drug administration fda review comment prior broadcast members public healthcare professionals send comments complaints dtc advertising phrmas office accountability reports comments responses companies fda fund diseaseawareness campaigns designed increase understanding specific disease linked promotion gsk products also governed dtc policy diseaseawareness campaigns include television print advertisements direct mail mention specific gsk products make people aware treatments available condition encourage see doctor campaign materials branded indicate produced gsk principles dtc advertising us policy requires dtc advertising dedicate appropriate amount time educating healthcare professionals prior initiating dtc promotion new medicine new therapeutic indication approved medicine designed educate public medicine condition prescribed accurate supported evidence include information risks benefits treatments provide information treatment options diet lifestyle changes referenced prescribing information product targeted audience least per cent adults overthecounter medicines consumer healthcare products advertising overthecounter medicines oral healthcare nutritional products governed national regulations codes practice advertising overthecounter medicines also promoted pharmacists doctors dentists sales teams belong consumer healthcare products association us comply code advertising practices nonprescription medicines gsk consumer healthcare advertising reviewed copy review committees larger markets medical legal personnel smaller markets publication ensure meets standards advertising children guidelines advertising children prohibit advertising designed appeal targeted children legally mandated minimum age example comply guidelines uk buy advertising space childrens media supply vending machines primary schools sports star sponsorship important brands lucozade sport guidelines state people set appropriate example used sponsorship appeal solely children age contents externally assured bureau veritas march back top home responsibility ethical conduct marketing ethics directtoconsumer advertising corporate responsibility report directtoconsumer advertising approach performance us pharmaceuticals business received three notices violation fdas division drug marketing advertising communications ddmac case immediately stopped advertisements still running retrained marketing staff required first february related television advertisement product avodart ddmac felt presented misleading suggestion superiority drug therapies overstated avodarts efficacy advertisement aired march september longer use time letter received took additional precaution discontinuing many avodart promotional materials revised marketing plan drug march ddmac wrote gsk regarding online banner advertisement treximet fda felt banner gave insufficient prominence safety information disclaimer text responded creating applying improved standards presentation safety information future gsk banner advertisements also march gsk one companies approached ddmac regarding paid online search listings known sponsored links fda felt sponsored links avandia avandamet avandaryl avodart coreg tykerb product indications described briefly product names prominent created applied standards sponsored links prohibit use brand name intended use within link also prohibited sponsored links products carry boxed warning indicating risk serious sideeffects two gsks commercial partners received similar letters regarding brands promote together case gsk corresponded fda believe complied requests take directions provided us fda seriously developing new standard operating procedures help ensure fda requirements reflected future advertising received one comment phrma office accountability relating television advertisement regarding product gsk copromotes comment addressed letter copromotion partner phrma contents externally assured bureau veritas march back top home responsibility ethical conduct marketing ethics directtoconsumer advertising corporate responsibility report directtoconsumer advertising approach performance us pharmaceuticals business received three notices violation fdas division drug marketing advertising communications ddmac case immediately stopped advertisements still running retrained marketing staff required first february related television advertisement product avodart ddmac felt presented misleading suggestion superiority drug therapies overstated avodarts efficacy advertisement aired march september longer use time letter received took additional precaution discontinuing many avodart promotional materials revised marketing plan drug march ddmac wrote gsk regarding online banner advertisement treximet fda felt banner gave insufficient prominence safety information disclaimer text responded creating applying improved standards presentation safety information future gsk banner advertisements also march gsk one companies approached ddmac regarding paid online search listings known sponsored links fda felt sponsored links avandia avandamet avandaryl avodart coreg tykerb product indications described briefly product names prominent created applied standards sponsored links prohibit use brand name intended use within link also prohibited sponsored links products carry boxed warning indicating risk serious sideeffects two gsks commercial partners received similar letters regarding brands promote together case gsk corresponded fda believe complied requests take directions provided us fda seriously developing new standard operating procedures help ensure fda requirements reflected future advertising received one comment phrma office accountability relating television advertisement regarding product gsk copromotes comment addressed letter copromotion partner phrma contents externally assured bureau veritas march back top home responsibility ethical conduct training awareness corporate responsibility report training awareness training awareness programmes help employees understand importance ethical conduct apply policies practice hiring new recruits carry extensive preemployment checks ensure share gsks values includes asking questions ethics integrity interviews gsks values patient focused show respect people commit transparency always demonstrate highest integrity conduct expect employees live gsk values reinforced relaunched employee guide business conduct senior leaders meetings employee broadcasts regular training courses also emphasise key ethics integrity messages example gsk unwavering commitment conducting business integrity full compliance law every gsk employee personally professionally responsible helping gsk maintain organisational integrity good reputation profits without principles short lived faced difficult ethical situations reference ethical decisionmaking model legal consistent company policy consistent gsk values code conduct explain family friends would comfortable printed newspaper corporate ethics compliance intranet contains links company policies ethics compliance training new recruits ethical decisionmaking model ethics quiz contact details compliance officers free phone numbers global confidential reporting line us integrity helpline employees also get advice guidance manager human resources legal departments local compliance officers champions read reporting channels ethical issues new employees uk us complete induction training code conduct available intranet also train new general managers site directors compliance responsibilities well wider monitoring compliance arrangements gsk annual management certification programme requires managers confirm comply ethics policies managers access three elearning modules ethical leadership company intranet specialised training provided employees working rd manufacturing sales marketing additional regulatory requirements training employees working sales marketing includes induction training testing marketing code practice detailed training sales representatives medicines promote diseases designed treat regular refresher courses held least year regular management updates risk management compliance boards europe emerging markets asia pacific regions us types unethical conduct detected disciplinary actions taken provide extra training guidance employees committing minor breaches prevent committing serious breaches future ethics training practice ethics training helps employees make right decisions apply policies practice run ethical decisionmaking training employees leaders explores ethical dilemmas may face work provides guidance help understand appropriate response one example ethical dilemma attending family dinner party uncle interested career asks current work particularly interested progress phase iii clinical trials drug considerable involvement sections gsks code conduct polgsk help make decision act situation share summary latest trial results information uncle without giving specifics b share information places gsk positive light c invite uncle visit gsk website see interesting pipeline information published discuss public information acceptable answer c contents externally assured bureau veritas march back tophome responsibility ethical conduct training awareness corporate responsibility report training awareness training awareness programmes help employees understand importance ethical conduct apply policies practice hiring new recruits carry extensive preemployment checks ensure share gsks values includes asking questions ethics integrity interviews gsks values patient focused show respect people commit transparency always demonstrate highest integrity conduct expect employees live gsk values reinforced relaunched employee guide business conduct senior leaders meetings employee broadcasts regular training courses also emphasise key ethics integrity messages example gsk unwavering commitment conducting business integrity full compliance law every gsk employee personally professionally responsible helping gsk maintain organisational integrity good reputation profits without principles short lived faced difficult ethical situations reference ethical decisionmaking model legal consistent company policy consistent gsk values code conduct explain family friends would comfortable printed newspaper corporate ethics compliance intranet contains links company policies ethics compliance training new recruits ethical decisionmaking model ethics quiz contact details compliance officers free phone numbers global confidential reporting line us integrity helpline employees also get advice guidance manager human resources legal departments local compliance officers champions read reporting channels ethical issues new employees uk us complete induction training code conduct available intranet also train new general managers site directors compliance responsibilities well wider monitoring compliance arrangements gsk annual management certification programme requires managers confirm comply ethics policies managers access three elearning modules ethical leadership company intranet specialised training provided employees working rd manufacturing sales marketing additional regulatory requirements training employees working sales marketing includes induction training testing marketing code practice detailed training sales representatives medicines promote diseases designed treat regular refresher courses held least year regular management updates risk management compliance boards europe emerging markets asia pacific regions us types unethical conduct detected disciplinary actions taken provide extra training guidance employees committing minor breaches prevent committing serious breaches future ethics training practice ethics training helps employees make right decisions apply policies practice run ethical decisionmaking training employees leaders explores ethical dilemmas may face work provides guidance help understand appropriate response one example ethical dilemma attending family dinner party uncle interested career asks current work particularly interested progress phase iii clinical trials drug considerable involvement sections gsks code conduct polgsk help make decision act situation share summary latest trial results information uncle without giving specifics b share information places gsk positive light c invite uncle visit gsk website see interesting pipeline information published discuss public information acceptable answer c contents externally assured bureau veritas march back top home responsibility ethical conduct training awareness corporate responsibility report training awareness training awareness programmes help employees understand importance ethical conduct apply policies practice hiring new recruits carry extensive preemployment checks ensure share gsks values includes asking questions ethics integrity interviews gsks values patient focused show respect people commit transparency always demonstrate highest integrity conduct expect employees live gsk values reinforced relaunched employee guide business conduct senior leaders meetings employee broadcasts regular training courses also emphasise key ethics integrity messages example gsk unwavering commitment conducting business integrity full compliance law every gsk employee personally professionally responsible helping gsk maintain organisational integrity good reputation profits without principles short lived faced difficult ethical situations reference ethical decisionmaking model legal consistent company policy consistent gsk values code conduct explain family friends would comfortable printed newspaper corporate ethics compliance intranet contains links company policies ethics compliance training new recruits ethical decisionmaking model ethics quiz contact details compliance officers free phone numbers global confidential reporting line us integrity helpline employees also get advice guidance manager human resources legal departments local compliance officers champions read reporting channels ethical issues new employees uk us complete induction training code conduct available intranet also train new general managers site directors compliance responsibilities well wider monitoring compliance arrangements gsk annual management certification programme requires managers confirm comply ethics policies managers access three elearning modules ethical leadership company intranet specialised training provided employees working rd manufacturing sales marketing additional regulatory requirements training employees working sales marketing includes induction training testing marketing code practice detailed training sales representatives medicines promote diseases designed treat regular refresher courses held least year regular management updates risk management compliance boards europe emerging markets asia pacific regions us types unethical conduct detected disciplinary actions taken provide extra training guidance employees committing minor breaches prevent committing serious breaches future ethics training practice ethics training helps employees make right decisions apply policies practice run ethical decisionmaking training employees leaders explores ethical dilemmas may face work provides guidance help understand appropriate response one example ethical dilemma attending family dinner party uncle interested career asks current work particularly interested progress phase iii clinical trials drug considerable involvement sections gsks code conduct polgsk help make decision act situation share summary latest trial results information uncle without giving specifics b share information places gsk positive light c invite uncle visit gsk website see interesting pipeline information published discuss public information acceptable answer c contents externally assured bureau veritas march back top home responsibility ethical conduct training awareness leading example corporate responsibility report leading example senior managers expected lead example complying company policies supporting staff reinforced annually formal management certification business ethics managers confirm understanding compliance company policies contained employee guide business conduct programme covers managers worldwide management certification promotes awareness gsks ethical standards company policies emphasises important role managers play embedding ethical culture ensuring employees understand apply policies full certification statement understand gsk committed principle performance integrity particular ensuring activities comply applicable laws received copy access gsk code conduct polgsk standards conduct stdgsk gsk corporate policies corporate policy index accessible corporate ethics compliance community read understand employee guide business conduct accessible corporate ethics compliance community complied applicable laws regulations gsk corporate local policies procedures understand responsibility promptly report actual suspected violations law regulations gsk corporate local policies procedures reported actual potential compliance issues aware concerning legal requirements company policies following statements also applicable supervisors personnel management responsibility people supervision received copies access gsk code conduct applicable gsk policies informed responsibilities put place appropriate measures ensure people supervision comply applicable laws regulations gsk corporate local policies procedures working behalf gsk new hire employees supervision completed scheduled complete gsk corporate ethics compliance new hire training programme gsk induction corporate ethics compliance community read understood shall comply fully policies procedures specified learning activity belgium france germany management certification wording adjusted comply local laws contents externally assured bureau veritas march home responsibility ethical conduct training awareness leading example corporate responsibility report leading example senior managers expected lead example complying company policies supporting staff reinforced annually formal management certification business ethics managers confirm understanding compliance company policies contained employee guide business conduct programme covers managers worldwide management certification promotes awareness gsks ethical standards company policies emphasises important role managers play embedding ethical culture ensuring employees understand apply policies full certification statement understand gsk committed principle performance integrity particular ensuring activities comply applicable laws received copy access gsk code conduct polgsk standards conduct stdgsk gsk corporate policies corporate policy index accessible corporate ethics compliance community read understand employee guide business conduct accessible corporate ethics compliance community complied applicable laws regulations gsk corporate local policies procedures understand responsibility promptly report actual suspected violations law regulations gsk corporate local policies procedures reported actual potential compliance issues aware concerning legal requirements company policies following statements also applicable supervisors personnel management responsibility people supervision received copies access gsk code conduct applicable gsk policies informed responsibilities put place appropriate measures ensure people supervision comply applicable laws regulations gsk corporate local policies procedures working behalf gsk new hire employees supervision completed scheduled complete gsk corporate ethics compliance new hire training programme gsk induction corporate ethics compliance community read understood shall comply fully policies procedures specified learning activity belgium france germany management certification wording adjusted comply local laws contents externally assured bureau veritas march home responsibility ethical conduct training awareness corporate responsibility report training awareness performance global training awareness activity included globally sales marketing staff required undertake annual refresher training promotion marketing codes example extent training undertaken us employees contractors completed compliance refresher training training new employees completed people launched redesigned training curriculum new us pharmaceuticals field sales employees integrates training ethical commercial practices sales training rather providing standalone modules also added ethics section employee manual commercial policies help employees make right decisions commercial interactions managers completed selfcertification process raised awareness global confidential reporting line reporting possible breaches policies extensive poster campaign awareness programmes intranet confidential reporting phone line available countries languages enhanced access reporting introducing internetbased reporting facility contents externally assured bureau veritas march back top home responsibility ethical conduct training awareness corporate responsibility report training awareness performance global training awareness activity included globally sales marketing staff required undertake annual refresher training promotion marketing codes example extent training undertaken us employees contractors completed compliance refresher training training new employees completed people launched redesigned training curriculum new us pharmaceuticals field sales employees integrates training ethical commercial practices sales training rather providing standalone modules also added ethics section employee manual commercial policies help employees make right decisions commercial interactions managers completed selfcertification process raised awareness global confidential reporting line reporting possible breaches policies extensive poster campaign awareness programmes intranet confidential reporting phone line available countries languages enhanced access reporting introducing internetbased reporting facility contents externally assured bureau veritas march back top home responsibility ethical conduct monitoring compliance corporate responsibility report monitoring compliance approach performance plans managers must ensure compliance company policies areas responsibility overseen seek advice corporate ethics compliance department promotes effective compliance programmes addresses compliance issues reports problems progress senior management board dedicated compliance officer business units rd manufacturing vaccines pharmaceuticals europe pharmaceuticals emerging markets pharmaceuticals asia pacific japan consumer healthcare corporate us pharmaceuticals additional compliance representatives markets compliance officers senior managers direct access leadership teams gsk functions source expertise anyone question ethics gsk policies corporate compliance officer reports directly ceo also fulltime compliance directors commonwealth independent states cis includes russia latin america middle east north africa asia pacific china provide additional support senior management teams large diverse regions existing partial roles expanded fulltime roles subsaharan africa south asia includes india review ethics compliance strategy every two years twice year gsk audit committee board assesses progress towards meeting strategy review objectives risk management risk oversight compliance council rocc includes several corporate executive team cet members oversees risk management internal control activities rocc supported gsks corporate assurance department corporate ethics compliance department gsks corporate compliance officer chairs rocc regularly reports significant risks cet audit committee board information risk management see corporate governance section annual report monitoring sales marketing sales representatives supervised managers regularly monitor educational events visits doctors expenses use riskbased approach determine frequency checks different districts individual sales representatives us sales representatives receive enquiries physicians offlabel uses gsk products must notify medical information department responds inquiry via medical information letter sales representatives must solicit offlabel questions physicians frequent medical information letter requests sales representative indicate employee prompting questions promoting offlabel uses gsk products monitor requests medical information letters internal audit department regularly audits sales marketing practices globally monitoring payments healthcare professionals organisations developing global system monitor report payments healthcare professionals hcps currently payments recorded monitored different ways different countries example us introduced state reporting system expenditure hcps line legislation several us states japan payments individual hcps medical institutions monitored quarterly basis results reported promotion compliance officers internal audit department reporting channels employees encouraged seek help ethical issues report concerns suspected cases misconduct line manager corporate ethics compliance department compliance officer compliance champion gsks human resources legal departments global confidential reporting line us integrity helpline global confidential reporting line available globally languages used reporting concerns employees may relating compliance policies code conduct global reporting mechanism strengthened addition internet reporting option us integrity helpline provides advice callers within outside company well reporting channel us employees also report concerns offsite post office box via email reporting channels promoted employee guide business conduct gsk intranet training also raise awareness global confidential reporting line company intranet addressing misconduct corporate ethics compliance department monitors tracks allegations suspected legal ethical policy infractions ensures allegations appropriately investigated disciplinary action including dismissal reporting relevant external authorities taken necessary serious violations policies reported audit committee board contents externally assured bureau veritas march back tophome responsibility ethical conduct monitoring compliance corporate responsibility report monitoring compliance approach performance plans managers must ensure compliance company policies areas responsibility overseen seek advice corporate ethics compliance department promotes effective compliance programmes addresses compliance issues reports problems progress senior management board dedicated compliance officer business units rd manufacturing vaccines pharmaceuticals europe pharmaceuticals emerging markets pharmaceuticals asia pacific japan consumer healthcare corporate us pharmaceuticals additional compliance representatives markets compliance officers senior managers direct access leadership teams gsk functions source expertise anyone question ethics gsk policies corporate compliance officer reports directly ceo also fulltime compliance directors commonwealth independent states cis includes russia latin america middle east north africa asia pacific china provide additional support senior management teams large diverse regions existing partial roles expanded fulltime roles subsaharan africa south asia includes india review ethics compliance strategy every two years twice year gsk audit committee board assesses progress towards meeting strategy review objectives risk management risk oversight compliance council rocc includes several corporate executive team cet members oversees risk management internal control activities rocc supported gsks corporate assurance department corporate ethics compliance department gsks corporate compliance officer chairs rocc regularly reports significant risks cet audit committee board information risk management see corporate governance section annual report monitoring sales marketing sales representatives supervised managers regularly monitor educational events visits doctors expenses use riskbased approach determine frequency checks different districts individual sales representatives us sales representatives receive enquiries physicians offlabel uses gsk products must notify medical information department responds inquiry via medical information letter sales representatives must solicit offlabel questions physicians frequent medical information letter requests sales representative indicate employee prompting questions promoting offlabel uses gsk products monitor requests medical information letters internal audit department regularly audits sales marketing practices globally monitoring payments healthcare professionals organisations developing global system monitor report payments healthcare professionals hcps currently payments recorded monitored different ways different countries example us introduced state reporting system expenditure hcps line legislation several us states japan payments individual hcps medical institutions monitored quarterly basis results reported promotion compliance officers internal audit department reporting channels employees encouraged seek help ethical issues report concerns suspected cases misconduct line manager corporate ethics compliance department compliance officer compliance champion gsks human resources legal departments global confidential reporting line us integrity helpline global confidential reporting line available globally languages used reporting concerns employees may relating compliance policies code conduct global reporting mechanism strengthened addition internet reporting option us integrity helpline provides advice callers within outside company well reporting channel us employees also report concerns offsite post office box via email reporting channels promoted employee guide business conduct gsk intranet training also raise awareness global confidential reporting line company intranet addressing misconduct corporate ethics compliance department monitors tracks allegations suspected legal ethical policy infractions ensures allegations appropriately investigated disciplinary action including dismissal reporting relevant external authorities taken necessary serious violations policies reported audit committee board contents externally assured bureau veritas march back top home responsibility ethical conduct monitoring compliance corporate responsibility report monitoring compliance approach performance plans managers must ensure compliance company policies areas responsibility overseen seek advice corporate ethics compliance department promotes effective compliance programmes addresses compliance issues reports problems progress senior management board dedicated compliance officer business units rd manufacturing vaccines pharmaceuticals europe pharmaceuticals emerging markets pharmaceuticals asia pacific japan consumer healthcare corporate us pharmaceuticals additional compliance representatives markets compliance officers senior managers direct access leadership teams gsk functions source expertise anyone question ethics gsk policies corporate compliance officer reports directly ceo also fulltime compliance directors commonwealth independent states cis includes russia latin america middle east north africa asia pacific china provide additional support senior management teams large diverse regions existing partial roles expanded fulltime roles subsaharan africa south asia includes india review ethics compliance strategy every two years twice year gsk audit committee board assesses progress towards meeting strategy review objectives risk management risk oversight compliance council rocc includes several corporate executive team cet members oversees risk management internal control activities rocc supported gsks corporate assurance department corporate ethics compliance department gsks corporate compliance officer chairs rocc regularly reports significant risks cet audit committee board information risk management see corporate governance section annual report monitoring sales marketing sales representatives supervised managers regularly monitor educational events visits doctors expenses use riskbased approach determine frequency checks different districts individual sales representatives us sales representatives receive enquiries physicians offlabel uses gsk products must notify medical information department responds inquiry via medical information letter sales representatives must solicit offlabel questions physicians frequent medical information letter requests sales representative indicate employee prompting questions promoting offlabel uses gsk products monitor requests medical information letters internal audit department regularly audits sales marketing practices globally monitoring payments healthcare professionals organisations developing global system monitor report payments healthcare professionals hcps currently payments recorded monitored different ways different countries example us introduced state reporting system expenditure hcps line legislation several us states japan payments individual hcps medical institutions monitored quarterly basis results reported promotion compliance officers internal audit department reporting channels employees encouraged seek help ethical issues report concerns suspected cases misconduct line manager corporate ethics compliance department compliance officer compliance champion gsks human resources legal departments global confidential reporting line us integrity helpline global confidential reporting line available globally languages used reporting concerns employees may relating compliance policies code conduct global reporting mechanism strengthened addition internet reporting option us integrity helpline provides advice callers within outside company well reporting channel us employees also report concerns offsite post office box via email reporting channels promoted employee guide business conduct gsk intranet training also raise awareness global confidential reporting line company intranet addressing misconduct corporate ethics compliance department monitors tracks allegations suspected legal ethical policy infractions ensures allegations appropriately investigated disciplinary action including dismissal reporting relevant external authorities taken necessary serious violations policies reported audit committee board contents externally assured bureau veritas march back top home responsibility ethical conduct monitoring compliance corporate responsibility report monitoring compliance approach performance plans contacts made ethics compliance channels included enquiries requests information guidance well allegations misconduct made via line managers compliance officers confidential integrity helplines offsite post office box us addressing misconduct employees disciplined policy violations dismissed agreed leave company voluntarily known separations disciplinary actions included documented warnings disciplinary actions included cases employees breaching sales marketing codes cases resulted dismissals separations company cases resulted documented warnings addition appropriate discipline employees staying company received retraining increased monitoring cases retraining also extended employees colleagues prevent making similar mistakes main types violations year included marketing promotional activities good manufacturinggood distribution practices falsification documents violation company car policies procedures travel expenses claims code conduct issues developing approach compliance risk management continued develop sophisticated compliance programme took steps embed ethical culture gsk read risk management compliance processes specifically expanding risk management capabilities developing audit plan better assess effectiveness company controls oversight compliance officers also established global privacy office enhance protection personal information hold employees others audit committee board reviews progress meeting assurance plans throughout year assurance plans include risk management ethics compliance audit activities completed demonstrate effective internal control framework gsk management board directors monitoring compliance suppliers us pharmaceuticals compliance procurement legal departments launched project improve monitoring ethics compliance performance suppliers involved sales marketing us suppliers agents engaging activities may subject gsks commercial practice policies contractually required read certify compliance ethics policies initiating services gsk simply process established webbased system communicate relevant policies suppliers update necessary read gsks supply chain contents externally assured bureau veritas march back tophome responsibility ethical conduct monitoring compliance corporate responsibility report monitoring compliance approach performance plans contacts made ethics compliance channels included enquiries requests information guidance well allegations misconduct made via line managers compliance officers confidential integrity helplines offsite post office box us addressing misconduct employees disciplined policy violations dismissed agreed leave company voluntarily known separations disciplinary actions included documented warnings disciplinary actions included cases employees breaching sales marketing codes cases resulted dismissals separations company cases resulted documented warnings addition appropriate discipline employees staying company received retraining increased monitoring cases retraining also extended employees colleagues prevent making similar mistakes main types violations year included marketing promotional activities good manufacturinggood distribution practices falsification documents violation company car policies procedures travel expenses claims code conduct issues developing approach compliance risk management continued develop sophisticated compliance programme took steps embed ethical culture gsk read risk management compliance processes specifically expanding risk management capabilities developing audit plan better assess effectiveness company controls oversight compliance officers also established global privacy office enhance protection personal information hold employees others audit committee board reviews progress meeting assurance plans throughout year assurance plans include risk management ethics compliance audit activities completed demonstrate effective internal control framework gsk management board directors monitoring compliance suppliers us pharmaceuticals compliance procurement legal departments launched project improve monitoring ethics compliance performance suppliers involved sales marketing us suppliers agents engaging activities may subject gsks commercial practice policies contractually required read certify compliance ethics policies initiating services gsk simply process established webbased system communicate relevant policies suppliers update necessary read gsks supply chain contents externally assured bureau veritas march back top home responsibility ethical conduct monitoring compliance corporate responsibility report monitoring compliance approach performance plans contacts made ethics compliance channels included enquiries requests information guidance well allegations misconduct made via line managers compliance officers confidential integrity helplines offsite post office box us addressing misconduct employees disciplined policy violations dismissed agreed leave company voluntarily known separations disciplinary actions included documented warnings disciplinary actions included cases employees breaching sales marketing codes cases resulted dismissals separations company cases resulted documented warnings addition appropriate discipline employees staying company received retraining increased monitoring cases retraining also extended employees colleagues prevent making similar mistakes main types violations year included marketing promotional activities good manufacturinggood distribution practices falsification documents violation company car policies procedures travel expenses claims code conduct issues developing approach compliance risk management continued develop sophisticated compliance programme took steps embed ethical culture gsk read risk management compliance processes specifically expanding risk management capabilities developing audit plan better assess effectiveness company controls oversight compliance officers also established global privacy office enhance protection personal information hold employees others audit committee board reviews progress meeting assurance plans throughout year assurance plans include risk management ethics compliance audit activities completed demonstrate effective internal control framework gsk management board directors monitoring compliance suppliers us pharmaceuticals compliance procurement legal departments launched project improve monitoring ethics compliance performance suppliers involved sales marketing us suppliers agents engaging activities may subject gsks commercial practice policies contractually required read certify compliance ethics policies initiating services gsk simply process established webbased system communicate relevant policies suppliers update necessary read gsks supply chain contents externally assured bureau veritas march back top home responsibility ethical conduct case studies corporate responsibility report case studies exercising good judgment following rules work hard raise awareness approach ethical conduct help employees live values example following text extract recent article north america compliance officer appeared high road newsletter employees north america article describes gsks expectations employees exercise good judgement follow rules many unwritten rules follow based principles judgement us policy acceptable use resources states gsk resources used professional manner must used engage offensive inappropriate behaviour policy try list every website could considered offensive presumption principle behind policy makes types sites self evident andrew wittys leadership us expected rely less rules values principles changed approach may make people uncomfortable rules make people feel safe know exactly acting principles using good judgement actually much safer think simply rule everything apply sound ethical judgement unfamiliar situation one without specific rule likely make right decision confident decision make policies list boundaries behavior ethics good judgment guiding operational force within boundaries dont get wrong policies rules always important framework business highly regulated essential know understand follow policies empowerment mean anything goes equally essentially however understand principles behind policies make sound decisions specific policy rule place faced decision consider actions align cpps guiding principles never provide money anything else value healthcare professional hcp organisation past future decisions purchase prescribe recommend gsk products keep product promotion truthful balanced onlabel consistent fdaapproved package insert never overstate benefits understate risks products develop relationships hcps intended benefit patients enhance practice medicine focus interactions informing hcps products providing scientific educational information interactions consumers patients patient advocacy consumer groups reflect gsks commitment honesty integrity focus best interests patient protect patient privacy focus underlying principle help identify whether may issues activity considering help assure keep purpose intent policies central guiding decisions still unsure act never hesitate use tools resources available help make right decision questions compliance activity talk manager business unit compliance officer call integrity helpline gskethics suitability gsks approved speaker list well ensuring employees comply policies vital people working behalf meet highest ethical standards make requirements clear people speaking gsks behalf monitor performance gsk removed two physicians approved speaker list used slides provided approved gsk inserted slides attempt inject humour programmes many attendees found slides offensive gsks president north american pharmaceuticals sent letter apology attendees events responsible marketing weight loss treatment nearly twothirds us adults around half adult population europe either clinically obese seriously overweight causing dramatic increase lifethreatening medical conditions heart disease diabetes adding strain national healthcare systems even small amount weight loss greatly reduce risk developing associated medical problems gsks overthecounter weight loss product alli orlistat mg helps overweight adults lose weight preventing per cent dietary fat absorbed gut helps people lose per cent weight diet exercise alone alli launched us june since sold million starter packs january european commission granted nonprescription licence product alli launched countries across europe approximately million people trying product first year vital alli marketed responsibly used right way need educate physicians dieticians pharmacists ensure alli sold appropriately patients receive right information treatment marketing emphasises using alli requires lifestyle changes including exercise lowfat diet produce right results without unwanted side effects safety efficacy profile orlistat well documented established data clinical studies set website wwwmyallicom provide support alli users enables people set targets track weight loss post success stories includes ready alli quiz asks potential users confirm commitment moderating diet taking exercise reading label carefully site also includes alli circles online moderated forum users share experiences help stay focused weight loss targets forum gives us valuable feedback patients effectiveness product monitor site reports adverse effects reported fda inappropriate content similar sites exist throughout europe donated dress success dfs us part ongoing partnership international nonprofit organisation provides business clothing career support disadvantaged women encourage alli users volunteer dfs donate clothing becomes big lose weight dfs received pieces clothing alli users first year alone continues share clothing alli users donate anderson j orlistat management overweight individuals obesity review potential mg overthecounter dosage expert opin pharmacother alli summary product characteristics spc jacob togerson j orlistat treatment beneficial primary care tertiary settings obesity reviews contents externally assured bureau veritas march back tophome responsibility ethical conduct case studies corporate responsibility report case studies exercising good judgment following rules work hard raise awareness approach ethical conduct help employees live values example following text extract recent article north america compliance officer appeared high road newsletter employees north america article describes gsks expectations employees exercise good judgement follow rules many unwritten rules follow based principles judgement us policy acceptable use resources states gsk resources used professional manner must used engage offensive inappropriate behaviour policy try list every website could considered offensive presumption principle behind policy makes types sites self evident andrew wittys leadership us expected rely less rules values principles changed approach may make people uncomfortable rules make people feel safe know exactly acting principles using good judgement actually much safer think simply rule everything apply sound ethical judgement unfamiliar situation one without specific rule likely make right decision confident decision make policies list boundaries behavior ethics good judgment guiding operational force within boundaries dont get wrong policies rules always important framework business highly regulated essential know understand follow policies empowerment mean anything goes equally essentially however understand principles behind policies make sound decisions specific policy rule place faced decision consider actions align cpps guiding principles never provide money anything else value healthcare professional hcp organisation past future decisions purchase prescribe recommend gsk products keep product promotion truthful balanced onlabel consistent fdaapproved package insert never overstate benefits understate risks products develop relationships hcps intended benefit patients enhance practice medicine focus interactions informing hcps products providing scientific educational information interactions consumers patients patient advocacy consumer groups reflect gsks commitment honesty integrity focus best interests patient protect patient privacy focus underlying principle help identify whether may issues activity considering help assure keep purpose intent policies central guiding decisions still unsure act never hesitate use tools resources available help make right decision questions compliance activity talk manager business unit compliance officer call integrity helpline gskethics suitability gsks approved speaker list well ensuring employees comply policies vital people working behalf meet highest ethical standards make requirements clear people speaking gsks behalf monitor performance gsk removed two physicians approved speaker list used slides provided approved gsk inserted slides attempt inject humour programmes many attendees found slides offensive gsks president north american pharmaceuticals sent letter apology attendees events responsible marketing weight loss treatment nearly twothirds us adults around half adult population europe either clinically obese seriously overweight causing dramatic increase lifethreatening medical conditions heart disease diabetes adding strain national healthcare systems even small amount weight loss greatly reduce risk developing associated medical problems gsks overthecounter weight loss product alli orlistat mg helps overweight adults lose weight preventing per cent dietary fat absorbed gut helps people lose per cent weight diet exercise alone alli launched us june since sold million starter packs january european commission granted nonprescription licence product alli launched countries across europe approximately million people trying product first year vital alli marketed responsibly used right way need educate physicians dieticians pharmacists ensure alli sold appropriately patients receive right information treatment marketing emphasises using alli requires lifestyle changes including exercise lowfat diet produce right results without unwanted side effects safety efficacy profile orlistat well documented established data clinical studies set website wwwmyallicom provide support alli users enables people set targets track weight loss post success stories includes ready alli quiz asks potential users confirm commitment moderating diet taking exercise reading label carefully site also includes alli circles online moderated forum users share experiences help stay focused weight loss targets forum gives us valuable feedback patients effectiveness product monitor site reports adverse effects reported fda inappropriate content similar sites exist throughout europe donated dress success dfs us part ongoing partnership international nonprofit organisation provides business clothing career support disadvantaged women encourage alli users volunteer dfs donate clothing becomes big lose weight dfs received pieces clothing alli users first year alone continues share clothing alli users donate anderson j orlistat management overweight individuals obesity review potential mg overthecounter dosage expert opin pharmacother alli summary product characteristics spc jacob togerson j orlistat treatment beneficial primary care tertiary settings obesity reviews contents externally assured bureau veritas march back top home responsibility ethical conduct case studies corporate responsibility report case studies exercising good judgment following rules work hard raise awareness approach ethical conduct help employees live values example following text extract recent article north america compliance officer appeared high road newsletter employees north america article describes gsks expectations employees exercise good judgement follow rules many unwritten rules follow based principles judgement us policy acceptable use resources states gsk resources used professional manner must used engage offensive inappropriate behaviour policy try list every website could considered offensive presumption principle behind policy makes types sites self evident andrew wittys leadership us expected rely less rules values principles changed approach may make people uncomfortable rules make people feel safe know exactly acting principles using good judgement actually much safer think simply rule everything apply sound ethical judgement unfamiliar situation one without specific rule likely make right decision confident decision make policies list boundaries behavior ethics good judgment guiding operational force within boundaries dont get wrong policies rules always important framework business highly regulated essential know understand follow policies empowerment mean anything goes equally essentially however understand principles behind policies make sound decisions specific policy rule place faced decision consider actions align cpps guiding principles never provide money anything else value healthcare professional hcp organisation past future decisions purchase prescribe recommend gsk products keep product promotion truthful balanced onlabel consistent fdaapproved package insert never overstate benefits understate risks products develop relationships hcps intended benefit patients enhance practice medicine focus interactions informing hcps products providing scientific educational information interactions consumers patients patient advocacy consumer groups reflect gsks commitment honesty integrity focus best interests patient protect patient privacy focus underlying principle help identify whether may issues activity considering help assure keep purpose intent policies central guiding decisions still unsure act never hesitate use tools resources available help make right decision questions compliance activity talk manager business unit compliance officer call integrity helpline gskethics suitability gsks approved speaker list well ensuring employees comply policies vital people working behalf meet highest ethical standards make requirements clear people speaking gsks behalf monitor performance gsk removed two physicians approved speaker list used slides provided approved gsk inserted slides attempt inject humour programmes many attendees found slides offensive gsks president north american pharmaceuticals sent letter apology attendees events responsible marketing weight loss treatment nearly twothirds us adults around half adult population europe either clinically obese seriously overweight causing dramatic increase lifethreatening medical conditions heart disease diabetes adding strain national healthcare systems even small amount weight loss greatly reduce risk developing associated medical problems gsks overthecounter weight loss product alli orlistat mg helps overweight adults lose weight preventing per cent dietary fat absorbed gut helps people lose per cent weight diet exercise alone alli launched us june since sold million starter packs january european commission granted nonprescription licence product alli launched countries across europe approximately million people trying product first year vital alli marketed responsibly used right way need educate physicians dieticians pharmacists ensure alli sold appropriately patients receive right information treatment marketing emphasises using alli requires lifestyle changes including exercise lowfat diet produce right results without unwanted side effects safety efficacy profile orlistat well documented established data clinical studies set website wwwmyallicom provide support alli users enables people set targets track weight loss post success stories includes ready alli quiz asks potential users confirm commitment moderating diet taking exercise reading label carefully site also includes alli circles online moderated forum users share experiences help stay focused weight loss targets forum gives us valuable feedback patients effectiveness product monitor site reports adverse effects reported fda inappropriate content similar sites exist throughout europe donated dress success dfs us part ongoing partnership international nonprofit organisation provides business clothing career support disadvantaged women encourage alli users volunteer dfs donate clothing becomes big lose weight dfs received pieces clothing alli users first year alone continues share clothing alli users donate anderson j orlistat management overweight individuals obesity review potential mg overthecounter dosage expert opin pharmacother alli summary product characteristics spc jacob togerson j orlistat treatment beneficial primary care tertiary settings obesity reviews contents externally assured bureau veritas march back top home responsibility ethical conduct case studies corporate responsibility report case studies exercising good judgment following rules work hard raise awareness approach ethical conduct help employees live values example following text extract recent article north america compliance officer appeared high road newsletter employees north america article describes gsks expectations employees exercise good judgement follow rules many unwritten rules follow based principles judgement us policy acceptable use resources states gsk resources used professional manner must used engage offensive inappropriate behaviour policy try list every website could considered offensive presumption principle behind policy makes types sites self evident andrew wittys leadership us expected rely less rules values principles changed approach may make people uncomfortable rules make people feel safe know exactly acting principles using good judgement actually much safer think simply rule everything apply sound ethical judgement unfamiliar situation one without specific rule likely make right decision confident decision make policies list boundaries behavior ethics good judgment guiding operational force within boundaries dont get wrong policies rules always important framework business highly regulated essential know understand follow policies empowerment mean anything goes equally essentially however understand principles behind policies make sound decisions specific policy rule place faced decision consider actions align cpps guiding principles never provide money anything else value healthcare professional hcp organisation past future decisions purchase prescribe recommend gsk products keep product promotion truthful balanced onlabel consistent fdaapproved package insert never overstate benefits understate risks products develop relationships hcps intended benefit patients enhance practice medicine focus interactions informing hcps products providing scientific educational information interactions consumers patients patient advocacy consumer groups reflect gsks commitment honesty integrity focus best interests patient protect patient privacy focus underlying principle help identify whether may issues activity considering help assure keep purpose intent policies central guiding decisions still unsure act never hesitate use tools resources available help make right decision questions compliance activity talk manager business unit compliance officer call integrity helpline gskethics suitability gsks approved speaker list well ensuring employees comply policies vital people working behalf meet highest ethical standards make requirements clear people speaking gsks behalf monitor performance gsk removed two physicians approved speaker list used slides provided approved gsk inserted slides attempt inject humour programmes many attendees found slides offensive gsks president north american pharmaceuticals sent letter apology attendees events responsible marketing weight loss treatment nearly twothirds us adults around half adult population europe either clinically obese seriously overweight causing dramatic increase lifethreatening medical conditions heart disease diabetes adding strain national healthcare systems even small amount weight loss greatly reduce risk developing associated medical problems gsks overthecounter weight loss product alli orlistat mg helps overweight adults lose weight preventing per cent dietary fat absorbed gut helps people lose per cent weight diet exercise alone alli launched us june since sold million starter packs january european commission granted nonprescription licence product alli launched countries across europe approximately million people trying product first year vital alli marketed responsibly used right way need educate physicians dieticians pharmacists ensure alli sold appropriately patients receive right information treatment marketing emphasises using alli requires lifestyle changes including exercise lowfat diet produce right results without unwanted side effects safety efficacy profile orlistat well documented established data clinical studies set website wwwmyallicom provide support alli users enables people set targets track weight loss post success stories includes ready alli quiz asks potential users confirm commitment moderating diet taking exercise reading label carefully site also includes alli circles online moderated forum users share experiences help stay focused weight loss targets forum gives us valuable feedback patients effectiveness product monitor site reports adverse effects reported fda inappropriate content similar sites exist throughout europe donated dress success dfs us part ongoing partnership international nonprofit organisation provides business clothing career support disadvantaged women encourage alli users volunteer dfs donate clothing becomes big lose weight dfs received pieces clothing alli users first year alone continues share clothing alli users donate anderson j orlistat management overweight individuals obesity review potential mg overthecounter dosage expert opin pharmacother alli summary product characteristics spc jacob togerson j orlistat treatment beneficial primary care tertiary settings obesity reviews contents externally assured bureau veritas march back top home responsibility ethical conduct assurance statement response corporate responsibility report assurance statement response commentary assurance bureau veritas independent assurance statement stakeholders gsk background recommendation previous assurance exercise access medicines extend assurance prominent material issues external review would benefit gsk stakeholders ethical conduct key area relation trust reputation bureau veritas uk limited bureau veritas engaged provide external assurance ethical conduct section gsks corporate responsibility cr report roles responsibilities content cr report sole responsibility gsk bureau veritas aim provide reassurance stakeholders accuracy reliability objectivity information express independent balanced opinion per scope assurance objectives scope assurance objectives review gsks approach ethical conduct across global operations identifies related risks emerging issues review gsk manages ethical conduct issues examination governance structures supporting policies related management implementation systems check accuracy associated information statements performance metrics data reporting period january december methodology conduct assurance undertook following interviews four senior managers gsks uk us offices build understanding ethical conduct strategy formulation policies identification management risks interviews eight regional divisional managers gsks uk us offices assess implementation ethical conduct policies commitments robustness effectiveness internal management systems verification performance data factual information interviews document review data sampling interrogation databases country visit gsks philadelphia research triangle park offices us evaluate implementation ethical conduct policies adherence related standards us chosen largest sales force addition phrma code updated january relation requirements interacting healthcare professionals hcps undertook materiality review conducting media analysis peer review internet research references gsk relation ethical conduct reporting period reviewed gsks stakeholder engagement activities took form survey hcps perception sales representatives avandia lovaza coreg products bureau veritas undertake direct stakeholder engagement except gsk staff interview gsk sales team field operatives external hcps opinion accuracy reliability based work opinion ethical conduct section gsks cr report provides fair summary gsks related performance activities contains factual information performance metrics data trends considered accurate reliable gsks approach ethical conduct key part gsks strategic priority build trust society strong culture throughout organisation demonstrated highest level role influencing policy industrywide improvements example work us trade organisation phrma ethical conduct well embedded organisation turn demonstrated company values principles implemented sound governance structure policies procedures ethical decisionmaking tools audit monitoring processes training awareness programmes report content materiality gsk strives leader ethical conduct reflected content cr report clearly communicates key challenges demonstrates understanding material issues although always identified complete systematic way report includes details issues managed presents performance data areas misconduct training transparency demonstrated publication payments hcps us plans extend disclosure globally bureau veritas also considers report balanced inclusion bad news stories violations received relation direct consumer dtc advertising gsks leadership approach ethical conduct associated reporting could improved addressing priority recommendations outlined observations recommendations increasing transparency managing risk observation gsk good understanding key risks relation ethical conduct include label promotion acquisition new companies due diligence increased outsourcing example emerging markets internal change management issues recommendation gsks cr report contain greater detail substantive information management performance key risk areas gsk consider demonstrate communicate stakeholders issues managed best practice performance areas would look like gsk examine applicability improved monitoring processes quantifiable targets key performance indicators kpis key risk areas gsk response gsk continued strengthen risk management processes completed risk identification prioritisation review identify significant risks actively developing implementing enhanced risk management plans address risks substantial progress made develop operate measure best practices relation risk management monitoring compliance processes emerging issues us healthcare reform observation key issue pharmaceutical sector healthcare reforms us industry wide changes increased government tendering pharmaceutical products opposed purchase directly hcps recommendation gsk continue ensure maintains consistency lobbying positions public policy statements monitor communicate impacts us healthcare reforms changes government tendering practices ethical conduct particular sales marketing activities gsk response gsk continue maintain consistency public policy statements positions advocate governments regulatory agencies public policy positions published report legal operations government affairs departments actively monitor new legislation changes government positions relate effects gsks business practices internal process improvements observation gsk operates countries operations spread number different cultures including emerging markets managing ethical conduct scale diversity creates particular challenges gsk responded simplifying developing consistent operating policies minimum standards across organisation number updated policies alignment data systems continues develop recommendation gsk ensure monitors reviews effectiveness newupdated policies across organisation relation data gsk continue look opportunities automate collection processes documented consistent enabling performance trends provided available gsk response gsk routinely reviews effectiveness policies including new updated policies recommended continue work improve monitoring reporting processes continuously upgrade efficiency effectiveness ethical conduct improvements supporting processes also subject simplification strategy moving forward core business areas gsk information analysis reporting key overall assurance programme managing detailed recommendations bureau veritas provided management gsk separate internal management report assurance standards used bureau veritas used range standards guidelines undertake assurance exercise included international standard assurance engagements isae criteria within global reporting initiative gri balance comparability accuracy timeliness reliability opinion formed basis subject inherent limitations outlined independent assurance statement assurance work planned carried provide reasonable rather absolute assurance believe provides reasonable basis conclusions limitations exclusions excluded scope work information relating activities outside defined reporting period company position statements including expression opinion belief aspiration expectation aim future intention provided gsk financial data taken gsks annual report accounts audited external financial auditor independent statement relied upon detect errors omissions misstatements may exist within report statement bureau veritas independence impartiality competence bureau veritas independent professional services company specialises quality environmental health safety social accountability years history providing independent assurance services annual turnover billion assurance team involvement bureau veritas projects gsk conflict services provided bureau veritas assurance team bureau veritas implemented code ethics across business intended ensure staff maintain high ethical standards daytoday business activities competence assurance team extensive experience conducting assurance environmental social ethical health safety information systems processes back tophome responsibility ethical conduct assurance statement response corporate responsibility report assurance statement response commentary assurance bureau veritas independent assurance statement stakeholders gsk background recommendation previous assurance exercise access medicines extend assurance prominent material issues external review would benefit gsk stakeholders ethical conduct key area relation trust reputation bureau veritas uk limited bureau veritas engaged provide external assurance ethical conduct section gsks corporate responsibility cr report roles responsibilities content cr report sole responsibility gsk bureau veritas aim provide reassurance stakeholders accuracy reliability objectivity information express independent balanced opinion per scope assurance objectives scope assurance objectives review gsks approach ethical conduct across global operations identifies related risks emerging issues review gsk manages ethical conduct issues examination governance structures supporting policies related management implementation systems check accuracy associated information statements performance metrics data reporting period january december methodology conduct assurance undertook following interviews four senior managers gsks uk us offices build understanding ethical conduct strategy formulation policies identification management risks interviews eight regional divisional managers gsks uk us offices assess implementation ethical conduct policies commitments robustness effectiveness internal management systems verification performance data factual information interviews document review data sampling interrogation databases country visit gsks philadelphia research triangle park offices us evaluate implementation ethical conduct policies adherence related standards us chosen largest sales force addition phrma code updated january relation requirements interacting healthcare professionals hcps undertook materiality review conducting media analysis peer review internet research references gsk relation ethical conduct reporting period reviewed gsks stakeholder engagement activities took form survey hcps perception sales representatives avandia lovaza coreg products bureau veritas undertake direct stakeholder engagement except gsk staff interview gsk sales team field operatives external hcps opinion accuracy reliability based work opinion ethical conduct section gsks cr report provides fair summary gsks related performance activities contains factual information performance metrics data trends considered accurate reliable gsks approach ethical conduct key part gsks strategic priority build trust society strong culture throughout organisation demonstrated highest level role influencing policy industrywide improvements example work us trade organisation phrma ethical conduct well embedded organisation turn demonstrated company values principles implemented sound governance structure policies procedures ethical decisionmaking tools audit monitoring processes training awareness programmes report content materiality gsk strives leader ethical conduct reflected content cr report clearly communicates key challenges demonstrates understanding material issues although always identified complete systematic way report includes details issues managed presents performance data areas misconduct training transparency demonstrated publication payments hcps us plans extend disclosure globally bureau veritas also considers report balanced inclusion bad news stories violations received relation direct consumer dtc advertising gsks leadership approach ethical conduct associated reporting could improved addressing priority recommendations outlined observations recommendations increasing transparency managing risk observation gsk good understanding key risks relation ethical conduct include label promotion acquisition new companies due diligence increased outsourcing example emerging markets internal change management issues recommendation gsks cr report contain greater detail substantive information management performance key risk areas gsk consider demonstrate communicate stakeholders issues managed best practice performance areas would look like gsk examine applicability improved monitoring processes quantifiable targets key performance indicators kpis key risk areas gsk response gsk continued strengthen risk management processes completed risk identification prioritisation review identify significant risks actively developing implementing enhanced risk management plans address risks substantial progress made develop operate measure best practices relation risk management monitoring compliance processes emerging issues us healthcare reform observation key issue pharmaceutical sector healthcare reforms us industry wide changes increased government tendering pharmaceutical products opposed purchase directly hcps recommendation gsk continue ensure maintains consistency lobbying positions public policy statements monitor communicate impacts us healthcare reforms changes government tendering practices ethical conduct particular sales marketing activities gsk response gsk continue maintain consistency public policy statements positions advocate governments regulatory agencies public policy positions published report legal operations government affairs departments actively monitor new legislation changes government positions relate effects gsks business practices internal process improvements observation gsk operates countries operations spread number different cultures including emerging markets managing ethical conduct scale diversity creates particular challenges gsk responded simplifying developing consistent operating policies minimum standards across organisation number updated policies alignment data systems continues develop recommendation gsk ensure monitors reviews effectiveness newupdated policies across organisation relation data gsk continue look opportunities automate collection processes documented consistent enabling performance trends provided available gsk response gsk routinely reviews effectiveness policies including new updated policies recommended continue work improve monitoring reporting processes continuously upgrade efficiency effectiveness ethical conduct improvements supporting processes also subject simplification strategy moving forward core business areas gsk information analysis reporting key overall assurance programme managing detailed recommendations bureau veritas provided management gsk separate internal management report assurance standards used bureau veritas used range standards guidelines undertake assurance exercise included international standard assurance engagements isae criteria within global reporting initiative gri balance comparability accuracy timeliness reliability opinion formed basis subject inherent limitations outlined independent assurance statement assurance work planned carried provide reasonable rather absolute assurance believe provides reasonable basis conclusions limitations exclusions excluded scope work information relating activities outside defined reporting period company position statements including expression opinion belief aspiration expectation aim future intention provided gsk financial data taken gsks annual report accounts audited external financial auditor independent statement relied upon detect errors omissions misstatements may exist within report statement bureau veritas independence impartiality competence bureau veritas independent professional services company specialises quality environmental health safety social accountability years history providing independent assurance services annual turnover billion assurance team involvement bureau veritas projects gsk conflict services provided bureau veritas assurance team bureau veritas implemented code ethics across business intended ensure staff maintain high ethical standards daytoday business activities competence assurance team extensive experience conducting assurance environmental social ethical health safety information systems processes back tophome responsibility ethical conduct assurance statement response corporate responsibility report assurance statement response commentary assurance bureau veritas independent assurance statement stakeholders gsk background recommendation previous assurance exercise access medicines extend assurance prominent material issues external review would benefit gsk stakeholders ethical conduct key area relation trust reputation bureau veritas uk limited bureau veritas engaged provide external assurance ethical conduct section gsks corporate responsibility cr report roles responsibilities content cr report sole responsibility gsk bureau veritas aim provide reassurance stakeholders accuracy reliability objectivity information express independent balanced opinion per scope assurance objectives scope assurance objectives review gsks approach ethical conduct across global operations identifies related risks emerging issues review gsk manages ethical conduct issues examination governance structures supporting policies related management implementation systems check accuracy associated information statements performance metrics data reporting period january december methodology conduct assurance undertook following interviews four senior managers gsks uk us offices build understanding ethical conduct strategy formulation policies identification management risks interviews eight regional divisional managers gsks uk us offices assess implementation ethical conduct policies commitments robustness effectiveness internal management systems verification performance data factual information interviews document review data sampling interrogation databases country visit gsks philadelphia research triangle park offices us evaluate implementation ethical conduct policies adherence related standards us chosen largest sales force addition phrma code updated january relation requirements interacting healthcare professionals hcps undertook materiality review conducting media analysis peer review internet research references gsk relation ethical conduct reporting period reviewed gsks stakeholder engagement activities took form survey hcps perception sales representatives avandia lovaza coreg products bureau veritas undertake direct stakeholder engagement except gsk staff interview gsk sales team field operatives external hcps opinion accuracy reliability based work opinion ethical conduct section gsks cr report provides fair summary gsks related performance activities contains factual information performance metrics data trends considered accurate reliable gsks approach ethical conduct key part gsks strategic priority build trust society strong culture throughout organisation demonstrated highest level role influencing policy industrywide improvements example work us trade organisation phrma ethical conduct well embedded organisation turn demonstrated company values principles implemented sound governance structure policies procedures ethical decisionmaking tools audit monitoring processes training awareness programmes report content materiality gsk strives leader ethical conduct reflected content cr report clearly communicates key challenges demonstrates understanding material issues although always identified complete systematic way report includes details issues managed presents performance data areas misconduct training transparency demonstrated publication payments hcps us plans extend disclosure globally bureau veritas also considers report balanced inclusion bad news stories violations received relation direct consumer dtc advertising gsks leadership approach ethical conduct associated reporting could improved addressing priority recommendations outlined observations recommendations increasing transparency managing risk observation gsk good understanding key risks relation ethical conduct include label promotion acquisition new companies due diligence increased outsourcing example emerging markets internal change management issues recommendation gsks cr report contain greater detail substantive information management performance key risk areas gsk consider demonstrate communicate stakeholders issues managed best practice performance areas would look like gsk examine applicability improved monitoring processes quantifiable targets key performance indicators kpis key risk areas gsk response gsk continued strengthen risk management processes completed risk identification prioritisation review identify significant risks actively developing implementing enhanced risk management plans address risks substantial progress made develop operate measure best practices relation risk management monitoring compliance processes emerging issues us healthcare reform observation key issue pharmaceutical sector healthcare reforms us industry wide changes increased government tendering pharmaceutical products opposed purchase directly hcps recommendation gsk continue ensure maintains consistency lobbying positions public policy statements monitor communicate impacts us healthcare reforms changes government tendering practices ethical conduct particular sales marketing activities gsk response gsk continue maintain consistency public policy statements positions advocate governments regulatory agencies public policy positions published report legal operations government affairs departments actively monitor new legislation changes government positions relate effects gsks business practices internal process improvements observation gsk operates countries operations spread number different cultures including emerging markets managing ethical conduct scale diversity creates particular challenges gsk responded simplifying developing consistent operating policies minimum standards across organisation number updated policies alignment data systems continues develop recommendation gsk ensure monitors reviews effectiveness newupdated policies across organisation relation data gsk continue look opportunities automate collection processes documented consistent enabling performance trends provided available gsk response gsk routinely reviews effectiveness policies including new updated policies recommended continue work improve monitoring reporting processes continuously upgrade efficiency effectiveness ethical conduct improvements supporting processes also subject simplification strategy moving forward core business areas gsk information analysis reporting key overall assurance programme managing detailed recommendations bureau veritas provided management gsk separate internal management report assurance standards used bureau veritas used range standards guidelines undertake assurance exercise included international standard assurance engagements isae criteria within global reporting initiative gri balance comparability accuracy timeliness reliability opinion formed basis subject inherent limitations outlined independent assurance statement assurance work planned carried provide reasonable rather absolute assurance believe provides reasonable basis conclusions limitations exclusions excluded scope work information relating activities outside defined reporting period company position statements including expression opinion belief aspiration expectation aim future intention provided gsk financial data taken gsks annual report accounts audited external financial auditor independent statement relied upon detect errors omissions misstatements may exist within report statement bureau veritas independence impartiality competence bureau veritas independent professional services company specialises quality environmental health safety social accountability years history providing independent assurance services annual turnover billion assurance team involvement bureau veritas projects gsk conflict services provided bureau veritas assurance team bureau veritas implemented code ethics across business intended ensure staff maintain high ethical standards daytoday business activities competence assurance team extensive experience conducting assurance envirpoangem en toaf l social ethical health safety information systems processes back tophome responsibility ethical conduct assurance statement response corporate responsibility report assurance statement response commentary assurance bureau veritas independent assurance statement stakeholders gsk background recommendation previous assurance exercise access medicines extend assurance prominent material issues external review would benefit gsk stakeholders ethical conduct key area relation trust reputation bureau veritas uk limited bureau veritas engaged provide external assurance ethical conduct section gsks corporate responsibility cr report roles responsibilities content cr report sole responsibility gsk bureau veritas aim provide reassurance stakeholders accuracy reliability objectivity information express independent balanced opinion per scope assurance objectives scope assurance objectives review gsks approach ethical conduct across global operations identifies related risks emerging issues review gsk manages ethical conduct issues examination governance structures supporting policies related management implementation systems check accuracy associated information statements performance metrics data reporting period january december methodology conduct assurance undertook following interviews four senior managers gsks uk us offices build understanding ethical conduct strategy formulation policies identification management risks interviews eight regional divisional managers gsks uk us offices assess implementation ethical conduct policies commitments robustness effectiveness internal management systems verification performance data factual information interviews document review data sampling interrogation databases country visit gsks philadelphia research triangle park offices us evaluate implementation ethical conduct policies adherence related standards us chosen largest sales force addition phrma code updated january relation requirements interacting healthcare professionals hcps undertook materiality review conducting media analysis peer review internet research references gsk relation ethical conduct reporting period reviewed gsks stakeholder engagement activities took form survey hcps perception sales representatives avandia lovaza coreg products bureau veritas undertake direct stakeholder engagement except gsk staff interview gsk sales team field operatives external hcps opinion accuracy reliability based work opinion ethical conduct section gsks cr report provides fair summary gsks related performance activities contains factual information performance metrics data trends considered accurate reliable gsks approach ethical conduct key part gsks strategic priority build trust society strong culture throughout organisation demonstrated highest level role influencing policy industrywide improvements example work us trade organisation phrma ethical conduct well embedded organisation turn demonstrated company values principles implemented sound governance structure policies procedures ethical decisionmaking tools audit monitoring processes training awareness programmes report content materiality gsk strives leader ethical conduct reflected content cr report clearly communicates key challenges demonstrates understanding material issues although always identified complete systematic way report includes details issues managed presents performance data areas misconduct training transparency demonstrated publication payments hcps us plans extend disclosure globally bureau veritas also considers report balanced inclusion bad news stories violations received relation direct consumer dtc advertising gsks leadership approach ethical conduct associated reporting could improved addressing priority recommendations outlined observations recommendations increasing transparency managing risk observation gsk good understanding key risks relation ethical conduct include label promotion acquisition new companies due diligence increased outsourcing example emerging markets internal change management issues recommendation gsks cr report contain greater detail substantive information management performance key risk areas gsk consider demonstrate communicate stakeholders issues managed best practice performance areas would look like gsk examine applicability improved monitoring processes quantifiable targets key performance indicators kpis key risk areas gsk response gsk continued strengthen risk management processes completed risk identification prioritisation review identify significant risks actively developing implementing enhanced risk management plans address risks substantial progress made develop operate measure best practices relation risk management monitoring compliance processes emerging issues us healthcare reform observation key issue pharmaceutical sector healthcare reforms us industry wide changes increased government tendering pharmaceutical products opposed purchase directly hcps recommendation gsk continue ensure maintains consistency lobbying positions public policy statements monitor communicate impacts us healthcare reforms changes government tendering practices ethical conduct particular sales marketing activities gsk response gsk continue maintain consistency public policy statements positions advocate governments regulatory agencies public policy positions published report legal operations government affairs departments actively monitor new legislation changes government positions relate effects gsks business practices internal process improvements observation gsk operates countries operations spread number different cultures including emerging markets managing ethical conduct scale diversity creates particular challenges gsk responded simplifying developing consistent operating policies minimum standards across organisation number updated policies alignment data systems continues develop recommendation gsk ensure monitors reviews effectiveness newupdated policies across organisation relation data gsk continue look opportunities automate collection processes documented consistent enabling performance trends provided available gsk response gsk routinely reviews effectiveness policies including new updated policies recommended continue work improve monitoring reporting processes continuously upgrade efficiency effectiveness ethical conduct improvements supporting processes also subject simplification strategy moving forward core business areas gsk information analysis reporting key overall assurance programme managing detailed recommendations bureau veritas provided management gsk separate internal management report assurance standards used bureau veritas used range standards guidelines undertake assurance exercise included international standard assurance engagements isae criteria within global reporting initiative gri balance comparability accuracy timeliness reliability opinion formed basis subject inherent limitations outlined independent assurance statement assurance work planned carried provide reasonable rather absolute assurance believe provides reasonable basis conclusions limitations exclusions excluded scope work information relating activities outside defined reporting period company position statements including expression opinion belief aspiration expectation aim future intention provided gsk financial data taken gsks annual report accounts audited external financial auditor independent statement relied upon detect errors omissions misstatements may exist within report statement bureau veritas independence impartiality competence bureau veritas independent professional services company specialises quality environmental health safety social accountability years history providing independent assurance services annual turnover billion assurance team involvement bureau veritas projects gsk conflict services provided bureau veritas assurance team bureau veritas implemented code ethics across business intended ensure staff maintain high ethical standards daytoday business activities competence assurance team extensive experience conducting assurance environmental social ethical health safety information systems processes back top home responsibility ethical conduct assurance statement response corporate responsibility report assurance statement response commentary assurance bureau veritas independent assurance statement stakeholders gsk background recommendation previous assurance exercise access medicines extend assurance prominent material issues external review would benefit gsk stakeholders ethical conduct key area relation trust reputation bureau veritas uk limited bureau veritas engaged provide external assurance ethical conduct section gsks corporate responsibility cr report roles responsibilities content cr report sole responsibility gsk bureau veritas aim provide reassurance stakeholders accuracy reliability objectivity information express independent balanced opinion per scope assurance objectives scope assurance objectives review gsks approach ethical conduct across global operations identifies related risks emerging issues review gsk manages ethical conduct issues examination governance structures supporting policies related management implementation systems check accuracy associated information statements performance metrics data reporting period january december methodology conduct assurance undertook following interviews four senior managers gsks uk us offices build understanding ethical conduct strategy formulation policies identification management risks interviews eight regional divisional managers gsks uk us offices assess implementation ethical conduct policies commitments robustness effectiveness internal management systems verification performance data factual information interviews document review data sampling interrogation databases country visit gsks philadelphia research triangle park offices us evaluate implementation ethical conduct policies adherence related standards us chosen largest sales force addition phrma code updated january relation requirements interacting healthcare professionals hcps undertook materiality review conducting media analysis peer review internet research references gsk relation ethical conduct reporting period reviewed gsks stakeholder engagement activities took form survey hcps perception sales representatives avandia lovaza coreg products bureau veritas undertake direct stakeholder engagement except gsk staff interview gsk sales team field operatives external hcps opinion accuracy reliability based work opinion ethical conduct section gsks cr report provides fair summary gsks related performance activities contains factual information performance metrics data trends considered accurate reliable gsks approach ethical conduct key part gsks strategic priority build trust society strong culture throughout organisation demonstrated highest level role influencing policy industrywide improvements example work us trade organisation phrma ethical conduct well embedded organisation turn demonstrated company values principles implemented sound governance structure policies procedures ethical decisionmaking tools audit monitoring processes training awareness programmes report content materiality gsk strives leader ethical conduct reflected content cr report clearly communicates key challenges demonstrates understanding material issues although always identified complete systematic way report includes details issues managed presents performance data areas misconduct training transparency demonstrated publication payments hcps us plans extend disclosure globally bureau veritas also considers report balanced inclusion bad news stories violations received relation direct consumer dtc advertising gsks leadership approach ethical conduct associated reporting could improved addressing priority recommendations outlined observations recommendations increasing transparency managing risk observation gsk good understanding key risks relation ethical conduct include label promotion acquisition new companies due diligence increased outsourcing example emerging markets internal change management issues recommendation gsks cr report contain greater detail substantive information management performance key risk areas gsk consider demonstrate communicate stakeholders issues managed best practice performance areas would look like gsk examine applicability improved monitoring processes quantifiable targets key performance indicators kpis key risk areas gsk response gsk continued strengthen risk management processes completed risk identification prioritisation review identify significant risks actively developing implementing enhanced risk management plans address risks substantial progress made develop operate measure best practices relation risk management monitoring compliance processes emerging issues us healthcare reform observation key issue pharmaceutical sector healthcare reforms us industry wide changes increased government tendering pharmaceutical products opposed purchase directly hcps recommendation gsk continue ensure maintains consistency lobbying positions public policy statements monitor communicate impacts us healthcare reforms changes government tendering practices ethical conduct particular sales marketing activities gsk response gsk continue maintain consistency public policy statements positions advocate governments regulatory agencies public policy positions published report legal operations government affairs departments actively monitor new legislation changes government positions relate effects gsks business practices internal process improvements observation gsk operates countries operations spread number different cultures including emerging markets managing ethical conduct scale diversity creates particular challenges gsk responded simplifying developing consistent operating policies minimum standards across organisation number updated policies alignment data systems continues develop recommendation gsk ensure monitors reviews effectiveness newupdated policies across organisation relation data gsk continue look opportunities automate collection processes documented consistent enabling performance trends provided available gsk response gsk routinely reviews effectiveness policies including new updated policies recommended continue work improve monitoring reporting processes continuously upgrade efficiency effectiveness ethical conduct improvements supporting processes also subject simplification strategy moving forward core business areas gsk information analysis reporting key overall assurance programme managing detailed recommendations bureau veritas provided management gsk separate internal management report assurance standards used bureau veritas used range standards guidelines undertake assurance exercise included international standard assurance engagements isae criteria within global reporting initiative gri balance comparability accuracy timeliness reliability opinion formed basis subject inherent limitations outlined independent assurance statement assurance work planned carried provide reasonable rather absolute assurance believe provides reasonable basis conclusions limitations exclusions excluded scope work information relating activities outside defined reporting period company position statements including expression opinion belief aspiration expectation aim future intention provided gsk financial data taken gsks annual report accounts audited external financial auditor independent statement relied upon detect errors omissions misstatements may exist within report statement bureau veritas independence impartiality competence bureau veritas independent professional services company specialises quality environmental health safety social accountability years history providing independent assurance services annual turnover billion assurance team involvement bureau veritas projects gsk conflict services provided bureau veritas assurance team bureau veritas implemented code ethics across business intended ensure staff maintain high ethical standards daytoday business activities competence assurance team extensive experience conducting assurance environmental social ethical health safety information systems processes back top home responsibility ethical conduct qas corporate responsibility report qas respond questions raised stakeholders one company establish high standards ethical conduct industry approach required set high standards ethical conduct hope establish benchmark companies judged also work companies trade associations develop high ethical standards believe best interest patients pharmaceutical industry adopts common high standards ethical conduct also help improve trust industry among stakeholders lot gsk employees dismissed unethical conduct policies working employees dismissed agreed leave company voluntarily result policy violations unethical conduct occurs companies believe figures demonstrate effectiveness monitoring compliance programmes furthering ethical culture recruiting right people providing right training tools improving checks encouraging people speak enable us identify address unethical conduct consistent responsive manner gsk unduly influencing doctors take several approaches protect inappropriate influence doctors including regional marketing codes practice regular training monitoring policies apply employees agents commit us promotional practices ethical responsible principled patient centred prohibit kickbacks bribery inducements doctors promotion unapproved uses medicines sales force regularly trained supervised managers monitor educational events visits doctors expenses commissioned consultant help us calculate fair market value payments healthcare professionals hcps makes payments consistent across business us limit payments hcps advise us year receive fees less year developing system disclose hcp fees began report payments us report payments markets prevent offlabel promotion gsk employees dealing healthcare professionals undergo extensive training monitoring instructed full accurate information may provided approved uses medicine must based valid scientific evidence must accurate balanced fair objective unambiguous date questions doctors offlabel uses products must referred medical information department us additional processes place monitoring referrals help us ensure representatives promoting offlabel uses monitor volume letters responding questions types referrals made individual representatives example number referrals relating particular product particular offlabel use additionally internal audit department audits sales marketing practices globally using risk based approach home responsibility ethical conduct qas corporate responsibility report qas respond questions raised stakeholders one company establish high standards ethical conduct industry approach required set high standards ethical conduct hope establish benchmark companies judged also work companies trade associations develop high ethical standards believe best interest patients pharmaceutical industry adopts common high standards ethical conduct also help improve trust industry among stakeholders lot gsk employees dismissed unethical conduct policies working employees dismissed agreed leave company voluntarily result policy violations unethical conduct occurs companies believe figures demonstrate effectiveness monitoring compliance programmes furthering ethical culture recruiting right people providing right training tools improving checks encouraging people speak enable us identify address unethical conduct consistent responsive manner gsk unduly influencing doctors take several approaches protect inappropriate influence doctors including regional marketing codes practice regular training monitoring policies apply employees agents commit us promotional practices ethical responsible principled patient centred prohibit kickbacks bribery inducements doctors promotion unapproved uses medicines sales force regularly trained supervised managers monitor educational events visits doctors expenses commissioned consultant help us calculate fair market value payments healthcare professionals hcps makes payments consistent across business us limit payments hcps advise us year receive fees less year developing system disclose hcp fees began report payments us report payments markets prevent offlabel promotion gsk employees dealing healthcare professionals undergo extensive training monitoring instructed full accurate information may provided approved uses medicine must based valid scientific evidence must accurate balanced fair objective unambiguous date questions doctors offlabel uses products must referred medical information department us additional processes place monitoring referrals help us ensure representatives promoting offlabel uses monitor volume letters responding questions types referrals made individual representatives example number referrals relating particular product particular offlabel use additionally internal audit department audits sales marketing practices globally using risk based approach home responsibility supply chain corporate responsibility report supply chain want source companies maintain high standards quality labour environment inadequate environment health safety ehs human rights standards indicator poor management impact quality compromise patient safety impede continuity supply essential medicines association poorly performing suppliers could also damage reputation suppliers critical supply chain must meet minimum standard work conduct detailed assessments new existing critical suppliers monitor performance ehs human rights issues also beginning measure environment health safety impacts manufacturing suppliers counterfeit drugs pose serious threat patients build anticounterfeiting features products packaging take steps prevent criminals making distributing fake gsk products supply chain number suppliers spend billion gsk made purchases suppliers around globe supply chain complex ranges strategic relationships suppliers manufacture active pharmaceutical ingredients intermediates raw materials packaging gsk medicines contracts goods services office equipment cleaning security back top home responsibility supply chain corporate responsibility report supply chain want source companies maintain high standards quality labour environment inadequate environment health safety ehs human rights standards indicator poor management impact quality compromise patient safety impede continuity supply essential medicines association poorly performing suppliers could also damage reputation suppliers critical supply chain must meet minimum standard work conduct detailed assessments new existing critical suppliers monitor performance ehs human rights issues also beginning measure environment health safety impacts manufacturing suppliers counterfeit drugs pose serious threat patients build anticounterfeiting features products packaging take steps prevent criminals making distributing fake gsk products supply chain number suppliers spend billion gsk made purchases suppliers around globe supply chain complex ranges strategic relationships suppliers manufacture active pharmaceutical ingredients intermediates raw materials packaging gsk medicines contracts goods services office equipment cleaning security back top home responsibility supply chain responsibility supply chain corporate responsibility report responsibility supply chain approach ensuring high ehs human rights standards among global suppliers includes preaudit assessments potential suppliers gather information help evaluation inclusion human rights clause supplier contracts full environment health safety ehs requirements contracts critical suppliers review ehs human rights routine supplier engagements ehs audits potential existing suppliers agreed improvement programmes suppliers regular progress monitoring advice update september april launched new third party code conduct suppliers sets expectations relating ethical conduct labour practices human rights environment health safety management systems interactions gsk employees code based pharmaceutical supply chain initiatives psci pharmaceutical industry principles responsible supply chain management approach supports programme establish secure supply continue look opportunities help raise awareness implementation standards conducted training awareness sessions help suppliers understand expectations strengthen ehs management systems also collaborating companies pharmaceutical supply chain initiative psci help promote ehs human rights standards supplier contracts supplier contracts contain ehs requirements based global ehs standards human rights clauses based international labour organization conventions un 's universal declaration human rights companies must agree ehs human rights requirements included supplier riskbased approach supply chain large complex use riskbased approach target engagement monitoring efforts focus critical suppliers represent approximately per cent supplier spend mostly based europe north america asia critical suppliers include contract manufacturers suppliers pivotal business consider following factors defining critical suppliers may present high risk gsk relevance supply essential medicines threats continuity supply value affected products gsk regulatory compliance requirements hazards associated manufacturing processes materials environmental impacts develop longterm relationships critical suppliers conduct regular monitoring support uninterrupted supply high quality materials services gsk training gsk procurement teams train new procurement employees standards requirements ehs human rights emphasises role promoting compliance standards key procurement employees including procurement managers receive ongoing training topics industry collaboration working others recognise achieve improve ehs human rights standards alone particularly developing countries collaborating companies pharmaceutical supply chain initiative psci psci developed principles responsible supply chain management provide guidance suppliers standards pharmaceutical industry expects align closely gsks ehs human rights standards gsk working psci members identify opportunities collaboration include projects improve communication evaluation wider base potential suppliers improve suppliers understanding importance ehs human rights standards environmental sustainability adding environmental sustainability topics questionnaires use assess potential new suppliers start introduce sustainability requirements existing critical suppliers use supplier review meetings encourage companies improve sustainability performance read efforts improve sustainability performance suppliers back tophome responsibility supply chain responsibility supply chain corporate responsibility report responsibility supply chain approach ensuring high ehs human rights standards among global suppliers includes preaudit assessments potential suppliers gather information help evaluation inclusion human rights clause supplier contracts full environment health safety ehs requirements contracts critical suppliers review ehs human rights routine supplier engagements ehs audits potential existing suppliers agreed improvement programmes suppliers regular progress monitoring advice update september april launched new third party code conduct suppliers sets expectations relating ethical conduct labour practices human rights environment health safety management systems interactions gsk employees code based pharmaceutical supply chain initiatives psci pharmaceutical industry principles responsible supply chain management approach supports programme establish secure supply continue look opportunities help raise awareness implementation standards conducted training awareness sessions help suppliers understand expectations strengthen ehs management systems also collaborating companies pharmaceutical supply chain initiative psci help promote ehs human rights standards supplier contracts supplier contracts contain ehs requirements based global ehs standards human rights clauses based international labour organization conventions un 's universal declaration human rights companies must agree ehs human rights requirements included supplier riskbased approach supply chain large complex use riskbased approach target engagement monitoring efforts focus critical suppliers represent approximately per cent supplier spend mostly based europe north america asia critical suppliers include contract manufacturers suppliers pivotal business consider following factors defining critical suppliers may present high risk gsk relevance supply essential medicines threats continuity supply value affected products gsk regulatory compliance requirements hazards associated manufacturing processes materials environmental impacts develop longterm relationships critical suppliers conduct regular monitoring support uninterrupted supply high quality materials services gsk training gsk procurement teams train new procurement employees standards requirements ehs human rights emphasises role promoting compliance standards key procurement employees including procurement managers receive ongoing training topics industry collaboration working others recognise achieve improve ehs human rights standards alone particularly developing countries collaborating companies pharmaceutical supply chain initiative psci psci developed principles responsible supply chain management provide guidance suppliers standards pharmaceutical industry expects align closely gsks ehs human rights standards gsk working psci members identify opportunities collaboration include projects improve communication evaluation wider base potential suppliers improve suppliers understanding importance ehs human rights standards environmental sustainability adding environmental sustainability topics questionnaires use assess potential new suppliers start introduce sustainability requirements existing critical suppliers use supplier review meetings encourage companies improve sustainability performance read efforts improve sustainability performance suppliers back top home responsibility supply chain responsibility supply chain corporate responsibility report responsibility supply chain approach ensuring high ehs human rights standards among global suppliers includes preaudit assessments potential suppliers gather information help evaluation inclusion human rights clause supplier contracts full environment health safety ehs requirements contracts critical suppliers review ehs human rights routine supplier engagements ehs audits potential existing suppliers agreed improvement programmes suppliers regular progress monitoring advice update september april launched new third party code conduct suppliers sets expectations relating ethical conduct labour practices human rights environment health safety management systems interactions gsk employees code based pharmaceutical supply chain initiatives psci pharmaceutical industry principles responsible supply chain management approach supports programme establish secure supply continue look opportunities help raise awareness implementation standards conducted training awareness sessions help suppliers understand expectations strengthen ehs management systems also collaborating companies pharmaceutical supply chain initiative psci help promote ehs human rights standards supplier contracts supplier contracts contain ehs requirements based global ehs standards human rights clauses based international labour organization conventions un 's universal declaration human rights companies must agree ehs human rights requirements included supplier riskbased approach supply chain large complex use riskbased approach target engagement monitoring efforts focus critical suppliers represent approximately per cent supplier spend mostly based europe north america asia critical suppliers include contract manufacturers suppliers pivotal business consider following factors defining critical suppliers may present high risk gsk relevance supply essential medicines threats continuity supply value affected products gsk regulatory compliance requirements hazards associated manufacturing processes materials environmental impacts develop longterm relationships critical suppliers conduct regular monitoring support uninterrupted supply high quality materials services gsk training gsk procurement teams train new procurement employees standards requirements ehs human rights emphasises role promoting compliance standards key procurement employees including procurement managers receive ongoing training topics industry collaboration working others recognise achieve improve ehs human rights standards alone particularly developing countries collaborating companies pharmaceutical supply chain initiative psci psci developed principles responsible supply chain management provide guidance suppliers standards pharmaceutical industry expects align closely gsks ehs human rights standards gsk working psci members identify opportunities collaboration include projects improve communication evaluation wider base potential suppliers improve suppliers understanding importance ehs human rights standards environmental sustainability adding environmental sustainability topics questionnaires use assess potential new suppliers start introduce sustainability requirements existing critical suppliers use supplier review meetings encourage companies improve sustainability performance read efforts improve sustainability performance suppliers back top home responsibility supply chain responsibility supply chain human rights clause corporate responsibility report human rights clause supplier contracts contain human rights clause based international labour organization 's conventions un 's universal declaration human rights may amend exact wording clause negotiations suppliers translation suit local law changes reduce contractual impact intent clause gsk standard contract clause ethical standards human rights unless otherwise required prohibited law supplier warrants best knowledge relation supply goods services terms agreement employ engage otherwise use child labour circumstances tasks performed child labour could reasonably foreseen cause either physical emotional impairment development child use forced labour form prison indentured bonded otherwise employees required lodge papers deposits starting work provides safe healthy workplace presenting immediate hazards employees housing provided supplier employees safe habitation supplier provides access clean water food emergency healthcare employees event accidents incidents supplier 's workplace discriminate employees ground including race religion disability gender engage support use corporal punishment mental physical sexual verbal abuse use cruel abusive disciplinary practices workplace pays employee least minimum wage fair representation prevailing industry wage whichever higher provides employee legally mandated benefits complies laws working hours employment rights countries operates respectful employees right join form independent trade unions freedom association supplier agrees responsible controlling supply chain shall encourage compliance ethical standards human rights subsequent supplier goods services used supplier performing obligations agreement supplier shall ensure ethical human rights policies appropriate complaints procedure deal breaches policies gsk reserves right upon reasonable notice unless inspection cause case notice shall necessary enter upon supplier 's premises monitor compliance supplier warranties set clause supplier shall subject compliance law furnish gsk relevant documents requested gsk relation thereto subsection required general right audit elsewhere within agreement back top home responsibility supply chain responsibility supply chain human rights clause corporate responsibility report human rights clause supplier contracts contain human rights clause based international labour organization 's conventions un 's universal declaration human rights may amend exact wording clause negotiations suppliers translation suit local law changes reduce contractual impact intent clause gsk standard contract clause ethical standards human rights unless otherwise required prohibited law supplier warrants best knowledge relation supply goods services terms agreement employ engage otherwise use child labour circumstances tasks performed child labour could reasonably foreseen cause either physical emotional impairment development child use forced labour form prison indentured bonded otherwise employees required lodge papers deposits starting work provides safe healthy workplace presenting immediate hazards employees housing provided supplier employees safe habitation supplier provides access clean water food emergency healthcare employees event accidents incidents supplier 's workplace discriminate employees ground including race religion disability gender engage support use corporal punishment mental physical sexual verbal abuse use cruel abusive disciplinary practices workplace pays employee least minimum wage fair representation prevailing industry wage whichever higher provides employee legally mandated benefits complies laws working hours employment rights countries operates respectful employees right join form independent trade unions freedom association supplier agrees responsible controlling supply chain shall encourage compliance ethical standards human rights subsequent supplier goods services used supplier performing obligations agreement supplier shall ensure ethical human rights policies appropriate complaints procedure deal breaches policies gsk reserves right upon reasonable notice unless inspection cause case notice shall necessary enter upon supplier 's premises monitor compliance supplier warranties set clause supplier shall subject compliance law furnish gsk relevant documents requested gsk relation thereto subsection required general right audit elsewhere within agreement back top home responsibility supply chain responsibility supply chain training capacity building corporate responsibility report choosing suppliers conduct detailed assessment critical suppliers part supplier assessment process critical suppliers include contract manufacturers suppliers supply products pivotal gsk use questionnaires preaudit assessments environment health safety ehs audits assess performance health safety environmental human rights issues environment health safety assess potential new critical suppliers ehs standards must achieve minimum audit score per cent standards join supply chain minimum score provides assurance suppliers managing basic ehs risks reducing likelihood significant incidents could harm people environment disrupt supply essential medicines following audit suppliers met requirements implement plans improve ehs performance many cases help suppliers improve identifying steps need take improve ehs management advising expert consultancies provide additional support also expect existing suppliers make improvements monitor progress reviews followup visits increased use preaudit assessments potential new suppliers emerging economies response large number companies countries failing meet minimum standard full ehs audits preaudit assessments focus key issues enable us identify suppliers likely meet standards subjected full audit well suppliers though unlikely initially meet standards capabilities improve suppliers unlikely meet standards given feedback make necessary improvements human rights audits also include questions help us identify potential breaches human rights clause included supplier contracts suppliers asked information policies practices relating age limits employees discrimination employees local population prevention abuse individuals wages benefits working hours whether meet legal minimum rights workers organise recognition worker organisations questions contribute ehs audit score may reason progress business supplier may result gsk escalating finding appropriate authorities read audit programme ensures compliance quality standards back top home responsibility supply chain responsibility supply chain training capacity building corporate responsibility report choosing suppliers conduct detailed assessment critical suppliers part supplier assessment process critical suppliers include contract manufacturers suppliers supply products pivotal gsk use questionnaires preaudit assessments environment health safety ehs audits assess performance health safety environmental human rights issues environment health safety assess potential new critical suppliers ehs standards must achieve minimum audit score per cent standards join supply chain minimum score provides assurance suppliers managing basic ehs risks reducing likelihood significant incidents could harm people environment disrupt supply essential medicines following audit suppliers met requirements implement plans improve ehs performance many cases help suppliers improve identifying steps need take improve ehs management advising expert consultancies provide additional support also expect existing suppliers make improvements monitor progress reviews followup visits increased use preaudit assessments potential new suppliers emerging economies response large number companies countries failing meet minimum standard full ehs audits preaudit assessments focus key issues enable us identify suppliers likely meet standards subjected full audit well suppliers though unlikely initially meet standards capabilities improve suppliers unlikely meet standards given feedback make necessary improvements human rights audits also include questions help us identify potential breaches human rights clause included supplier contracts suppliers asked information policies practices relating age limits employees discrimination employees local population prevention abuse individuals wages benefits working hours whether meet legal minimum rights workers organise recognition worker organisations questions contribute ehs audit score may reason progress business supplier may result gsk escalating finding appropriate authorities read audit programme ensures compliance quality standards back top home responsibility supply chain responsibility supply chain monitoring engagement corporate responsibility report monitoring engagement supplier selected monitor performance standards routine interactions including reviews followup visits gsk staff responsible procurement quality ehs consider ehs human rights issues interactions hold global regional supplier review meetings senior gsk managers interact suppliers key issues provide contract manufacturers information ehs risks associated gsk materials producing handling supplier booklet work gsk production supplier guide reiterates gsks expectation suppliers operate highest ethical standards act responsibly comply law industry guidelines conduct regular ehs loss prevention audits critical suppliers supply chain focus higherrisk suppliers supplier facilities evaluated ehs standards must achieve score least per cent standards demonstrate acceptable performance continue supply gsk suppliers develop improvement plans based audit findings follow monitor progress plans provide feedback suppliers identify issues questions relating human rights require corrective action issues present potential breach human rights clause included supplier contracts suppliers promotional materials many promotional materials indian business sourced within india industry higher risk use child labour conduct unannounced spot checks suppliers often night focus maintaining quality standards also used check suppliers using child labour spot checks conducted gsk procurement regional sales staff used findings programme india strengthen promotional supplier qualification process regions conducting detailed inspections assembly sites added extra checks regions child labour common back top home responsibility supply chain responsibility supply chain monitoring engagement corporate responsibility report monitoring engagement supplier selected monitor performance standards routine interactions including reviews followup visits gsk staff responsible procurement quality ehs consider ehs human rights issues interactions hold global regional supplier review meetings senior gsk managers interact suppliers key issues provide contract manufacturers information ehs risks associated gsk materials producing handling supplier booklet work gsk production supplier guide reiterates gsks expectation suppliers operate highest ethical standards act responsibly comply law industry guidelines conduct regular ehs loss prevention audits critical suppliers supply chain focus higherrisk suppliers supplier facilities evaluated ehs standards must achieve score least per cent standards demonstrate acceptable performance continue supply gsk suppliers develop improvement plans based audit findings follow monitor progress plans provide feedback suppliers identify issues questions relating human rights require corrective action issues present potential breach human rights clause included supplier contracts suppliers promotional materials many promotional materials indian business sourced within india industry higher risk use child labour conduct unannounced spot checks suppliers often night focus maintaining quality standards also used check suppliers using child labour spot checks conducted gsk procurement regional sales staff used findings programme india strengthen promotional supplier qualification process regions conducting detailed inspections assembly sites added extra checks regions child labour common back top home responsibility supply chain responsibility supply chain supply chain performance corporate responsibility report supply chain performance conducted supplier audits average audit score gsk ehs standards per cent highest score achieved per cent lowest per cent helping raise standards engaging potential new suppliers fifteen suppliers initially failed meet requirements achieved minimum ehs criteria following engagement efforts ehs audit scores key suppliers americas north america south america regions higher average scores north america europe contrast lower average scores asia largely related maturity ehs management systems supporting legislative framework enforcement regions broad range scores asia region reflects higherperforming suppliers longterm intervention gsk lower scores relate suppliers undertaken initial audits found significant deficiencies ehs management risk control ten potential suppliers failed meet minimum requirements preaudit assessments identified eight potential suppliers unlikely meet minimum requirements significant audit findings similar found occurred mainly developing countries included infrastructure fire protection poor emergency response capabilities absence fundamental risk controls process safety poor control exposure hazardous substances poor waste management environmental controls frequent regulatory findings significant issues identified relating human rights questions ask audits based analysis audit findings continue develop information assist suppliers understanding gsk ehs requirements help better understanding common significant issues improve ehs management systems number types audits americas europe asia africa total type supplier primary raw materials intermediates active pharmaceutical ingredients pharmaceutical formulations consumer healthcare excipients actives raw materials type engagement audit review average audit score per cent americas north america south america regions number suppliers audited total number americas europe asia africa cumulative total number visits visits americas north america south america regions suppliers promotional materials increased spot checks suppliers promotional materials conducted total announced unannounced spot checks found evidence child labour violations contract terms back tophome responsibility supply chain responsibility supply chain supply chain performance corporate responsibility report supply chain performance conducted supplier audits average audit score gsk ehs standards per cent highest score achieved per cent lowest per cent helping raise standards engaging potential new suppliers fifteen suppliers initially failed meet requirements achieved minimum ehs criteria following engagement efforts ehs audit scores key suppliers americas north america south america regions higher average scores north america europe contrast lower average scores asia largely related maturity ehs management systems supporting legislative framework enforcement regions broad range scores asia region reflects higherperforming suppliers longterm intervention gsk lower scores relate suppliers undertaken initial audits found significant deficiencies ehs management risk control ten potential suppliers failed meet minimum requirements preaudit assessments identified eight potential suppliers unlikely meet minimum requirements significant audit findings similar found occurred mainly developing countries included infrastructure fire protection poor emergency response capabilities absence fundamental risk controls process safety poor control exposure hazardous substances poor waste management environmental controls frequent regulatory findings significant issues identified relating human rights questions ask audits based analysis audit findings continue develop information assist suppliers understanding gsk ehs requirements help better understanding common significant issues improve ehs management systems number types audits americas europe asia africa total type supplier primary raw materials intermediates active pharmaceutical ingredients pharmaceutical formulations consumer healthcare excipients actives raw materials type engagement audit review average audit score per cent americas north america south america regions number suppliers audited total number americas europe asia africa cumulative total number visits visits americas north america south america regions suppliers promotional materials increased spot checks suppliers promotional materials conducted total announced unannounced spot checks found evidence child labour violations contract terms back top home responsibility supply chain responsibility supply chain supply chain performance corporate responsibility report supply chain performance conducted supplier audits average audit score gsk ehs standards per cent highest score achieved per cent lowest per cent helping raise standards engaging potential new suppliers fifteen suppliers initially failed meet requirements achieved minimum ehs criteria following engagement efforts ehs audit scores key suppliers americas north america south america regions higher average scores north america europe contrast lower average scores asia largely related maturity ehs management systems supporting legislative framework enforcement regions broad range scores asia region reflects higherperforming suppliers longterm intervention gsk lower scores relate suppliers undertaken initial audits found significant deficiencies ehs management risk control ten potential suppliers failed meet minimum requirements preaudit assessments identified eight potential suppliers unlikely meet minimum requirements significant audit findings similar found occurred mainly developing countries included infrastructure fire protection poor emergency response capabilities absence fundamental risk controls process safety poor control exposure hazardous substances poor waste management environmental controls frequent regulatory findings significant issues identified relating human rights questions ask audits based analysis audit findings continue develop information assist suppliers understanding gsk ehs requirements help better understanding common significant issues improve ehs management systems number types audits americas europe asia africa total type supplier primary raw materials intermediates active pharmaceutical ingredients pharmaceutical formulations consumer healthcare excipients actives raw materials type engagement audit review average audit score per cent americas north america south america regions number suppliers audited total number americas europe asia africa cumulative total number visits visits americas north america south america regions suppliers promotional materials increased spot checks suppliers promotional materials conducted total announced unannounced spot checks found evidence child labour violations contract terms back top home responsibility supply chain responsibility supply chain training capacity building corporate responsibility report training capacity building communication training use experience auditing developing countries identify opportunities improve supplier understanding good ehs management held workshop china attended companies workshop raised awareness common significant issues find audits including fire protection emergency response process safety environmental controls initial feedback attendees encouraging reviewing potential hold similar workshops future also encouraging suppliers use external consultants help improve systems identified list preferred consultants participate meetings supplier consultant ensure understand requirements highly protected risk status continued pilot project strategic supplier achieve highly protected risk hpr status achieve hpr status best class insurance industry designation companies must adopt engineering approach minimising property supply chain risks plan extend strategic suppliers starting building ehs management capacity key suppliers larger suppliers number facilities engaging senior management encourage develop ehs governance systems help improve ehs performance enable companies develop ehs management strategies align previously largely worked managers site level focusing suppliers influence mostly companies longstanding relationships us derive large amount business gsk trialled strategic approach company based india provides gsk range essential ingredients multiple sites using workshops improvement tools helped supplier develop three fiveyear improvement plan includes measures strengthen internal audit procedures system managing corrective actions plan also includes steps improve communication gsk develop performance improvement goals line trial success benefiting supplier gsk supplier improved understanding expectations project helped strengthen working relationship provide foundation support future investment increasing ownership ehs management also helped improve engagement motivation among suppliers employees project given us increased confidence suppliers management ehs loss prevention supplier implements improvement plan enable us rely less site visits move system verification suppliers ehs management systems expand approach key suppliers back top home responsibility supply chain responsibility supply chain training capacity building corporate responsibility report training capacity building communication training use experience auditing developing countries identify opportunities improve supplier understanding good ehs management held workshop china attended companies workshop raised awareness common significant issues find audits including fire protection emergency response process safety environmental controls initial feedback attendees encouraging reviewing potential hold similar workshops future also encouraging suppliers use external consultants help improve systems identified list preferred consultants participate meetings supplier consultant ensure understand requirements highly protected risk status continued pilot project strategic supplier achieve highly protected risk hpr status achieve hpr status best class insurance industry designation companies must adopt engineering approach minimising property supply chain risks plan extend strategic suppliers starting building ehs management capacity key suppliers larger suppliers number facilities engaging senior management encourage develop ehs governance systems help improve ehs performance enable companies develop ehs management strategies align previously largely worked managers site level focusing suppliers influence mostly companies longstanding relationships us derive large amount business gsk trialled strategic approach company based india provides gsk range essential ingredients multiple sites using workshops improvement tools helped supplier develop three fiveyear improvement plan includes measures strengthen internal audit procedures system managing corrective actions plan also includes steps improve communication gsk develop performance improvement goals line trial success benefiting supplier gsk supplier improved understanding expectations project helped strengthen working relationship provide foundation support future investment increasing ownership ehs management also helped improve engagement motivation among suppliers employees project given us increased confidence suppliers management ehs loss prevention supplier implements improvement plan enable us rely less site visits move system verification suppliers ehs management systems expand approach key suppliers back top home responsibility supply chain responsibility supply chain training capacity building corporate responsibility report training capacity building communication training use experience auditing developing countries identify opportunities improve supplier understanding good ehs management held workshop china attended companies workshop raised awareness common significant issues find audits including fire protection emergency response process safety environmental controls initial feedback attendees encouraging reviewing potential hold similar workshops future also encouraging suppliers use external consultants help improve systems identified list preferred consultants participate meetings supplier consultant ensure understand requirements highly protected risk status continued pilot project strategic supplier achieve highly protected risk hpr status achieve hpr status best class insurance industry designation companies must adopt engineering approach minimising property supply chain risks plan extend strategic suppliers starting building ehs management capacity key suppliers larger suppliers number facilities engaging senior management encourage develop ehs governance systems help improve ehs performance enable companies develop ehs management strategies align previously largely worked managers site level focusing suppliers influence mostly companies longstanding relationships us derive large amount business gsk trialled strategic approach company based india provides gsk range essential ingredients multiple sites using workshops improvement tools helped supplier develop three fiveyear improvement plan includes measures strengthen internal audit procedures system managing corrective actions plan also includes steps improve communication gsk develop performance improvement goals line trial success benefiting supplier gsk supplier improved understanding expectations project helped strengthen working relationship provide foundation support future investment increasing ownership ehs management also helped improve engagement motivation among suppliers employees project given us increased confidence suppliers management ehs loss prevention supplier implements improvement plan enable us rely less site visits move system verification suppliers ehs management systems expand approach key suppliers back top home responsibility supply chain responsibility supply chain supplier diversity corporate responsibility report supplier diversity small companies owned women minority groups often underrepresented supply chains large companies response us government many large companies require suppliers source diverse companies gsk developed supplier diversity programme identify develop position diverse businesses support commercial ambitions gsk contributing social responsibility improve economies global communities serve recognise value diverse businesses diverse communities therefore committed provide opportunities prepare sustainability beyond gsk commitment resulted per cent us pharma consumer healthcare discretionary spend small diverse businesses work increase diversity supply chain providing opportunities small diverse businesses provide us goods services enabling suppliers sustain businesses create jobs boost local economies moreover business also benefits beyond complying regulations supplier diversity also encourages innovation exposes us new perspectives fresh ideas addition identifying new business opportunities diverse suppliers work build capabilities expand business compete global contracts gsk multinational companies diverse supply base must meet gsk 's standards quality service read case study helped diverse supplier meet quality standards needed business gsk implement business strategy simplify operating model rationalising supply base selecting fewer suppliers taking steps ensure diverse suppliers benefit opportunities example included number diverse suppliers bid temporary staffing contract contract awarded minority supplier global capacity us programme us dedicated team working create opportunities diverse suppliers work gsk channel procurement spend companies owned women minorities veterans disabled veterans team collaborates procurement supplier diversity advocacy team help ensure diverse supplier inclusion throughout gsk proactively developing supplier diversity goals developing ways engage business partners supplier diversity teams activities include participating national local diversity councils mentoring highpotential diverse suppliers providing improvement grants help expand business gsk corporations read case study sponsoring diverse business leaders attend executive programmes tuck school business kellogg school management sponsoring attending outreach networking conferences example senior employees gsk legal supplier diversity team participated american bar associations national summit diversity gsk major sponsor diversity alliance science fair hosting workshops enable diverse suppliers understand business requirements organising matchmaking forums give diverse suppliers opportunity meet key senior executives buyers within gsk hosted forums identify develop diverse suppliers engineering facilities rd marketing services part adopt neighbourhood development initiative procurement community relations teams work local communities durham north carolina philadelphia pennsylvania areas historically deprived often overlooked companies choosing locate businesses gsk provides annual grant help communities develop become attractive business locations outside us gsks dedicated supplier diversity team based us procurement employees worldwide responsible supporting diverse suppliers possible supplier diversity goals became part performance evaluations procurement employees globally us diverse supplier capabilities provide goods services globally team works procurement regions enable supplier compete contracts outside us sponsor global link programme part role international advisory board us national minority supplier development council programme helps diverse suppliers develop partnerships local businesses around world explore activities outside core business share risks opportunities access new innovative technology gsk member new uk minority supplier development council council forms link corporations certified minority business enterprises aim increasing procurement business development opportunities recognition supplier diversity efforts recognised corporate impact award carolinas minority supplier development council also nominated national minority supplier development councils corporation year testimonials 'our association gsk positively impacted every aspect operations gsk 's impact felt beyond walls business shared gains local minority business council began mentoring peers developing businesses ' worldwide labels packaging memphis tennessee 'the gsk mentoring program catalyst provide company different mindset solve issues improve efficiencies obtain goal set ' aten solutions cary north carolina back tophome responsibility supply chain responsibility supply chain supplier diversity corporate responsibility report supplier diversity small companies owned women minority groups often underrepresented supply chains large companies response us government many large companies require suppliers source diverse companies gsk developed supplier diversity programme identify develop position diverse businesses support commercial ambitions gsk contributing social responsibility improve economies global communities serve recognise value diverse businesses diverse communities therefore committed provide opportunities prepare sustainability beyond gsk commitment resulted per cent us pharma consumer healthcare discretionary spend small diverse businesses work increase diversity supply chain providing opportunities small diverse businesses provide us goods services enabling suppliers sustain businesses create jobs boost local economies moreover business also benefits beyond complying regulations supplier diversity also encourages innovation exposes us new perspectives fresh ideas addition identifying new business opportunities diverse suppliers work build capabilities expand business compete global contracts gsk multinational companies diverse supply base must meet gsk 's standards quality service read case study helped diverse supplier meet quality standards needed business gsk implement business strategy simplify operating model rationalising supply base selecting fewer suppliers taking steps ensure diverse suppliers benefit opportunities example included number diverse suppliers bid temporary staffing contract contract awarded minority supplier global capacity us programme us dedicated team working create opportunities diverse suppliers work gsk channel procurement spend companies owned women minorities veterans disabled veterans team collaborates procurement supplier diversity advocacy team help ensure diverse supplier inclusion throughout gsk proactively developing supplier diversity goals developing ways engage business partners supplier diversity teams activities include participating national local diversity councils mentoring highpotential diverse suppliers providing improvement grants help expand business gsk corporations read case study sponsoring diverse business leaders attend executive programmes tuck school business kellogg school management sponsoring attending outreach networking conferences example senior employees gsk legal supplier diversity team participated american bar associations national summit diversity gsk major sponsor diversity alliance science fair hosting workshops enable diverse suppliers understand business requirements organising matchmaking forums give diverse suppliers opportunity meet key senior executives buyers within gsk hosted forums identify develop diverse suppliers engineering facilities rd marketing services part adopt neighbourhood development initiative procurement community relations teams work local communities durham north carolina philadelphia pennsylvania areas historically deprived often overlooked companies choosing locate businesses gsk provides annual grant help communities develop become attractive business locations outside us gsks dedicated supplier diversity team based us procurement employees worldwide responsible supporting diverse suppliers possible supplier diversity goals became part performance evaluations procurement employees globally us diverse supplier capabilities provide goods services globally team works procurement regions enable supplier compete contracts outside us sponsor global link programme part role international advisory board us national minority supplier development council programme helps diverse suppliers develop partnerships local businesses around world explore activities outside core business share risks opportunities access new innovative technology gsk member new uk minority supplier development council council forms link corporations certified minority business enterprises aim increasing procurement business development opportunities recognition supplier diversity efforts recognised corporate impact award carolinas minority supplier development council also nominated national minority supplier development councils corporation year testimonials 'our association gsk positively impacted every aspect operations gsk 's impact felt beyond walls business shared gains local minority business council began mentoring peers developing businesses ' worldwide labels packaging memphis tennessee 'the gsk mentoring program catalyst provide company different mindset solve issues improve efficiencies obtain goal set ' aten solutions cary north carolina back top home responsibility supply chain responsibility supply chain supplier diversity corporate responsibility report supplier diversity small companies owned women minority groups often underrepresented supply chains large companies response us government many large companies require suppliers source diverse companies gsk developed supplier diversity programme identify develop position diverse businesses support commercial ambitions gsk contributing social responsibility improve economies global communities serve recognise value diverse businesses diverse communities therefore committed provide opportunities prepare sustainability beyond gsk commitment resulted per cent us pharma consumer healthcare discretionary spend small diverse businesses work increase diversity supply chain providing opportunities small diverse businesses provide us goods services enabling suppliers sustain businesses create jobs boost local economies moreover business also benefits beyond complying regulations supplier diversity also encourages innovation exposes us new perspectives fresh ideas addition identifying new business opportunities diverse suppliers work build capabilities expand business compete global contracts gsk multinational companies diverse supply base must meet gsk 's standards quality service read case study helped diverse supplier meet quality standards needed business gsk implement business strategy simplify operating model rationalising supply base selecting fewer suppliers taking steps ensure diverse suppliers benefit opportunities example included number diverse suppliers bid temporary staffing contract contract awarded minority supplier global capacity us programme us dedicated team working create opportunities diverse suppliers work gsk channel procurement spend companies owned women minorities veterans disabled veterans team collaborates procurement supplier diversity advocacy team help ensure diverse supplier inclusion throughout gsk proactively developing supplier diversity goals developing ways engage business partners supplier diversity teams activities include participating national local diversity councils mentoring highpotential diverse suppliers providing improvement grants help expand business gsk corporations read case study sponsoring diverse business leaders attend executive programmes tuck school business kellogg school management sponsoring attending outreach networking conferences example senior employees gsk legal supplier diversity team participated american bar associations national summit diversity gsk major sponsor diversity alliance science fair hosting workshops enable diverse suppliers understand business requirements organising matchmaking forums give diverse suppliers opportunity meet key senior executives buyers within gsk hosted forums identify develop diverse suppliers engineering facilities rd marketing services part adopt neighbourhood development initiative procurement community relations teams work local communities durham north carolina philadelphia pennsylvania areas historically deprived often overlooked companies choosing locate businesses gsk provides annual grant help communities develop become attractive business locations outside us gsks dedicated supplier diversity team based us procurement employees worldwide responsible supporting diverse suppliers possible supplier diversity goals became part performance evaluations procurement employees globally us diverse supplier capabilities provide goods services globally team works procurement regions enable supplier compete contracts outside us sponsor global link programme part role international advisory board us national minority supplier development council programme helps diverse suppliers develop partnerships local businesses around world explore activities outside core business share risks opportunities access new innovative technology gsk member new uk minority supplier development council council forms link corporations certified minority business enterprises aim increasing procurement business development opportunities recognition supplier diversity efforts recognised corporate impact award carolinas minority supplier development council also nominated national minority supplier development councils corporation year testimonials 'our association gsk positively impacted every aspect operations gsk 's impact felt beyond walls business shared gains local minority business council began mentoring peers developing businesses ' worldwide labels packaging memphis tennessee 'the gsk mentoring program catalyst provide company different mindset solve issues improve efficiencies obtain goal set ' aten solutions cary north carolina back top home responsibility supply chain responsibility supply chain fair treatment suppliers corporate responsibility report fair treatment suppliers important foster relationships suppliers characterised mutual trust respect gsk established procurement policies processes requiring high standards ethical conduct integrity general terms conditions published website plan implement third party code conduct reinforcing principles values gsk expects business partners adopting code suppliers strengthen mutual trust respect gsk fair bidding gsk supports impartiality phases procurement cycle global electronic bid system ensures suppliers treated fairly equally vast majority suppliers providing goods services gsk registered system companies invited bid products services sourced gsk receive information time ensure fair ethical bidding process managed bids negotiations countries system highly competitive goods services system even transparent allow suppliers see bids rank competition monitoring concerns gsk employees suppliers third parties report concerns confidential reporting lines callers remain anonymous line includes technology prevent caller identification provided case reference number enables call back receive feedback status report gsk 's uk confidential reporting line access code us integrity helpline gskethics payment suppliers gsk changed standard payment terms minimum days receipt invoice step taken part corporate programme reduce working capital sixtyday payment terms bring gsk line practice industries faster terms set companies gsk procurement reviewing payment terms suppliers revise line corporate initiative back top home responsibility supply chain responsibility supply chain fair treatment suppliers corporate responsibility report fair treatment suppliers important foster relationships suppliers characterised mutual trust respect gsk established procurement policies processes requiring high standards ethical conduct integrity general terms conditions published website plan implement third party code conduct reinforcing principles values gsk expects business partners adopting code suppliers strengthen mutual trust respect gsk fair bidding gsk supports impartiality phases procurement cycle global electronic bid system ensures suppliers treated fairly equally vast majority suppliers providing goods services gsk registered system companies invited bid products services sourced gsk receive information time ensure fair ethical bidding process managed bids negotiations countries system highly competitive goods services system even transparent allow suppliers see bids rank competition monitoring concerns gsk employees suppliers third parties report concerns confidential reporting lines callers remain anonymous line includes technology prevent caller identification provided case reference number enables call back receive feedback status report gsk 's uk confidential reporting line access code us integrity helpline gskethics payment suppliers gsk changed standard payment terms minimum days receipt invoice step taken part corporate programme reduce working capital sixtyday payment terms bring gsk line practice industries faster terms set companies gsk procurement reviewing payment terms suppliers revise line corporate initiative back top home responsibility supply chain maintaining quality corporate responsibility report maintaining quality maintaining quality products make materials buy essential safety patients success business conduct quality assessments suppliers ingredients packaging materials used products agree specifications ingredients packaging materials suppliers apply set global auditing standards type ingredient packaging material buy use riskbased approach determine frequency audits conducted quality audits ingredient packaging material suppliers compared receipt gsk sites samples taken testing performed according testing protocol samples tested identity every batch also tested quality specification examples additional measures place maintain quality supply chain prevent contamination include use dedicated transport use tamperevident seals use sophisticated analytical tools check authenticity materials receive quality teams established regional country teams quality managers greater understanding local culture language ensure standards training reporting applied consistently also developed global database quality information previously held site level helping suppliers meet quality standards conduct quality assessments potential suppliers enables us identify companies meet required standards well work make necessary improvements example one suppliers asia inspection european regulatory agency five major findings gsk worked closely supplier help better understand expectations european regulator gsk quality department staff visited company three times six months educate supplier continually assess progress improvement plan reinspection took place november confirmed supplier successfully addressed findings working others improve quality rx industry consortium working set global standards auditing materials suppliers make easier suppliers understand expectations industry rather every company standards longterm goal move towards shared audit model lowerrisk suppliers suppliers used number companies would audited rather multiple times results shared purchasing companies consortium aims agree commons standards quality statement quality heart activities support discovery supply marketing products patients customers quality critical building trust society therefore future business success andrew witty chief executive officer back tophome responsibility supply chain maintaining quality corporate responsibility report maintaining quality maintaining quality products make materials buy essential safety patients success business conduct quality assessments suppliers ingredients packaging materials used products agree specifications ingredients packaging materials suppliers apply set global auditing standards type ingredient packaging material buy use riskbased approach determine frequency audits conducted quality audits ingredient packaging material suppliers compared receipt gsk sites samples taken testing performed according testing protocol samples tested identity every batch also tested quality specification examples additional measures place maintain quality supply chain prevent contamination include use dedicated transport use tamperevident seals use sophisticated analytical tools check authenticity materials receive quality teams established regional country teams quality managers greater understanding local culture language ensure standards training reporting applied consistently also developed global database quality information previously held site level helping suppliers meet quality standards conduct quality assessments potential suppliers enables us identify companies meet required standards well work make necessary improvements example one suppliers asia inspection european regulatory agency five major findings gsk worked closely supplier help better understand expectations european regulator gsk quality department staff visited company three times six months educate supplier continually assess progress improvement plan reinspection took place november confirmed supplier successfully addressed findings working others improve quality rx industry consortium working set global standards auditing materials suppliers make easier suppliers understand expectations industry rather every company standards longterm goal move towards shared audit model lowerrisk suppliers suppliers used number companies would audited rather multiple times results shared purchasing companies consortium aims agree commons standards quality statement quality heart activities support discovery supply marketing products patients customers quality critical building trust society therefore future business success andrew witty chief executive officer back top home responsibility supply chain maintaining quality corporate responsibility report maintaining quality maintaining quality products make materials buy essential safety patients success business conduct quality assessments suppliers ingredients packaging materials used products agree specifications ingredients packaging materials suppliers apply set global auditing standards type ingredient packaging material buy use riskbased approach determine frequency audits conducted quality audits ingredient packaging material suppliers compared receipt gsk sites samples taken testing performed according testing protocol samples tested identity every batch also tested quality specification examples additional measures place maintain quality supply chain prevent contamination include use dedicated transport use tamperevident seals use sophisticated analytical tools check authenticity materials receive quality teams established regional country teams quality managers greater understanding local culture language ensure standards training reporting applied consistently also developed global database quality information previously held site level helping suppliers meet quality standards conduct quality assessments potential suppliers enables us identify companies meet required standards well work make necessary improvements example one suppliers asia inspection european regulatory agency five major findings gsk worked closely supplier help better understand expectations european regulator gsk quality department staff visited company three times six months educate supplier continually assess progress improvement plan reinspection took place november confirmed supplier successfully addressed findings working others improve quality rx industry consortium working set global standards auditing materials suppliers make easier suppliers understand expectations industry rather every company standards longterm goal move towards shared audit model lowerrisk suppliers suppliers used number companies would audited rather multiple times results shared purchasing companies consortium aims agree commons standards quality statement quality heart activities support discovery supply marketing products patients customers quality critical building trust society therefore future business success andrew witty chief executive officer back top home responsibility supply chain security supply corporate responsibility report security supply ensuring continuous supply highquality medicines essential patients depend products well success business vital security supply compromised stage distribution chain prepare major incidents may disrupt supply ranging largescale theft products natural manmade disasters near facility gsks global manufacturing supply business implements contingency plans medically critical products define products medically critical lifesaving available patients likelihood serious detriment health known alternative plans defined productbyproduct basis may include holding sufficient stocks products active pharmaceutical ingredients work critical suppliers encourage implement contingency plans highrisk countries set joint ventures ensure maintain control distribution chain two global contracts suppliers deliver goods across borders gsk manufacturing sites gsk distribution centres conduct regular highlevel operational reviews suppliers include security elements also include security requirements contracts road air freight carriers move goods distribution centres market read measures taking protect employees event pandemic flu outbreak ensure supply critical medicines disrupted back top home responsibility supply chain security supply corporate responsibility report security supply ensuring continuous supply highquality medicines essential patients depend products well success business vital security supply compromised stage distribution chain prepare major incidents may disrupt supply ranging largescale theft products natural manmade disasters near facility gsks global manufacturing supply business implements contingency plans medically critical products define products medically critical lifesaving available patients likelihood serious detriment health known alternative plans defined productbyproduct basis may include holding sufficient stocks products active pharmaceutical ingredients work critical suppliers encourage implement contingency plans highrisk countries set joint ventures ensure maintain control distribution chain two global contracts suppliers deliver goods across borders gsk manufacturing sites gsk distribution centres conduct regular highlevel operational reviews suppliers include security elements also include security requirements contracts road air freight carriers move goods distribution centres market read measures taking protect employees event pandemic flu outbreak ensure supply critical medicines disrupted back top home responsibility supply chain counterfeiting corporate responsibility report counterfeiting approach performance according world health organization less one per cent pharmaceutical products sold developed countries counterfeit developing world figure may higher per cent per cent countries counterfeit drugs come many variations may contain none legitimate active ingredient active ingredient reduced subtherapeutic amounts completely different andor inappropriate active ingredient impurities unapproved colourants microorganisms packaging falsifies product description expiry date vast majority counterfeit drugs subject quality control hygiene standards testing ingredients monitoring product specifications equipment counterfeiting threat public health potentially causing harm patients even death add anticounterfeiting features product packaging include holograms security seals complex background patterns difficult photocopy scan well wide variety covert identifiers added using print technologies sophisticated markers help us identify counterfeits gather evidence offenders packing design technology security team uk carries forensic examinations suspected counterfeit gsk products gsk country managers required identify products likely counterfeited develop training sales representatives sales representatives worldwide play important role helping discover counterfeit products constant contact detailed knowledge markets outlets counterfeit products likely sold corporate security department investigates every potential case counterfeiting uses internal external investigators collect evidence criminal prosecutions authorities civil enforcement proceedings legal department well removing fake products market one primary aims trace products back source shut manufacturers partners example packaging printers distributors provide training regulatory authorities state food drug administration sfda china law enforcement agencies customs officers many parts world gsk works closely wider pharmaceutical industry investigate cases counterfeiting also raise awareness governments internationally pressing stricter laws severe penalties gsk founding member pharmaceutical security institute psi coordinates information collection investigations within industry internationally psi influential helping shape anticounterfeiting policy among national governments international organisations together psi gsk major contributor whos internationally represented anticounterfeiting working groups back top home responsibility supply chain counterfeiting corporate responsibility report counterfeiting approach performance according world health organization less one per cent pharmaceutical products sold developed countries counterfeit developing world figure may higher per cent per cent countries counterfeit drugs come many variations may contain none legitimate active ingredient active ingredient reduced subtherapeutic amounts completely different andor inappropriate active ingredient impurities unapproved colourants microorganisms packaging falsifies product description expiry date vast majority counterfeit drugs subject quality control hygiene standards testing ingredients monitoring product specifications equipment counterfeiting threat public health potentially causing harm patients even death add anticounterfeiting features product packaging include holograms security seals complex background patterns difficult photocopy scan well wide variety covert identifiers added using print technologies sophisticated markers help us identify counterfeits gather evidence offenders packing design technology security team uk carries forensic examinations suspected counterfeit gsk products gsk country managers required identify products likely counterfeited develop training sales representatives sales representatives worldwide play important role helping discover counterfeit products constant contact detailed knowledge markets outlets counterfeit products likely sold corporate security department investigates every potential case counterfeiting uses internal external investigators collect evidence criminal prosecutions authorities civil enforcement proceedings legal department well removing fake products market one primary aims trace products back source shut manufacturers partners example packaging printers distributors provide training regulatory authorities state food drug administration sfda china law enforcement agencies customs officers many parts world gsk works closely wider pharmaceutical industry investigate cases counterfeiting also raise awareness governments internationally pressing stricter laws severe penalties gsk founding member pharmaceutical security institute psi coordinates information collection investigations within industry internationally psi influential helping shape anticounterfeiting policy among national governments international organisations together psi gsk major contributor whos internationally represented anticounterfeiting working groups back top home responsibility supply chain counterfeiting corporate responsibility report counterfeiting approach performance according world health organization less one per cent pharmaceutical products sold developed countries counterfeit developing world figure may higher per cent per cent countries counterfeit drugs come many variations may contain none legitimate active ingredient active ingredient reduced subtherapeutic amounts completely different andor inappropriate active ingredient impurities unapproved colourants microorganisms packaging falsifies product description expiry date vast majority counterfeit drugs subject quality control hygiene standards testing ingredients monitoring product specifications equipment counterfeiting threat public health potentially causing harm patients even death add anticounterfeiting features product packaging include holograms security seals complex background patterns difficult photocopy scan well wide variety covert identifiers added using print technologies sophisticated markers help us identify counterfeits gather evidence offenders packing design technology security team uk carries forensic examinations suspected counterfeit gsk products gsk country managers required identify products likely counterfeited develop training sales representatives sales representatives worldwide play important role helping discover counterfeit products constant contact detailed knowledge markets outlets counterfeit products likely sold corporate security department investigates every potential case counterfeiting uses internal external investigators collect evidence criminal prosecutions authorities civil enforcement proceedings legal department well removing fake products market one primary aims trace products back source shut manufacturers partners example packaging printers distributors provide training regulatory authorities state food drug administration sfda china law enforcement agencies customs officers many parts world gsk works closely wider pharmaceutical industry investigate cases counterfeiting also raise awareness governments internationally pressing stricter laws severe penalties gsk founding member pharmaceutical security institute psi coordinates information collection investigations within industry internationally psi influential helping shape anticounterfeiting policy among national governments international organisations together psi gsk major contributor whos internationally represented anticounterfeiting working groups back top home responsibility supply chain counterfeiting performance corporate responsibility report counterfeiting approach performance reported cases counterfeiting gsk products resulted raids authorities suspected counterfeiters arrested raids took place criminal manufacturing facilities wholesaledistribution outlets factories represent criminal operations capable mass production counterfeit medicines healthcare products raids facilities undoubtedly prevented huge amounts counterfeit product entering legitimate markets around world anticounterfeiting practice conducted number successful anticounterfeiting operations focusing china primary source counterfeit products chinese domestic market international markets gsk corporate security undercover operation led arrest successful prosecution three counterfeiters china seizure counterfeit seroxat tablets tablets counterfeited major licensed pharmaceutical company north china result longterm undercover operation chinese prosecutors guangzhou city charged six defendants involved manufacturing distribution illegal export counterfeit panadol china taiwan investigation culminated raid chinese police factory two warehouses guangzhou city guangdong province taiwanese authorities also arrested person coordinating illicit distribution network taiwan result gsk operation chinese authorities raided factory shenzhen guangdong province seized counterfeit zinnat tablets cartons zinnat leaflets rolls counterfeit zinnat blister pack foil counterfeiting machinery seized three counterfeiters arrested medicine produced african middle eastern markets anticounterfeiting number reported number raids number arrests cases counterfeit back top home responsibility supply chain counterfeiting performance corporate responsibility report counterfeiting approach performance reported cases counterfeiting gsk products resulted raids authorities suspected counterfeiters arrested raids took place criminal manufacturing facilities wholesaledistribution outlets factories represent criminal operations capable mass production counterfeit medicines healthcare products raids facilities undoubtedly prevented huge amounts counterfeit product entering legitimate markets around world anticounterfeiting practice conducted number successful anticounterfeiting operations focusing china primary source counterfeit products chinese domestic market international markets gsk corporate security undercover operation led arrest successful prosecution three counterfeiters china seizure counterfeit seroxat tablets tablets counterfeited major licensed pharmaceutical company north china result longterm undercover operation chinese prosecutors guangzhou city charged six defendants involved manufacturing distribution illegal export counterfeit panadol china taiwan investigation culminated raid chinese police factory two warehouses guangzhou city guangdong province taiwanese authorities also arrested person coordinating illicit distribution network taiwan result gsk operation chinese authorities raided factory shenzhen guangdong province seized counterfeit zinnat tablets cartons zinnat leaflets rolls counterfeit zinnat blister pack foil counterfeiting machinery seized three counterfeiters arrested medicine produced african middle eastern markets anticounterfeiting number reported number raids number arrests cases counterfeit back top home responsibility supply chain case studies corporate responsibility report case studies mentoring diverse suppliers us callis construction services ccs minorityowned contracting company durham north carolina companys president jesse callis took part diverse supplier mentoring programme beginning helps suppliers form partnerships gsk large corporations part programme assessed ccss business processes identified issues preventing company becoming gsk preferred supplier concerns ranged management accessibility ability scale supply needs gsk company implemented improvements based recommendations enabled become preferred supplier win business worth around million success partnership enabled ccs contribute local community paid two employees attend local university mr callis developed training programme durham technical college prepares minority construction workers management positions major projects area asked relationship gsk mr callis said gsk wonderful mentor real leader commitment actions help diverse minority suppliers case provided assistance led significant growth business turn provided jobs others durham surrounding area ensuring monies paid gsk stay local communities win everyone involved ' improving supplier performance developing countries large number potential raw material suppliers china failing meet minimum ehs criteria took action improve standards increased use preaudit assessments determine potential new suppliers capability commitment improve using results assessments facilitated meetings supplier expert consultants identify implement pragmatic improvement plans example gsk approached chinese pharmaceutical manufacturing company assess whether could provide key ingredients needed manufacture asthma medicines initial audit identified multiple deficiencies ehs standards including poor approaches fire prevention protection significant gaps design safe operation process equipment supplier agreed work gsk employ services expert consultants make necessary improvements involved commitment senior management team regularly met gsk monitored progress reaudit demonstrated company meets minimum standards put place management systems provide foundation improvements supplier manufacturing trial quantities materials assessing possibility establishing longterm supply contract pleased note supplier introduced ehs loss prevention improvements design construction operation new site recently built using approach regularly china india back top home responsibility supply chain case studies corporate responsibility report case studies mentoring diverse suppliers us callis construction services ccs minorityowned contracting company durham north carolina companys president jesse callis took part diverse supplier mentoring programme beginning helps suppliers form partnerships gsk large corporations part programme assessed ccss business processes identified issues preventing company becoming gsk preferred supplier concerns ranged management accessibility ability scale supply needs gsk company implemented improvements based recommendations enabled become preferred supplier win business worth around million success partnership enabled ccs contribute local community paid two employees attend local university mr callis developed training programme durham technical college prepares minority construction workers management positions major projects area asked relationship gsk mr callis said gsk wonderful mentor real leader commitment actions help diverse minority suppliers case provided assistance led significant growth business turn provided jobs others durham surrounding area ensuring monies paid gsk stay local communities win everyone involved ' improving supplier performance developing countries large number potential raw material suppliers china failing meet minimum ehs criteria took action improve standards increased use preaudit assessments determine potential new suppliers capability commitment improve using results assessments facilitated meetings supplier expert consultants identify implement pragmatic improvement plans example gsk approached chinese pharmaceutical manufacturing company assess whether could provide key ingredients needed manufacture asthma medicines initial audit identified multiple deficiencies ehs standards including poor approaches fire prevention protection significant gaps design safe operation process equipment supplier agreed work gsk employ services expert consultants make necessary improvements involved commitment senior management team regularly met gsk monitored progress reaudit demonstrated company meets minimum standards put place management systems provide foundation improvements supplier manufacturing trial quantities materials assessing possibility establishing longterm supply contract pleased note supplier introduced ehs loss prevention improvements design construction operation new site recently built using approach regularly china india back top home responsibility supply chain qas corporate responsibility report qas respond questions raised stakeholders raise standards supply chain longterm relationships critical suppliers offer training support help raise standards monitoring process key part raising awareness expectations identifying areas suppliers need improve work suppliers help make necessary changes identified human rights risks supply chain gsks supply chain large complex like similar supply chains contains risk human rights violations risks vary considerably based type supplier goods service sourcing manufacturing rd suppliers employ skilled workers lower risk human rights violations ehs audits help provide assurance good working conditions place supplier facilities considerably higher human rights risks suppliers employ lowskilled workers example promotional goods suppliers conduct spot checks suppliers india supplier selection process aims ensure enter relationships suppliers respect human rights also include clauses contracts suppliers specify upholding human rights condition business gsk supply chain plan flu pandemic implemented contingency plan ensure operations supply medically critical products compromised flu pandemic encouraging critical suppliers implement contingency plans outsourcing manufacturing mean less control products increasing risk patients manufacture medicines vaccines closely controlled subject quality standards regardless whether produce outsource process contract manufacturers outsourcing stage manufacturing process confirm contractor carry required processes high standards contract manufacturers must also approved relevant regulatory authorities subject inspection gsk regulators back top home responsibility supply chain qas corporate responsibility report qas respond questions raised stakeholders raise standards supply chain longterm relationships critical suppliers offer training support help raise standards monitoring process key part raising awareness expectations identifying areas suppliers need improve work suppliers help make necessary changes identified human rights risks supply chain gsks supply chain large complex like similar supply chains contains risk human rights violations risks vary considerably based type supplier goods service sourcing manufacturing rd suppliers employ skilled workers lower risk human rights violations ehs audits help provide assurance good working conditions place supplier facilities considerably higher human rights risks suppliers employ lowskilled workers example promotional goods suppliers conduct spot checks suppliers india supplier selection process aims ensure enter relationships suppliers respect human rights also include clauses contracts suppliers specify upholding human rights condition business gsk supply chain plan flu pandemic implemented contingency plan ensure operations supply medically critical products compromised flu pandemic encouraging critical suppliers implement contingency plans outsourcing manufacturing mean less control products increasing risk patients manufacture medicines vaccines closely controlled subject quality standards regardless whether produce outsource process contract manufacturers outsourcing stage manufacturing process confirm contractor carry required processes high standards contract manufacturers must also approved relevant regulatory authorities subject inspection gsk regulators back top home responsibility environmental sustainability corporate responsibility report environmental sustainability stepping efforts become sustainable oversight new sustainability council senior executives vision ultimately transform business following principles industrial ecology optimising efficiency processes increasing use renewable materials energy recognise challenging journey many hard decisions since implementing climate change programme ambitious targets emissions energy use operations transport aiming per cent reduction per unit sales cut per cent levels emissions energy consumption per unit sales fell five per cent six per cent respectively reductions follow two years limited progress need outstanding performance meet interim per cent target unlikely achieve target however committed achieving target looking incentives engage motivate staff operations achieve necessary leap forward increasing efficiency use materials priority increased target per cent introduced target per cent efficiency new products moving rd manufacturing first time also set mass efficiency target manufacturing sites achieve additional improvements raising mass efficiency three per cent take processes rd longterm aspiration achieve five per cent efficiency five times typical level pharmaceutical industry reduce input materials waste per cent average mass efficiency since stands per cent latephase development compounds compared target per cent end understand sustainability requires holistic view everything especially optimal use resources water particularly important natural resource recognise businesses play positive role managing sustainably endorsed united nations ceo water mandate water consumption fell five per cent per unit sales exceeds target want go beyond saving water operations engage range water issues relevant healthcare business water borne diseases transparency key element sustainability strategy report plays important part open aims performance however want report performance individual operations putting system place data section assured sgs united kingdom independent assurance provider read assurance statement management environmental sustainability driven plans supporting three environmental sustainability strategic priorities embed environment health safety fundamentals business embrace environmental sustainability maintain open transparent external relations update environment plan broadening plan sustainability new challenging targets recognise need better job integrating environmental social economic opportunities order create truly sustainable solutions address concerns updated plan back top home responsibility environmental sustainability corporate responsibility report environmental sustainability stepping efforts become sustainable oversight new sustainability council senior executives vision ultimately transform business following principles industrial ecology optimising efficiency processes increasing use renewable materials energy recognise challenging journey many hard decisions since implementing climate change programme ambitious targets emissions energy use operations transport aiming per cent reduction per unit sales cut per cent levels emissions energy consumption per unit sales fell five per cent six per cent respectively reductions follow two years limited progress need outstanding performance meet interim per cent target unlikely achieve target however committed achieving target looking incentives engage motivate staff operations achieve necessary leap forward increasing efficiency use materials priority increased target per cent introduced target per cent efficiency new products moving rd manufacturing first time also set mass efficiency target manufacturing sites achieve additional improvements raising mass efficiency three per cent take processes rd longterm aspiration achieve five per cent efficiency five times typical level pharmaceutical industry reduce input materials waste per cent average mass efficiency since stands per cent latephase development compounds compared target per cent end understand sustainability requires holistic view everything especially optimal use resources water particularly important natural resource recognise businesses play positive role managing sustainably endorsed united nations ceo water mandate water consumption fell five per cent per unit sales exceeds target want go beyond saving water operations engage range water issues relevant healthcare business water borne diseases transparency key element sustainability strategy report plays important part open aims performance however want report performance individual operations putting system place data section assured sgs united kingdom independent assurance provider read assurance statement management environmental sustainability driven plans supporting three environmental sustainability strategic priorities embed environment health safety fundamentals business embrace environmental sustainability maintain open transparent external relations update environment plan broadening plan sustainability new challenging targets recognise need better job integrating environmental social economic opportunities order create truly sustainable solutions address concerns updated plan back top home responsibility environmental sustainability sustainability gsk corporate responsibility report sustainability gsk environmental sustainability important component gsks activities need use resources efficiently good business contribute addressing many challenges facing world copenhagen climate summit december placed climate change firmly top sustainability agenda water gained almost equal prominence gsk joined ceo water mandate sustainability means resources must conserved need optimise resource consumption eliminate waste finding beneficial uses byproducts social economic aspects sustainability also critical covered sections report need integrate environmental activity social economic aspects fully develop sustainability business vision transformation vision sustainability transform business align natural cycle use renewable resources convert wastes byproducts become inputs processes approach industrial ecology requires optimise efficiency processes increase use renewable materials energy eliminate waste streams converting useful byproducts sustainability strategy developed embed environmental fundamentals eliminate adverse impacts embrace sustainability use resources responsibly provide transparency inform stakeholders actions gsk path sustainability since formation company legacy companies working issues early years emphasis improving immediate impacts operations creating management framework policies standards targets improve use energy resources reduce emissions broadening focus looking transform way operate become sustainable operational objective become efficient facilities processes ultimate aim changing waste byproducts process outputs currently regarded waste must become products reused either gsk businesses may mean fundamental reappraisal sourcing manufacturing processes possible adopting different approach sourcing renewable raw materials manufacturing pharmaceuticals efficiently could significantly reduce energy water materials required time improving quality safety saving money ultimately may mean using renewable material well renewable energy material derived organic matter rather petroleum also need work towards closed loop systems beginning consumer healthcare business per cent recycled plastic bottles developments created sustainability council direct efforts area demonstrating seriousness taking challenge council consists senior managers across business individual businesses also developing already pursuing specific sustainability strategies year also introduced ceos sustainability award recognise innovations gsk teams created real benefits society environment business award replaces environment health safety excellence award reflecting greater focus sustainability rather narrower ehs agenda feedback engage formally stakeholders external stakeholder panel always eager hear views plans progress contact us corporate responsibility matters csrcontactgskcom back tophome responsibility environmental sustainability sustainability gsk corporate responsibility report sustainability gsk environmental sustainability important component gsks activities need use resources efficiently good business contribute addressing many challenges facing world copenhagen climate summit december placed climate change firmly top sustainability agenda water gained almost equal prominence gsk joined ceo water mandate sustainability means resources must conserved need optimise resource consumption eliminate waste finding beneficial uses byproducts social economic aspects sustainability also critical covered sections report need integrate environmental activity social economic aspects fully develop sustainability business vision transformation vision sustainability transform business align natural cycle use renewable resources convert wastes byproducts become inputs processes approach industrial ecology requires optimise efficiency processes increase use renewable materials energy eliminate waste streams converting useful byproducts sustainability strategy developed embed environmental fundamentals eliminate adverse impacts embrace sustainability use resources responsibly provide transparency inform stakeholders actions gsk path sustainability since formation company legacy companies working issues early years emphasis improving immediate impacts operations creating management framework policies standards targets improve use energy resources reduce emissions broadening focus looking transform way operate become sustainable operational objective become efficient facilities processes ultimate aim changing waste byproducts process outputs currently regarded waste must become products reused either gsk businesses may mean fundamental reappraisal sourcing manufacturing processes possible adopting different approach sourcing renewable raw materials manufacturing pharmaceuticals efficiently could significantly reduce energy water materials required time improving quality safety saving money ultimately may mean using renewable material well renewable energy material derived organic matter rather petroleum also need work towards closed loop systems beginning consumer healthcare business per cent recycled plastic bottles developments created sustainability council direct efforts area demonstrating seriousness taking challenge council consists senior managers across business individual businesses also developing already pursuing specific sustainability strategies year also introduced ceos sustainability award recognise innovations gsk teams created real benefits society environment business award replaces environment health safety excellence award reflecting greater focus sustainability rather narrower ehs agenda feedback engage formally stakeholders external stakeholder panel always eager hear views plans progress contact us corporate responsibility matters csrcontactgskcom back top home responsibility environmental sustainability sustainability gsk corporate responsibility report sustainability gsk environmental sustainability important component gsks activities need use resources efficiently good business contribute addressing many challenges facing world copenhagen climate summit december placed climate change firmly top sustainability agenda water gained almost equal prominence gsk joined ceo water mandate sustainability means resources must conserved need optimise resource consumption eliminate waste finding beneficial uses byproducts social economic aspects sustainability also critical covered sections report need integrate environmental activity social economic aspects fully develop sustainability business vision transformation vision sustainability transform business align natural cycle use renewable resources convert wastes byproducts become inputs processes approach industrial ecology requires optimise efficiency processes increase use renewable materials energy eliminate waste streams converting useful byproducts sustainability strategy developed embed environmental fundamentals eliminate adverse impacts embrace sustainability use resources responsibly provide transparency inform stakeholders actions gsk path sustainability since formation company legacy companies working issues early years emphasis improving immediate impacts operations creating management framework policies standards targets improve use energy resources reduce emissions broadening focus looking transform way operate become sustainable operational objective become efficient facilities processes ultimate aim changing waste byproducts process outputs currently regarded waste must become products reused either gsk businesses may mean fundamental reappraisal sourcing manufacturing processes possible adopting different approach sourcing renewable raw materials manufacturing pharmaceuticals efficiently could significantly reduce energy water materials required time improving quality safety saving money ultimately may mean using renewable material well renewable energy material derived organic matter rather petroleum also need work towards closed loop systems beginning consumer healthcare business per cent recycled plastic bottles developments created sustainability council direct efforts area demonstrating seriousness taking challenge council consists senior managers across business individual businesses also developing already pursuing specific sustainability strategies year also introduced ceos sustainability award recognise innovations gsk teams created real benefits society environment business award replaces environment health safety excellence award reflecting greater focus sustainability rather narrower ehs agenda feedback engage formally stakeholders external stakeholder panel always eager hear views plans progress contact us corporate responsibility matters csrcontactgskcom back top home responsibility environmental sustainability managing environmental sustainability corporate responsibility report managing environmental sustainability revised approach managing sustainability environmental issues part drive widen focus gsks efforts address environmental sustainability broadly focused improving immediate impacts energy waste aiming transform way operate holistic way become sustainable management health safety transferred human resources function gsk two centres excellence covering health safety performance sustainability environment environment health safety directors moved central organisation become embedded businesses supporting integration sustainability operations developing business focus business units developing sustainability strategies specific businesses need coordinate ensure pursue integrated approach governance focus sustainability supported new sustainability council senior executives across business council oversees gsks sustainability plans progress meets via teleconference four times year reviewed plans several key aspects sustainability gsk submitted endorsement corporate executive team cet overall responsibility sustainability environment rests cet chief staff management responsibility operational responsibility lies business heads vice president sustainability environment board subcommittees oversight respectively risk compliance audit corporate responsibility committees regularly review performance progress vision strategy gsks environment health safety sustainability ehss vision achieve sustainable competitive business advantage environmental sustainability leadership excellence strategy begin embedding environmental fundamentals energy management waste reduction eliminate adverse impacts operations second stage embrace sustainability businesses developing culture product stewardship sustainable resource use strategy also requires transparency making sure inform stakeholders actions results gsk ehss policy ehss policy defines aspiration global leadership excellence outlines broad scope plans achieved revised policy approved cet leaders ehss performance protecting environment communities work enabling healthy motivated employees fully engaged success maintain culture continuous improvement ehs fundamentals risk impacts embed ehs fundamentals fabric business implementing management systems ehs governance risk management practices address risks impacts facilities processes contract research manufacturing organisations suppliers sustainability integrate sustainability principles aspects healthcare business working stakeholders operating within environmentally sustainable limits lowering ecological footprint enhancing social equity addressing future issues open ehss communication open transparent stakeholders efforts address ehss responsibilities ehss performance corporate executive team cet ensure risks tracked mitigated communication significant risks escalated within business management structure commensurate risks impacts involved cet ensure effective management involvement staff clearly assigned accountability responsibility management systems manage sustainability environment occupational health safety issues using management system aligned recognised international standards iso ohsas management system based structured framework building vision policies supported standards guidance materials tools training recognition audits help businesses manage issues targets set fiveyear periods originally currently developing targets new metrics reflect revised focus environmental sustainability rather narrower environment impacts back tophome responsibility environmental sustainability managing environmental sustainability corporate responsibility report managing environmental sustainability revised approach managing sustainability environmental issues part drive widen focus gsks efforts address environmental sustainability broadly focused improving immediate impacts energy waste aiming transform way operate holistic way become sustainable management health safety transferred human resources function gsk two centres excellence covering health safety performance sustainability environment environment health safety directors moved central organisation become embedded businesses supporting integration sustainability operations developing business focus business units developing sustainability strategies specific businesses need coordinate ensure pursue integrated approach governance focus sustainability supported new sustainability council senior executives across business council oversees gsks sustainability plans progress meets via teleconference four times year reviewed plans several key aspects sustainability gsk submitted endorsement corporate executive team cet overall responsibility sustainability environment rests cet chief staff management responsibility operational responsibility lies business heads vice president sustainability environment board subcommittees oversight respectively risk compliance audit corporate responsibility committees regularly review performance progress vision strategy gsks environment health safety sustainability ehss vision achieve sustainable competitive business advantage environmental sustainability leadership excellence strategy begin embedding environmental fundamentals energy management waste reduction eliminate adverse impacts operations second stage embrace sustainability businesses developing culture product stewardship sustainable resource use strategy also requires transparency making sure inform stakeholders actions results gsk ehss policy ehss policy defines aspiration global leadership excellence outlines broad scope plans achieved revised policy approved cet leaders ehss performance protecting environment communities work enabling healthy motivated employees fully engaged success maintain culture continuous improvement ehs fundamentals risk impacts embed ehs fundamentals fabric business implementing management systems ehs governance risk management practices address risks impacts facilities processes contract research manufacturing organisations suppliers sustainability integrate sustainability principles aspects healthcare business working stakeholders operating within environmentally sustainable limits lowering ecological footprint enhancing social equity addressing future issues open ehss communication open transparent stakeholders efforts address ehss responsibilities ehss performance corporate executive team cet ensure risks tracked mitigated communication significant risks escalated within business management structure commensurate risks impacts involved cet ensure effective management involvement staff clearly assigned accountability responsibility management systems manage sustainability environment occupational health safety issues using management system aligned recognised international standards iso ohsas management system based structured framework building vision policies supported standards guidance materials tools training recognition audits help businesses manage issues targets set fiveyear periods originally currently developing targets new metrics reflect revised focus environmental sustainability rather narrower environment impacts back top home responsibility environmental sustainability managing environmental sustainability corporate responsibility report managing environmental sustainability revised approach managing sustainability environmental issues part drive widen focus gsks efforts address environmental sustainability broadly focused improving immediate impacts energy waste aiming transform way operate holistic way become sustainable management health safety transferred human resources function gsk two centres excellence covering health safety performance sustainability environment environment health safety directors moved central organisation become embedded businesses supporting integration sustainability operations developing business focus business units developing sustainability strategies specific businesses need coordinate ensure pursue integrated approach governance focus sustainability supported new sustainability council senior executives across business council oversees gsks sustainability plans progress meets via teleconference four times year reviewed plans several key aspects sustainability gsk submitted endorsement corporate executive team cet overall responsibility sustainability environment rests cet chief staff management responsibility operational responsibility lies business heads vice president sustainability environment board subcommittees oversight respectively risk compliance audit corporate responsibility committees regularly review performance progress vision strategy gsks environment health safety sustainability ehss vision achieve sustainable competitive business advantage environmental sustainability leadership excellence strategy begin embedding environmental fundamentals energy management waste reduction eliminate adverse impacts operations second stage embrace sustainability businesses developing culture product stewardship sustainable resource use strategy also requires transparency making sure inform stakeholders actions results gsk ehss policy ehss policy defines aspiration global leadership excellence outlines broad scope plans achieved revised policy approved cet leaders ehss performance protecting environment communities work enabling healthy motivated employees fully engaged success maintain culture continuous improvement ehs fundamentals risk impacts embed ehs fundamentals fabric business implementing management systems ehs governance risk management practices address risks impacts facilities processes contract research manufacturing organisations suppliers sustainability integrate sustainability principles aspects healthcare business working stakeholders operating within environmentally sustainable limits lowering ecological footprint enhancing social equity addressing future issues open ehss communication open transparent stakeholders efforts address ehss responsibilities ehss performance corporate executive team cet ensure risks tracked mitigated communication significant risks escalated within business management structure commensurate risks impacts involved cet ensure effective management involvement staff clearly assigned accountability responsibility management systems manage sustainability environment occupational health safety issues using management system aligned recognised international standards iso ohsas management system based structured framework building vision policies supported standards guidance materials tools training recognition audits help businesses manage issues targets set fiveyear periods originally currently developing targets new metrics reflect revised focus environmental sustainability rather narrower environment impacts back top home responsibility environmental sustainability managing environmental sustainability plans targets corporate responsibility report plans targets approach performance plans gsk sustainability environment strategy implemented plan excellence group wide goals improve performance work external stakeholder panel define plan review performance plan supports three strategic priorities embed environment health safety fundamentals business embrace environmental sustainability maintain open transparent external relations individual plans place key elements strategic priority shown chart sustainability environment health safety performance strategic framework strategic priorities plans embed ehs fundamentals provide governance business use management systems include ehs business processes engage internal stakeholders support ehs embrace sustainability develop sustainability culture adopt product stewardship approach promote resource efficiency utilise sustainable operations develop health performance sustainability maintain transparent external relations provide transparent reporting engage external stakeholders work partnerships initially plan covered period midterm review extended period currently preparing extend plan period revision named plan sustainability reflecting increased focus sustainability plan introduce new kinds metrics related sustainability impacts well direct environmental performance include measures extent building sustainability decisionmaking daytoday operations well operational measures carbon reduction resource efficiency identification appropriate metrics informed stakeholders views environmental sustainability priorities gsk gsks businesses developing sustainability strategies relevant business strategies operations consumer healthcare adopted strategy embed sustainability business plans brands including making part new product development process packaging key issue consumer healthcare sustainability strategy goes beyond packaging address whole supply chain also addresses water energy consumption developing formulations minimise environmental impacts targets align group targets targets believe important set achieve targets lower resource consumption less emissions waste benefit environment gsk plan excellence includes groupwide targets improve environmental health safety performance targets based site specific practical improvement plans forecasts manufacturing operations compare proposals company targets put forward operations benchmarking information environment health safety professionals management teams throughout business closely review agree final target numbers track meet seven nine targets recognise difficult meet within time set explain progress targets discussions individual performance sections back tophome responsibility environmental sustainability managing environmental sustainability plans targets corporate responsibility report plans targets approach performance plans gsk sustainability environment strategy implemented plan excellence group wide goals improve performance work external stakeholder panel define plan review performance plan supports three strategic priorities embed environment health safety fundamentals business embrace environmental sustainability maintain open transparent external relations individual plans place key elements strategic priority shown chart sustainability environment health safety performance strategic framework strategic priorities plans embed ehs fundamentals provide governance business use management systems include ehs business processes engage internal stakeholders support ehs embrace sustainability develop sustainability culture adopt product stewardship approach promote resource efficiency utilise sustainable operations develop health performance sustainability maintain transparent external relations provide transparent reporting engage external stakeholders work partnerships initially plan covered period midterm review extended period currently preparing extend plan period revision named plan sustainability reflecting increased focus sustainability plan introduce new kinds metrics related sustainability impacts well direct environmental performance include measures extent building sustainability decisionmaking daytoday operations well operational measures carbon reduction resource efficiency identification appropriate metrics informed stakeholders views environmental sustainability priorities gsk gsks businesses developing sustainability strategies relevant business strategies operations consumer healthcare adopted strategy embed sustainability business plans brands including making part new product development process packaging key issue consumer healthcare sustainability strategy goes beyond packaging address whole supply chain also addresses water energy consumption developing formulations minimise environmental impacts targets align group targets targets believe important set achieve targets lower resource consumption less emissions waste benefit environment gsk plan excellence includes groupwide targets improve environmental health safety performance targets based site specific practical improvement plans forecasts manufacturing operations compare proposals company targets put forward operations benchmarking information environment health safety professionals management teams throughout business closely review agree final target numbers track meet seven nine targets recognise difficult meet within time set explain progress targets discussions individual performance sections back top home responsibility environmental sustainability managing environmental sustainability plans targets corporate responsibility report plans targets approach performance plans gsk sustainability environment strategy implemented plan excellence group wide goals improve performance work external stakeholder panel define plan review performance plan supports three strategic priorities embed environment health safety fundamentals business embrace environmental sustainability maintain open transparent external relations individual plans place key elements strategic priority shown chart sustainability environment health safety performance strategic framework strategic priorities plans embed ehs fundamentals provide governance business use management systems include ehs business processes engage internal stakeholders support ehs embrace sustainability develop sustainability culture adopt product stewardship approach promote resource efficiency utilise sustainable operations develop health performance sustainability maintain transparent external relations provide transparent reporting engage external stakeholders work partnerships initially plan covered period midterm review extended period currently preparing extend plan period revision named plan sustainability reflecting increased focus sustainability plan introduce new kinds metrics related sustainability impacts well direct environmental performance include measures extent building sustainability decisionmaking daytoday operations well operational measures carbon reduction resource efficiency identification appropriate metrics informed stakeholders views environmental sustainability priorities gsk gsks businesses developing sustainability strategies relevant business strategies operations consumer healthcare adopted strategy embed sustainability business plans brands including making part new product development process packaging key issue consumer healthcare sustainability strategy goes beyond packaging address whole supply chain also addresses water energy consumption developing formulations minimise environmental impacts targets align group targets targets believe important set achieve targets lower resource consumption less emissions waste benefit environment gsk plan excellence includes groupwide targets improve environmental health safety performance targets based site specific practical improvement plans forecasts manufacturing operations compare proposals company targets put forward operations benchmarking information environment health safety professionals management teams throughout business closely review agree final target numbers track meet seven nine targets recognise difficult meet within time set explain progress targets discussions individual performance sections back top home responsibility environmental sustainability managing environmental sustainability plans targets performance plans corporate responsibility report plans targets approach performance plans targets progress group target progress energy operations transport reduction per unit reduced per sales sales baseline cumulative since climate change impact energy reduction per unit reduced per sales operations transport sales baseline cumulative since mass efficiency new processes average transferred average mass efficiency products period achieved water annual reduction reduced per sales baseline per unit cumulative since sales wastewater chemical oxygen demand annual reduction reduced per sales baseline per unit cumulative since sales solid waste disposed annual reduction reduced per sales baseline per unit cumulative since sales ozone depletion elimination cfcs processes eliminated equipment air emissions volatile organic annual reduction reduced per sales emissions baseline per unit cumulative since sales ehs audit scores average average minimum minimum note figures per unit sales calculated constant exchange rates cer figures energy climate change relatively unchanged progress achieved numbers reflect sites scored corporate audits made progress targets cases already exceeded target end others especially energy track meet target energy consumption per sales fell six per cent greenhouse gas emissions fell five per cent earlier investments started pay however cumulative reductions six per cent energy five per cent greenhouse gas emissions compared target per cent end clearly need step performance average mass efficiency transferred products increased exceeded average two per cent target exceeded targets especially wastewater emissions air measures sensitive changes business especially manufacturing future progress necessarily follow trend environmental audit scores moving right direction targets sgs verified back tophome responsibility environmental sustainability managing environmental sustainability plans targets performance plans corporate responsibility report plans targets approach performance plans targets progress group target progress energy operations transport reduction per unit reduced per sales sales baseline cumulative since climate change impact energy reduction per unit reduced per sales operations transport sales baseline cumulative since mass efficiency new processes average transferred average mass efficiency products period achieved water annual reduction reduced per sales baseline per unit cumulative since sales wastewater chemical oxygen demand annual reduction reduced per sales baseline per unit cumulative since sales solid waste disposed annual reduction reduced per sales baseline per unit cumulative since sales ozone depletion elimination cfcs processes eliminated equipment air emissions volatile organic annual reduction reduced per sales emissions baseline per unit cumulative since sales ehs audit scores average average minimum minimum note figures per unit sales calculated constant exchange rates cer figures energy climate change relatively unchanged progress achieved numbers reflect sites scored corporate audits made progress targets cases already exceeded target end others especially energy track meet target energy consumption per sales fell six per cent greenhouse gas emissions fell five per cent earlier investments started pay however cumulative reductions six per cent energy five per cent greenhouse gas emissions compared target per cent end clearly need step performance average mass efficiency transferred products increased exceeded average two per cent target exceeded targets especially wastewater emissions air measures sensitive changes business especially manufacturing future progress necessarily follow trend environmental audit scores moving right direction targets sgs verified back top home responsibility environmental sustainability managing environmental sustainability plans targets performance plans corporate responsibility report plans targets approach performance plans targets progress group target progress energy operations transport reduction per unit reduced per sales sales baseline cumulative since climate change impact energy reduction per unit reduced per sales operations transport sales baseline cumulative since mass efficiency new processes average transferred average mass efficiency products period achieved water annual reduction reduced per sales baseline per unit cumulative since sales wastewater chemical oxygen demand annual reduction reduced per sales baseline per unit cumulative since sales solid waste disposed annual reduction reduced per sales baseline per unit cumulative since sales ozone depletion elimination cfcs processes eliminated equipment air emissions volatile organic annual reduction reduced per sales emissions baseline per unit cumulative since sales ehs audit scores average average minimum minimum note figures per unit sales calculated constant exchange rates cer figures energy climate change relatively unchanged progress achieved numbers reflect sites scored corporate audits made progress targets cases already exceeded target end others especially energy track meet target energy consumption per sales fell six per cent greenhouse gas emissions fell five per cent earlier investments started pay however cumulative reductions six per cent energy five per cent greenhouse gas emissions compared target per cent end clearly need step performance average mass efficiency transferred products increased exceeded average two per cent target exceeded targets especially wastewater emissions air measures sensitive changes business especially manufacturing future progress necessarily follow trend environmental audit scores moving right direction targets sgs verified back top home responsibility environmental sustainability managing environmental sustainability integration business principles corporate responsibility report integration business principles achieve improved performance sustainability environmental management integrated businesses rather addon developed processes programmes help scientists engineers managers support sustainability environment goals part everyday activity milestone aligned process helps scientists identify address sustainability environmental issues new product development supply activities ensures scientists understand environment health safety sustainability principles impacts manage products life cycle new products processes developed harm people property environment opportunities identified process efficiencies elimination waste reduce ehss impacts improve product development supply procurement acquisitions gsk procurement activities support sustainability environmental goals areas sourcing renewable recycled materials appropriate choosing safe energyefficient equipment managing sustainability environmental risks supply chain capital project technical review process designed ensure consider sustainability environment loss prevention design new facilities processes identifying sustainability environmental issues early project engineer facilities processes efficient safe environment still cost effective due diligence process acquiring divesting businesses ensures sustainability environmental issues considered contract negotiations adequate management systems place work acquired companies develop action plans align sustainability environmental practices gsks emergency response crisis management discovery development manufacture pharmaceutical consumer products involve use hazardous materials processes sites incorporate emergency response crisis management programmes management plans programmes ensure accidents effectively managed occur impact business local community environment minimised site conducts annual review internal emergency response programmes technical capabilities develops plans address areas needing improvement back top home responsibility environmental sustainability managing environmental sustainability integration business principles corporate responsibility report integration business principles achieve improved performance sustainability environmental management integrated businesses rather addon developed processes programmes help scientists engineers managers support sustainability environment goals part everyday activity milestone aligned process helps scientists identify address sustainability environmental issues new product development supply activities ensures scientists understand environment health safety sustainability principles impacts manage products life cycle new products processes developed harm people property environment opportunities identified process efficiencies elimination waste reduce ehss impacts improve product development supply procurement acquisitions gsk procurement activities support sustainability environmental goals areas sourcing renewable recycled materials appropriate choosing safe energyefficient equipment managing sustainability environmental risks supply chain capital project technical review process designed ensure consider sustainability environment loss prevention design new facilities processes identifying sustainability environmental issues early project engineer facilities processes efficient safe environment still cost effective due diligence process acquiring divesting businesses ensures sustainability environmental issues considered contract negotiations adequate management systems place work acquired companies develop action plans align sustainability environmental practices gsks emergency response crisis management discovery development manufacture pharmaceutical consumer products involve use hazardous materials processes sites incorporate emergency response crisis management programmes management plans programmes ensure accidents effectively managed occur impact business local community environment minimised site conducts annual review internal emergency response programmes technical capabilities develops plans address areas needing improvement back top home responsibility environmental sustainability managing environmental sustainability awareness recognition corporate responsibility report awareness recognition recognise responsibility make gsk community aware environmental sustainability issues engage people levels organisation take sustainability account work decisionmaking offer training orientation business leaders understand issues best respond launched new training packages ehs training connect intranet site specific sustainability environmental training managed individual sites relevant job roles sustainability environment professionals receive induction training undertake regular updates ensure aware latest technical information fields still need continue upgrade level competence site environmental staff companys global internal communications include regular messages environmental sustainability issues included features global employee publications regular calendar internal news releases environment sustainability issues intranet site containing regularly updated material gsks climate change energy reduction initiatives ceos sustainability award programme see launched gives highest level recognition employees furthered gsks environmental sustainability agenda awareness raise employee awareness sustainability environment intranet regular internal publications events however passive communication need develop interactive communications engage employees several areas gsk intranet support sustainability environment including main site known myehss way news sustainability environmental programmes health safety shared within group source supporting materials ehss framework policy standards guidelines training materials documents also use collect data measuring performance reporting results launched climate change microsite called climate change gsk site explains importance climate change everyone needs act gsk individuals includes items reporting action cut carbon dioxide emissions across business celebrates successes included gsk named carbon disclosure projects global carbon disclosure leadership index awarded certification carbon trust standard uk publications available electronically print publish articles sustainability environment spirit internal magazine brief news stories internal web pages many sites celebrate earthweek raise awareness environmental issues encourage integrating environmental concerns gsk culture earthweek encourages employees think impact environment sustainability awards ceos sustainability award programme recognises gsk teams innovation creates benefits society environment business creativity achieves genuine step change towards sustainability publicise innovative practices win awards dedicated intranet site team gsk may considered award except sustainability environment centre excellence administers scheme internal review committee agrees shortlist winners chosen panel includes experts academia government public interest groups winner receives trophy selects charity receive donation gsk awards given three categories environmental sustainability creative adventurous thinking reduces total impact business environment builds trust communities work health safety sustainability innovative ideas create measurable improvements employee performance due health safety initiatives sustainable science technology scientific engineering breakthroughs size scale change things good leave lasting legacy feed support continued innovation entries countries honours went projects belgium india uk us special honour vanguard award went team rd stevenage uk project continuous manufacturing active pharmaceutical ingredients sixyear project overcame significant technical hurdles develop efficient process less waste lower emissions volatile organic compounds vocs lower costs read winning sustainability environment projects back tophome responsibility environmental sustainability managing environmental sustainability awareness recognition corporate responsibility report awareness recognition recognise responsibility make gsk community aware environmental sustainability issues engage people levels organisation take sustainability account work decisionmaking offer training orientation business leaders understand issues best respond launched new training packages ehs training connect intranet site specific sustainability environmental training managed individual sites relevant job roles sustainability environment professionals receive induction training undertake regular updates ensure aware latest technical information fields still need continue upgrade level competence site environmental staff companys global internal communications include regular messages environmental sustainability issues included features global employee publications regular calendar internal news releases environment sustainability issues intranet site containing regularly updated material gsks climate change energy reduction initiatives ceos sustainability award programme see launched gives highest level recognition employees furthered gsks environmental sustainability agenda awareness raise employee awareness sustainability environment intranet regular internal publications events however passive communication need develop interactive communications engage employees several areas gsk intranet support sustainability environment including main site known myehss way news sustainability environmental programmes health safety shared within group source supporting materials ehss framework policy standards guidelines training materials documents also use collect data measuring performance reporting results launched climate change microsite called climate change gsk site explains importance climate change everyone needs act gsk individuals includes items reporting action cut carbon dioxide emissions across business celebrates successes included gsk named carbon disclosure projects global carbon disclosure leadership index awarded certification carbon trust standard uk publications available electronically print publish articles sustainability environment spirit internal magazine brief news stories internal web pages many sites celebrate earthweek raise awareness environmental issues encourage integrating environmental concerns gsk culture earthweek encourages employees think impact environment sustainability awards ceos sustainability award programme recognises gsk teams innovation creates benefits society environment business creativity achieves genuine step change towards sustainability publicise innovative practices win awards dedicated intranet site team gsk may considered award except sustainability environment centre excellence administers scheme internal review committee agrees shortlist winners chosen panel includes experts academia government public interest groups winner receives trophy selects charity receive donation gsk awards given three categories environmental sustainability creative adventurous thinking reduces total impact business environment builds trust communities work health safety sustainability innovative ideas create measurable improvements employee performance due health safety initiatives sustainable science technology scientific engineering breakthroughs size scale change things good leave lasting legacy feed support continued innovation entries countries honours went projects belgium india uk us special honour vanguard award went team rd stevenage uk project continuous manufacturing active pharmaceutical ingredients sixyear project overcame significant technical hurdles develop efficient process less waste lower emissions volatile organic compounds vocs lower costs read winning sustainability environment projects back top home responsibility environmental sustainability managing environmental sustainability awareness recognition corporate responsibility report awareness recognition recognise responsibility make gsk community aware environmental sustainability issues engage people levels organisation take sustainability account work decisionmaking offer training orientation business leaders understand issues best respond launched new training packages ehs training connect intranet site specific sustainability environmental training managed individual sites relevant job roles sustainability environment professionals receive induction training undertake regular updates ensure aware latest technical information fields still need continue upgrade level competence site environmental staff companys global internal communications include regular messages environmental sustainability issues included features global employee publications regular calendar internal news releases environment sustainability issues intranet site containing regularly updated material gsks climate change energy reduction initiatives ceos sustainability award programme see launched gives highest level recognition employees furthered gsks environmental sustainability agenda awareness raise employee awareness sustainability environment intranet regular internal publications events however passive communication need develop interactive communications engage employees several areas gsk intranet support sustainability environment including main site known myehss way news sustainability environmental programmes health safety shared within group source supporting materials ehss framework policy standards guidelines training materials documents also use collect data measuring performance reporting results launched climate change microsite called climate change gsk site explains importance climate change everyone needs act gsk individuals includes items reporting action cut carbon dioxide emissions across business celebrates successes included gsk named carbon disclosure projects global carbon disclosure leadership index awarded certification carbon trust standard uk publications available electronically print publish articles sustainability environment spirit internal magazine brief news stories internal web pages many sites celebrate earthweek raise awareness environmental issues encourage integrating environmental concerns gsk culture earthweek encourages employees think impact environment sustainability awards ceos sustainability award programme recognises gsk teams innovation creates benefits society environment business creativity achieves genuine step change towards sustainability publicise innovative practices win awards dedicated intranet site team gsk may considered award except sustainability environment centre excellence administers scheme internal review committee agrees shortlist winners chosen panel includes experts academia government public interest groups winner receives trophy selects charity receive donation gsk awards given three categories environmental sustainability creative adventurous thinking reduces total impact business environment builds trust communities work health safety sustainability innovative ideas create measurable improvements employee performance due health safety initiatives sustainable science technology scientific engineering breakthroughs size scale change things good leave lasting legacy feed support continued innovation entries countries honours went projects belgium india uk us special honour vanguard award went team rd stevenage uk project continuous manufacturing active pharmaceutical ingredients sixyear project overcame significant technical hurdles develop efficient process less waste lower emissions volatile organic compounds vocs lower costs read winning sustainability environment projects back top home responsibility environmental sustainability managing environmental sustainability audits compliance corporate responsibility report audits compliance approach performance regularly audited operations contract manufacturers key suppliers assess systems manage risks impacts compliance legislation performance environment health safety sustainability standards audits also assess whether appropriate management systems place improve performance maintain compliance internal auditors certified lead auditors iso ohsas standards gsk created audit assurance function environment health safety sustainability ehss audit team integrated new group provides independent audit assurance function separate ehss management organisation examine areas considers high level risks business gsk audit assurance function developed standardised simplified audit process group used audit management environmental risk new integrated process launched provide greater focus thematic risks across group audit strategies developed achieve greater coverage sustainability environmental impacts require operations develop stronger self audits address areas may longer included new audit approach gsk manufacturing rd sites audited least every four years actual frequency determined level risk impacts sites performance managing risks audited sites including ten followup audits see performance details see supply chain section supplier audits certification reviewed programme certify manufacturing sites international standards iso ohsas businesses concluded certification equally benefit sites concentrate need make significant improvement sites identified based performance internal audits required achieve certification sites required robust self audit systems place encouraged certified longer formal requirement back top home responsibility environmental sustainability managing environmental sustainability audits compliance corporate responsibility report audits compliance approach performance regularly audited operations contract manufacturers key suppliers assess systems manage risks impacts compliance legislation performance environment health safety sustainability standards audits also assess whether appropriate management systems place improve performance maintain compliance internal auditors certified lead auditors iso ohsas standards gsk created audit assurance function environment health safety sustainability ehss audit team integrated new group provides independent audit assurance function separate ehss management organisation examine areas considers high level risks business gsk audit assurance function developed standardised simplified audit process group used audit management environmental risk new integrated process launched provide greater focus thematic risks across group audit strategies developed achieve greater coverage sustainability environmental impacts require operations develop stronger self audits address areas may longer included new audit approach gsk manufacturing rd sites audited least every four years actual frequency determined level risk impacts sites performance managing risks audited sites including ten followup audits see performance details see supply chain section supplier audits certification reviewed programme certify manufacturing sites international standards iso ohsas businesses concluded certification equally benefit sites concentrate need make significant improvement sites identified based performance internal audits required achieve certification sites required robust self audit systems place encouraged certified longer formal requirement back top home responsibility environmental sustainability managing environmental sustainability audits compliance performance corporate responsibility report audits compliance approach performance conducted audits gsk facilities covering implementation ehs standards conducted audit followup reviews ten facilities scored audits average performance score per cent compared per cent improvement may reflect quality sites selected lowest score consider acceptable per cent site scored level lowest score per cent three sites achieved leadership scores per cent two eight achieved scores least per cent high audit scores indicate good management systems control risks critical findings indicate lack proper management risks potentially serious consequences concerning environment best performance environmental issues related waste management systems sites generally weakest environmental risk assessment processes sustained improvement audit performance reflects emphasis ensuring robust effective management systems use across operations regardless formal certification pharmaceuticals consumer healthcare manufacturing sites certified iso ohsas standards three certified iso three sites newly certified one consumer healthcare rd site certified standards one gsk vaccines site one pharmaceuticals rd site certified iso certified sites argentina australia brazil china egypt france germany india italy japan kenya mexico panama philippines poland romania saudi arabia singapore spain us uk compliance remain vigilant stay full compliance environmental laws regulations incurred two environmental fines new jersey department environmental protection failure clearly mark two containers hazardous waste failure list date use drums romania discharging polluted wastewater permitted limits back top home responsibility environmental sustainability managing environmental sustainability audits compliance performance corporate responsibility report audits compliance approach performance conducted audits gsk facilities covering implementation ehs standards conducted audit followup reviews ten facilities scored audits average performance score per cent compared per cent improvement may reflect quality sites selected lowest score consider acceptable per cent site scored level lowest score per cent three sites achieved leadership scores per cent two eight achieved scores least per cent high audit scores indicate good management systems control risks critical findings indicate lack proper management risks potentially serious consequences concerning environment best performance environmental issues related waste management systems sites generally weakest environmental risk assessment processes sustained improvement audit performance reflects emphasis ensuring robust effective management systems use across operations regardless formal certification pharmaceuticals consumer healthcare manufacturing sites certified iso ohsas standards three certified iso three sites newly certified one consumer healthcare rd site certified standards one gsk vaccines site one pharmaceuticals rd site certified iso certified sites argentina australia brazil china egypt france germany india italy japan kenya mexico panama philippines poland romania saudi arabia singapore spain us uk compliance remain vigilant stay full compliance environmental laws regulations incurred two environmental fines new jersey department environmental protection failure clearly mark two containers hazardous waste failure list date use drums romania discharging polluted wastewater permitted limits back top home responsibility environmental sustainability climate change energy corporate responsibility report climate change energy widely acknowledged human activity primarily burning fossil fuels produce energy contributing climate change intergovernmental panel climate change ipcc worlds leading climate authority stated urgent action needed mitigate adapt effects climate change including rising sea levels frequent extreme weather events droughts floods hurricanes worlds governments met auspices united nations copenhagen december try agree new approach curbing climate change main output meeting copenhagen accord agreement reached us china india brazil south africa specific targets agreed accord recognises goal limit global greenhouse gas emissions ensure increase global temperatures kept two degrees celsius also includes commitments developed countries provide funding developing countries help mitigate effects climate change establishes principles international governance accord intended form basis new agreement replace kyoto un anxious new legally binding treaty soon possible gsk supports need international treaty legally binding targets help us plan future want part solution committed reducing impact however finding best approach challenging well benefiting environment taking action climate change helps us cut costs improves reputation stakeholders helps us prepare future legislation emissions climate change programme biggest direct climate impact comes propellants used inhalers diseases asthma reduced impact replacing cfc gases continue research ways minimise greenhouse gases released products emissions began fall result phaseout increased since global warming potential energy transport inhaler use launched new climate change programme operations includes commitment reduce climate change impact co equivalent emissions energy use operations transport per cent per unit sales per cent levels challenging targets represent stepchange ambitions replacing previous improvement target energy one per cent per year reflecting increasing recognition responsibility address climate change emissions plan achieve new targets making buildings equipment energy efficient installing onsite renewable technologies wind turbines photovoltaic panels buying electricity produced renewable sources reducing climate impact travel transport switching air sea freight transporting per load reduce number journeys needed energy reduction identified key objective business result energy consumption included key business metrics remuneration senior managers manufacturing linked achievement energyreduction targets resulted eight per cent absolute reduction energy usage demonstrating effectiveness appropriate incentives also created central fund help finance energysaving projects far helped avoid tonnes greenhouse gas emissions estimate saved million since energy reduction projects raising awareness among staff important achieving targets launched climate change intranet microsite publicises activity progress making people aware issues general awarenessraising supports sitespecific activity recognition gsk commended approach climate change disclosure carbon disclosure project independent notforprofit organisation represents institutional investors uk awarded carbon trust standard recognising uk operations effective climate change energy reduction systems place hope able achieve global certification carbon trust standard based constant exchange rate avoid distortions caused currency swings back tophome responsibility environmental sustainability climate change energy corporate responsibility report climate change energy widely acknowledged human activity primarily burning fossil fuels produce energy contributing climate change intergovernmental panel climate change ipcc worlds leading climate authority stated urgent action needed mitigate adapt effects climate change including rising sea levels frequent extreme weather events droughts floods hurricanes worlds governments met auspices united nations copenhagen december try agree new approach curbing climate change main output meeting copenhagen accord agreement reached us china india brazil south africa specific targets agreed accord recognises goal limit global greenhouse gas emissions ensure increase global temperatures kept two degrees celsius also includes commitments developed countries provide funding developing countries help mitigate effects climate change establishes principles international governance accord intended form basis new agreement replace kyoto un anxious new legally binding treaty soon possible gsk supports need international treaty legally binding targets help us plan future want part solution committed reducing impact however finding best approach challenging well benefiting environment taking action climate change helps us cut costs improves reputation stakeholders helps us prepare future legislation emissions climate change programme biggest direct climate impact comes propellants used inhalers diseases asthma reduced impact replacing cfc gases continue research ways minimise greenhouse gases released products emissions began fall result phaseout increased since global warming potential energy transport inhaler use launched new climate change programme operations includes commitment reduce climate change impact co equivalent emissions energy use operations transport per cent per unit sales per cent levels challenging targets represent stepchange ambitions replacing previous improvement target energy one per cent per year reflecting increasing recognition responsibility address climate change emissions plan achieve new targets making buildings equipment energy efficient installing onsite renewable technologies wind turbines photovoltaic panels buying electricity produced renewable sources reducing climate impact travel transport switching air sea freight transporting per load reduce number journeys needed energy reduction identified key objective business result energy consumption included key business metrics remuneration senior managers manufacturing linked achievement energyreduction targets resulted eight per cent absolute reduction energy usage demonstrating effectiveness appropriate incentives also created central fund help finance energysaving projects far helped avoid tonnes greenhouse gas emissions estimate saved million since energy reduction projects raising awareness among staff important achieving targets launched climate change intranet microsite publicises activity progress making people aware issues general awarenessraising supports sitespecific activity recognition gsk commended approach climate change disclosure carbon disclosure project independent notforprofit organisation represents institutional investors uk awarded carbon trust standard recognising uk operations effective climate change energy reduction systems place hope able achieve global certification carbon trust standard based constant exchange rate avoid distortions caused currency swings back top home responsibility environmental sustainability climate change energy corporate responsibility report climate change energy widely acknowledged human activity primarily burning fossil fuels produce energy contributing climate change intergovernmental panel climate change ipcc worlds leading climate authority stated urgent action needed mitigate adapt effects climate change including rising sea levels frequent extreme weather events droughts floods hurricanes worlds governments met auspices united nations copenhagen december try agree new approach curbing climate change main output meeting copenhagen accord agreement reached us china india brazil south africa specific targets agreed accord recognises goal limit global greenhouse gas emissions ensure increase global temperatures kept two degrees celsius also includes commitments developed countries provide funding developing countries help mitigate effects climate change establishes principles international governance accord intended form basis new agreement replace kyoto un anxious new legally binding treaty soon possible gsk supports need international treaty legally binding targets help us plan future want part solution committed reducing impact however finding best approach challenging well benefiting environment taking action climate change helps us cut costs improves reputation stakeholders helps us prepare future legislation emissions climate change programme biggest direct climate impact comes propellants used inhalers diseases asthma reduced impact replacing cfc gases continue research ways minimise greenhouse gases released products emissions began fall result phaseout increased since global warming potential energy transport inhaler use launched new climate change programme operations includes commitment reduce climate change impact co equivalent emissions energy use operations transport per cent per unit sales per cent levels challenging targets represent stepchange ambitions replacing previous improvement target energy one per cent per year reflecting increasing recognition responsibility address climate change emissions plan achieve new targets making buildings equipment energy efficient installing onsite renewable technologies wind turbines photovoltaic panels buying electricity produced renewable sources reducing climate impact travel transport switching air sea freight transporting per load reduce number journeys needed energy reduction identified key objective business result energy consumption included key business metrics remuneration senior managers manufacturing linked achievement energyreduction targets resulted eight per cent absolute reduction energy usage demonstrating effectiveness appropriate incentives also created central fund help finance energysaving projects far helped avoid tonnes greenhouse gas emissions estimate saved million since energy reduction projects raising awareness among staff important achieving targets launched climate change intranet microsite publicises activity progress making people aware issues general awarenessraising supports sitespecific activity recognition gsk commended approach climate change disclosure carbon disclosure project independent notforprofit organisation represents institutional investors uk awarded carbon trust standard recognising uk operations effective climate change energy reduction systems place hope able achieve global certification carbon trust standard based constant exchange rate avoid distortions caused currency swings back top home responsibility environmental sustainability climate change energy propellants corporate responsibility report propellants majority climate impact comes propellants used inhalers asthma chronic obstructive pulmonary disease products contain either hydrofluoroalkanes hfas chlorofluorocarbons cfcs potent greenhouse gases cfcs also deplete ozone layer committed phasing cfcs end researching ways minimise hfas released remaining products introduced dry powder inhalers use propellant unsuitable patients treatments per cent inhalers sold included propellants continue seek ways minimising release propellants contribute climate change back top home responsibility environmental sustainability climate change energy propellants corporate responsibility report propellants majority climate impact comes propellants used inhalers asthma chronic obstructive pulmonary disease products contain either hydrofluoroalkanes hfas chlorofluorocarbons cfcs potent greenhouse gases cfcs also deplete ozone layer committed phasing cfcs end researching ways minimise hfas released remaining products introduced dry powder inhalers use propellant unsuitable patients treatments per cent inhalers sold included propellants continue seek ways minimising release propellants contribute climate change back top home responsibility environmental sustainability climate change energy facilities processes corporate responsibility report facilities processes climate change programme commits gsk reduce climate change impact energy use operations transport per cent per cent compared levels target expressed emissions co equivalent energy per unit sales based constant exchange rate comparisons distorted exchange rate fluctuations plan develop absolute energy greenhouse gas emissions targets aim achieve targets facilities processes becoming energyefficient using renewable energy see transport created central fund help finance energysaving investments potential projects identified completed nearly projects potential savings mwh nearly tonnes emissions follows projects completed expected annual savings mwh gj energy tonnes greenhouse gas emissions two main priorities reducing emissions energy use combined heat power chp chp simultaneously generates usable heat power usually electricity single process heat produced recovered provide steam hot water even cooling achieving overall efficiencies excess per cent point use compared less per cent conventional power plants heating ventilation cooling hvac hvac responsible per cent operational energy consume equipment essential maintain correct environmental conditions within production areas aim identify opportunities reduce energy required renewable energy also help us reduce emissions solar photovoltaic panels installed two sites belgium us systems expected generate around mwh electricity estimated save around tonnes coequivalent emissions solar water heating systems also installed belgium mexico australia emissions trading gsk sites participated european union emissions trading scheme collectively sites emitted specified co allowances generating surplus carbon credits proceeds sale carbon credits invested energysaving projects several uk sites participate uk governments voluntary climate change agreement programme provides companies energy tax rebates meet agreed energyefficiency targets gsk reported compliance agreements participating gsk sites found comply climate change agreements back top home responsibility environmental sustainability climate change energy facilities processes corporate responsibility report facilities processes climate change programme commits gsk reduce climate change impact energy use operations transport per cent per cent compared levels target expressed emissions co equivalent energy per unit sales based constant exchange rate comparisons distorted exchange rate fluctuations plan develop absolute energy greenhouse gas emissions targets aim achieve targets facilities processes becoming energyefficient using renewable energy see transport created central fund help finance energysaving investments potential projects identified completed nearly projects potential savings mwh nearly tonnes emissions follows projects completed expected annual savings mwh gj energy tonnes greenhouse gas emissions two main priorities reducing emissions energy use combined heat power chp chp simultaneously generates usable heat power usually electricity single process heat produced recovered provide steam hot water even cooling achieving overall efficiencies excess per cent point use compared less per cent conventional power plants heating ventilation cooling hvac hvac responsible per cent operational energy consume equipment essential maintain correct environmental conditions within production areas aim identify opportunities reduce energy required renewable energy also help us reduce emissions solar photovoltaic panels installed two sites belgium us systems expected generate around mwh electricity estimated save around tonnes coequivalent emissions solar water heating systems also installed belgium mexico australia emissions trading gsk sites participated european union emissions trading scheme collectively sites emitted specified co allowances generating surplus carbon credits proceeds sale carbon credits invested energysaving projects several uk sites participate uk governments voluntary climate change agreement programme provides companies energy tax rebates meet agreed energyefficiency targets gsk reported compliance agreements participating gsk sites found comply climate change agreements back top home responsibility environmental sustainability climate change energy transport corporate responsibility report transport travel estimate transport products sales fleet employees business air travel accounted tonnes co compared tonnes per cent total climate change impact excluding propellants co emissions transport travel arise roughly equal proportions business air travel sales fleet transport products manufacturing plants distributors plans reducing impact product transport include consolidating freight shipments reducing number shipping points making use round tripping managing inbound freight trucks return empty switching air sea transport possible travel green travel plans number sites encourage employees reduce environmental impact travel work example gsk house brentford uk reserved parking spaces given carsharers drivers fuelefficient cars provide changing rooms showers cyclists well discounts bicycle equipment repairs see case study philadelphia office cost public transport subsidised global travel services uk reports quarterly airline mileage encouraging use rail air within europe use rail increased per cent amending selfbooking tool encourage progress travellers request co calculated noted itinerary gsk leadership forum brings together approximately senior executives virtual event instead travelling single location participants met video conferencing also enabled six times many people join estimate avoided longhaul flights saving tonnes emissions transport measured weight threequarters shipments sea per cent air approximately per cent shipments currently sent air aiming reduce use air freight global manufacturing supply distributes four billion packs markets around world developed air ocean programme transport modelling identifies preferable routes based tradeoff freight cost distribution time inventory investment switching sea freight make big difference emissions costs transporting one metric tonne london paulo air freight generates kilograms co sea kilograms since programme introduced gsk transport routes switched ocean freight saving tonnes emissions alone tonnes savings achieved changes transport however ocean freight increased slightly air freight also increased due increased volume business came number new business arrangements required movement large volumes product increased sales existing products developing countries including shipments pandemic flu vaccine focus partnering global distribution gsks strategic logistics service providers way developing longerterm strategy reduce carbon footprint freight management initiatives identified drive network efficiencies consolidation supplies back tophome responsibility environmental sustainability climate change energy transport corporate responsibility report transport travel estimate transport products sales fleet employees business air travel accounted tonnes co compared tonnes per cent total climate change impact excluding propellants co emissions transport travel arise roughly equal proportions business air travel sales fleet transport products manufacturing plants distributors plans reducing impact product transport include consolidating freight shipments reducing number shipping points making use round tripping managing inbound freight trucks return empty switching air sea transport possible travel green travel plans number sites encourage employees reduce environmental impact travel work example gsk house brentford uk reserved parking spaces given carsharers drivers fuelefficient cars provide changing rooms showers cyclists well discounts bicycle equipment repairs see case study philadelphia office cost public transport subsidised global travel services uk reports quarterly airline mileage encouraging use rail air within europe use rail increased per cent amending selfbooking tool encourage progress travellers request co calculated noted itinerary gsk leadership forum brings together approximately senior executives virtual event instead travelling single location participants met video conferencing also enabled six times many people join estimate avoided longhaul flights saving tonnes emissions transport measured weight threequarters shipments sea per cent air approximately per cent shipments currently sent air aiming reduce use air freight global manufacturing supply distributes four billion packs markets around world developed air ocean programme transport modelling identifies preferable routes based tradeoff freight cost distribution time inventory investment switching sea freight make big difference emissions costs transporting one metric tonne london paulo air freight generates kilograms co sea kilograms since programme introduced gsk transport routes switched ocean freight saving tonnes emissions alone tonnes savings achieved changes transport however ocean freight increased slightly air freight also increased due increased volume business came number new business arrangements required movement large volumes product increased sales existing products developing countries including shipments pandemic flu vaccine focus partnering global distribution gsks strategic logistics service providers way developing longerterm strategy reduce carbon footprint freight management initiatives identified drive network efficiencies consolidation supplies back top home responsibility environmental sustainability climate change energy transport corporate responsibility report transport travel estimate transport products sales fleet employees business air travel accounted tonnes co compared tonnes per cent total climate change impact excluding propellants co emissions transport travel arise roughly equal proportions business air travel sales fleet transport products manufacturing plants distributors plans reducing impact product transport include consolidating freight shipments reducing number shipping points making use round tripping managing inbound freight trucks return empty switching air sea transport possible travel green travel plans number sites encourage employees reduce environmental impact travel work example gsk house brentford uk reserved parking spaces given carsharers drivers fuelefficient cars provide changing rooms showers cyclists well discounts bicycle equipment repairs see case study philadelphia office cost public transport subsidised global travel services uk reports quarterly airline mileage encouraging use rail air within europe use rail increased per cent amending selfbooking tool encourage progress travellers request co calculated noted itinerary gsk leadership forum brings together approximately senior executives virtual event instead travelling single location participants met video conferencing also enabled six times many people join estimate avoided longhaul flights saving tonnes emissions transport measured weight threequarters shipments sea per cent air approximately per cent shipments currently sent air aiming reduce use air freight global manufacturing supply distributes four billion packs markets around world developed air ocean programme transport modelling identifies preferable routes based tradeoff freight cost distribution time inventory investment switching sea freight make big difference emissions costs transporting one metric tonne london paulo air freight generates kilograms co sea kilograms since programme introduced gsk transport routes switched ocean freight saving tonnes emissions alone tonnes savings achieved changes transport however ocean freight increased slightly air freight also increased due increased volume business came number new business arrangements required movement large volumes product increased sales existing products developing countries including shipments pandemic flu vaccine focus partnering global distribution gsks strategic logistics service providers way developing longerterm strategy reduce carbon footprint freight management initiatives identified drive network efficiencies consolidation supplies back top home responsibility environmental sustainability climate change energy performance plans corporate responsibility report performance plans gsks carbon footprint includes greenhouse gases released cooling systems production inhaler products wastewater treatment processes total energy emissions carbon footprint equivalent million tonnes co compared million tonnes majority emissions come use inhalers patients respiratory disease eliminating production cfc inhalers partly offset simultaneous increase use hfa meant climate change emissions patient use inhalers fell per cent million metric tonnes co excluding manufacture use inhalers carbon footprint operations energy transport reduced slightly million tonnes co million tonnes mainly reflects lower emissions greenhouse gases pharmaceutical manufacturing million tonnes million tonnes energy use operations transport caused co emissions decreased per cent million gigajoules million gigajoules salesrelated data targets based emissions energy consumption operations transport per million sales normalised emissions decreased per cent previous year energy use per million sales fell per cent gigajoules per million sales cumulatively cut normalised emissions per cent energy use per cent since climate change impact operations energy transport sales adjusted constant exchange rates energy use operations transport sales adjusted constant exchange rates explanation trends since peaking total emissions fell removed cfcs inhalers levelled climate change targets discussion set aggressive targets reduce energy use related climate change emissions per cent per unit sales end progress towards targets first two years limited accelerated due implementation energy reduction programmes manufacturing rd may achieve target remain committed target per cent improvement progress due incentives manufacturing rd reductions rewarded performance encouraged everyone participate resulted investment many small projects improve heating ventilation air conditioning hvac steam generation energy uses achieved significant efficiency improvements several facilities high energy users total energy consumption rd pharmaceutical manufacturing fell eight per cent due incentives offsetting increase biologicals due higher vaccine production total energy use biologicals per cent higher must set per cent increase sales representing improvement energy intensity elsewhere sites managed reduce energy use despite production increases manufacturing site scotland global manufacturing energy reduction challenge reducing energy use ten per cent production volume increased achieved energy efficiency projects optimising solvent recovery raising employees awareness energy wastage result saving tonnes co estimated savings million per year plans develop new plan identify mitigation strategies reduce climate change impact aligning global efforts curb climate change also undertake work identify ways respond changing disease patterns due climate change inhalers represent roughly twothirds climate impact major focus want minimise use hfa propellants aspire ultimately phase operations plan optimise number facilities make remaining facilities energy efficient reducing climate impact using efficient processes renewable materials renewable energy power operations reinforce efforts engaging employees encouraging adopt energysaving practices including alternative commuting virtual conferences phone meetings switching combined heat power chp beginning reduce overall climate change impact chp efficient resulting lower emissions equivalent electricity imported power stations however consumption electricity generated facilities rather imported power station means losses generation transmission eliminated large vaccines manufacturing sites belgium among first install chp equipment see case study also work suppliers understand embedded carbon supply chain encourage suppliers improve energy efficiency use renewable energy sgs verified back tophome responsibility environmental sustainability climate change energy performance plans corporate responsibility report performance plans gsks carbon footprint includes greenhouse gases released cooling systems production inhaler products wastewater treatment processes total energy emissions carbon footprint equivalent million tonnes co compared million tonnes majority emissions come use inhalers patients respiratory disease eliminating production cfc inhalers partly offset simultaneous increase use hfa meant climate change emissions patient use inhalers fell per cent million metric tonnes co excluding manufacture use inhalers carbon footprint operations energy transport reduced slightly million tonnes co million tonnes mainly reflects lower emissions greenhouse gases pharmaceutical manufacturing million tonnes million tonnes energy use operations transport caused co emissions decreased per cent million gigajoules million gigajoules salesrelated data targets based emissions energy consumption operations transport per million sales normalised emissions decreased per cent previous year energy use per million sales fell per cent gigajoules per million sales cumulatively cut normalised emissions per cent energy use per cent since climate change impact operations energy transport sales adjusted constant exchange rates energy use operations transport sales adjusted constant exchange rates explanation trends since peaking total emissions fell removed cfcs inhalers levelled climate change targets discussion set aggressive targets reduce energy use related climate change emissions per cent per unit sales end progress towards targets first two years limited accelerated due implementation energy reduction programmes manufacturing rd may achieve target remain committed target per cent improvement progress due incentives manufacturing rd reductions rewarded performance encouraged everyone participate resulted investment many small projects improve heating ventilation air conditioning hvac steam generation energy uses achieved significant efficiency improvements several facilities high energy users total energy consumption rd pharmaceutical manufacturing fell eight per cent due incentives offsetting increase biologicals due higher vaccine production total energy use biologicals per cent higher must set per cent increase sales representing improvement energy intensity elsewhere sites managed reduce energy use despite production increases manufacturing site scotland global manufacturing energy reduction challenge reducing energy use ten per cent production volume increased achieved energy efficiency projects optimising solvent recovery raising employees awareness energy wastage result saving tonnes co estimated savings million per year plans develop new plan identify mitigation strategies reduce climate change impact aligning global efforts curb climate change also undertake work identify ways respond changing disease patterns due climate change inhalers represent roughly twothirds climate impact major focus want minimise use hfa propellants aspire ultimately phase operations plan optimise number facilities make remaining facilities energy efficient reducing climate impact using efficient processes renewable materials renewable energy power operations reinforce efforts engaging employees encouraging adopt energysaving practices including alternative commuting virtual conferences phone meetings switching combined heat power chp beginning reduce overall climate change impact chp efficient resulting lower emissions equivalent electricity imported power stations however consumption electricity generated facilities rather imported power station means losses generation transmission eliminated large vaccines manufacturing sites belgium among first install chp equipment see case study also work suppliers understand embedded carbon supply chain encourage suppliers improve energy efficiency use renewable energy sgs verified back tophome responsibility environmental sustainability climate change energy performance plans corporate responsibility report performance plans gsks carbon footprint includes greenhouse gases released cooling systems production inhaler products wastewater treatment processes total energy emissions carbon footprint equivalent million tonnes co compared million tonnes majority emissions come use inhalers patients respiratory disease eliminating production cfc inhalers partly offset simultaneous increase use hfa meant climate change emissions patient use inhalers fell per cent million metric tonnes co excluding manufacture use inhalers carbon footprint operations energy transport reduced slightly million tonnes co million tonnes mainly reflects lower emissions greenhouse gases pharmaceutical manufacturing million tonnes million tonnes energy use operations transport caused co emissions decreased per cent million gigajoules million gigajoules salesrelated data targets based emissions energy consumption operations transport per million sales normalised emissions decreased per cent previous year energy use per million sales fell per cent gigajoules per million sales cumulatively cut normalised emissions per cent energy use per cent since climate change impact operations energy transport sales adjusted constant exchange rates energy use operations transport sales adjusted constant exchange rates explanation trends since peaking total emissions fell removed cfcs inhalers levelled climate change targets discussion set aggressive targets reduce energy use related climate change emissions per cent per unit sales end progress towards targets first two years limited accelerated due implementation energy reduction programmes manufacturing rd may achieve target remain committed target per cent improvement progress due incentives manufacturing rd reductions rewarded performance encouraged everyone participate resulted investment many small projects improve heating ventilation air conditioning hvac steam generation energy uses achieved significant efficiency improvements several facilities high energy users total energy consumption rd pharmaceutical manufacturing fell eight per cent due incentives offsetting increase biologicals due higher vaccine production total energy use biologicals per cent higher must set per cent increase sales representing improvement energy intensity elsewhere sites managed reduce energy use despite production increases manufacturing site scotland global manufacturing energy reduction challenge reducing energy use ten per cent production volume increased achieved energy efficiency projects optimising solvent recovery raising employees awareness energy wastage result saving tonnes co estimated savings million per year plans develop new plan identify mitigation strategies reduce climate change impact aligning global efforts curb climate change also undertake work identify ways respond changing disease patterns due climate change inhalers represent roughly twothirds climate impact major focus want minimise use hfa propellants aspire ultimately phase operations plan optimise number facilities make remaining facilities energy efficient reducing climate impact using efficient processes renewable materials renewable energy power operations reinforce efforts engaging employees encouraging adopt energysaving practices including alternative commuting virtual conferences phone meetings switching combined heat power chp beginning reduce overall climate change impact chp efficient resulting lower emissions equivalent electricity imported power stations however consumption electricity generated facilities rather imported power station means losses generation transmission eliminated large vaccines manufacturing sites belgium among first install chp equipment see case study also work suppliers understand embedded carbon supply chain encourage suppliers improve energy efficiency use renewable energy sgs verified back top home responsibility environmental sustainability climate change energy performance plans corporate responsibility report performance plans gsks carbon footprint includes greenhouse gases released cooling systems production inhaler products wastewater treatment processes total energy emissions carbon footprint equivalent million tonnes co compared million tonnes majority emissions come use inhalers patients respiratory disease eliminating production cfc inhalers partly offset simultaneous increase use hfa meant climate change emissions patient use inhalers fell per cent million metric tonnes co excluding manufacture use inhalers carbon footprint operations energy transport reduced slightly million tonnes co million tonnes mainly reflects lower emissions greenhouse gases pharmaceutical manufacturing million tonnes million tonnes energy use operations transport caused co emissions decreased per cent million gigajoules million gigajoules salesrelated data targets based emissions energy consumption operations transport per million sales normalised emissions decreased per cent previous year energy use per million sales fell per cent gigajoules per million sales cumulatively cut normalised emissions per cent energy use per cent since climate change impact operations energy transport sales adjusted constant exchange rates energy use operations transport sales adjusted constant exchange rates explanation trends since peaking total emissions fell removed cfcs inhalers levelled climate change targets discussion set aggressive targets reduce energy use related climate change emissions per cent per unit sales end progress towards targets first two years limited accelerated due implementation energy reduction programmes manufacturing rd may achieve target remain committed target per cent improvement progress due incentives manufacturing rd reductions rewarded performance encouraged everyone participate resulted investment many small projects improve heating ventilation air conditioning hvac steam generation energy uses achieved significant efficiency improvements several facilities high energy users total energy consumption rd pharmaceutical manufacturing fell eight per cent due incentives offsetting increase biologicals due higher vaccine production total energy use biologicals per cent higher must set per cent increase sales representing improvement energy intensity elsewhere sites managed reduce energy use despite production increases manufacturing site scotland global manufacturing energy reduction challenge reducing energy use ten per cent production volume increased achieved energy efficiency projects optimising solvent recovery raising employees awareness energy wastage result saving tonnes co estimated savings million per year plans develop new plan identify mitigation strategies reduce climate change impact aligning global efforts curb climate change also undertake work identify ways respond changing disease patterns due climate change inhalers represent roughly twothirds climate impact major focus want minimise use hfa propellants aspire ultimately phase operations plan optimise number facilities make remaining facilities energy efficient reducing climate impact using efficient processes renewable materials renewable energy power operations reinforce efforts engaging employees encouraging adopt energysaving practices including alternative commuting virtual conferences phone meetings switching combined heat power chp beginning reduce overall climate change impact chp efficient resulting lower emissions equivalent electricity imported power stations however consumption electricity generated facilities rather imported power station means losses generation transmission eliminated large vaccines manufacturing sites belgium among first install chp equipment see case study also work suppliers understand embedded carbon supply chain encourage suppliers improve energy efficiency use renewable energy sgs verified back top home responsibility environmental sustainability materials corporate responsibility report materials aim use materials efficiently safely minimising waste avoiding harm humans environment need take environment account across entire life cycle products beginning process design continuing manufacturing use patients eventual disposal also need routinely evaluate environmental footprint processes explore ways minimise impacts instance rd manufacturing operations regularly assess environmental footprint different chemical processes using webbased tool known fast life cycle assessment synthetic chemistry flasc enables us identify sustainable processes materials smaller environmental footprint using materials sustainably requires changing business processes consume fewer resources generate less waste removing hazardous substances possible eliminating waste persistent toxic bioaccumulative wastes used solvents reused processes raw material another industry achieving known cradle cradle approach instance sites manufacture active pharmaceutical ingredients recover solvents reuse pilot plants also send solvents ethyl acetate ethanol external recovery reuse evaluating feasibility using methanol used cleaning windshield wiper solutions aim increase efficiency convert raw materials finished products aspiring achieve level five times performance introduced new targets research development introduced mass efficiency target manufacturing first time water valuable natural resource recognise businesses play positive role managing sustainably gsk endorsed united nations ceo water mandate potential hazards pharmaceutical processes use potentially hazardous input materials eliminate substances concern persistent bioaccumulative toxic possible use genetically modified microorganisms research development new medicines produce products contain viable organisms actively investigating opportunities use nanomaterials currently nanomaterial products market eus registration evaluation authorisation restriction chemicals reach legislation requires registration certain materials engaged suppliers adapted procurement programmes ensure compliance ensure meet november registration deadline active pharmaceutical ingredients may enter environment excreted patients current evidence suggests pose risk people environment continue conduct tests risk assessments evaluate potential effects read packaging work reduce environmental impact packaging well products materials developed integrated companywide strategy drive towards sustainable packaging covering consumer healthcare pharmaceuticals biologicals businesses particularly important consumer healthcare business already uses recycled plastic ribena bottles consumer business india reduced amount packaging also reduced waste see case study consumer healthcare adopted sustainability strategy includes plans significantly reduce packaging impacts however recognise many opportunities consumer healthcare business pharmaceuticals business reduce amount packaging currenptalyge u se f back tophome responsibility environmental sustainability materials corporate responsibility report materials aim use materials efficiently safely minimising waste avoiding harm humans environment need take environment account across entire life cycle products beginning process design continuing manufacturing use patients eventual disposal also need routinely evaluate environmental footprint processes explore ways minimise impacts instance rd manufacturing operations regularly assess environmental footprint different chemical processes using webbased tool known fast life cycle assessment synthetic chemistry flasc enables us identify sustainable processes materials smaller environmental footprint using materials sustainably requires changing business processes consume fewer resources generate less waste removing hazardous substances possible eliminating waste persistent toxic bioaccumulative wastes used solvents reused processes raw material another industry achieving known cradle cradle approach instance sites manufacture active pharmaceutical ingredients recover solvents reuse pilot plants also send solvents ethyl acetate ethanol external recovery reuse evaluating feasibility using methanol used cleaning windshield wiper solutions aim increase efficiency convert raw materials finished products aspiring achieve level five times performance introduced new targets research development introduced mass efficiency target manufacturing first time water valuable natural resource recognise businesses play positive role managing sustainably gsk endorsed united nations ceo water mandate potential hazards pharmaceutical processes use potentially hazardous input materials eliminate substances concern persistent bioaccumulative toxic possible use genetically modified microorganisms research development new medicines produce products contain viable organisms actively investigating opportunities use nanomaterials currently nanomaterial products market eus registration evaluation authorisation restriction chemicals reach legislation requires registration certain materials engaged suppliers adapted procurement programmes ensure compliance ensure meet november registration deadline active pharmaceutical ingredients may enter environment excreted patients current evidence suggests pose risk people environment continue conduct tests risk assessments evaluate potential effects read packaging work reduce environmental impact packaging well products materials developed integrated companywide strategy drive towards sustainable packaging covering consumer healthcare pharmaceuticals biologicals businesses particularly important consumer healthcare business already uses recycled plastic ribena bottles consumer business india reduced amount packaging also reduced waste see case study consumer healthcare adopted sustainability strategy includes plans significantly reduce packaging impacts however recognise many opportunities consumer healthcare business pharmaceuticals business reduce amount packaging currently use back top home responsibility environmental sustainability materials corporate responsibility report materials aim use materials efficiently safely minimising waste avoiding harm humans environment need take environment account across entire life cycle products beginning process design continuing manufacturing use patients eventual disposal also need routinely evaluate environmental footprint processes explore ways minimise impacts instance rd manufacturing operations regularly assess environmental footprint different chemical processes using webbased tool known fast life cycle assessment synthetic chemistry flasc enables us identify sustainable processes materials smaller environmental footprint using materials sustainably requires changing business processes consume fewer resources generate less waste removing hazardous substances possible eliminating waste persistent toxic bioaccumulative wastes used solvents reused processes raw material another industry achieving known cradle cradle approach instance sites manufacture active pharmaceutical ingredients recover solvents reuse pilot plants also send solvents ethyl acetate ethanol external recovery reuse evaluating feasibility using methanol used cleaning windshield wiper solutions aim increase efficiency convert raw materials finished products aspiring achieve level five times performance introduced new targets research development introduced mass efficiency target manufacturing first time water valuable natural resource recognise businesses play positive role managing sustainably gsk endorsed united nations ceo water mandate potential hazards pharmaceutical processes use potentially hazardous input materials eliminate substances concern persistent bioaccumulative toxic possible use genetically modified microorganisms research development new medicines produce products contain viable organisms actively investigating opportunities use nanomaterials currently nanomaterial products market eus registration evaluation authorisation restriction chemicals reach legislation requires registration certain materials engaged suppliers adapted procurement programmes ensure compliance ensure meet november registration deadline active pharmaceutical ingredients may enter environment excreted patients current evidence suggests pose risk people environment continue conduct tests risk assessments evaluate potential effects read packaging work reduce environmental impact packaging well products materials developed integrated companywide strategy drive towards sustainable packaging covering consumer healthcare pharmaceuticals biologicals businesses particularly important consumer healthcare business already uses recycled plastic ribena bottles consumer business india reduced amount packaging also reduced waste see case study consumer healthcare adopted sustainability strategy includes plans significantly reduce packaging impacts however recognise many opportunities consumer healthcare business pharmaceuticals business reduce amount packaging currently use back top home responsibility environmental sustainability materials mass efficiency corporate responsibility report mass efficiency approach performance encourage innovation manufacturing process increase efficiency convert raw materials finished products known mass efficiency helps reduce resources use waste generate cost production requires innovation way discover manufacture products historically industry used tonnes material every tonne active pharmaceutical ingredient api produced pharmaceutical processes often complex usually requiring large amounts solvents raw materials take several processes obtain right purity pharmaceutical want finalise processes quickly avoid delaying drug approval production originally set target rd double average mass efficiency processes new products would achieve two per cent mass efficiency instead typical one per cent increased target aiming additional per cent increase efficiency new products launched taking mass efficiency target per cent one project uk site increased output ten per cent saving solvents water see case study also set mass efficiency target three per cent manufacturing sites achieve products launched longterm aspiration achieve five per cent efficiency well improving individual process efficiency targets designed improve overall environmental footprint give weight efficiency gains products larger production volumes include efficiency rates across product life cycle including final formulations tablet production include efficiency rates contract manufacturers preproduction ingredients process design effective process design essential minimise environmental impacts determines chemicals processes used manufacturing well impacts production waste sustainability environment centre excellence works process development teams incorporate sustainability ehs considerations process design materials sourcing identify potential sustainability ehs risks manufacturing back top home responsibility environmental sustainability materials mass efficiency corporate responsibility report mass efficiency approach performance encourage innovation manufacturing process increase efficiency convert raw materials finished products known mass efficiency helps reduce resources use waste generate cost production requires innovation way discover manufacture products historically industry used tonnes material every tonne active pharmaceutical ingredient api produced pharmaceutical processes often complex usually requiring large amounts solvents raw materials take several processes obtain right purity pharmaceutical want finalise processes quickly avoid delaying drug approval production originally set target rd double average mass efficiency processes new products would achieve two per cent mass efficiency instead typical one per cent increased target aiming additional per cent increase efficiency new products launched taking mass efficiency target per cent one project uk site increased output ten per cent saving solvents water see case study also set mass efficiency target three per cent manufacturing sites achieve products launched longterm aspiration achieve five per cent efficiency well improving individual process efficiency targets designed improve overall environmental footprint give weight efficiency gains products larger production volumes include efficiency rates across product life cycle including final formulations tablet production include efficiency rates contract manufacturers preproduction ingredients process design effective process design essential minimise environmental impacts determines chemicals processes used manufacturing well impacts production waste sustainability environment centre excellence works process development teams incorporate sustainability ehs considerations process design materials sourcing identify potential sustainability ehs risks manufacturing back top home responsibility environmental sustainability materials performance corporate responsibility report mass efficiency approach performance mass efficiency average chart shows range mass efficiency average process stage manufacturing process developed rd demonstrates improve mass efficiency compounds move development stages early stages many processes achieve less one per cent mass efficiency last stage process transferred rd manufacturing average per cent mass efficiency improvements mass efficiency translate economic well environmental benefits instance development compounds progress early stages last stage estimated cost raw materials fallen per cent since fewer different materials less needed produce amount active pharmaceutical ingredient back top home responsibility environmental sustainability materials performance corporate responsibility report mass efficiency approach performance mass efficiency average chart shows range mass efficiency average process stage manufacturing process developed rd demonstrates improve mass efficiency compounds move development stages early stages many processes achieve less one per cent mass efficiency last stage process transferred rd manufacturing average per cent mass efficiency improvements mass efficiency translate economic well environmental benefits instance development compounds progress early stages last stage estimated cost raw materials fallen per cent since fewer different materials less needed produce amount active pharmaceutical ingredient back top home responsibility environmental sustainability materials input materials corporate responsibility report input materials materials used pharmaceutical processes raise concerns potential impact people environment include certain chemicals well genetically modified microorganisms gmms nanomaterials materials concern materials concern chemicals scientific evidence shows probable serious longterm effects humans environment existing potential future legislation may restrict use compounds include substances persist environment accumulate animals plants toxic life carcinogens mutagens reproductive toxins substances known cause asthma endocrinedisrupting chemicals ozonedepleting substances operational sustainability team works process development teams develop strategies eliminate substitute use materials continuously examine use materials concern across phases development determine substances used identify replaced development instance result process aluminium trichloride chloroform eliminated process manufacture novel antibiotic addition dichloromethane lithium dioxane eliminated process key intermediate projects received ceos sustainability awards used metric tonnes materials concern tonnes five solvents accounted per cent volume solvent waste production destroyed incineration although recycled instance development campaigns pilot plants recovered reused processes acetonitrile toluene isopropyl acetate plans development processes goal eliminate compounds use genetically modified microorganisms use gmm research development new therapeutic agents manufacture certain medical products vaccines help us identify genetic targets causes disease develop new antibiotics drugs conditions heart disease diabetes depression use number different gmm predominantly harmless organisms disabled strains bacterium ecoli eukaryotic cells culture also manufacture number products derived gmm hepatitis b vaccine produce plan produce products contain viable genetically modified micro organisms gsk committed ensuring control risks employees environment use gmm technology develop manufacture products work gmm assessed controlled applying best practices across facilities follows environment health safety sustainability standards ensure risks handling gmm minimised standards meet exceed requirements local national international regulations work gmm subject risk assessment identify appropriate controls including safe conditions use storage disposal emergency management procedures minimise contact gmm humans environment manage use gmm bodies site institutional biosafety committees genetic modification safety committees line national local regulations require gmm inactive waste streams ensure safety human health environment evaluate risks associated gmm use employ processes effective inactivating waste streams routinely undertake research development involving cultivation genetically modified plant species nanomaterials nanotechnology uses materials atomic molecular scale may future offer many benefits patients could used develop new medicines oral healthcare products gsk actively investigating number opportunities use nanomaterials research development programmes however currently products market contain deliberately engineered nanomaterials developed public position paper use nanomaterials back tophome responsibility environmental sustainability materials input materials corporate responsibility report input materials materials used pharmaceutical processes raise concerns potential impact people environment include certain chemicals well genetically modified microorganisms gmms nanomaterials materials concern materials concern chemicals scientific evidence shows probable serious longterm effects humans environment existing potential future legislation may restrict use compounds include substances persist environment accumulate animals plants toxic life carcinogens mutagens reproductive toxins substances known cause asthma endocrinedisrupting chemicals ozonedepleting substances operational sustainability team works process development teams develop strategies eliminate substitute use materials continuously examine use materials concern across phases development determine substances used identify replaced development instance result process aluminium trichloride chloroform eliminated process manufacture novel antibiotic addition dichloromethane lithium dioxane eliminated process key intermediate projects received ceos sustainability awards used metric tonnes materials concern tonnes five solvents accounted per cent volume solvent waste production destroyed incineration although recycled instance development campaigns pilot plants recovered reused processes acetonitrile toluene isopropyl acetate plans development processes goal eliminate compounds use genetically modified microorganisms use gmm research development new therapeutic agents manufacture certain medical products vaccines help us identify genetic targets causes disease develop new antibiotics drugs conditions heart disease diabetes depression use number different gmm predominantly harmless organisms disabled strains bacterium ecoli eukaryotic cells culture also manufacture number products derived gmm hepatitis b vaccine produce plan produce products contain viable genetically modified micro organisms gsk committed ensuring control risks employees environment use gmm technology develop manufacture products work gmm assessed controlled applying best practices across facilities follows environment health safety sustainability standards ensure risks handling gmm minimised standards meet exceed requirements local national international regulations work gmm subject risk assessment identify appropriate controls including safe conditions use storage disposal emergency management procedures minimise contact gmm humans environment manage use gmm bodies site institutional biosafety committees genetic modification safety committees line national local regulations require gmm inactive waste streams ensure safety human health environment evaluate risks associated gmm use employ processes effective inactivating waste streams routinely undertake research development involving cultivation genetically modified plant species nanomaterials nanotechnology uses materials atomic molecular scale may future offer many benefits patients could used develop new medicines oral healthcare products gsk actively investigating number opportunities use nanomaterials research development programmes however currently products market contain deliberately engineered nanomaterials developed public position paper use nanomaterials back top home responsibility environmental sustainability materials input materials corporate responsibility report input materials materials used pharmaceutical processes raise concerns potential impact people environment include certain chemicals well genetically modified microorganisms gmms nanomaterials materials concern materials concern chemicals scientific evidence shows probable serious longterm effects humans environment existing potential future legislation may restrict use compounds include substances persist environment accumulate animals plants toxic life carcinogens mutagens reproductive toxins substances known cause asthma endocrinedisrupting chemicals ozonedepleting substances operational sustainability team works process development teams develop strategies eliminate substitute use materials continuously examine use materials concern across phases development determine substances used identify replaced development instance result process aluminium trichloride chloroform eliminated process manufacture novel antibiotic addition dichloromethane lithium dioxane eliminated process key intermediate projects received ceos sustainability awards used metric tonnes materials concern tonnes five solvents accounted per cent volume solvent waste production destroyed incineration although recycled instance development campaigns pilot plants recovered reused processes acetonitrile toluene isopropyl acetate plans development processes goal eliminate compounds use genetically modified microorganisms use gmm research development new therapeutic agents manufacture certain medical products vaccines help us identify genetic targets causes disease develop new antibiotics drugs conditions heart disease diabetes depression use number different gmm predominantly harmless organisms disabled strains bacterium ecoli eukaryotic cells culture also manufacture number products derived gmm hepatitis b vaccine produce plan produce products contain viable genetically modified micro organisms gsk committed ensuring control risks employees environment use gmm technology develop manufacture products work gmm assessed controlled applying best practices across facilities follows environment health safety sustainability standards ensure risks handling gmm minimised standards meet exceed requirements local national international regulations work gmm subject risk assessment identify appropriate controls including safe conditions use storage disposal emergency management procedures minimise contact gmm humans environment manage use gmm bodies site institutional biosafety committees genetic modification safety committees line national local regulations require gmm inactive waste streams ensure safety human health environment evaluate risks associated gmm use employ processes effective inactivating waste streams routinely undertake research development involving cultivation genetically modified plant species nanomaterials nanotechnology uses materials atomic molecular scale may future offer many benefits patients could used develop new medicines oral healthcare products gsk actively investigating number opportunities use nanomaterials research development programmes however currently products market contain deliberately engineered nanomaterials developed public position paper use nanomaterials back top home responsibility environmental sustainability materials reach corporate responsibility report reach started earnest implement requirements eus registration evaluation authorisation restriction chemicals reach legislation involved incorporating reach compliance activities procurement programmes training staff involved purchasing chemicals identifying gsks use chemicals ensuring suppliers include reach registrations adopting lead registrant status developing data necessary prepare registration dossiers two highvolume substances requiring registration november registering new substances manufacture import volumes greater one tonne per year read position reach reach plans reach fully embedded rd procurement operations approach help us ensure meet november registration deadline substances import manufacture volumes tonnes year continue register new substances originating rd pipeline continue engage suppliers ensure meet registration obligations begin working ensure meet new eu requirements notify classification labelling information hazardous substances place market import central inventory maintained european chemicals agency global harmonisation updated gsk safety data sheet sds format allow production ghscompliant sdss reclassified substances meet eu ghs implementation deadline november developed elearning posters facilitate employee training new hazard warning symbols labels introduced part ghs identified new software allow printing ghs labels gsk manufacturing sites continue staff awareness training new ghs label elements submit eu ghs classification labelling information eu chemicals agency inventory end plan gsk substance safety data sheets available intranet site new ghs format back top home responsibility environmental sustainability materials reach corporate responsibility report reach started earnest implement requirements eus registration evaluation authorisation restriction chemicals reach legislation involved incorporating reach compliance activities procurement programmes training staff involved purchasing chemicals identifying gsks use chemicals ensuring suppliers include reach registrations adopting lead registrant status developing data necessary prepare registration dossiers two highvolume substances requiring registration november registering new substances manufacture import volumes greater one tonne per year read position reach reach plans reach fully embedded rd procurement operations approach help us ensure meet november registration deadline substances import manufacture volumes tonnes year continue register new substances originating rd pipeline continue engage suppliers ensure meet registration obligations begin working ensure meet new eu requirements notify classification labelling information hazardous substances place market import central inventory maintained european chemicals agency global harmonisation updated gsk safety data sheet sds format allow production ghscompliant sdss reclassified substances meet eu ghs implementation deadline november developed elearning posters facilitate employee training new hazard warning symbols labels introduced part ghs identified new software allow printing ghs labels gsk manufacturing sites continue staff awareness training new ghs label elements submit eu ghs classification labelling information eu chemicals agency inventory end plan gsk substance safety data sheets available intranet site new ghs format back top home responsibility environmental sustainability materials pharmaceuticals environment corporate responsibility report pharmaceuticals environment portion active pharmaceutical ingredients apis substances make medicines work eventually excreted humans enter environment wastewater treatment removes pharmaceutical residues small concentrations end rivers sea low concentrations pharmaceuticals occasionally found drinking water countries wastewater treated higher concentrations may enter environment continue conduct tests risk assessments evaluate potential effects pharmaceutical products environment previous years results indicate products appear pose risk humans environment based current risk assessment methodologies information important continue monitoring issue conduct retrospective analysis environmental data refine testing methodology assessment models recently revised material testing strategies include chronic testing determine impact products environment long term mode action analysis identify sensitive species meet new regulatory guidelines improve understanding possible environmental effects committed transparency data collect make environmental data publicly available assessments environmental data individual apis provided online safety data sheets data also available swedish doctors prescribing guide see publish results risk assessments scientific journals continue monitor latest scientific studies findings improve risk assessment methodology addition conduct contribute environmental research area published scientific paper assessing potential impacts human health environmental exposures apis included gsks pharmaceutical products portfolio published february journal regulatory toxicology pharmacology see box also continue identify study emerging issues related presence extremely low levels pharmaceuticals household products environment although main source pharmaceuticals environment patients excreting medicines gsk established limits active pharmaceutical ingredients wastewater manufacturing sites based studies established maximum levels apis expected adversely impact environment assess process waste concentrations levels treat wastewater required ensure safe levels achieved read public position statement pharmaceuticals environment industry collaboration work pharmaceutical companies universities research groups pharmaceuticals environment also collaborate joint projects industry groups sponsor academic studies advance scientific understanding risks example submit environmental data products part swedish classification system pharmaceuticals collaboration swedish pharmaceutical association swedish government voluntary transparency initiative making information environmental risks available public doctors scientists participate technical working groups pharmaceuticals environment continually engage regulatory scientists us environmental protection agency us food drug administration uk environment agency home responsibility environmental sustainability materials pharmaceuticals environment corporate responsibility report pharmaceuticals environment portion active pharmaceutical ingredients apis substances make medicines work eventually excreted humans enter environment wastewater treatment removes pharmaceutical residues small concentrations end rivers sea low concentrations pharmaceuticals occasionally found drinking water countries wastewater treated higher concentrations may enter environment continue conduct tests risk assessments evaluate potential effects pharmaceutical products environment previous years results indicate products appear pose risk humans environment based current risk assessment methodologies information important continue monitoring issue conduct retrospective analysis environmental data refine testing methodology assessment models recently revised material testing strategies include chronic testing determine impact products environment long term mode action analysis identify sensitive species meet new regulatory guidelines improve understanding possible environmental effects committed transparency data collect make environmental data publicly available assessments environmental data individual apis provided online safety data sheets data also available swedish doctors prescribing guide see publish results risk assessments scientific journals continue monitor latest scientific studies findings improve risk assessment methodology addition conduct contribute environmental research area published scientific paper assessing potential impacts human health environmental exposures apis included gsks pharmaceutical products portfolio published february journal regulatory toxicology pharmacology see box also continue identify study emerging issues related presence extremely low levels pharmaceuticals household products environment although main source pharmaceuticals environment patients excreting medicines gsk established limits active pharmaceutical ingredients wastewater manufacturing sites based studies established maximum levels apis expected adversely impact environment assess process waste concentrations levels treat wastewater required ensure safe levels achieved read public position statement pharmaceuticals environment industry collaboration work pharmaceutical companies universities research groups pharmaceuticals environment also collaborate joint projects industry groups sponsor academic studies advance scientific understanding risks example submit environmental data products part swedish classification system pharmaceuticals collaboration swedish pharmaceutical association swedish government voluntary transparency initiative making information environmental risks available public doctors scientists participate technical working groups pharmaceuticals environment continually engage regulatory scientists us environmental protection agency us food drug administration uk environment agency home responsibility environmental sustainability materials pharmaceuticals environment corporate responsibility report pharmaceuticals environment portion active pharmaceutical ingredients apis substances make medicines work eventually excreted humans enter environment wastewater treatment removes pharmaceutical residues small concentrations end rivers sea low concentrations pharmaceuticals occasionally found drinking water countries wastewater treated higher concentrations may enter environment continue conduct tests risk assessments evaluate potential effects pharmaceutical products environment previous years results indicate products appear pose risk humans environment based current risk assessment methodologies information important continue monitoring issue conduct retrospective analysis environmental data refine testing methodology assessment models recently revised material testing strategies include chronic testing determine impact products environment long term mode action analysis identify sensitive species meet new regulatory guidelines improve understanding possible environmental effects committed transparency data collect make environmental data publicly available assessments environmental data individual apis provided online safety data sheets data also available swedish doctors prescribing guide see publish results risk assessments scientific journals continue monitor latest scientific studies findings improve risk assessment methodology addition conduct contribute environmental research area published scientific paper assessing potential impacts human health environmental exposures apis included gsks pharmaceutical products portfolio published february journal regulatory toxicology pharmacology see box also continue identify study emerging issues related presence extremely low levels pharmaceuticals household products environment although main source pharmaceuticals environment patients excreting medicines gsk established limits active pharmaceutical ingredients wastewater manufacturing sites based studies established maximum levels apis expected adversely impact environment assess process waste concentrations levels treat wastewater required ensure safe levels achieved read public position statement pharmaceuticals environment industry collaboration work pharmaceutical companies universities research groups pharmaceuticals environment also collaborate joint projects industry groups sponsor academic studies advance scientific understanding risks example submit environmental data products part swedish classification system pharmaceuticals collaboration swedish pharmaceutical association swedish government voluntary transparency initiative making information environmental risks available public doctors scientists participate technical working groups pharmaceuticals environment continually engage regulatory scientists us environmental protection agency us food drug administration uk environment agency home responsibility environmental sustainability materials packaging corporate responsibility report packaging working reduce environmental impact packaging pharmaceutical consumer healthcare products recognise substantial opportunities improve packaging profile green packaging guide provides guidance evaluating selecting packaging allows designers managers benchmark new existing packaging designs using five metrics manufacturing impacts mass material biodegradability pvc content resource depletion petrochemical feedstocks developed companywide strategy drive towards sustainable packaging covering consumer healthcare pharmaceuticals biologicals businesses strategy set gsks sustainable packaging principles rs reduce mass materials complexity life cycle footprint packaging remove materials sustainability ehs issues example pvc phthalates reuse increase use recycled materials packaging recycle design recyclability renew increase use materials energy renewable sources reward make sound packaging decisions account cost needs patients customers consumers respect utilise responsible supplier selection gsks consumer healthcare ch business adopted sustainability strategy includes objective measure reduce packaging environmental impacts throughout product life cycle include identifying ways support postconsumer recovery recycling gsk consumer packaging business work reducing packaging weight improving recyclability increasing recycled content using materials sustainable sources ch set system collecting reporting packaging data set improvement targets one example reducing impact packaging use per cent recycled plastic ribena bottles achieved despite challenge sourcing sufficient quantities recycled plastic back top home responsibility environmental sustainability materials packaging corporate responsibility report packaging working reduce environmental impact packaging pharmaceutical consumer healthcare products recognise substantial opportunities improve packaging profile green packaging guide provides guidance evaluating selecting packaging allows designers managers benchmark new existing packaging designs using five metrics manufacturing impacts mass material biodegradability pvc content resource depletion petrochemical feedstocks developed companywide strategy drive towards sustainable packaging covering consumer healthcare pharmaceuticals biologicals businesses strategy set gsks sustainable packaging principles rs reduce mass materials complexity life cycle footprint packaging remove materials sustainability ehs issues example pvc phthalates reuse increase use recycled materials packaging recycle design recyclability renew increase use materials energy renewable sources reward make sound packaging decisions account cost needs patients customers consumers respect utilise responsible supplier selection gsks consumer healthcare ch business adopted sustainability strategy includes objective measure reduce packaging environmental impacts throughout product life cycle include identifying ways support postconsumer recovery recycling gsk consumer packaging business work reducing packaging weight improving recyclability increasing recycled content using materials sustainable sources ch set system collecting reporting packaging data set improvement targets one example reducing impact packaging use per cent recycled plastic ribena bottles achieved despite challenge sourcing sufficient quantities recycled plastic back top home responsibility environmental sustainability environmental performance corporate responsibility report environmental performance working reduce direct environmental impacts operations many years continue reducing water use waste generation emissions gsk manufacturing facilities research laboratories numerous offices warehouses large fleet vehicles use substantial volumes water solvents well substances result damaging emissions hazardous waste see climate change energy coverage energy greenhouse gas emissions aim create culture environmental considerations part everyday business decisions initially focused effectively managing resource use emissions continue work improving areas adopting broader approach goal transform environmental impacts thinking broadly sustainability example may able change production business processes avoid waste source rather simply treating waste emissions arise focused particularly water use underlined commitment signing un ceo water mandate back top home responsibility environmental sustainability environmental performance corporate responsibility report environmental performance working reduce direct environmental impacts operations many years continue reducing water use waste generation emissions gsk manufacturing facilities research laboratories numerous offices warehouses large fleet vehicles use substantial volumes water solvents well substances result damaging emissions hazardous waste see climate change energy coverage energy greenhouse gas emissions aim create culture environmental considerations part everyday business decisions initially focused effectively managing resource use emissions continue work improving areas adopting broader approach goal transform environmental impacts thinking broadly sustainability example may able change production business processes avoid waste source rather simply treating waste emissions arise focused particularly water use underlined commitment signing un ceo water mandate back top home responsibility environmental sustainability environmental performance water corporate responsibility report water approach performance plans fresh water finite vulnerable resource essential sustaining life development environment increasing demands water sources together effects climate change mean many areas waterstressed estimated third world 's population suffer severe chronic water shortages due impacts climate change population growth increased affluence result environmental damage political conflict many deaths water related diseases committed continuous improvement areas improving water use benefits gsk increasing water security improving manufacturing efficiency strengthening reputation relationships stakeholders gsk requires access clean water mostly manufacturing processes products cooling cleaning well rd general site uses drinking food services sanitation aim use water sustainably seek minimise negative environmental social impacts overall target reduce water consumption two per cent per annum per unit sales consider sitespecific targets facilities waterstressed regions using clean water important public health operate philanthropic personal hygiene sanitation education phase programme simple handwashing programme teaching children reduce spread infection un water mandate gsk endorsed united nations ceo water mandate first communication progress demonstrates recognition water valuable natural resource businesses play positive role managing endorsing mandate pledge improve water sustainability direct operations supply chain work organisations governments encourage sustainable policy practices engage sites ' local communities providing education support water sanitation accurate transparent reporting waterrelated issues short term understand measure suppliers use water factories make use sustainable longer term integrate water strategy overall strategy develop metric measures water sustainability well assessing direct water footprint gsk 's suppliers ' operations focus developing ideas water neutrality waterrelated risks vary widely location important focus efforts areas water scarce gsk used world business council sustainable development 's wbcsd 's water tool identify sites areas likely suffer water shortages tool identified five sites areas concern india pakistan south africa kenya nigeria seven sites algeria morocco pakistan singapore areas considered moderate risk water shortages sites investigated water consumption detail identified waterrelated risks based availability water effects extreme weather events social regulatory environments operate sites developed riskmitigation strategies one sites australia slightly less waterstressed area implemented measures rainwater capture gardens cooling waterless urinals using waste water flushing toilets evaluate strategies monitor implementation supply chain watershed management ceo water mandate pledged encourage support suppliers reporting water use improving sustainability practices collected water use suppliers api see supplier performance section also pledged help protect manage watersheds operate engagement governments organisations sites water stressed areas routinely engage local communities government authorities water however gsk yet joined water advocacy organisations integrated strategy guide engagement organisations back tophome responsibility environmental sustainability environmental performance water corporate responsibility report water approach performance plans fresh water finite vulnerable resource essential sustaining life development environment increasing demands water sources together effects climate change mean many areas waterstressed estimated third world 's population suffer severe chronic water shortages due impacts climate change population growth increased affluence result environmental damage political conflict many deaths water related diseases committed continuous improvement areas improving water use benefits gsk increasing water security improving manufacturing efficiency strengthening reputation relationships stakeholders gsk requires access clean water mostly manufacturing processes products cooling cleaning well rd general site uses drinking food services sanitation aim use water sustainably seek minimise negative environmental social impacts overall target reduce water consumption two per cent per annum per unit sales consider sitespecific targets facilities waterstressed regions using clean water important public health operate philanthropic personal hygiene sanitation education phase programme simple handwashing programme teaching children reduce spread infection un water mandate gsk endorsed united nations ceo water mandate first communication progress demonstrates recognition water valuable natural resource businesses play positive role managing endorsing mandate pledge improve water sustainability direct operations supply chain work organisations governments encourage sustainable policy practices engage sites ' local communities providing education support water sanitation accurate transparent reporting waterrelated issues short term understand measure suppliers use water factories make use sustainable longer term integrate water strategy overall strategy develop metric measures water sustainability well assessing direct water footprint gsk 's suppliers ' operations focus developing ideas water neutrality waterrelated risks vary widely location important focus efforts areas water scarce gsk used world business council sustainable development 's wbcsd 's water tool identify sites areas likely suffer water shortages tool identified five sites areas concern india pakistan south africa kenya nigeria seven sites algeria morocco pakistan singapore areas considered moderate risk water shortages sites investigated water consumption detail identified waterrelated risks based availability water effects extreme weather events social regulatory environments operate sites developed riskmitigation strategies one sites australia slightly less waterstressed area implemented measures rainwater capture gardens cooling waterless urinals using waste water flushing toilets evaluate strategies monitor implementation supply chain watershed management ceo water mandate pledged encourage support suppliers reporting water use improving sustainability practices collected water use suppliers api see supplier performance section also pledged help protect manage watersheds operate engagement governments organisations sites water stressed areas routinely engage local communities government authorities water however gsk yet joined water advocacy organisations integrated strategy guide engagement organisations back top home responsibility environmental sustainability environmental performance water corporate responsibility report water approach performance plans fresh water finite vulnerable resource essential sustaining life development environment increasing demands water sources together effects climate change mean many areas waterstressed estimated third world 's population suffer severe chronic water shortages due impacts climate change population growth increased affluence result environmental damage political conflict many deaths water related diseases committed continuous improvement areas improving water use benefits gsk increasing water security improving manufacturing efficiency strengthening reputation relationships stakeholders gsk requires access clean water mostly manufacturing processes products cooling cleaning well rd general site uses drinking food services sanitation aim use water sustainably seek minimise negative environmental social impacts overall target reduce water consumption two per cent per annum per unit sales consider sitespecific targets facilities waterstressed regions using clean water important public health operate philanthropic personal hygiene sanitation education phase programme simple handwashing programme teaching children reduce spread infection un water mandate gsk endorsed united nations ceo water mandate first communication progress demonstrates recognition water valuable natural resource businesses play positive role managing endorsing mandate pledge improve water sustainability direct operations supply chain work organisations governments encourage sustainable policy practices engage sites ' local communities providing education support water sanitation accurate transparent reporting waterrelated issues short term understand measure suppliers use water factories make use sustainable longer term integrate water strategy overall strategy develop metric measures water sustainability well assessing direct water footprint gsk 's suppliers ' operations focus developing ideas water neutrality waterrelated risks vary widely location important focus efforts areas water scarce gsk used world business council sustainable development 's wbcsd 's water tool identify sites areas likely suffer water shortages tool identified five sites areas concern india pakistan south africa kenya nigeria seven sites algeria morocco pakistan singapore areas considered moderate risk water shortages sites investigated water consumption detail identified waterrelated risks based availability water effects extreme weather events social regulatory environments operate sites developed riskmitigation strategies one sites australia slightly less waterstressed area implemented measures rainwater capture gardens cooling waterless urinals using waste water flushing toilets evaluate strategies monitor implementation supply chain watershed management ceo water mandate pledged encourage support suppliers reporting water use improving sustainability practices collected water use suppliers api see supplier performance section also pledged help protect manage watersheds operate engagement governments organisations sites water stressed areas routinely engage local communities government authorities water however gsk yet joined water advocacy organisations integrated strategy guide engagement organisations back top home responsibility environmental sustainability environmental performance performance corporate responsibility report water approach performance plans water consumption gsk 's worldwide water use totalled billion litres equivalent almost uk households saved almost million litres water compared despite significant increased use biologicals increased vaccine production explanation trend progress due continued conservation especially waterstressed areas singapore india however even areas less water stress implemented ideas save water gsk site spain following suggestions staff fountain replaced planted area native drought resistant bushes trees require natural watering consumption also fell lower production waterintensive processes water consumption per unit sales per cent lower exceeding two per cent target pharmaceutical manufacturing water use fell nearly six per cent cumulatively water use per unit sales fallen per cent since ahead two per cent annual reduction target however continue look water use impact particularly sites water stressed areas sgs verified back top home responsibility environmental sustainability environmental performance performance corporate responsibility report water approach performance plans water consumption gsk 's worldwide water use totalled billion litres equivalent almost uk households saved almost million litres water compared despite significant increased use biologicals increased vaccine production explanation trend progress due continued conservation especially waterstressed areas singapore india however even areas less water stress implemented ideas save water gsk site spain following suggestions staff fountain replaced planted area native drought resistant bushes trees require natural watering consumption also fell lower production waterintensive processes water consumption per unit sales per cent lower exceeding two per cent target pharmaceutical manufacturing water use fell nearly six per cent cumulatively water use per unit sales fallen per cent since ahead two per cent annual reduction target however continue look water use impact particularly sites water stressed areas sgs verified back top home responsibility environmental sustainability environmental performance wastewater corporate responsibility report wastewater approach performance gsk sites discharge wastewater municipal treatment facilities locations onsite wastewater treatment systems permitted discharge wastewater direct sea quality wastewater discharged measured using chemical oxygen demand cod measure oxygen required chemically oxidise compounds water lower cods correspond cleaner water gsk 's target three per cent reduction cod levels per year per unit sales vast majority cod comes manufacturing active pharmaceutical ingredients 'domestic use ' example washrooms canteens included measurements separated waste water measured sites discharge permits require monitoring back top home responsibility environmental sustainability environmental performance wastewater corporate responsibility report wastewater approach performance gsk sites discharge wastewater municipal treatment facilities locations onsite wastewater treatment systems permitted discharge wastewater direct sea quality wastewater discharged measured using chemical oxygen demand cod measure oxygen required chemically oxidise compounds water lower cods correspond cleaner water gsk 's target three per cent reduction cod levels per year per unit sales vast majority cod comes manufacturing active pharmaceutical ingredients 'domestic use ' example washrooms canteens included measurements separated waste water measured sites discharge permits require monitoring back top home responsibility environmental sustainability environmental performance performance corporate responsibility report wastewater approach performance chemical oxygen demand wastewater generated billion litres wastewater per cent lower per cent baseline chemical oxygen demand cod wastewater also fell per cent cod per million sales fell per cent reaching cumulative per cent baseline puts us ahead target decrease three per cent per year however years water pollution goes depending products made year fluctuations business mean may miss targets explanation trend quality wastewater discharged closely related types amount materials produced manufacture active pharmaceutical ingredients consumer products significant decrease year due three factors lower production waterintensive processes manufacture active pharmaceutical ingredients newly commissioned wastewater treatment plant toothpaste factory uk reverse osmosis system installed pharmaceutical ingredient manufacturing plant india changes levels wastewater pollution year year due changes production addition continued improvements wastewater treatment waste minimisation work improve manufacturing efficiency continue decrease wastewater pollution future sgs verified back top home responsibility environmental sustainability environmental performance performance corporate responsibility report wastewater approach performance chemical oxygen demand wastewater generated billion litres wastewater per cent lower per cent baseline chemical oxygen demand cod wastewater also fell per cent cod per million sales fell per cent reaching cumulative per cent baseline puts us ahead target decrease three per cent per year however years water pollution goes depending products made year fluctuations business mean may miss targets explanation trend quality wastewater discharged closely related types amount materials produced manufacture active pharmaceutical ingredients consumer products significant decrease year due three factors lower production waterintensive processes manufacture active pharmaceutical ingredients newly commissioned wastewater treatment plant toothpaste factory uk reverse osmosis system installed pharmaceutical ingredient manufacturing plant india changes levels wastewater pollution year year due changes production addition continued improvements wastewater treatment waste minimisation work improve manufacturing efficiency continue decrease wastewater pollution future sgs verified back top home responsibility environmental sustainability environmental performance waste corporate responsibility report waste approach performance plans production research sales activities produce waste production hazardous wastes solvents chemicals rd quality control laboratories small amounts chemicals including products intermediates well broken glassware plastics offices paper standard commercial waste building renovations produce nonroutine waste obsolete equipment office furniture structural materials significant proportion waste classified hazardous mainly contains solvents chemicals used manufacture active pharmaceutical ingredients nonhazardous waste general material office waste paper kitchen waste nonhazardous substances used manufacturing aim eliminate waste reduce eliminate reuse materials possible recycle waste dispose remaining material sensitively hierarchy also applies solvents first choice reuse recycle used solvent recovered purified site reused original manufacturing process sold commercial reprocessing companies reuse recycling possible solvents mostly incinerated energy recovered wherever possible regulations vary widely around world working hierarchy aim manage waste way meets exceeds regulatory requirements require disposal contractors comply requirements local regulations sites audit waste contractors hire consultants carry audits target reduce nonhazardous waste disposed per unit sales one per cent per annum give us reduction four per cent end set target reduction hazardous waste aiming improve material efficiency reduce volume hazardous waste addition production changes reduce waste volumes sites aggressively working recycle much waste possible minimise disposal eliminating waste sent landfill team one consumer healthcare manufacturing sites india succeeded reducing waste well water energy use reducing amount packaging see case study back top home responsibility environmental sustainability environmental performance waste corporate responsibility report waste approach performance plans production research sales activities produce waste production hazardous wastes solvents chemicals rd quality control laboratories small amounts chemicals including products intermediates well broken glassware plastics offices paper standard commercial waste building renovations produce nonroutine waste obsolete equipment office furniture structural materials significant proportion waste classified hazardous mainly contains solvents chemicals used manufacture active pharmaceutical ingredients nonhazardous waste general material office waste paper kitchen waste nonhazardous substances used manufacturing aim eliminate waste reduce eliminate reuse materials possible recycle waste dispose remaining material sensitively hierarchy also applies solvents first choice reuse recycle used solvent recovered purified site reused original manufacturing process sold commercial reprocessing companies reuse recycling possible solvents mostly incinerated energy recovered wherever possible regulations vary widely around world working hierarchy aim manage waste way meets exceeds regulatory requirements require disposal contractors comply requirements local regulations sites audit waste contractors hire consultants carry audits target reduce nonhazardous waste disposed per unit sales one per cent per annum give us reduction four per cent end set target reduction hazardous waste aiming improve material efficiency reduce volume hazardous waste addition production changes reduce waste volumes sites aggressively working recycle much waste possible minimise disposal eliminating waste sent landfill team one consumer healthcare manufacturing sites india succeeded reducing waste well water energy use reducing amount packaging see case study back top home responsibility environmental sustainability environmental performance performance plans corporate responsibility report waste approach performance plans nonhazardous waste nonhazardous waste disposed destination nonhazardous waste data include nonroutine waste construction demolition rubble similar material related daytoday operations amount nonhazardous waste disposed fell per cent per cent lower baseline tonnes waste per million sales per cent lower year per cent beyond one per cent per year improvement target still need plan set aggressive targets future target specific nonhazardous waste disposed also measure total nonhazardous waste generated includes waste recycled generated tonnes nonhazardous waste slightly higher previous year per cent recycled per cent disposed via landfill incineration figures showing improvements explanation trend decrease nonhazardous waste disposed partly reflects continuing efforts manage recycle waste especially pharmaceutical consumer manufacturing operations also due part decreased production pharmaceutical products balanced increasing waste vaccines business continues grow impact hn swine flu vaccine production resulted per cent increase waste generated biologicals sites including tonnes one site due eggs used vaccine production site accounted nearly per cent nonhazardous waste disposed continue look ways reduce waste recycling finding ways use less raw material focus making manufacturing processes efficient also reduce amount waste disposed sgs verified hazardous waste hazardous waste disposed destination hazardous waste generated tonnes hazardous waste less one per cent waste went landfill per cent recycled similar proportion hazardous waste disposed tonnes per cent lower waste disposed per million sales fell per cent per cent level explanation trend decrease hazardous waste disposed due continued efforts manage recycle especially solvents also due part decreased production products used significant quantities solvent amount disposed related types quantities products made amount solvent used factories manufacture active pharmaceutical ingredients solvent waste per cent hazardous waste generated five largest sites manufacture active pharmaceutical ingredients together account per cent solvent waste disposed target reducing hazardous waste disposed instead focus attention improving manufacturing efficiency efficiency improvements mean less material used manufacturing process therefore less waste generated example team rd developed continuous manufacturing pilot plant could significantly reduce amount solvent waste see case study sgs verified back tophome responsibility environmental sustainability environmental performance performance plans corporate responsibility report waste approach performance plans nonhazardous waste nonhazardous waste disposed destination nonhazardous waste data include nonroutine waste construction demolition rubble similar material related daytoday operations amount nonhazardous waste disposed fell per cent per cent lower baseline tonnes waste per million sales per cent lower year per cent beyond one per cent per year improvement target still need plan set aggressive targets future target specific nonhazardous waste disposed also measure total nonhazardous waste generated includes waste recycled generated tonnes nonhazardous waste slightly higher previous year per cent recycled per cent disposed via landfill incineration figures showing improvements explanation trend decrease nonhazardous waste disposed partly reflects continuing efforts manage recycle waste especially pharmaceutical consumer manufacturing operations also due part decreased production pharmaceutical products balanced increasing waste vaccines business continues grow impact hn swine flu vaccine production resulted per cent increase waste generated biologicals sites including tonnes one site due eggs used vaccine production site accounted nearly per cent nonhazardous waste disposed continue look ways reduce waste recycling finding ways use less raw material focus making manufacturing processes efficient also reduce amount waste disposed sgs verified hazardous waste hazardous waste disposed destination hazardous waste generated tonnes hazardous waste less one per cent waste went landfill per cent recycled similar proportion hazardous waste disposed tonnes per cent lower waste disposed per million sales fell per cent per cent level explanation trend decrease hazardous waste disposed due continued efforts manage recycle especially solvents also due part decreased production products used significant quantities solvent amount disposed related types quantities products made amount solvent used factories manufacture active pharmaceutical ingredients solvent waste per cent hazardous waste generated five largest sites manufacture active pharmaceutical ingredients together account per cent solvent waste disposed target reducing hazardous waste disposed instead focus attention improving manufacturing efficiency efficiency improvements mean less material used manufacturing process therefore less waste generated example team rd developed continuous manufacturing pilot plant could significantly reduce amount solvent waste see case study sgs verified back tophome responsibility environmental sustainability environmental performance performance plans corporate responsibility report waste approach performance plans nonhazardous waste nonhazardous waste disposed destination nonhazardous waste data include nonroutine waste construction demolition rubble similar material related daytoday operations amount nonhazardous waste disposed fell per cent per cent lower baseline tonnes waste per million sales per cent lower year per cent beyond one per cent per year improvement target still need plan set aggressive targets future target specific nonhazardous waste disposed also measure total nonhazardous waste generated includes waste recycled generated tonnes nonhazardous waste slightly higher previous year per cent recycled per cent disposed via landfill incineration figures showing improvements explanation trend decrease nonhazardous waste disposed partly reflects continuing efforts manage recycle waste especially pharmaceutical consumer manufacturing operations also due part decreased production pharmaceutical products balanced increasing waste vaccines business continues grow impact hn swine flu vaccine production resulted per cent increase waste generated biologicals sites including tonnes one site due eggs used vaccine production site accounted nearly per cent nonhazardous waste disposed continue look ways reduce waste recycling finding ways use less raw material focus making manufacturing processes efficient also reduce amount waste disposed sgs verified hazardous waste hazardous waste disposed destination hazardous waste generated tonnes hazardous waste less one per cent waste went landfill per cent recycled similar proportion hazardous waste disposed tonnes per cent lower waste disposed per million sales fell per cent per cent level explanation trend decrease hazardous waste disposed due continued efforts manage recycle especially solvents also due part decreased production products used significant quantities solvent amount disposed related types quantities products made amount solvent used factories manufacture active pharmaceutical ingredients solvent waste per cent hazardous waste generated five largest sites manufacture active pharmaceutical ingredients together account per cent solvent waste disposed target reducing hazardous waste disposed instead focus attention improving manufacturing efficiency efficiency improvements mean less material used manufacturing process therefore less waste generated example team rd developed continuous manufacturing pilot plant could significantly reduce amount solvent waste see case study sgs verified back top home responsibility environmental sustainability environmental performance performance plans corporate responsibility report waste approach performance plans nonhazardous waste nonhazardous waste disposed destination nonhazardous waste data include nonroutine waste construction demolition rubble similar material related daytoday operations amount nonhazardous waste disposed fell per cent per cent lower baseline tonnes waste per million sales per cent lower year per cent beyond one per cent per year improvement target still need plan set aggressive targets future target specific nonhazardous waste disposed also measure total nonhazardous waste generated includes waste recycled generated tonnes nonhazardous waste slightly higher previous year per cent recycled per cent disposed via landfill incineration figures showing improvements explanation trend decrease nonhazardous waste disposed partly reflects continuing efforts manage recycle waste especially pharmaceutical consumer manufacturing operations also due part decreased production pharmaceutical products balanced increasing waste vaccines business continues grow impact hn swine flu vaccine production resulted per cent increase waste generated biologicals sites including tonnes one site due eggs used vaccine production site accounted nearly per cent nonhazardous waste disposed continue look ways reduce waste recycling finding ways use less raw material focus making manufacturing processes efficient also reduce amount waste disposed sgs verified hazardous waste hazardous waste disposed destination hazardous waste generated tonnes hazardous waste less one per cent waste went landfill per cent recycled similar proportion hazardous waste disposed tonnes per cent lower waste disposed per million sales fell per cent per cent level explanation trend decrease hazardous waste disposed due continued efforts manage recycle especially solvents also due part decreased production products used significant quantities solvent amount disposed related types quantities products made amount solvent used factories manufacture active pharmaceutical ingredients solvent waste per cent hazardous waste generated five largest sites manufacture active pharmaceutical ingredients together account per cent solvent waste disposed target reducing hazardous waste disposed instead focus attention improving manufacturing efficiency efficiency improvements mean less material used manufacturing process therefore less waste generated example team rd developed continuous manufacturing pilot plant could significantly reduce amount solvent waste see case study sgs verified back top home responsibility environmental sustainability environmental performance emissions air corporate responsibility report emissions air approach performance plans main emissions gsk sites apart greenhouse gases gases damage ozone layer volatile organic compounds vocs cause lowlevel pollution ozone depletion ozonedepleting substances odss damage ozone layer upper atmosphere exposing people radiation cause skin cancer health problems industrial use odss mainly chlorofluorocarbons cfcs hydrochlorofluorocarbons hcfcs halons common negative effects understood used cfcs propellant gas metered dose inhalers gas released patients use inhalers small amount escapes production stopped manufacturing cfc inhalers gsk sites two contract manufacturing sites unable obtain information quantity cfcs inhalers manufactured two contract manufacturers data included report read also use odss cooling systems ancillary uses gsk facilities released event leak maintenance switched using hydrofluorocarbons hfcs ammonia hydrocarbons aim eliminate cfcs hcfcs cooling systems aim remove larger pieces equipment service end volatile organic compounds volatile organic compounds vocs react nitrogen oxides presence sunlight creating ozone lower atmosphere results smog factor human respiratory illness emit vocs atmosphere mainly solvents used manufacture active pharmaceutical ingredients rd pilot plants target reduce voc emissions per unit sales two per cent per year give us reduction eight per cent end began voc reduction programme concentrating three sites responsible threequarters vocs released primary supply sites projects initiated included tank insulation changing pump technology see case study back top home responsibility environmental sustainability environmental performance emissions air corporate responsibility report emissions air approach performance plans main emissions gsk sites apart greenhouse gases gases damage ozone layer volatile organic compounds vocs cause lowlevel pollution ozone depletion ozonedepleting substances odss damage ozone layer upper atmosphere exposing people radiation cause skin cancer health problems industrial use odss mainly chlorofluorocarbons cfcs hydrochlorofluorocarbons hcfcs halons common negative effects understood used cfcs propellant gas metered dose inhalers gas released patients use inhalers small amount escapes production stopped manufacturing cfc inhalers gsk sites two contract manufacturing sites unable obtain information quantity cfcs inhalers manufactured two contract manufacturers data included report read also use odss cooling systems ancillary uses gsk facilities released event leak maintenance switched using hydrofluorocarbons hfcs ammonia hydrocarbons aim eliminate cfcs hcfcs cooling systems aim remove larger pieces equipment service end volatile organic compounds volatile organic compounds vocs react nitrogen oxides presence sunlight creating ozone lower atmosphere results smog factor human respiratory illness emit vocs atmosphere mainly solvents used manufacture active pharmaceutical ingredients rd pilot plants target reduce voc emissions per unit sales two per cent per year give us reduction eight per cent end began voc reduction programme concentrating three sites responsible threequarters vocs released primary supply sites projects initiated included tank insulation changing pump technology see case study back top home responsibility environmental sustainability environmental performance emissions air corporate responsibility report emissions air approach performance plans ozone depletion ozone depletion potential equipment production cfc equivalent odp equipment production losses decreased per cent thousand kilograms follows similarly substantial reduction means almost met target eliminate losses cfcs hcfcs production equipment twothirds cfc releases occur production inhalers estimate kilograms cfc equivalent emitted equipment releases patient use inhalers small maintain register significant pieces equipment contain refrigerants use track progress towards target eliminate cfcs hcfcs refrigeration equipment pieces equipment containing one kilogram cfcs amounting kilograms total items equipment contain odss kilograms cfc equivalent explanation trend production cfccontaining inhalers decreases amount gases lost stages production use also declines sgs verified volatile organic compounds volatile organic compound emissions volatile organic compound voc emissions decreased per cent tonnes emissions fallen nearly per cent since vocs released air per million sales decreased per cent means achieved target continues trend reductions previous years takes total reduction per unit sales per cent since explanation trend emissions voc air affected management solvents mix products made year voc emissions one focus areas concentrated top three emitting sites uk india singapore improvements mainly result changes venting arrangements projects initiated take effect plans several projects defined implemented projects initiated changing types dryers pumps reducing leakage tanks expect continuing improvement voc emissions completed projects projects planned sgs verified back tophome responsibility environmental sustainability environmental performance emissions air corporate responsibility report emissions air approach performance plans ozone depletion ozone depletion potential equipment production cfc equivalent odp equipment production losses decreased per cent thousand kilograms follows similarly substantial reduction means almost met target eliminate losses cfcs hcfcs production equipment twothirds cfc releases occur production inhalers estimate kilograms cfc equivalent emitted equipment releases patient use inhalers small maintain register significant pieces equipment contain refrigerants use track progress towards target eliminate cfcs hcfcs refrigeration equipment pieces equipment containing one kilogram cfcs amounting kilograms total items equipment contain odss kilograms cfc equivalent explanation trend production cfccontaining inhalers decreases amount gases lost stages production use also declines sgs verified volatile organic compounds volatile organic compound emissions volatile organic compound voc emissions decreased per cent tonnes emissions fallen nearly per cent since vocs released air per million sales decreased per cent means achieved target continues trend reductions previous years takes total reduction per unit sales per cent since explanation trend emissions voc air affected management solvents mix products made year voc emissions one focus areas concentrated top three emitting sites uk india singapore improvements mainly result changes venting arrangements projects initiated take effect plans several projects defined implemented projects initiated changing types dryers pumps reducing leakage tanks expect continuing improvement voc emissions completed projects projects planned sgs verified back top home responsibility environmental sustainability environmental performance emissions air corporate responsibility report emissions air approach performance plans ozone depletion ozone depletion potential equipment production cfc equivalent odp equipment production losses decreased per cent thousand kilograms follows similarly substantial reduction means almost met target eliminate losses cfcs hcfcs production equipment twothirds cfc releases occur production inhalers estimate kilograms cfc equivalent emitted equipment releases patient use inhalers small maintain register significant pieces equipment contain refrigerants use track progress towards target eliminate cfcs hcfcs refrigeration equipment pieces equipment containing one kilogram cfcs amounting kilograms total items equipment contain odss kilograms cfc equivalent explanation trend production cfccontaining inhalers decreases amount gases lost stages production use also declines sgs verified volatile organic compounds volatile organic compound emissions volatile organic compound voc emissions decreased per cent tonnes emissions fallen nearly per cent since vocs released air per million sales decreased per cent means achieved target continues trend reductions previous years takes total reduction per unit sales per cent since explanation trend emissions voc air affected management solvents mix products made year voc emissions one focus areas concentrated top three emitting sites uk india singapore improvements mainly result changes venting arrangements projects initiated take effect plans several projects defined implemented projects initiated changing types dryers pumps reducing leakage tanks expect continuing improvement voc emissions completed projects projects planned sgs verified back top home responsibility environmental sustainability environmental performance land corporate responsibility report land involved number projects uk us remediate sites land contaminated due past handling practices chemicals practices prevent contamination unless accidental releases identified five sites uk sites us require remediation waste disposal sites gsk one several responsible parties gsk heritage companies spent million cleaning sites us last years continuing work figures included data verification back top home responsibility environmental sustainability environmental performance land corporate responsibility report land involved number projects uk us remediate sites land contaminated due past handling practices chemicals practices prevent contamination unless accidental releases identified five sites uk sites us require remediation waste disposal sites gsk one several responsible parties gsk heritage companies spent million cleaning sites us last years continuing work figures included data verification back top home responsibility environmental sustainability transparency supplier performance corporate responsibility report supplier performance gsk selects suppliers appropriate level environmental health safety management systems control want understand total environmental footprint processes used make products investigating suppliers impacts including contract manufacturers gsk committed introducing sustainability concepts supply chain achieving require data collection analysis using information sourcing decisions setting objectives integrating current procurement performance review processes support greater transparency key suppliers active pharmaceutical ingredients api intermediates asked provide data energy usage co emissions waste disposal water usage ten companies responded details manufacturing sites yet position make reasonable comparison gsk production processes total energy used production contract manufacturers estimated million gigajoules less one per cent sustainable sources resulting co emissions tonnes contract suppliers reported total estimated disposal tonnes solvent waste reused recovered recycled per cent solvent waste incinerated per cent less one per cent went landfill water obtained municipal sources wells boreholes used gsk processes totalled cubic metres data verified sgs addition collecting data suppliers looking way estimate environmental footprint contract manufacturers evaluating resource consumption waste generation process steps outsourced manufacture products resources energy consumed waste generated estimated looking detailed process descriptions applying engineering standards complete energy mass balances unit operation production process unit operations included reactors filtration crystallisation method calculates energy use climate change impact based amount material purchase gives highlevel estimation environmental profile suppliers data available directly suppliers sample processes studied estimate gigajoules energy cubic metres water used estimations refined information becomes available suppliers back top home responsibility environmental sustainability transparency supplier performance corporate responsibility report supplier performance gsk selects suppliers appropriate level environmental health safety management systems control want understand total environmental footprint processes used make products investigating suppliers impacts including contract manufacturers gsk committed introducing sustainability concepts supply chain achieving require data collection analysis using information sourcing decisions setting objectives integrating current procurement performance review processes support greater transparency key suppliers active pharmaceutical ingredients api intermediates asked provide data energy usage co emissions waste disposal water usage ten companies responded details manufacturing sites yet position make reasonable comparison gsk production processes total energy used production contract manufacturers estimated million gigajoules less one per cent sustainable sources resulting co emissions tonnes contract suppliers reported total estimated disposal tonnes solvent waste reused recovered recycled per cent solvent waste incinerated per cent less one per cent went landfill water obtained municipal sources wells boreholes used gsk processes totalled cubic metres data verified sgs addition collecting data suppliers looking way estimate environmental footprint contract manufacturers evaluating resource consumption waste generation process steps outsourced manufacture products resources energy consumed waste generated estimated looking detailed process descriptions applying engineering standards complete energy mass balances unit operation production process unit operations included reactors filtration crystallisation method calculates energy use climate change impact based amount material purchase gives highlevel estimation environmental profile suppliers data available directly suppliers sample processes studied estimate gigajoules energy cubic metres water used estimations refined information becomes available suppliers back top home responsibility environmental sustainability transparency corporate responsibility report transparency commitment open communications stakeholders key element gsks environmental sustainability policy strategy aim transparent environmental impacts products processes engage stakeholders understand respond concerns reporting important aspect transparency assurance environmental sustainability data helps build trust stakeholders well reporting progress environmental sustainability objectives respond specific requests information throughout year engage formally stakeholder panel reporting primary objective collecting environmental performance data help operations manage environmental issues effectively done ehs manager webbased information management system also includes health safety data focus external reporting environmental issues relevant gsk interest stakeholders see stakeholder engagement understand stakeholder views respond report basis reporting targets performance normalised sales based constant exchange rate using rate means normalised figures previous years different shown last year 's report data may also vary slightly earlier reports errors found data prior years corrected use greenhouse gas protocol calculations co emissions energy use also updated factors climate change emissions propellants refrigerants using wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring project report pages geneva switzerland chapter eight environmental data collected pharmaceuticals consumer healthcare manufacturing sites vaccines sites pharmaceuticals consumer healthcare rd sites us uk headquarters buildings smaller offices distribution centres collect environmental data acquired entities first full year group year acquisition back top home responsibility environmental sustainability transparency corporate responsibility report transparency commitment open communications stakeholders key element gsks environmental sustainability policy strategy aim transparent environmental impacts products processes engage stakeholders understand respond concerns reporting important aspect transparency assurance environmental sustainability data helps build trust stakeholders well reporting progress environmental sustainability objectives respond specific requests information throughout year engage formally stakeholder panel reporting primary objective collecting environmental performance data help operations manage environmental issues effectively done ehs manager webbased information management system also includes health safety data focus external reporting environmental issues relevant gsk interest stakeholders see stakeholder engagement understand stakeholder views respond report basis reporting targets performance normalised sales based constant exchange rate using rate means normalised figures previous years different shown last year 's report data may also vary slightly earlier reports errors found data prior years corrected use greenhouse gas protocol calculations co emissions energy use also updated factors climate change emissions propellants refrigerants using wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring project report pages geneva switzerland chapter eight environmental data collected pharmaceuticals consumer healthcare manufacturing sites vaccines sites pharmaceuticals consumer healthcare rd sites us uk headquarters buildings smaller offices distribution centres collect environmental data acquired entities first full year group year acquisition back top home responsibility environmental sustainability transparency summary data corporate responsibility report summary data table summary five years environmental performance breakdown components metric data see detailed data table energy consumption operations transport million gigajoules climate change impacts thousand tonnes operations inhaler use patients total climate change impacts water use million cubic metres wastewater volume million cubic metres cod thousand tonnes hazardous waste generated thousand tonnes disposed recycling nonhazardous waste generated thousand tonnes disposed recycling waste generated thousand tonnes disposed recycling volatile organic compounds emissions thousand tonnes ozone depleting substance releases tonnes production refrigerant releases patient use inhalers total ods ozone depleting potential refrigerants equipment tonnes data available back tophome responsibility environmental sustainability transparency summary data corporate responsibility report summary data table summary five years environmental performance breakdown components metric data see detailed data table energy consumption operations transport million gigajoules climate change impacts thousand tonnes operations inhaler use patients total climate change impacts water use million cubic metres wastewater volume million cubic metres cod thousand tonnes hazardous waste generated thousand tonnes disposed recycling nonhazardous waste generated thousand tonnes disposed recycling waste generated thousand tonnes disposed recycling volatile organic compounds emissions thousand tonnes ozone depleting substance releases tonnes production refrigerant releases patient use inhalers total ods ozone depleting potential refrigerants equipment tonnes data available back top home responsibility environmental sustainability transparency summary data corporate responsibility report summary data table summary five years environmental performance breakdown components metric data see detailed data table energy consumption operations transport million gigajoules climate change impacts thousand tonnes operations inhaler use patients total climate change impacts water use million cubic metres wastewater volume million cubic metres cod thousand tonnes hazardous waste generated thousand tonnes disposed recycling nonhazardous waste generated thousand tonnes disposed recycling waste generated thousand tonnes disposed recycling volatile organic compounds emissions thousand tonnes ozone depleting substance releases tonnes production refrigerant releases patient use inhalers total ods ozone depleting potential refrigerants equipment tonnes data available back top home responsibility environmental sustainability transparency stakeholder engagement corporate responsibility report stakeholder engagement many sites engage stakeholders locally activities open days newsletters community projects environment health safety stakeholder panel uk provided independent feedback companywide performance since panel drawn customers suppliers regulators public interest groups investors expanded include members european regulatory environmental organisations two senior ehss representatives gsk regularly participate gsk managers attend discussions specific topics panel facilitated environment council independent charity responded panel suggestions focusing challenges company faces encouraging panel members ' input allowing time discussion including fewer items meeting agenda panel met twice debate issues including ehs reporting economics ecosystems water packaging waste chemical exposure use feedback stakeholder panel inform environmental sustainability health safety programmes panel also interact gsk sustainability council senior managers across company back top home responsibility environmental sustainability transparency stakeholder engagement corporate responsibility report stakeholder engagement many sites engage stakeholders locally activities open days newsletters community projects environment health safety stakeholder panel uk provided independent feedback companywide performance since panel drawn customers suppliers regulators public interest groups investors expanded include members european regulatory environmental organisations two senior ehss representatives gsk regularly participate gsk managers attend discussions specific topics panel facilitated environment council independent charity responded panel suggestions focusing challenges company faces encouraging panel members ' input allowing time discussion including fewer items meeting agenda panel met twice debate issues including ehs reporting economics ecosystems water packaging waste chemical exposure use feedback stakeholder panel inform environmental sustainability health safety programmes panel also interact gsk sustainability council senior managers across company back top home responsibility environmental sustainability transparency assurance corporate responsibility report assurance assurance statement sgs united kingdom ltds report environment health safety data glaxosmithkline corporate responsibility report nature scope assurance plans performance targets table health safety management audits compliance performance safety programmes ergonomics driver safety climate change energy performance performance injury illness rates plans transport travel performance injury illness causes water performance targets performance fatalities serious injuries wastewater performance targets performance illness injury milestones waste performance targets emissions air performance targets summary full environment health safety data tables information gsk cr report presentation responsibility directors management gsk sgs united kingdom ltd involved preparation material included cr report responsibility express opinion data graphs statements within scope verification intention inform gsks stakeholders financial data drawn directly independently audited financial accounts checked back source part assurance report assured moderate level scrutiny using protocols evaluation content veracity assurance comprised combination interviews relevant employees documentation record review eighteen gsk locations end reporting year follows interim site visits october december belgium rixensart wavre china beijing gskt tskf germany dresden india worli ireland dungarvan singapore jurong quality road spain aranda uk harlow rd ware rd weybridge usa aiken interviews ehs director management team primary supply november january end year site visits january february uk montrose ulverston corporate csr function london sites selected included submitting high proportions key data parts gsk business statement independence competence sgs group companies world leader inspection testing verification operating countries providing services including management systems service certification quality environmental social ethical auditing training environmental social sustainability report assurance sgs united kingdom ltd affirm independence gsk free bias conflicts interest organisation subsidiaries stakeholders assurance team assembled based knowledge experience qualifications assignment comprised auditors assurors registered irca iema emas verifiers assurance opinion basis methodology described verification work performed satisfied environmental health safety data contained within gsk corporate responsibility report reliable provides fair balanced representation gsk 's environmental health safety activities assurance team opinion report used reporting organisation 's stakeholders summary findings key areas improvement data collection submission manipulation identified assurance process addressed far possible incorporate improvements report improvement opportunities outlined enable review establish need system process changes future reporting cycles site level reporting working hours found undertaken using variety methods cases required minor modifications ensure accuracy data reported recognise implementing universal system calculation data point may practical investigation made reduce level errors reported information identified occasional misinterpretation reporting categories tended relation exceptional circumstances sites encouraged request clarification reporting categories minimise errors addition good practice noted following areas increased comments explanations made sites inputting data explain significant changes estimations calculations analysis data corporate level made ongoing improvements including detailed review reports illustrating significant changes data sitebysite basis extensive requests sites explanations significant changes performance anomalous data reported review graphical display illustrating yearonyear trends kpi recommendations future data verification process include extending ehs director level review performance supply chains expanding scope data verification parts report currently assured signed behalf sgs united kingdom ltd back tophome responsibility environmental sustainability transparency assurance corporate responsibility report assurance assurance statement sgs united kingdom ltds report environment health safety data glaxosmithkline corporate responsibility report nature scope assurance plans performance targets table health safety management audits compliance performance safety programmes ergonomics driver safety climate change energy performance performance injury illness rates plans transport travel performance injury illness causes water performance targets performance fatalities serious injuries wastewater performance targets performance illness injury milestones waste performance targets emissions air performance targets summary full environment health safety data tables information gsk cr report presentation responsibility directors management gsk sgs united kingdom ltd involved preparation material included cr report responsibility express opinion data graphs statements within scope verification intention inform gsks stakeholders financial data drawn directly independently audited financial accounts checked back source part assurance report assured moderate level scrutiny using protocols evaluation content veracity assurance comprised combination interviews relevant employees documentation record review eighteen gsk locations end reporting year follows interim site visits october december belgium rixensart wavre china beijing gskt tskf germany dresden india worli ireland dungarvan singapore jurong quality road spain aranda uk harlow rd ware rd weybridge usa aiken interviews ehs director management team primary supply november january end year site visits january february uk montrose ulverston corporate csr function london sites selected included submitting high proportions key data parts gsk business statement independence competence sgs group companies world leader inspection testing verification operating countries providing services including management systems service certification quality environmental social ethical auditing training environmental social sustainability report assurance sgs united kingdom ltd affirm independence gsk free bias conflicts interest organisation subsidiaries stakeholders assurance team assembled based knowledge experience qualifications assignment comprised auditors assurors registered irca iema emas verifiers assurance opinion basis methodology described verification work performed satisfied environmental health safety data contained within gsk corporate responsibility report reliable provides fair balanced representation gsk 's environmental health safety activities assurance team opinion report used reporting organisation 's stakeholders summary findings key areas improvement data collection submission manipulation identified assurance process addressed far possible incorporate improvements report improvement opportunities outlined enable review establish need system process changes future reporting cycles site level reporting working hours found undertaken using variety methods cases required minor modifications ensure accuracy data reported recognise implementing universal system calculation data point may practical investigation made reduce level errors reported information identified occasional misinterpretation reporting categories tended relation exceptional circumstances sites encouraged request clarification reporting categories minimise errors addition good practice noted following areas increased comments explanations made sites inputting data explain significant changes estimations calculations analysis data corporate level made ongoing improvements including detailed review reports illustrating significant changes data sitebysite basis extensive requests sites explanations significant changes performance anomalous data reported review graphical display illustrating yearonyear trends kpi recommendations future data verification process include extending ehs director level review performance supply chains expanding scope data verification parts report currently assured signed behalf sgs united kingdom ltd back top home responsibility environmental sustainability transparency assurance corporate responsibility report assurance assurance statement sgs united kingdom ltds report environment health safety data glaxosmithkline corporate responsibility report nature scope assurance plans performance targets table health safety management audits compliance performance safety programmes ergonomics driver safety climate change energy performance performance injury illness rates plans transport travel performance injury illness causes water performance targets performance fatalities serious injuries wastewater performance targets performance illness injury milestones waste performance targets emissions air performance targets summary full environment health safety data tables information gsk cr report presentation responsibility directors management gsk sgs united kingdom ltd involved preparation material included cr report responsibility express opinion data graphs statements within scope verification intention inform gsks stakeholders financial data drawn directly independently audited financial accounts checked back source part assurance report assured moderate level scrutiny using protocols evaluation content veracity assurance comprised combination interviews relevant employees documentation record review eighteen gsk locations end reporting year follows interim site visits october december belgium rixensart wavre china beijing gskt tskf germany dresden india worli ireland dungarvan singapore jurong quality road spain aranda uk harlow rd ware rd weybridge usa aiken interviews ehs director management team primary supply november january end year site visits january february uk montrose ulverston corporate csr function london sites selected included submitting high proportions key data parts gsk business statement independence competence sgs group companies world leader inspection testing verification operating countries providing services including management systems service certification quality environmental social ethical auditing training environmental social sustainability report assurance sgs united kingdom ltd affirm independence gsk free bias conflicts interest organisation subsidiaries stakeholders assurance team assembled based knowledge experience qualifications assignment comprised auditors assurors registered irca iema emas verifiers assurance opinion basis methodology described verification work performed satisfied environmental health safety data contained within gsk corporate responsibility report reliable provides fair balanced representation gsk 's environmental health safety activities assurance team opinion report used reporting organisation 's stakeholders summary findings key areas improvement data collection submission manipulation identified assurance process addressed far possible incorporate improvements report improvement opportunities outlined enable review establish need system process changes future reporting cycles site level reporting working hours found undertaken using variety methods cases required minor modifications ensure accuracy data reported recognise implementing universal system calculation data point may practical investigation made reduce level errors reported information identified occasional misinterpretation reporting categories tended relation exceptional circumstances sites encouraged request clarification reporting categories minimise errors addition good practice noted following areas increased comments explanations made sites inputting data explain significant changes estimations calculations analysis data corporate level made ongoing improvements including detailed review reports illustrating significant changes data sitebysite basis extensive requests sites explanations significant changes performance anomalous data reported review graphical display illustrating yearonyear trends kpi recommendations future data verification process include extending ehs director level review performance supply chains expanding scope data verification parts report currently assured signed behalf sgs united kingdom ltd back top home responsibility environmental sustainability transparency gsk response assurance corporate responsibility report gsk response assurance fourth year sgs reviewed data environment section health safety pages corporate responsibility report independent view processes valuable adopted suggestions years improving processes sites selected review gsk businesses special focus sites particular problems data past years suggested sgs verification statement data corporate responsibility report used sites improve management environmental programmes health safety programmes introduced midyear evaluation data encourage sites track progress assist management ehss continue find challenges collecting complete accurate data timely fashion committed improving ultimate goal providing accurate data public website real time responses key areas improvement improving sitelevel reporting working hours continues challenge single system capture information leaving site devise process continue try improve reporting continued training reminding reporters errors occasional misinterpretation reporting categories particular concern waste data several different categories emphasise training year enhance onscreen definition details data points extending ehs director level review performance supply chains introduced central review data active pharmaceutical ingredient manufacturing group ehs director group helped us identify errors understand reasons changes request ehs directors groups participate review expanding scope data verification parts report currently assured evaluate report identify additional areas may appropriate verification could include data packaging data collect suppliers back top home responsibility environmental sustainability transparency gsk response assurance corporate responsibility report gsk response assurance fourth year sgs reviewed data environment section health safety pages corporate responsibility report independent view processes valuable adopted suggestions years improving processes sites selected review gsk businesses special focus sites particular problems data past years suggested sgs verification statement data corporate responsibility report used sites improve management environmental programmes health safety programmes introduced midyear evaluation data encourage sites track progress assist management ehss continue find challenges collecting complete accurate data timely fashion committed improving ultimate goal providing accurate data public website real time responses key areas improvement improving sitelevel reporting working hours continues challenge single system capture information leaving site devise process continue try improve reporting continued training reminding reporters errors occasional misinterpretation reporting categories particular concern waste data several different categories emphasise training year enhance onscreen definition details data points extending ehs director level review performance supply chains introduced central review data active pharmaceutical ingredient manufacturing group ehs director group helped us identify errors understand reasons changes request ehs directors groups participate review expanding scope data verification parts report currently assured evaluate report identify additional areas may appropriate verification could include data packaging data collect suppliers back top home responsibility environmental sustainability case studies corporate responsibility report case studies radical alternative manufacturing approach innovative manufacturing initiative imi visionary programme longterm goal radically improve way gsk manufactures active pharmaceutical ingredients api gsk 's rd team stevenage uk pioneered groundbreaking manufacturing technology transform way develop chemical processes improve efficiency control environmental footprint future pharmaceutical production multidisciplinary team based chemical development successfully built demonstrated believes worlds first continuous manufacturing pilot plant raw materials api culmination eightyear project develop leading edge technological solutions meet increasing demands regulators 'quality design ' manufacture gsk 's sustainability ambitions longterm vision deliver fully continuous manufacturing plant provides economic safer energy efficient environmentally benign production facility estimate approximately per cent manufacturing processes could adapted new approach continuous processing used routinely industries oil gas recognised efficient method large scale production pharmaceutical production generally limited traditional batch processing methods manufacturing process split discrete stages unit operations weeks months produce api imi uses continuous processing run unit operations concurrently eliminates need isolated chemical intermediates reduces elapsed time hours days combining creative chemistry design imi enabling technologies manufacturing process usually efficient reduces equipment cleaning times eliminates need store large volumes intermediate materials may unstable imi processes designed use fewer solvents facilitate recycling remove operator exposure chemical intermediates significantly reduce aqueous waste streams hazardous chemistry amenable batch processing may run continuously offering greater potential simpler sustainable processes team stevenage completed construction continuous manufacturing pilot plant processes operated material cost savings six ten per cent compared similar batch process along reduction number unit operations continuous manufacturing facilities also cheaper construct capital saving per cent compared batch plant due significantly smaller footprint approach actively applied new chemical entity portfolio redevelopment older products reduce manufacturing costs environmental impacts team vanguard award ceo sustainability awards sustainable route antibiotic production gsk 's rd team upper merion pennsylvania developed improved manufacturing process antibiotic currently undergoing latestage clinical trials save substantial resources make move fullscale commercial manufacturing financially viable team first place ceo sustainability awards antibiotic 's complex structure meant scaling process used produce small volumes needed clinical trials would expensive wasteful inefficient process also required use several hazardous environmentally damaging substances new process reduced number stages eight bringing significant savings overall yields increased fold fold increase mass efficiency measure efficiency materials used manufacturing materials waste cut per cent long term projected cut production costs per cent well avoiding supply shortages saving resources april june team based worthing developed second generation process production calcium nadroparin anticoagulant active ingredient used stop blood clots forming success project significantly increased output improved process efficiency helping avoid threatened supply shortages new process avoids consumption reagent materials solvents water project originated small team examined feasibility alternative ideas improving production process team identified two promising approaches second generation approach identified opportunity realise benefits relatively short period remaining within registered process details successfully developed resulting pilot batches completed april second generation process commercially validated june compared original process achieved per cent increase output per cent reduction ethanol usage per cent reduction water usage per cent reduction reagents per cent reduction vessel usage plant time longer term goal radical thirdgeneration process could improve process efficiency environmental impact still development team winner ceo sustainability awards cutting emissions irvine expect per cent cut emissions achieved site irvine scotland continuing progress already made since exercise identified top three sources emissions carried work concentrating first eliminating reducing emissions source recovering reusing solvent vapour vents endofpipe techniques scrubbers bio filters incinerators ruled costly best environmental option first full year implementation expect vocs reduce per cent level due value solvent recovered programme paid within five years sustainable growth sustained responsibility energy savings one outcome project covering three biologicals sites belgium project embraces range sustainability initiatives seeking minimise environmental health safety risks impacts includes improving health wellbeing staff 'wellness together ' programme supporting health safety environment community improved waste management recycling facilities mean per cent gsk biologicals belgium 's nonhazardous waste recycled energy front gsk biologicals ' sites rixensart wavre gembloux achieved combined annual savings almost mwh tonnes co emissions represented per cent gsk 's total energy savings savings achieved number measures including installing solar panels automatic lighting improved insulation efficient heating ventilation systems meanwhile new vaccine quality control laboratory office complex wavre act blueprint future facilities across gsk biologicals future users participated design facilities choice materials ensure building would functional userfriendly ensure safe effective maintainability building members local maintenance team also contributed design resulting laboratories efficient functional ergonomic building operates independently terms energy production unit minimises energy loss largely made glass active dual layer facade picture windows doubleglazed outside singleglazed inside air ventilation extracted building passes two layers increases thermal insulation building air collected heat technical areas situated underneath building doublelayered system saves estimated per cent energy office areas system also brings advantages terms comfort users building quieter classic air conditioning ensures constant temperature throughout building quality control building first gsk biologicals building belgium implement energysaving system serves model numerous buildings construction also incorporate latest technology maximise renewable energy achievements mean gsk biologicals belgium track achieve target per cent improvement energy efficiency compared achievements marked first place ceo environmental sustainability awards combined heat power biologicals biologicals business belgium embarked combined heat power chp programme using gas engines selected excellent efficiency suitability big sites wavre well smaller sites gembloux wavre biologicals ' second largest manufacturing facility producing major vaccines global market wavre secondlargest energy user gsk consuming mwh energy per year gembloux smaller associated site sites energy demand profile favours chp continuous heat power loads year demand hot water hours per day summer winter hot water centrally produced distributed across site also supply natural gas gembloux 's chp system went live august wavre installing chp system power plants first came stream end units savings gembloux mwh two power plants wavre expected save mwhyear tonnes co third chp plant currently designed minimising materials packaging gsk 's consumer healthcare business india country 's largest producer nutritional healthcare products manufacturing business 's biggest environmental impact comes packaging crossdepartmental team based gsk 's guragon site identifying opportunities reduce environmental footprint team saved tonnes per year packaging materials around ten per cent total packaging material savings come redesigning packaging use less material yet retain strength wastage reduction programme entire supply chain packaging savings equivalent annual energy savings six million kwh tonnes co seven million litres water project brought additional benefits encouraging design teams include sustainability considerations design new packaging team created plan achieving reductions identified additional potential savings tonnes per year comprehensive sustainable packaging strategy development includes use materials renewable resources recycling team second place ceo environmental sustainability awards integrated transport strategy encouraging employees use cars daily commute helping gsk cut carbon footprint relieving congestion busy streets west london location gsk 's global corporate headquarters also gives employees opportunity save money improve fitness led transport team introduced number initiatives encourage use public transport cycling car pooling walking employees gsk house examples include partnered charity living streets develop walking maps area local launched national walk work week along weekly lunchtime walks free breakfasts registered walkers lease fleet shuttle buses powered waste vegetable oil ferry employees gsk sites local london underground stations awardwinning gsk house cycle centre run partnership cycling organisation wizzbike provides changing drying facilities wizzbike employees offer cycling advice operate daily maintenance repair service wizzbike also maintains pool bicycles employees interested cycling work initiatives made headway cutting singleoccupancy car use gsk house per cent per cent per cent employees travelled work public transport average employees use peak time shuttles gsk house neighbouring underground stations employees registered cyclists project awarded third place ceo environmental sustainability awards back tophome responsibility environmental sustainability case studies corporate responsibility report case studies radical alternative manufacturing approach innovative manufacturing initiative imi visionary programme longterm goal radically improve way gsk manufactures active pharmaceutical ingredients api gsk 's rd team stevenage uk pioneered groundbreaking manufacturing technology transform way develop chemical processes improve efficiency control environmental footprint future pharmaceutical production multidisciplinary team based chemical development successfully built demonstrated believes worlds first continuous manufacturing pilot plant raw materials api culmination eightyear project develop leading edge technological solutions meet increasing demands regulators 'quality design ' manufacture gsk 's sustainability ambitions longterm vision deliver fully continuous manufacturing plant provides economic safer energy efficient environmentally benign production facility estimate approximately per cent manufacturing processes could adapted new approach continuous processing used routinely industries oil gas recognised efficient method large scale production pharmaceutical production generally limited traditional batch processing methods manufacturing process split discrete stages unit operations weeks months produce api imi uses continuous processing run unit operations concurrently eliminates need isolated chemical intermediates reduces elapsed time hours days combining creative chemistry design imi enabling technologies manufacturing process usually efficient reduces equipment cleaning times eliminates need store large volumes intermediate materials may unstable imi processes designed use fewer solvents facilitate recycling remove operator exposure chemical intermediates significantly reduce aqueous waste streams hazardous chemistry amenable batch processing may run continuously offering greater potential simpler sustainable processes team stevenage completed construction continuous manufacturing pilot plant processes operated material cost savings six ten per cent compared similar batch process along reduction number unit operations continuous manufacturing facilities also cheaper construct capital saving per cent compared batch plant due significantly smaller footprint approach actively applied new chemical entity portfolio redevelopment older products reduce manufacturing costs environmental impacts team vanguard award ceo sustainability awards sustainable route antibiotic production gsk 's rd team upper merion pennsylvania developed improved manufacturing process antibiotic currently undergoing latestage clinical trials save substantial resources make move fullscale commercial manufacturing financially viable team first place ceo sustainability awards antibiotic 's complex structure meant scaling process used produce small volumes needed clinical trials would expensive wasteful inefficient process also required use several hazardous environmentally damaging substances new process reduced number stages eight bringing significant savings overall yields increased fold fold increase mass efficiency measure efficiency materials used manufacturing materials waste cut per cent long term projected cut production costs per cent well avoiding supply shortages saving resources april june team based worthing developed second generation process production calcium nadroparin anticoagulant active ingredient used stop blood clots forming success project significantly increased output improved process efficiency helping avoid threatened supply shortages new process avoids consumption reagent materials solvents water project originated small team examined feasibility alternative ideas improving production process team identified two promising approaches second generation approach identified opportunity realise benefits relatively short period remaining within registered process details successfully developed resulting pilot batches completed april second generation process commercially validated june compared original process achieved per cent increase output per cent reduction ethanol usage per cent reduction water usage per cent reduction reagents per cent reduction vessel usage plant time longer term goal radical thirdgeneration process could improve process efficiency environmental impact still development team winner ceo sustainability awards cutting emissions irvine expect per cent cut emissions achieved site irvine scotland continuing progress already made since exercise identified top three sources emissions carried work concentrating first eliminating reducing emissions source recovering reusing solvent vapour vents endofpipe techniques scrubbers bio filters incinerators ruled costly best environmental option first full year implementation expect vocs reduce per cent level due value solvent recovered programme paid within five years sustainable growth sustained responsibility energy savings one outcome project covering three biologicals sites belgium project embraces range sustainability initiatives seeking minimise environmental health safety risks impacts includes improving health wellbeing staff 'wellness together ' programme supporting health safety environment community improved waste management recycling facilities mean per cent gsk biologicals belgium 's nonhazardous waste recycled energy front gsk biologicals ' sites rixensart wavre gembloux achieved combined annual savings almost mwh tonnes co emissions represented per cent gsk 's total energy savings savings achieved number measures including installing solar panels automatic lighting improved insulation efficient heating ventilation systems meanwhile new vaccine quality control laboratory office complex wavre act blueprint future facilities across gsk biologicals future users participated design facilities choice materials ensure building would functional userfriendly ensure safe effective maintainability building members local maintenance team also contributed design resulting laboratories efficient functional ergonomic building operates independently terms energy production unit minimises energy loss largely made glass active dual layer facade picture windows doubleglazed outside singleglazed inside air ventilation extracted building passes two layers increases thermal insulation building air collected heat technical areas situated underneath building doublelayered system saves estimated per cent energy office areas system also brings advantages terms comfort users building quieter classic air conditioning ensures constant temperature throughout building quality control building first gsk biologicals building belgium implement energysaving system serves model numerous buildings construction also incorporate latest technology maximise renewable energy achievements mean gsk biologicals belgium track achieve target per cent improvement energy efficiency compared achievements marked first place ceo environmental sustainability awards combined heat power biologicals biologicals business belgium embarked combined heat power chp programme using gas engines selected excellent efficiency suitability big sites wavre well smaller sites gembloux wavre biologicals ' second largest manufacturing facility producing major vaccines global market wavre secondlargest energy user gsk consuming mwh energy per year gembloux smaller associated site sites energy demand profile favours chp continuous heat power loads year demand hot water hours per day summer winter hot water centrally produced distributed across site also supply natural gas gembloux 's chp system went live august wavre installing chp system power plants first came stream end units savings gembloux mwh two power plants wavre expected save mwhyear tonnes co third chp plant currently designed minimising materials packaging gsk 's consumer healthcare business india country 's largest producer nutritional healthcare products manufacturing business 's biggest environmental impact comes packaging crossdepartmental team based gsk 's guragon site identifying opportunities reduce environmental footprint team saved tonnes per year packaging materials around ten per cent total packaging material savings come redesigning packaging use less material yet retain strength wastage reduction programme entire supply chain packaging savings equivalent annual energy savings six million kwh tonnes co seven million litres water project brought additional benefits encouraging design teams include sustainability considerations design new packaging team created plan achieving reductions identified additional potential savings tonnes per year comprehensive sustainable packaging strategy development includes use materials renewable resources recycling team second place ceo environmental sustainability awards integrated transport strategy encouraging employees use cars daily commute helping gsk cut carbon footprint relieving congestion busy streets west london location gsk 's global corporate headquarters also gives employees opportunity save money improve fitness led transport team introduced number initiatives encourage use public transport cycling car pooling walking employees gsk house examples include partnered charity living streets develop walking maps area local launched national walk work week along weekly lunchtime walks free breakfasts registered walkers lease fleet shuttle buses powered waste vegetable oil ferry employees gsk sites local london underground stations awardwinning gsk house cycle centre run partnership cycling organisation wizzbike provides changing drying facilities wizzbike employees offer cycling advice operate daily maintenance repair service wizzbike also maintains pool bicycles employees interested cycling work initiatives made headway cutting singleoccupancy car use gsk house per cent per cent per cent employees travelled work public transport average employees use peak time shuttles gsk house neighbouring underground stations employees registered cyclists project awarded third place ceo environmental sustainability awards back tophome responsibility environmental sustainability case studies corporate responsibility report case studies radical alternative manufacturing approach innovative manufacturing initiative imi visionary programme longterm goal radically improve way gsk manufactures active pharmaceutical ingredients api gsk 's rd team stevenage uk pioneered groundbreaking manufacturing technology transform way develop chemical processes improve efficiency control environmental footprint future pharmaceutical production multidisciplinary team based chemical development successfully built demonstrated believes worlds first continuous manufacturing pilot plant raw materials api culmination eightyear project develop leading edge technological solutions meet increasing demands regulators 'quality design ' manufacture gsk 's sustainability ambitions longterm vision deliver fully continuous manufacturing plant provides economic safer energy efficient environmentally benign production facility estimate approximately per cent manufacturing processes could adapted new approach continuous processing used routinely industries oil gas recognised efficient method large scale production pharmaceutical production generally limited traditional batch processing methods manufacturing process split discrete stages unit operations weeks months produce api imi uses continuous processing run unit operations concurrently eliminates need isolated chemical intermediates reduces elapsed time hours days combining creative chemistry design imi enabling technologies manufacturing process usually efficient reduces equipment cleaning times eliminates need store large volumes intermediate materials may unstable imi processes designed use fewer solvents facilitate recycling remove operator exposure chemical intermediates significantly reduce aqueous waste streams hazardous chemistry amenable batch processing may run continuously offering greater potential simpler sustainable processes team stevenage completed construction continuous manufacturing pilot plant processes operated material cost savings six ten per cent compared similar batch process along reduction number unit operations continuous manufacturing facilities also cheaper construct capital saving per cent compared batch plant due significantly smaller footprint approach actively applied new chemical entity portfolio redevelopment older products reduce manufacturing costs environmental impacts team vanguard award ceo sustainability awards sustainable route antibiotic production gsk 's rd team upper merion pennsylvania developed improved manufacturing process antibiotic currently undergoing latestage clinical trials save substantial resources make move fullscale commercial manufacturing financially viable team first place ceo sustainability awards antibiotic 's complex structure meant scaling process used produce small volumes needed clinical trials would expensive wasteful inefficient process also required use several hazardous environmentally damaging substances new process reduced number stages eight bringing significant savings overall yields increased fold fold increase mass efficiency measure efficiency materials used manufacturing materials waste cut per cent long term projected cut production costs per cent well avoiding supply shortages saving resources april june team based worthing developed second generation process production calcium nadroparin anticoagulant active ingredient used stop blood clots forming success project significantly increased output improved process efficiency helping avoid threatened supply shortages new process avoids consumption reagent materials solvents water project originated small team examined feasibility alternative ideas improving production process team identified two promising approaches second generation approach identified opportunity realise benefits relatively short period remaining within registered process details successfully developed resulting pilot batches completed april second generation process commercially validated june compared original process achieved per cent increase output per cent reduction ethanol usage per cent reduction water usage per cent reduction reagents per cent reduction vessel usage plant time longer term goal radical thirdgeneration process could improve process efficiency environmental impact still development team winner ceo sustainability awards cutting emissions irvine expect per cent cut emissions achieved site irvine scotland continuing progress already made since exercise identified top three sources emissions carried work concentrating first eliminating reducing emissions source recovering reusing solvent vapour vents endofpipe techniques scrubbers bio filters incinerators ruled costly best environmental option first full year implementation expect vocs reduce per cent level due value solvent recovered programme paid within five years sustainable growth sustained responsibility energy savings one outcome project covering three biologicals sites belgium project embraces range sustainability initiatives seeking minimise environmental health safety risks impacts includes improving health wellbeing staff 'wellness together ' programme supporting health safety environment community improved waste management recycling facilities mean per cent gsk biologicals belgium 's nonhazardous waste recycled energy front gsk biologicals ' sites rixensart wavre gembloux achieved combined annual savings almost mwh tonnes co emissions represented per cent gsk 's total energy savings savings achieved number measures including installing solar panels automatic lighting improved insulation efficient heating ventilation systems meanwhile new vaccine quality control laboratory office complex wavre act blueprint future facilities across gsk biologicals future users participated design facilities choice materials ensure building would functional userfriendly ensure safe effective maintainability building members local maintenance team also contributed design resulting laboratories efficient functional ergonomic building operates independently terms energy production unit minimises energy loss largely made glass active dual layer facade picture windows doubleglazed outside singleglazed inside air ventilation extracted building passes two layers increases thermal insulation building air collected heat technical areas situated underneath building doublelayered system saves estimated per cent energy office areas system also brings advantages terms comfort users building quieter classic air conditioning ensures constant temperature throughout building quality control building first gsk biologicals building belgium implement energysaving system serves model numerous buildings construction also incorporate latest technology maximise renewable energy achievements mean gsk biologicals belgium track achieve target per cent improvement energy efficiency compared achievements marked first place ceo environmental sustainability awards combined heat power biologicals biologicals business belgium embarked combined heat power chp programme using gas engines selected excellent efficiency suitability big sites wavre well smaller sites gembloux wavre biologicals ' second largest manufacturing facility producing major vaccines global market wavre secondlargest energy user gsk consuming mwh energy per year gembloux smaller associated site sites energy demand profile favours chp continuous heat power loads year demand hot water hours per day summer winter hot water centrally produced distributed across site also supply natural gas gembloux 's chp system went live august wavre installing chp system power plants first came stream end units savings gembloux mwh two power plants wavre expected save mwhyear tonnes co third chp plant currently designed minimising materials packaging gsk 's consumer healthcare business india country 's largest producer nutritional healthcare products manufacturing business 's biggest environmental impact comes packaging crossdepartmental team based gsk 's guragon site identifying opportunities reduce environmental footprint team saved tonnes per year packaging materials around ten per cent total packaging material savings come redesigning packaging use less material yet retain strength wastage reduction programme entire supply chain packaging savings equivalent annual energy savings six million kwh tonnes co seven million litres water project brought additional benefits encouraging design teams include sustainability considerations design new packaging team created plan achieving reductions identified additional potential savings tonnes per year comprehensive sustainable packaging strategy development includes use materials renepwagaeb le resources recycling team second place ceo environmental sustainability awards integrated transport strategy encouraging employees use cars daily commute helping gsk cut carbon footprint relieving congestion busy streets west london location gsk 's global corporate headquarters also gives employees opportunity save money improve fitness led transport team introduced number initiatives encourage use public transport cycling car pooling walking employees gsk house examples include partnered charity living streets develop walking maps area local launched national walk work week along weekly lunchtime walks free breakfasts registered walkers lease fleet shuttle buses powered waste vegetable oil ferry employees gsk sites local london underground stations awardwinning gsk house cycle centre run partnership cycling organisation wizzbike provides changing drying facilities wizzbike employees offer cycling advice operate daily maintenance repair service wizzbike also maintains pool bicycles employees interested cycling work initiatives made headway cutting singleoccupancy car use gsk house per cent per cent per cent employees travelled work public transport average employees use peak time shuttles gsk house neighbouring underground stations employees registered cyclists project awarded third place ceo environmental sustainability awards back tophome responsibility environmental sustainability case studies corporate responsibility report case studies radical alternative manufacturing approach innovative manufacturing initiative imi visionary programme longterm goal radically improve way gsk manufactures active pharmaceutical ingredients api gsk 's rd team stevenage uk pioneered groundbreaking manufacturing technology transform way develop chemical processes improve efficiency control environmental footprint future pharmaceutical production multidisciplinary team based chemical development successfully built demonstrated believes worlds first continuous manufacturing pilot plant raw materials api culmination eightyear project develop leading edge technological solutions meet increasing demands regulators 'quality design ' manufacture gsk 's sustainability ambitions longterm vision deliver fully continuous manufacturing plant provides economic safer energy efficient environmentally benign production facility estimate approximately per cent manufacturing processes could adapted new approach continuous processing used routinely industries oil gas recognised efficient method large scale production pharmaceutical production generally limited traditional batch processing methods manufacturing process split discrete stages unit operations weeks months produce api imi uses continuous processing run unit operations concurrently eliminates need isolated chemical intermediates reduces elapsed time hours days combining creative chemistry design imi enabling technologies manufacturing process usually efficient reduces equipment cleaning times eliminates need store large volumes intermediate materials may unstable imi processes designed use fewer solvents facilitate recycling remove operator exposure chemical intermediates significantly reduce aqueous waste streams hazardous chemistry amenable batch processing may run continuously offering greater potential simpler sustainable processes team stevenage completed construction continuous manufacturing pilot plant processes operated material cost savings six ten per cent compared similar batch process along reduction number unit operations continuous manufacturing facilities also cheaper construct capital saving per cent compared batch plant due significantly smaller footprint approach actively applied new chemical entity portfolio redevelopment older products reduce manufacturing costs environmental impacts team vanguard award ceo sustainability awards sustainable route antibiotic production gsk 's rd team upper merion pennsylvania developed improved manufacturing process antibiotic currently undergoing latestage clinical trials save substantial resources make move fullscale commercial manufacturing financially viable team first place ceo sustainability awards antibiotic 's complex structure meant scaling process used produce small volumes needed clinical trials would expensive wasteful inefficient process also required use several hazardous environmentally damaging substances new process reduced number stages eight bringing significant savings overall yields increased fold fold increase mass efficiency measure efficiency materials used manufacturing materials waste cut per cent long term projected cut production costs per cent well avoiding supply shortages saving resources april june team based worthing developed second generation process production calcium nadroparin anticoagulant active ingredient used stop blood clots forming success project significantly increased output improved process efficiency helping avoid threatened supply shortages new process avoids consumption reagent materials solvents water project originated small team examined feasibility alternative ideas improving production process team identified two promising approaches second generation approach identified opportunity realise benefits relatively short period remaining within registered process details successfully developed resulting pilot batches completed april second generation process commercially validated june compared original process achieved per cent increase output per cent reduction ethanol usage per cent reduction water usage per cent reduction reagents per cent reduction vessel usage plant time longer term goal radical thirdgeneration process could improve process efficiency environmental impact still development team winner ceo sustainability awards cutting emissions irvine expect per cent cut emissions achieved site irvine scotland continuing progress already made since exercise identified top three sources emissions carried work concentrating first eliminating reducing emissions source recovering reusing solvent vapour vents endofpipe techniques scrubbers bio filters incinerators ruled costly best environmental option first full year implementation expect vocs reduce per cent level due value solvent recovered programme paid within five years sustainable growth sustained responsibility energy savings one outcome project covering three biologicals sites belgium project embraces range sustainability initiatives seeking minimise environmental health safety risks impacts includes improving health wellbeing staff 'wellness together ' programme supporting health safety environment community improved waste management recycling facilities mean per cent gsk biologicals belgium 's nonhazardous waste recycled energy front gsk biologicals ' sites rixensart wavre gembloux achieved combined annual savings almost mwh tonnes co emissions represented per cent gsk 's total energy savings savings achieved number measures including installing solar panels automatic lighting improved insulation efficient heating ventilation systems meanwhile new vaccine quality control laboratory office complex wavre act blueprint future facilities across gsk biologicals future users participated design facilities choice materials ensure building would functional userfriendly ensure safe effective maintainability building members local maintenance team also contributed design resulting laboratories efficient functional ergonomic building operates independently terms energy production unit minimises energy loss largely made glass active dual layer facade picture windows doubleglazed outside singleglazed inside air ventilation extracted building passes two layers increases thermal insulation building air collected heat technical areas situated underneath building doublelayered system saves estimated per cent energy office areas system also brings advantages terms comfort users building quieter classic air conditioning ensures constant temperature throughout building quality control building first gsk biologicals building belgium implement energysaving system serves model numerous buildings construction also incorporate latest technology maximise renewable energy achievements mean gsk biologicals belgium track achieve target per cent improvement energy efficiency compared achievements marked first place ceo environmental sustainability awards combined heat power biologicals biologicals business belgium embarked combined heat power chp programme using gas engines selected excellent efficiency suitability big sites wavre well smaller sites gembloux wavre biologicals ' second largest manufacturing facility producing major vaccines global market wavre secondlargest energy user gsk consuming mwh energy per year gembloux smaller associated site sites energy demand profile favours chp continuous heat power loads year demand hot water hours per day summer winter hot water centrally produced distributed across site also supply natural gas gembloux 's chp system went live august wavre installing chp system power plants first came stream end units savings gembloux mwh two power plants wavre expected save mwhyear tonnes co third chp plant currently designed minimising materials packaging gsk 's consumer healthcare business india country 's largest producer nutritional healthcare products manufacturing business 's biggest environmental impact comes packaging crossdepartmental team based gsk 's guragon site identifying opportunities reduce environmental footprint team saved tonnes per year packaging materials around ten per cent total packaging material savings come redesigning packaging use less material yet retain strength wastage reduction programme entire supply chain packaging savings equivalent annual energy savings six million kwh tonnes co seven million litres water project brought additional benefits encouraging design teams include sustainability considerations design new packaging team created plan achieving reductions identified additional potential savings tonnes per year comprehensive sustainable packaging strategy development includes use materials renewable resources recycling team second place ceo environmental sustainability awards integrated transport strategy encouraging employees use cars daily commute helping gsk cut carbon footprint relieving congestion busy streets west london location gsk 's global corporate headquarters also gives employees opportunity save money improve fitness led transport team introduced number initiatives encourage use public transport cycling car pooling walking employees gsk house examples include partnered charity living streets develop walking maps area local launched national walk work week along weekly lunchtime walks free breakfasts registered walkers lease fleet shuttle buses powered waste vegetable oil ferry employees gsk sites local london underground stations awardwinning gsk house cycle centre run partnership cycling organisation wizzbike provides changing drying facilities wizzbike employees offer cycling advice operate daily maintenance repair service wizzbike also maintains pool bicycles employees interested cycling work initiatives made headway cutting singleoccupancy car use gsk house per cent per cent per cent employees travelled work public transport average employees use peak time shuttles gsk house neighbouring underground stations employees registered cyclists project awarded third place ceo environmental sustainability awards back top home responsibility environmental sustainability case studies corporate responsibility report case studies radical alternative manufacturing approach innovative manufacturing initiative imi visionary programme longterm goal radically improve way gsk manufactures active pharmaceutical ingredients api gsk 's rd team stevenage uk pioneered groundbreaking manufacturing technology transform way develop chemical processes improve efficiency control environmental footprint future pharmaceutical production multidisciplinary team based chemical development successfully built demonstrated believes worlds first continuous manufacturing pilot plant raw materials api culmination eightyear project develop leading edge technological solutions meet increasing demands regulators 'quality design ' manufacture gsk 's sustainability ambitions longterm vision deliver fully continuous manufacturing plant provides economic safer energy efficient environmentally benign production facility estimate approximately per cent manufacturing processes could adapted new approach continuous processing used routinely industries oil gas recognised efficient method large scale production pharmaceutical production generally limited traditional batch processing methods manufacturing process split discrete stages unit operations weeks months produce api imi uses continuous processing run unit operations concurrently eliminates need isolated chemical intermediates reduces elapsed time hours days combining creative chemistry design imi enabling technologies manufacturing process usually efficient reduces equipment cleaning times eliminates need store large volumes intermediate materials may unstable imi processes designed use fewer solvents facilitate recycling remove operator exposure chemical intermediates significantly reduce aqueous waste streams hazardous chemistry amenable batch processing may run continuously offering greater potential simpler sustainable processes team stevenage completed construction continuous manufacturing pilot plant processes operated material cost savings six ten per cent compared similar batch process along reduction number unit operations continuous manufacturing facilities also cheaper construct capital saving per cent compared batch plant due significantly smaller footprint approach actively applied new chemical entity portfolio redevelopment older products reduce manufacturing costs environmental impacts team vanguard award ceo sustainability awards sustainable route antibiotic production gsk 's rd team upper merion pennsylvania developed improved manufacturing process antibiotic currently undergoing latestage clinical trials save substantial resources make move fullscale commercial manufacturing financially viable team first place ceo sustainability awards antibiotic 's complex structure meant scaling process used produce small volumes needed clinical trials would expensive wasteful inefficient process also required use several hazardous environmentally damaging substances new process reduced number stages eight bringing significant savings overall yields increased fold fold increase mass efficiency measure efficiency materials used manufacturing materials waste cut per cent long term projected cut production costs per cent well avoiding supply shortages saving resources april june team based worthing developed second generation process production calcium nadroparin anticoagulant active ingredient used stop blood clots forming success project significantly increased output improved process efficiency helping avoid threatened supply shortages new process avoids consumption reagent materials solvents water project originated small team examined feasibility alternative ideas improving production process team identified two promising approaches second generation approach identified opportunity realise benefits relatively short period remaining within registered process details successfully developed resulting pilot batches completed april second generation process commercially validated june compared original process achieved per cent increase output per cent reduction ethanol usage per cent reduction water usage per cent reduction reagents per cent reduction vessel usage plant time longer term goal radical thirdgeneration process could improve process efficiency environmental impact still development team winner ceo sustainability awards cutting emissions irvine expect per cent cut emissions achieved site irvine scotland continuing progress already made since exercise identified top three sources emissions carried work concentrating first eliminating reducing emissions source recovering reusing solvent vapour vents endofpipe techniques scrubbers bio filters incinerators ruled costly best environmental option first full year implementation expect vocs reduce per cent level due value solvent recovered programme paid within five years sustainable growth sustained responsibility energy savings one outcome project covering three biologicals sites belgium project embraces range sustainability initiatives seeking minimise environmental health safety risks impacts includes improving health wellbeing staff 'wellness together ' programme supporting health safety environment community improved waste management recycling facilities mean per cent gsk biologicals belgium 's nonhazardous waste recycled energy front gsk biologicals ' sites rixensart wavre gembloux achieved combined annual savings almost mwh tonnes co emissions represented per cent gsk 's total energy savings savings achieved number measures including installing solar panels automatic lighting improved insulation efficient heating ventilation systems meanwhile new vaccine quality control laboratory office complex wavre act blueprint future facilities across gsk biologicals future users participated design facilities choice materials ensure building would functional userfriendly ensure safe effective maintainability building members local maintenance team also contributed design resulting laboratories efficient functional ergonomic building operates independently terms energy production unit minimises energy loss largely made glass active dual layer facade picture windows doubleglazed outside singleglazed inside air ventilation extracted building passes two layers increases thermal insulation building air collected heat technical areas situated underneath building doublelayered system saves estimated per cent energy office areas system also brings advantages terms comfort users building quieter classic air conditioning ensures constant temperature throughout building quality control building first gsk biologicals building belgium implement energysaving system serves model numerous buildings construction also incorporate latest technology maximise renewable energy achievements mean gsk biologicals belgium track achieve target per cent improvement energy efficiency compared achievements marked first place ceo environmental sustainability awards combined heat power biologicals biologicals business belgium embarked combined heat power chp programme using gas engines selected excellent efficiency suitability big sites wavre well smaller sites gembloux wavre biologicals ' second largest manufacturing facility producing major vaccines global market wavre secondlargest energy user gsk consuming mwh energy per year gembloux smaller associated site sites energy demand profile favours chp continuous heat power loads year demand hot water hours per day summer winter hot water centrally produced distributed across site also supply natural gas gembloux 's chp system went live august wavre installing chp system power plants first came stream end units savings gembloux mwh two power plants wavre expected save mwhyear tonnes co third chp plant currently designed minimising materials packaging gsk 's consumer healthcare business india country 's largest producer nutritional healthcare products manufacturing business 's biggest environmental impact comes packaging crossdepartmental team based gsk 's guragon site identifying opportunities reduce environmental footprint team saved tonnes per year packaging materials around ten per cent total packaging material savings come redesigning packaging use less material yet retain strength wastage reduction programme entire supply chain packaging savings equivalent annual energy savings six million kwh tonnes co seven million litres water project brought additional benefits encouraging design teams include sustainability considerations design new packaging team created plan achieving reductions identified additional potential savings tonnes per year comprehensive sustainable packaging strategy development includes use materials renewable resources recycling team second place ceo environmental sustainability awards integrated transport strategy encouraging employees use cars daily commute helping gsk cut carbon footprint relieving congestion busy streets west london location gsk 's global corporate headquarters also gives employees opportunity save money improve fitness led transport team introduced number initiatives encourage use public transport cycling car pooling walking employees gsk house examples include partnered charity living streets develop walking maps area local launched national walk work week along weekly lunchtime walks free breakfasts registered walkers lease fleet shuttle buses powered waste vegetable oil ferry employees gsk sites local london underground stations awardwinning gsk house cycle centre run partnership cycling organisation wizzbike provides changing drying facilities wizzbike employees offer cycling advice operate daily maintenance repair service wizzbike also maintains pool bicycles employees interested cycling work initiatives made headway cutting singleoccupancy car use gsk house per cent per cent per cent employees travelled work public transport average employees use peak time shuttles gsk house neighbouring underground stations employees registered cyclists project awarded third place ceo environmental sustainability awards back top home responsibility environmental sustainability qas corporate responsibility report qas respond questions raised stakeholders inhaler products large environmental impact phasing cfcs inhaler products last years replacing gases hfas lower climate change impact per cent cfcs less two per cent inhalers contain cfcs committed complete phaseout end part new climate strategy exploring ways reduce amount hfas released inhaler products looking alternative propellants also offer dry powder inhalers asthma sufferers contain greenhouse gases suitable patients particularly children elderly contain propellants rely persons lung power active ingredients administered pharmaceutical manufacturing process made efficient making medicines highly regulated complicated due number process steps required despite constraints aim increase efficiency convert raw materials finished products aspiring achieve level five times performance one approach adopt continuous manufacturing rather batch processing first pharmaceutical company pilot process see case study pharmaceutical residues present drinking water risk humans studies shown gsk pharmaceutical products either present watercourses present low concentrations risk assessments demonstrate concentrations pose risk human health environment complacent continually monitor latest scientific studies findings improve risk assessment methodology back top home responsibility environmental sustainability qas corporate responsibility report qas respond questions raised stakeholders inhaler products large environmental impact phasing cfcs inhaler products last years replacing gases hfas lower climate change impact per cent cfcs less two per cent inhalers contain cfcs committed complete phaseout end part new climate strategy exploring ways reduce amount hfas released inhaler products looking alternative propellants also offer dry powder inhalers asthma sufferers contain greenhouse gases suitable patients particularly children elderly contain propellants rely persons lung power active ingredients administered pharmaceutical manufacturing process made efficient making medicines highly regulated complicated due number process steps required despite constraints aim increase efficiency convert raw materials finished products aspiring achieve level five times performance one approach adopt continuous manufacturing rather batch processing first pharmaceutical company pilot process see case study pharmaceutical residues present drinking water risk humans studies shown gsk pharmaceutical products either present watercourses present low concentrations risk assessments demonstrate concentrations pose risk human health environment complacent continually monitor latest scientific studies findings improve risk assessment methodology back top home responsibility people corporate responsibility report people employ people countries across world goal gsk recognised employer choice value empower people within workplace culture value people commitment good employment practices including inclusive diverse workplace robust programmes employee development change management employee communication reward recognition health safety employment policies apply everyone works gsk employees expected understand adhere principles outlined spirit gsk defines mission strategies values behaviours also gsk particular focus individual empowerment employees define trusting people job using good judgment within clearly defined understood framework responsibility individual means demonstrating highest level integrity clarity role ensuring accountable decisions managers means giving people confidence make decisions providing clear direction support advice empowerment enables better faster decision making creates agile responsive organisation results simplified processes also helps motivate people encourages innovation improves ability deal challenges section explain values behaviours underpin ways working approach creating inclusive diverse workplace develop people gsk 's leadership strategy restructuring approach communicate employees reward recognition programmes approach embedding health safety culture across gsk employment awards employment awards gsk achieved per cent score corporate equality index us ranked fifth overall management today magazines admired company awards uk listed working mother magazine 's top companies us ranked among aarp formerly american association retired persons top companies employees us britain 's top employers uk top graduate employers uk ranked tenth overall best place work mexico awarded hrm excellence award employers federation pakistan best employer hungary slovakia czech republic poland back tophome responsibility people corporate responsibility report people employ people countries across world goal gsk recognised employer choice value empower people within workplace culture value people commitment good employment practices including inclusive diverse workplace robust programmes employee development change management employee communication reward recognition health safety employment policies apply everyone works gsk employees expected understand adhere principles outlined spirit gsk defines mission strategies values behaviours also gsk particular focus individual empowerment employees define trusting people job using good judgment within clearly defined understood framework responsibility individual means demonstrating highest level integrity clarity role ensuring accountable decisions managers means giving people confidence make decisions providing clear direction support advice empowerment enables better faster decision making creates agile responsive organisation results simplified processes also helps motivate people encourages innovation improves ability deal challenges section explain values behaviours underpin ways working approach creating inclusive diverse workplace develop people gsk 's leadership strategy restructuring approach communicate employees reward recognition programmes approach embedding health safety culture across gsk employment awards employment awards gsk achieved per cent score corporate equality index us ranked fifth overall management today magazines admired company awards uk listed working mother magazine 's top companies us ranked among aarp formerly american association retired persons top companies employees us britain 's top employers uk top graduate employers uk ranked tenth overall best place work mexico awarded hrm excellence award employers federation pakistan best employer hungary slovakia czech republic poland back top home responsibility people corporate responsibility report people employ people countries across world goal gsk recognised employer choice value empower people within workplace culture value people commitment good employment practices including inclusive diverse workplace robust programmes employee development change management employee communication reward recognition health safety employment policies apply everyone works gsk employees expected understand adhere principles outlined spirit gsk defines mission strategies values behaviours also gsk particular focus individual empowerment employees define trusting people job using good judgment within clearly defined understood framework responsibility individual means demonstrating highest level integrity clarity role ensuring accountable decisions managers means giving people confidence make decisions providing clear direction support advice empowerment enables better faster decision making creates agile responsive organisation results simplified processes also helps motivate people encourages innovation improves ability deal challenges section explain values behaviours underpin ways working approach creating inclusive diverse workplace develop people gsk 's leadership strategy restructuring approach communicate employees reward recognition programmes approach embedding health safety culture across gsk employment awards employment awards gsk achieved per cent score corporate equality index us ranked fifth overall management today magazines admired company awards uk listed working mother magazine 's top companies us ranked among aarp formerly american association retired persons top companies employees us britain 's top employers uk top graduate employers uk ranked tenth overall best place work mexico awarded hrm excellence award employers federation pakistan best employer hungary slovakia czech republic poland back top home responsibility people values behaviours corporate responsibility report values behaviours mission improve quality human life enabling people feel better live longer pursuit goal place great emphasis achieve also achieve values behaviours integral performance gsk 's values gsks values show respect people patient focused commit transparency always demonstrate highest integrity conduct values underpin decision making gsk way employees expected work valuesbased company seek people high integrity make good honest decisions patients mind values relationship gsks policies also described employee guide business conduct updated gsk behaviours changes healthcare market past decade mean need change business model one centred needs customer innovative perform collective organisation determine success order effective growing complexity speed change external environment gsk needs create internal learning culture embodied six behaviours flexible thinking work must allow multiple options perspectives potential scenarios built systemically plan make decisions enable drive change ideas must brought life customer realise business growth continuous improvement must measure improve performance order regularly exceed customer expectations customer driven must build strategies fundamentally raise importance customers organisation developing people one person answers must lead people create environment supports individual growth building relationships climate trust openness enables people feel free speak knowing heard values behaviours brought life embedded organisation many ways gsk completed companywide survey towards end employees received invitations participate online opinion survey gather feedback individual empowerment employee engagement company values results available early degree feedback tool mandatory senior leaders gsk measures individual collective effectiveness values behaviours ceo andrew witty speaks directly gsk employees globally via realtime webcasts reinforcing importance gsk values highlighting employees demonstrate effective use behaviours programmes leadership development mentoring coaching well performance development planning process incorporate gsk values behaviourshome responsibility people values behaviours corporate responsibility report values behaviours mission improve quality human life enabling people feel better live longer pursuit goal place great emphasis achieve also achieve values behaviours integral performance gsk 's values gsks values show respect people patient focused commit transparency always demonstrate highest integrity conduct values underpin decision making gsk way employees expected work valuesbased company seek people high integrity make good honest decisions patients mind values relationship gsks policies also described employee guide business conduct updated gsk behaviours changes healthcare market past decade mean need change business model one centred needs customer innovative perform collective organisation determine success order effective growing complexity speed change external environment gsk needs create internal learning culture embodied six behaviours flexible thinking work must allow multiple options perspectives potential scenarios built systemically plan make decisions enable drive change ideas must brought life customer realise business growth continuous improvement must measure improve performance order regularly exceed customer expectations customer driven must build strategies fundamentally raise importance customers organisation developing people one person answers must lead people create environment supports individual growth building relationships climate trust openness enables people feel free speak knowing heard values behaviours brought life embedded organisation many ways gsk completed companywide survey towards end employees received invitations participate online opinion survey gather feedback individual empowerment employee engagement company values results available early degree feedback tool mandatory senior leaders gsk measures individual collective effectiveness values behaviours ceo andrew witty speaks directly gsk employees globally via realtime webcasts reinforcing importance gsk values highlighting employees demonstrate effective use behaviours programmes leadership development mentoring coaching well performance development planning process incorporate gsk values behaviours home responsibility people values behaviours corporate responsibility report values behaviours mission improve quality human life enabling people feel better live longer pursuit goal place great emphasis achieve also achieve values behaviours integral performance gsk 's values gsks values show respect people patient focused commit transparency always demonstrate highest integrity conduct values underpin decision making gsk way employees expected work valuesbased company seek people high integrity make good honest decisions patients mind values relationship gsks policies also described employee guide business conduct updated gsk behaviours changes healthcare market past decade mean need change business model one centred needs customer innovative perform collective organisation determine success order effective growing complexity speed change external environment gsk needs create internal learning culture embodied six behaviours flexible thinking work must allow multiple options perspectives potential scenarios built systemically plan make decisions enable drive change ideas must brought life customer realise business growth continuous improvement must measure improve performance order regularly exceed customer expectations customer driven must build strategies fundamentally raise importance customers organisation developing people one person answers must lead people create environment supports individual growth building relationships climate trust openness enables people feel free speak knowing heard values behaviours brought life embedded organisation many ways gsk completed companywide survey towards end employees received invitations participate online opinion survey gather feedback individual empowerment employee engagement company values results available early degree feedback tool mandatory senior leaders gsk measures individual collective effectiveness values behaviours ceo andrew witty speaks directly gsk employees globally via realtime webcasts reinforcing importance gsk values highlighting employees demonstrate effective use behaviours programmes leadership development mentoring coaching well performance development planning process incorporate gsk values behaviours home responsibility people inclusion diversity corporate responsibility report inclusion diversity approach performance recognise value different knowledge perspectives experiences working styles bring gsk approach based respect employees global inclusion diversity strategy aims create working environment employees feel valued included unique qualities bring empowered contribute full potential global inclusion diversity strategy sponsored senior executive reports directly ceo section outline inclusion diversity policies explain approach gender diversity disability describe gsks employee resource groups inclusion diversity policies global policy equal inclusive treatment employees aspire create workplace culture values respects every employee gsk condone harassment discrimination whether relating race colour religion belief gender sexual orientation gender identity expression age national origin genetic makeup disability chronic health conditions protect employees ' privacy confidentiality recognise human rights help ensure adherence equal inclusive treatment employees gsk provides anonymous ethics compliance hotline confidential disclosure questionable andor noncompliant behaviours global hivaids policy discriminate prospective current employees based hiv status require medical testing prerequisite employment maintain medical confidentiality times provide information training staff hivaids prevention addressing problems stigma relating disease provide hivaids testing voluntary counselling treatment programmes including free antiretrovirals employees families countries easily available via government healthcare programmes disability work ensure people disabilities access full range recruitment career opportunities gsk uk partner employers ' forum disability strive 'disability confident ' organisation disability confident describes companies create culture inclusion remove barriers access make adjustments enable individuals disabilities contribute employees customers partners hold 'two ticks ' symbol jobcentreplus demonstrates gsks commitment employing disabled people flexible work culture identified flexible thinking one six critical behaviours gsk employees supporting creative agile work practices including learning opportunities teach flexible thinking skills employment practices support career development benefits rewards reflect changing needs performancebased flexible work practices policies meet business personal life needs working environments flextime parttime jobshares well collaborative workspaces technology growing tactics support flexible work culture want employees empowered discuss line manager work environment enable best work expect line managers support conversation employee resource groups gsk actively supports employee resource groups also known networks encourage professional growth provide forum people similar interests backgrounds meet discuss shared experiences work together help make company inclusive workplace helps engage empower employees beyond daytoday responsibilities addition resource groups provide gsk managers views insights diversity help media marketing teams better understand diverse customers stakeholders gsk employee resource groups include asian african american hispanic groups cancer survivors gay lesbian bisexual transgender midcareer beyond veterans families friends young professionals women group executive sponsor helps set achieve goals obtain resources promote objectives us network leaders given twoday training course develop leadership strategic thinking skills although employee resource groups us gay lesbian bisexual transgender group also council uk young professionals group councils several countries including australia uk china india brazil information commitment diversity including gsks approach customer stakeholder diversity available inclusion diversity section gskcom example inclusion diversity action gsk employees across us learning work issues faced lesbian gay bisexual transgender lgbt employees part initiative foster increased sense acceptance inclusion work safezone programme six training sessions facilitated develop employees 'lgbt advocates ' led consultant university pennsylvania participants discussed workplace challenges arise lgbt community devised strategies address additional resources available employees including internal external web communities offering variety tools resources help create inclusive workplace back tophome responsibility people inclusion diversity corporate responsibility report inclusion diversity approach performance recognise value different knowledge perspectives experiences working styles bring gsk approach based respect employees global inclusion diversity strategy aims create working environment employees feel valued included unique qualities bring empowered contribute full potential global inclusion diversity strategy sponsored senior executive reports directly ceo section outline inclusion diversity policies explain approach gender diversity disability describe gsks employee resource groups inclusion diversity policies global policy equal inclusive treatment employees aspire create workplace culture values respects every employee gsk condone harassment discrimination whether relating race colour religion belief gender sexual orientation gender identity expression age national origin genetic makeup disability chronic health conditions protect employees ' privacy confidentiality recognise human rights help ensure adherence equal inclusive treatment employees gsk provides anonymous ethics compliance hotline confidential disclosure questionable andor noncompliant behaviours global hivaids policy discriminate prospective current employees based hiv status require medical testing prerequisite employment maintain medical confidentiality times provide information training staff hivaids prevention addressing problems stigma relating disease provide hivaids testing voluntary counselling treatment programmes including free antiretrovirals employees families countries easily available via government healthcare programmes disability work ensure people disabilities access full range recruitment career opportunities gsk uk partner employers ' forum disability strive 'disability confident ' organisation disability confident describes companies create culture inclusion remove barriers access make adjustments enable individuals disabilities contribute employees customers partners hold 'two ticks ' symbol jobcentreplus demonstrates gsks commitment employing disabled people flexible work culture identified flexible thinking one six critical behaviours gsk employees supporting creative agile work practices including learning opportunities teach flexible thinking skills employment practices support career development benefits rewards reflect changing needs performancebased flexible work practices policies meet business personal life needs working environments flextime parttime jobshares well collaborative workspaces technology growing tactics support flexible work culture want employees empowered discuss line manager work environment enable best work expect line managers support conversation employee resource groups gsk actively supports employee resource groups also known networks encourage professional growth provide forum people similar interests backgrounds meet discuss shared experiences work together help make company inclusive workplace helps engage empower employees beyond daytoday responsibilities addition resource groups provide gsk managers views insights diversity help media marketing teams better understand diverse customers stakeholders gsk employee resource groups include asian african american hispanic groups cancer survivors gay lesbian bisexual transgender midcareer beyond veterans families friends young professionals women group executive sponsor helps set achieve goals obtain resources promote objectives us network leaders given twoday training course develop leadership strategic thinking skills although employee resource groups us gay lesbian bisexual transgender group also council uk young professionals group councils several countries including australia uk china india brazil information commitment diversity including gsks approach customer stakeholder diversity available inclusion diversity section gskcom example inclusion diversity action gsk employees across us learning work issues faced lesbian gay bisexual transgender lgbt employees part initiative foster increased sense acceptance inclusion work safezone programme six training sessions facilitated develop employees 'lgbt advocates ' led consultant university pennsylvania participants discussed workplace challenges arise lgbt community devised strategies address additional resources available employees including internal external web communities offering variety tools resources help create inclusive workplace back top home responsibility people inclusion diversity corporate responsibility report inclusion diversity approach performance recognise value different knowledge perspectives experiences working styles bring gsk approach based respect employees global inclusion diversity strategy aims create working environment employees feel valued included unique qualities bring empowered contribute full potential global inclusion diversity strategy sponsored senior executive reports directly ceo section outline inclusion diversity policies explain approach gender diversity disability describe gsks employee resource groups inclusion diversity policies global policy equal inclusive treatment employees aspire create workplace culture values respects every employee gsk condone harassment discrimination whether relating race colour religion belief gender sexual orientation gender identity expression age national origin genetic makeup disability chronic health conditions protect employees ' privacy confidentiality recognise human rights help ensure adherence equal inclusive treatment employees gsk provides anonymous ethics compliance hotline confidential disclosure questionable andor noncompliant behaviours global hivaids policy discriminate prospective current employees based hiv status require medical testing prerequisite employment maintain medical confidentiality times provide information training staff hivaids prevention addressing problems stigma relating disease provide hivaids testing voluntary counselling treatment programmes including free antiretrovirals employees families countries easily available via government healthcare programmes disability work ensure people disabilities access full range recruitment career opportunities gsk uk partner employers ' forum disability strive 'disability confident ' organisation disability confident describes companies create culture inclusion remove barriers access make adjustments enable individuals disabilities contribute employees customers partners hold 'two ticks ' symbol jobcentreplus demonstrates gsks commitment employing disabled people flexible work culture identified flexible thinking one six critical behaviours gsk employees supporting creative agile work practices including learning opportunities teach flexible thinking skills employment practices support career development benefits rewards reflect changing needs performancebased flexible work practices policies meet business personal life needs working environments flextime parttime jobshares well collaborative workspaces technology growing tactics support flexible work culture want employees empowered discuss line manager work environment enable best work expect line managers support conversation employee resource groups gsk actively supports employee resource groups also known networks encourage professional growth provide forum people similar interests backgrounds meet discuss shared experiences work together help make company inclusive workplace helps engage empower employees beyond daytoday responsibilities addition resource groups provide gsk managers views insights diversity help media marketing teams better understand diverse customers stakeholders gsk employee resource groups include asian african american hispanic groups cancer survivors gay lesbian bisexual transgender midcareer beyond veterans families friends young professionals women group executive sponsor helps set achieve goals obtain resources promote objectives us network leaders given twoday training course develop leadership strategic thinking skills although employee resource groups us gay lesbian bisexual transgender group also council uk young professionals group councils several countries including australia uk china india brazil information commitment diversity including gsks approach customer stakeholder diversity available inclusion diversity section gskcom example inclusion diversity action gsk employees across us learning work issues faced lesbian gay bisexual transgender lgbt employees part initiative foster increased sense acceptance inclusion work safezone programme six training sessions facilitated develop employees 'lgbt advocates ' led consultant university pennsylvania participants discussed workplace challenges arise lgbt community devised strategies address additional resources available employees including internal external web communities offering variety tools resources help create inclusive workplace back top home responsibility people inclusion diversity corporate responsibility report inclusion diversity approach performance recognise value different knowledge perspectives experiences working styles bring gsk approach based respect employees global inclusion diversity strategy aims create working environment employees feel valued included unique qualities bring empowered contribute full potential global inclusion diversity strategy sponsored senior executive reports directly ceo section outline inclusion diversity policies explain approach gender diversity disability describe gsks employee resource groups inclusion diversity policies global policy equal inclusive treatment employees aspire create workplace culture values respects every employee gsk condone harassment discrimination whether relating race colour religion belief gender sexual orientation gender identity expression age national origin genetic makeup disability chronic health conditions protect employees ' privacy confidentiality recognise human rights help ensure adherence equal inclusive treatment employees gsk provides anonymous ethics compliance hotline confidential disclosure questionable andor noncompliant behaviours global hivaids policy discriminate prospective current employees based hiv status require medical testing prerequisite employment maintain medical confidentiality times provide information training staff hivaids prevention addressing problems stigma relating disease provide hivaids testing voluntary counselling treatment programmes including free antiretrovirals employees families countries easily available via government healthcare programmes disability work ensure people disabilities access full range recruitment career opportunities gsk uk partner employers ' forum disability strive 'disability confident ' organisation disability confident describes companies create culture inclusion remove barriers access make adjustments enable individuals disabilities contribute employees customers partners hold 'two ticks ' symbol jobcentreplus demonstrates gsks commitment employing disabled people flexible work culture identified flexible thinking one six critical behaviours gsk employees supporting creative agile work practices including learning opportunities teach flexible thinking skills employment practices support career development benefits rewards reflect changing needs performancebased flexible work practices policies meet business personal life needs working environments flextime parttime jobshares well collaborative workspaces technology growing tactics support flexible work culture want employees empowered discuss line manager work environment enable best work expect line managers support conversation employee resource groups gsk actively supports employee resource groups also known networks encourage professional growth provide forum people similar interests backgrounds meet discuss shared experiences work together help make company inclusive workplace helps engage empower employees beyond daytoday responsibilities addition resource groups provide gsk managers views insights diversity help media marketing teams better understand diverse customers stakeholders gsk employee resource groups include asian african american hispanic groups cancer survivors gay lesbian bisexual transgender midcareer beyond veterans families friends young professionals women group executive sponsor helps set achieve goals obtain resources promote objectives us network leaders given twoday training course develop leadership strategic thinking skills although employee resource groups us gay lesbian bisexual transgender group also council uk young professionals group councils several countries including australia uk china india brazil information commitment diversity including gsks approach customer stakeholder diversity available inclusion diversity section gskcom example inclusion diversity action gsk employees across us learning work issues faced lesbian gay bisexual transgender lgbt employees part initiative foster increased sense acceptance inclusion work safezone programme six training sessions facilitated develop employees 'lgbt advocates ' led consultant university pennsylvania participants discussed workplace challenges arise lgbt community devised strategies address additional resources available employees including internal external web communities offering variety tools resources help create inclusive workplace back top home responsibility people inclusion diversity corporate responsibility report inclusion diversity approach performance developed new global policy equal inclusive treatment employees policy raises bar practice application equality inclusion emphasis importance inclusion addition diversity knowledge perspectives experiences working styles genetics raise awareness new policy gender diversity seen continuing increase percentage women across levels management gsk women continue account per cent management positions globally remain committed maintaining trend increasing number women managerial ranks line inclusive employment approach gender diversity management positions held women svp vp director manager total ethnic diversity us minorities defined blacks hispanics asians pacific islanders american indians alaskan natives made per cent workforce compared per cent per cent per cent us census bureau reports minority population accounts per cent nation 's total population last reported july uk ethnic minorities accounted per cent employees compared per cent per cent per cent ethnic minorities accounted per cent uk population england wales last uk census use uk commission racial equality definition ethnic minorities includes anyone identify white british means people identified white irish north american european included minorities also measure diversity uk counting number employees define non white per cent employees defined nonwhite compared per cent per cent per cent ethnic minorities us ethnic minorities uk back tophome responsibility people inclusion diversity corporate responsibility report inclusion diversity approach performance developed new global policy equal inclusive treatment employees policy raises bar practice application equality inclusion emphasis importance inclusion addition diversity knowledge perspectives experiences working styles genetics raise awareness new policy gender diversity seen continuing increase percentage women across levels management gsk women continue account per cent management positions globally remain committed maintaining trend increasing number women managerial ranks line inclusive employment approach gender diversity management positions held women svp vp director manager total ethnic diversity us minorities defined blacks hispanics asians pacific islanders american indians alaskan natives made per cent workforce compared per cent per cent per cent us census bureau reports minority population accounts per cent nation 's total population last reported july uk ethnic minorities accounted per cent employees compared per cent per cent per cent ethnic minorities accounted per cent uk population england wales last uk census use uk commission racial equality definition ethnic minorities includes anyone identify white british means people identified white irish north american european included minorities also measure diversity uk counting number employees define non white per cent employees defined nonwhite compared per cent per cent per cent ethnic minorities us ethnic minorities uk back top home responsibility people inclusion diversity corporate responsibility report inclusion diversity approach performance developed new global policy equal inclusive treatment employees policy raises bar practice application equality inclusion emphasis importance inclusion addition diversity knowledge perspectives experiences working styles genetics raise awareness new policy gender diversity seen continuing increase percentage women across levels management gsk women continue account per cent management positions globally remain committed maintaining trend increasing number women managerial ranks line inclusive employment approach gender diversity management positions held women svp vp director manager total ethnic diversity us minorities defined blacks hispanics asians pacific islanders american indians alaskan natives made per cent workforce compared per cent per cent per cent us census bureau reports minority population accounts per cent nation 's total population last reported july uk ethnic minorities accounted per cent employees compared per cent per cent per cent ethnic minorities accounted per cent uk population england wales last uk census use uk commission racial equality definition ethnic minorities includes anyone identify white british means people identified white irish north american european included minorities also measure diversity uk counting number employees define non white per cent employees defined nonwhite compared per cent per cent per cent ethnic minorities us ethnic minorities uk back top home responsibility people developing people corporate responsibility report developing people training development opportunities help employees feel valued engaged enable advance careers many aspects career development gsk approach includes training mentoring coaching performance appraisals volunteering opportunities support individual empowerment initiative employees use empowerme intranet share empowerment means discuss issues obtain tools inspiration need empower teams make confident decisions training gsk provides workrelated training courses employees offered learning programmes languages gsk employees countries programmes offered via online learning management system also offer project secondments help employees learn new skills read extensive health safety environment training mentoring coaching mentoring system provides support inspiration highperforming employees helping create future generations leaders top three tiers gsk management made commitment mentor least one employee identify employees mentoring talent review process variety resources targeted mentors mentees available gsks mentoring web community coaching also important component employee development especially among leaders company use internal external coaching resources help accelerate development enhance leadership skills performance appraisals majority employees participate performance appraisals performance development planning pdp process pdp key people process within gsk basis establish achieve personal objectives well achieve gsk behaviours pdp process also encompasses development planning review progress throughout year objectives behaviours development tool individual contributions aligned gsks business goals appraisals impact reward future career development employee volunteering encourage employee volunteering gsk volunteering provides muchneeded support communities organisations around world also helps gsk employees gain new experiences skills many instances helps deepen understanding patient needs important component patient focused value many gsk locations run volunteering programmes make easier employees get involved locally starting gsk gives every employee one paid day year volunteer community april launched pulse gsk 's new volunteer initiative gives employees opportunity make significant difference underserved communities home abroad transformational change happen employees use share pass professional skills knowledge three six month immersion experience within nonprofit nongovernmental organisation ngo volunteers address clear ngo need developing leadership capabilities pulse programme tangible expression culture values embodies philosophy improving lives others supporting talent development intake pulse volunteers assignments ngos save children americares direct relief international british red cross countries employees continue receive gsk salary placement represented inkind donation back tophome responsibility people developing people corporate responsibility report developing people training development opportunities help employees feel valued engaged enable advance careers many aspects career development gsk approach includes training mentoring coaching performance appraisals volunteering opportunities support individual empowerment initiative employees use empowerme intranet share empowerment means discuss issues obtain tools inspiration need empower teams make confident decisions training gsk provides workrelated training courses employees offered learning programmes languages gsk employees countries programmes offered via online learning management system also offer project secondments help employees learn new skills read extensive health safety environment training mentoring coaching mentoring system provides support inspiration highperforming employees helping create future generations leaders top three tiers gsk management made commitment mentor least one employee identify employees mentoring talent review process variety resources targeted mentors mentees available gsks mentoring web community coaching also important component employee development especially among leaders company use internal external coaching resources help accelerate development enhance leadership skills performance appraisals majority employees participate performance appraisals performance development planning pdp process pdp key people process within gsk basis establish achieve personal objectives well achieve gsk behaviours pdp process also encompasses development planning review progress throughout year objectives behaviours development tool individual contributions aligned gsks business goals appraisals impact reward future career development employee volunteering encourage employee volunteering gsk volunteering provides muchneeded support communities organisations around world also helps gsk employees gain new experiences skills many instances helps deepen understanding patient needs important component patient focused value many gsk locations run volunteering programmes make easier employees get involved locally starting gsk gives every employee one paid day year volunteer community april launched pulse gsk 's new volunteer initiative gives employees opportunity make significant difference underserved communities home abroad transformational change happen employees use share pass professional skills knowledge three six month immersion experience within nonprofit nongovernmental organisation ngo volunteers address clear ngo need developing leadership capabilities pulse programme tangible expression culture values embodies philosophy improving lives others supporting talent development intake pulse volunteers assignments ngos save children americares direct relief international british red cross countries employees continue receive gsk salary placement represented inkind donation back top home responsibility people developing people corporate responsibility report developing people training development opportunities help employees feel valued engaged enable advance careers many aspects career development gsk approach includes training mentoring coaching performance appraisals volunteering opportunities support individual empowerment initiative employees use empowerme intranet share empowerment means discuss issues obtain tools inspiration need empower teams make confident decisions training gsk provides workrelated training courses employees offered learning programmes languages gsk employees countries programmes offered via online learning management system also offer project secondments help employees learn new skills read extensive health safety environment training mentoring coaching mentoring system provides support inspiration highperforming employees helping create future generations leaders top three tiers gsk management made commitment mentor least one employee identify employees mentoring talent review process variety resources targeted mentors mentees available gsks mentoring web community coaching also important component employee development especially among leaders company use internal external coaching resources help accelerate development enhance leadership skills performance appraisals majority employees participate performance appraisals performance development planning pdp process pdp key people process within gsk basis establish achieve personal objectives well achieve gsk behaviours pdp process also encompasses development planning review progress throughout year objectives behaviours development tool individual contributions aligned gsks business goals appraisals impact reward future career development employee volunteering encourage employee volunteering gsk volunteering provides muchneeded support communities organisations around world also helps gsk employees gain new experiences skills many instances helps deepen understanding patient needs important component patient focused value many gsk locations run volunteering programmes make easier employees get involved locally starting gsk gives every employee one paid day year volunteer community april launched pulse gsk 's new volunteer initiative gives employees opportunity make significant difference underserved communities home abroad transformational change happen employees use share pass professional skills knowledge three six month immersion experience within nonprofit nongovernmental organisation ngo volunteers address clear ngo need developing leadership capabilities pulse programme tangible expression culture values embodies philosophy improving lives others supporting talent development intake pulse volunteers assignments ngos save children americares direct relief international british red cross countries employees continue receive gsk salary placement represented inkind donation back top home responsibility people leading people corporate responsibility report leading people leaders play critical role gsk quality leadership make biggest difference company execution strategy ability live values behaviours developed robust leadership strategy identify develop highly skilled leadership cadre need place strategy looks manage invest talented people ensure effective succession planning leadership gsk take global approach making talented workforce looking quality depth breadth leaders across world impacts businesses functions equally develop maintain realistic ready lists successors critical roles need good succession plans senior roles critical positions across organisation completed succession plans top critical roles organisation also using systematic disciplined approach leadership development providing tools programmes help leaders master skills needed meet customer employee investor expectations targeting three groups employees first line leaders middle management high potential talent launched first line leader programme new leaders whether new gsk new managing people also launched gskwide mentoring scheme senior leader mentor least one individual mentors forge connectivity individuals broader organisation instrumental helping engage retain employees leaders gsk expected demonstrate values behaviours manage teams responsible team 's understanding employment practices accountable developing talent successors high priority every leader degree assessments provide leaders objective feedback supervise colleagues managers others assessments structured around gsk 's values behaviours help managers reflect others perceive improve relationships within outside company andrew wittys assessment included feedback gsk board shareholders analysts performance ceo also two self assessments help leaders understand preferences career values leadership orientation questionnaire career values questionnaire back top home responsibility people leading people corporate responsibility report leading people leaders play critical role gsk quality leadership make biggest difference company execution strategy ability live values behaviours developed robust leadership strategy identify develop highly skilled leadership cadre need place strategy looks manage invest talented people ensure effective succession planning leadership gsk take global approach making talented workforce looking quality depth breadth leaders across world impacts businesses functions equally develop maintain realistic ready lists successors critical roles need good succession plans senior roles critical positions across organisation completed succession plans top critical roles organisation also using systematic disciplined approach leadership development providing tools programmes help leaders master skills needed meet customer employee investor expectations targeting three groups employees first line leaders middle management high potential talent launched first line leader programme new leaders whether new gsk new managing people also launched gskwide mentoring scheme senior leader mentor least one individual mentors forge connectivity individuals broader organisation instrumental helping engage retain employees leaders gsk expected demonstrate values behaviours manage teams responsible team 's understanding employment practices accountable developing talent successors high priority every leader degree assessments provide leaders objective feedback supervise colleagues managers others assessments structured around gsk 's values behaviours help managers reflect others perceive improve relationships within outside company andrew wittys assessment included feedback gsk board shareholders analysts performance ceo also two self assessments help leaders understand preferences career values leadership orientation questionnaire career values questionnaire back top home responsibility people restructuring corporate responsibility report restructuring improve effectiveness productivity operations ensure long term sustainability gsk company time time undertake restructuring programmes conscious effect restructuring employees options exist achieve financial goals still preserve jobs everything consult employees representatives implement measures affect outsourcing site closures staff reductions always speak affected employees first except local regulations allow works councils trade unions employee representatives appropriate aim treat employees dignity respect offer wide range support affected employees includes competitive severance package outplacement support assistance finding alternative employment career counselling retraining also work hard maintain morale employees gsk restructuring activity back top home responsibility people restructuring corporate responsibility report restructuring improve effectiveness productivity operations ensure long term sustainability gsk company time time undertake restructuring programmes conscious effect restructuring employees options exist achieve financial goals still preserve jobs everything consult employees representatives implement measures affect outsourcing site closures staff reductions always speak affected employees first except local regulations allow works councils trade unions employee representatives appropriate aim treat employees dignity respect offer wide range support affected employees includes competitive severance package outplacement support assistance finding alternative employment career counselling retraining also work hard maintain morale employees gsk restructuring activity back top home responsibility people communication consultation corporate responsibility report communication consultation approach performance regular twoway communication employees vital contributes enhanced morale productivity reflects values transparency respect people aim keep everyone well informed involved company activities provide opportunities get feedback internal communications channels include facetoface communications example town hall style meetings lunches corporate executive team conferences team meetings gsk experience twoday induction programme new starters uk us countries arrange induction programmes locally spirit internal magazine available print intranet introduced video interviews give employees closer connection people projects products featured global intranet site mygsk provides updates company industry news large range information resources employees mygsk several features employees including myceo dedicated part intranet staff pose questions chief executive officer ceo members corporate executive team employees ask approximately questions month ceos answers posted regularly site interactive intranet feature story allows employees share stories inspires impacts work company email cascade system messages sent business leaders share employees example details latest financial results surveys enable us monitor employee engagement help us track impact internal communications addition business units communicate directly employees intranet town hall meetings facetoface meetings broadcasts video messages andrew witty talks regularly employees global forums broadcasts ceo advisory board made employees across company acts informal sounding board ideas many members corporate executive team also run live web chats host qa sessions intranet communities ensuring employees aware areas concern within regions business units functional areas employee surveys achieving strategic goals requires environment within gsk employees feel engaged empowered capable performing highest levels integrity one mechanisms use achieve employee surveys consultation europe staff works councils meet regularly providing opportunity employees company management discuss key issues developments business also recognise trade unions consultation collective bargaining many countries worldwide european employee consultation forum includes employee representatives eu countries works alongside national consultation processes governed uk law operating subcommittee six employee representatives meets four times year six management representatives receive updates review proposals affecting structure business extraordinary operating subcommittee meetings called need arise whole forum meets year annual meeting receive business update senior gsk executives back tophome responsibility people communication consultation corporate responsibility report communication consultation approach performance regular twoway communication employees vital contributes enhanced morale productivity reflects values transparency respect people aim keep everyone well informed involved company activities provide opportunities get feedback internal communications channels include facetoface communications example town hall style meetings lunches corporate executive team conferences team meetings gsk experience twoday induction programme new starters uk us countries arrange induction programmes locally spirit internal magazine available print intranet introduced video interviews give employees closer connection people projects products featured global intranet site mygsk provides updates company industry news large range information resources employees mygsk several features employees including myceo dedicated part intranet staff pose questions chief executive officer ceo members corporate executive team employees ask approximately questions month ceos answers posted regularly site interactive intranet feature story allows employees share stories inspires impacts work company email cascade system messages sent business leaders share employees example details latest financial results surveys enable us monitor employee engagement help us track impact internal communications addition business units communicate directly employees intranet town hall meetings facetoface meetings broadcasts video messages andrew witty talks regularly employees global forums broadcasts ceo advisory board made employees across company acts informal sounding board ideas many members corporate executive team also run live web chats host qa sessions intranet communities ensuring employees aware areas concern within regions business units functional areas employee surveys achieving strategic goals requires environment within gsk employees feel engaged empowered capable performing highest levels integrity one mechanisms use achieve employee surveys consultation europe staff works councils meet regularly providing opportunity employees company management discuss key issues developments business also recognise trade unions consultation collective bargaining many countries worldwide european employee consultation forum includes employee representatives eu countries works alongside national consultation processes governed uk law operating subcommittee six employee representatives meets four times year six management representatives receive updates review proposals affecting structure business extraordinary operating subcommittee meetings called need arise whole forum meets year annual meeting receive business update senior gsk executives back top home responsibility people communication consultation corporate responsibility report communication consultation approach performance regular twoway communication employees vital contributes enhanced morale productivity reflects values transparency respect people aim keep everyone well informed involved company activities provide opportunities get feedback internal communications channels include facetoface communications example town hall style meetings lunches corporate executive team conferences team meetings gsk experience twoday induction programme new starters uk us countries arrange induction programmes locally spirit internal magazine available print intranet introduced video interviews give employees closer connection people projects products featured global intranet site mygsk provides updates company industry news large range information resources employees mygsk several features employees including myceo dedicated part intranet staff pose questions chief executive officer ceo members corporate executive team employees ask approximately questions month ceos answers posted regularly site interactive intranet feature story allows employees share stories inspires impacts work company email cascade system messages sent business leaders share employees example details latest financial results surveys enable us monitor employee engagement help us track impact internal communications addition business units communicate directly employees intranet town hall meetings facetoface meetings broadcasts video messages andrew witty talks regularly employees global forums broadcasts ceo advisory board made employees across company acts informal sounding board ideas many members corporate executive team also run live web chats host qa sessions intranet communities ensuring employees aware areas concern within regions business units functional areas employee surveys achieving strategic goals requires environment within gsk employees feel engaged empowered capable performing highest levels integrity one mechanisms use achieve employee surveys consultation europe staff works councils meet regularly providing opportunity employees company management discuss key issues developments business also recognise trade unions consultation collective bargaining many countries worldwide european employee consultation forum includes employee representatives eu countries works alongside national consultation processes governed uk law operating subcommittee six employee representatives meets four times year six management representatives receive updates review proposals affecting structure business extraordinary operating subcommittee meetings called need arise whole forum meets year annual meeting receive business update senior gsk executives back top home responsibility people communication consultation corporate responsibility report communication consultation approach performance ceo communications ceo andrew witty hosted two global employee broadcasts recorded live front employee audience broadcast countries different sites employees tuned live event broadcast andrew reviews five strategic priorities giving examples successes shortcomings emphasises importance continuing embed organisational values behaviours year andrew responds employee questions let 's talk feature myceo intranet site communicating senior leaders andrew witty hosted global broadcast gsks top leaders update company news gsk leadership forum also held online first time rather facetoface meeting allowing us extend attendee list top top leaders gsk employee surveys conducted two employee surveys early conducted empowerment survey establish baseline measure empowered employees feel end year revised conducted internal online opinion survey employees invited provide feedback individual empowerment employee engagement company values highlights survey results included next update corporate responsibility report empowerme empowerme community internal source gsk employees share ideas discuss issues celebrate empowerment aim empowerme give employees tools inspiration needed empower teams make decisions confidence accountability last year postings shared empowerme site sharing insights colleagues around world one many ways gsk employees become empowered consultation appropriate consult employees representatives implement measures affect outsourcing site closures staff reductions linked one core values respect people always speak affected employees first except local regulations allow works councils trade unions employee representatives appropriate annual meeting held june european employee consultation forum heard proposed changes within european commercial operation including formation viiv healthcare new hiv joint venture pfizer integration stiefel also received updates rd global community partnerships finance departments also discuss issues national consultation forums example uk information consultation ic forum consists gskelected employee representatives seven managers meets three times year ic forum received updates business transformation plans uk new global platform changes uk benefits package include ability employees purchase extra vacation days plans continually reviewing effectiveness communications identifying areas improvement employees encouraged ask questions comment information provide channels use technology updated easier us encourage direct communication discussion employees launch updated company intranet expand use technology social media tools personalised web pages designed encourage greater collaboration communication across gsk break barriers good communication within business back tophome responsibility people communication consultation corporate responsibility report communication consultation approach performance ceo communications ceo andrew witty hosted two global employee broadcasts recorded live front employee audience broadcast countries different sites employees tuned live event broadcast andrew reviews five strategic priorities giving examples successes shortcomings emphasises importance continuing embed organisational values behaviours year andrew responds employee questions let 's talk feature myceo intranet site communicating senior leaders andrew witty hosted global broadcast gsks top leaders update company news gsk leadership forum also held online first time rather facetoface meeting allowing us extend attendee list top top leaders gsk employee surveys conducted two employee surveys early conducted empowerment survey establish baseline measure empowered employees feel end year revised conducted internal online opinion survey employees invited provide feedback individual empowerment employee engagement company values highlights survey results included next update corporate responsibility report empowerme empowerme community internal source gsk employees share ideas discuss issues celebrate empowerment aim empowerme give employees tools inspiration needed empower teams make decisions confidence accountability last year postings shared empowerme site sharing insights colleagues around world one many ways gsk employees become empowered consultation appropriate consult employees representatives implement measures affect outsourcing site closures staff reductions linked one core values respect people always speak affected employees first except local regulations allow works councils trade unions employee representatives appropriate annual meeting held june european employee consultation forum heard proposed changes within european commercial operation including formation viiv healthcare new hiv joint venture pfizer integration stiefel also received updates rd global community partnerships finance departments also discuss issues national consultation forums example uk information consultation ic forum consists gskelected employee representatives seven managers meets three times year ic forum received updates business transformation plans uk new global platform changes uk benefits package include ability employees purchase extra vacation days plans continually reviewing effectiveness communications identifying areas improvement employees encouraged ask questions comment information provide channels use technology updated easier us encourage direct communication discussion employees launch updated company intranet expand use technology social media tools personalised web pages designed encourage greater collaboration communication across gsk break barriers good communication within business back top home responsibility people communication consultation corporate responsibility report communication consultation approach performance ceo communications ceo andrew witty hosted two global employee broadcasts recorded live front employee audience broadcast countries different sites employees tuned live event broadcast andrew reviews five strategic priorities giving examples successes shortcomings emphasises importance continuing embed organisational values behaviours year andrew responds employee questions let 's talk feature myceo intranet site communicating senior leaders andrew witty hosted global broadcast gsks top leaders update company news gsk leadership forum also held online first time rather facetoface meeting allowing us extend attendee list top top leaders gsk employee surveys conducted two employee surveys early conducted empowerment survey establish baseline measure empowered employees feel end year revised conducted internal online opinion survey employees invited provide feedback individual empowerment employee engagement company values highlights survey results included next update corporate responsibility report empowerme empowerme community internal source gsk employees share ideas discuss issues celebrate empowerment aim empowerme give employees tools inspiration needed empower teams make decisions confidence accountability last year postings shared empowerme site sharing insights colleagues around world one many ways gsk employees become empowered consultation appropriate consult employees representatives implement measures affect outsourcing site closures staff reductions linked one core values respect people always speak affected employees first except local regulations allow works councils trade unions employee representatives appropriate annual meeting held june european employee consultation forum heard proposed changes within european commercial operation including formation viiv healthcare new hiv joint venture pfizer integration stiefel also received updates rd global community partnerships finance departments also discuss issues national consultation forums example uk information consultation ic forum consists gskelected employee representatives seven managers meets three times year ic forum received updates business transformation plans uk new global platform changes uk benefits package include ability employees purchase extra vacation days plans continually reviewing effectiveness communications identifying areas improvement employees encouraged ask questions comment information provide channels use technology updated easier us encourage direct communication discussion employees launch updated company intranet expand use technology social media tools personalised web pages designed encourage greater collaboration communication across gsk break barriers good communication within business back top home responsibility people reward recognition corporate responsibility report reward recognition gsk offers employees competitive salary based industry benchmarks well performancerelated incentives benefits helps us attract retain motivate best people reward employees good performance annual objectives demonstration gsk behaviours appropriate role development plan approach reward recognition programme called totalreward helps us recognise good performance enables managers share gsk 's success use feedback managers identify types reward prefer components totalreward include pay including base salary bonus recognition awards base salaries allocated within defined bands different employment levels shares savings pension provision share schemes including longterm incentives eligible employees healthcare vacation childcare support employee car ownership programmes performance component added totalreward performance development planning programme helps employees identify need order perform better achieve higher reward future totalreward applies gsk managers around world uk us employees component parts employee 's package differ country accordance local legislation best practice share ownership share ownership schemes help create culture ownership among employees gsk managers worldwide eligible participate share programmes part totalreward package countries employees opportunity shares high level participation example uk per cent employees participate sharereward scheme back top home responsibility people reward recognition corporate responsibility report reward recognition gsk offers employees competitive salary based industry benchmarks well performancerelated incentives benefits helps us attract retain motivate best people reward employees good performance annual objectives demonstration gsk behaviours appropriate role development plan approach reward recognition programme called totalreward helps us recognise good performance enables managers share gsk 's success use feedback managers identify types reward prefer components totalreward include pay including base salary bonus recognition awards base salaries allocated within defined bands different employment levels shares savings pension provision share schemes including longterm incentives eligible employees healthcare vacation childcare support employee car ownership programmes performance component added totalreward performance development planning programme helps employees identify need order perform better achieve higher reward future totalreward applies gsk managers around world uk us employees component parts employee 's package differ country accordance local legislation best practice share ownership share ownership schemes help create culture ownership among employees gsk managers worldwide eligible participate share programmes part totalreward package countries employees opportunity shares high level participation example uk per cent employees participate sharereward scheme back top home responsibility people health safety corporate responsibility report health safety keeping employees contractors healthy safe priority rigorous management system reduces risk harm employees helps stay healthy part broader environment health safety sustainability ehss programme well right thing improves business performance increasing attendance improving productivity reducing healthcare insurance costs occupational health safety target reduce reportable injuries illnesses five per cent year placed within top quartile comparable industry ratings section explains approach health safety management hazard assessment communication safety programmes health wellbeing programmes health business continuity training awareness performance back top home responsibility people health safety corporate responsibility report health safety keeping employees contractors healthy safe priority rigorous management system reduces risk harm employees helps stay healthy part broader environment health safety sustainability ehss programme well right thing improves business performance increasing attendance improving productivity reducing healthcare insurance costs occupational health safety target reduce reportable injuries illnesses five per cent year placed within top quartile comparable industry ratings section explains approach health safety management hazard assessment communication safety programmes health wellbeing programmes health business continuity training awareness performance back top home responsibility people health safety health safety management corporate responsibility report health safety management manage health safety integrated environment health safety sustainability ehss management system reviewed updated system aligned recognised international standards iso ohsas incorporates ehs sustainability vision policy associated standards ehss plan excellence sets targets improving ehss performance parallel gsk created new centre excellence called health safety performance focused human sustainability goal nurture safe healthy resilient energized engaged workforce complement gsks sustainable business environmental practices focus next three five years three areas first nurture transformation safety health culture compliance values driven variety cultural organizational interventions build individual organisational accountability empower workforce proactively address safety health concerns work secondly focus greatest energy workplace personal safety health risks highest toll productivity health cost gsk data analysis identified musculoskeletal human factors issues driver 's safety depression finally focus top line growth global winning practices living safety personal team resilience energy performance also adapt programmes address risks safety health systematically assess manage occupational health safety risks performance incidents happen identify root causes take action prevent reoccurrence addressing causes incidents helps eliminate risks hazards prevent future occupational injuries illnesses employ health safety professionals across sites within business units global level manage health safety risks occupational health safety data independently assured ehss assurance process audits conduct occupational health safety audits sites every one four years assess health safety systems well compliance legislation ehss standards frequency audit visits determined degree risk site health safety performance issues raised previous audits audit results presented audit committee board directors audited gsk sites conducted followup visits ten facilities average audit score per cent per cent track towards target per cent eleven sites demonstrated excellent health safety management scores least per cent three achieving per cent site achieved score minimum per cent overall areas best performance included commitment sites occupational health safety employee health management fire safety weakest performance areas included ergonomics machinery safety audits identify critical health safety risks established gsk sites reveal four risks newly acquired sites monitoring facilities ensure appropriate action taken mitigate risks comply standards read overall environment health safety sustainability audits ohsas certification thirtyone gsk sites including pharmaceuticals consumer healthcare manufacturing sites one consumer healthcare rd site certified international health safety standard ohsas including three sites achieved certification evaluated ohsas certification programme decided certification benefit sites equally instead select sites certification based performance internal health safety audits high performing sites need become certified change previous goal manufacturing sites jointly certified ohsas environmental standard iso end ohsas certified sites argentina australia brazil china egypt france germany india japan kenya mexico panama philippines poland romania singapore spain saudi arabia turkey us uk back tophome responsibility people health safety health safety management corporate responsibility report health safety management manage health safety integrated environment health safety sustainability ehss management system reviewed updated system aligned recognised international standards iso ohsas incorporates ehs sustainability vision policy associated standards ehss plan excellence sets targets improving ehss performance parallel gsk created new centre excellence called health safety performance focused human sustainability goal nurture safe healthy resilient energized engaged workforce complement gsks sustainable business environmental practices focus next three five years three areas first nurture transformation safety health culture compliance values driven variety cultural organizational interventions build individual organisational accountability empower workforce proactively address safety health concerns work secondly focus greatest energy workplace personal safety health risks highest toll productivity health cost gsk data analysis identified musculoskeletal human factors issues driver 's safety depression finally focus top line growth global winning practices living safety personal team resilience energy performance also adapt programmes address risks safety health systematically assess manage occupational health safety risks performance incidents happen identify root causes take action prevent reoccurrence addressing causes incidents helps eliminate risks hazards prevent future occupational injuries illnesses employ health safety professionals across sites within business units global level manage health safety risks occupational health safety data independently assured ehss assurance process audits conduct occupational health safety audits sites every one four years assess health safety systems well compliance legislation ehss standards frequency audit visits determined degree risk site health safety performance issues raised previous audits audit results presented audit committee board directors audited gsk sites conducted followup visits ten facilities average audit score per cent per cent track towards target per cent eleven sites demonstrated excellent health safety management scores least per cent three achieving per cent site achieved score minimum per cent overall areas best performance included commitment sites occupational health safety employee health management fire safety weakest performance areas included ergonomics machinery safety audits identify critical health safety risks established gsk sites reveal four risks newly acquired sites monitoring facilities ensure appropriate action taken mitigate risks comply standards read overall environment health safety sustainability audits ohsas certification thirtyone gsk sites including pharmaceuticals consumer healthcare manufacturing sites one consumer healthcare rd site certified international health safety standard ohsas including three sites achieved certification evaluated ohsas certification programme decided certification benefit sites equally instead select sites certification based performance internal health safety audits high performing sites need become certified change previous goal manufacturing sites jointly certified ohsas environmental standard iso end ohsas certified sites argentina australia brazil china egypt france germany india japan kenya mexico panama philippines poland romania singapore spain saudi arabia turkey us uk back top home responsibility people health safety health safety management corporate responsibility report health safety management manage health safety integrated environment health safety sustainability ehss management system reviewed updated system aligned recognised international standards iso ohsas incorporates ehs sustainability vision policy associated standards ehss plan excellence sets targets improving ehss performance parallel gsk created new centre excellence called health safety performance focused human sustainability goal nurture safe healthy resilient energized engaged workforce complement gsks sustainable business environmental practices focus next three five years three areas first nurture transformation safety health culture compliance values driven variety cultural organizational interventions build individual organisational accountability empower workforce proactively address safety health concerns work secondly focus greatest energy workplace personal safety health risks highest toll productivity health cost gsk data analysis identified musculoskeletal human factors issues driver 's safety depression finally focus top line growth global winning practices living safety personal team resilience energy performance also adapt programmes address risks safety health systematically assess manage occupational health safety risks performance incidents happen identify root causes take action prevent reoccurrence addressing causes incidents helps eliminate risks hazards prevent future occupational injuries illnesses employ health safety professionals across sites within business units global level manage health safety risks occupational health safety data independently assured ehss assurance process audits conduct occupational health safety audits sites every one four years assess health safety systems well compliance legislation ehss standards frequency audit visits determined degree risk site health safety performance issues raised previous audits audit results presented audit committee board directors audited gsk sites conducted followup visits ten facilities average audit score per cent per cent track towards target per cent eleven sites demonstrated excellent health safety management scores least per cent three achieving per cent site achieved score minimum per cent overall areas best performance included commitment sites occupational health safety employee health management fire safety weakest performance areas included ergonomics machinery safety audits identify critical health safety risks established gsk sites reveal four risks newly acquired sites monitoring facilities ensure appropriate action taken mitigate risks comply standards read overall environment health safety sustainability audits ohsas certification thirtyone gsk sites including pharmaceuticals consumer healthcare manufacturing sites one consumer healthcare rd site certified international health safety standard ohsas including three sites achieved certification evaluated ohsas certification programme decided certification benefit sites equally instead select sites certification based performance internal health safety audits high performing sites need become certified change previous goal manufacturing sites jointly certified ohsas environmental standard iso end ohsas certified sites argentina australia brazil china egypt france germany india japan kenya mexico panama philippines poland romania singapore spain saudi arabia turkey us uk back top home responsibility people health safety hazard assessment communication corporate responsibility report hazard assessment communication assessment understanding potential hazards posed materials produce use research development manufacturing essential effectively manage health safety risks prevent damage environment occupational toxicologists environmental scientists assess materials hazards throughout product development increasingly use computerbased modelling vitro methods instead animal tests use hazard information assign occupational environmental exposure limits used design systems protect employees ' health protect environment chemical contamination hazard assessments help us meet regulatory requirements new eu registration evaluation authorisation chemicals reach legislation globally harmonised system classification labelling chemicals ghs communication provide hazard information enable employees contract manufacturing partners customers handle dispose materials products safely develop safety data sheets new materials products progress development process ensures health safety information readily available staff handle chemicals customers product launched enable effectively control workplace risks distribute safety data sheets via website provides health safety environmental information nearly gsk materials key manufacturing process chemicals also includes safety data sheets pharmaceutical biological consumer healthcare products information regularly updated available english french german italian portuguese spanish safety data sheets products available website also communicated directly customers via fax demand customer response centres safe transport materials transport materials require special handling chemicals biological radioactive materials use research manufacturing finished products network employees trained ensure materials transported safely compliance national international laws conventions use two systems support tracking classification emergency information transportation chemical biological radioactive materials gsk shipper system used rd sites manufacturing sites use sap system understanding fire explosion risks inhouse fire explosion laboratory tests materials handled rd manufacturing determine risk fire explosion work primarily driven requirements eu regulations explosive atmospheres directive ec atex manufacturing sites receive hazard data testing laboratories undertake risk assessments design work practices eliminate reduce risk fires dust explosions back top home responsibility people health safety hazard assessment communication corporate responsibility report hazard assessment communication assessment understanding potential hazards posed materials produce use research development manufacturing essential effectively manage health safety risks prevent damage environment occupational toxicologists environmental scientists assess materials hazards throughout product development increasingly use computerbased modelling vitro methods instead animal tests use hazard information assign occupational environmental exposure limits used design systems protect employees ' health protect environment chemical contamination hazard assessments help us meet regulatory requirements new eu registration evaluation authorisation chemicals reach legislation globally harmonised system classification labelling chemicals ghs communication provide hazard information enable employees contract manufacturing partners customers handle dispose materials products safely develop safety data sheets new materials products progress development process ensures health safety information readily available staff handle chemicals customers product launched enable effectively control workplace risks distribute safety data sheets via website provides health safety environmental information nearly gsk materials key manufacturing process chemicals also includes safety data sheets pharmaceutical biological consumer healthcare products information regularly updated available english french german italian portuguese spanish safety data sheets products available website also communicated directly customers via fax demand customer response centres safe transport materials transport materials require special handling chemicals biological radioactive materials use research manufacturing finished products network employees trained ensure materials transported safely compliance national international laws conventions use two systems support tracking classification emergency information transportation chemical biological radioactive materials gsk shipper system used rd sites manufacturing sites use sap system understanding fire explosion risks inhouse fire explosion laboratory tests materials handled rd manufacturing determine risk fire explosion work primarily driven requirements eu regulations explosive atmospheres directive ec atex manufacturing sites receive hazard data testing laboratories undertake risk assessments design work practices eliminate reduce risk fires dust explosions back top home responsibility people health safety hazard assessment communication corporate responsibility report hazard assessment communication assessment understanding potential hazards posed materials produce use research development manufacturing essential effectively manage health safety risks prevent damage environment occupational toxicologists environmental scientists assess materials hazards throughout product development increasingly use computerbased modelling vitro methods instead animal tests use hazard information assign occupational environmental exposure limits used design systems protect employees ' health protect environment chemical contamination hazard assessments help us meet regulatory requirements new eu registration evaluation authorisation chemicals reach legislation globally harmonised system classification labelling chemicals ghs communication provide hazard information enable employees contract manufacturing partners customers handle dispose materials products safely develop safety data sheets new materials products progress development process ensures health safety information readily available staff handle chemicals customers product launched enable effectively control workplace risks distribute safety data sheets via website provides health safety environmental information nearly gsk materials key manufacturing process chemicals also includes safety data sheets pharmaceutical biological consumer healthcare products information regularly updated available english french german italian portuguese spanish safety data sheets products available website also communicated directly customers via fax demand customer response centres safe transport materials transport materials require special handling chemicals biological radioactive materials use research manufacturing finished products network employees trained ensure materials transported safely compliance national international laws conventions use two systems support tracking classification emergency information transportation chemical biological radioactive materials gsk shipper system used rd sites manufacturing sites use sap system understanding fire explosion risks inhouse fire explosion laboratory tests materials handled rd manufacturing determine risk fire explosion work primarily driven requirements eu regulations explosive atmospheres directive ec atex manufacturing sites receive hazard data testing laboratories undertake risk assessments design work practices eliminate reduce risk fires dust explosions back top home responsibility people health safety safety programmes corporate responsibility report safety programmes operate number programmes keep employees contractors safe chemical exposure rigorous procedures controls protect employees exposure chemicals goal make per cent existing operations involving handling hazardous compounds 'respirator free ' end decided extend target previously focus adapting operations highest degree risk first rather easiest adapt new facilities 'respirator free ' start 'respirator free ' means employees need wear respiratory protective equipment routine production tasks instead sites install technology prevents release hazardous compounds work environment example facility cork ireland long established technical expertise containment ways working handling highly potent materials penicillin facility pakistan special containment system also developed proprietary manufacturing technology greatly reduces operator exposure medicines manufactured gsk site monitors air quality assess exposure hazardous compounds implements controls achieve 'respirator free ' goal occupational hygienists employee health staff engineers work together site regional global levels reduce employees ' exposure chemicals end monitoring showed per cent operations 'respirator free ' situations possible respirator free employees remain protected appropriate respiratory equipment process safety many products begin formulation processing hazardous materials flammable solvents combustible powders scientists look opportunities eliminate use hazardous materials green chemistry green technology programmes substitution elimination option aim ensure safety built manufacturing research development processes employees receive training understand risks implement appropriate controls engineers use online system assess safety process plant designs develop plant maintenance strategies share hazard information control strategies across gsk updated process safety management system continued integrate ehss management systems gsk sites system updated response explosion irvine factory injured two employees includes new global engineering standards process safety assessments engineering standards gap analyses upgraded standardised process hazard identification risk assessment techniques represent current good practice process safety performance indicators applied highest risk areas business steps embed process safety overall safety culture new training competence programmes sites implement process safety management system analysing gaps six elements practices correcting deficiencies implementation overseen director process safety position established around process safety incidents none resulted injuries environmental damage safety engineering safety engineering programme focuses improving construction plant safety ensuring effective emergency response systems developed online safety engineering guides managing risk fire explosion provide guidance machine guarding electrical hazards provide standardised approach managing safety risks across gsk work closely property insurance company ensure sites designed constructed maintained eliminate minimise incidents would result property loss business interruption safety also built maintained sites risk assessment control processes construction contractor safety programme capital project ehs review process emergency response programmes 'living safety ' living safety programme designed embed strong safety culture throughout gsk currently deployed manufacturing research organisations teaches employees behaviours expect demonstrate everyday work keep colleagues safe example everyone including contractors responsible implementing health safety management system everyone must follow rules report potential risks encounter get involved improving safety performance supervisors play vital role ensuring gsks health safety standards understood implemented maintained team including contractors supervisors must ensure compliance policies encourage team get involved improving safety performance promote risk awareness managers attitudes health safety important employees set good example managers must establish high health safety standards communicate openly employees issues quickly address risks identify involve others efforts improve safety performance ergonomics human factors musculoskeletal illnesses repetitive strain injuries leading causes time away work target reduce number illnesses injuries five per cent year ranked within top quartile industry ratings good workplace job design known ergonomics human factors helps employees jobs effectively reducing risk musculoskeletal illnesses injuries ergonomics human factors applied properly reduce illnesses injuries well work performance errors lost time teams working across gsk assess manage ergonomic risks existing operations planned projects teams include members manufacturing quality safety health medical services teams work together identify risks develop solutions share best practice globally dedicated ergonomics intranet community addition nearly trained facilitators help manage computerbased ergonomic risk assessments almost employees assessments give employees opportunity talk discomfort experience using computers discuss ways reduce discomfort injury risk information ergonomics computer best practice also available employees ergonomics community intranet pages focused improving risk assessments reducing ergonomicsrelated injury illness establishing new system quickly identify risks employees use computers frequently report discomfort creating training new ergonomics improvement teams brazil china india us continuing put measures place manufacturing operations example limit injuries manual lifting achieved per cent improvement ergonomicsrelated injury illness rate double per cent improvement target time period driver safety sales representatives spend significant amounts time driving risk involved road traffic incidents driving accidents common cause fatalities caused death one gsk employee per cent injuries lost time due motor vehicle accidents per cent injuries without lost time see fatalities serious injuries aim reduce risk road traffic accidents global driver safety programme includes instructions guidelines driver training vehicle selection risk assessment accident reporting motorbike rider safety manual employees countries provide motorbikes scooters back tophome responsibility people health safety safety programmes corporate responsibility report safety programmes operate number programmes keep employees contractors safe chemical exposure rigorous procedures controls protect employees exposure chemicals goal make per cent existing operations involving handling hazardous compounds 'respirator free ' end decided extend target previously focus adapting operations highest degree risk first rather easiest adapt new facilities 'respirator free ' start 'respirator free ' means employees need wear respiratory protective equipment routine production tasks instead sites install technology prevents release hazardous compounds work environment example facility cork ireland long established technical expertise containment ways working handling highly potent materials penicillin facility pakistan special containment system also developed proprietary manufacturing technology greatly reduces operator exposure medicines manufactured gsk site monitors air quality assess exposure hazardous compounds implements controls achieve 'respirator free ' goal occupational hygienists employee health staff engineers work together site regional global levels reduce employees ' exposure chemicals end monitoring showed per cent operations 'respirator free ' situations possible respirator free employees remain protected appropriate respiratory equipment process safety many products begin formulation processing hazardous materials flammable solvents combustible powders scientists look opportunities eliminate use hazardous materials green chemistry green technology programmes substitution elimination option aim ensure safety built manufacturing research development processes employees receive training understand risks implement appropriate controls engineers use online system assess safety process plant designs develop plant maintenance strategies share hazard information control strategies across gsk updated process safety management system continued integrate ehss management systems gsk sites system updated response explosion irvine factory injured two employees includes new global engineering standards process safety assessments engineering standards gap analyses upgraded standardised process hazard identification risk assessment techniques represent current good practice process safety performance indicators applied highest risk areas business steps embed process safety overall safety culture new training competence programmes sites implement process safety management system analysing gaps six elements practices correcting deficiencies implementation overseen director process safety position established around process safety incidents none resulted injuries environmental damage safety engineering safety engineering programme focuses improving construction plant safety ensuring effective emergency response systems developed online safety engineering guides managing risk fire explosion provide guidance machine guarding electrical hazards provide standardised approach managing safety risks across gsk work closely property insurance company ensure sites designed constructed maintained eliminate minimise incidents would result property loss business interruption safety also built maintained sites risk assessment control processes construction contractor safety programme capital project ehs review process emergency response programmes 'living safety ' living safety programme designed embed strong safety culture throughout gsk currently deployed manufacturing research organisations teaches employees behaviours expect demonstrate everyday work keep colleagues safe example everyone including contractors responsible implementing health safety management system everyone must follow rules report potential risks encounter get involved improving safety performance supervisors play vital role ensuring gsks health safety standards understood implemented maintained team including contractors supervisors must ensure compliance policies encourage team get involved improving safety performance promote risk awareness managers attitudes health safety important employees set good example managers must establish high health safety standards communicate openly employees issues quickly address risks identify involve others efforts improve safety performance ergonomics human factors musculoskeletal illnesses repetitive strain injuries leading causes time away work target reduce number illnesses injuries five per cent year ranked within top quartile industry ratings good workplace job design known ergonomics human factors helps employees jobs effectively reducing risk musculoskeletal illnesses injuries ergonomics human factors applied properly reduce illnesses injuries well work performance errors lost time teams working across gsk assess manage ergonomic risks existing operations planned projects teams include members manufacturing quality safety health medical services teams work together identify risks develop solutions share best practice globally dedicated ergonomics intranet community addition nearly trained facilitators help manage computerbased ergonomic risk assessments almost employees assessments give employees opportunity talk discomfort experience using computers discuss ways reduce discomfort injury risk information ergonomics computer best practice also available employees ergonomics community intranet pages focused improving risk assessments reducing ergonomicsrelated injury illness establishing new system quickly identify risks employees use computers frequently report discomfort creating training new ergonomics improvement teams brazil china india us continuing put measures place manufacturing operations example limit injuries manual lifting achieved per cent improvement ergonomicsrelated injury illness rate double per cent improvement target time period driver safety sales representatives spend significant amounts time driving risk involved road traffic incidents driving accidents common cause fatalities caused death one gsk employee per cent injuries lost time due motor vehicle accidents per cent injuries without lost time see fatalities serious injuries aim reduce risk road traffic accidents global driver safety programme includes instructions guidelines driver training vehicle selection risk assessment accident reporting motorbike rider safety manual employees countries provide motorbikes scooters back tophome responsibility people health safety safety programmes corporate responsibility report safety programmes operate number programmes keep employees contractors safe chemical exposure rigorous procedures controls protect employees exposure chemicals goal make per cent existing operations involving handling hazardous compounds 'respirator free ' end decided extend target previously focus adapting operations highest degree risk first rather easiest adapt new facilities 'respirator free ' start 'respirator free ' means employees need wear respiratory protective equipment routine production tasks instead sites install technology prevents release hazardous compounds work environment example facility cork ireland long established technical expertise containment ways working handling highly potent materials penicillin facility pakistan special containment system also developed proprietary manufacturing technology greatly reduces operator exposure medicines manufactured gsk site monitors air quality assess exposure hazardous compounds implements controls achieve 'respirator free ' goal occupational hygienists employee health staff engineers work together site regional global levels reduce employees ' exposure chemicals end monitoring showed per cent operations 'respirator free ' situations possible respirator free employees remain protected appropriate respiratory equipment process safety many products begin formulation processing hazardous materials flammable solvents combustible powders scientists look opportunities eliminate use hazardous materials green chemistry green technology programmes substitution elimination option aim ensure safety built manufacturing research development processes employees receive training understand risks implement appropriate controls engineers use online system assess safety process plant designs develop plant maintenance strategies share hazard information control strategies across gsk updated process safety management system continued integrate ehss management systems gsk sites system updated response explosion irvine factory injured two employees includes new global engineering standards process safety assessments engineering standards gap analyses upgraded standardised process hazard identification risk assessment techniques represent current good practice process safety performance indicators applied highest risk areas business steps embed process safety overall safety culture new training competence programmes sites implement process safety management system analysing gaps six elements practices correcting deficiencies implementation overseen director process safety position established around process safety incidents none resulted injuries environmental damage safety engineering safety engineering programme focuses improving construction plant safety ensuring effective emergency response systems developed online safety engineering guides managing risk fire explosion provide guidance machine guarding electrical hazards provide standardised approach managing safety risks across gsk work closely property insurance company ensure sites designed constructed maintained eliminate minimise incidents would result property loss business interruption safety also built maintained sites risk assessment control processes construction contractor safety programme capital project ehs review process emergency response programmes 'living safety ' living safety programme designed embed strong safety culture throughout gsk currently deployed manufacturing research organisations teaches employees behaviours expect demonstrate everyday work keep colleagues safe example everyone including contractors responsible implementing health safety management system everyone must follow rules report potential risks encounter get involved improving safety performance supervisors play vital role ensuring gsks health safety standards understood implemented maintained team including contractors supervisors must ensure compliance policies encourage team get involved improving safety performance promote risk awareness managers attitudes health safety important employees set good example managers must establish high health safety standards communicate openly employees issues quickly address risks identify involve others efforts improve safety performance ergonomics human factors musculoskeletal illnesses repetitive strain injuries leading causes time away work target reduce number illnesses injuries five per cent year ranked within top quartile industry ratings good workplace job design known ergonomics human factors helps employees jobs effectively reducing risk musculoskeletal illnesses injuries ergonomics human factors applied properly reduce illnesses injuries well work performance errors lost time teams working across gsk assess manage ergonomic risks existing operations planned projects teams include members manufacturing quality safety health medical services teams work together identify risks develop solutions share best practice globally dedicated ergonomics intranet community addition nearly trained facilitators help manage computerbased ergonomic risk assessments almost employees assessments give employees opportunity talk discomfort experience using computers discuss ways reduce discomfort injury risk information ergonomics computer best practice also available employees ergonomics community intranet pages focused improving risk assessments reducing ergonomicsrelated injury illness establishing new system quickly identify risks employees use computers frequently report discomfort creating training new ergonomics improvement teams brazil china india us continuing put measures place manufacturing operations example limit injuries manual lifting achieved per cent improvement ergonomicsrelated injury illness rate double per cent improvement target time period driver safety sales representatives spend significant amounts time driving risk involved road traffic incidents driving accidents common cause fatalities caused death one gsk employee per cent injuries lost time due motor vehicle accidents per cent injuries without lost time see fatalities serious injuries aim reduce risk road traffic accidents global driver safety programme includes instructions guidelines driver training vehicle selection risk assessment accident reporting motorbike rider safety manual employees countries provide motorbikes scooters back top home responsibility people health safety safety programmes corporate responsibility report safety programmes operate number programmes keep employees contractors safe chemical exposure rigorous procedures controls protect employees exposure chemicals goal make per cent existing operations involving handling hazardous compounds 'respirator free ' end decided extend target previously focus adapting operations highest degree risk first rather easiest adapt new facilities 'respirator free ' start 'respirator free ' means employees need wear respiratory protective equipment routine production tasks instead sites install technology prevents release hazardous compounds work environment example facility cork ireland long established technical expertise containment ways working handling highly potent materials penicillin facility pakistan special containment system also developed proprietary manufacturing technology greatly reduces operator exposure medicines manufactured gsk site monitors air quality assess exposure hazardous compounds implements controls achieve 'respirator free ' goal occupational hygienists employee health staff engineers work together site regional global levels reduce employees ' exposure chemicals end monitoring showed per cent operations 'respirator free ' situations possible respirator free employees remain protected appropriate respiratory equipment process safety many products begin formulation processing hazardous materials flammable solvents combustible powders scientists look opportunities eliminate use hazardous materials green chemistry green technology programmes substitution elimination option aim ensure safety built manufacturing research development processes employees receive training understand risks implement appropriate controls engineers use online system assess safety process plant designs develop plant maintenance strategies share hazard information control strategies across gsk updated process safety management system continued integrate ehss management systems gsk sites system updated response explosion irvine factory injured two employees includes new global engineering standards process safety assessments engineering standards gap analyses upgraded standardised process hazard identification risk assessment techniques represent current good practice process safety performance indicators applied highest risk areas business steps embed process safety overall safety culture new training competence programmes sites implement process safety management system analysing gaps six elements practices correcting deficiencies implementation overseen director process safety position established around process safety incidents none resulted injuries environmental damage safety engineering safety engineering programme focuses improving construction plant safety ensuring effective emergency response systems developed online safety engineering guides managing risk fire explosion provide guidance machine guarding electrical hazards provide standardised approach managing safety risks across gsk work closely property insurance company ensure sites designed constructed maintained eliminate minimise incidents would result property loss business interruption safety also built maintained sites risk assessment control processes construction contractor safety programme capital project ehs review process emergency response programmes 'living safety ' living safety programme designed embed strong safety culture throughout gsk currently deployed manufacturing research organisations teaches employees behaviours expect demonstrate everyday work keep colleagues safe example everyone including contractors responsible implementing health safety management system everyone must follow rules report potential risks encounter get involved improving safety performance supervisors play vital role ensuring gsks health safety standards understood implemented maintained team including contractors supervisors must ensure compliance policies encourage team get involved improving safety performance promote risk awareness managers attitudes health safety important employees set good example managers must establish high health safety standards communicate openly employees issues quickly address risks identify involve others efforts improve safety performance ergonomics human factors musculoskeletal illnesses repetitive strain injuries leading causes time away work target reduce number illnesses injuries five per cent year ranked within top quartile industry ratings good workplace job design known ergonomics human factors helps employees jobs effectively reducing risk musculoskeletal illnesses injuries ergonomics human factors applied properly reduce illnesses injuries well work performance errors lost time teams working across gsk assess manage ergonomic risks existing operations planned projects teams include members manufacturing quality safety health medical services teams work together identify risks develop solutions share best practice globally dedicated ergonomics intranet community addition nearly trained facilitators help manage computerbased ergonomic risk assessments almost employees assessments give employees opportunity talk discomfort experience using computers discuss ways reduce discomfort injury risk information ergonomics computer best practice also available employees ergonomics community intranet pages focused improving risk assessments reducing ergonomicsrelated injury illness establishing new system quickly identify risks employees use computers frequently report discomfort creating training new ergonomics improvement teams brazil china india us continuing put measures place manufacturing operations example limit injuries manual lifting achieved per cent improvement ergonomicsrelated injury illness rate double per cent improvement target time period driver safety sales representatives spend significant amounts time driving risk involved road traffic incidents driving accidents common cause fatalities caused death one gsk employee per cent injuries lost time due motor vehicle accidents per cent injuries without lost time see fatalities serious injuries aim reduce risk road traffic accidents global driver safety programme includes instructions guidelines driver training vehicle selection risk assessment accident reporting motorbike rider safety manual employees countries provide motorbikes scooters back top home responsibility people health safety health wellbeing programmes corporate responsibility report health wellbeing programmes gsk offers programmes boost employee health wellbeing helps sustain employee energy engagement work contribute improved productivity performance support employee wellbeing gsk includes flexible working options initiatives health risk appraisals screening diabetes hypertension smoking control support fitness nutritional advice immunisations focus leading causes employee illness disability depression nonworkrelated injuries heart disease stroke respiratory infections increasingly focusing ways encourage team personal energy resilience times high pressure energy resilience resilience described ability successful highpressure fastpaced continuously changing work environment resilience helps prevent mental illness due stress leading cause ill health disability work also supports good performance energy performance employees energy focus better work efficiently energy performance ep programme teaches participants manage physical mental energy effectively helps develop habits improve performance work employees participated ep workshops total employees countries attended ep workshops per cent reported significant improvement physical mental performance emotional energy participants found improved energy levels persisted least months workshop personal resilience run workshops employees want enhance build personal resilience focusing improving work home life programme aims help employees increase focus energy confidence also helping reduce tension anxiety fatigue since programme started employees participated programme team resilience healthy collaborative motivated teams critical business success team resilience programme helps employees managers identify sources pressure teams process complexity lack workplace flexibility accountability take action address concerns programme helps teams take control work eliminate manage sources pressure lead ill health inefficiency since programme began completed teams countries comprising employees participants identified positive outcomes including successful team work efficient machine operation better sales per cent drop worklife conflict per cent increase satisfaction gsk employer also recorded wellbeing worklife balance gsk offers programmes improve health employees families find increases employee commitment productivity reduces absenteeism cost ill health support varies countries according local needs sites use public health gsk data identify high risk areas investments lead significant health cost improvements programmes often include benefits onsite health fitness centres flexible working arrangements immunisations regular medical checkups assistance stop smoking disease screening management family support services health education also assist employees suffering chronic diseases ensure access correct longterm treatment support programmes help local healthcare services focusing health education prevention awareness management current conditions created network gsk employee health professionals share health wellbeing best practice gsk also supports key public health efforts world aids day world health organization 's health day tobacco free day global handwashing day back tophome responsibility people health safety health wellbeing programmes corporate responsibility report health wellbeing programmes gsk offers programmes boost employee health wellbeing helps sustain employee energy engagement work contribute improved productivity performance support employee wellbeing gsk includes flexible working options initiatives health risk appraisals screening diabetes hypertension smoking control support fitness nutritional advice immunisations focus leading causes employee illness disability depression nonworkrelated injuries heart disease stroke respiratory infections increasingly focusing ways encourage team personal energy resilience times high pressure energy resilience resilience described ability successful highpressure fastpaced continuously changing work environment resilience helps prevent mental illness due stress leading cause ill health disability work also supports good performance energy performance employees energy focus better work efficiently energy performance ep programme teaches participants manage physical mental energy effectively helps develop habits improve performance work employees participated ep workshops total employees countries attended ep workshops per cent reported significant improvement physical mental performance emotional energy participants found improved energy levels persisted least months workshop personal resilience run workshops employees want enhance build personal resilience focusing improving work home life programme aims help employees increase focus energy confidence also helping reduce tension anxiety fatigue since programme started employees participated programme team resilience healthy collaborative motivated teams critical business success team resilience programme helps employees managers identify sources pressure teams process complexity lack workplace flexibility accountability take action address concerns programme helps teams take control work eliminate manage sources pressure lead ill health inefficiency since programme began completed teams countries comprising employees participants identified positive outcomes including successful team work efficient machine operation better sales per cent drop worklife conflict per cent increase satisfaction gsk employer also recorded wellbeing worklife balance gsk offers programmes improve health employees families find increases employee commitment productivity reduces absenteeism cost ill health support varies countries according local needs sites use public health gsk data identify high risk areas investments lead significant health cost improvements programmes often include benefits onsite health fitness centres flexible working arrangements immunisations regular medical checkups assistance stop smoking disease screening management family support services health education also assist employees suffering chronic diseases ensure access correct longterm treatment support programmes help local healthcare services focusing health education prevention awareness management current conditions created network gsk employee health professionals share health wellbeing best practice gsk also supports key public health efforts world aids day world health organization 's health day tobacco free day global handwashing day back top home responsibility people health safety health wellbeing programmes corporate responsibility report health wellbeing programmes gsk offers programmes boost employee health wellbeing helps sustain employee energy engagement work contribute improved productivity performance support employee wellbeing gsk includes flexible working options initiatives health risk appraisals screening diabetes hypertension smoking control support fitness nutritional advice immunisations focus leading causes employee illness disability depression nonworkrelated injuries heart disease stroke respiratory infections increasingly focusing ways encourage team personal energy resilience times high pressure energy resilience resilience described ability successful highpressure fastpaced continuously changing work environment resilience helps prevent mental illness due stress leading cause ill health disability work also supports good performance energy performance employees energy focus better work efficiently energy performance ep programme teaches participants manage physical mental energy effectively helps develop habits improve performance work employees participated ep workshops total employees countries attended ep workshops per cent reported significant improvement physical mental performance emotional energy participants found improved energy levels persisted least months workshop personal resilience run workshops employees want enhance build personal resilience focusing improving work home life programme aims help employees increase focus energy confidence also helping reduce tension anxiety fatigue since programme started employees participated programme team resilience healthy collaborative motivated teams critical business success team resilience programme helps employees managers identify sources pressure teams process complexity lack workplace flexibility accountability take action address concerns programme helps teams take control work eliminate manage sources pressure lead ill health inefficiency since programme began completed teams countries comprising employees participants identified positive outcomes including successful team work efficient machine operation better sales per cent drop worklife conflict per cent increase satisfaction gsk employer also recorded wellbeing worklife balance gsk offers programmes improve health employees families find increases employee commitment productivity reduces absenteeism cost ill health support varies countries according local needs sites use public health gsk data identify high risk areas investments lead significant health cost improvements programmes often include benefits onsite health fitness centres flexible working arrangements immunisations regular medical checkups assistance stop smoking disease screening management family support services health education also assist employees suffering chronic diseases ensure access correct longterm treatment support programmes help local healthcare services focusing health education prevention awareness management current conditions created network gsk employee health professionals share health wellbeing best practice gsk also supports key public health efforts world aids day world health organization 's health day tobacco free day global handwashing day back top home responsibility people health safety health business continuity corporate responsibility report health business continuity contingency plans place protect employees business event natural disasters manmade emergencies pandemic rapid global spread hn influenza demonstrated critical measures ensuring business continue function continue supply critical medicines patients pandemic preparations helping us protect staff dependants key complementary workers countries stockpile multiple antiviral medicines used prevent treat pandemic flu including relenza pandemic vaccine meant could quickly treat employees suffering flu developed special website accessible intranet externally acts single source global local flu information across gsk hn outbreak already offered employees annual seasonal flu vaccination per cent markets well travel health programmes help keep employees healthy well visiting countries work read response hn flu pandemic back top home responsibility people health safety health business continuity corporate responsibility report health business continuity contingency plans place protect employees business event natural disasters manmade emergencies pandemic rapid global spread hn influenza demonstrated critical measures ensuring business continue function continue supply critical medicines patients pandemic preparations helping us protect staff dependants key complementary workers countries stockpile multiple antiviral medicines used prevent treat pandemic flu including relenza pandemic vaccine meant could quickly treat employees suffering flu developed special website accessible intranet externally acts single source global local flu information across gsk hn outbreak already offered employees annual seasonal flu vaccination per cent markets well travel health programmes help keep employees healthy well visiting countries work read response hn flu pandemic back top home responsibility people health safety training awareness corporate responsibility report training awareness training helps create workplace culture occupational health safety taken seriously employees responsible managing occupational health safety issues sites business units receive regular training turn instruct employees safe working give training environment health safety sustainability ehss standards well programmes process safety chemical exposure protection identifying risk auditing ergonomics sites develop conduct training based local needs capabilities use internal learning tools commercially available training programmes locally available government university sponsored training programmes developed training framework identifies gaps employees knowledge health safety provides inhouse external training courses health safety professionals share knowledge best practice via teleconferences intranet communities training programmes discussion forums raise awareness employee health safety issues announcements myehs community intranet sites ceo 's sustainability awards programme health safety week celebrations held site level inspire employees address potential risks work home november launched new section company intranet provides employees access ehss training packages across business joining ehs training connect employees become involved network gsk 's health safety professionals learn one another health safety best practice ran ten courses train facilitators living safety programme two process safety courses several sites completed machinery safety training employees completed training module control hazardous substances back top home responsibility people health safety training awareness corporate responsibility report training awareness training helps create workplace culture occupational health safety taken seriously employees responsible managing occupational health safety issues sites business units receive regular training turn instruct employees safe working give training environment health safety sustainability ehss standards well programmes process safety chemical exposure protection identifying risk auditing ergonomics sites develop conduct training based local needs capabilities use internal learning tools commercially available training programmes locally available government university sponsored training programmes developed training framework identifies gaps employees knowledge health safety provides inhouse external training courses health safety professionals share knowledge best practice via teleconferences intranet communities training programmes discussion forums raise awareness employee health safety issues announcements myehs community intranet sites ceo 's sustainability awards programme health safety week celebrations held site level inspire employees address potential risks work home november launched new section company intranet provides employees access ehss training packages across business joining ehs training connect employees become involved network gsk 's health safety professionals learn one another health safety best practice ran ten courses train facilitators living safety programme two process safety courses several sites completed machinery safety training employees completed training module control hazardous substances back top home responsibility people health safety performance corporate responsibility report performance performance data table safetyrelated fines penalties injury illness rates main health safety measure reportable injury illness rate also measure number injuries illnesses result lost days well number days lost injuries illnesses provides indication severity incidents although rough guide set targets improve injury illness rates injury illness target injury illness target progress reduce reportable injury illness per cent rate five per cent year end average per year reduce reportable musculoskeletal per cent illness injury rate five per cent average per year year end rank first quartile industry fourth quartile benchmark group data cover gsk employees contract workers directly supervise report separately data contractors work gsk sites supervise staff data table contractors ' data externally verified injury illness data collected pharmaceuticals consumer healthcare manufacturing sites vaccines sites pharmaceutical consumer healthcare research development sites us uk headquarters sites offices sales groups one million hours worked smaller offices distribution centres six sales office sites report injury illness data collect environmental data acquired entities first full year group year acquisition reportable injury illness rate reportable injury illness rate continues improve average five per cent annually across gsk injuries illnesses resulting total reportable injury illness rate per hours worked improvement per cent exceeding target machinery safety projects many manufacturing sites projects encouraging employee safety awareness examples initiatives contributing improvement reportable ergonomicsrelated injury illness rate improved per cent since reportable injury illness rate continues improve industry benchmark group also continues improve means gsk remains lowest quartile industry benchmark continue implement safety programmes like zero access living safety programmes improve position within benchmark sgs verified injury illness causes frequent types incident overall ergonomic mainly musculoskeletal illnesses repetitive strain injuries accounting per cent injuries illnesses continue expand ergonomics programmes address cause injury illness second frequent reportable injuries slips trips falls account per cent injuries illnesses injuries due machinery accounted five per cent injuries illnesses manufacturing sites renewing focus machine safety continue improvements area launched 'zero access ' machinery safety programme implemented secondary consumer healthcare manufacturing sites road traffic accidents accounted per cent injuries illnesses accounted one fatality driver safety continuing area focus especially sales force mental ill health accounts five per cent illnesses cases result highest number days lost days per case average per cent total number days lost illnesses addressed resilience programme sgs verified fatalities serious injuries employee fatalities eight year trend employee fatalities one sales employees egypt killed driving business meeting employee hit traffic light trying avoid pedestrian stepped traffic addition one employee death housekeeping contractor slipped fell china commercial sales administrative offices subsequently died due injuries sustained fall three amputations gsk employees one involving contractor three employee amputations machinery incidents operators placed hands equipment switched summary incidents follows amputation right thumb clearing jam bottle packaging line operator removed fixed guard placed fingers rotary valve resulting amputation middle index finger right hand amputation two fingers clearing jam palletiser amputation finger contract worker caught object truck machine guarding zero access programme continue emphasised sgs verified injury illness milestones gsk operations strive work without experiencing losttime injuries illnesses issue certificates signed business heads sites reach one million hours worked without losttime injury illness sites reach two million hours worked without losttime injury illness awarded certificates signed chief executive officer small sites fewer employees obtain certificate three years worked without losttime injury illness milestones achieved hours worked without losttime injury illness million hours sites million hours site million hours sites years site years site back tophome responsibility people health safety performance corporate responsibility report performance performance data table safetyrelated fines penalties injury illness rates main health safety measure reportable injury illness rate also measure number injuries illnesses result lost days well number days lost injuries illnesses provides indication severity incidents although rough guide set targets improve injury illness rates injury illness target injury illness target progress reduce reportable injury illness per cent rate five per cent year end average per year reduce reportable musculoskeletal per cent illness injury rate five per cent average per year year end rank first quartile industry fourth quartile benchmark group data cover gsk employees contract workers directly supervise report separately data contractors work gsk sites supervise staff data table contractors ' data externally verified injury illness data collected pharmaceuticals consumer healthcare manufacturing sites vaccines sites pharmaceutical consumer healthcare research development sites us uk headquarters sites offices sales groups one million hours worked smaller offices distribution centres six sales office sites report injury illness data collect environmental data acquired entities first full year group year acquisition reportable injury illness rate reportable injury illness rate continues improve average five per cent annually across gsk injuries illnesses resulting total reportable injury illness rate per hours worked improvement per cent exceeding target machinery safety projects many manufacturing sites projects encouraging employee safety awareness examples initiatives contributing improvement reportable ergonomicsrelated injury illness rate improved per cent since reportable injury illness rate continues improve industry benchmark group also continues improve means gsk remains lowest quartile industry benchmark continue implement safety programmes like zero access living safety programmes improve position within benchmark sgs verified injury illness causes frequent types incident overall ergonomic mainly musculoskeletal illnesses repetitive strain injuries accounting per cent injuries illnesses continue expand ergonomics programmes address cause injury illness second frequent reportable injuries slips trips falls account per cent injuries illnesses injuries due machinery accounted five per cent injuries illnesses manufacturing sites renewing focus machine safety continue improvements area launched 'zero access ' machinery safety programme implemented secondary consumer healthcare manufacturing sites road traffic accidents accounted per cent injuries illnesses accounted one fatality driver safety continuing area focus especially sales force mental ill health accounts five per cent illnesses cases result highest number days lost days per case average per cent total number days lost illnesses addressed resilience programme sgs verified fatalities serious injuries employee fatalities eight year trend employee fatalities one sales employees egypt killed driving business meeting employee hit traffic light trying avoid pedestrian stepped traffic addition one employee death housekeeping contractor slipped fell china commercial sales administrative offices subsequently died due injuries sustained fall three amputations gsk employees one involving contractor three employee amputations machinery incidents operators placed hands equipment switched summary incidents follows amputation right thumb clearing jam bottle packaging line operator removed fixed guard placed fingers rotary valve resulting amputation middle index finger right hand amputation two fingers clearing jam palletiser amputation finger contract worker caught object truck machine guarding zero access programme continue emphasised sgs verified injury illness milestones gsk operations strive work without experiencing losttime injuries illnesses issue certificates signed business heads sites reach one million hours worked without losttime injury illness sites reach two million hours worked without losttime injury illness awarded certificates signed chief executive officer small sites fewer employees obtain certificate three years worked without losttime injury illness milestones achieved hours worked without losttime injury illness million hours sites million hours site million hours sites years site years site back tophome responsibility people health safety performance corporate responsibility report performance performance data table safetyrelated fines penalties injury illness rates main health safety measure reportable injury illness rate also measure number injuries illnesses result lost days well number days lost injuries illnesses provides indication severity incidents although rough guide set targets improve injury illness rates injury illness target injury illness target progress reduce reportable injury illness per cent rate five per cent year end average per year reduce reportable musculoskeletal per cent illness injury rate five per cent average per year year end rank first quartile industry fourth quartile benchmark group data cover gsk employees contract workers directly supervise report separately data contractors work gsk sites supervise staff data table contractors ' data externally verified injury illness data collected pharmaceuticals consumer healthcare manufacturing sites vaccines sites pharmaceutical consumer healthcare research development sites us uk headquarters sites offices sales groups one million hours worked smaller offices distribution centres six sales office sites report injury illness data collect environmental data acquired entities first full year group year acquisition reportable injury illness rate reportable injury illness rate continues improve average five per cent annually across gsk injuries illnesses resulting total reportable injury illness rate per hours worked improvement per cent exceeding target machinery safety projects many manufacturing sites projects encouraging employee safety awareness examples initiatives contributing improvement reportable ergonomicsrelated injury illness rate improved per cent since reportable injury illness rate continues improve industry benchmark group also continues improve means gsk remains lowest quartile industry benchmark continue implement safety programmes like zero access living safety programmes improve position within benchmark sgs verified injury illness causes frequent types incident overall ergonomic mainly musculoskeletal illnesses repetitive strain injuries accounting per cent injuries illnesses continue expand ergonomics programmes address cause injury illness second frequent reportable injuries slips trips falls account per cent injuries illnesses injuries due machinery accounted five per cent injuries illnesses manufacturing sites renewing focus machine safety continue improvements area launched 'zero access ' machinery safety programme implemented secondary consumer healthcare manufacturing sites road traffic accidents accounted per cent injuries illnesses accounted one fatality driver safety continuing area focus especially sales force mental ill health accounts five per cent illnesses cases result highest number days lost days per case average per cent total number days lost illnesses addressed resilience programme sgs verified fatalities serious injuries employee fatalities eight year trend employee fatalities one sales employees egypt killed driving business meeting employee hit traffic light trying avoid pedestrian stepped traffic addition one employee death housekeeping contractor slipped fell china commercial sales administrative offices subsequently died due injuries sustained fall three amputations gsk employees one involving contractor three employee amputations machinery incidents operators placed hands equipment switched summary incidents follows amputation right thumb clearing jam bottle packaging line operator removed fixed guard placed fingers rotary valve resulting amputation middle index finger right hand amputation two fingers clearing jam palletiser amputation finger contract worker caught object truck machine guarding zero access programme continue emphasised sgs verified injury illness milestones gsk operations strive work without experiencing losttime injuries illnesses issue certificates signed business heads sites reach one million hours worked without losttime injury illness sites reach two million hours worked without losttime injury illness awarded certificates signed chief executive officer small sites fewer employees obtain certificate three years worked without losttime injury illness milestones achieved hours worked without losttime injury illness million hours sites million hours site million hours sites years site years site back tophome responsibility people health safety performance corporate responsibility report performance performance data table safetyrelated fines penalties injury illness rates main health safety measure reportable injury illness rate also measure number injuries illnesses result lost days well number days lost injuries illnesses provides indication severity incidents although rough guide set targets improve injury illness rates injury illness target injury illness target progress reduce reportable injury illness per cent rate five per cent year end average per year reduce reportable musculoskeletal per cent illness injury rate five per cent average per year year end rank first quartile industry fourth quartile benchmark group data cover gsk employees contract workers directly supervise report separately data contractors work gsk sites supervise staff data table contractors ' data externally verified injury illness data collected pharmaceuticals consumer healthcare manufacturing sites vaccines sites pharmaceutical consumer healthcare research development sites us uk headquarters sites offices sales groups one million hours worked smaller offices distribution centres six sales office sites report injury illness data collect environmental data acquired entities first full year group year acquisition reportable injury illness rate reportable injury illness rate continues improve average five per cent annually across gsk injuries illnesses resulting total reportable injury illness rate per hours worked improvement per cent exceeding target machinery safety projects many manufacturing sites projects encouraging employee safety awareness examples initiatives contributing improvement reportable ergonomicsrelated injury illness rate improved per cent since reportable injury illness rate continues improve industry benchmark group also continues improve means gsk remains lowest quartile industry benchmark continue implement safety programmes like zero access living safety programmes improve position within benchmark sgs verified injury illness causes frequent types incident overall ergonomic mainly musculoskeletal illnesses repetitive strain injuries accounting per cent injuries illnesses continue expand ergonomics programmes address cause injury illness second frequent reportable injuries slips trips falls account per cent injuries illnesses injuries due machinery accounted five per cent injuries illnesses manufacturing sites renewing focus machine safety continue improvements area launched 'zero access ' machinery safety programme implemented secondary consumer healthcare manufacturing sites road traffic accidents accounted per cent injuries illnesses accounted one fatality driver safety continuing area focus especially sales force mental ill health accounts five per cent illnesses cases result highest number days lost days per case average per cent total number days lost illnesses addressed resilience programme sgs verified fatalities serious injuries employee fatalities eight year trend employee fatalities one sales employees egypt killed driving business meeting employee hit traffic light trying avoid pedestrian stepped traffic addition one employee death housekeeping contractor slipped fell china commercial sales administrative offices subsequently died due injuries sustained fall three amputations gsk employees one involving contractor three employee amputations machinery incidents operators placed hands equipment switched summary incidents follows amputation right thumb clearing jam bottle packaging line operator removed fixed guard placed fingers rotary valve resulting amputation middle index finger right hand amputation two fingers clearing jam palletiser amputation finger contract worker caught object truck machine guarding zero access programme continue emphasised sgs verified injury illness milestones gsk operations strive work without experiencing losttime injuries illnesses issue certificates signed business heads sites reach one million hours worked without losttime injury illness sites reach two million hours worked without losttime injury illness awarded certificates signed chief executive officer small sites fewer employees obtain certificate three years worked without losttime injury illness milestones achieved hours worked without losttime injury illness million hours sites million hours site million hours sites years site years site back top home responsibility people health safety performance corporate responsibility report performance performance data table safetyrelated fines penalties injury illness rates main health safety measure reportable injury illness rate also measure number injuries illnesses result lost days well number days lost injuries illnesses provides indication severity incidents although rough guide set targets improve injury illness rates injury illness target injury illness target progress reduce reportable injury illness per cent rate five per cent year end average per year reduce reportable musculoskeletal per cent illness injury rate five per cent average per year year end rank first quartile industry fourth quartile benchmark group data cover gsk employees contract workers directly supervise report separately data contractors work gsk sites supervise staff data table contractors ' data externally verified injury illness data collected pharmaceuticals consumer healthcare manufacturing sites vaccines sites pharmaceutical consumer healthcare research development sites us uk headquarters sites offices sales groups one million hours worked smaller offices distribution centres six sales office sites report injury illness data collect environmental data acquired entities first full year group year acquisition reportable injury illness rate reportable injury illness rate continues improve average five per cent annually across gsk injuries illnesses resulting total reportable injury illness rate per hours worked improvement per cent exceeding target machinery safety projects many manufacturing sites projects encouraging employee safety awareness examples initiatives contributing improvement reportable ergonomicsrelated injury illness rate improved per cent since reportable injury illness rate continues improve industry benchmark group also continues improve means gsk remains lowest quartile industry benchmark continue implement safety programmes like zero access living safety programmes improve position within benchmark sgs verified injury illness causes frequent types incident overall ergonomic mainly musculoskeletal illnesses repetitive strain injuries accounting per cent injuries illnesses continue expand ergonomics programmes address cause injury illness second frequent reportable injuries slips trips falls account per cent injuries illnesses injuries due machinery accounted five per cent injuries illnesses manufacturing sites renewing focus machine safety continue improvements area launched 'zero access ' machinery safety programme implemented secondary consumer healthcare manufacturing sites road traffic accidents accounted per cent injuries illnesses accounted one fatality driver safety continuing area focus especially sales force mental ill health accounts five per cent illnesses cases result highest number days lost days per case average per cent total number days lost illnesses addressed resilience programme sgs verified fatalities serious injuries employee fatalities eight year trend employee fatalities one sales employees egypt killed driving business meeting employee hit traffic light trying avoid pedestrian stepped traffic addition one employee death housekeeping contractor slipped fell china commercial sales administrative offices subsequently died due injuries sustained fall three amputations gsk employees one involving contractor three employee amputations machinery incidents operators placed hands equipment switched summary incidents follows amputation right thumb clearing jam bottle packaging line operator removed fixed guard placed fingers rotary valve resulting amputation middle index finger right hand amputation two fingers clearing jam palletiser amputation finger contract worker caught object truck machine guarding zero access programme continue emphasised sgs verified injury illness milestones gsk operations strive work without experiencing losttime injuries illnesses issue certificates signed business heads sites reach one million hours worked without losttime injury illness sites reach two million hours worked without losttime injury illness awarded certificates signed chief executive officer small sites fewer employees obtain certificate three years worked without losttime injury illness milestones achieved hours worked without losttime injury illness million hours sites million hours site million hours sites years site years site back top home responsibility people health safety performance corporate responsibility report performance performance data table see detailed breakdown data employee injury illness injury illness gsk employees hours worked millions fatalities number injuries lost time calendar days lost injuries number illnesses lost time calendar days lost illnesses number injuries without lost time number illnesses without lost time lost time injury illness rate reportable injury illness rate ergonomic lost time injury illness rate ergonomic reportable injury illness rate calendar days lost rate injury illness non gsk employees verified sgs hours worked millions fatalities number injuries illnesses lost time calendar days lost number injuries illnesses without lost time lost time injury illness rate reportable injury illness rate calendar days lost rate occupational health safety data cover employees contract workers directly supervised gsk employees report snapshot injury illness performance year cases may added end year prior years may change losttime injuries illnesses workrelated injuries illnesses serious enough result one days away work rates per hours worked lost calendar days calendar days including weekends employees could work workrelated injuries illnesses helps provide measure severity injuries illnesses reportable injuries illnesses without lost time incidents result time away work lost time serious first aid serious enough result lost time sgs verified back tophome responsibility people health safety performance corporate responsibility report performance performance data table see detailed breakdown data employee injury illness injury illness gsk employees hours worked millions fatalities number injuries lost time calendar days lost injuries number illnesses lost time calendar days lost illnesses number injuries without lost time number illnesses without lost time lost time injury illness rate reportable injury illness rate ergonomic lost time injury illness rate ergonomic reportable injury illness rate calendar days lost rate injury illness non gsk employees verified sgs hours worked millions fatalities number injuries illnesses lost time calendar days lost number injuries illnesses without lost time lost time injury illness rate reportable injury illness rate calendar days lost rate occupational health safety data cover employees contract workers directly supervised gsk employees report snapshot injury illness performance year cases may added end year prior years may change losttime injuries illnesses workrelated injuries illnesses serious enough result one days away work rates per hours worked lost calendar days calendar days including weekends employees could work workrelated injuries illnesses helps provide measure severity injuries illnesses reportable injuries illnesses without lost time incidents result time away work lost time serious first aid serious enough result lost time sgs verified back top home responsibility people health safety performance corporate responsibility report performance performance data table see detailed breakdown data employee injury illness injury illness gsk employees hours worked millions fatalities number injuries lost time calendar days lost injuries number illnesses lost time calendar days lost illnesses number injuries without lost time number illnesses without lost time lost time injury illness rate reportable injury illness rate ergonomic lost time injury illness rate ergonomic reportable injury illness rate calendar days lost rate injury illness non gsk employees verified sgs hours worked millions fatalities number injuries illnesses lost time calendar days lost number injuries illnesses without lost time lost time injury illness rate reportable injury illness rate calendar days lost rate occupational health safety data cover employees contract workers directly supervised gsk employees report snapshot injury illness performance year cases may added end year prior years may change losttime injuries illnesses workrelated injuries illnesses serious enough result one days away work rates per hours worked lost calendar days calendar days including weekends employees could work workrelated injuries illnesses helps provide measure severity injuries illnesses reportable injuries illnesses without lost time incidents result time away work lost time serious first aid serious enough result lost time sgs verified back top home responsibility people case studies corporate responsibility report case studies external business partners share gsk values want business gsk must share culture inclusion diversity 's message give suppliers contractors third parties strive ensure inclusive diverse working environment throughout supply chain used inclusion diversity criteria selection vendors provide us global facility maintenance catering site security services assessed prospective suppliers diversity figures policies programmes efforts promote diversity supply chains result three suppliers awarded contracts list vendors bid contracts pulse change established new employee volunteering programme called pulse first year pulse provided opportunity employees around world take three six month break jobs gsk help others travelled across globe azerbaijan bolivia el salvador ethiopia tajikistan tanzania whereas others worked closer home pulse volunteer works full time host nongovernmental organisation ngo using personal knowledge skills abilities build positive sustainable change host safe knowledge support local management job filled absence continue receive usual pay experience also helps pulse volunteers accelerate leadership development bring lessons learned back roles gsk demand take part pulse high select volunteers excel work gsk possess skills could help ngos demonstrate flexibility desire learn awareness community needs gsk empowerme empowers san jose costa rica gsk blogger writes giving control responsibility china another offers perspective behind empowerment switzerland third shares lessons learned countries employees common using gsk empowerme intranet community share stories teams felt empowered make positive change example feeling inspired watched video empowerment costa rican employee immediately looked ways empower others agreed staff give control making decisions willing step plate make decisions time made commitment provide team mentoring coaching need make effective decisions result highly motivated team better decisionmaking skills trust many employee postings empowerme site one message clear everyone something important contribute gsk benefit greatly bringing best every employee back top home responsibility people case studies corporate responsibility report case studies external business partners share gsk values want business gsk must share culture inclusion diversity 's message give suppliers contractors third parties strive ensure inclusive diverse working environment throughout supply chain used inclusion diversity criteria selection vendors provide us global facility maintenance catering site security services assessed prospective suppliers diversity figures policies programmes efforts promote diversity supply chains result three suppliers awarded contracts list vendors bid contracts pulse change established new employee volunteering programme called pulse first year pulse provided opportunity employees around world take three six month break jobs gsk help others travelled across globe azerbaijan bolivia el salvador ethiopia tajikistan tanzania whereas others worked closer home pulse volunteer works full time host nongovernmental organisation ngo using personal knowledge skills abilities build positive sustainable change host safe knowledge support local management job filled absence continue receive usual pay experience also helps pulse volunteers accelerate leadership development bring lessons learned back roles gsk demand take part pulse high select volunteers excel work gsk possess skills could help ngos demonstrate flexibility desire learn awareness community needs gsk empowerme empowers san jose costa rica gsk blogger writes giving control responsibility china another offers perspective behind empowerment switzerland third shares lessons learned countries employees common using gsk empowerme intranet community share stories teams felt empowered make positive change example feeling inspired watched video empowerment costa rican employee immediately looked ways empower others agreed staff give control making decisions willing step plate make decisions time made commitment provide team mentoring coaching need make effective decisions result highly motivated team better decisionmaking skills trust many employee postings empowerme site one message clear everyone something important contribute gsk benefit greatly bringing best every employee back top home responsibility people qas corporate responsibility report qas respond questions raised stakeholders reduce workforce ensure remaining employees faced additional stress jobs recognise stress work important issue established programmes help individuals teams remain fully engaged physically mentally emotionally spiritually work home also variety programmes support team personal resilience help identify manage significant sources pressure work home variety interventions place employees use onsite health fitness centres flexible working arrangements employee assistance programmes backup child care family support services health education overlaying gsk aims simplify operating model create culture individual empowerment employee takes responsibility work empowering individuals make decisions carry work without layers bureaucracy support goal reducing unwanted stress jobs operational excellence programme affecting employees regrettably operational excellence oe programme involves job losses many jobs remain however oe also positive impacts increasing scope impact many cases autonomy within jobs empowers staff greater decisionmaking latitude everything support employees leaving company including providing competitive severance package outplacement support assistance identifying alternative employment career counselling retraining also work hard ensure programme negative impact morale staff produced guide managers information support employees uncertainty anxiety stress encountered major organisational change increase number women senior positions gsk pleased percentage women management increased incrementally last four years however recognise still room improvement especially senior management positions roles within historically maledominated disciplines science engineering percentage women management increasing committed internal succession planning ensures highpotential women identified every stage careers provided coaching mentoring clear career development opportunities health safety performance industry average needs improve know need improve performance area identified ergonomic improvements need address attitudes empowerment act health safety workplace key focus areas improving performance targeting intervention awareness training programmes areas also launched toolkit called 'living safety ' help sites get degree view risks attitudes beliefs behaviours designed embed strong safety culture throughout gsk teaching employees levels behaviours expect demonstrate everyday work keep colleagues safe adopted pharmaceutical consumer healthcare manufacturing operations used selectively groups progress made toward 'respirator free ' target use results baseline monitoring level exposure chemicals workplace tpoa gdee fin eof new upgraded engineering controls needed meet target employees per cent operations able work without needing wear respiratory protection initial target set achieve however due prioritisation safety health initiatives target postponed nevertheless made good progress committed completing programme furthermore advantages postponement allow us take advantages synergies programmes energy reduction adapting operations highest degree risk first half operations achieved level engineering control pending completion full verification monitoring continue upgrade engineering controls achieve 'respirator free ' levels control situations engineering controls possible make sure appropriate respiratory protective equipment used back tophome responsibility people qas corporate responsibility report qas respond questions raised stakeholders reduce workforce ensure remaining employees faced additional stress jobs recognise stress work important issue established programmes help individuals teams remain fully engaged physically mentally emotionally spiritually work home also variety programmes support team personal resilience help identify manage significant sources pressure work home variety interventions place employees use onsite health fitness centres flexible working arrangements employee assistance programmes backup child care family support services health education overlaying gsk aims simplify operating model create culture individual empowerment employee takes responsibility work empowering individuals make decisions carry work without layers bureaucracy support goal reducing unwanted stress jobs operational excellence programme affecting employees regrettably operational excellence oe programme involves job losses many jobs remain however oe also positive impacts increasing scope impact many cases autonomy within jobs empowers staff greater decisionmaking latitude everything support employees leaving company including providing competitive severance package outplacement support assistance identifying alternative employment career counselling retraining also work hard ensure programme negative impact morale staff produced guide managers information support employees uncertainty anxiety stress encountered major organisational change increase number women senior positions gsk pleased percentage women management increased incrementally last four years however recognise still room improvement especially senior management positions roles within historically maledominated disciplines science engineering percentage women management increasing committed internal succession planning ensures highpotential women identified every stage careers provided coaching mentoring clear career development opportunities health safety performance industry average needs improve know need improve performance area identified ergonomic improvements need address attitudes empowerment act health safety workplace key focus areas improving performance targeting intervention awareness training programmes areas also launched toolkit called 'living safety ' help sites get degree view risks attitudes beliefs behaviours designed embed strong safety culture throughout gsk teaching employees levels behaviours expect demonstrate everyday work keep colleagues safe adopted pharmaceutical consumer healthcare manufacturing operations used selectively groups progress made toward 'respirator free ' target use results baseline monitoring level exposure chemicals workplace define new upgraded engineering controls needed meet target employees per cent operations able work without needing wear respiratory protection initial target set achieve however due prioritisation safety health initiatives target postponed nevertheless made good progress committed completing programme furthermore advantages postponement allow us take advantages synergies programmes energy reduction adapting operations highest degree risk first half operations achieved level engineering control pending completion full verification monitoring continue upgrade engineering controls achieve 'respirator free ' levels control situations engineering controls possible make sure appropriate respiratory protective equipment used back top home responsibility people qas corporate responsibility report qas respond questions raised stakeholders reduce workforce ensure remaining employees faced additional stress jobs recognise stress work important issue established programmes help individuals teams remain fully engaged physically mentally emotionally spiritually work home also variety programmes support team personal resilience help identify manage significant sources pressure work home variety interventions place employees use onsite health fitness centres flexible working arrangements employee assistance programmes backup child care family support services health education overlaying gsk aims simplify operating model create culture individual empowerment employee takes responsibility work empowering individuals make decisions carry work without layers bureaucracy support goal reducing unwanted stress jobs operational excellence programme affecting employees regrettably operational excellence oe programme involves job losses many jobs remain however oe also positive impacts increasing scope impact many cases autonomy within jobs empowers staff greater decisionmaking latitude everything support employees leaving company including providing competitive severance package outplacement support assistance identifying alternative employment career counselling retraining also work hard ensure programme negative impact morale staff produced guide managers information support employees uncertainty anxiety stress encountered major organisational change increase number women senior positions gsk pleased percentage women management increased incrementally last four years however recognise still room improvement especially senior management positions roles within historically maledominated disciplines science engineering percentage women management increasing committed internal succession planning ensures highpotential women identified every stage careers provided coaching mentoring clear career development opportunities health safety performance industry average needs improve know need improve performance area identified ergonomic improvements need address attitudes empowerment act health safety workplace key focus areas improving performance targeting intervention awareness training programmes areas also launched toolkit called 'living safety ' help sites get degree view risks attitudes beliefs behaviours designed embed strong safety culture throughout gsk teaching employees levels behaviours expect demonstrate everyday work keep colleagues safe adopted pharmaceutical consumer healthcare manufacturing operations used selectively groups progress made toward 'respirator free ' target use results baseline monitoring level exposure chemicals workplace define new upgraded engineering controls needed meet target employees per cent operations able work without needing wear respiratory protection initial target set achieve however due prioritisation safety health initiatives target postponed nevertheless made good progress committed completing programme furthermore advantages postponement allow us take advantages synergies programmes energy reduction adapting operations highest degree risk first half operations achieved level engineering control pending completion full verification monitoring continue upgrade engineering controls achieve 'respirator free ' levels control situations engineering controls possible make sure appropriate respiratory protective equipment used back top home responsibility human rights corporate responsibility report human rights committed upholding un universal declaration human rights oecd guidelines multinational enterprises core labour standards set international labour organization signatory un global compact voluntary global standard human rights labour environment anticorruption believe governments responsibility define enforce legal framework human rights accordance international laws agreements businesses also responsibilities work hard uphold human rights within sphere influence includes employees suppliers communities society direct control human rights operations marketer medicines strive make widely available possible running business sustainable way approach includes research partnerships diseases developing world flexible pricing make products affordable developing countries put safeguards place ensure human rights people taking part clinical research protected includes informed consent process procedures protect patient privacy especially careful protect rights children involved clinical trials recognise support role convention biological diversity cbd plays providing framework conservation biological diversity protecting rights countries communities access share benefits arising read approach cbd use biological materials maintaining high standards human rights benefits business helping us get best employees supporting relationships communities near sites ensuring supplier contracts run smoothly provide reliable supply highquality products protecting reputation information gsk human rights human rights relevant many issues covered report section gives overview approach information see human rights clause included contracts suppliers read supply chain read efforts improve access medicines read investment local communities read employment practices read informed consent process approach clinical trials involving children read position statement convention biological diversity back tophome responsibility human rights corporate responsibility report human rights committed upholding un universal declaration human rights oecd guidelines multinational enterprises core labour standards set international labour organization signatory un global compact voluntary global standard human rights labour environment anticorruption believe governments responsibility define enforce legal framework human rights accordance international laws agreements businesses also responsibilities work hard uphold human rights within sphere influence includes employees suppliers communities society direct control human rights operations marketer medicines strive make widely available possible running business sustainable way approach includes research partnerships diseases developing world flexible pricing make products affordable developing countries put safeguards place ensure human rights people taking part clinical research protected includes informed consent process procedures protect patient privacy especially careful protect rights children involved clinical trials recognise support role convention biological diversity cbd plays providing framework conservation biological diversity protecting rights countries communities access share benefits arising read approach cbd use biological materials maintaining high standards human rights benefits business helping us get best employees supporting relationships communities near sites ensuring supplier contracts run smoothly provide reliable supply highquality products protecting reputation information gsk human rights human rights relevant many issues covered report section gives overview approach information see human rights clause included contracts suppliers read supply chain read efforts improve access medicines read investment local communities read employment practices read informed consent process approach clinical trials involving children read position statement convention biological diversity back top home responsibility human rights corporate responsibility report human rights committed upholding un universal declaration human rights oecd guidelines multinational enterprises core labour standards set international labour organization signatory un global compact voluntary global standard human rights labour environment anticorruption believe governments responsibility define enforce legal framework human rights accordance international laws agreements businesses also responsibilities work hard uphold human rights within sphere influence includes employees suppliers communities society direct control human rights operations marketer medicines strive make widely available possible running business sustainable way approach includes research partnerships diseases developing world flexible pricing make products affordable developing countries put safeguards place ensure human rights people taking part clinical research protected includes informed consent process procedures protect patient privacy especially careful protect rights children involved clinical trials recognise support role convention biological diversity cbd plays providing framework conservation biological diversity protecting rights countries communities access share benefits arising read approach cbd use biological materials maintaining high standards human rights benefits business helping us get best employees supporting relationships communities near sites ensuring supplier contracts run smoothly provide reliable supply highquality products protecting reputation information gsk human rights human rights relevant many issues covered report section gives overview approach information see human rights clause included contracts suppliers read supply chain read efforts improve access medicines read investment local communities read employment practices read informed consent process approach clinical trials involving children read position statement convention biological diversity back top home responsibility human rights employees corporate responsibility report employees employment standards issues diversity equal opportunities health safety protect employees ' human rights employer committed providing fair salary good employment conditions committed providing healthy safe secure workplace employees contractors opposed discrimination work committed promoting respect diversity committed promoting personal development dignity every employee respectful employees right join independent trade union freedom association opposed forms slavery exploitative child labour work appropriate partners address problem responsibly wherever encounter introduced new global policy equal inclusive treatment employees designed ensure consistently high standards across gsk audit adherence policy alongside human resources policies part regular employment practices review employees report concerns supervisor line manager human resources department ethics compliance office also use global confidential reporting line calls alleging human rights violations made line read employment practices back top home responsibility human rights employees corporate responsibility report employees employment standards issues diversity equal opportunities health safety protect employees ' human rights employer committed providing fair salary good employment conditions committed providing healthy safe secure workplace employees contractors opposed discrimination work committed promoting respect diversity committed promoting personal development dignity every employee respectful employees right join independent trade union freedom association opposed forms slavery exploitative child labour work appropriate partners address problem responsibly wherever encounter introduced new global policy equal inclusive treatment employees designed ensure consistently high standards across gsk audit adherence policy alongside human resources policies part regular employment practices review employees report concerns supervisor line manager human resources department ethics compliance office also use global confidential reporting line calls alleging human rights violations made line read employment practices back top home responsibility human rights suppliers corporate responsibility report suppliers buyer raw materials manufactured goods services around world require suppliers contractors business partners meet standards human rights gsk human rights clauses included contracts conduct regular audits existing suppliers engage new suppliers meet expectations supply chain large complex target audits areas greatest risk knowingly use suppliers responsible human rights infringements consider human rights issues routine interactions critical suppliers contract manufacturers suppliers present greatest risk gsk one key risk areas environmental health safety ehs audits potential new existing critical suppliers also include questions help us identify potential breaches human rights clauses suppliers asked information policies practices relating age limits employees discrimination employees local population prevention abuse individuals wages benefits working hours whether meet legal minimum rights workers organise recognition worker organisations questions contribute ehs audit score may reason progress business supplier identify human rights issues make recommendations supplier improve performance require supplier submit regular progress reports undertake site visits ensure improve performance members pharmaceutical supply chain initiative psci industry collaboration set guiding principles standards suppliers cover human rights labour issues psci looking ways improve supplier standards especially emerging markets read supply chain back top home responsibility human rights suppliers corporate responsibility report suppliers buyer raw materials manufactured goods services around world require suppliers contractors business partners meet standards human rights gsk human rights clauses included contracts conduct regular audits existing suppliers engage new suppliers meet expectations supply chain large complex target audits areas greatest risk knowingly use suppliers responsible human rights infringements consider human rights issues routine interactions critical suppliers contract manufacturers suppliers present greatest risk gsk one key risk areas environmental health safety ehs audits potential new existing critical suppliers also include questions help us identify potential breaches human rights clauses suppliers asked information policies practices relating age limits employees discrimination employees local population prevention abuse individuals wages benefits working hours whether meet legal minimum rights workers organise recognition worker organisations questions contribute ehs audit score may reason progress business supplier identify human rights issues make recommendations supplier improve performance require supplier submit regular progress reports undertake site visits ensure improve performance members pharmaceutical supply chain initiative psci industry collaboration set guiding principles standards suppliers cover human rights labour issues psci looking ways improve supplier standards especially emerging markets read supply chain back top home responsibility human rights communities corporate responsibility report communities respect promote rights people communities near operations example local communities gsk aims good relationships communities around sites operate ways infringe human rights seek minimise impacts local environment operate sites safely aim bring social economic benefits areas presence read investment local communities un convention biological diversity cbd convention biological diversity provides framework conservation sustainable use biodiversity also promotes fair equitable sharing benefits arising use genetic resources including used research development new medicines vaccines gsk supports cbd 's role given diversity biological materials many ways used research development possible generalise role play biomedical research fundamental value material particular project product careful consideration therefore needed seeking define implement monitor appropriate access genetic resources sharing benefits arising use context participate ongoing international discussions possible legislative framework access benefit sharing provisions legislation agreed needs strike appropriate balance enables pharmaceutical companies search new compounds might treat cure disease time protecting interests countries communities genetic resources sourced gsk currently involved product development using genetic resources collected since cbd ratified currently looking resources known bioprospecting result access benefitsharing agreements place possible future may undertake development work using natural genetic resources indigenous particular country instance access resources would obtained accordance cbd reflected local laws would ensure relevant parties received agreed benefits use resources example monetary payments read position statement convention biological diversity back top home responsibility human rights communities corporate responsibility report communities respect promote rights people communities near operations example local communities gsk aims good relationships communities around sites operate ways infringe human rights seek minimise impacts local environment operate sites safely aim bring social economic benefits areas presence read investment local communities un convention biological diversity cbd convention biological diversity provides framework conservation sustainable use biodiversity also promotes fair equitable sharing benefits arising use genetic resources including used research development new medicines vaccines gsk supports cbd 's role given diversity biological materials many ways used research development possible generalise role play biomedical research fundamental value material particular project product careful consideration therefore needed seeking define implement monitor appropriate access genetic resources sharing benefits arising use context participate ongoing international discussions possible legislative framework access benefit sharing provisions legislation agreed needs strike appropriate balance enables pharmaceutical companies search new compounds might treat cure disease time protecting interests countries communities genetic resources sourced gsk currently involved product development using genetic resources collected since cbd ratified currently looking resources known bioprospecting result access benefitsharing agreements place possible future may undertake development work using natural genetic resources indigenous particular country instance access resources would obtained accordance cbd reflected local laws would ensure relevant parties received agreed benefits use resources example monetary payments read position statement convention biological diversity back top home responsibility human rights society corporate responsibility report society un declaration human rights states 'everyone right standard living adequate health wellbeing family including medical care ' improving healthcare one society 's greatest challenges particularly developing world gsk contributes healthcare worldwide discovering new treatments vaccines make wide range products affordable developing countries preferential pricing voluntary licence agreements generic manufacturers also making contribution least developed countries community investment projects contribute improvements healthcare infrastructure patient assistance programmes improve access thousands uninsured patients us engage governments multilateral agencies ngos pharmaceutical companies help improve access medicines read approach access medicines work communities may former un special rapporteur right health paul hunt published review gsk 's policies practices access medicines following series indepth interviews senior management well identifying good practices obstacles improving access report makes series recommendations gsk pharmaceutical industry broadly support people 's right health report presented current un special rapporteur un human rights council geneva june statement council un special rapporteur welcomed recent initiatives commended us cooperative approach throughout mission line longstanding position commented 'the special rapporteur notes however access medicines shared responsibility whether pharmaceutical company able fully discharge righttohealth responsibilities sometimes depend upon states donors others fulfilling human rights responsibilities barriers hindering access medicines developing developed countries make difficult pharmaceutical companies enhance access medicines may mentioned weak health systems regulatory environments corruption lack distribution channels ' welcome special rapporteurs constructive engagement gsk provided response report presented un human rights council geneva june read engaging right health httpwwwohchrorgenglishbodieshrcouncildocssession ahrcaddpdf back top home responsibility human rights society corporate responsibility report society un declaration human rights states 'everyone right standard living adequate health wellbeing family including medical care ' improving healthcare one society 's greatest challenges particularly developing world gsk contributes healthcare worldwide discovering new treatments vaccines make wide range products affordable developing countries preferential pricing voluntary licence agreements generic manufacturers also making contribution least developed countries community investment projects contribute improvements healthcare infrastructure patient assistance programmes improve access thousands uninsured patients us engage governments multilateral agencies ngos pharmaceutical companies help improve access medicines read approach access medicines work communities may former un special rapporteur right health paul hunt published review gsk 's policies practices access medicines following series indepth interviews senior management well identifying good practices obstacles improving access report makes series recommendations gsk pharmaceutical industry broadly support people 's right health report presented current un special rapporteur un human rights council geneva june statement council un special rapporteur welcomed recent initiatives commended us cooperative approach throughout mission line longstanding position commented 'the special rapporteur notes however access medicines shared responsibility whether pharmaceutical company able fully discharge righttohealth responsibilities sometimes depend upon states donors others fulfilling human rights responsibilities barriers hindering access medicines developing developed countries make difficult pharmaceutical companies enhance access medicines may mentioned weak health systems regulatory environments corruption lack distribution channels ' welcome special rapporteurs constructive engagement gsk provided response report presented un human rights council geneva june read engaging right health httpwwwohchrorgenglishbodieshrcouncildocssession ahrcaddpdf back top home responsibility human rights activities embargoed countries corporate responsibility report activities embargoed countries stakeholders concerned gsks business activity countries subject trade embargo burma myanmar north korea iran sudan share uns belief see box people denied access medicines regime operating country aim provide medicines vaccines countries need wish purchase observing sanctions trading controls apply countries many nations longstanding commitment presence predate introduction measures trade embargoes periods governmentimposed trade embargoes ensured continuity supply subject specific legal restrictions due demand products embargoed countries countries business support committed upholding universal declaration human rights core standards set international labour organization observe local laws regulations un statement right highest attainable standard health paragraphs relating access medicines embargoed countries paragraph 'health facilities goods services must accessible everyone without discrimination within jurisdiction state party ' paragraph 'parties refrain times imposing embargoes similar measures restricting supply another state adequate medicines medical equipment restrictions goods never used instrument political economic pressure ' paragraph 'while states parties covenant thus ultimately accountable compliance members society individuals including health professionals families local communities intergovernmental nongovernmental organizations civil society organizations well private business sector responsibilities regarding realization right health state parties therefore provide environment facilitates discharge responsibilities ' read full un statement right highest attainable standard health back top home responsibility human rights activities embargoed countries corporate responsibility report activities embargoed countries stakeholders concerned gsks business activity countries subject trade embargo burma myanmar north korea iran sudan share uns belief see box people denied access medicines regime operating country aim provide medicines vaccines countries need wish purchase observing sanctions trading controls apply countries many nations longstanding commitment presence predate introduction measures trade embargoes periods governmentimposed trade embargoes ensured continuity supply subject specific legal restrictions due demand products embargoed countries countries business support committed upholding universal declaration human rights core standards set international labour organization observe local laws regulations un statement right highest attainable standard health paragraphs relating access medicines embargoed countries paragraph 'health facilities goods services must accessible everyone without discrimination within jurisdiction state party ' paragraph 'parties refrain times imposing embargoes similar measures restricting supply another state adequate medicines medical equipment restrictions goods never used instrument political economic pressure ' paragraph 'while states parties covenant thus ultimately accountable compliance members society individuals including health professionals families local communities intergovernmental nongovernmental organizations civil society organizations well private business sector responsibilities regarding realization right health state parties therefore provide environment facilitates discharge responsibilities ' read full un statement right highest attainable standard health back top home responsibility public policy patient advocacy corporate responsibility report public policy patient advocacy pharmaceutical industry highly regulated government policy legislation regulations significant impact business important engage governments stakeholders legislative policy process public policy activity work towards legislation policy encourage scientific innovation balance interests business stakeholders also work patient groups professional groups help give members voice healthcare debate believe conduct advocacy work responsibly make valuable contribution debate public policy issues impact business particularly relating research development use pharmaceuticals healthcare aim increase stakeholder trust gsk transparent lobbying public policy work address concerns stakeholders pharmaceutical industry strong influence governments publish annual public policy activity website report key memberships trade associations us federal eu institution lobbying expenditures also publish information work patient groups including details funding provide gsk make political contributions provide information approach working doctors healthcare professionals research practices ethical conduct sections website back top home responsibility public policy patient advocacy corporate responsibility report public policy patient advocacy pharmaceutical industry highly regulated government policy legislation regulations significant impact business important engage governments stakeholders legislative policy process public policy activity work towards legislation policy encourage scientific innovation balance interests business stakeholders also work patient groups professional groups help give members voice healthcare debate believe conduct advocacy work responsibly make valuable contribution debate public policy issues impact business particularly relating research development use pharmaceuticals healthcare aim increase stakeholder trust gsk transparent lobbying public policy work address concerns stakeholders pharmaceutical industry strong influence governments publish annual public policy activity website report key memberships trade associations us federal eu institution lobbying expenditures also publish information work patient groups including details funding provide gsk make political contributions provide information approach working doctors healthcare professionals research practices ethical conduct sections website back top home responsibility public policy patient advocacy approach external affairs corporate responsibility report approach external affairs employees involved public policy work must abide employee guide business conduct based three principles partnership committed working governments regulatory authorities stakeholders constructive way communication well giving views take board concerns external audiences enables us assess improve business practices integrity base public policy work research analysis facts respect opinions look constructive solutions external affairs work must line code conduct relevant policies including related competition law preventing corrupt practices political contributions external affairs teams major regions business units monitor proposed legislative reforms policy developments concerns stakeholders meet regularly government officials stakeholders example multilateral organisations ngos explain views range public policy issues tailor approach suit different cultures political traditions countries engage public policy process ensuring position discussions fully consistent gsk policies public policy statements ensure standards set guide business conduct applied globally lobbying issues affecting whole pharmaceutical industry sometimes conducted trade associations may also hire professional lobbyists support public policy work trade associations gsk member many trade industry organisations including association british pharmaceutical industry abpi bioindustry association bia biotechnology industry organization bio british pharma group bpg confederation british industry cbi european federation pharmaceutical industries associations efpia international chamber commerce icc intellectual property owners association ipo international federation pharmaceutical manufacturers associations ifpma japan pharmaceutical manufacturers association jpma national association manufacturers nam organisation pharmaceutical producers india oppi organization international investment ofii pharmaceutical research manufacturers america phrma rdbased pharmaceutical association committee rdpac important lobbying conducted trade associations reflects policies values work members help set policies may also attend lobbying meetings governments stakeholders sometimes share views particular issue members trade association trade association adopts public policy position agree participate advocacy activity related subject senior gsk managers sit boards majority industry trade associations members raise concerns may particular advocacy position back tophome responsibility public policy patient advocacy approach external affairs corporate responsibility report approach external affairs employees involved public policy work must abide employee guide business conduct based three principles partnership committed working governments regulatory authorities stakeholders constructive way communication well giving views take board concerns external audiences enables us assess improve business practices integrity base public policy work research analysis facts respect opinions look constructive solutions external affairs work must line code conduct relevant policies including related competition law preventing corrupt practices political contributions external affairs teams major regions business units monitor proposed legislative reforms policy developments concerns stakeholders meet regularly government officials stakeholders example multilateral organisations ngos explain views range public policy issues tailor approach suit different cultures political traditions countries engage public policy process ensuring position discussions fully consistent gsk policies public policy statements ensure standards set guide business conduct applied globally lobbying issues affecting whole pharmaceutical industry sometimes conducted trade associations may also hire professional lobbyists support public policy work trade associations gsk member many trade industry organisations including association british pharmaceutical industry abpi bioindustry association bia biotechnology industry organization bio british pharma group bpg confederation british industry cbi european federation pharmaceutical industries associations efpia international chamber commerce icc intellectual property owners association ipo international federation pharmaceutical manufacturers associations ifpma japan pharmaceutical manufacturers association jpma national association manufacturers nam organisation pharmaceutical producers india oppi organization international investment ofii pharmaceutical research manufacturers america phrma rdbased pharmaceutical association committee rdpac important lobbying conducted trade associations reflects policies values work members help set policies may also attend lobbying meetings governments stakeholders sometimes share views particular issue members trade association trade association adopts public policy position agree participate advocacy activity related subject senior gsk managers sit boards majority industry trade associations members raise concerns may particular advocacy position back top home responsibility public policy patient advocacy approach external affairs corporate responsibility report approach external affairs employees involved public policy work must abide employee guide business conduct based three principles partnership committed working governments regulatory authorities stakeholders constructive way communication well giving views take board concerns external audiences enables us assess improve business practices integrity base public policy work research analysis facts respect opinions look constructive solutions external affairs work must line code conduct relevant policies including related competition law preventing corrupt practices political contributions external affairs teams major regions business units monitor proposed legislative reforms policy developments concerns stakeholders meet regularly government officials stakeholders example multilateral organisations ngos explain views range public policy issues tailor approach suit different cultures political traditions countries engage public policy process ensuring position discussions fully consistent gsk policies public policy statements ensure standards set guide business conduct applied globally lobbying issues affecting whole pharmaceutical industry sometimes conducted trade associations may also hire professional lobbyists support public policy work trade associations gsk member many trade industry organisations including association british pharmaceutical industry abpi bioindustry association bia biotechnology industry organization bio british pharma group bpg confederation british industry cbi european federation pharmaceutical industries associations efpia international chamber commerce icc intellectual property owners association ipo international federation pharmaceutical manufacturers associations ifpma japan pharmaceutical manufacturers association jpma national association manufacturers nam organisation pharmaceutical producers india oppi organization international investment ofii pharmaceutical research manufacturers america phrma rdbased pharmaceutical association committee rdpac important lobbying conducted trade associations reflects policies values work members help set policies may also attend lobbying meetings governments stakeholders sometimes share views particular issue members trade association trade association adopts public policy position agree participate advocacy activity related subject senior gsk managers sit boards majority industry trade associations members raise concerns may particular advocacy position back top home responsibility public policy patient advocacy public policy activity corporate responsibility report public policy activity engage governments stakeholders wide range issues affect industry publish position key issues relating corporate responsibility including access medicines developing countries ethical conduct research development intellectual property environment public health competitiveness pricing reimbursement market access counterfeiting healthcare products key issues engaged healthcare reform access healthcare disease prevention regulations relating research practices patient safety intellectual property pricing competitiveness happy discuss position issues legitimate parties contact corporate responsibility team csrcontactgskcom back top home responsibility public policy patient advocacy public policy activity corporate responsibility report public policy activity engage governments stakeholders wide range issues affect industry publish position key issues relating corporate responsibility including access medicines developing countries ethical conduct research development intellectual property environment public health competitiveness pricing reimbursement market access counterfeiting healthcare products key issues engaged healthcare reform access healthcare disease prevention regulations relating research practices patient safety intellectual property pricing competitiveness happy discuss position issues legitimate parties contact corporate responsibility team csrcontactgskcom back top home responsibility public policy patient advocacy public policy activity advocacy healthcare reform corporate responsibility report advocacy healthcare reform us activity principles us healthcare reform organisations engaged us congress white house industry associations involved phrma bio nam gsk position us healthcare system provides advanced medical care available world many americans uninsured underinsured access healthcare sporadic inadequate improvements needed quality affordability care americans together commitment reform healthcare enable longterm viability gsk supports white house congress achieving comprehensive healthcare reform ensure americans access highquality affordable coverage support agreement put forward industry group phrma provide billion costs savings next ten years principles healthcare reform use competitive marketbased system improve quality care patient outcomes control overall healthcare costs encourage medical innovation build upon current publicprivate partnership appropriate roles government private sector include maximising effectiveness employersponsored health coverage well providing support public programmes people low income including medicaid state childrens health insurance program schip address improvements financing delivery healthcare achieve quality patient outcomes contain costs across spectrum healthcare services improve quality care reduce costs focusing prevention personal responsibility removing barriers access coordinating care improving management chronic disease chronic disease much preventable accounts per cent healthcare spending us healthcare reform must include appropriate incentives encourage wellness prevention manage chronic diseases efficiently maintain strong incentives continued medical innovation meet unmet medical needs alzheimers disease read advocacy increased investment chronic disease prevention treatment us read healthcare reform position paper update september march us president obama signed law patient protection affordable care act ppaca significantly changes provision healthcare us gsk supported efforts congress obama administration increase access improve quality reduce cost growth us health system us government countrys largest health insurance provider million us citizens access health insurance resulting coverage countrys population expanded rebates discounts became effective immediately policy changes occur next years new law implemented gsk focus public policy efforts interpretation implementation ppaca priority ensure legislation implemented ways reflect best interests patients preserving environment values medical research development innovation continue guided principles healthcare reform see regulatory pathway fda approval biosimilars organisations engaged us congress white house industry associations involved bio phrma gsk position part us healthcare reform efforts congress debating legislation would create regulatory pathway fda approve biosimilars versions biological medicines vaccines also called followon biologics similar innovator products biologics derived living organisms cell cultures animals fungi plants include vaccines human insulin proponents legislation claim biosimilars could offer significant cost savings others believe cost savings would much less due substantial expense associated producing testing biological products gsk supports legislation establish regulatory pathway biosimilars provided ensures patient safety requiring companies provide adequate clinical data offers fair incentives continued biopharmaceutical research requiring least years data exclusivity maintain incentives innovation update september new us patient protection affordable care act ppaca see created regulatory pathway us food drug administration fda approve biosimilars reassured legislation recognises importance medical innovation includes years data exclusivity date licence innovator product act also provides fda authority declare biosimilar interchangeable innovator product allows pharmacists substitute biosimilar innovator product without consent prescribing healthcare practitioner gsk encouraging fda require companies using new regulatory pathway provide clinical data show safety efficacy biosimilar sufficiently similar innovator product establish pharmacovigilance framework identifying evaluating minimising safety issues regulatory approval comparative effectiveness research organisations engaged us congress white house industry associations involved phrma gsk position february congress allocated billion expand federal governments comparative effectiveness research cer efforts cer comparison two treatment options healthcare delivery strategies determine effective us healthcare reform legislation would establish national cer centre either within federal government agency independent institute dedicated conducting supporting cer believe independent publicprivate cer institute could play valuable role improving health outcomes healthcare system helping identify effective approaches treatments provided cer institute adheres principles design use cer respect support central role healthcare professional patient treatment decisions stakeholders including patients healthcare professionals public private payers manufacturers opportunity provide input research priorities design voice governance cer institute national cer institute examine aspects healthcare including differing approaches care delivery care management benefit plan design cer institute focus expertise evaluating clinical effectiveness treatments engage costeffectiveness analysis issue coverage treatment decisions recommendations institute develop champion robust wellvalidated methodologies evaluating data inform clinical effectiveness assessments institute make results clinical effectiveness assessments widely available patients providers payers use consideration genetic gender age differences factors individuals differ respond treatment research results based studies populations might hold true specific patient subgroup patients cer must explicitly designed results communicated differences mind update september us patient protection affordable care act ppaca see established patient centered outcomes research institute pcori publicprivate nonprofit corporation sponsor promote comparative clinical effectiveness research cer gsk believes pcori play valuable role improving health outcomes us healthcare system helping identify effective treatments approaches care institutes stated mission scope governance structure consistent principles patientcentered care outlined asian activity healthcare reform china organisations engaged chinese government pharmaceutical industry businesses china us eu member state governments european commission academics chinese think tanks industry associations involved bpg efpia rdpac phrma uschina business council cpea cpa cmda gsk position half healthcare bills paid pocket china significant disparity healthcare coverage rural urban areas system largely hospitalbased chinese government plans invest rmb billion billion around three per cent gdp improve countrys healthcare system narrow current ruralurban healthcare gap plans healthcare reforms include expanding basic medical insurance cover per cent population establishing network local clinics improving services public hospitals government also plans establish essential drug system require healthcare institutions purchase certain drugs ensure available public appropriate dosage forms affordable price gsk welcomes announced healthcare reforms help ensure better access medicines vaccines chinese patients particularly rural areas committed working chinese authorities meet objectives reflecting pricing market access policies ensure better access innovative drugs vaccines across china also increasing investment china including expanding rd activities increasing technology transfers enable local production agreed joint ventures chinese company shenzen neptunus develop manufacture influenza vaccines chinese market jiangsu walvax biotech company produce vaccines measles mumps rubella mmr investments help improve chinese patients access innovative drugs vaccines back tophome responsibility public policy patient advocacy public policy activity advocacy healthcare reform corporate responsibility report advocacy healthcare reform us activity principles us healthcare reform organisations engaged us congress white house industry associations involved phrma bio nam gsk position us healthcare system provides advanced medical care available world many americans uninsured underinsured access healthcare sporadic inadequate improvements needed quality affordability care americans together commitment reform healthcare enable longterm viability gsk supports white house congress achieving comprehensive healthcare reform ensure americans access highquality affordable coverage support agreement put forward industry group phrma provide billion costs savings next ten years principles healthcare reform use competitive marketbased system improve quality care patient outcomes control overall healthcare costs encourage medical innovation build upon current publicprivate partnership appropriate roles government private sector include maximising effectiveness employersponsored health coverage well providing support public programmes people low income including medicaid state childrens health insurance program schip address improvements financing delivery healthcare achieve quality patient outcomes contain costs across spectrum healthcare services improve quality care reduce costs focusing prevention personal responsibility removing barriers access coordinating care improving management chronic disease chronic disease much preventable accounts per cent healthcare spending us healthcare reform must include appropriate incentives encourage wellness prevention manage chronic diseases efficiently maintain strong incentives continued medical innovation meet unmet medical needs alzheimers disease read advocacy increased investment chronic disease prevention treatment us read healthcare reform position paper update september march us president obama signed law patient protection affordable care act ppaca significantly changes provision healthcare us gsk supported efforts congress obama administration increase access improve quality reduce cost growth us health system us government countrys largest health insurance provider million us citizens access health insurance resulting coverage countrys population expanded rebates discounts became effective immediately policy changes occur next years new law implemented gsk focus public policy efforts interpretation implementation ppaca priority ensure legislation implemented ways reflect best interests patients preserving environment values medical research development innovation continue guided principles healthcare reform see regulatory pathway fda approval biosimilars organisations engaged us congress white house industry associations involved bio phrma gsk position part us healthcare reform efforts congress debating legislation would create regulatory pathway fda approve biosimilars versions biological medicines vaccines also called followon biologics similar innovator products biologics derived living organisms cell cultures animals fungi plants include vaccines human insulin proponents legislation claim biosimilars could offer significant cost savings others believe cost savings would much less due substantial expense associated producing testing biological products gsk supports legislation establish regulatory pathway biosimilars provided ensures patient safety requiring companies provide adequate clinical data offers fair incentives continued biopharmaceutical research requiring least years data exclusivity maintain incentives innovation update september new us patient protection affordable care act ppaca see created regulatory pathway us food drug administration fda approve biosimilars reassured legislation recognises importance medical innovation includes years data exclusivity date licence innovator product act also provides fda authority declare biosimilar interchangeable innovator product allows pharmacists substitute biosimilar innovator product without consent prescribing healthcare practitioner gsk encouraging fda require companies using new regulatory pathway provide clinical data show safety efficacy biosimilar sufficiently similar innovator product establish pharmacovigilance framework identifying evaluating minimising safety issues regulatory approval comparative effectiveness research organisations engaged us congress white house industry associations involved phrma gsk position february congress allocated billion expand federal governments comparative effectiveness research cer efforts cer comparison two treatment options healthcare delivery strategies determine effective us healthcare reform legislation would establish national cer centre either within federal government agency independent institute dedicated conducting supporting cer believe independent publicprivate cer institute could play valuable role improving health outcomes healthcare system helping identify effective approaches treatments provided cer institute adheres principles design use cer respect support central role healthcare professional patient treatment decisions stakeholders including patients healthcare professionals public private payers manufacturers opportunity provide input research priorities design voice governance cer institute national cer institute examine aspects healthcare including differing approaches care delivery care management benefit plan design cer institute focus expertise evaluating clinical effectiveness treatments engage costeffectiveness analysis issue coverage treatment decisions recommendations institute develop champion robust wellvalidated methodologies evaluating data inform clinical effectiveness assessments institute make results clinical effectiveness assessments widely available patients providers payers use consideration genetic gender age differences factors individuals differ respond treatment research results based studies populations might hold true specific patient subgroup patients cer must explicitly designed results communicated differences mind update september us patient protection affordable care act ppaca see established patient centered outcomes research institute pcori publicprivate nonprofit corporation sponsor promote comparative clinical effectiveness research cer gsk believes pcori play valuable role improving health outcomes us healthcare system helping identify effective treatments approaches care institutes stated mission scope governance structure consistent principles patientcentered care outlined asian activity healthcare reform china organisations engaged chinese government pharmaceutical industry businesses china us eu member state governments european commission academics chinese think tanks industry associations involved bpg efpia rdpac phrma uschina business council cpea cpa cmda gsk position half healthcare bills paid pocket china significant disparity healthcare coverage rural urban areas system largely hospitalbased chinese government plans invest rmb billion billion around three per cent gdp improve countrys healthcare system narrow current ruralurban healthcare gap plans healthcare reforms include expanding basic medical insurance cover per cent population establishing network local clinics improving services public hospitals government also plans establish essential drug system require healthcare institutions purchase certain drugs ensure available public appropriate dosage forms affordable price gsk welcomes announced healthcare reforms help ensure better access medicines vaccines chinese patients particularly rural areas committed working chinese authorities meet objectives reflecting pricing market access policies ensure better access innovative drugs vaccines across china also increasing investment china including expanding rd activities increasing technology transfers enable local production agreed joint ventures chinese company shenzen neptunus develop manufacture influenza vaccines chinese market jiangsu walvax biotech company produce vaccines measles mumps rubella mmr investments help improve chinese patients access innovative drugs vaccines back tophome responsibility public policy patient advocacy public policy activity advocacy healthcare reform corporate responsibility report advocacy healthcare reform us activity principles us healthcare reform organisations engaged us congress white house industry associations involved phrma bio nam gsk position us healthcare system provides advanced medical care available world many americans uninsured underinsured access healthcare sporadic inadequate improvements needed quality affordability care americans together commitment reform healthcare enable longterm viability gsk supports white house congress achieving comprehensive healthcare reform ensure americans access highquality affordable coverage support agreement put forward industry group phrma provide billion costs savings next ten years principles healthcare reform use competitive marketbased system improve quality care patient outcomes control overall healthcare costs encourage medical innovation build upon current publicprivate partnership appropriate roles government private sector include maximising effectiveness employersponsored health coverage well providing support public programmes people low income including medicaid state childrens health insurance program schip address improvements financing delivery healthcare achieve quality patient outcomes contain costs across spectrum healthcare services improve quality care reduce costs focusing prevention personal responsibility removing barriers access coordinating care improving management chronic disease chronic disease much preventable accounts per cent healthcare spending us healthcare reform must include appropriate incentives encourage wellness prevention manage chronic diseases efficiently maintain strong incentives continued medical innovation meet unmet medical needs alzheimers disease read advocacy increased investment chronic disease prevention treatment us read healthcare reform position paper update september march us president obama signed law patient protection affordable care act ppaca significantly changes provision healthcare us gsk supported efforts congress obama administration increase access improve quality reduce cost growth us health system us government countrys largest health insurance provider million us citizens access health insurance resulting coverage countrys population expanded rebates discounts became effective immediately policy changes occur next years new law implemented gsk focus public policy efforts interpretation implementation ppaca priority ensure legislation implemented ways reflect best interests patients preserving environment values medical research development innovation continue guided principles healthcare reform see regulatory pathway fda approval biosimilars organisations engaged us congress white house industry associations involved bio phrma gsk position part us healthcare reform efforts congress debating legislation would create regulatory pathway fda approve biosimilars versions biological medicines vaccines also called followon biologics similar innovator products biologics derived living organisms cell cultures animals fungi plants include vaccines human insulin proponents legislation claim biosimilars could offer significant cost savings others believe cost savings would much less due substantial expense associated producing testing biological products gsk supports legislation establish regulatory pathway biosimilars provided ensures patient safety requiring companies provide adequate clinical data offers fair incentives continued biopharmaceutical research requiring least years data exclusivity maintain incentives innovation update september new us patient protection affordable care act ppaca see created regulatory pathway us food drug administration fda approve biosimilars reassured legislation recognises importance medical innovation includes years data exclusivity date licence innovator product act also provides fda authority declare biosimilar interchangeable innovator product allows pharmacists substitute biosimilar innovator product without consent prescribing healthcare practitioner gsk encouraging fda require companies using new regulatory pathway provide clinical data show safety efficacy biosimilar sufficiently similar innovator product establish pharmacovigilance framework identifying evaluating minimising safety issues regulatory approval comparative effectiveness research organisations engaged us congress white house industry associations involved phrma gsk position february congress allocated billion expand federal governments comparative effectiveness research cer efforts cer comparison two treatment options healthcare delivery strategies determine effective us healthcare reform legislation would establish national cer centre either within federal government agency independent institute dedicated conducting supporting cer believe independent publicprivate cer institute could play valuable role improving health outcomes healthcare system helping identify effective approaches treatments provided cer institute adheres principles design use cer respect support central role healthcare professional patient treatment decisions stakeholders including patients healthcare professionals public private payers manufacturers opportunity provide input research priorities design voice governance cer institute national cer institute examine aspects healthcare including differing approaches care delivery care management benefit plan design cer institute focus expertise evaluating clinical effectiveness treatments engage costeffectiveness analysis issue coverage treatment decisions recommendations institute develop champion robust wellvalidated methodologies evaluating data inform clinical effectiveness assessments institute make results clinical effectiveness assessments widely available patients providers payers use consideration genetic gender age differences factors individuals differ respond treatment research results based studies populations might hold true specific patient subgroup patients cer must explicitly designed results communicated differences mind update september us patient protection affordable care act ppaca see established patient centered outcomes research institute pcori publicprivate nonprofit corporation sponsor promote comparative clinical effectiveness research cer gsk believes pcori play valuable role improving health outcomes us healthcare system helping identify effective treatments approaches care institutes stated mission scope governance structure consistent principles patientcentered care outlined asian activity healthcare reform china organisations engaged chinese government pharmaceutical industry businesses china us eu member state governments european commission academics chinese think tanks industry associations involved bpg efpia rdpac phrma uschina business council cpea cpa cmda gsk position half healthcare bills paid pocket china significant disparity healthcare coverage rural urban areas system largely hospitalbased chinese government plans invest rmb billion billion around three per cent gdp improve countrys healthcare system narrow current ruralurban healthcare gap plans healthcare reforms include expanding basic medical insurance cover per cent population establishing network local clinics improving services public hospitals government also plans establish essential drug system require healthcare institutions purchase certain drugs ensure available public appropriate dosage forms affordable price gsk welcomes announced healthcare reforms help ensure better access medicines vaccines chinese patients particularly rural areas committed working chinese authorities meet objectives reflecting pricing market access policies ensure better access innovative drugs vaccines across china also increasing investment china including expanding rd activities increasing technology transfers enable local production agreed joint ventures chinese company shenzen neptunus develop manufacture influenza vaccines chinese market jiangsu walvax biotech company produce vaccines measles mumps rubella mmr invpeasgtem en otfs help improve chinese patients access innovative drugs vaccines back tophome responsibility public policy patient advocacy public policy activity advocacy healthcare reform corporate responsibility report advocacy healthcare reform us activity principles us healthcare reform organisations engaged us congress white house industry associations involved phrma bio nam gsk position us healthcare system provides advanced medical care available world many americans uninsured underinsured access healthcare sporadic inadequate improvements needed quality affordability care americans together commitment reform healthcare enable longterm viability gsk supports white house congress achieving comprehensive healthcare reform ensure americans access highquality affordable coverage support agreement put forward industry group phrma provide billion costs savings next ten years principles healthcare reform use competitive marketbased system improve quality care patient outcomes control overall healthcare costs encourage medical innovation build upon current publicprivate partnership appropriate roles government private sector include maximising effectiveness employersponsored health coverage well providing support public programmes people low income including medicaid state childrens health insurance program schip address improvements financing delivery healthcare achieve quality patient outcomes contain costs across spectrum healthcare services improve quality care reduce costs focusing prevention personal responsibility removing barriers access coordinating care improving management chronic disease chronic disease much preventable accounts per cent healthcare spending us healthcare reform must include appropriate incentives encourage wellness prevention manage chronic diseases efficiently maintain strong incentives continued medical innovation meet unmet medical needs alzheimers disease read advocacy increased investment chronic disease prevention treatment us read healthcare reform position paper update september march us president obama signed law patient protection affordable care act ppaca significantly changes provision healthcare us gsk supported efforts congress obama administration increase access improve quality reduce cost growth us health system us government countrys largest health insurance provider million us citizens access health insurance resulting coverage countrys population expanded rebates discounts became effective immediately policy changes occur next years new law implemented gsk focus public policy efforts interpretation implementation ppaca priority ensure legislation implemented ways reflect best interests patients preserving environment values medical research development innovation continue guided principles healthcare reform see regulatory pathway fda approval biosimilars organisations engaged us congress white house industry associations involved bio phrma gsk position part us healthcare reform efforts congress debating legislation would create regulatory pathway fda approve biosimilars versions biological medicines vaccines also called followon biologics similar innovator products biologics derived living organisms cell cultures animals fungi plants include vaccines human insulin proponents legislation claim biosimilars could offer significant cost savings others believe cost savings would much less due substantial expense associated producing testing biological products gsk supports legislation establish regulatory pathway biosimilars provided ensures patient safety requiring companies provide adequate clinical data offers fair incentives continued biopharmaceutical research requiring least years data exclusivity maintain incentives innovation update september new us patient protection affordable care act ppaca see created regulatory pathway us food drug administration fda approve biosimilars reassured legislation recognises importance medical innovation includes years data exclusivity date licence innovator product act also provides fda authority declare biosimilar interchangeable innovator product allows pharmacists substitute biosimilar innovator product without consent prescribing healthcare practitioner gsk encouraging fda require companies using new regulatory pathway provide clinical data show safety efficacy biosimilar sufficiently similar innovator product establish pharmacovigilance framework identifying evaluating minimising safety issues regulatory approval comparative effectiveness research organisations engaged us congress white house industry associations involved phrma gsk position february congress allocated billion expand federal governments comparative effectiveness research cer efforts cer comparison two treatment options healthcare delivery strategies determine effective us healthcare reform legislation would establish national cer centre either within federal government agency independent institute dedicated conducting supporting cer believe independent publicprivate cer institute could play valuable role improving health outcomes healthcare system helping identify effective approaches treatments provided cer institute adheres principles design use cer respect support central role healthcare professional patient treatment decisions stakeholders including patients healthcare professionals public private payers manufacturers opportunity provide input research priorities design voice governance cer institute national cer institute examine aspects healthcare including differing approaches care delivery care management benefit plan design cer institute focus expertise evaluating clinical effectiveness treatments engage costeffectiveness analysis issue coverage treatment decisions recommendations institute develop champion robust wellvalidated methodologies evaluating data inform clinical effectiveness assessments institute make results clinical effectiveness assessments widely available patients providers payers use consideration genetic gender age differences factors individuals differ respond treatment research results based studies populations might hold true specific patient subgroup patients cer must explicitly designed results communicated differences mind update september us patient protection affordable care act ppaca see established patient centered outcomes research institute pcori publicprivate nonprofit corporation sponsor promote comparative clinical effectiveness research cer gsk believes pcori play valuable role improving health outcomes us healthcare system helping identify effective treatments approaches care institutes stated mission scope governance structure consistent principles patientcentered care outlined asian activity healthcare reform china organisations engaged chinese government pharmaceutical industry businesses china us eu member state governments european commission academics chinese think tanks industry associations involved bpg efpia rdpac phrma uschina business council cpea cpa cmda gsk position half healthcare bills paid pocket china significant disparity healthcare coverage rural urban areas system largely hospitalbased chinese government plans invest rmb billion billion around three per cent gdp improve countrys healthcare system narrow current ruralurban healthcare gap plans healthcare reforms include expanding basic medical insurance cover per cent population establishing network local clinics improving services public hospitals government also plans establish essential drug system require healthcare institutions purchase certain drugs ensure available public appropriate dosage forms affordable price gsk welcomes announced healthcare reforms help ensure better access medicines vaccines chinese patients particularly rural areas committed working chinese authorities meet objectives reflecting pricing market access policies ensure better access innovative drugs vaccines across china also increasing investment china including expanding rd activities increasing technology transfers enable local production agreed joint ventures chinese company shenzen neptunus develop manufacture influenza vaccines chinese market jiangsu walvax biotech company produce vaccines measles mumps rubella mmr investments help improve chinese patients access innovative drugs vaccines back top home responsibility public policy patient advocacy public policy activity advocacy healthcare reform corporate responsibility report advocacy healthcare reform us activity principles us healthcare reform organisations engaged us congress white house industry associations involved phrma bio nam gsk position us healthcare system provides advanced medical care available world many americans uninsured underinsured access healthcare sporadic inadequate improvements needed quality affordability care americans together commitment reform healthcare enable longterm viability gsk supports white house congress achieving comprehensive healthcare reform ensure americans access highquality affordable coverage support agreement put forward industry group phrma provide billion costs savings next ten years principles healthcare reform use competitive marketbased system improve quality care patient outcomes control overall healthcare costs encourage medical innovation build upon current publicprivate partnership appropriate roles government private sector include maximising effectiveness employersponsored health coverage well providing support public programmes people low income including medicaid state childrens health insurance program schip address improvements financing delivery healthcare achieve quality patient outcomes contain costs across spectrum healthcare services improve quality care reduce costs focusing prevention personal responsibility removing barriers access coordinating care improving management chronic disease chronic disease much preventable accounts per cent healthcare spending us healthcare reform must include appropriate incentives encourage wellness prevention manage chronic diseases efficiently maintain strong incentives continued medical innovation meet unmet medical needs alzheimers disease read advocacy increased investment chronic disease prevention treatment us read healthcare reform position paper update september march us president obama signed law patient protection affordable care act ppaca significantly changes provision healthcare us gsk supported efforts congress obama administration increase access improve quality reduce cost growth us health system us government countrys largest health insurance provider million us citizens access health insurance resulting coverage countrys population expanded rebates discounts became effective immediately policy changes occur next years new law implemented gsk focus public policy efforts interpretation implementation ppaca priority ensure legislation implemented ways reflect best interests patients preserving environment values medical research development innovation continue guided principles healthcare reform see regulatory pathway fda approval biosimilars organisations engaged us congress white house industry associations involved bio phrma gsk position part us healthcare reform efforts congress debating legislation would create regulatory pathway fda approve biosimilars versions biological medicines vaccines also called followon biologics similar innovator products biologics derived living organisms cell cultures animals fungi plants include vaccines human insulin proponents legislation claim biosimilars could offer significant cost savings others believe cost savings would much less due substantial expense associated producing testing biological products gsk supports legislation establish regulatory pathway biosimilars provided ensures patient safety requiring companies provide adequate clinical data offers fair incentives continued biopharmaceutical research requiring least years data exclusivity maintain incentives innovation update september new us patient protection affordable care act ppaca see created regulatory pathway us food drug administration fda approve biosimilars reassured legislation recognises importance medical innovation includes years data exclusivity date licence innovator product act also provides fda authority declare biosimilar interchangeable innovator product allows pharmacists substitute biosimilar innovator product without consent prescribing healthcare practitioner gsk encouraging fda require companies using new regulatory pathway provide clinical data show safety efficacy biosimilar sufficiently similar innovator product establish pharmacovigilance framework identifying evaluating minimising safety issues regulatory approval comparative effectiveness research organisations engaged us congress white house industry associations involved phrma gsk position february congress allocated billion expand federal governments comparative effectiveness research cer efforts cer comparison two treatment options healthcare delivery strategies determine effective us healthcare reform legislation would establish national cer centre either within federal government agency independent institute dedicated conducting supporting cer believe independent publicprivate cer institute could play valuable role improving health outcomes healthcare system helping identify effective approaches treatments provided cer institute adheres principles design use cer respect support central role healthcare professional patient treatment decisions stakeholders including patients healthcare professionals public private payers manufacturers opportunity provide input research priorities design voice governance cer institute national cer institute examine aspects healthcare including differing approaches care delivery care management benefit plan design cer institute focus expertise evaluating clinical effectiveness treatments engage costeffectiveness analysis issue coverage treatment decisions recommendations institute develop champion robust wellvalidated methodologies evaluating data inform clinical effectiveness assessments institute make results clinical effectiveness assessments widely available patients providers payers use consideration genetic gender age differences factors individuals differ respond treatment research results based studies populations might hold true specific patient subgroup patients cer must explicitly designed results communicated differences mind update september us patient protection affordable care act ppaca see established patient centered outcomes research institute pcori publicprivate nonprofit corporation sponsor promote comparative clinical effectiveness research cer gsk believes pcori play valuable role improving health outcomes us healthcare system helping identify effective treatments approaches care institutes stated mission scope governance structure consistent principles patientcentered care outlined asian activity healthcare reform china organisations engaged chinese government pharmaceutical industry businesses china us eu member state governments european commission academics chinese think tanks industry associations involved bpg efpia rdpac phrma uschina business council cpea cpa cmda gsk position half healthcare bills paid pocket china significant disparity healthcare coverage rural urban areas system largely hospitalbased chinese government plans invest rmb billion billion around three per cent gdp improve countrys healthcare system narrow current ruralurban healthcare gap plans healthcare reforms include expanding basic medical insurance cover per cent population establishing network local clinics improving services public hospitals government also plans establish essential drug system require healthcare institutions purchase certain drugs ensure available public appropriate dosage forms affordable price gsk welcomes announced healthcare reforms help ensure better access medicines vaccines chinese patients particularly rural areas committed working chinese authorities meet objectives reflecting pricing market access policies ensure better access innovative drugs vaccines across china also increasing investment china including expanding rd activities increasing technology transfers enable local production agreed joint ventures chinese company shenzen neptunus develop manufacture influenza vaccines chinese market jiangsu walvax biotech company produce vaccines measles mumps rubella mmr investments help improve chinese patients access innovative drugs vaccines back top home responsibility public policy patient advocacy public policy activity advocacy healthcare disease prevention corporate responsibility report advocacy healthcare disease prevention global activity safeguarding timely unrestricted access influenza viruses organisations engaged world health organization key developed developing country governments eu institutions industry associations involved efpia evm ifpma ivs phrma gsk position influenza virus unstable mutate quickly governments need remain vigilant emergence new strains virus must share virus strains freely governments free sharing viruses best interests global public health enables development vaccines response whos global influenza surveillance network gisn recommends content influenza vaccines twice year recently acted well global alert mechanism hn pandemic international community unconditionally support network relies receiving information virus strains governments despite importance timely unrestricted access viruses indonesia stopped sharing influenza viruses insisting benefits exchange access viruses response international community including vaccine industry spent mapping way help developing countries prepare pandemic much late implementing plan response included product donations technology transfer tiered pricing despite extensive voluntary efforts member countries intergovernmental meeting igm continue call system mandatory contributions system could oblige holders intellectual property rights derived materials received gisn grant nonexclusive royaltyfree licence passed licensees implementation international agreement along lines could undermine spirit voluntary collaboration resulted comprehensive pandemic response ever gsk rest pharmaceutical industry continue resist calls system mandatory contributions hopeful solution assures industry access potential pandemic viruses return ongoing commitment voluntary benefit sharing agreed intellectual property innovation diseases developing world organisations engaged world health organization uk government department international development department health intellectual property office eu commission various governments ngos industry organisations involved ifpma phrma efpia abpi bpg bio gsk position following work commission intellectual property innovation public health world health organization created intergovernmental working group igwg develop global strategy plan action aimed secure enhanced sustainable basis needsdriven essential health research development relevant diseases disproportionately affect developing countries proposing clear objectives priorities research development estimating funding needs gsk supported objectives igwg much process activity stakeholders focused attacking intellectual property ip based model innovation meeting needs patients developing countries fundamental business model based respect intellectual property ip rights play vital role encouraging innovation needed develop new treatments enabling us generate returns investment needed fund new research attempts weaken ip environment deflecting attention seeking appropriate solutions addressing lack rd diseases developing world commercial opportunities exist incentivising prioritising rd diseases ensuring sustainable financing working coalition trade associations contributed development pragmatic global strategy plan action gspoa agreed consensus world health assembly may many current initiatives improve healthcare developing world aligned gspoa seek opportunities contribute implementation wha resolution us activity investment chronic disease prevention treatment organisations engaged us department health human services us congress white house state legislators governors offices various state health agencies partnership fight chronic disease industry associations involved phrma gsk position chronic diseases diabetes heart disease lung disease account three quarters healthcare spending relatively little invested prevention even though many chronic diseases costly complications preventable increasingly manageable advocating threepart approach achieving lowercost higherquality healthcare increasing prevention improving treatment accelerating research better treatments chronic disease healthcare providers need incentives promote preventative services address major causes chronic disease obesity smoking healthcare policy needs reform better encourage reward medical research improved treatments costly unmet medical needs alzheimers disease preventing better managing chronic diseases reduce overall healthcare costs long term read advocacy us healthcare reform supporting petition protect americans fraudulent weight loss claims organisations engaged us food drug administration industry associations involved none see healthcare associations involved gsk position us twothirds adults overweight obese increasing risk illnesses cancer heart disease type diabetes dozens dietary supplements market us manufacturers claim help people lose weight claims reviewed food drug administration fda supported credible scientific evidence ineffective weight loss products prevent people getting support need lose weight us federal trade commissions consumer fraud survey recently highlighted victims fraudulent weightloss products million american consumers victims frauds covered survey gsk manufactures alli overthecounter weight loss product gained fda approval safety efficacy april gsk three research advocacy organisations american dietetic association obesity society shaping americas health submitted citizens petition fda asking provide greater protection americans fraudulent weight loss claims petition requests fda treats weight loss claims way unsubstantiated claims efficacy disease permitted dietary supplement health education act petition calls fda require rigorous scientific evidence claims also aims raise awareness educate public issue fraudulent weight loss products separate development january fda demanded recall large number weightloss supplement products warned number companies might liable criminal charges among fdas complaints supplement products us illegal inclusion regulated unapproved withdrawn prescription pharmaceuticals including sibutramine rimonabant weight loss phenytoin antiseizure phenolphthalein laxative previously withdrawn fda due carcinogenicity gsk supports continue work fda help protect public false unsubstantiated weight loss claims possibly unsafe products european activity eu health council recommendation seasonal flu vaccination coverage organisations engaged directorate general health consumers dg sanco european centre disease prevention control ecdc industry associations involved european vaccine manufacturers evm national vaccine industry groups gsk position seasonal flu preventable disease cause deaths year europe depending severity season many deaths could prevented expanding vaccination coverage europe currently low urges member states increase vaccination high risk groups certain medical conditions healthcare workers aim vaccination coverage least per cent elderly despite vaccination groups included national recommendations eu countries reimbursed coverage remains low variable coverage elderly people years old ranges per cent poland per cent uk coverage risk groups years old example asthmatics diabetics cardiac ranges per cent poland per cent uk coverage healthcare workers ranges nine per cent poland per cent uk european parliament endorsed recommendations increase coverage levels per cent groups european usage remained flat recent years unlike regions increased significantly believe seasonal vaccination coverage europe increased target level per cent well reducing deaths illness help increase vaccine manufacturing capacity currently insufficient meet needs pandemic vaccine supply recognised european parliament resolutions advocacy key factor driving proposal issued european commission july calls member states develop concrete plans increase coverage rates per cent target level annual monitoring coverage rates member states encouraged eu order monitor progress proposal adopted health council december position paper influenza vaccines august szucs journal infection asian activity engaging governments asia value vaccines organisations engaged asiapacific economic cooperation apec forum industry associations involved none gsk position vaccines play major role preventing eliminating disease still underused many countries gsk engaging governments stakeholders asia raise awareness importance investment preventative health measures behalf industry gsk supported organised stakeholder perception survey life sciences innovation forum lsif official sub group asiapacific economic cooperation forum apec established apec leading regional organisation facilitating economic growth cooperation trade investment asia pacific region important forum reaching senior government officials policymakers asian countries recently lsif focused raising awareness among apec governments need invest health innovation help manage increasing costs ageing populations rising incidence chronic disease support work gsk initiated study stakeholder perceptions determine define value vaccines survey assessed current perceptions among legislators civil servants health finance economic planning ministries industry medical key opinion leaders vaccine advocacy groups thailand taiwan known chinese taipei apec showed stakeholders see value vaccines prevention death serious illness infectious diseases means reduce direct healthcare costs related treatment diseases however low awareness positive impact vaccines workforce participation productivity related benefits higher incomes economic growth little consideration benefits vaccine policymaking highlighting need make investment case vaccines among government agencies responsible budget allocation survey findings featured strongly lsif report endorsed apec foreign economictrade ministers meeting singapore gsk welcomes support apec ministers continuing raise awareness among government decisionmakers asia need invest preventive measures part health policy gsk committed ongoing dialogue stakeholders across asia continued involvement lsifs important work back tophome responsibility public policy patient advocacy public policy activity advocacy healthcare disease prevention corporate responsibility report advocacy healthcare disease prevention global activity safeguarding timely unrestricted access influenza viruses organisations engaged world health organization key developed developing country governments eu institutions industry associations involved efpia evm ifpma ivs phrma gsk position influenza virus unstable mutate quickly governments need remain vigilant emergence new strains virus must share virus strains freely governments free sharing viruses best interests global public health enables development vaccines response whos global influenza surveillance network gisn recommends content influenza vaccines twice year recently acted well global alert mechanism hn pandemic international community unconditionally support network relies receiving information virus strains governments despite importance timely unrestricted access viruses indonesia stopped sharing influenza viruses insisting benefits exchange access viruses response international community including vaccine industry spent mapping way help developing countries prepare pandemic much late implementing plan response included product donations technology transfer tiered pricing despite extensive voluntary efforts member countries intergovernmental meeting igm continue call system mandatory contributions system could oblige holders intellectual property rights derived materials received gisn grant nonexclusive royaltyfree licence passed licensees implementation international agreement along lines could undermine spirit voluntary collaboration resulted comprehensive pandemic response ever gsk rest pharmaceutical industry continue resist calls system mandatory contributions hopeful solution assures industry access potential pandemic viruses return ongoing commitment voluntary benefit sharing agreed intellectual property innovation diseases developing world organisations engaged world health organization uk government department international development department health intellectual property office eu commission various governments ngos industry organisations involved ifpma phrma efpia abpi bpg bio gsk position following work commission intellectual property innovation public health world health organization created intergovernmental working group igwg develop global strategy plan action aimed secure enhanced sustainable basis needsdriven essential health research development relevant diseases disproportionately affect developing countries proposing clear objectives priorities research development estimating funding needs gsk supported objectives igwg much process activity stakeholders focused attacking intellectual property ip based model innovation meeting needs patients developing countries fundamental business model based respect intellectual property ip rights play vital role encouraging innovation needed develop new treatments enabling us generate returns investment needed fund new research attempts weaken ip environment deflecting attention seeking appropriate solutions addressing lack rd diseases developing world commercial opportunities exist incentivising prioritising rd diseases ensuring sustainable financing working coalition trade associations contributed development pragmatic global strategy plan action gspoa agreed consensus world health assembly may many current initiatives improve healthcare developing world aligned gspoa seek opportunities contribute implementation wha resolution us activity investment chronic disease prevention treatment organisations engaged us department health human services us congress white house state legislators governors offices various state health agencies partnership fight chronic disease industry associations involved phrma gsk position chronic diseases diabetes heart disease lung disease account three quarters healthcare spending relatively little invested prevention even though many chronic diseases costly complications preventable increasingly manageable advocating threepart approach achieving lowercost higherquality healthcare increasing prevention improving treatment accelerating research better treatments chronic disease healthcare providers need incentives promote preventative services address major causes chronic disease obesity smoking healthcare policy needs reform better encourage reward medical research improved treatments costly unmet medical needs alzheimers disease preventing better managing chronic diseases reduce overall healthcare costs long term read advocacy us healthcare reform supporting petition protect americans fraudulent weight loss claims organisations engaged us food drug administration industry associations involved none see healthcare associations involved gsk position us twothirds adults overweight obese increasing risk illnesses cancer heart disease type diabetes dozens dietary supplements market us manufacturers claim help people lose weight claims reviewed food drug administration fda supported credible scientific evidence ineffective weight loss products prevent people getting support need lose weight us federal trade commissions consumer fraud survey recently highlighted victims fraudulent weightloss products million american consumers victims frauds covered survey gsk manufactures alli overthecounter weight loss product gained fda approval safety efficacy april gsk three research advocacy organisations american dietetic association obesity society shaping americas health submitted citizens petition fda asking provide greater protection americans fraudulent weight loss claims petition requests fda treats weight loss claims way unsubstantiated claims efficacy disease permitted dietary supplement health education act petition calls fda require rigorous scientific evidence claims also aims raise awareness educate public issue fraudulent weight loss products separate development january fda demanded recall large number weightloss supplement products warned number companies might liable criminal charges among fdas complaints supplement products us illegal inclusion regulated unapproved withdrawn prescription pharmaceuticals including sibutramine rimonabant weight loss phenytoin antiseizure phenolphthalein laxative previously withdrawn fda due carcinogenicity gsk supports continue work fda help protect public false unsubstantiated weight loss claims possibly unsafe products european activity eu health council recommendation seasonal flu vaccination coverage organisations engaged directorate general health consumers dg sanco european centre disease prevention control ecdc industry associations involved european vaccine manufacturers evm national vaccine industry groups gsk position seasonal flu preventable disease cause deaths year europe depending severity season many deaths could prevented expanding vaccination coverage europe currently low urges member states increase vaccination high risk groups certain medical conditions healthcare workers aim vaccination coverage least per cent elderly despite vaccination groups included national recommendations eu countries reimbursed coverage remains low variable coverage elderly people years old ranges per cent poland per cent uk coverage risk groups years old example asthmatics diabetics cardiac ranges per cent poland per cent uk coverage healthcare workers ranges nine per cent poland per cent uk european parliament endorsed recommendations increase coverage levels per cent groups european usage remained flat recent years unlike regions increased significantly believe seasonal vaccination coverage europe increased target level per cent well reducing deaths illness help increase vaccine manufacturing capacity currently insufficient meet needs pandemic vaccine supply recognised european parliament resolutions advocacy key factor driving proposal issued european commission july calls member states develop concrete plans increase coverage rates per cent target level annual monitoring coverage rates member states encouraged eu order monitor progress proposal adopted health council december position paper influenza vaccines august szucs journal infection asian activity engaging governments asia value vaccines organisations engaged asiapacific economic cooperation apec forum industry associations involved none gsk position vaccines play major role preventing eliminating disease still underused many countries gsk engaging governments stakeholders asia raise awareness importance investment preventative health measures behalf industry gsk supported organised stakeholder perception survey life sciences innovation forum lsif official sub group asiapacific economic cooperation forum apec established apec leading regional organisation facilitating economic growth cooperation trade investment asia pacific region important forum reaching senior government officials policymakers asian countries recently lsif focused raising awareness among apec governments need invest health innovation help manage increasing costs ageing populations rising incidence chronic disease support work gsk initiated study stakeholder perceptions determine define value vaccines survey assessed current perceptions among legislators civil servants health finance economic planning ministries industry medical key opinion leaders vaccine advocacy groups thailand taiwan known chinese taipei apec showed stakeholders see value vaccines prevention death serious illness infectious diseases means reduce direct healthcare costs related treatment diseases however low awareness positive impact vaccines workforce participation productivity related benefits higher incomes economic growth little consideration benefits vaccine policymaking highlighting need make investment case vaccines among government agencies responsible budget allocation survey findings featured strongly lsif report endorsed apec foreign economictrade ministers meeting singapore gsk welcomes support apec ministers continuing raise awareness among government decisionmakers asia need invest preventive measures part health policy gsk committed ongoing dialogue stakeholders across asia continued involvement lsifs important work back tophome responsibility public policy patient advocacy public policy activity advocacy healthcare disease prevention corporate responsibility report advocacy healthcare disease prevention global activity safeguarding timely unrestricted access influenza viruses organisations engaged world health organization key developed developing country governments eu institutions industry associations involved efpia evm ifpma ivs phrma gsk position influenza virus unstable mutate quickly governments need remain vigilant emergence new strains virus must share virus strains freely governments free sharing viruses best interests global public health enables development vaccines response whos global influenza surveillance network gisn recommends content influenza vaccines twice year recently acted well global alert mechanism hn pandemic international community unconditionally support network relies receiving information virus strains governments despite importance timely unrestricted access viruses indonesia stopped sharing influenza viruses insisting benefits exchange access viruses response international community including vaccine industry spent mapping way help developing countries prepare pandemic much late implementing plan response included product donations technology transfer tiered pricing despite extensive voluntary efforts member countries intergovernmental meeting igm continue call system mandatory contributions system could oblige holders intellectual property rights derived materials received gisn grant nonexclusive royaltyfree licence passed licensees implementation international agreement along lines could undermine spirit voluntary collaboration resulted comprehensive pandemic response ever gsk rest pharmaceutical industry continue resist calls system mandatory contributions hopeful solution assures industry access potential pandemic viruses return ongoing commitment voluntary benefit sharing agreed intellectual property innovation diseases developing world organisations engaged world health organization uk government department international development department health intellectual property office eu commission various governments ngos industry organisations involved ifpma phrma efpia abpi bpg bio gsk position following work commission intellectual property innovation public health world health organization created intergovernmental working group igwg develop global strategy plan action aimed secure enhanced sustainable basis needsdriven essential health research development relevant diseases disproportionately affect developing countries proposing clear objectives priorities research development estimating funding needs gsk supported objectives igwg much process activity stakeholders focused attacking intellectual property ip based model innovation meeting needs patients developing countries fundamental business model based respect intellectual property ip rights play vital role encouraging innovation needed develop new treatments enabling us generate returns investment needed fund new research attempts weaken ip environment deflecting attention seeking appropriate solutions addressing lack rd diseases developing world commercial opportunities exist incentivising prioritising rd diseases ensuring sustainable financing working coalition trade associations contributed development pragmatic global strategy plan action gspoa agreed consensus world health assembly may many current initiatives improve healthcare developing world aligned gspoa seek opportunities contribute implementation wha resolution us activity investment chronic disease prevention treatment organisations engaged us department health human services us congress white house state legislators governors offices various state health agencies partnership fight chronic disease industry associations involved phrma gsk position chronic diseases diabetes heart disease lung disease account three quarters healthcare spending relatively little invested prevention even though many chronic diseases costly complications preventable increasingly manageable advocating threepart approach achieving lowercost higherquality healthcare increasing prevention improving treatment accelerating research better treatments chronic disease healthcare providers need incentives promote preventative services address major causes chronic disease obesity smoking healthcare policy needs reform better encourage reward medical research improved treatments costly unmet medical needs alzheimers disease preventing better managing chronic diseases reduce overall healthcare costs long term read advocacy us healthcare reform supporting petition protect americans fraudulent weight loss claims organisations engaged us food drug administration industry associations involved none see healthcare associations involved gsk position us twothirds adults overweight obese increasing risk illnesses cancer heart disease type diabetes dozens dietary supplements market us manufacturers claim help people lose weight claims reviewed food drug administration fda supported credible scientific evidence ineffective weight loss products prevent people getting support need lose weight us federal trade commissions consumer fraud survey recently highlighted victims fraudulent weightloss products million american consumers victims frauds covered survey gsk manufactures alli overthecounter weight loss product gained fda approval safety efficacy april gsk three research advocacy organisations american dietetic association obesity society shaping americas health submitted citizens petition fda asking provide greater protection americans fraudulent weight loss claims petition requests fda treats weight loss claims way unsubstantiated claims efficacy disease permitted dietary supplement health education act petition calls fda require rigorous scientific evidence claims also aims raise awareness educate public issue fraudulent weight loss products separate development january fda demanded recall large number weightloss supplement products warned number companies might liable criminal charges among fdas complaints supplement products us illegal inclusion regulated unapproved withdrawn prescription pharmaceuticals including sibutramine rimonabant weight loss phenytoin antiseizure phenolphthalein laxative previously withdrawn fda due carcinogenicity gsk supports continue work fda help protect public false unsubstantiated weight loss claims possibly unsafe products european activity eu health council recommendation seasonal flu vaccination coverage organisations engaged directorate general health consumers dg sanco european centre disease prevention control ecdc industry associations involved european vaccine manufacturers evm national vaccine industry groups gsk position seasonal flu preventable disease cause deaths year europe depending severity season many deaths could prevented expanding vaccination coverage europe currently low urges member states increase vaccination high risk groups certain medical conditions healthcare workers aim vaccination coverage least per cent elderly despite vaccination groups included national recommendations eu countries reimbursed coverage remains low variable coverage elderly people years old ranges per cent poland per cent uk coverage risk groups years old example asthmatics diabetics cardiac ranges per cent poland per cent uk coverage healthcare workers ranges nine per cent poland per cent uk european parliament endorsed recommendations increase coverage levels per cent groups european usage remained flat recent years unlike regions increased significantly believe seasonal vaccination coverage europe increased target level per cent well reducing deaths illness help increase vaccine manufacturing capacity currently insufficient meet needs pandemic vaccine supply recognised european parliament resolutions advocacy key factor driving proposal issued european commission july calls member states develop concrete plans increase coverage rates per cent target level annual monitoring coverage rates member states encouraged eu order monitor progress proposal adopted health council december position paper influenza vaccines august szucs journal infection asian activity engaging governments asia value vaccines organisations engaged asiapacific economic cooperation apec forum industry associations involved none gsk position vaccines play major role preventing eliminating disease still underused many countries gsk engaging governments stakeholders asia raise awareness importance investment preventative health measures behalf industry gsk supported organised stakeholder perception survey life sciences innovation forum lsif official sub group asiapacific economic cooperation forum apec established apec leading regional organisation facilitating economic growth cooperation trade investment asia pacific region important forum reaching senior government officials policymakers asian countries recently lsif focused raising awareness among apec governments need invest health innovation help manage increasing costs ageing populations rising incidence chronic disease support work gsk initiated study stakeholder perceptions determine define value vaccines survey assessed current perceptions among legislators civil servants health finance economic planning ministries industry medical key opinion leaders vaccine advocacy groups thailand taiwan known chinese taipei apec showed stakeholders see value vaccines prevention death serious illness infectious diseases means reduce direct healthcare costs related treatment diseases however low awareness positive impact vaccines workforce participation productivity related benefits higher incomes economic growth little consideration benefits vaccine policymaking highlighting need make investment case vaccines among government agencies responsible budget allocation survey findings featured strongly lsif report endorsed apec foreign economictrade ministers meeting singapore gsk welcomes support apec ministers continuing raise awareness among government decisionmakers asia need invest preventive measures part health policy gsk committed ongoing dialogue stakeholders across asia continued involvement lsifs important work back tophome responsibility public policy patient advocacy public policy activity advocacy healthcare disease prevention corporate responsibility report advocacy healthcare disease prevention global activity safeguarding timely unrestricted access influenza viruses organisations engaged world health organization key developed developing country governments eu institutions industry associations involved efpia evm ifpma ivs phrma gsk position influenza virus unstable mutate quickly governments need remain vigilant emergence new strains virus must share virus strains freely governments free sharing viruses best interests global public health enables development vaccines response whos global influenza surveillance network gisn recommends content influenza vaccines twice year recently acted well global alert mechanism hn pandemic international community unconditionally support network relies receiving information virus strains governments despite importance timely unrestricted access viruses indonesia stopped sharing influenza viruses insisting benefits exchange access viruses response international community including vaccine industry spent mapping way help developing countries prepare pandemic much late implementing plan response included product donations technology transfer tiered pricing despite extensive voluntary efforts member countries intergovernmental meeting igm continue call system mandatory contributions system could oblige holders intellectual property rights derived materials received gisn grant nonexclusive royaltyfree licence passed licensees implementation international agreement along lines could undermine spirit voluntary collaboration resulted comprehensive pandemic response ever gsk rest pharmaceutical industry continue resist calls system mandatory contributions hopeful solution assures industry access potential pandemic viruses return ongoing commitment voluntary benefit sharing agreed intellectual property innovation diseases developing world organisations engaged world health organization uk government department international development department health intellectual property office eu commission various governments ngos industry organisations involved ifpma phrma efpia abpi bpg bio gsk position following work commission intellectual property innovation public health world health organization created intergovernmental working group igwg develop global strategy plan action aimed secure enhanced sustainable basis needsdriven essential health research development relevant diseases disproportionately affect developing countries proposing clear objectives priorities research development estimating funding needs gsk supported objectives igwg much process activity stakeholders focused attacking intellectual property ip based model innovation meeting needs patients developing countries fundamental business model based respect intellectual property ip rights play vital role encouraging innovation needed develop new treatments enabling us generate returns investment needed fund new research attempts weaken ip environment deflecting attention seeking appropriate solutions addressing lack rd diseases developing world commercial opportunities exist incentivising prioritising rd diseases ensuring sustainable financing working coalition trade associations contributed development pragmatic global strategy plan action gspoa agreed consensus world health assembly may many current initiatives improve healthcare developing world aligned gspoa seek opportunities contribute implementation wha resolution us activity investment chronic disease prevention treatment organisations engaged us department health human services us congress white house state legislators governors offices various state health agencies partnership fight chronic disease industry associations involved phrma gsk position chronic diseases diabetes heart disease lung disease account three quarters healthcare spending relatively little invested prevention even though many chronic diseases costly complications preventable increasingly manageable advocating threepart approach achieving lowercost higherquality healthcare increasing prevention improving treatment accelerating research better treatments chronic disease healthcare providers need incentives promote preventative services address major causes chronic disease obesity smoking healthcare policy needs reform better encourage reward medical research improved treatments costly unmet medical needs alzheimers disease preventing better managing chronic diseases reduce overall healthcare costs long term read advocacy us healthcare reform supporting petition protect americans fraudulent weight loss claims organisations engaged us food drug administration industry associations involved none see healthcare associations involved gsk position us twothirds adults overweight obese increasing risk illnesses cancer heart disease type diabetes dozens dietary supplements market us manufacturers claim help people lose weight claims reviewed food drug administration fda supported credible scientific evidence ineffective weight loss products prevent people getting support need lose weight us federal trade commissions consumer fraud survey recently highlighted victims fraudulent weightloss products million american consumers victims frauds covered survey gsk manufactures alli overthecounter weight loss product gained fda approval safety efficacy april gsk three research advocacy organisations american dietetic association obesity society shaping americas health submitted citizens petition fda asking provide greater protection americans fraudulent weight loss claims petition requests fda treats weight loss claims way unsubstantiated claims efficacy disease permitted dietary supplement health education act petition calls fda require rigorous scientific evidence claims also aims raise awareness educate public issue fraudulent weight loss products separate development january fda demanded recall large number weightloss supplement products warned number companies might liable criminal charges among fdas complaints supplement products us illegal inclusion regulated unapproved withdrawn prescription pharmaceuticals including sibutramine rimonabant weight loss phenytoin antiseizure phenolphthalein laxative previously withdrawn fda due carcinogenicity gsk supports continue work fda help protect public false unsubstantiated weight loss claims possibly unsafe products european activity eu health council recommendation seasonal flu vaccination coverage organisations engaged directorate general health consumers dg sanco european centre disease prevention control ecdc industry associations involved european vaccine manufacturers evm national vaccine industry groups gsk position seasonal flu preventable disease cause deaths year europe depending severity season many deaths could prevented expanding vaccination coverage europe currently low urges member states increase vaccination high risk groups certain medical conditions healthcare workers aim vaccination coverage least per cent elderly despite vaccination groups included national recommendations eu countries reimbursed coverage remains low variable coverage elderly people years old ranges per cent poland per cent uk coverage risk groups years old example asthmatics diabetics cardiac ranges per cent poland per cent uk coverage healthcare workers ranges nine per cent poland per cent uk european parliament endorsed recommendations increase coverage levels per cent groups european usage remained flat recent years unlike regions increased significantly believe seasonal vaccination coverage europe increased target level per cent well reducing deaths illness help increase vaccine manufacturing capacity currently insufficient meet needs pandemic vaccine supply recognised european parliament resolutions advocacy key factor driving proposal issued european commission july calls member states develop concrete plans increase coverage rates per cent target level annual monitoring coverage rates member states encouraged eu order monitor progress proposal adopted health council december position paper influenza vaccines august szucs journal infection asian activity engaging governments asia value vaccines organisations engaged asiapacific economic cooperation apec forum industry associations involved none gsk position vaccines play major role preventing eliminating disease still underused many countries gsk engaging governments stakeholders asia raise awareness importance investment preventative health measures behalf industry gsk supported organised stakeholder perception survey life sciences innovation forum lsif official sub group asiapacific economic cooperation forum apec established apec leading regional organisation facilitating economic growth cooperation trade investment asia pacific region important forum reaching senior government officials policymakers asian countries recently lsif focused raising awareness among apec governments need invest health innovation help manage increasing costs ageing populations rising incidence chronic disease support work gsk initiated study stakeholder perceptions determine define value vaccines survey assessed current perceptions among legislators civil servants health finance economic planning ministries industry medical key opinion leaders vaccine advocacy groups thailand taiwan known chinese taipei apec showed stakeholders see value vaccines prevention death serious illness infectious diseases means reduce direct healthcare costs related treatment diseases however low awareness positive impact vaccines workforce participation productivity related benefits higher incomes economic growth little consideration benefits vaccine policymaking highlighting need make investment case vaccines among government agencies responsible budget allocation survey findings featured strongly lsif report endorsed apec foreign economictrade ministers meeting singapore gsk welcomes support apec ministers continuing raise awareness among government decisionmakers asia need invest preventive measures part health policy gsk committed ongoing dialogue stakeholders across asia continued involvement lsifs important work back top home responsibility public policy patient advocacy public policy activity advocacy healthcare disease prevention corporate responsibility report advocacy healthcare disease prevention global activity safeguarding timely unrestricted access influenza viruses organisations engaged world health organization key developed developing country governments eu institutions industry associations involved efpia evm ifpma ivs phrma gsk position influenza virus unstable mutate quickly governments need remain vigilant emergence new strains virus must share virus strains freely governments free sharing viruses best interests global public health enables development vaccines response whos global influenza surveillance network gisn recommends content influenza vaccines twice year recently acted well global alert mechanism hn pandemic international community unconditionally support network relies receiving information virus strains governments despite importance timely unrestricted access viruses indonesia stopped sharing influenza viruses insisting benefits exchange access viruses response international community including vaccine industry spent mapping way help developing countries prepare pandemic much late implementing plan response included product donations technology transfer tiered pricing despite extensive voluntary efforts member countries intergovernmental meeting igm continue call system mandatory contributions system could oblige holders intellectual property rights derived materials received gisn grant nonexclusive royaltyfree licence passed licensees implementation international agreement along lines could undermine spirit voluntary collaboration resulted comprehensive pandemic response ever gsk rest pharmaceutical industry continue resist calls system mandatory contributions hopeful solution assures industry access potential pandemic viruses return ongoing commitment voluntary benefit sharing agreed intellectual property innovation diseases developing world organisations engaged world health organization uk government department international development department health intellectual property office eu commission various governments ngos industry organisations involved ifpma phrma efpia abpi bpg bio gsk position following work commission intellectual property innovation public health world health organization created intergovernmental working group igwg develop global strategy plan action aimed secure enhanced sustainable basis needsdriven essential health research development relevant diseases disproportionately affect developing countries proposing clear objectives priorities research development estimating funding needs gsk supported objectives igwg much process activity stakeholders focused attacking intellectual property ip based model innovation meeting needs patients developing countries fundamental business model based respect intellectual property ip rights play vital role encouraging innovation needed develop new treatments enabling us generate returns investment needed fund new research attempts weaken ip environment deflecting attention seeking appropriate solutions addressing lack rd diseases developing world commercial opportunities exist incentivising prioritising rd diseases ensuring sustainable financing working coalition trade associations contributed development pragmatic global strategy plan action gspoa agreed consensus world health assembly may many current initiatives improve healthcare developing world aligned gspoa seek opportunities contribute implementation wha resolution us activity investment chronic disease prevention treatment organisations engaged us department health human services us congress white house state legislators governors offices various state health agencies partnership fight chronic disease industry associations involved phrma gsk position chronic diseases diabetes heart disease lung disease account three quarters healthcare spending relatively little invested prevention even though many chronic diseases costly complications preventable increasingly manageable advocating threepart approach achieving lowercost higherquality healthcare increasing prevention improving treatment accelerating research better treatments chronic disease healthcare providers need incentives promote preventative services address major causes chronic disease obesity smoking healthcare policy needs reform better encourage reward medical research improved treatments costly unmet medical needs alzheimers disease preventing better managing chronic diseases reduce overall healthcare costs long term read advocacy us healthcare reform supporting petition protect americans fraudulent weight loss claims organisations engaged us food drug administration industry associations involved none see healthcare associations involved gsk position us twothirds adults overweight obese increasing risk illnesses cancer heart disease type diabetes dozens dietary supplements market us manufacturers claim help people lose weight claims reviewed food drug administration fda supported credible scientific evidence ineffective weight loss products prevent people getting support need lose weight us federal trade commissions consumer fraud survey recently highlighted victims fraudulent weightloss products million american consumers victims frauds covered survey gsk manufactures alli overthecounter weight loss product gained fda approval safety efficacy april gsk three research advocacy organisations american dietetic association obesity society shaping americas health submitted citizens petition fda asking provide greater protection americans fraudulent weight loss claims petition requests fda treats weight loss claims way unsubstantiated claims efficacy disease permitted dietary supplement health education act petition calls fda require rigorous scientific evidence claims also aims raise awareness educate public issue fraudulent weight loss products separate development january fda demanded recall large number weightloss supplement products warned number companies might liable criminal charges among fdas complaints supplement products us illegal inclusion regulated unapproved withdrawn prescription pharmaceuticals including sibutramine rimonabant weight loss phenytoin antiseizure phenolphthalein laxative previously withdrawn fda due carcinogenicity gsk supports continue work fda help protect public false unsubstantiated weight loss claims possibly unsafe products european activity eu health council recommendation seasonal flu vaccination coverage organisations engaged directorate general health consumers dg sanco european centre disease prevention control ecdc industry associations involved european vaccine manufacturers evm national vaccine industry groups gsk position seasonal flu preventable disease cause deaths year europe depending severity season many deaths could prevented expanding vaccination coverage europe currently low urges member states increase vaccination high risk groups certain medical conditions healthcare workers aim vaccination coverage least per cent elderly despite vaccination groups included national recommendations eu countries reimbursed coverage remains low variable coverage elderly people years old ranges per cent poland per cent uk coverage risk groups years old example asthmatics diabetics cardiac ranges per cent poland per cent uk coverage healthcare workers ranges nine per cent poland per cent uk european parliament endorsed recommendations increase coverage levels per cent groups european usage remained flat recent years unlike regions increased significantly believe seasonal vaccination coverage europe increased target level per cent well reducing deaths illness help increase vaccine manufacturing capacity currently insufficient meet needs pandemic vaccine supply recognised european parliament resolutions advocacy key factor driving proposal issued european commission july calls member states develop concrete plans increase coverage rates per cent target level annual monitoring coverage rates member states encouraged eu order monitor progress proposal adopted health council december position paper influenza vaccines august szucs journal infection asian activity engaging governments asia value vaccines organisations engaged asiapacific economic cooperation apec forum industry associations involved none gsk position vaccines play major role preventing eliminating disease still underused many countries gsk engaging governments stakeholders asia raise awareness importance investment preventative health measures behalf industry gsk supported organised stakeholder perception survey life sciences innovation forum lsif official sub group asiapacific economic cooperation forum apec established apec leading regional organisation facilitating economic growth cooperation trade investment asia pacific region important forum reaching senior government officials policymakers asian countries recently lsif focused raising awareness among apec governments need invest health innovation help manage increasing costs ageing populations rising incidence chronic disease support work gsk initiated study stakeholder perceptions determine define value vaccines survey assessed current perceptions among legislators civil servants health finance economic planning ministries industry medical key opinion leaders vaccine advocacy groups thailand taiwan known chinese taipei apec showed stakeholders see value vaccines prevention death serious illness infectious diseases means reduce direct healthcare costs related treatment diseases however low awareness positive impact vaccines workforce participation productivity related benefits higher incomes economic growth little consideration benefits vaccine policymaking highlighting need make investment case vaccines among government agencies responsible budget allocation survey findings featured strongly lsif report endorsed apec foreign economictrade ministers meeting singapore gsk welcomes support apec ministers continuing raise awareness among government decisionmakers asia need invest preventive measures part health policy gsk committed ongoing dialogue stakeholders across asia continued involvement lsifs important work back top home responsibility public policy patient advocacy public policy activity advocacy research practices corporate responsibility report advocacy research practices regularly engage policy makers stakeholders issues concerns relating research practices research environment read research practices us activity implementation clinical trial registration requirements us organisations engaged us food drug administration us national library medicine industry associations involved phrma bio gsk position food drug administration amendments act fdaaa extends requirements post protocol summaries clinical trials initiated diseases national library medicines website clinicaltrialsgov previously requirement related serious lifethreatening diseases conditions act also includes requirements post results clinical trials phase drugs approved use us prior requirements gsk voluntarily posted protocol summaries clinical trials including phase studies clinicaltrialsgov fdaaa stated three years enactment information clinicaltrialsgov may expanded include following information provided secretary health human services determines type summary included without misleading promotional summary clinical trial results written nontechnical language patients summary clinical trial results technical nature fdaaa also includes language regarding potential study results posted unapproved products point future technical lay summaries believe scientific journals primary channel technical summaries provide necessary level detail technical audiences information subject peer review appropriate results published independent source research sponsor studies published journals example enough interest journals readers voluntarily committed summarising study findings clinical study register providing necessary context interpretation supplement result summary believe producing lay summaries individual trials raises number concerns needs carefully considered example producing lay summaries requires significant interpretation judgement author absence peer review could result concerns around introduction biases potential conflicts interest timing results reporting policy report results investigational medicines time approval within year decision terminate research compound believe required disclose results prior approval would provide little benefit patients doctors case products gain approval disclosure within year termination compound helps researchers determine whether development similar compound likely successful therefore helps reduce unnecessary patient exposure clinical trials european activity changes disclosure european clinical trials database organisations engaged european commission industry associations involved efpia gsk position pharmaceutical companies europe required post clinical trials protocols european clinical trials database eudract part application process regulatory approval trial european commission proposing parts eudract made publically available database expanded include results information commission also proposing discussion interpretation trial results sponsor competent authority made public eudract trial results made public within year end trial irrespective whether medicine approved believe proposals best interests patients scientific community could threaten data exclusivity highlighting concerns changes reasons outlined us clinical trial registration requirements example advocacy revision eu variations regulations organisations engaged european commission european parliament eu member states national regulatory agencies emea industry associations involved efpia evm europabio national trade associations gsk position medicinal product approved marketing changes example manufacturing processes prescribing information considered variations must handled according complex regulatory framework defined eu law variations regulations however historical reasons large majority products fell outside eu legislation subject divergent national rules procedures lack harmonisation places significant administrative burden industry national regulatory authorities adds unnecessary complexity objective revision variations regulations simplify legislative framework harmonise rules apply medicinal products gsk welcomed revision advocated simpler clearer flexible framework variations reduces number regulatory events associated postapproval changes associated regulatory burden enables predictability variations procedure timelines order beneficial changes introduced timely manner provides legislative framework accommodates 'flexible regulatory approaches ' outlined ich qqq guidelines introduces science riskbased approach managing postauthorisation changes facilitates innovation continual improvement pharmaceutical manufacturing european commission adopted framework legislation recently finalised key supporting guidelines intended ensure implementation manner consistent objectives advocacy european animal directive organisations engaged european commission european parliament european member states industry associations involved abpi efpia gsk position european animal directive originally introduced governs use animals experimental scientific purposes aims establish framework animal research activities within eu european commission published draft revision directive controls use laboratory animals sets minimum standards housing care gsk welcomes review directive recognises need revised reflect advances animal welfare science welcome many recommendations draft revision many already integrated current practices example welcome rules relating replacement reduction refinement use animals research known rs need animal welfare bodies establishments use animals research essential legislative changes achieve high animal welfare standards supporting environment allows research leads new medicines vaccines meet patients needs regard raised number concerns example proposed restrictions use non human primates diseases considered lifethreatening seriously debilitating read position statement use nonhuman primates research supporting new approach pharmacovigilance eu organisations engaged european commission european medicines agency uk government industry associations involved abpi efpia gsk position gsk seeks new approach pharmacovigilance regulation eu allow pharmaceutical companies regulators focus resources safety evaluation activities instead compliance unclear complex regulatory demands new pharmacovigilance legislation contain clear concise provisions simplify strengthen provide legal certainty eu legislative framework pharmacovigilance specifically contain single set simplified rules single reporting point adverse drug reactions eu require reporting serious cases electronic reporting system implemented contain clear flexible provisions allow individual companies appoint number qualified persons pharmacovigilance qppvs require provide consistent standards inspections company pharmacovigilance departments emea eu member state authorities back tophome responsibility public policy patient advocacy public policy activity advocacy research practices corporate responsibility report advocacy research practices regularly engage policy makers stakeholders issues concerns relating research practices research environment read research practices us activity implementation clinical trial registration requirements us organisations engaged us food drug administration us national library medicine industry associations involved phrma bio gsk position food drug administration amendments act fdaaa extends requirements post protocol summaries clinical trials initiated diseases national library medicines website clinicaltrialsgov previously requirement related serious lifethreatening diseases conditions act also includes requirements post results clinical trials phase drugs approved use us prior requirements gsk voluntarily posted protocol summaries clinical trials including phase studies clinicaltrialsgov fdaaa stated three years enactment information clinicaltrialsgov may expanded include following information provided secretary health human services determines type summary included without misleading promotional summary clinical trial results written nontechnical language patients summary clinical trial results technical nature fdaaa also includes language regarding potential study results posted unapproved products point future technical lay summaries believe scientific journals primary channel technical summaries provide necessary level detail technical audiences information subject peer review appropriate results published independent source research sponsor studies published journals example enough interest journals readers voluntarily committed summarising study findings clinical study register providing necessary context interpretation supplement result summary believe producing lay summaries individual trials raises number concerns needs carefully considered example producing lay summaries requires significant interpretation judgement author absence peer review could result concerns around introduction biases potential conflicts interest timing results reporting policy report results investigational medicines time approval within year decision terminate research compound believe required disclose results prior approval would provide little benefit patients doctors case products gain approval disclosure within year termination compound helps researchers determine whether development similar compound likely successful therefore helps reduce unnecessary patient exposure clinical trials european activity changes disclosure european clinical trials database organisations engaged european commission industry associations involved efpia gsk position pharmaceutical companies europe required post clinical trials protocols european clinical trials database eudract part application process regulatory approval trial european commission proposing parts eudract made publically available database expanded include results information commission also proposing discussion interpretation trial results sponsor competent authority made public eudract trial results made public within year end trial irrespective whether medicine approved believe proposals best interests patients scientific community could threaten data exclusivity highlighting concerns changes reasons outlined us clinical trial registration requirements example advocacy revision eu variations regulations organisations engaged european commission european parliament eu member states national regulatory agencies emea industry associations involved efpia evm europabio national trade associations gsk position medicinal product approved marketing changes example manufacturing processes prescribing information considered variations must handled according complex regulatory framework defined eu law variations regulations however historical reasons large majority products fell outside eu legislation subject divergent national rules procedures lack harmonisation places significant administrative burden industry national regulatory authorities adds unnecessary complexity objective revision variations regulations simplify legislative framework harmonise rules apply medicinal products gsk welcomed revision advocated simpler clearer flexible framework variations reduces number regulatory events associated postapproval changes associated regulatory burden enables predictability variations procedure timelines order beneficial changes introduced timely manner provides legislative framework accommodates 'flexible regulatory approaches ' outlined ich qqq guidelines introduces science riskbased approach managing postauthorisation changes facilitates innovation continual improvement pharmaceutical manufacturing european commission adopted framework legislation recently finalised key supporting guidelines intended ensure implementation manner consistent objectives advocacy european animal directive organisations engaged european commission european parliament european member states industry associations involved abpi efpia gsk position european animal directive originally introduced governs use animals experimental scientific purposes aims establish framework animal research activities within eu european commission published draft revision directive controls use laboratory animals sets minimum standards housing care gsk welcomes review directive recognises need revised reflect advances animal welfare science welcome many recommendations draft revision many already integrated current practices example welcome rules relating replacement reduction refinement use animals research known rs need animal welfare bodies establishments use animals research essential legislative changes achieve high animal welfare standards supporting environment allows research leads new medicines vaccines meet patients needs regard raised number concerns example proposed restrictions use non human primates diseases considered lifethreatening seriously debilitating read position statement use nonhuman primates research supporting new approach pharmacovigilance eu organisations engaged european commission european medicines agency uk government industry associations involved abpi efpia gsk position gsk seeks new approach pharmacovigilance regulation eu allow pharmaceutical companies regulators focus resources safety evaluation activities instead compliance unclear complex regulatory demands new pharmacovigilance legislation contain clear concise provisions simplify strengthen provide legal certainty eu legislative framework pharmacovigilance specifically contain single set simplified rules single reporting point adverse drug reactions eu require reporting serious cases electronic reporting system implemented contain clear flexible provisions allow individual companies appoint number qualified persons pharmacovigilance qppvs require provide consistent standards inspections company pharmacovigilance departments emea eu member state authorities back tophome responsibility public policy patient advocacy public policy activity advocacy research practices corporate responsibility report advocacy research practices regularly engage policy makers stakeholders issues concerns relating research practices research environment read research practices us activity implementation clinical trial registration requirements us organisations engaged us food drug administration us national library medicine industry associations involved phrma bio gsk position food drug administration amendments act fdaaa extends requirements post protocol summaries clinical trials initiated diseases national library medicines website clinicaltrialsgov previously requirement related serious lifethreatening diseases conditions act also includes requirements post results clinical trials phase drugs approved use us prior requirements gsk voluntarily posted protocol summaries clinical trials including phase studies clinicaltrialsgov fdaaa stated three years enactment information clinicaltrialsgov may expanded include following information provided secretary health human services determines type summary included without misleading promotional summary clinical trial results written nontechnical language patients summary clinical trial results technical nature fdaaa also includes language regarding potential study results posted unapproved products point future technical lay summaries believe scientific journals primary channel technical summaries provide necessary level detail technical audiences information subject peer review appropriate results published independent source research sponsor studies published journals example enough interest journals readers voluntarily committed summarising study findings clinical study register providing necessary context interpretation supplement result summary believe producing lay summaries individual trials raises number concerns needs carefully considered example producing lay summaries requires significant interpretation judgement author absence peer review could result concerns around introduction biases potential conflicts interest timing results reporting policy report results investigational medicines time approval within year decision terminate research compound believe required disclose results prior approval would provide little benefit patients doctors case products gain approval disclosure within year termination compound helps researchers determine whether development similar compound likely successful therefore helps reduce unnecessary patient exposure clinical trials european activity changes disclosure european clinical trials database organisations engaged european commission industry associations involved efpia gsk position pharmaceutical companies europe required post clinical trials protocols european clinical trials database eudract part application process regulatory approval trial european commission proposing parts eudract made publically available database expanded include results information commission also proposing discussion interpretation trial results sponsor competent authority made public eudract trial results made public within year end trial irrespective whether medicine approved believe proposals best interests patients scientific community could threaten data exclusivity highlighting concerns changes reasons outlined us clinical trial registration requirements example advocacy revision eu variations regulations organisations engaged european commission european parliament eu member states national regulatory agencies emea industry associations involved efpia evm europabio national trade associations gsk position medicinal product approved marketing changes example manufacturing processes prescribing information considered variations must handled according complex regulatory framework defined eu law variations regulations however historical reasons large majority products fell outside eu legislation subject divergent national rules procedures lack harmonisation places significant administrative burden industry national regulatory authorities adds unnecessary complexity objective revision variations regulations simplify legislative framework harmonise rules apply medicinal products gsk welcomed revision advocated simpler clearer flexible framework variations reduces number regulatory events associated postapproval changes associated regulatory burden enables predictability variations procedure timelines order beneficial changes introduced timely manner provides legislative framework accommodates 'flexible regulatory approaches ' outlined ich qqq guidelines introduces science riskbased approach managing postauthorisation changes facilitates innovation continual improvement pharmaceutical manufacturing european commission adopted framework legislation recently finalised key supporting guidelines intended ensure implementation manner consistent objectives advocacy european animal directive organisations engaged european commission european parliament european member states industry associations involved abpi efpia gsk position european animal directive originally introduced governs use animals experimental scientific purposes aims establish framework animal research activities within eu european commission published draft revision directive controls use laboratory animals sets minimum standards housing care gsk welcomes review directive recognises need revised reflect advances animal welfare science welcome many recommendations draft revision many already integrated current practices example welcome rules relating replacement reduction refinement use animals research known rs need animal welfare bodies establishments use animals research essential legislative changes achieve high animal welfare standards supporting environment allows research leads new medicines vaccines meet patients needs regard raised number concerns example proposed restrictions use non human primates diseases considered lifethreatening seriously debilitating read position statement use nonhuman primates research supporting new approach pharmacovigilance eu organisations engaged european commission european medicines agency uk government industry associations involved abpi efpia gsk position gsk seeks new approach pharmacovigilance regulation eu allow pharmaceutical companies regulators focus resources safety evaluation activities instead compliance unclear complex regulatory demands new pharmacovigilance legislation contain clear concise provisions simplify strengthen provide legal certainty eu legislative framework pharmacovigilance specifically contain single set simplified rules single reporting point adverse drug reactions eu require reporting serious cases electronic reporting system implemented contain clear flexible provisions allow individual companies appoint number qualified persons pharmacovigilance qppvs require provide consistent standards inspections company pharmacovigilance departments emea eu member state authorities back top home responsibility public policy patient advocacy public policy activity advocacy research practices corporate responsibility report advocacy research practices regularly engage policy makers stakeholders issues concerns relating research practices research environment read research practices us activity implementation clinical trial registration requirements us organisations engaged us food drug administration us national library medicine industry associations involved phrma bio gsk position food drug administration amendments act fdaaa extends requirements post protocol summaries clinical trials initiated diseases national library medicines website clinicaltrialsgov previously requirement related serious lifethreatening diseases conditions act also includes requirements post results clinical trials phase drugs approved use us prior requirements gsk voluntarily posted protocol summaries clinical trials including phase studies clinicaltrialsgov fdaaa stated three years enactment information clinicaltrialsgov may expanded include following information provided secretary health human services determines type summary included without misleading promotional summary clinical trial results written nontechnical language patients summary clinical trial results technical nature fdaaa also includes language regarding potential study results posted unapproved products point future technical lay summaries believe scientific journals primary channel technical summaries provide necessary level detail technical audiences information subject peer review appropriate results published independent source research sponsor studies published journals example enough interest journals readers voluntarily committed summarising study findings clinical study register providing necessary context interpretation supplement result summary believe producing lay summaries individual trials raises number concerns needs carefully considered example producing lay summaries requires significant interpretation judgement author absence peer review could result concerns around introduction biases potential conflicts interest timing results reporting policy report results investigational medicines time approval within year decision terminate research compound believe required disclose results prior approval would provide little benefit patients doctors case products gain approval disclosure within year termination compound helps researchers determine whether development similar compound likely successful therefore helps reduce unnecessary patient exposure clinical trials european activity changes disclosure european clinical trials database organisations engaged european commission industry associations involved efpia gsk position pharmaceutical companies europe required post clinical trials protocols european clinical trials database eudract part application process regulatory approval trial european commission proposing parts eudract made publically available database expanded include results information commission also proposing discussion interpretation trial results sponsor competent authority made public eudract trial results made public within year end trial irrespective whether medicine approved believe proposals best interests patients scientific community could threaten data exclusivity highlighting concerns changes reasons outlined us clinical trial registration requirements example advocacy revision eu variations regulations organisations engaged european commission european parliament eu member states national regulatory agencies emea industry associations involved efpia evm europabio national trade associations gsk position medicinal product approved marketing changes example manufacturing processes prescribing information considered variations must handled according complex regulatory framework defined eu law variations regulations however historical reasons large majority products fell outside eu legislation subject divergent national rules procedures lack harmonisation places significant administrative burden industry national regulatory authorities adds unnecessary complexity objective revision variations regulations simplify legislative framework harmonise rules apply medicinal products gsk welcomed revision advocated simpler clearer flexible framework variations reduces number regulatory events associated postapproval changes associated regulatory burden enables predictability variations procedure timelines order beneficial changes introduced timely manner provides legislative framework accommodates 'flexible regulatory approaches ' outlined ich qqq guidelines introduces science riskbased approach managing postauthorisation changes facilitates innovation continual improvement pharmaceutical manufacturing european commission adopted framework legislation recently finalised key supporting guidelines intended ensure implementation manner consistent objectives advocacy european animal directive organisations engaged european commission european parliament european member states industry associations involved abpi efpia gsk position european animal directive originally introduced governs use animals experimental scientific purposes aims establish framework animal research activities within eu european commission published draft revision directive controls use laboratory animals sets minimum standards housing care gsk welcomes review directive recognises need revised reflect advances animal welfare science welcome many recommendations draft revision many already integrated current practices example welcome rules relating replacement reduction refinement use animals research known rs need animal welfare bodies establishments use animals research essential legislative changes achieve high animal welfare standards supporting environment allows research leads new medicines vaccines meet patients needs regard raised number concerns example proposed restrictions use non human primates diseases considered lifethreatening seriously debilitating read position statement use nonhuman primates research supporting new approach pharmacovigilance eu organisations engaged european commission european medicines agency uk government industry associations involved abpi efpia gsk position gsk seeks new approach pharmacovigilance regulation eu allow pharmaceutical companies regulators focus resources safety evaluation activities instead compliance unclear complex regulatory demands new pharmacovigilance legislation contain clear concise provisions simplify strengthen provide legal certainty eu legislative framework pharmacovigilance specifically contain single set simplified rules single reporting point adverse drug reactions eu require reporting serious cases electronic reporting system implemented contain clear flexible provisions allow individual companies appoint number qualified persons pharmacovigilance qppvs require provide consistent standards inspections company pharmacovigilance departments emea eu member state authorities back top home responsibility public policy patient advocacy public policy activity advocacy patient safety corporate responsibility report advocacy patient safety us activity legislation prescription medicine imports organisations engaged us department health human services food drug administration fda us congress state boards pharmacy state legislators governors offices industry associations involved bio phrma gsk position current us law prevents prescription medicines imported us unless safety cost savings certifications secretary health human services pending legislation would remove safety savings certification requirements making easier legally import medicines would undermine fdas ability protect us distribution system counterfeit unsafe medicines could harm patients also guarantee consumers would save money department health human services found thirdparty payers insurance companies likely benefit gsk supports safer alternatives help patients afford medicines partnership prescription assistance ppa example gives access public private patient assistance programmes patients lack prescription drug coverage read gsks patient assistance programs read advocacy us healthcare reform european activity enhancing patient safety harmonised serialisation pharmaceutical products europe organisations engaged patient groups european commission european parliament eu member states wholesalers pharmacists sick funds industry associations involved efpia local pharmaceutical trade associations association european selfmedication industry aesgp europabio gsk position pharmaceutical supply chain europe complex millions packs moving around region year via numerous wholesaler intermediaries traders creates risk counterfeit products enter legitimate supply chain makes detecting tracing counterfeit medicines difficult world health organization identified trade involving several intermediaries free trade zones key driver counterfeiting activity december european commission introduced proposal tighten supervision european supply chain mandate introduction safety features aimed tracing authenticating pharmaceutical products key outcome commission proposal likely introduction serialisation whereby unique product identification codes applied prescription medicines allow tracking authentication prior dispensing patient gsk welcomes european commissions plans however believe number areas could strengthened enhance patient safety particular harmonised approach across europe standardised approach identification verification medicines across eu essential order pharmacist eu member state check whether pack dispensed helping detect duplicate counterfeit products supply chain whatever country origin without standardisation identification verification systems may differ countries making difficult identify products originating countries around million packs medicines currently parallel traded bought pharmaceutical companies one member state sold another year within eu system limited national schemes would ignore crossborder nature counterfeiting principle single market serialisation system based data matrix gsi standards data matrix ecc currently efficient effective data carrier available capable meeting needs stakeholders pharmaceutical supply chain highly reliable quickly read enables large amount data stored small space compared methods data carrier could implemented products within three four years reasonable cost commission proposal discussed voted european parliament council codecision procedure first half use consultation advocate need european harmonisation read position statement counterfeiting back tophome responsibility public policy patient advocacy public policy activity advocacy patient safety corporate responsibility report advocacy patient safety us activity legislation prescription medicine imports organisations engaged us department health human services food drug administration fda us congress state boards pharmacy state legislators governors offices industry associations involved bio phrma gsk position current us law prevents prescription medicines imported us unless safety cost savings certifications secretary health human services pending legislation would remove safety savings certification requirements making easier legally import medicines would undermine fdas ability protect us distribution system counterfeit unsafe medicines could harm patients also guarantee consumers would save money department health human services found thirdparty payers insurance companies likely benefit gsk supports safer alternatives help patients afford medicines partnership prescription assistance ppa example gives access public private patient assistance programmes patients lack prescription drug coverage read gsks patient assistance programs read advocacy us healthcare reform european activity enhancing patient safety harmonised serialisation pharmaceutical products europe organisations engaged patient groups european commission european parliament eu member states wholesalers pharmacists sick funds industry associations involved efpia local pharmaceutical trade associations association european selfmedication industry aesgp europabio gsk position pharmaceutical supply chain europe complex millions packs moving around region year via numerous wholesaler intermediaries traders creates risk counterfeit products enter legitimate supply chain makes detecting tracing counterfeit medicines difficult world health organization identified trade involving several intermediaries free trade zones key driver counterfeiting activity december european commission introduced proposal tighten supervision european supply chain mandate introduction safety features aimed tracing authenticating pharmaceutical products key outcome commission proposal likely introduction serialisation whereby unique product identification codes applied prescription medicines allow tracking authentication prior dispensing patient gsk welcomes european commissions plans however believe number areas could strengthened enhance patient safety particular harmonised approach across europe standardised approach identification verification medicines across eu essential order pharmacist eu member state check whether pack dispensed helping detect duplicate counterfeit products supply chain whatever country origin without standardisation identification verification systems may differ countries making difficult identify products originating countries around million packs medicines currently parallel traded bought pharmaceutical companies one member state sold another year within eu system limited national schemes would ignore crossborder nature counterfeiting principle single market serialisation system based data matrix gsi standards data matrix ecc currently efficient effective data carrier available capable meeting needs stakeholders pharmaceutical supply chain highly reliable quickly read enables large amount data stored small space compared methods data carrier could implemented products within three four years reasonable cost commission proposal discussed voted european parliament council codecision procedure first half use consultation advocate need european harmonisation read position statement counterfeiting back top home responsibility public policy patient advocacy public policy activity advocacy patient safety corporate responsibility report advocacy patient safety us activity legislation prescription medicine imports organisations engaged us department health human services food drug administration fda us congress state boards pharmacy state legislators governors offices industry associations involved bio phrma gsk position current us law prevents prescription medicines imported us unless safety cost savings certifications secretary health human services pending legislation would remove safety savings certification requirements making easier legally import medicines would undermine fdas ability protect us distribution system counterfeit unsafe medicines could harm patients also guarantee consumers would save money department health human services found thirdparty payers insurance companies likely benefit gsk supports safer alternatives help patients afford medicines partnership prescription assistance ppa example gives access public private patient assistance programmes patients lack prescription drug coverage read gsks patient assistance programs read advocacy us healthcare reform european activity enhancing patient safety harmonised serialisation pharmaceutical products europe organisations engaged patient groups european commission european parliament eu member states wholesalers pharmacists sick funds industry associations involved efpia local pharmaceutical trade associations association european selfmedication industry aesgp europabio gsk position pharmaceutical supply chain europe complex millions packs moving around region year via numerous wholesaler intermediaries traders creates risk counterfeit products enter legitimate supply chain makes detecting tracing counterfeit medicines difficult world health organization identified trade involving several intermediaries free trade zones key driver counterfeiting activity december european commission introduced proposal tighten supervision european supply chain mandate introduction safety features aimed tracing authenticating pharmaceutical products key outcome commission proposal likely introduction serialisation whereby unique product identification codes applied prescription medicines allow tracking authentication prior dispensing patient gsk welcomes european commissions plans however believe number areas could strengthened enhance patient safety particular harmonised approach across europe standardised approach identification verification medicines across eu essential order pharmacist eu member state check whether pack dispensed helping detect duplicate counterfeit products supply chain whatever country origin without standardisation identification verification systems may differ countries making difficult identify products originating countries around million packs medicines currently parallel traded bought pharmaceutical companies one member state sold another year within eu system limited national schemes would ignore crossborder nature counterfeiting principle single market serialisation system based data matrix gsi standards data matrix ecc currently efficient effective data carrier available capable meeting needs stakeholders pharmaceutical supply chain highly reliable quickly read enables large amount data stored small space compared methods data carrier could implemented products within three four years reasonable cost commission proposal discussed voted european parliament council codecision procedure first half use consultation advocate need european harmonisation read position statement counterfeiting back top home responsibility public policy patient advocacy public policy activity advocacy intellectual property corporate responsibility report advocacy intellectual property global activity access benefit sharing disclosure obligation patent law organisations engaged secretariat convention biological diversity cbd ad hoc working group access benefit sharing uk department environment food rural affairs dg trade european commission national european governments us government world intellectual property organization world trade organization industry associations involved bio bpg efpia icc ifpma phrma gsk position benefit sharing means sharing benefits arising use genetic resources proposed international regime access benefit sharing still discussion within convention biological diversity cbd believe outcome discussions formal deadline october consistent cbd treaty provide guidance achieve access benefit sharing objectives rather prescribing rules apply genetic resources defined cbd broader class materials extend human genetic resources derivatives pathogens viruses respect national borders excluded scope international regime article cbd defines biological genetic resources either actual potential use value humanity however pathogens present threat biodiversity overall ecosystem hence societal efforts eradicate control pathogens means reasonable interpretation article exclude pathogens scope regime believe countries adopted local laws envisaged cbd receive kind protection compensation envisaged convention makes introduction disclosure obligation whereby patent applications would disclose origin genetic resources used invention unnecessary disclosure obligation would also create legal commercial uncertainties researchers companies developing products using genetic resources discouraging innovation ultimately leading fewer benefits share read position statement proposals disclosure requirement patent applications read position statement convention biological diversity us activity us patent system reform federal legislation organisations engaged patent trademark office pto us congress industry associations involved bio coalition st century patent reform phrma gsk position patent law framework provides business certainty long period promotes investment essential researchbased pharmaceutical industry wide range manufacturers long lead times research market us congress made progress drafting legislation provides meaningful patent reform preserving incentives necessary sustain innovation spur creation highwage highvalue jobs thoughtful compromise key issues including postgrant review damages allow bill move legislative process near future gsk working coalition researchbased companies manufacturers universities small inventors promote us patent reform stimulates investment research strengthens patent system support patent reforms clear provide business certainty improve qualityp aogfe pate onf ts remove subjectivity litigation issues european activity creation uk patent box taxation foreign profits made british companies organisations engaged uk government office life sciences hm treasury industry associations involved confederation british industry cbi hundred group association british pharmaceutical industry abpi bioindustry association bia gsk position july uk treasury published draft proposals change way foreign profits uk companies taxed part impose uk tax income attributed intellectual property ip wherever world income generated proposal gave us serious cause concern high percentage profits pharmaceutical industry attributed patents gsk operations around globe managed approximately subsidiaries four per cent sales uk implemented draft proposal would potentially increased global tax rate several percent gsks global tax rate already one highest pharmaceutical sector increase would make business less competitive annual report provides detail tax rate relatively high corporation tax burden uk historically contributed decision increase investment primarily manufacturing countries competitive rates tax singapore ireland belgium accepted need reform tax rules foreign profits urged government think proposal tax global income attributed ip support abpi bia cbi proposed government introduces patent box would provide low rate tax income attributed ip would encourage researchbased companies invest uk december prebudget report government announced introduce patent box uk following consultation period gsk welcomes development since announced invest additional million uk assuming consultation delivers effective patent box asian activity healthcare intellectual property india organisations engaged relevant agencies indian government members pharmaceutical industry wider business community india indian academics civil society representatives us eu member state governments european commission industry associations involved bpg efpia organisation pharmaceutical producers india oppi phrma gsk position believe indias tremendous strengths science pharmaceuticals coupled rapid economic growth offer government opportunity tackle fundamental characteristics healthcare system policy base improvements indias intellectual property ip regime level provided eu us could encourage investment collaborative rd without constituting major barrier access believe reform increased investment indian healthcare system particularly areas prevention vaccination priority want active partners addressing challenges back tophome responsibility public policy patient advocacy public policy activity advocacy intellectual property corporate responsibility report advocacy intellectual property global activity access benefit sharing disclosure obligation patent law organisations engaged secretariat convention biological diversity cbd ad hoc working group access benefit sharing uk department environment food rural affairs dg trade european commission national european governments us government world intellectual property organization world trade organization industry associations involved bio bpg efpia icc ifpma phrma gsk position benefit sharing means sharing benefits arising use genetic resources proposed international regime access benefit sharing still discussion within convention biological diversity cbd believe outcome discussions formal deadline october consistent cbd treaty provide guidance achieve access benefit sharing objectives rather prescribing rules apply genetic resources defined cbd broader class materials extend human genetic resources derivatives pathogens viruses respect national borders excluded scope international regime article cbd defines biological genetic resources either actual potential use value humanity however pathogens present threat biodiversity overall ecosystem hence societal efforts eradicate control pathogens means reasonable interpretation article exclude pathogens scope regime believe countries adopted local laws envisaged cbd receive kind protection compensation envisaged convention makes introduction disclosure obligation whereby patent applications would disclose origin genetic resources used invention unnecessary disclosure obligation would also create legal commercial uncertainties researchers companies developing products using genetic resources discouraging innovation ultimately leading fewer benefits share read position statement proposals disclosure requirement patent applications read position statement convention biological diversity us activity us patent system reform federal legislation organisations engaged patent trademark office pto us congress industry associations involved bio coalition st century patent reform phrma gsk position patent law framework provides business certainty long period promotes investment essential researchbased pharmaceutical industry wide range manufacturers long lead times research market us congress made progress drafting legislation provides meaningful patent reform preserving incentives necessary sustain innovation spur creation highwage highvalue jobs thoughtful compromise key issues including postgrant review damages allow bill move legislative process near future gsk working coalition researchbased companies manufacturers universities small inventors promote us patent reform stimulates investment research strengthens patent system support patent reforms clear provide business certainty improve quality patents remove subjectivity litigation issues european activity creation uk patent box taxation foreign profits made british companies organisations engaged uk government office life sciences hm treasury industry associations involved confederation british industry cbi hundred group association british pharmaceutical industry abpi bioindustry association bia gsk position july uk treasury published draft proposals change way foreign profits uk companies taxed part impose uk tax income attributed intellectual property ip wherever world income generated proposal gave us serious cause concern high percentage profits pharmaceutical industry attributed patents gsk operations around globe managed approximately subsidiaries four per cent sales uk implemented draft proposal would potentially increased global tax rate several percent gsks global tax rate already one highest pharmaceutical sector increase would make business less competitive annual report provides detail tax rate relatively high corporation tax burden uk historically contributed decision increase investment primarily manufacturing countries competitive rates tax singapore ireland belgium accepted need reform tax rules foreign profits urged government think proposal tax global income attributed ip support abpi bia cbi proposed government introduces patent box would provide low rate tax income attributed ip would encourage researchbased companies invest uk december prebudget report government announced introduce patent box uk following consultation period gsk welcomes development since announced invest additional million uk assuming consultation delivers effective patent box asian activity healthcare intellectual property india organisations engaged relevant agencies indian government members pharmaceutical industry wider business community india indian academics civil society representatives us eu member state governments european commission industry associations involved bpg efpia organisation pharmaceutical producers india oppi phrma gsk position believe indias tremendous strengths science pharmaceuticals coupled rapid economic growth offer government opportunity tackle fundamental characteristics healthcare system policy base improvements indias intellectual property ip regime level provided eu us could encourage investment collaborative rd without constituting major barrier access believe reform increased investment indian healthcare system particularly areas prevention vaccination priority want active partners addressing challenges back top home responsibility public policy patient advocacy public policy activity advocacy intellectual property corporate responsibility report advocacy intellectual property global activity access benefit sharing disclosure obligation patent law organisations engaged secretariat convention biological diversity cbd ad hoc working group access benefit sharing uk department environment food rural affairs dg trade european commission national european governments us government world intellectual property organization world trade organization industry associations involved bio bpg efpia icc ifpma phrma gsk position benefit sharing means sharing benefits arising use genetic resources proposed international regime access benefit sharing still discussion within convention biological diversity cbd believe outcome discussions formal deadline october consistent cbd treaty provide guidance achieve access benefit sharing objectives rather prescribing rules apply genetic resources defined cbd broader class materials extend human genetic resources derivatives pathogens viruses respect national borders excluded scope international regime article cbd defines biological genetic resources either actual potential use value humanity however pathogens present threat biodiversity overall ecosystem hence societal efforts eradicate control pathogens means reasonable interpretation article exclude pathogens scope regime believe countries adopted local laws envisaged cbd receive kind protection compensation envisaged convention makes introduction disclosure obligation whereby patent applications would disclose origin genetic resources used invention unnecessary disclosure obligation would also create legal commercial uncertainties researchers companies developing products using genetic resources discouraging innovation ultimately leading fewer benefits share read position statement proposals disclosure requirement patent applications read position statement convention biological diversity us activity us patent system reform federal legislation organisations engaged patent trademark office pto us congress industry associations involved bio coalition st century patent reform phrma gsk position patent law framework provides business certainty long period promotes investment essential researchbased pharmaceutical industry wide range manufacturers long lead times research market us congress made progress drafting legislation provides meaningful patent reform preserving incentives necessary sustain innovation spur creation highwage highvalue jobs thoughtful compromise key issues including postgrant review damages allow bill move legislative process near future gsk working coalition researchbased companies manufacturers universities small inventors promote us patent reform stimulates investment research strengthens patent system support patent reforms clear provide business certainty improve quality patents remove subjectivity litigation issues european activity creation uk patent box taxation foreign profits made british companies organisations engaged uk government office life sciences hm treasury industry associations involved confederation british industry cbi hundred group association british pharmaceutical industry abpi bioindustry association bia gsk position july uk treasury published draft proposals change way foreign profits uk companies taxed part impose uk tax income attributed intellectual property ip wherever world income generated proposal gave us serious cause concern high percentage profits pharmaceutical industry attributed patents gsk operations around globe managed approximately subsidiaries four per cent sales uk implemented draft proposal would potentially increased global tax rate several percent gsks global tax rate already one highest pharmaceutical sector increase would make business less competitive annual report provides detail tax rate relatively high corporation tax burden uk historically contributed decision increase investment primarily manufacturing countries competitive rates tax singapore ireland belgium accepted need reform tax rules foreign profits urged government think proposal tax global income attributed ip support abpi bia cbi proposed government introduces patent box would provide low rate tax income attributed ip would encourage researchbased companies invest uk december prebudget report government announced introduce patent box uk following consultation period gsk welcomes development since announced invest additional million uk assuming consultation delivers effective patent box asian activity healthcare intellectual property india organisations engaged relevant agencies indian government members pharmaceutical industry wider business community india indian academics civil society representatives us eu member state governments european commission industry associations involved bpg efpia organisation pharmaceutical producers india oppi phrma gsk position believe indias tremendous strengths science pharmaceuticals coupled rapid economic growth offer government opportunity tackle fundamental characteristics healthcare system policy base improvements indias intellectual property ip regime level provided eu us could encourage investment collaborative rd without constituting major barrier access believe reform increased investment indian healthcare system particularly areas prevention vaccination priority want active partners addressing challenges back top home responsibility public policy patient advocacy public policy activity advocacy pricing competitiveness corporate responsibility report advocacy pricing competitiveness european activity office life sciences organisations engaged uk government office life sciences department health industry associations involved association british pharmaceutical industry abpi bioindustry association bia british vitro diagnostic association bivda association british healthcare industries abhi gsk position following impact global financial crisis uk economy government working assess action could taken ensure less reliance financial sector allow sectors make greater economic contribution uk office life sciences ols established february find ways strengthen uk life sciences sector ols focused three key areas take action stem decline ukbased pharmaceutical manufacturing create increased opportunities collaboration industry academia develop stronger biotech base ensure uk gains maximum advantage pharmaceutical industry 's increasingly open rd model improve use innovative new medicines national health service nhs consequently perception uk country embraces medical innovation developed series proposals partnership uk trade associations companies gsk took lead following proposals patent box proposed creation 'patent box ' uk provide low rate corporation tax income attributed patents read creating patent box government announced december introduce patent box creation life science clusters promote industryacademic collaboration believe could done encourage greater collaboration industry academia life science sector january government announced plans new uk life sciences super cluster supported million government investment bring together industry academia nhs helping deliver next generation medicines technologies needed support patients chronic diseases addition gsk wellcome trust partnership government fund development biosciences park gsk 's rd site stevenage innovation pass government agreed ringfence funding new technologies used small patient populations promise delivering real patient benefit launch data available show costeffectiveness extent required national institute health clinical excellence nice medicines receive 'innovation pass ' funded nhs three years needing go nice formal review consultation launched november anticipate first medicines funded new system back top home responsibility public policy patient advocacy public policy activity advocacy pricing competitiveness corporate responsibility report advocacy pricing competitiveness european activity office life sciences organisations engaged uk government office life sciences department health industry associations involved association british pharmaceutical industry abpi bioindustry association bia british vitro diagnostic association bivda association british healthcare industries abhi gsk position following impact global financial crisis uk economy government working assess action could taken ensure less reliance financial sector allow sectors make greater economic contribution uk office life sciences ols established february find ways strengthen uk life sciences sector ols focused three key areas take action stem decline ukbased pharmaceutical manufacturing create increased opportunities collaboration industry academia develop stronger biotech base ensure uk gains maximum advantage pharmaceutical industry 's increasingly open rd model improve use innovative new medicines national health service nhs consequently perception uk country embraces medical innovation developed series proposals partnership uk trade associations companies gsk took lead following proposals patent box proposed creation 'patent box ' uk provide low rate corporation tax income attributed patents read creating patent box government announced december introduce patent box creation life science clusters promote industryacademic collaboration believe could done encourage greater collaboration industry academia life science sector january government announced plans new uk life sciences super cluster supported million government investment bring together industry academia nhs helping deliver next generation medicines technologies needed support patients chronic diseases addition gsk wellcome trust partnership government fund development biosciences park gsk 's rd site stevenage innovation pass government agreed ringfence funding new technologies used small patient populations promise delivering real patient benefit launch data available show costeffectiveness extent required national institute health clinical excellence nice medicines receive 'innovation pass ' funded nhs three years needing go nice formal review consultation launched november anticipate first medicines funded new system back top home responsibility public policy patient advocacy political contributions lobbying expenditures corporate responsibility report political contributions lobbying expenditures gsk make corporate political contributions disclose voluntary political contributions made us employees political action committee federal lobbying expenditure costs well costs lobbying eu institutions political action committee contributions accordance federal election campaign act gsk established political action committee pac facilitates voluntary political contributions eligible employees pac controlled gsk decisions amount recipients contributions made participating employees exercising legal right pool resources make political contributions pac contributions voluntary contributions subject strict limitations example gsk pac may contribute per election individual candidate federal office pac run governing board participating gsk employees across company required law pac contributions reported federal elections commission fec gsk employees pac contributed per cent republicans per cent democrats per cent unaffiliated party candidates running state federal offices lobbying expenditure europe december gsk signed european commissions new code conduct voluntary register organisations working influence eu institutions transparency register interest declared costs associated lobbying eu institutions range includes running brussels advocacy office salaries external events educational materials figure takes account proportion employee time spent interest representation us report us lobbying expenditures us congress accordance lobbying disclosure act spent million federal lobbying activities us includes costs salaries benefits employees registered lobby us government use lobbying consultants support lobbying contacts planning activities research running gsk washington dc government affairs office support staff portion trade association fees associated federal lobbying also report state lobbying expenses line applicable state laws contributions policy groups gsk contributes various groups provide forum policy analysis debate includes think tanks number countries `` organisations us home responsibility public policy patient advocacy political contributions lobbying expenditures corporate responsibility report political contributions lobbying expenditures gsk make corporate political contributions disclose voluntary political contributions made us employees political action committee federal lobbying expenditure costs well costs lobbying eu institutions political action committee contributions accordance federal election campaign act gsk established political action committee pac facilitates voluntary political contributions eligible employees pac controlled gsk decisions amount recipients contributions made participating employees exercising legal right pool resources make political contributions pac contributions voluntary contributions subject strict limitations example gsk pac may contribute per election individual candidate federal office pac run governing board participating gsk employees across company required law pac contributions reported federal elections commission fec gsk employees pac contributed per cent republicans per cent democrats per cent unaffiliated party candidates running state federal offices lobbying expenditure europe december gsk signed european commissions new code conduct voluntary register organisations working influence eu institutions transparency register interest declared costs associated lobbying eu institutions range includes running brussels advocacy office salaries external events educational materials figure takes account proportion employee time spent interest representation us report us lobbying expenditures us congress accordance lobbying disclosure act spent million federal lobbying activities us includes costs salaries benefits employees registered lobby us government use lobbying consultants support lobbying contacts planning activities research running gsk washington dc government affairs office support staff portion trade association fees associated federal lobbying also report state lobbying expenses line applicable state laws contributions policy groups gsk contributes various groups provide forum policy analysis debate includes think tanks number countries `` organisations us home responsibility public policy patient advocacy patient advocacy corporate responsibility report patient advocacy patient groups nonprofit organisations founded patients caregivers family members health professionals provide members information condition guidance live disease engage healthcare providers governments media promote improved treatment services patients campaign change issues affect patients carers lives carry vital research causes potential treatments specific conditions gsk works wide range patient groups disease areas cancer asthma diabetes alzheimers disease multiple sclerosis hivaids gsk patient groups share common concern healthcare systems focus preventing treating managing disease parties believe patients access quality medicines services information disease patient groups important stakeholders gsk engage part commitment patientfocused company relationships patient groups mutually beneficial help us better understand patient needs illnesses work patient groups strengthen support patients throughout illness diagnosis chronic treatment endoflife care support helps patients make voice heard healthcare debate alongside stakeholders approach support patient groups across world number different ways include providing core funding support daytoday running group oneoff donations help patient groups conduct specific event activity example breast cancer awareness day educational support training staff management skills disease education working together disease awarenessprevention projects relationship patient group defined written agreement specifying group use funding benefit members stakeholders concerned pharmaceutical companies use patient groups way marketing products support patient groups designed market products influence factors dictate whether new medicines made available patients whether patients access kind treatments need committed maintaining highest ethical standards transparency area developed detailed guidance standard operating procedures sops employees major regions policies used conjunction gsks patient advocacy manual ensure gsk employees work patient groups comply applicable laws regulations standards read summary sop want raise standards across whole sector collaborate companies industry groups develop industrywide standards employees outside agencies working gsk likely interact patient groups must abide guidelines sops provide training employees understand requirements patient advocacy teams europe asia pacific japan emerging markets region coordinate interaction patient groups adherence policies global principles us patient advocacy decentralised across public policy advocacy function well rd communications marketing took steps consolidate patient advocacy activities grouping policy related activities public policy advocacy function employees regions access patient advocacy resource intranet site europe also publish newsletter raise employee awareness internal external developments relating patient groups us developing customer relationship management system improve coordination employees working external groups system enable employees learn past interactions patient groups help us allocate resources patient groups efficiently piloted database plan launch system across company encouraging independence believe patient groups independent encourage seek financial support wide range organisations possible ensure funding give patient groups appropriate size guidelines state gsk funding make per cent groups overall income vast majority instances actual percentage much lower allow exemptions per cent cap groups supported limited incomes small donation example would exceed limit groups difficulty attracting funding nature activity example providing needle exchange drug users cases must approved general manager local operating company also encourage patient groups seek funding multiple sources hold workshops make funding applicationshome responsibility public policy patient advocacy patient advocacy corporate responsibility report patient advocacy patient groups nonprofit organisations founded patients caregivers family members health professionals provide members information condition guidance live disease engage healthcare providers governments media promote improved treatment services patients campaign change issues affect patients carers lives carry vital research causes potential treatments specific conditions gsk works wide range patient groups disease areas cancer asthma diabetes alzheimers disease multiple sclerosis hivaids gsk patient groups share common concern healthcare systems focus preventing treating managing disease parties believe patients access quality medicines services information disease patient groups important stakeholders gsk engage part commitment patientfocused company relationships patient groups mutually beneficial help us better understand patient needs illnesses work patient groups strengthen support patients throughout illness diagnosis chronic treatment endoflife care support helps patients make voice heard healthcare debate alongside stakeholders approach support patient groups across world number different ways include providing core funding support daytoday running group oneoff donations help patient groups conduct specific event activity example breast cancer awareness day educational support training staff management skills disease education working together disease awarenessprevention projects relationship patient group defined written agreement specifying group use funding benefit members stakeholders concerned pharmaceutical companies use patient groups way marketing products support patient groups designed market products influence factors dictate whether new medicines made available patients whether patients access kind treatments need committed maintaining highest ethical standards transparency area developed detailed guidance standard operating procedures sops employees major regions policies used conjunction gsks patient advocacy manual ensure gsk employees work patient groups comply applicable laws regulations standards read summary sop want raise standards across whole sector collaborate companies industry groups develop industrywide standards employees outside agencies working gsk likely interact patient groups must abide guidelines sops provide training employees understand requirements patient advocacy teams europe asia pacific japan emerging markets region coordinate interaction patient groups adherence policies global principles us patient advocacy decentralised across public policy advocacy function well rd communications marketing took steps consolidate patient advocacy activities grouping policy related activities public policy advocacy function employees regions access patient advocacy resource intranet site europe also publish newsletter raise employee awareness internal external developments relating patient groups us developing customer relationship management system improve coordination employees working external groups system enable employees learn past interactions patient groups help us allocate resources patient groups efficiently piloted database plan launch system across company encouraging independence believe patient groups independent encourage seek financial support wide range organisations possible ensure funding give patient groups appropriate size guidelines state gsk funding make per cent groups overall income vast majority instances actual percentage much lower allow exemptions per cent cap groups supported limited incomes small donation example would exceed limit groups difficulty attracting funding nature activity example providing needle exchange drug users cases must approved general manager local operating company also encourage patient groups seek funding multiple sources hold workshops make funding applications home responsibility public policy patient advocacy patient advocacy corporate responsibility report patient advocacy patient groups nonprofit organisations founded patients caregivers family members health professionals provide members information condition guidance live disease engage healthcare providers governments media promote improved treatment services patients campaign change issues affect patients carers lives carry vital research causes potential treatments specific conditions gsk works wide range patient groups disease areas cancer asthma diabetes alzheimers disease multiple sclerosis hivaids gsk patient groups share common concern healthcare systems focus preventing treating managing disease parties believe patients access quality medicines services information disease patient groups important stakeholders gsk engage part commitment patientfocused company relationships patient groups mutually beneficial help us better understand patient needs illnesses work patient groups strengthen support patients throughout illness diagnosis chronic treatment endoflife care support helps patients make voice heard healthcare debate alongside stakeholders approach support patient groups across world number different ways include providing core funding support daytoday running group oneoff donations help patient groups conduct specific event activity example breast cancer awareness day educational support training staff management skills disease education working together disease awarenessprevention projects relationship patient group defined written agreement specifying group use funding benefit members stakeholders concerned pharmaceutical companies use patient groups way marketing products support patient groups designed market products influence factors dictate whether new medicines made available patients whether patients access kind treatments need committed maintaining highest ethical standards transparency area developed detailed guidance standard operating procedures sops employees major regions policies used conjunction gsks patient advocacy manual ensure gsk employees work patient groups comply applicable laws regulations standards read summary sop want raise standards across whole sector collaborate companies industry groups develop industrywide standards employees outside agencies working gsk likely interact patient groups must abide guidelines sops provide training employees understand requirements patient advocacy teams europe asia pacific japan emerging markets region coordinate interaction patient groups adherence policies global principles us patient advocacy decentralised across public policy advocacy function well rd communications marketing took steps consolidate patient advocacy activities grouping policy related activities public policy advocacy function employees regions access patient advocacy resource intranet site europe also publish newsletter raise employee awareness internal external developments relating patient groups us developing customer relationship management system improve coordination employees working external groups system enable employees learn past interactions patient groups help us allocate resources patient groups efficiently piloted database plan launch system across company encouraging independence believe patient groups independent encourage seek financial support wide range organisations possible ensure funding give patient groups appropriate size guidelines state gsk funding make per cent groups overall income vast majority instances actual percentage much lower allow exemptions per cent cap groups supported limited incomes small donation example would exceed limit groups difficulty attracting funding nature activity example providing needle exchange drug users cases must approved general manager local operating company also encourage patient groups seek funding multiple sources hold workshops make funding applications home responsibility public policy patient advocacy patient advocacy transparency corporate responsibility report transparency believe transparent support patient groups helps build trust stakeholders including groups publish information work patient groups europe asia pacific japan emerging markets regions well information support patient groups working globally including details funding received see details funding patient organisations first pharmaceutical company publish level information goes beyond industry codes practice require list groups funded detailed information gsk australia canada found websites us february began publishing information educational charitable grants provided healthrelated organisations including hospitals teaching institutions patient advocacy groups report updated quarterly working patient groups standard operating procedures state involvement patient organisation must declared transparent gsk must neither seek patient organisation endorsement medicines pay patient groups endorse gsk services medicines must promoted patient organisations gsk must create patient organisations must sole funding sponsor patient organisation provide per cent funding patient organisations exceptions may allowed case rare disease focus startup funding per cent however must agreed directly local country region general manager head regional government affairs gsk must seek direct return investment funding patient organisation information gsk pipeline compounds must factual nonpromotional provided patient organisations part scientific dialogue acceptable gsk clinical trials medical personnel work patient organisations ensure optimal clinical trial recruitment consult clinical trial design protocols gsk must directly sponsor patient organisation representatives attend medical congresses conferences healthcare professional events exceptions include representative invited speak conference medical congress specific workstream designed patients gsk may sponsor representatives attend nonmedical congresses gsk may pay modest honorarium speaker fee patient organisation advisory board member speaker represents third party working gsk given project must fully transparent relationship interacting patient group project back top home responsibility public policy patient advocacy patient advocacy transparency corporate responsibility report transparency believe transparent support patient groups helps build trust stakeholders including groups publish information work patient groups europe asia pacific japan emerging markets regions well information support patient groups working globally including details funding received see details funding patient organisations first pharmaceutical company publish level information goes beyond industry codes practice require list groups funded detailed information gsk australia canada found websites us february began publishing information educational charitable grants provided healthrelated organisations including hospitals teaching institutions patient advocacy groups report updated quarterly working patient groups standard operating procedures state involvement patient organisation must declared transparent gsk must neither seek patient organisation endorsement medicines pay patient groups endorse gsk services medicines must promoted patient organisations gsk must create patient organisations must sole funding sponsor patient organisation provide per cent funding patient organisations exceptions may allowed case rare disease focus startup funding per cent however must agreed directly local country region general manager head regional government affairs gsk must seek direct return investment funding patient organisation information gsk pipeline compounds must factual nonpromotional provided patient organisations part scientific dialogue acceptable gsk clinical trials medical personnel work patient organisations ensure optimal clinical trial recruitment consult clinical trial design protocols gsk must directly sponsor patient organisation representatives attend medical congresses conferences healthcare professional events exceptions include representative invited speak conference medical congress specific workstream designed patients gsk may sponsor representatives attend nonmedical congresses gsk may pay modest honorarium speaker fee patient organisation advisory board member speaker represents third party working gsk given project must fully transparent relationship interacting patient group project back top home responsibility public policy patient advocacy patient advocacy understanding patients corporate responsibility report understanding patients help us better understand patient needs set advisory boards us europe include representatives wide range patient groups advisory boards independent chairs meet regularly attended senior gsk managers boards enable voice patients heard highest levels gsk also allow us access views patient groups seek feedback subjects clinical trials pharmacogenetics information provided patients ethical issues regions invite speakers patient groups meet gsk employees including scientists researchers marketers discuss issues affecting members well improving understanding patient needs shows gsk employees difference work make peoples lives read focus patient initiative helping us better understand patient needs develop better medicines also engage patient groups patient advocacy leaders summits pals bring groups together discuss health policy concerns develop new skills andor ways expand influence pals also give patient groups opportunity learn gsk tell company better support work involved running total summits five meetings european countries one japan ten throughout us discussions pals focused broad range issues including healthcare reform health disparities us including reform debate include discussions prevention innovation intervention efforts us see detail national pals meeting read advocacy us healthcare reform contribution vaccines public health overcome misinformation misperceptions immunisations us mental health prevention wellness military us role patient organisations scientific research netherlands costs swiss healthcare system implications patients introduction managed care systems new fee paying system swiss hospitals switzerland improving healthcare japan including empower patients improve working condition hospital doctors japan patient access medicines latvia european patient forum gsk cosponsored european patient forums annual conference gothenburg pharmaceutical companies pfizer amgen brought together approximately patient groups stakeholders exchange ideas improving healthcare increasing involvement patient organisations delivery healthcare us national pals meeting us national pals meeting focused healthcare reform health disparities participants discussed reform debate include prevention innovation intervention efforts speakers included former us surgeon general leaders minority health associations us following event held regional conferences webinars delved deeper regional concerns addressed specific ways overcome barriers healthcare patient groups represented across events approximately participants total back top home responsibility public policy patient advocacy patient advocacy understanding patients corporate responsibility report understanding patients help us better understand patient needs set advisory boards us europe include representatives wide range patient groups advisory boards independent chairs meet regularly attended senior gsk managers boards enable voice patients heard highest levels gsk also allow us access views patient groups seek feedback subjects clinical trials pharmacogenetics information provided patients ethical issues regions invite speakers patient groups meet gsk employees including scientists researchers marketers discuss issues affecting members well improving understanding patient needs shows gsk employees difference work make peoples lives read focus patient initiative helping us better understand patient needs develop better medicines also engage patient groups patient advocacy leaders summits pals bring groups together discuss health policy concerns develop new skills andor ways expand influence pals also give patient groups opportunity learn gsk tell company better support work involved running total summits five meetings european countries one japan ten throughout us discussions pals focused broad range issues including healthcare reform health disparities us including reform debate include discussions prevention innovation intervention efforts us see detail national pals meeting read advocacy us healthcare reform contribution vaccines public health overcome misinformation misperceptions immunisations us mental health prevention wellness military us role patient organisations scientific research netherlands costs swiss healthcare system implications patients introduction managed care systems new fee paying system swiss hospitals switzerland improving healthcare japan including empower patients improve working condition hospital doctors japan patient access medicines latvia european patient forum gsk cosponsored european patient forums annual conference gothenburg pharmaceutical companies pfizer amgen brought together approximately patient groups stakeholders exchange ideas improving healthcare increasing involvement patient organisations delivery healthcare us national pals meeting us national pals meeting focused healthcare reform health disparities participants discussed reform debate include prevention innovation intervention efforts speakers included former us surgeon general leaders minority health associations us following event held regional conferences webinars delved deeper regional concerns addressed specific ways overcome barriers healthcare patient groups represented across events approximately participants total back top home responsibility public policy patient advocacy patient advocacy understanding patients corporate responsibility report understanding patients help us better understand patient needs set advisory boards us europe include representatives wide range patient groups advisory boards independent chairs meet regularly attended senior gsk managers boards enable voice patients heard highest levels gsk also allow us access views patient groups seek feedback subjects clinical trials pharmacogenetics information provided patients ethical issues regions invite speakers patient groups meet gsk employees including scientists researchers marketers discuss issues affecting members well improving understanding patient needs shows gsk employees difference work make peoples lives read focus patient initiative helping us better understand patient needs develop better medicines also engage patient groups patient advocacy leaders summits pals bring groups together discuss health policy concerns develop new skills andor ways expand influence pals also give patient groups opportunity learn gsk tell company better support work involved running total summits five meetings european countries one japan ten throughout us discussions pals focused broad range issues including healthcare reform health disparities us including reform debate include discussions prevention innovation intervention efforts us see detail national pals meeting read advocacy us healthcare reform contribution vaccines public health overcome misinformation misperceptions immunisations us mental health prevention wellness military us role patient organisations scientific research netherlands costs swiss healthcare system implications patients introduction managed care systems new fee paying system swiss hospitals switzerland improving healthcare japan including empower patients improve working condition hospital doctors japan patient access medicines latvia european patient forum gsk cosponsored european patient forums annual conference gothenburg pharmaceutical companies pfizer amgen brought together approximately patient groups stakeholders exchange ideas improving healthcare increasing involvement patient organisations delivery healthcare us national pals meeting us national pals meeting focused healthcare reform health disparities participants discussed reform debate include prevention innovation intervention efforts speakers included former us surgeon general leaders minority health associations us following event held regional conferences webinars delved deeper regional concerns addressed specific ways overcome barriers healthcare patient groups represented across events approximately participants total back top home responsibility public policy patient advocacy patient advocacy advocacy corporate responsibility report advocacy describe training support activities undertook partnership patient groups training capability building europe helping patient groups develop italy patient groups rely funding able support members carry vital advocacy work important receive funding variety sources remain independent become reliant single donor gsk organised series workshops help italian patient groups apply win public funding attending gsk workshop onda national observatory women 's health italian umbrella group studies main conditions affecting women applied funding european health programme onda use funding participate threeyear project promote early cervical screening fight cervical cancer eu aurora project focus hard reach groups including young people minorities people living rural areas developing innovative ways train patient groups skills need succeed launched web portal italian patient groups use access online training programmes include sessions apply win funding training managerial skills chaired leading expert nonprofit organisations web portal means patient group members travel training sessions takes time money often difficult health reasons patient groups also use portal form virtual networks collaborate share experiences fundraising training spain gsk provided funding enable foundation health science training organisation run free workshops seminars inform patient groups seek donors win funding twoday training sessions designed equip patient group managers knowledge skills develop successful fundraising campaign course provided specific advice tailor organisations approach contacting private individuals corporate public organisations international donors training trainer germany supporting training programme help members national patient organisation kindernetzwerk ev work efficiently develop media communications skills kindernetzwerk made regional patient groups germany representing parents children suffering chronic diseases organisation surveyed members understand challenges face future showed parents concerned well caring sick child struggle cope increase demands time patient groups become involved healthcare germany gsk donated training programme enable kindernetzwerk members manage time better work efficiently effectively course designed train trainer programme volunteers group could pass learnt rest patient group activities supporting breast cancer awareness australia donated almost aud mcgrath foundation organisation fundsp sapgee cia loisf breast care nurses australian women living breast cancer raises awareness disease among women foundation cofounded jane mcgrath wife cricketer glenn mcgrath jane mcgrath since passed away funding used research project assessing levels awareness attitudes towards breast cancer among women aged foundation use results study inform media campaigns educate younger women need greater breast awareness dangers breast cancer gsks support help establish mcgrath foundation advocate breast awareness building core activity providing funding nurses supporting veterans us partnering organisations raise awareness serious health issues affect many veterans us together washington redskins professional football team hosted health screening event veterans redskins locker room fedex field veterans local participating patient groups assessed risk developing conditions diabetes cholesterol osteoporosis prostate conditions hiv breast cancer ocular disorders physicians healthcare professionals offered counselling services local national health advocacy organisations also contributed also partnered national alliance mental illness hosting event new england educated patients family members legislators veterans health groups mental health issues veterans families experience back tophome responsibility public policy patient advocacy patient advocacy advocacy corporate responsibility report advocacy describe training support activities undertook partnership patient groups training capability building europe helping patient groups develop italy patient groups rely funding able support members carry vital advocacy work important receive funding variety sources remain independent become reliant single donor gsk organised series workshops help italian patient groups apply win public funding attending gsk workshop onda national observatory women 's health italian umbrella group studies main conditions affecting women applied funding european health programme onda use funding participate threeyear project promote early cervical screening fight cervical cancer eu aurora project focus hard reach groups including young people minorities people living rural areas developing innovative ways train patient groups skills need succeed launched web portal italian patient groups use access online training programmes include sessions apply win funding training managerial skills chaired leading expert nonprofit organisations web portal means patient group members travel training sessions takes time money often difficult health reasons patient groups also use portal form virtual networks collaborate share experiences fundraising training spain gsk provided funding enable foundation health science training organisation run free workshops seminars inform patient groups seek donors win funding twoday training sessions designed equip patient group managers knowledge skills develop successful fundraising campaign course provided specific advice tailor organisations approach contacting private individuals corporate public organisations international donors training trainer germany supporting training programme help members national patient organisation kindernetzwerk ev work efficiently develop media communications skills kindernetzwerk made regional patient groups germany representing parents children suffering chronic diseases organisation surveyed members understand challenges face future showed parents concerned well caring sick child struggle cope increase demands time patient groups become involved healthcare germany gsk donated training programme enable kindernetzwerk members manage time better work efficiently effectively course designed train trainer programme volunteers group could pass learnt rest patient group activities supporting breast cancer awareness australia donated almost aud mcgrath foundation organisation funds specialist breast care nurses australian women living breast cancer raises awareness disease among women foundation cofounded jane mcgrath wife cricketer glenn mcgrath jane mcgrath since passed away funding used research project assessing levels awareness attitudes towards breast cancer among women aged foundation use results study inform media campaigns educate younger women need greater breast awareness dangers breast cancer gsks support help establish mcgrath foundation advocate breast awareness building core activity providing funding nurses supporting veterans us partnering organisations raise awareness serious health issues affect many veterans us together washington redskins professional football team hosted health screening event veterans redskins locker room fedex field veterans local participating patient groups assessed risk developing conditions diabetes cholesterol osteoporosis prostate conditions hiv breast cancer ocular disorders physicians healthcare professionals offered counselling services local national health advocacy organisations also contributed also partnered national alliance mental illness hosting event new england educated patients family members legislators veterans health groups mental health issues veterans families experience back top home responsibility public policy patient advocacy patient advocacy advocacy corporate responsibility report advocacy describe training support activities undertook partnership patient groups training capability building europe helping patient groups develop italy patient groups rely funding able support members carry vital advocacy work important receive funding variety sources remain independent become reliant single donor gsk organised series workshops help italian patient groups apply win public funding attending gsk workshop onda national observatory women 's health italian umbrella group studies main conditions affecting women applied funding european health programme onda use funding participate threeyear project promote early cervical screening fight cervical cancer eu aurora project focus hard reach groups including young people minorities people living rural areas developing innovative ways train patient groups skills need succeed launched web portal italian patient groups use access online training programmes include sessions apply win funding training managerial skills chaired leading expert nonprofit organisations web portal means patient group members travel training sessions takes time money often difficult health reasons patient groups also use portal form virtual networks collaborate share experiences fundraising training spain gsk provided funding enable foundation health science training organisation run free workshops seminars inform patient groups seek donors win funding twoday training sessions designed equip patient group managers knowledge skills develop successful fundraising campaign course provided specific advice tailor organisations approach contacting private individuals corporate public organisations international donors training trainer germany supporting training programme help members national patient organisation kindernetzwerk ev work efficiently develop media communications skills kindernetzwerk made regional patient groups germany representing parents children suffering chronic diseases organisation surveyed members understand challenges face future showed parents concerned well caring sick child struggle cope increase demands time patient groups become involved healthcare germany gsk donated training programme enable kindernetzwerk members manage time better work efficiently effectively course designed train trainer programme volunteers group could pass learnt rest patient group activities supporting breast cancer awareness australia donated almost aud mcgrath foundation organisation funds specialist breast care nurses australian women living breast cancer raises awareness disease among women foundation cofounded jane mcgrath wife cricketer glenn mcgrath jane mcgrath since passed away funding used research project assessing levels awareness attitudes towards breast cancer among women aged foundation use results study inform media campaigns educate younger women need greater breast awareness dangers breast cancer gsks support help establish mcgrath foundation advocate breast awareness building core activity providing funding nurses supporting veterans us partnering organisations raise awareness serious health issues affect many veterans us together washington redskins professional football team hosted health screening event veterans redskins locker room fedex field veterans local participating patient groups assessed risk developing conditions diabetes cholesterol osteoporosis prostate conditions hiv breast cancer ocular disorders physicians healthcare professionals offered counselling services local national health advocacy organisations also contributed also partnered national alliance mental illness hosting event new england educated patients family members legislators veterans health groups mental health issues veterans families experience back top home responsibility public policy patient advocacy qas corporate responsibility report qas respond questions raised stakeholders make sure lobbying activity doesnt contradict undermine corporate responsibility work corporate responsibility central business aim ensure lobbying activity reflects values set report well sensitive views stakeholders employees involved public policy must abide employee guide business conduct commits acting honesty integrity wellestablished public policy positions developed wide consultation approved corporate executive team employees lobby gsk closely involved developing positions believe transparency key building trust stakeholders disclose public policy positions lobbying expenditure brussels washington website gsk make political contributions socalled organisations yes support number organisations democratic governors association republican governors association organisation us taxexempt organisation created primarily influence policy development promote issue discussion organisations prohibited making expenditures directly advocate election defeat specific candidate gsk influence `` organisations use gsk contributions however support enables organisation develop advocate policy positions us participate functions debate discuss important issues gsk organisations public policy makers contributions organisations defined political contributions subject policy stop corporate political contributions isnt support patient groups another marketing tool gsk neither promotes medicines patient groups would ever ask patient group endorse gsk medicine work patient groups number areas including improving clinical trials run disease awareness initiatives bigger agenda ensuring new medicines made available patients gsk provides funding trying buy favours patient organisation never ask endorsement medicines return investment support careful support organisation compromise independence based trust mutual respect complies highest standards code conduct groups maintain independence receive significant funding companies gsk encourage patient groups diversify funding sources public private sector patient groups never become dependent one funder either sector guidelines state provide per cent groups overall income except exceptional circumstances home responsibility public policy patient advocacy qas corporate responsibility report qas respond questions raised stakeholders make sure lobbying activity doesnt contradict undermine corporate responsibility work corporate responsibility central business aim ensure lobbying activity reflects values set report well sensitive views stakeholders employees involved public policy must abide employee guide business conduct commits acting honesty integrity wellestablished public policy positions developed wide consultation approved corporate executive team employees lobby gsk closely involved developing positions believe transparency key building trust stakeholders disclose public policy positions lobbying expenditure brussels washington website gsk make political contributions socalled organisations yes support number organisations democratic governors association republican governors association organisation us taxexempt organisation created primarily influence policy development promote issue discussion organisations prohibited making expenditures directly advocate election defeat specific candidate gsk influence `` organisations use gsk contributions however support enables organisation develop advocate policy positions us participate functions debate discuss important issues gsk organisations public policy makers contributions organisations defined political contributions subject policy stop corporate political contributions isnt support patient groups another marketing tool gsk neither promotes medicines patient groups would ever ask patient group endorse gsk medicine work patient groups number areas including improving clinical trials run disease awareness initiatives bigger agenda ensuring new medicines made available patients gsk provides funding trying buy favours patient organisation never ask endorsement medicines return investment support careful support organisation compromise independence based trust mutual respect complies highest standards code conduct groups maintain independence receive significant funding companies gsk encourage patient groups diversify funding sources public private sector patient groups never become dependent one funder either sector guidelines state provide per cent groups overall income except exceptional circumstances home responsibility work communities corporate responsibility report work communities donate money time medicines equipment support communities around world programmes long term focus addressing healthcare challenges increasing access medicines also invest improving education especially science education provide support art environment initiatives committed reinvest per cent profits sales medicines least developed countries ldcs back projects strengthen healthcare infrastructure help widen access essential medicines countries believe contributing profits benefit communities part responsible company community investment also brings us longterm business benefits improving reputation boosting employee morale helping us build good relations governments use community investment way generating sales select projects relevant business skills people bring benefit communities gsk investment made nonprofit organisations expert healthcare education organisations best placed understand local community needs target resources effectively donations made company level individual sites ask partner organisations larger programmes report annually progress projects supported gsk ensure money give greatest possible impact review results partners identify changes required achieve programmes objectives november announced official laboratory services provider supplier london games buildup working london organising committee olympic games paralympic games locog provide facilities equipment enable kings college london operate world antidoping agency wada accredited satellite laboratory games section describes support innovative projects three areas preventing disease building capacity communities community organisations promoting education particularly science back top home responsibility work communities corporate responsibility report work communities donate money time medicines equipment support communities around world programmes long term focus addressing healthcare challenges increasing access medicines also invest improving education especially science education provide support art environment initiatives committed reinvest per cent profits sales medicines least developed countries ldcs back projects strengthen healthcare infrastructure help widen access essential medicines countries believe contributing profits benefit communities part responsible company community investment also brings us longterm business benefits improving reputation boosting employee morale helping us build good relations governments use community investment way generating sales select projects relevant business skills people bring benefit communities gsk investment made nonprofit organisations expert healthcare education organisations best placed understand local community needs target resources effectively donations made company level individual sites ask partner organisations larger programmes report annually progress projects supported gsk ensure money give greatest possible impact review results partners identify changes required achieve programmes objectives november announced official laboratory services provider supplier london games buildup working london organising committee olympic games paralympic games locog provide facilities equipment enable kings college london operate world antidoping agency wada accredited satellite laboratory games section describes support innovative projects three areas preventing disease building capacity communities community organisations promoting education particularly science back top home responsibility work communities community investment corporate responsibility report community investment global community investment million million compared million million like like basis maintained increased corporate giving levels despite global economic crisis knowing contributions important recipients critical success initiatives support increase due expansion us patient assistance programs increased humanitarian product donations scale donation albendazole lymphatic filariasis lf programme second year valued donations using cost average cost goods rather wholesale acquisition cost wac approach valuing donations accurate reflection true cost gsk continue also report wac value donations benchmarking purposes belong uks london benchmarking group lbg us committee encouraging corporate philanthropy cecp lbg guidelines report product donations cost whereas cecp guidelines report product donations market value comparative purposes total value giving using wac products would million million compared million million giving figure built following way method giving million breakdown cash giving product donations made three main programmes patient assistance programs support lowincome patients us totalling million average cost goods humanitarian product donations underserved communities countries including people affected series natural disasters asia pacific totalling million average cost goods donation million albendazole tablets million average cost goods lymphatic filariasis lf elimination programme following outbreak pandemic flu hn made commitment donate million doses hn vaccine world health organization use developing countries accounting purposes provided full cost donations although delivery vaccines take place mainly reason total global community investment figure include cost hn vaccine donation reported product donation read response pandemic flu publish data charitable grants made patient groups european emerging markets asia pacific regions increased transparency publishing details charitable grants find grants retained communitymark ongoing work local national level uk well larger international programmes one first companies achieve mark outstanding investment community following independent assessment communitymark companies awarded threeyear period monitored ensure continued commitment excellence mark founded business community endorsed uk government voluntary sector leaders back tophome responsibility work communities community investment corporate responsibility report community investment global community investment million million compared million million like like basis maintained increased corporate giving levels despite global economic crisis knowing contributions important recipients critical success initiatives support increase due expansion us patient assistance programs increased humanitarian product donations scale donation albendazole lymphatic filariasis lf programme second year valued donations using cost average cost goods rather wholesale acquisition cost wac approach valuing donations accurate reflection true cost gsk continue also report wac value donations benchmarking purposes belong uks london benchmarking group lbg us committee encouraging corporate philanthropy cecp lbg guidelines report product donations cost whereas cecp guidelines report product donations market value comparative purposes total value giving using wac products would million million compared million million giving figure built following way method giving million breakdown cash giving product donations made three main programmes patient assistance programs support lowincome patients us totalling million average cost goods humanitarian product donations underserved communities countries including people affected series natural disasters asia pacific totalling million average cost goods donation million albendazole tablets million average cost goods lymphatic filariasis lf elimination programme following outbreak pandemic flu hn made commitment donate million doses hn vaccine world health organization use developing countries accounting purposes provided full cost donations although delivery vaccines take place mainly reason total global community investment figure include cost hn vaccine donation reported product donation read response pandemic flu publish data charitable grants made patient groups european emerging markets asia pacific regions increased transparency publishing details charitable grants find grants retained communitymark ongoing work local national level uk well larger international programmes one first companies achieve mark outstanding investment community following independent assessment communitymark companies awarded threeyear period monitored ensure continued commitment excellence mark founded business community endorsed uk government voluntary sector leaders back top home responsibility work communities community investment corporate responsibility report community investment global community investment million million compared million million like like basis maintained increased corporate giving levels despite global economic crisis knowing contributions important recipients critical success initiatives support increase due expansion us patient assistance programs increased humanitarian product donations scale donation albendazole lymphatic filariasis lf programme second year valued donations using cost average cost goods rather wholesale acquisition cost wac approach valuing donations accurate reflection true cost gsk continue also report wac value donations benchmarking purposes belong uks london benchmarking group lbg us committee encouraging corporate philanthropy cecp lbg guidelines report product donations cost whereas cecp guidelines report product donations market value comparative purposes total value giving using wac products would million million compared million million giving figure built following way method giving million breakdown cash giving product donations made three main programmes patient assistance programs support lowincome patients us totalling million average cost goods humanitarian product donations underserved communities countries including people affected series natural disasters asia pacific totalling million average cost goods donation million albendazole tablets million average cost goods lymphatic filariasis lf elimination programme following outbreak pandemic flu hn made commitment donate million doses hn vaccine world health organization use developing countries accounting purposes provided full cost donations although delivery vaccines take place mainly reason total global community investment figure include cost hn vaccine donation reported product donation read response pandemic flu publish data charitable grants made patient groups european emerging markets asia pacific regions increased transparency publishing details charitable grants find grants retained communitymark ongoing work local national level uk well larger international programmes one first companies achieve mark outstanding investment community following independent assessment communitymark companies awarded threeyear period monitored ensure continued commitment excellence mark founded business community endorsed uk government voluntary sector leaders back top home responsibility work communities employee involvement corporate responsibility report employee involvement encourage employees active support causes care run volunteering programmes make easier get involved employee volunteering companywide employee volunteer initiative launched gives every gsk employee one paid day year volunteer good cause employees supported wide range charities projects held hundreds group activities including delivering books computers school affected earthquake sichuan china well painting library fixing broken desks teaching science classes clearing rubbish visiting schools planting trees vegetables kibera kenya africa 's largest slum planting trees mexico refurbishing nursing homes sri lanka volunteering charity shops uk distributing food homeless north carolina series us events coincide president obamas nationwide service initiative united serve culminating september national day service remembrance date nearly gsk employees volunteered variety projects new york city philippines volunteering day turned week activities employees came aid communities affected typhoon ondoy including nearly gsk staff put place programmes clean colleagues flooded homes pack relief goods donation including bags food toiletries benefited around families worst hit areas gsk volunteers served hot meals people two days read support disaster relief efforts pulse also launched pulse volunteer partnership international programme gives highperforming employees opportunity use professional skills support nonprofit partners three six months intake pulse volunteers working different countries non governmental organisations ngos read pulse gsk challenge fund amref set challenge raising african medical research foundation amref amref leading health development organisation africa saving transforming lives worlds poorest people amref partners gsk positive action phase activities africa ceo andrew witty kicked initiative april running london marathon raise funds employees able donate fund dedicated website highlighted could buy ten rapid malaria testing kits help ensure prompt effective treatment would provide health worker basic general medical kit matched employee contributions make total donation back tophome responsibility work communities employee involvement corporate responsibility report employee involvement encourage employees active support causes care run volunteering programmes make easier get involved employee volunteering companywide employee volunteer initiative launched gives every gsk employee one paid day year volunteer good cause employees supported wide range charities projects held hundreds group activities including delivering books computers school affected earthquake sichuan china well painting library fixing broken desks teaching science classes clearing rubbish visiting schools planting trees vegetables kibera kenya africa 's largest slum planting trees mexico refurbishing nursing homes sri lanka volunteering charity shops uk distributing food homeless north carolina series us events coincide president obamas nationwide service initiative united serve culminating september national day service remembrance date nearly gsk employees volunteered variety projects new york city philippines volunteering day turned week activities employees came aid communities affected typhoon ondoy including nearly gsk staff put place programmes clean colleagues flooded homes pack relief goods donation including bags food toiletries benefited around families worst hit areas gsk volunteers served hot meals people two days read support disaster relief efforts pulse also launched pulse volunteer partnership international programme gives highperforming employees opportunity use professional skills support nonprofit partners three six months intake pulse volunteers working different countries non governmental organisations ngos read pulse gsk challenge fund amref set challenge raising african medical research foundation amref amref leading health development organisation africa saving transforming lives worlds poorest people amref partners gsk positive action phase activities africa ceo andrew witty kicked initiative april running london marathon raise funds employees able donate fund dedicated website highlighted could buy ten rapid malaria testing kits help ensure prompt effective treatment would provide health worker basic general medical kit matched employee contributions make total donation back top home responsibility work communities employee involvement corporate responsibility report employee involvement encourage employees active support causes care run volunteering programmes make easier get involved employee volunteering companywide employee volunteer initiative launched gives every gsk employee one paid day year volunteer good cause employees supported wide range charities projects held hundreds group activities including delivering books computers school affected earthquake sichuan china well painting library fixing broken desks teaching science classes clearing rubbish visiting schools planting trees vegetables kibera kenya africa 's largest slum planting trees mexico refurbishing nursing homes sri lanka volunteering charity shops uk distributing food homeless north carolina series us events coincide president obamas nationwide service initiative united serve culminating september national day service remembrance date nearly gsk employees volunteered variety projects new york city philippines volunteering day turned week activities employees came aid communities affected typhoon ondoy including nearly gsk staff put place programmes clean colleagues flooded homes pack relief goods donation including bags food toiletries benefited around families worst hit areas gsk volunteers served hot meals people two days read support disaster relief efforts pulse also launched pulse volunteer partnership international programme gives highperforming employees opportunity use professional skills support nonprofit partners three six months intake pulse volunteers working different countries non governmental organisations ngos read pulse gsk challenge fund amref set challenge raising african medical research foundation amref amref leading health development organisation africa saving transforming lives worlds poorest people amref partners gsk positive action phase activities africa ceo andrew witty kicked initiative april running london marathon raise funds employees able donate fund dedicated website highlighted could buy ten rapid malaria testing kits help ensure prompt effective treatment would provide health worker basic general medical kit matched employee contributions make total donation back top home responsibility work communities preventing disease corporate responsibility report preventing disease infectious diseases kill millions people developing world year cause misery cost billions dollars slow economic growth preventing infection effective treatment significant social economic benefits vaccines play significant role preventing disease support innovative community approaches disease prevention tailored local settings needs decade supported initiatives eliminate lymphatic filariasis lf worldwide well handwashing programme phase prevent diarrhoearelated disease also support wide range local programmes help prevent disease communities operate back top home responsibility work communities preventing disease corporate responsibility report preventing disease infectious diseases kill millions people developing world year cause misery cost billions dollars slow economic growth preventing infection effective treatment significant social economic benefits vaccines play significant role preventing disease support innovative community approaches disease prevention tailored local settings needs decade supported initiatives eliminate lymphatic filariasis lf worldwide well handwashing programme phase prevent diarrhoearelated disease also support wide range local programmes help prevent disease communities operate back top home responsibility work communities preventing disease eliminating lymphatic filariasis corporate responsibility report eliminating lymphatic filariasis lf committed donate many tablets albendazole antiparasitic drug needed eliminate lymphatic filariasis lf lf disfiguring disease prevalent tropical subtropical countries transmitted mosquitoes lead severe swelling arms legs breasts genitals thickening skin lf one worlds leading causes permanent disability estimated billion people approximately onefifth worlds population risk infection countries considered neglected tropical disease lf disproportionately impacts poor marginalised populations donated million albendazole treatments countries compared million treatments per cent increase since programme began donated billion albendazole tablets lfaffected countries opened new production line nashik western india help meet increased worldwide demand nashik facility fully operational aim manufacture million tablets per year enhanced manufacturing capacity means able donate million tables india country largest lf burden million economic cost lf india estimated exceed us million due treatment costs reduced working time coauthored paper annals tropical medicine parasitology tenyear collaboration pharmaceutical company merck co inc eliminate lf donating antiparasitic drugs help stop transmission disease collaboration also offer financial support advice coordinating lf elimination efforts year countries working fight lf received major boost significant funding commitments made uk department international development us agency international development control elimination neglected tropical diseases albendazole tablets given prevent lf additional benefit treating intestinal worms parasites particularly affect children causing anaemia malnutrition stunting growth estimate since beginning lf programme million albendazole treatments administered children million women childbearing age positive impact overall health infected intestinal worms interrupt transmission lf world health organization recommends treating entire atrisk communities least five years albendazole plus either mectizan diethylcarbamazine dec several countries completed five annual mass drug administrations mdas process monitoring populations evaluate impact programme disease assessments conducted egypt togo vanuatu pacific island nation showed lf eliminated areas countries programmes tanzania madagascar burkina faso also reported unexpected benefit mdas beyond reducing infection rates countries patients already infected lf describing alleviation symptoms mdas including reduced leg swelling reduction frequency length acute attacks spells feverishness loss energy acute attacks incapacitating frequent symptom lf read approach lf patients living disease home responsibility work communities preventing disease eliminating lymphatic filariasis corporate responsibility report eliminating lymphatic filariasis lf committed donate many tablets albendazole antiparasitic drug needed eliminate lymphatic filariasis lf lf disfiguring disease prevalent tropical subtropical countries transmitted mosquitoes lead severe swelling arms legs breasts genitals thickening skin lf one worlds leading causes permanent disability estimated billion people approximately onefifth worlds population risk infection countries considered neglected tropical disease lf disproportionately impacts poor marginalised populations donated million albendazole treatments countries compared million treatments per cent increase since programme began donated billion albendazole tablets lfaffected countries opened new production line nashik western india help meet increased worldwide demand nashik facility fully operational aim manufacture million tablets per year enhanced manufacturing capacity means able donate million tables india country largest lf burden million economic cost lf india estimated exceed us million due treatment costs reduced working time coauthored paper annals tropical medicine parasitology tenyear collaboration pharmaceutical company merck co inc eliminate lf donating antiparasitic drugs help stop transmission disease collaboration also offer financial support advice coordinating lf elimination efforts year countries working fight lf received major boost significant funding commitments made uk department international development us agency international development control elimination neglected tropical diseases albendazole tablets given prevent lf additional benefit treating intestinal worms parasites particularly affect children causing anaemia malnutrition stunting growth estimate since beginning lf programme million albendazole treatments administered children million women childbearing age positive impact overall health infected intestinal worms interrupt transmission lf world health organization recommends treating entire atrisk communities least five years albendazole plus either mectizan diethylcarbamazine dec several countries completed five annual mass drug administrations mdas process monitoring populations evaluate impact programme disease assessments conducted egypt togo vanuatu pacific island nation showed lf eliminated areas countries programmes tanzania madagascar burkina faso also reported unexpected benefit mdas beyond reducing infection rates countries patients already infected lf describing alleviation symptoms mdas including reduced leg swelling reduction frequency length acute attacks spells feverishness loss energy acute attacks incapacitating frequent symptom lf read approach lf patients living disease home responsibility work communities preventing disease personal hygiene sanitation education corporate responsibility report personal hygiene sanitation education phase every year two million people die diarrhoearelated disease mostly children developing countries deaths often easily prevented better handwashing sanitation phase schoolbased programme helps reduce diarrhoearelated disease encouraging school children wash hands established phase since invested million million programme phase operates countries reached children phase run partnership african medical research foundation amref save children earth institute columbia university well ministries health education countries programme operates extended phase slum areas mumbai india partner pratham investment three years provide pratham technical support needed implement phase municipal schools reaching approximately children households pratham also introduce phase ten shelter homes runs across india house children expanded phase programme uganda june reaches children nearly primary schools success stories date include reduction absenteeism per cent per cent seemingly due improvements children 's health better performance primary school examinations result per cent latrines local communities percentage households handwashing facilities increased zero per cent advocating incorporation initiative national policy replicated easily sustainably worldwide already local governments involved phase developed relevant bylaws also launched uk phase pilot project three schools hounslow greater london near global headquarters school assemblies fun lessons children learned phase initiatives around world importance washing hands properly expand programme schools early aim phase reach one million children part continuing efforts plan expand programme brazil philippines brazil phase pilot project reach children schools slums rio de janeiro introduction phase philippines build success existing fit school programme also supported gsk aims improve children 's health teaching handwashing well toothbrushing oral health programme also provides children soap toothbrushes toothpaste conducts two mass deworming initiatives year makes improvements water sanitation facilities apply lessons learned fit school phase teaches children oral health well handwashing mexico phase award community liaison best practice mexican center philanthropy mexican social responsibility alliance supporting millennium development goals world leaders agreed millennium development goals mdgs meet needs world 's poorest people mdgs include targets halve extreme poverty hunger improve education health gender equality environmental sustainability part project coordinated columbia university 's earth institute introduced phase two millennium villages malawi senegal millennium villages research projects african communities designed find practical ways meet mdgs senegal project brings phase west africa first time translating educational materials french global handwashing day second global handwashing day held schoolchildren phase schools adults participated fun handwashingrelated activities celebrate day including mexico children took part games workshops health rallies community campaigns states across country uganda school health clubs made water containers materials brought home students india group clowns hosted threehour handwashing event govandi mumbais largest dumping ground read phase global handwashing day back tophome responsibility work communities preventing disease personal hygiene sanitation education corporate responsibility report personal hygiene sanitation education phase every year two million people die diarrhoearelated disease mostly children developing countries deaths often easily prevented better handwashing sanitation phase schoolbased programme helps reduce diarrhoearelated disease encouraging school children wash hands established phase since invested million million programme phase operates countries reached children phase run partnership african medical research foundation amref save children earth institute columbia university well ministries health education countries programme operates extended phase slum areas mumbai india partner pratham investment three years provide pratham technical support needed implement phase municipal schools reaching approximately children households pratham also introduce phase ten shelter homes runs across india house children expanded phase programme uganda june reaches children nearly primary schools success stories date include reduction absenteeism per cent per cent seemingly due improvements children 's health better performance primary school examinations result per cent latrines local communities percentage households handwashing facilities increased zero per cent advocating incorporation initiative national policy replicated easily sustainably worldwide already local governments involved phase developed relevant bylaws also launched uk phase pilot project three schools hounslow greater london near global headquarters school assemblies fun lessons children learned phase initiatives around world importance washing hands properly expand programme schools early aim phase reach one million children part continuing efforts plan expand programme brazil philippines brazil phase pilot project reach children schools slums rio de janeiro introduction phase philippines build success existing fit school programme also supported gsk aims improve children 's health teaching handwashing well toothbrushing oral health programme also provides children soap toothbrushes toothpaste conducts two mass deworming initiatives year makes improvements water sanitation facilities apply lessons learned fit school phase teaches children oral health well handwashing mexico phase award community liaison best practice mexican center philanthropy mexican social responsibility alliance supporting millennium development goals world leaders agreed millennium development goals mdgs meet needs world 's poorest people mdgs include targets halve extreme poverty hunger improve education health gender equality environmental sustainability part project coordinated columbia university 's earth institute introduced phase two millennium villages malawi senegal millennium villages research projects african communities designed find practical ways meet mdgs senegal project brings phase west africa first time translating educational materials french global handwashing day second global handwashing day held schoolchildren phase schools adults participated fun handwashingrelated activities celebrate day including mexico children took part games workshops health rallies community campaigns states across country uganda school health clubs made water containers materials brought home students india group clowns hosted threehour handwashing event govandi mumbais largest dumping ground read phase global handwashing day back top home responsibility work communities preventing disease personal hygiene sanitation education corporate responsibility report personal hygiene sanitation education phase every year two million people die diarrhoearelated disease mostly children developing countries deaths often easily prevented better handwashing sanitation phase schoolbased programme helps reduce diarrhoearelated disease encouraging school children wash hands established phase since invested million million programme phase operates countries reached children phase run partnership african medical research foundation amref save children earth institute columbia university well ministries health education countries programme operates extended phase slum areas mumbai india partner pratham investment three years provide pratham technical support needed implement phase municipal schools reaching approximately children households pratham also introduce phase ten shelter homes runs across india house children expanded phase programme uganda june reaches children nearly primary schools success stories date include reduction absenteeism per cent per cent seemingly due improvements children 's health better performance primary school examinations result per cent latrines local communities percentage households handwashing facilities increased zero per cent advocating incorporation initiative national policy replicated easily sustainably worldwide already local governments involved phase developed relevant bylaws also launched uk phase pilot project three schools hounslow greater london near global headquarters school assemblies fun lessons children learned phase initiatives around world importance washing hands properly expand programme schools early aim phase reach one million children part continuing efforts plan expand programme brazil philippines brazil phase pilot project reach children schools slums rio de janeiro introduction phase philippines build success existing fit school programme also supported gsk aims improve children 's health teaching handwashing well toothbrushing oral health programme also provides children soap toothbrushes toothpaste conducts two mass deworming initiatives year makes improvements water sanitation facilities apply lessons learned fit school phase teaches children oral health well handwashing mexico phase award community liaison best practice mexican center philanthropy mexican social responsibility alliance supporting millennium development goals world leaders agreed millennium development goals mdgs meet needs world 's poorest people mdgs include targets halve extreme poverty hunger improve education health gender equality environmental sustainability part project coordinated columbia university 's earth institute introduced phase two millennium villages malawi senegal millennium villages research projects african communities designed find practical ways meet mdgs senegal project brings phase west africa first time translating educational materials french global handwashing day second global handwashing day held schoolchildren phase schools adults participated fun handwashingrelated activities celebrate day including mexico children took part games workshops health rallies community campaigns states across country uganda school health clubs made water containers materials brought home students india group clowns hosted threehour handwashing event govandi mumbais largest dumping ground read phase global handwashing day back top home responsibility work communities preventing disease local programmes corporate responsibility report local programmes support wide range programmes help prevent disease communities operate fund programmes corporate local level examples china working improve health migrant workers chinas industrial cities attract large numbers temporary migrant workers mostly rural areas many lack education access public health services among chinas vulnerable groups migrant communities infectious diseases occupational ill health common supporting health education programme shanghai run xintu centre community health protection programme aims improve health migrants families raising awareness health issues hivaids provided funding three years programme us preventing childhood obesity childhood obesity major health concern us donated support threeyear project north carolina prevention partners develop test ways raising awareness obesity among students elementary middle high schools north carolina project far reached young people also supporting expansion programme people learn obesity remotely using webbased training us product donations improve community health effort help bridge oral care gap appalachia region kentucky families access dental care donated toothbrushes tubes toothpaste families partnership kids first dental care made pledge provide additional support organisation assisting efforts provide access comprehensive dental treatment children kentucky uk improving sexual health services disabled people donated three years leonard cheshire disability project give young disabled people better access sexual health services project addresses knowledge understanding gaps relating disabled peoples sexual health issues threeyear period organisation run focus groups workshops identify key issues develop range materials support sexual health workers work disabled people preparing funding stops programmes run number years recognising takes time build change start plan happen end funding work hard community organisations bring results life project usually around three years help organisations win funding sources continue work start require partners work budget make sure funding spent effectively makes positive impact also ask partners demonstrate achievements producing annual progress report reports show evidence success crucial part attracting new donorshome responsibility work communities preventing disease local programmes corporate responsibility report local programmes support wide range programmes help prevent disease communities operate fund programmes corporate local level examples china working improve health migrant workers chinas industrial cities attract large numbers temporary migrant workers mostly rural areas many lack education access public health services among chinas vulnerable groups migrant communities infectious diseases occupational ill health common supporting health education programme shanghai run xintu centre community health protection programme aims improve health migrants families raising awareness health issues hivaids provided funding three years programme us preventing childhood obesity childhood obesity major health concern us donated support threeyear project north carolina prevention partners develop test ways raising awareness obesity among students elementary middle high schools north carolina project far reached young people also supporting expansion programme people learn obesity remotely using webbased training us product donations improve community health effort help bridge oral care gap appalachia region kentucky families access dental care donated toothbrushes tubes toothpaste families partnership kids first dental care made pledge provide additional support organisation assisting efforts provide access comprehensive dental treatment children kentucky uk improving sexual health services disabled people donated three years leonard cheshire disability project give young disabled people better access sexual health services project addresses knowledge understanding gaps relating disabled peoples sexual health issues threeyear period organisation run focus groups workshops identify key issues develop range materials support sexual health workers work disabled people preparing funding stops programmes run number years recognising takes time build change start plan happen end funding work hard community organisations bring results life project usually around three years help organisations win funding sources continue work start require partners work budget make sure funding spent effectively makes positive impact also ask partners demonstrate achievements producing annual progress report reports show evidence success crucial part attracting new donors home responsibility work communities preventing disease local programmes corporate responsibility report local programmes support wide range programmes help prevent disease communities operate fund programmes corporate local level examples china working improve health migrant workers chinas industrial cities attract large numbers temporary migrant workers mostly rural areas many lack education access public health services among chinas vulnerable groups migrant communities infectious diseases occupational ill health common supporting health education programme shanghai run xintu centre community health protection programme aims improve health migrants families raising awareness health issues hivaids provided funding three years programme us preventing childhood obesity childhood obesity major health concern us donated support threeyear project north carolina prevention partners develop test ways raising awareness obesity among students elementary middle high schools north carolina project far reached young people also supporting expansion programme people learn obesity remotely using webbased training us product donations improve community health effort help bridge oral care gap appalachia region kentucky families access dental care donated toothbrushes tubes toothpaste families partnership kids first dental care made pledge provide additional support organisation assisting efforts provide access comprehensive dental treatment children kentucky uk improving sexual health services disabled people donated three years leonard cheshire disability project give young disabled people better access sexual health services project addresses knowledge understanding gaps relating disabled peoples sexual health issues threeyear period organisation run focus groups workshops identify key issues develop range materials support sexual health workers work disabled people preparing funding stops programmes run number years recognising takes time build change start plan happen end funding work hard community organisations bring results life project usually around three years help organisations win funding sources continue work start require partners work budget make sure funding spent effectively makes positive impact also ask partners demonstrate achievements producing annual progress report reports show evidence success crucial part attracting new donors home responsibility work communities preventing disease responding disasters around world corporate responsibility report responding disasters around world provide humanitarian assistance form cash product donations times emergency natural disasters give supplies products humanitarian aid organisations distribute quickly efficiently soon event occurs responding earthquake haiti immediately following devastating earthquake struck haiti january gsk provided donations medicines valued million stocks held warehouses nonprofit partners americares direct relief international health partners international canada map international ima world health project hope initial wave included urgently needed oral topical antibiotics used immediately first line treatment subsequent product donations support medium longerterm primary healthcare needs included antibiotics well respiratory diabetes treatment valued valued approximately million wac additionally consumer division provided range consumer products including toothpastes antacids pain relievers vitamins donated british red cross meet water sanitation needs affected disaster support displaced people construction emergency latrines distribution essential hygiene kits provision water sanitation facilities paramount reduce mortality infection rates significantly committed responding huge needs emerging haiti support longerterm reconstruction recovery efforts responding multiple natural disasters asia pacific region donated products humanitarian relief many parts asia pacific region following series natural disasters total donated product worth million average cost goods activities included indonesia partnered humanitarian relief agencies americares international medical corps donate antacids antibiotics inhalers paracetamol people affected earthquake also donated funds towards provision water food sanitation made cash contribution save childrens emergency appeal value combined contributions came part gsk indonesias volunteer activities employees also worked red cross organise blood donations also provided americares collaborating project ministry health office health provision local hospital directors ngo medical personnel install new water system supply djamil hospital provide rehabilitation education equipment people injured earthquake help restore capacity hospitals clinics damaged earthquake treat patients samoan earthquake subsequent tsunami worked new zealand government assess islands medical needs sent donation basic antibiotics request samoan authorities also donated new zealand red cross towards continuing aid efforts following typhoon ketsana worked humanitarian aid givers direct relief international help communities vietnam affected storm flooding caused donated medicines funding outpatient hospital hue vietnam delivers free medicines runs clinics specialising healthcare education including hivaids counselling philippines helping communities recover flooding typhoon ondoy part employee volunteering activities following major tsunami gsk pledged million support rehabilitation reconstruction efforts affected communities supported range initiatives many continue enabling people rebuild lives restore livelihoods access effective healthcare provision include aceh tengah indonesia provision highquality education midwifery students attending takengon midwifery academy bring quality maternal newborn care services line national standards thailand support local fishing villages ranong phang nga krabi help restore livelihoods also funded microcredit programme helping families communities rebuild lives achieve self sufficiency increase life coping skills health promotion reduce poverty individual collective income generation schemes well enable schoolage children attend school sri lanka funded projects partners direct relief international guardian foundation shilpa children 's trust help restore healthcare system tsunamiaffected communities improve service capacity beyond pretsunami levels projects include operating mobile clinics coastal ampara district displaced persons camps affected towns villages construction clinic provision medical dental nutritional psychosocial services tsunamiaffected children southern sri lanka nias indonesia worked save children indonesia introduce phase hand hygiene programme chennai india provided funds train local young women nursing assistants part longterm rehabilitation strategy addressing acute shortage trained medical personnel december began working leonard cheshire disability galle sri lanka support people disabilities many disabled tsunami access rehabilitation services mainstream education livelihood opportunities travel packs physicians involved humanitarian relief support healthcare professionals travel abroad provide medical care disadvantaged people including disaster relief efforts remote communities visit travelling doctor may medical treatment available donate essential medicines inclusion travel packs healthcare professionals hcps take trips affected areas packs contain broadspectrum antibiotics medicines well rehydration salts vitamins general medical supplies extended range products packs contain include consumer healthcare products analgaesics antacids pack contains treatments fight infection treat common illnesses medicines pack worth around hcps need pay taxdeductible fee medical assistance programs map international ngo partner distribute packs hcps need support back tophome responsibility work communities preventing disease responding disasters around world corporate responsibility report responding disasters around world provide humanitarian assistance form cash product donations times emergency natural disasters give supplies products humanitarian aid organisations distribute quickly efficiently soon event occurs responding earthquake haiti immediately following devastating earthquake struck haiti january gsk provided donations medicines valued million stocks held warehouses nonprofit partners americares direct relief international health partners international canada map international ima world health project hope initial wave included urgently needed oral topical antibiotics used immediately first line treatment subsequent product donations support medium longerterm primary healthcare needs included antibiotics well respiratory diabetes treatment valued valued approximately million wac additionally consumer division provided range consumer products including toothpastes antacids pain relievers vitamins donated british red cross meet water sanitation needs affected disaster support displaced people construction emergency latrines distribution essential hygiene kits provision water sanitation facilities paramount reduce mortality infection rates significantly committed responding huge needs emerging haiti support longerterm reconstruction recovery efforts responding multiple natural disasters asia pacific region donated products humanitarian relief many parts asia pacific region following series natural disasters total donated product worth million average cost goods activities included indonesia partnered humanitarian relief agencies americares international medical corps donate antacids antibiotics inhalers paracetamol people affected earthquake also donated funds towards provision water food sanitation made cash contribution save childrens emergency appeal value combined contributions came part gsk indonesias volunteer activities employees also worked red cross organise blood donations also provided americares collaborating project ministry health office health provision local hospital directors ngo medical personnel install new water system supply djamil hospital provide rehabilitation education equipment people injured earthquake help restore capacity hospitals clinics damaged earthquake treat patients samoan earthquake subsequent tsunami worked new zealand government assess islands medical needs sent donation basic antibiotics request samoan authorities also donated new zealand red cross towards continuing aid efforts following typhoon ketsana worked humanitarian aid givers direct relief international help communities vietnam affected storm flooding caused donated medicines funding outpatient hospital hue vietnam delivers free medicines runs clinics specialising healthcare education including hivaids counselling philippines helping communities recover flooding typhoon ondoy part employee volunteering activities following major tsunami gsk pledged million support rehabilitation reconstruction efforts affected communities supported range initiatives many continue enabling people rebuild lives restore livelihoods access effective healthcare provision include aceh tengah indonesia provision highquality education midwifery students attending takengon midwifery academy bring quality maternal newborn care services line national standards thailand support local fishing villages ranong phang nga krabi help restore livelihoods also funded microcredit programme helping families communities rebuild lives achieve self sufficiency increase life coping skills health promotion reduce poverty individual collective income generation schemes well enable schoolage children attend school sri lanka funded projects partners direct relief international guardian foundation shilpa children 's trust help restore healthcare system tsunamiaffected communities improve service capacity beyond pretsunami levels projects include operating mobile clinics coastal ampara district displaced persons camps affected towns villages construction clinic provision medical dental nutritional psychosocial services tsunamiaffected children southern sri lanka nias indonesia worked save children indonesia introduce phase hand hygiene programme chennai india provided funds train local young women nursing assistants part longterm rehabilitation strategy addressing acute shortage trained medical personnel december began working leonard cheshire disability galle sri lanka support people disabilities many disabled tsunami access rehabilitation services mainstream education livelihood opportunities travel packs physicians involved humanitarian relief support healthcare professionals travel abroad provide medical care disadvantaged people including disaster relief efforts remote communities visit travelling doctor may medical treatment available donate essential medicines inclusion travel packs healthcare professionals hcps take trips affected areas packs contain broadspectrum antibiotics medicines well rehydration salts vitamins general medical supplies extended range products packs contain include consumer healthcare products analgaesics antacids pack contains treatments fight infection treat common illnesses medicines pack worth around hcps need pay taxdeductible fee medical assistance programs map international ngo partner distribute packs hcps need support back top home responsibility work communities preventing disease responding disasters around world corporate responsibility report responding disasters around world provide humanitarian assistance form cash product donations times emergency natural disasters give supplies products humanitarian aid organisations distribute quickly efficiently soon event occurs responding earthquake haiti immediately following devastating earthquake struck haiti january gsk provided donations medicines valued million stocks held warehouses nonprofit partners americares direct relief international health partners international canada map international ima world health project hope initial wave included urgently needed oral topical antibiotics used immediately first line treatment subsequent product donations support medium longerterm primary healthcare needs included antibiotics well respiratory diabetes treatment valued valued approximately million wac additionally consumer division provided range consumer products including toothpastes antacids pain relievers vitamins donated british red cross meet water sanitation needs affected disaster support displaced people construction emergency latrines distribution essential hygiene kits provision water sanitation facilities paramount reduce mortality infection rates significantly committed responding huge needs emerging haiti support longerterm reconstruction recovery efforts responding multiple natural disasters asia pacific region donated products humanitarian relief many parts asia pacific region following series natural disasters total donated product worth million average cost goods activities included indonesia partnered humanitarian relief agencies americares international medical corps donate antacids antibiotics inhalers paracetamol people affected earthquake also donated funds towards provision water food sanitation made cash contribution save childrens emergency appeal value combined contributions came part gsk indonesias volunteer activities employees also worked red cross organise blood donations also provided americares collaborating project ministry health office health provision local hospital directors ngo medical personnel install new water system supply djamil hospital provide rehabilitation education equipment people injured earthquake help restore capacity hospitals clinics damaged earthquake treat patients samoan earthquake subsequent tsunami worked new zealand government assess islands medical needs sent donation basic antibiotics request samoan authorities also donated new zealand red cross towards continuing aid efforts following typhoon ketsana worked humanitarian aid givers direct relief international help communities vietnam affected storm flooding caused donated medicines funding outpatient hospital hue vietnam delivers free medicines runs clinics specialising healthcare education including hivaids counselling philippines helping communities recover flooding typhoon ondoy part employee volunteering activities following major tsunami gsk pledged million support rehabilitation reconstruction efforts affected communities supported range initiatives many continue enabling people rebuild lives restore livelihoods access effective healthcare provision include aceh tengah indonesia provision highquality education midwifery students attending takengon midwifery academy bring quality maternal newborn care services line national standards thailand support local fishing villages ranong phang nga krabi help restore livelihoods also funded microcredit programme helping families communities rebuild lives achieve self sufficiency increase life coping skills health promotion reduce poverty individual collective income generation schemes well enable schoolage children attend school sri lanka funded projects partners direct relief international guardian foundation shilpa children 's trust help restore healthcare system tsunamiaffected communities improve service capacity beyond pretsunami levels projects include operating mobile clinics coastal ampara district displaced persons camps affected towns villages construction clinic provision medical dental nutritional psychosocial services tsunamiaffected children southern sri lanka nias indonesia worked save children indonesia introduce phase hand hygiene programme chennai india provided funds train local young women nursing assistants part longterm rehabilitation strategy addressing acute shortage trained medical personnel december began working leonard cheshire disability galle sri lanka support people disabilities many disabled tsunami access rehabilitation services mainstream education livelihood opportunities travel packs physicians involved humanitarian relief support healthcare professionals travel abroad provide medical care disadvantaged people including disaster relief efforts remote communities visit travelling doctor may medical treatment available donate essential medicines inclusion travel packs healthcare professionals hcps take trips affected areas packs contain broadspectrum antibiotics medicines well rehydration salts vitamins general medical supplies extended range products packs contain include consumer healthcare products analgaesics antacids pack contains treatments fight infection treat common illnesses medicines pack worth around hcps need pay taxdeductible fee medical assistance programs map international ngo partner distribute packs hcps need support back top home responsibility work communities building community capacity corporate responsibility report building community capacity lack healthcare infrastructure including clinics trained healthcare professionals cultural attitudes significant barriers treatment many developing countries global programmes help build capacity healthcare developing country communities positive action example works communities affected hiv aids african malaria partnership improving prevention access malaria treatment support local initiatives help overcome stigma build capacity communities provide healthcare combat disease committed reinvest per cent profits sales medicines least developed countries ldcs back projects widen access essential medicines strengthen healthcare infrastructure ldcs sales ldcs relatively low investment limited however hope actions encourage companies operating ldcs adopt similar approach also provide humanitarian relief times emergency natural disasters back top home responsibility work communities building community capacity corporate responsibility report building community capacity lack healthcare infrastructure including clinics trained healthcare professionals cultural attitudes significant barriers treatment many developing countries global programmes help build capacity healthcare developing country communities positive action example works communities affected hiv aids african malaria partnership improving prevention access malaria treatment support local initiatives help overcome stigma build capacity communities provide healthcare combat disease committed reinvest per cent profits sales medicines least developed countries ldcs back projects widen access essential medicines strengthen healthcare infrastructure ldcs sales ldcs relatively low investment limited however hope actions encourage companies operating ldcs adopt similar approach also provide humanitarian relief times emergency natural disasters back top home responsibility work communities building community capacity supporting healthcare ldcs corporate responsibility report supporting healthcare least developed countries committed reinvest per cent profits sales medicines least developed countries ldcs back projects address priority healthcare challenges provide support governments remove barriers stop patients accessing quality healthcare strengthen basic healthcare infrastructure selected six ldcs reinvestment initial activities targeted primarily improving maternal newborn child health high priorities ministries health essential achieving millennium development goals mdgs specifically goal four reduce child mortality goal five improve maternal health total reinvested allocated another programmes yet start table summarises reinvestment activities region programme scope partner programme budget country africa communitybased health infrastructure federal democratic republic ethiopia capacity building support reduce maternal ethiopia ministry health neonatal child mortality year three years democratic health infrastructure support improve catholic relief services crs republic neonatal child health year three years congo expanding network business format franchise nurserun clinics improve access healthstore foundation rwanda quality basic healthcare essential year three years medicines ministry health sudan ngos motorcycle ambulances pregnant women sudan unfpa community oneyear programme commence leaders us asia partenaires organisation de water sanitation programmes schools myanmar solidarit internationale us suburban areas primary healthcare infrastructure project cambodia plan international us construction health centre facilities maternal child survival initiatives cambodia community based health infrastructure clinical racha us training centre midwives building healthcare network rwanda helping improve access healthcare people rural rwanda supporting healthstore foundations efforts expand child family wellness cfw initiative country contribution helping ngo build network small pharmacies clinics make essential medicines treatment readily available children families remote areas organisation already successfully established similar healthcare network kenya cfw microfranchising model trained nurses operate businesses treat common diseases malaria pneumonia seeing around patients average every day also provide health education teach visitors disease prevention healthstore foundation aims open clinics across rwanda end back tophome responsibility work communities building community capacity supporting healthcare ldcs corporate responsibility report supporting healthcare least developed countries committed reinvest per cent profits sales medicines least developed countries ldcs back projects address priority healthcare challenges provide support governments remove barriers stop patients accessing quality healthcare strengthen basic healthcare infrastructure selected six ldcs reinvestment initial activities targeted primarily improving maternal newborn child health high priorities ministries health essential achieving millennium development goals mdgs specifically goal four reduce child mortality goal five improve maternal health total reinvested allocated another programmes yet start table summarises reinvestment activities region programme scope partner programme budget country africa communitybased health infrastructure federal democratic republic ethiopia capacity building support reduce maternal ethiopia ministry health neonatal child mortality year three years democratic health infrastructure support improve catholic relief services crs republic neonatal child health year three years congo expanding network business format franchise nurserun clinics improve access healthstore foundation rwanda quality basic healthcare essential year three years medicines ministry health sudan ngos motorcycle ambulances pregnant women sudan unfpa community oneyear programme commence leaders us asia partenaires organisation de water sanitation programmes schools myanmar solidarit internationale us suburban areas primary healthcare infrastructure project cambodia plan international us construction health centre facilities maternal child survival initiatives cambodia community based health infrastructure clinical racha us training centre midwives building healthcare network rwanda helping improve access healthcare people rural rwanda supporting healthstore foundations efforts expand child family wellness cfw initiative country contribution helping ngo build network small pharmacies clinics make essential medicines treatment readily available children families remote areas organisation already successfully established similar healthcare network kenya cfw microfranchising model trained nurses operate businesses treat common diseases malaria pneumonia seeing around patients average every day also provide health education teach visitors disease prevention healthstore foundation aims open clinics across rwanda end back top home responsibility work communities building community capacity supporting healthcare ldcs corporate responsibility report supporting healthcare least developed countries committed reinvest per cent profits sales medicines least developed countries ldcs back projects address priority healthcare challenges provide support governments remove barriers stop patients accessing quality healthcare strengthen basic healthcare infrastructure selected six ldcs reinvestment initial activities targeted primarily improving maternal newborn child health high priorities ministries health essential achieving millennium development goals mdgs specifically goal four reduce child mortality goal five improve maternal health total reinvested allocated another programmes yet start table summarises reinvestment activities region programme scope partner programme budget country africa communitybased health infrastructure federal democratic republic ethiopia capacity building support reduce maternal ethiopia ministry health neonatal child mortality year three years democratic health infrastructure support improve catholic relief services crs republic neonatal child health year three years congo expanding network business format franchise nurserun clinics improve access healthstore foundation rwanda quality basic healthcare essential year three years medicines ministry health sudan ngos motorcycle ambulances pregnant women sudan unfpa community oneyear programme commence leaders us asia partenaires organisation de water sanitation programmes schools myanmar solidarit internationale us suburban areas primary healthcare infrastructure project cambodia plan international us construction health centre facilities maternal child survival initiatives cambodia community based health infrastructure clinical racha us training centre midwives building healthcare network rwanda helping improve access healthcare people rural rwanda supporting healthstore foundations efforts expand child family wellness cfw initiative country contribution helping ngo build network small pharmacies clinics make essential medicines treatment readily available children families remote areas organisation already successfully established similar healthcare network kenya cfw microfranchising model trained nurses operate businesses treat common diseases malaria pneumonia seeing around patients average every day also provide health education teach visitors disease prevention healthstore foundation aims open clinics across rwanda end back top home responsibility work communities building community capacity combating hivaids positive action corporate responsibility report combating hivaids positive action positive action works community organisations build capacity counter ignorance stigma surrounding hiv outreach education advocacy provided million funding projects countries across africa asia latin america eastern europe positive action pioneered support vulnerable communities including men sex men intravenous drug users sex workers migrants young people orphans vulnerable children marginalised poor rural women groups limited human rights public voice essential work groups expect make difference epidemic positive action programmes involve grassroots organisations able continue support communities projects come end july launched new positive action children fund make million million available ten years help prevent mothertochild transmission hiv support orphans vulnerable children fund positive action programmes managed viiv healthcare new gskpfizer company focusing hivaids supported positive action programmes countries key projects include fighting stigma discrimination mexico among vulnerable sectors population bringing hiv education vulnerable women india selfhelp groups improving access treatment kenya promoting greater understanding involvement communities supporting staying alive foundation efforts raise awareness hivaids prevention among young people worldwide foundation launched television channel mtv makes grants organisations run young people work prevent hiv infection alleviate stigma discrimination associated disease also supported journalist competition run british newspaper guardian raise awareness health development issues poor countries sponsored journalist write issues faced people living hivaids kenya winning story published dedicated supplement november read positive action back top home responsibility work communities building community capacity combating hivaids positive action corporate responsibility report combating hivaids positive action positive action works community organisations build capacity counter ignorance stigma surrounding hiv outreach education advocacy provided million funding projects countries across africa asia latin america eastern europe positive action pioneered support vulnerable communities including men sex men intravenous drug users sex workers migrants young people orphans vulnerable children marginalised poor rural women groups limited human rights public voice essential work groups expect make difference epidemic positive action programmes involve grassroots organisations able continue support communities projects come end july launched new positive action children fund make million million available ten years help prevent mothertochild transmission hiv support orphans vulnerable children fund positive action programmes managed viiv healthcare new gskpfizer company focusing hivaids supported positive action programmes countries key projects include fighting stigma discrimination mexico among vulnerable sectors population bringing hiv education vulnerable women india selfhelp groups improving access treatment kenya promoting greater understanding involvement communities supporting staying alive foundation efforts raise awareness hivaids prevention among young people worldwide foundation launched television channel mtv makes grants organisations run young people work prevent hiv infection alleviate stigma discrimination associated disease also supported journalist competition run british newspaper guardian raise awareness health development issues poor countries sponsored journalist write issues faced people living hivaids kenya winning story published dedicated supplement november read positive action back top home responsibility work communities building community capacity combating malaria africa malaria partnership corporate responsibility report combating malaria gsk african malaria partnership every year million people affected malaria one million die mostly young children africa disease prevented controlling breeding mosquitoes using lowcost measures insecticidetreated nets malaria cured treated promptly effective medicines established gsk african malaria partnership improve prevention access treatment malaria subsaharan africa since invested million initiatives combat disease extended support mobilising malaria extra year mobilising malaria advocacy initiative generate greater awareness political commitment sustained funding malaria europe africa national coalitions malaria launched uk belgium france ethiopia cameroon mozambique bringing together advocates activists public sector ngos media private sector political academic scientific communities extra year funding enable national coalitions become better established secure sources funding sustain activities gsk african malaria partnership awarded four new grants total donation million three years include enable save children uk reduce malaria outbreaks floodaffected communities kenya indoor spraying insecticide distributing bed nets raising awareness communities clinics training health professionals prevent malaria manage symptoms family health international increase community health workers ' capacity tackle malaria ghana raise community awareness disease african medical research foundation amref project train community health workers tanzania prevent treat raise awareness malaria villages planned parenthood foundation nigeria reduce prevalence malaria six communities increase use bed nets promote sanitation reduce mosquito breeding sites read malaria programmes back top home responsibility work communities building community capacity combating malaria africa malaria partnership corporate responsibility report combating malaria gsk african malaria partnership every year million people affected malaria one million die mostly young children africa disease prevented controlling breeding mosquitoes using lowcost measures insecticidetreated nets malaria cured treated promptly effective medicines established gsk african malaria partnership improve prevention access treatment malaria subsaharan africa since invested million initiatives combat disease extended support mobilising malaria extra year mobilising malaria advocacy initiative generate greater awareness political commitment sustained funding malaria europe africa national coalitions malaria launched uk belgium france ethiopia cameroon mozambique bringing together advocates activists public sector ngos media private sector political academic scientific communities extra year funding enable national coalitions become better established secure sources funding sustain activities gsk african malaria partnership awarded four new grants total donation million three years include enable save children uk reduce malaria outbreaks floodaffected communities kenya indoor spraying insecticide distributing bed nets raising awareness communities clinics training health professionals prevent malaria manage symptoms family health international increase community health workers ' capacity tackle malaria ghana raise community awareness disease african medical research foundation amref project train community health workers tanzania prevent treat raise awareness malaria villages planned parenthood foundation nigeria reduce prevalence malaria six communities increase use bed nets promote sanitation reduce mosquito breeding sites read malaria programmes back top home responsibility work communities building community capacity local programmes corporate responsibility report local programmes support wide range programmes build healthcare capacity communities operate fund programmes corporate local levels local programme examples building india 's immunisation infrastructure seeking explore new innovative approaches towards philanthropic investment ultimately play greater role helping deliver better access healthcare education step towards achieving bold objective developing project seek improve vaccine coverage among unreached populations mumbai urban slums serve framework implemented elsewhere hosted workshop mumbai involving indias ministry health family welfare ngos including unicef save children workshop identified solutions reaching remote communities vaccine supplies including need improved cold chain better information management systems pivotal delivering immunisations next phase partner ngo local expertise develop intervention project urban slum areas working alongside government india training nurses pakistan pakistan lacks qualified nurses one available every patients made threeyear commitment support centre nursing excellence programme improve nursing education quality maternal child healthcare across country centre admits students year sixmonth course disease prevention nurses graduated april also qualified pass lessons learned nursing staff hospitals three years allocated project facilitating access healthcare disadvantaged children sole supporter childrens health fund chf initiative us ensure continuity care medicallyunderserved children high risk disease provided almost million date chf programmes referral management initiative eliminates barriers including distance cost cultural issues often prevent children many homeless receiving specialist healthcare initially established new york programme grown also operates dallas south florida los angeles philadelphia washington dc already helped tens thousands disadvantaged children need specialist care initiative succeeded increasing number children referred specialist actually make appointment five per cent programme began per cent today supported chfs pilot telemedicine project help patients rural areas access specialist care memphis hospital remotely using stateoftheart videoconferencing technology chf acknowledged support affiliation annual report support advanced breast cancer sufferers breast cancer sufferers play active role fighting cancer experience improved quality life may even improve chances recovery according cancer support communitys patient active concept contributed help fund cancer support communitys frankly speaking living advanced breast cancer initiative us national patient programme consisting community seminars support groups online support support medicines senior pharmassist helps people aged years older durham nc obtain medicines need tap community resources support health independence past three years provided support important work programme evaluations demonstrated participants report reduced visits hospital feel healthier healthcare homeless pittsburgh grant three years support pittsburgh mercy foundations operation safety net healthcare outreach programme homeless population men women living streets given access healthcare designed meet unique needs programme began pittsburgh area expanded partner street medicine international programme us europe asia central south america home nursing children cancer greece donating three years floga greek association parents children cancer develop home nursing programme children cancer initiative enables children need daily care receive home trained nurses reducing number hospital visits required substantially improving quality life promoting healthy living dutch children helping dutch health institute nigz promote weight management strategies young people risk developing obesity obesity increasing netherlands nigz encourages schoolchildren physically active eat healthily support worth three years enable organisation raise awareness obesity schools lowincome areas nigz hold focus groups bring together young people teachers design initiatives inspire children make healthy lifestyle choices rewarding community healthcare organisations uk us year gsk impact awards recognise voluntary organisations significantly improved health local communities uk ten winning charities receive overall winner awarded extra managers winning organisations trained leadership networking fundraising skills helps strengthen small charities often unable afford vital skills training gsk impact awards us provide support charities facilitate access healthcare underserved communities philadelphia surrounding counties launched similar impact awards programme near research triangle park facility awarded winning charity read gsk impact awards winning organisations back tophome responsibility work communities building community capacity local programmes corporate responsibility report local programmes support wide range programmes build healthcare capacity communities operate fund programmes corporate local levels local programme examples building india 's immunisation infrastructure seeking explore new innovative approaches towards philanthropic investment ultimately play greater role helping deliver better access healthcare education step towards achieving bold objective developing project seek improve vaccine coverage among unreached populations mumbai urban slums serve framework implemented elsewhere hosted workshop mumbai involving indias ministry health family welfare ngos including unicef save children workshop identified solutions reaching remote communities vaccine supplies including need improved cold chain better information management systems pivotal delivering immunisations next phase partner ngo local expertise develop intervention project urban slum areas working alongside government india training nurses pakistan pakistan lacks qualified nurses one available every patients made threeyear commitment support centre nursing excellence programme improve nursing education quality maternal child healthcare across country centre admits students year sixmonth course disease prevention nurses graduated april also qualified pass lessons learned nursing staff hospitals three years allocated project facilitating access healthcare disadvantaged children sole supporter childrens health fund chf initiative us ensure continuity care medicallyunderserved children high risk disease provided almost million date chf programmes referral management initiative eliminates barriers including distance cost cultural issues often prevent children many homeless receiving specialist healthcare initially established new york programme grown also operates dallas south florida los angeles philadelphia washington dc already helped tens thousands disadvantaged children need specialist care initiative succeeded increasing number children referred specialist actually make appointment five per cent programme began per cent today supported chfs pilot telemedicine project help patients rural areas access specialist care memphis hospital remotely using stateoftheart videoconferencing technology chf acknowledged support affiliation annual report support advanced breast cancer sufferers breast cancer sufferers play active role fighting cancer experience improved quality life may even improve chances recovery according cancer support communitys patient active concept contributed help fund cancer support communitys frankly speaking living advanced breast cancer initiative us national patient programme consisting community seminars support groups online support support medicines senior pharmassist helps people aged years older durham nc obtain medicines need tap community resources support health independence past three years provided support important work programme evaluations demonstrated participants report reduced visits hospital feel healthier healthcare homeless pittsburgh grant three years support pittsburgh mercy foundations operation safety net healthcare outreach programme homeless population men women living streets given access healthcare designed meet unique needs programme began pittsburgh area expanded partner street medicine international programme us europe asia central south america home nursing children cancer greece donating three years floga greek association parents children cancer develop home nursing programme children cancer initiative enables children need daily care receive home trained nurses reducing number hospital visits required substantially improving quality life promoting healthy living dutch children helping dutch health institute nigz promote weight management strategies young people risk developing obesity obesity increasing netherlands nigz encourages schoolchildren physically active eat healthily support worth three years enable organisation raise awareness obesity schools lowincome areas nigz hold focus groups bring together young people teachers design initiatives inspire children make healthy lifestyle choices rewarding community healthcare organisations uk us year gsk impact awards recognise voluntary organisations significantly improved health local communities uk ten winning charities receive overall winner awarded extra managers winning organisations trained leadership networking fundraising skills helps strengthen small charities often unable afford vital skills training gsk impact awards us provide support charities facilitate access healthcare underserved communities philadelphia surrounding counties launched similar impact awards programme near research triangle park facility awarded winning charity read gsk impact awards winning organisations back top home responsibility work communities building community capacity local programmes corporate responsibility report local programmes support wide range programmes build healthcare capacity communities operate fund programmes corporate local levels local programme examples building india 's immunisation infrastructure seeking explore new innovative approaches towards philanthropic investment ultimately play greater role helping deliver better access healthcare education step towards achieving bold objective developing project seek improve vaccine coverage among unreached populations mumbai urban slums serve framework implemented elsewhere hosted workshop mumbai involving indias ministry health family welfare ngos including unicef save children workshop identified solutions reaching remote communities vaccine supplies including need improved cold chain better information management systems pivotal delivering immunisations next phase partner ngo local expertise develop intervention project urban slum areas working alongside government india training nurses pakistan pakistan lacks qualified nurses one available every patients made threeyear commitment support centre nursing excellence programme improve nursing education quality maternal child healthcare across country centre admits students year sixmonth course disease prevention nurses graduated april also qualified pass lessons learned nursing staff hospitals three years allocated project facilitating access healthcare disadvantaged children sole supporter childrens health fund chf initiative us ensure continuity care medicallyunderserved children high risk disease provided almost million date chf programmes referral management initiative eliminates barriers including distance cost cultural issues often prevent children many homeless receiving specialist healthcare initially established new york programme grown also operates dallas south florida los angeles philadelphia washington dc already helped tens thousands disadvantaged children need specialist care initiative succeeded increasing number children referred specialist actually make appointment five per cent programme began per cent today supported chfs pilot telemedicine project help patients rural areas access specialist care memphis hospital remotely using stateoftheart videoconferencing technology chf acknowledged support affiliation annual report support advanced breast cancer sufferers breast cancer sufferers play active role fighting cancer experience improved quality life may even improve chances recovery according cancer support communitys patient active concept contributed help fund cancer support communitys frankly speaking living advanced breast cancer initiative us national patient programme consisting community seminars support groups online support support medicines senior pharmassist helps people aged years older durham nc obtain medicines need tap community resources support health independence past three years provided support important work programme evaluations demonstrated participants report reduced visits hospital feel healthier healthcare homeless pittsburgh grant three years support pittsburgh mercy foundations operation safety net healthcare outreach programme homeless population men women living streets given access healthcare designed meet unique needs programme began pittsburgh area expanded partner street medicine international programme us europe asia central south america home nursing children cancer greece donating three years floga greek association parents children cancer develop home nursing programme children cancer initiative enables children need daily care receive home trained nurses reducing number hospital visits required substantially improving quality life promoting healthy living dutch children helping dutch health institute nigz promote weight management strategies young people risk developing obesity obesity increasing netherlands nigz encourages schoolchildren physically active eat healthily support worth three years enable organisation raise awareness obesity schools lowincome areas nigz hold focus groups bring together young people teachers design initiatives inspire children make healthy lifestyle choices rewarding community healthcare organisations uk us year gsk impact awards recognise voluntary organisations significantly improved health local communities uk ten winning charities receive overall winner awarded extra managers winning organisations trained leadership networking fundraising skills helps strengthen small charities often unable afford vital skills training gsk impact awards us provide support charities facilitate access healthcare underserved communities philadelphia surrounding counties launched similar impact awards programme near research triangle park facility awarded winning charity read gsk impact awards winning organisations back top home responsibility work communities supporting science education corporate responsibility report supporting science education uk us numbers young people choosing science subjects falling many students lack proficiency either reading mathematics result countries face significant skills shortage success business relies us able recruit talented individuals particularly science qualifications also want young people make sound decisions sciencerelated issues come across everyday life healthy eating vaccinations value medicines education programmes help make science relevant young people uk us stimulating interest science encouraging pursue sciencerelated career also support training development science teachers uk project enthuse half secondary school science teachers uk subject training within past five years project enthuse launched aims improve continuing professional development science teachers helps use latest techniques interest pupils science committed million million coming uk government wellcome trust eight industry partners teachers assistants technicians apply enthuse award study national science learning centre university york award covers course fees travel accommodation teachers year schools receive funding cover cost replacement teacher course small grant help implement new ideas teacher returns classroom enthuse helped teachers school science technicians aims provide nearly training days fouryear period royal society chemistry continue support royal society chemistry rsc programme target science teachers chemistry specialists provide key skills confidence effective chemistry teaching funding commitment three years rsc teamed gsk develop course help nonspecialist chemistry teachers deliver quality chemistry education year olds twoday residential course teachers opportunity discuss health safety issues difficult chemical concepts new contemporary contexts teaching chemistry rsc charity long standing reputation delivering highquality highly regarded training teachers us america 's promise alliance us national highschool dropout rate greater per cent greater per cent minorities helping reduce supporting americas promise alliance dropout prevention initiative alliance leading national movement towards goal every american child graduate high school ready college work life committed three years initiative institute competitive workforce icw working us chamber commerce institute competitive workforce increase business communitys understanding educational workforce development issues hope initiative contribute improvement quality us education system skills future workforce provided support icws education workforce summit washington dc attended stakeholders north carolina new schools project partner north carolina new schools project provide innovative teaching methods ten stem science technology engineering math schools schools located areas especially hardhit loss agricultural manufacturing jobs provided support project aim better prepare graduates college life careers success far evident fact schools programme half dropout rate schools north carolina opportunity scholarship sponsor opportunity scholarship programme million endowment recognises individuals overcome adversity including physical sexual abuse serious illness personal loss yet pursued education means changing lives provides scholarships means removing one obstacles continuing education able afford initiative initially focused north carolina additional million endowment established philadelphia philadelphia education fund lead corporate sponsor philadelphia math science coalition partnership businesses universities school district philadelphia nonprofit organisations coalition develops highly qualified mathematics science teachers partnerships schools universities corporations aim improve quality mathematics science teaching students succeed education careers require scientific backgrounds supported programme donation two years science summer sole supporter science summer free education programme designed get young people pittsburgh pennsylvania greater philadelphia north carolina interested science classes held local libraries give children chance take part handson experiments courses ranging genetics oceanography programme began invested across sites children participated programme back tophome responsibility work communities supporting science education corporate responsibility report supporting science education uk us numbers young people choosing science subjects falling many students lack proficiency either reading mathematics result countries face significant skills shortage success business relies us able recruit talented individuals particularly science qualifications also want young people make sound decisions sciencerelated issues come across everyday life healthy eating vaccinations value medicines education programmes help make science relevant young people uk us stimulating interest science encouraging pursue sciencerelated career also support training development science teachers uk project enthuse half secondary school science teachers uk subject training within past five years project enthuse launched aims improve continuing professional development science teachers helps use latest techniques interest pupils science committed million million coming uk government wellcome trust eight industry partners teachers assistants technicians apply enthuse award study national science learning centre university york award covers course fees travel accommodation teachers year schools receive funding cover cost replacement teacher course small grant help implement new ideas teacher returns classroom enthuse helped teachers school science technicians aims provide nearly training days fouryear period royal society chemistry continue support royal society chemistry rsc programme target science teachers chemistry specialists provide key skills confidence effective chemistry teaching funding commitment three years rsc teamed gsk develop course help nonspecialist chemistry teachers deliver quality chemistry education year olds twoday residential course teachers opportunity discuss health safety issues difficult chemical concepts new contemporary contexts teaching chemistry rsc charity long standing reputation delivering highquality highly regarded training teachers us america 's promise alliance us national highschool dropout rate greater per cent greater per cent minorities helping reduce supporting americas promise alliance dropout prevention initiative alliance leading national movement towards goal every american child graduate high school ready college work life committed three years initiative institute competitive workforce icw working us chamber commerce institute competitive workforce increase business communitys understanding educational workforce development issues hope initiative contribute improvement quality us education system skills future workforce provided support icws education workforce summit washington dc attended stakeholders north carolina new schools project partner north carolina new schools project provide innovative teaching methods ten stem science technology engineering math schools schools located areas especially hardhit loss agricultural manufacturing jobs provided support project aim better prepare graduates college life careers success far evident fact schools programme half dropout rate schools north carolina opportunity scholarship sponsor opportunity scholarship programme million endowment recognises individuals overcome adversity including physical sexual abuse serious illness personal loss yet pursued education means changing lives provides scholarships means removing one obstacles continuing education able afford initiative initially focused north carolina additional million endowment established philadelphia philadelphia education fund lead corporate sponsor philadelphia math science coalition partnership businesses universities school district philadelphia nonprofit organisations coalition develops highly qualified mathematics science teachers partnerships schools universities corporations aim improve quality mathematics science teaching students succeed education careers require scientific backgrounds supported programme donation two years science summer sole supporter science summer free education programme designed get young people pittsburgh pennsylvania greater philadelphia north carolina interested science classes held local libraries give children chance take part handson experiments courses ranging genetics oceanography programme began invested across sites children participated programme back top